Clustering O 0 9.768909876584075e-06
of O 0 7.382460012195224e-07
missense O 0 6.182668585097417e-06
mutations O 0 4.853875452681677e-07
in O 0 1.1697520108100434e-07
the O 0 0.0001659465197008103
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 1.3538247912947554e-05
in O 0 1.1747381023496928e-07
a O 0 9.995252980843361e-08
sporadic B-Disease 0 0.002163468161597848
T I-Disease 1 0.9999899864196777
- I-Disease 1 0.9639778137207031
cell I-Disease 0 0.02668624371290207
leukaemia I-Disease 0 0.2143937200307846
. O 0 2.620116219986812e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999998807907104
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.519670291827424e-07
is O 0 1.6255072843307516e-09
a O 0 7.105708910160047e-09
recessive B-Disease 0 3.088803350692615e-05
multi I-Disease 0 0.001030694111250341
- I-Disease 0 0.0001656769309192896
system I-Disease 0 2.1489122445927933e-06
disorder I-Disease 0 1.1011868537025293e-06
caused O 0 5.562780014400914e-09
by O 0 6.943511876578157e-10
mutations O 0 4.401595976588624e-09
in O 0 5.347602805017004e-09
the O 0 5.327529351006888e-08
ATM O 0 2.917085566878086e-06
gene O 0 3.965734052258085e-08
at O 0 5.058276428826503e-07
11q22 O 0 2.3690543002885533e-06
- O 0 7.666447459087067e-07
q23 O 0 1.0478967169547104e-06
( O 0 1.1580193692850571e-08
ref O 0 3.3020256751115085e-07
. O 0 4.986101309611968e-09
3 O 0 7.547389913042934e-08
) O 0 1.3229437101358599e-08
. O 0 2.543279720157443e-07

The O 0 1.3688278386325692e-06
risk O 0 1.4951416460462497e-06
of O 0 1.5256733831847669e-06
cancer B-Disease 0 6.797607784392312e-05
, O 0 1.72731073888599e-08
especially O 0 8.428108344560314e-08
lymphoid B-Disease 0 0.025274628773331642
neoplasias I-Disease 0 0.0014920862158760428
, O 0 1.7603914770347728e-08
is O 0 2.0484123286479416e-09
substantially O 0 1.9152544439293706e-08
elevated O 0 3.6533504044200527e-07
in O 0 4.106036044504435e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.2291651785290014e-07
and O 0 5.062110286502275e-09
has O 0 8.912211524325642e-10
long O 0 4.415400545187964e-10
been O 0 7.03893332509864e-10
associated O 0 6.958390752487276e-09
with O 0 1.17386864673108e-08
chromosomal O 1 1.0
instability O 1 1.0
. O 0 5.011083703720942e-05

By O 0 4.534685160706431e-07
analysing O 0 9.349278116133064e-06
tumour B-Disease 1 1.0
DNA O 0 1.7675738206435199e-07
from O 0 3.3435156865380122e-09
patients O 0 1.4740350051667406e-09
with O 0 1.3212810845431022e-09
sporadic B-Disease 0 1.3696577298105694e-05
T I-Disease 1 0.9996600151062012
- I-Disease 1 0.938306987285614
cell I-Disease 1 0.6450684666633606
prolymphocytic I-Disease 0 0.005851092282682657
leukaemia I-Disease 1 0.9917675256729126
( O 0 2.496639410765056e-07
T B-Disease 0 4.5987675548531115e-05
- I-Disease 0 2.488930249455734e-06
PLL I-Disease 0 6.95861899657757e-06
) O 0 2.9555593528129975e-09
, O 0 4.6495235439536486e-10
a O 0 1.7111175809603196e-09
rare O 0 3.273423843097589e-08
clonal B-Disease 0 1.3574115200754022e-06
malignancy I-Disease 0 2.0881948330497835e-06
with O 0 2.3611419486258e-09
similarities O 0 3.573712703541787e-08
to O 0 9.875465778463877e-09
a O 0 6.746686409542235e-08
mature B-Disease 0 0.0010098962811753154
T I-Disease 0 0.05525021255016327
- I-Disease 0 0.00010557976929703727
cell I-Disease 0 3.859737262246199e-05
leukaemia I-Disease 0 0.0013672756031155586
seen O 0 1.7213052316833455e-08
in O 0 5.145947223894609e-09
A B-Disease 1 0.999998927116394
- I-Disease 1 0.9999877214431763
T I-Disease 1 1.0
, O 0 5.67904567816413e-09
we O 0 1.2030630935910835e-09
demonstrate O 0 2.109975971720246e-09
a O 0 7.953232517010633e-10
high O 0 1.120188031222824e-08
frequency O 0 3.702588458054379e-08
of O 0 1.2513129199476225e-08
ATM O 0 7.521758220718766e-07
mutations O 0 1.0562468588659613e-07
in O 0 1.6989710616144293e-07
T B-Disease 0 0.00011377282498870045
- I-Disease 0 2.9628434276673943e-05
PLL I-Disease 0 0.00015233471640385687
. O 0 2.7173070975550218e-06

In O 0 4.01141420525164e-07
marked O 0 1.954397816916753e-07
contrast O 0 2.1047879883440146e-08
to O 0 4.368692074763203e-09
the O 0 2.3067110888064235e-08
ATM O 0 1.3760565025222604e-06
mutation O 0 6.285760889568337e-08
pattern O 0 1.2139797433974309e-07
in O 0 6.038595756763243e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 1.2017564721134022e-08
the O 0 1.9769137438174766e-09
most O 0 9.068176765048008e-11
frequent O 0 9.139594636664583e-11
nucleotide O 0 5.245818779364697e-10
changes O 0 2.2438687019565862e-10
in O 0 1.2903086932247732e-10
this O 0 2.27728377821812e-10
leukaemia B-Disease 0 4.558124544473685e-07
were O 0 2.302658153041648e-08
missense O 0 9.82408437266713e-07
mutations O 0 1.6312716297761654e-06
. O 0 3.674412937471061e-06

These O 0 1.66517111210851e-07
clustered O 0 2.8836703336310165e-07
in O 0 4.28369517635474e-09
the O 0 8.14136047466718e-09
region O 0 8.115160099464447e-09
corresponding O 0 1.0257545923764155e-08
to O 0 5.4925424208818185e-09
the O 0 1.867618415474226e-08
kinase O 0 5.675182990216854e-08
domain O 0 5.083939047523245e-09
, O 0 2.1862903154534763e-10
which O 0 9.733985145699009e-11
is O 0 1.0074516915148379e-10
highly O 0 1.989358011655895e-09
conserved O 0 1.2221071266083072e-08
in O 0 6.4691798584703974e-09
ATM O 0 5.490648504746787e-07
- O 0 4.2278760048475306e-08
related O 0 3.370735468521957e-09
proteins O 0 2.7318544648657905e-10
in O 0 1.1310530290131737e-09
mouse O 0 7.938854018618713e-09
, O 0 1.2366915269623746e-09
yeast O 0 5.056728014096734e-08
and O 0 4.9197307561144044e-08
Drosophila O 0 1.8571236068964936e-06
. O 0 5.046948103881732e-07

The O 0 3.0756070827919757e-06
resulting O 0 2.8718604880850762e-06
amino O 0 1.2281145700399065e-06
- O 0 3.380356758952985e-07
acid O 0 2.7651987366539288e-08
substitutions O 0 5.2995670074551526e-08
are O 0 2.7903952481977967e-09
predicted O 0 6.321012335774867e-08
to O 0 1.0331865141210983e-08
interfere O 0 1.5648728890482744e-07
with O 0 1.623921441762377e-08
ATP O 0 8.258290108642541e-06
binding O 0 1.8620735886543116e-07
or O 0 2.309674052014543e-08
substrate O 0 1.8233779996990052e-07
recognition O 0 1.1078792283569783e-07
. O 0 8.064950520747516e-07

Two O 0 8.445808248325193e-07
of O 0 7.718872438999824e-07
seventeen O 0 4.005204573331866e-06
mutated O 0 2.0809329726034775e-06
T B-Disease 0 5.2663472160929814e-05
- I-Disease 0 2.7108026188216172e-06
PLL I-Disease 0 5.237758159637451e-06
samples O 0 4.849815216090292e-09
had O 0 2.70789901613e-09
a O 0 2.390742714908356e-09
previously O 0 2.5539588222045495e-08
reported O 0 2.3377474178687407e-07
A B-Disease 1 0.999998927116394
- I-Disease 1 0.9999979734420776
T I-Disease 1 1.0
allele O 0 0.00015019660349935293
. O 0 5.793427590106148e-06

In O 0 2.3242914437560103e-07
contrast O 0 1.0484669843435768e-07
, O 0 6.477452796360694e-09
no O 0 3.2737843547181456e-09
mutations O 0 5.218964815867366e-09
were O 0 7.659517464730925e-09
detected O 0 4.7958459425956335e-09
in O 0 2.125697617927358e-09
the O 0 7.159637327447399e-09
p53 O 0 1.3102195772773939e-08
gene O 0 7.8854007767859e-09
, O 0 1.2750894784474553e-09
suggesting O 0 2.8389040007681388e-09
that O 0 3.4509317625719405e-10
this O 0 1.846028108154485e-09
tumour B-Disease 1 1.0
suppressor O 0 5.918615784139547e-07
is O 0 5.536694991370439e-10
not O 0 6.277141584298818e-10
frequently O 0 3.027305295333349e-09
altered O 0 2.696134515645099e-08
in O 0 5.436541439252096e-09
this O 0 5.7407113729368575e-08
leukaemia B-Disease 0 0.0001481333893025294
. O 0 3.9767664929968305e-06

Occasional O 0 2.8969418508495437e-06
missense O 0 5.214393240748905e-06
mutations O 0 1.52618568449725e-07
in O 0 3.0023620922747796e-08
ATM O 0 3.300525122540421e-06
were O 0 8.526090766736161e-08
also O 0 1.5385269724887962e-09
found O 0 3.6835678951518958e-09
in O 0 1.5774631378917547e-08
tumour B-Disease 1 1.0
DNA O 0 3.255405545132817e-07
from O 0 7.139591584603977e-09
patients O 0 2.8769739923717452e-09
with O 0 3.5716940516294926e-09
B B-Disease 0 0.00011188072676304728
- I-Disease 0 7.142704998841509e-05
cell I-Disease 0 0.0002260851179016754
non I-Disease 0 0.0032417220063507557
- I-Disease 0 0.0007356386631727219
Hodgkins I-Disease 1 0.9999932050704956
lymphomas I-Disease 0 1.0545098120928742e-05
( O 0 1.2916199665369277e-08
B B-Disease 0 3.467658871159074e-07
- I-Disease 0 4.062822966943713e-08
NHL I-Disease 0 1.9813279550362495e-07
) O 0 8.554425501294816e-10
and O 0 1.6673085134755183e-09
a O 0 8.906029691502226e-09
B B-Disease 0 1.3844532986695413e-06
- I-Disease 0 6.498622724393499e-07
NHL I-Disease 0 1.1657927643682342e-05
cell O 0 3.5709169878828106e-06
line O 0 1.463815806346247e-06
. O 0 1.5264098465195275e-06

The O 0 2.9097401466060546e-07
evidence O 0 1.6206206510105403e-07
of O 0 2.6154619803264723e-08
a O 0 1.9652890426158365e-09
significant O 0 5.455061291570473e-09
proportion O 0 1.4826470717821394e-08
of O 0 4.0741216622564025e-08
loss O 0 6.628849860135233e-07
- O 0 3.364449412401882e-07
of O 0 9.75341777120775e-07
- O 0 7.618198196723824e-07
function O 0 8.122813710542687e-08
mutations O 0 1.035115637648687e-08
and O 0 1.3575250923381077e-09
a O 0 5.959560067658742e-10
complete O 0 4.548919907421123e-09
absence O 0 2.8955826181231714e-08
of O 0 1.1523083820463853e-08
the O 0 4.23725454723467e-09
normal O 0 2.634516382826746e-09
copy O 0 7.616221431305803e-09
of O 0 4.14988088337509e-09
ATM O 0 4.260401453848317e-08
in O 0 1.444372621506318e-09
the O 0 2.17878159958218e-09
majority O 0 3.8265364210587904e-09
of O 0 9.967932612653385e-08
mutated O 0 3.469551757007139e-06
tumours B-Disease 1 1.0
establishes O 0 2.0594970351339725e-07
somatic O 0 1.3742857163379085e-07
inactivation O 0 1.1383432507727775e-07
of O 0 1.0338784939278867e-08
this O 0 1.0641038050707152e-09
gene O 0 1.4082224275568933e-09
in O 0 1.4663654734903275e-09
the O 0 1.1016247469797236e-08
pathogenesis O 0 3.5386838135309517e-06
of O 0 2.252529185398089e-07
sporadic B-Disease 0 0.0005778033519163728
T I-Disease 1 0.9988106489181519
- I-Disease 0 0.0021507814526557922
PLL I-Disease 0 1.1601730875554495e-05
and O 0 6.646775574381536e-09
suggests O 0 3.4706371110360124e-09
that O 0 4.790988716862898e-10
ATM O 0 6.377055683515209e-08
acts O 0 1.1799248689214892e-08
as O 0 9.836552905539975e-09
a O 0 7.378350375120135e-08
tumour B-Disease 1 1.0
suppressor O 0 0.0005151510122232139
. O 0 9.875026080408134e-06

As O 0 1.4455203256602545e-07
constitutional O 0 9.854393283603713e-07
DNA O 0 6.436027177869619e-08
was O 0 4.980607481996913e-09
not O 0 2.8973198840098746e-10
available O 0 5.648117973322542e-09
, O 0 2.450838421097501e-09
a O 0 9.736687900385732e-09
putative O 0 2.015867039517616e-06
hereditary O 1 0.8105688095092773
predisposition O 0 0.00017478549852967262
to O 0 2.232432598248124e-05
T B-Disease 1 0.9999994039535522
- I-Disease 1 0.999848484992981
PLL I-Disease 0 0.00026926855207420886
will O 0 9.597955319406992e-09
require O 0 4.075176640583322e-09
further O 0 9.125529665254817e-09
investigation O 0 1.9536852136070593e-08
. O 0 6.030065335949075e-09
. O 0 2.1552467899255134e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 2.7136426069773734e-05
kinase O 0 4.317488730976038e-07
is O 0 3.1121200061434706e-10
involved O 0 1.528094317748696e-10
in O 0 1.44581610572736e-10
the O 0 7.621303033111815e-10
modulation O 0 1.1827121504381921e-08
of O 0 1.864264964623885e-09
the O 0 2.2135147048629733e-09
Ca2 O 0 4.374088646841301e-08
+ O 0 2.353964703161182e-07
homeostasis O 0 5.138863912179659e-07
in O 0 2.4490173444746688e-08
skeletal O 0 6.92512048772187e-06
muscle O 0 8.382751843782899e-07
cells O 0 3.5275008940516273e-06
. O 0 2.1207049485383322e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999688863754272
DM B-Disease 1 1.0
) O 0 1.5258612506841018e-07
, O 0 2.8552660236158545e-09
the O 0 2.0548613921533843e-09
most O 0 2.2876243122027518e-09
prevalent O 0 0.0022126503754407167
muscular B-Disease 1 0.9999998807907104
disorder I-Disease 0 0.007610030937939882
in O 0 1.5270556374957778e-08
adults O 0 3.244860025120033e-08
, O 0 1.1629658347445115e-09
is O 0 5.500066513342006e-10
caused O 0 1.1460548954289607e-08
by O 0 8.42389358268747e-09
( O 0 1.407275362907967e-08
CTG O 0 1.7401880541001447e-06
) O 0 4.047499224668627e-09
n O 0 2.764549833500496e-08
- O 0 4.214379512035293e-09
repeat O 0 3.812607118902633e-09
expansion O 0 1.6324422924540727e-09
in O 0 3.6141661885480403e-10
a O 0 8.241803350905741e-10
gene O 0 1.4136207759918307e-09
encoding O 0 2.608129179293428e-08
a O 0 1.6324181117965963e-08
protein O 0 1.1113798592532476e-07
kinase O 0 1.2041504078297294e-06
( O 0 1.360867969424362e-07
DM B-Disease 1 0.999915599822998
protein O 0 1.0027580543692238e-07
kinase O 0 2.3438589735746973e-08
; O 0 1.3829566380962888e-09
DMPK O 0 9.982322808355093e-07
) O 0 8.654238436989203e-10
and O 0 1.2458087894628989e-09
involves O 0 1.8329237017056244e-09
changes O 0 4.94548757501434e-09
in O 0 3.5537814913055854e-09
cytoarchitecture O 0 1.013653331938258e-06
and O 0 4.2156766966172654e-08
ion O 0 3.0365443308255635e-05
homeostasis O 0 0.0001438017061445862
. O 0 4.739265932585113e-06

To O 0 2.420707687633694e-07
obtain O 0 6.033001795913151e-07
clues O 0 7.110049295988574e-07
to O 0 3.430863815268026e-09
the O 0 6.356433157606034e-09
normal O 0 1.3869963844115318e-08
biological O 0 3.961402228469524e-08
role O 0 2.142754951250936e-08
of O 0 9.112992671589382e-08
DMPK O 0 4.8689784307498485e-05
in O 0 2.2529417265104712e-07
cellular O 0 2.035092848018394e-06
ion O 0 5.045815487392247e-05
homeostasis O 0 2.2579526557819918e-05
, O 0 6.057351065180683e-09
we O 0 1.8659405132126494e-09
have O 0 3.588127295284238e-10
compared O 0 1.915249958628351e-09
the O 0 1.2652149328218343e-09
resting O 0 4.0322976957440915e-08
[ O 0 1.4234267098345299e-08
Ca2 O 0 1.7773992055936105e-08
+ O 0 3.168587170421233e-08
] O 0 1.495638635162777e-08
i O 0 6.371958960471602e-09
, O 0 5.216215792636092e-10
the O 0 8.763537118205988e-10
amplitude O 0 1.7524316220374203e-08
and O 0 2.029879597742479e-09
shape O 0 7.505915533556617e-08
of O 0 5.6456009644989535e-08
depolarization O 0 3.872812328609143e-07
- O 0 2.1872169497783034e-07
induced O 0 9.552848467819786e-08
Ca2 O 0 6.196707857952788e-08
+ O 0 1.0221028645673869e-07
transients O 0 6.201117486170915e-08
, O 0 5.935408831092559e-10
and O 0 4.22108709097202e-10
the O 0 1.0542653416933945e-09
content O 0 4.395052322081483e-09
of O 0 1.1334291727393975e-08
ATP O 0 7.823970804565761e-07
- O 0 4.365262284977689e-08
driven O 0 5.689565441002742e-08
ion O 0 4.980624908057507e-07
pumps O 0 1.0172794873142266e-07
in O 0 5.90678581602333e-08
cultured O 0 2.756181629592902e-06
skeletal O 0 4.074699972989038e-06
muscle O 0 4.251204543948006e-08
cells O 0 4.153240240611922e-08
of O 0 3.185043695452805e-08
wild O 0 1.6682763614994656e-08
- O 0 9.30145116484482e-09
type O 0 2.2002900834650063e-08
and O 0 2.3861156606130862e-08
DMPK O 0 3.646977347671054e-05
[ O 0 6.959892857594241e-07
- O 0 1.1069283800679841e-06
/ O 0 2.529765197323286e-06
- O 0 1.6133266171891592e-06
] O 0 1.1840335218948894e-06
knockout O 0 0.0030838490929454565
mice O 0 8.201216587622184e-06
. O 0 1.635430749047373e-06

In O 0 4.362821528047789e-06
vitro O 0 1.3040987141721416e-05
- O 0 3.973817001678981e-06
differentiated O 0 6.990991550992476e-06
DMPK O 0 8.841084490995854e-05
[ O 0 3.519050324030104e-06
- O 0 5.96575728195603e-06
/ O 0 7.3082183007500134e-06
- O 0 1.4344780083774822e-06
] O 0 1.994644662772771e-07
myotubes O 0 9.44709938721644e-07
exhibit O 0 1.6713210371221976e-08
a O 0 6.211378078546659e-09
higher O 0 1.295511395937865e-07
resting O 0 8.545413265892421e-07
[ O 0 8.270502860341367e-08
Ca2 O 0 7.367325594032081e-08
+ O 0 9.731603967111369e-08
] O 0 5.40599884857329e-08
i O 0 1.4651027058221189e-08
than O 0 1.316825426478374e-09
do O 0 4.349809401560378e-09
wild O 0 1.552953499128762e-08
- O 0 9.448053894800523e-09
type O 0 1.6559663862381058e-08
myotubes O 0 1.8689320313569624e-07
because O 0 1.5237991979333287e-09
of O 0 2.5918323043327973e-09
an O 0 2.4059837455681077e-10
altered O 0 7.636731247373518e-09
open O 0 1.540033700564436e-08
probability O 0 1.532401050496901e-08
of O 0 1.3746023874716684e-08
voltage O 0 5.213142912907642e-07
- O 0 1.459568181871873e-07
dependent O 0 6.227015347803899e-08
l O 0 6.835882260247672e-08
- O 0 5.623287613332195e-09
type O 0 4.50693038445138e-09
Ca2 O 0 1.0135721595361247e-08
+ O 0 1.6411499714763522e-08
and O 0 7.321011796790344e-09
Na O 0 4.1273077044934325e-07
+ O 0 7.30388833858342e-08
channels O 0 1.633613209151008e-07
. O 0 3.2079256584438554e-07

The O 0 3.3857618291222025e-06
mutant O 0 6.149097771412926e-06
myotubes O 0 9.603096259525046e-06
exhibit O 0 1.2407032556893682e-07
smaller O 0 4.512532569833638e-08
and O 0 4.661213637291439e-08
slower O 0 1.4944359350010927e-07
Ca2 O 0 7.653765976556315e-08
+ O 0 4.237070783119634e-08
responses O 0 5.006705272592171e-09
upon O 0 1.3108344631973523e-08
triggering O 0 2.528551057423556e-08
by O 0 1.8814183544435537e-09
acetylcholine O 0 2.41166500103418e-08
or O 0 7.413358815711035e-09
high O 0 9.178827298228498e-08
external O 0 4.024377062705753e-07
K O 0 6.921210911059461e-07
+ O 0 3.1198348438010726e-07
. O 0 4.244423621457827e-07

In O 0 1.8958414216285746e-07
addition O 0 2.4254395825096253e-08
, O 0 5.082281262502875e-09
we O 0 1.7392973727936578e-09
observed O 0 1.0562317687146106e-09
that O 0 7.27282192802825e-11
these O 0 6.582605016625109e-10
Ca2 O 0 1.6865190133330543e-08
+ O 0 1.2548218819574686e-07
transients O 0 1.427233229378544e-07
partially O 0 1.1883448003402464e-08
result O 0 2.6217288340291134e-09
from O 0 3.9769709747616844e-10
an O 0 8.436169818271111e-11
influx O 0 1.6077866815678021e-09
of O 0 8.7387048708365e-09
extracellular O 0 3.0480780566222165e-08
Ca2 O 0 3.4951252558812484e-08
+ O 0 1.8016807601384244e-08
through O 0 1.4441300377754374e-09
the O 0 3.5942187004422976e-09
l O 0 2.7052365680901858e-08
- O 0 3.165480322309122e-09
type O 0 5.011080883576824e-09
Ca2 O 0 4.067715764222157e-08
+ O 0 8.969347220499913e-08
channel O 0 1.4507601520108437e-07
. O 0 3.5849882351612905e-07

Neither O 0 2.838829914253438e-06
the O 0 5.640413291985169e-08
content O 0 1.7102994576134734e-08
nor O 0 3.4299169726637047e-08
the O 0 4.236786033118278e-09
activity O 0 5.723554519221352e-09
of O 0 2.662046583168376e-08
Na O 0 8.786540206529025e-07
+ O 0 3.184971433256578e-07
/ O 0 2.9081198249514273e-07
K O 0 4.807929485650675e-07
+ O 0 2.952136526346294e-07
ATPase O 0 1.8405955870548496e-06
and O 0 1.0335871536426566e-07
sarcoplasmic O 0 1.5190789781627245e-06
reticulum O 0 5.436154424387496e-07
Ca2 O 0 1.1094997489635716e-06
+ O 0 1.0760420536826132e-06
- O 0 2.1707506903112517e-07
ATPase O 0 1.8687163105823856e-07
are O 0 8.149093622122905e-10
affected O 0 4.7573540662426694e-09
by O 0 5.206020059489447e-09
DMPK O 0 4.2432417103555053e-05
absence O 0 9.918621799442917e-06
. O 0 4.847944637731416e-06

In O 0 2.760575057436654e-07
conclusion O 0 7.921294695734105e-07
, O 0 1.3074910043542332e-08
our O 0 1.042072739210198e-08
data O 0 2.46446529850175e-09
suggest O 0 1.3022611877744339e-09
that O 0 4.816845811106418e-10
DMPK O 0 6.398852860911575e-07
is O 0 6.553890763427717e-10
involved O 0 1.598491117249523e-09
in O 0 1.419432460458836e-09
modulating O 0 6.644204830763556e-08
the O 0 5.570413907918237e-09
initial O 0 6.087336856808179e-09
events O 0 6.851895939519181e-09
of O 0 3.882996324477972e-08
excitation O 0 6.910370575496927e-05
- O 0 8.317077117681038e-06
contraction O 0 6.73893154612415e-08
coupling O 0 7.07006222455675e-08
in O 0 2.086994754790794e-08
skeletal O 0 1.0022166861745063e-05
muscle O 0 4.5009710447629914e-07
. O 0 1.9783674076734314e-07
. O 0 1.55609404828283e-06

Constitutional O 0 0.001536292489618063
RB1 O 1 0.7870762348175049
- O 0 0.00011175937834195793
gene O 0 1.0109930315138627e-07
mutations O 0 7.71566419643932e-08
in O 0 7.50661399706587e-09
patients O 0 6.007805364305341e-09
with O 0 5.888840082235447e-09
isolated O 0 4.4874360582980444e-07
unilateral B-Disease 0 3.6651214031735435e-05
retinoblastoma I-Disease 1 0.9999942779541016
. O 0 0.0008764955564402044

In O 0 1.3174710034036252e-07
most O 0 5.72711433832751e-09
patients O 0 1.813609262768523e-09
with O 0 3.6910280387658645e-10
isolated O 0 2.97461415499356e-08
unilateral B-Disease 0 4.1383732423128095e-06
retinoblastoma I-Disease 1 0.9999799728393555
, O 0 6.29535961138572e-08
tumor B-Disease 0 1.8398005749986623e-06
development O 0 7.982038852105688e-08
is O 0 3.9113207117580373e-10
initiated O 0 7.87325760143176e-09
by O 0 4.4850098634974245e-10
somatic O 0 2.1009014972150908e-08
inactivation O 0 6.940234698049608e-08
of O 0 4.8113761863533e-09
both O 0 2.955300004714445e-09
alleles O 0 3.849444141224012e-08
of O 0 5.675247649605808e-08
the O 0 1.8080672248288465e-07
RB1 O 0 4.445687591214664e-05
gene O 0 1.2966650047019357e-06
. O 0 4.307525159674697e-06

However O 0 9.794038078325684e-07
, O 0 2.2063710858333252e-08
some O 0 1.9335730794267647e-09
of O 0 6.184330825220741e-09
these O 0 1.925836379257362e-09
patients O 0 5.64006574776954e-09
can O 0 7.73733876968663e-09
transmit O 0 6.471231586147042e-07
retinoblastoma B-Disease 0 3.4854296245612204e-05
predisposition O 0 3.0227866432142037e-07
to O 0 2.09328572253753e-08
their O 0 6.780382477700186e-08
offspring O 0 5.943945211583923e-07
. O 0 9.071281965589151e-07

To O 0 4.465398717456992e-08
determine O 0 1.0727494270668103e-07
the O 0 1.0271171468900775e-08
frequency O 0 8.862316036584161e-08
and O 0 3.151058969308451e-09
nature O 0 1.3325823111642876e-08
of O 0 1.4441335238757347e-08
constitutional O 0 4.033447112306021e-06
RB1 O 0 0.000163882490596734
- O 0 4.876155230704171e-07
gene O 0 6.867360902163e-09
mutations O 0 6.00016747398513e-09
in O 0 7.063087337222385e-10
patients O 0 4.65895988455145e-10
with O 0 6.128305640729081e-10
isolated O 0 2.9162563919271633e-08
unilateral B-Disease 0 4.6951922172411287e-07
retinoblastoma I-Disease 0 0.004737812094390392
, O 0 1.897521251237322e-08
we O 0 8.42762215569337e-09
analyzed O 0 1.4200721487611645e-08
DNA O 0 1.2764894030681262e-08
from O 0 2.308955027174875e-09
peripheral O 0 1.7207645441885688e-07
blood O 0 8.454303923599582e-08
and O 0 5.926206725348493e-08
from O 0 2.744930682752056e-08
tumor B-Disease 0 8.517469723301474e-06
tissue O 0 1.3141851013642736e-05
. O 0 6.8236308834457304e-06

The O 0 3.5306203471918707e-07
analysis O 0 9.60044843623109e-08
of O 0 2.202766040682036e-07
tumors B-Disease 1 0.9999998807907104
from O 0 2.5439243600544614e-08
54 O 0 8.512359528367597e-08
( O 0 2.610436977690256e-09
71 O 0 1.6015619053177943e-08
% O 0 1.677755934181846e-09
) O 0 1.0552008156139436e-09
of O 0 1.5902415384516644e-08
76 O 0 1.7009180908189592e-07
informative O 0 1.2016653272439726e-07
patients O 0 3.902469902783423e-09
showed O 0 1.1342292438598633e-08
loss O 0 7.904845489292711e-08
of O 0 2.1484396484083845e-07
constitutional O 0 4.547889329842292e-05
heterozygosity O 0 0.007879654876887798
( O 0 1.967452135431813e-06
LOH O 0 0.0019426505314186215
) O 0 1.5048632917569194e-07
at O 0 1.593471210981079e-06
intragenic O 0 3.434360769460909e-05
loci O 0 1.939441790455021e-05
. O 0 1.551031346025411e-05

Three O 0 5.62804302717268e-07
of O 0 3.138360398224904e-07
13 O 0 1.8072413467962178e-06
uninformative O 0 0.00017726075020618737
patients O 0 1.5743722769911983e-07
had O 0 1.1044338776855511e-07
constitutional O 0 6.801599738537334e-06
deletions O 0 1.8520495359553024e-05
. O 0 6.273152848734753e-06

For O 0 1.1193623095095973e-06
39 O 0 1.5120128864509752e-06
randomly O 0 3.5157455613443744e-07
selected O 0 3.292307610536227e-06
tumors B-Disease 1 1.0
, O 0 8.689326591593272e-07
SSCP O 0 0.0015485236654058099
, O 0 6.093821980357461e-07
hetero O 0 1.9048382455366664e-05
- O 0 6.17057764884521e-07
duplex O 0 3.6734530795001774e-07
analysis O 0 4.0691960911942715e-09
, O 0 7.298519011378346e-10
sequencing O 0 2.0928814237208826e-09
, O 0 4.75110395470324e-10
and O 0 1.0829906971210335e-09
Southern O 0 8.971363207876948e-09
blot O 0 6.684116726773937e-08
analysis O 0 3.350908661658991e-09
were O 0 8.258987937992401e-10
used O 0 6.563886656429929e-10
to O 0 2.2591708503938435e-09
identify O 0 1.5181797152763465e-07
mutations O 0 2.7475712158775423e-06
. O 0 7.557467597507639e-06

Mutations O 0 2.0928598587488523e-06
were O 0 1.4781625168325263e-07
detected O 0 3.087815869662336e-08
in O 0 5.504309008586006e-09
21 O 0 1.150329183019494e-07
( O 0 5.166482353047286e-09
91 O 0 4.4720046332713537e-08
% O 0 3.670683756951121e-09
) O 0 2.5527302494054993e-09
of O 0 1.3937527398866223e-07
23 O 0 7.909149280749261e-05
tumors B-Disease 1 1.0
with O 0 9.774718637345359e-05
LOH O 1 0.9999979734420776
. O 0 4.4908672862220556e-05

In O 0 1.7004055052893818e-07
6 O 0 1.0425906111777294e-06
( O 0 7.200970042475774e-09
38 O 0 2.6214451054329402e-08
% O 0 2.051865122254526e-09
) O 0 3.8621137399275085e-09
of O 0 1.0197855715432524e-07
16 O 0 5.2792751375818625e-05
tumors B-Disease 1 1.0
without O 0 0.014277155511081219
LOH O 1 0.9997667670249939
, O 0 3.3422085099488186e-09
one O 0 8.939758378012641e-10
mutation O 0 1.0933411953573113e-09
was O 0 2.050425385036192e-09
detected O 0 1.2086197598293325e-09
, O 0 1.629284068771497e-10
and O 0 3.972732975920934e-10
in O 0 9.356464492071837e-10
9 O 0 7.880984043140415e-08
( O 0 1.893644352435331e-09
56 O 0 7.279434832696552e-09
% O 0 8.489862146632277e-10
) O 0 1.0264703531603914e-09
of O 0 1.650847991641058e-08
the O 0 3.117613118774898e-07
tumors B-Disease 1 1.0
without O 0 5.5671149311820045e-05
LOH O 0 0.3255617618560791
, O 0 2.4048427693657004e-09
both O 0 2.1980322006953656e-09
mutations O 0 3.440406715071731e-08
were O 0 3.4328291320662174e-08
found O 0 1.0817509377147871e-07
. O 0 1.3910811276218737e-06

Thus O 0 1.4361835383169819e-06
, O 0 1.6656436230277905e-08
a O 0 1.4603450670946927e-09
total O 0 7.718056194150336e-10
of O 0 2.6777602357697106e-09
45 O 0 4.100070505330677e-09
mutations O 0 4.988022883622989e-09
were O 0 1.8145998481600145e-08
identified O 0 8.587488764533191e-08
in O 0 9.027650804682708e-08
tumors B-Disease 1 1.0
of O 0 0.0003878124407492578
36 O 0 1.3879928701499011e-05
patients O 0 9.564960237185005e-07
. O 0 4.73594036520808e-06

Thirty O 0 3.339828981552273e-05
- O 0 2.0074623989785323e-06
nine O 0 9.81137233679874e-08
of O 0 1.7667018070710583e-08
the O 0 7.068670093701712e-09
mutations O 0 4.2567304348040125e-08
- O 0 2.7382112577356565e-08
including O 0 1.5721995927364674e-09
34 O 0 3.198943332449744e-08
small O 0 3.2865976606899494e-09
mutations O 0 3.721038055459758e-08
, O 0 7.200708473931172e-09
2 O 0 1.0021691565498259e-07
large O 0 1.821250350531045e-08
structural O 0 5.90407034906093e-06
alterations O 0 1.8128911278836313e-06
, O 0 1.1335415273094895e-08
and O 0 2.0667760836090565e-08
hypermethylation O 0 6.315393420663895e-06
in O 0 1.2473861943362863e-07
3 O 0 7.056877802824602e-05
tumors O 1 1.0
- O 0 1.794939635146875e-06
were O 0 1.6395889090858873e-08
not O 0 2.0371520026429835e-09
detected O 0 6.639768734828522e-09
in O 0 1.1119746234911076e-09
the O 0 7.279462366227563e-09
corresponding O 0 2.7110269584795788e-08
peripheral O 0 9.486544172432332e-07
blood O 0 1.807806881970464e-07
DNA O 0 5.314872737471887e-07
. O 0 6.725718435518502e-07

In O 0 3.0786893034928653e-07
6 O 0 1.3829568388246116e-06
( O 0 7.437620741512774e-09
17 O 0 1.4560403549523926e-08
% O 0 1.0069777234278376e-09
) O 0 4.218302096514748e-10
of O 0 2.635230034186975e-09
the O 0 6.6763803374669806e-09
36 O 0 5.994347418436519e-08
patients O 0 3.0210063339808357e-09
, O 0 1.1274711164688256e-09
a O 0 1.035531771442777e-09
mutation O 0 3.680744598000274e-09
was O 0 1.2237865831821182e-08
detected O 0 4.038669398909178e-09
in O 0 7.586089534328266e-10
constitutional O 0 4.967555611301577e-08
DNA O 0 1.0257956262194057e-08
, O 0 3.5461758529642395e-10
and O 0 3.4649735858316433e-10
1 O 0 4.990220681122537e-09
of O 0 9.962544122998906e-10
these O 0 2.356663753033672e-10
mutations O 0 1.5254857377300368e-09
is O 0 9.195759431701589e-11
known O 0 3.638200574140882e-10
to O 0 3.433788531292947e-10
be O 0 3.3522702391763914e-09
associated O 0 2.3999042753075628e-08
with O 0 6.941661467863014e-09
reduced O 0 8.923682344175177e-07
expressivity O 0 0.00020349389524199069
. O 0 4.008070391137153e-06

The O 0 2.227739201998702e-07
presence O 0 1.5732084079900233e-08
of O 0 2.8373465355002736e-08
a O 0 7.392010559215123e-09
constitutional O 0 2.1160552421406464e-07
mutation O 0 1.6334832153575007e-08
was O 0 4.364144601254338e-09
not O 0 2.677968402586828e-10
associated O 0 1.7165832089105493e-09
with O 0 6.705228039471933e-11
an O 0 1.1700315716289822e-10
early O 0 1.4162068850964715e-08
age O 0 1.1177979786225478e-07
at O 0 2.425329057587078e-07
treatment O 0 2.2703734714468737e-07
. O 0 1.022010792439687e-06

In O 0 3.496152771731431e-07
1 O 0 1.3610488167614676e-06
patient O 0 1.0886829215905891e-07
, O 0 1.292874607372596e-08
somatic O 0 1.564156718814047e-06
mosaicism O 0 6.602744633710245e-06
was O 0 8.846221533076459e-08
demonstrated O 0 1.8614269237104963e-08
by O 0 6.540341601635191e-10
molecular O 0 9.882286988727174e-09
analysis O 0 1.6002116298707847e-09
of O 0 1.3326044712158591e-09
DNA O 0 6.303046973243909e-09
and O 0 4.703059275357191e-09
RNA O 0 2.8465560575341442e-08
from O 0 1.3779782648271066e-08
peripheral O 0 2.7097350994154112e-06
blood O 0 1.29691727579484e-06
. O 0 2.6879661163548008e-06

In O 0 4.730920579731901e-07
2 O 0 1.6436113128293073e-06
patients O 0 1.4769738321263048e-08
without O 0 5.718491014050642e-09
a O 0 4.572990874862626e-09
detectable O 0 2.3777205626629438e-07
mutation O 0 1.2154469430925019e-08
in O 0 2.7538229474544096e-09
peripheral O 0 5.325294409885828e-07
blood O 0 1.240698423998765e-07
, O 0 1.3480718763503319e-08
mosaicism O 0 2.679323415577528e-06
was O 0 3.267996362410486e-08
suggested O 0 3.262613734733577e-09
because O 0 7.373531785148657e-10
1 O 0 1.9953402485839433e-08
of O 0 7.493567544258894e-09
the O 0 1.0503280023499428e-08
patients O 0 7.439581395374262e-08
showed O 0 2.1411897250800394e-06
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 7.956077752169222e-08
the O 0 1.1243191266885333e-08
other O 0 4.809675990813389e-10
later O 0 1.4495895150901106e-08
developed O 0 1.0154823826269421e-07
bilateral B-Disease 0 3.3632502891123295e-05
retinoblastoma I-Disease 0 0.029142435640096664
. O 0 3.2764401112217456e-06

In O 0 1.5327962898936676e-07
conclusion O 0 1.1187860309291864e-06
, O 0 2.6100998695710587e-08
our O 0 2.8951021135981136e-08
results O 0 1.3283469435521056e-08
emphasize O 0 5.677193826159055e-09
that O 0 2.708445134835813e-10
the O 0 1.967171536776391e-09
manifestation O 0 5.563791205531743e-08
and O 0 5.584083417886632e-09
transmissibility O 0 6.480458409896528e-07
of O 0 2.3914008551173538e-08
retinoblastoma B-Disease 0 6.555397362717486e-07
depend O 0 1.3189375813738025e-08
on O 0 2.5578053453045868e-08
the O 0 2.46815323734495e-09
nature O 0 3.809670801047105e-09
of O 0 3.6827387805971057e-09
the O 0 2.373726548654531e-09
first O 0 2.9796265454962167e-09
mutation O 0 2.5573405615375577e-09
, O 0 3.428409223182882e-10
its O 0 3.088896638470118e-10
time O 0 3.4088492029127337e-09
in O 0 7.03420932612886e-10
development O 0 8.429262621234557e-09
, O 0 4.841531064947446e-10
and O 0 5.641160316649518e-10
the O 0 6.197824475862035e-10
number O 0 4.4240661134509196e-10
and O 0 2.7972521521313354e-10
types O 0 2.0954178392429412e-09
of O 0 9.904965736495797e-10
cells O 0 6.82499778914547e-10
that O 0 1.5968172617508714e-10
are O 0 2.799755427496109e-10
affected O 0 5.119456414348633e-09
. O 0 1.7292160592319306e-08
. O 0 5.80274445383111e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.999775230884552
the I-Disease 0 4.4864842493552715e-05
fifth I-Disease 0 1.2766180361722945e-06
component I-Disease 0 4.975700917952963e-08
of I-Disease 0 2.3546309790845044e-08
complement I-Disease 0 4.454858526514727e-08
in O 0 4.812635623352435e-08
man O 0 3.985308921983233e-06
. O 0 4.181755684840027e-06

I O 0 0.0020273553673177958
. O 0 4.14151800214313e-05

Clinical O 0 8.021686517167836e-05
, O 0 1.1604298322254181e-07
immunochemical O 0 4.3178074520255905e-06
, O 0 1.6198042018800152e-08
and O 0 1.9708906506821222e-08
family O 0 1.4586699847995988e-08
studies O 0 2.0470997696975246e-07
. O 0 7.387545224446512e-07

The O 0 2.5810209081100766e-07
first O 0 5.814921166802378e-08
recognized O 0 6.61393499967744e-08
human O 0 2.821002453856636e-07
kindred O 0 4.2079100239789113e-05
with O 0 9.756971621754928e-07
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9979954957962036
the I-Disease 0 9.704848707769997e-06
fifth I-Disease 0 6.95425342200906e-07
component I-Disease 0 1.692971274280808e-08
of I-Disease 0 3.7390378793134005e-08
complement I-Disease 0 8.260350625732826e-08
( O 0 4.533902497882991e-08
C5 O 0 0.00028228855808265507
) O 0 7.262391132911716e-09
is O 0 2.401675303076445e-09
described O 0 1.1685344958323185e-07
. O 0 1.2578210544234025e-06

The O 0 3.527046828821767e-06
proband O 0 8.253516716649756e-05
, O 0 5.475432729440399e-08
a O 0 2.744663696319094e-08
20 O 0 7.939947721524732e-08
- O 0 9.13521631673575e-08
year O 0 1.0343735645790275e-08
- O 0 1.923585699614705e-07
old O 0 4.0192372807723586e-07
black O 0 5.593296137362813e-08
female O 0 1.0619430668157293e-08
with O 0 1.3165448287111303e-08
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.38513725996017456
age O 0 0.00046365580055862665
11 O 0 8.313647299473814e-07
, O 0 8.972595111345072e-09
lacked O 0 1.2125547073082998e-06
serum O 0 3.229926903713931e-07
hemolytic O 0 6.679778380203061e-06
complement O 0 2.3992543063400262e-08
activity O 0 1.579275377139311e-08
, O 0 7.290046344365919e-10
even O 0 1.5183824197961826e-09
during O 0 4.66237821683535e-08
remission O 0 4.663739048282878e-07
. O 0 3.10749669552024e-07

C5 O 1 0.6691809892654419
was O 0 5.591755780187668e-06
undetectable O 0 2.3459579097107053e-06
in O 0 7.411365743337228e-09
her O 0 1.2619973954741681e-09
serum O 0 6.556332365903472e-09
by O 0 8.558783126666469e-10
both O 0 1.2873945465230463e-08
immunodiffusion O 0 6.058276539988583e-06
and O 0 2.79654074120117e-07
hemolytic O 0 0.21447567641735077
assays O 0 3.51121743733529e-05
. O 0 1.2859196431236342e-05

Other O 0 1.7871965241056387e-08
complement O 0 1.0409900497165836e-08
components O 0 1.9606622103651716e-08
were O 0 9.127879785353343e-09
normal O 0 6.938749130824817e-09
during O 0 3.994343966695624e-09
remission O 0 2.1078735201740528e-08
of O 0 5.989053697419422e-09
lupus O 0 9.821677622312563e-07
, O 0 9.315423987743543e-09
but O 0 3.8441026362079356e-08
C1 O 0 0.0003302801924291998
, O 0 1.1454129378307698e-07
C4 O 0 0.002035973360762
, O 0 2.4025057498988645e-08
C2 O 0 3.8583129935432225e-06
, O 0 7.809499713573587e-09
and O 0 3.231075496046287e-08
C3 O 0 0.00034393256646580994
levels O 0 1.968762262549717e-06
fell O 0 7.326467311941087e-06
during O 0 7.01139015291119e-07
exacerbations O 0 9.169532131636515e-05
. O 0 3.6890160117764026e-06

A O 0 1.5189651094260626e-05
younger O 0 1.3781282177660614e-05
half O 0 6.691514613521576e-07
- O 0 3.6807507513003657e-06
sister O 0 3.323889075090847e-07
, O 0 8.775751680900612e-09
who O 0 4.192604485808715e-09
had O 0 1.3315431424132385e-08
no O 0 4.620734017635186e-08
underlying O 0 0.39121806621551514
disease O 0 9.766742732608691e-05
, O 0 3.1926694621375873e-09
was O 0 7.272304713978883e-08
also O 0 1.934244542312058e-09
found O 0 1.9271666484854677e-09
to O 0 6.672981278654788e-09
lack O 0 1.9633232568594394e-06
immunochemically O 0 0.0001841833145590499
detectable O 0 0.002672328380867839
C5 O 1 0.5768892765045166
. O 0 9.634799425839446e-06

By O 0 2.8226834274391877e-06
hemolytic O 1 0.5091326832771301
assay O 0 1.012317261483986e-05
, O 0 3.382284319286555e-08
she O 0 2.9827256220471554e-09
exhibited O 0 1.3556524791624724e-08
1 O 0 1.2298897900109296e-07
- O 0 3.7977233802166666e-08
2 O 0 2.7211134678850613e-08
% O 0 5.409035996883915e-10
of O 0 3.1035320979810876e-09
the O 0 8.520591343597061e-09
normal O 0 5.1943985113211966e-08
serum O 0 9.213978557909286e-08
C5 O 0 8.320267625094857e-06
level O 0 1.9242645521444501e-07
and O 0 1.3133915066632085e-09
normal O 0 1.7115810990731006e-09
concentrations O 0 1.956555584214925e-09
of O 0 1.6006054259776192e-09
other O 0 7.834784487847912e-10
complement O 0 1.0562444252570913e-08
components O 0 1.4073215481857915e-07
. O 0 5.449500122267636e-07

C5 O 0 0.0007671315688639879
levels O 0 8.018643598006747e-07
of O 0 9.491713370834987e-08
other O 0 1.970322127675672e-09
family O 0 1.6642963673874078e-09
members O 0 3.3267330556974173e-10
were O 0 2.861901382544829e-09
either O 0 4.552539678570611e-09
normal O 0 5.265501457074606e-08
or O 0 2.736053827945284e-09
approximately O 0 1.4748449128632046e-09
half O 0 3.6442378004153397e-09
- O 0 6.567220989239786e-09
normal O 0 6.9175536410170935e-09
, O 0 4.0063360962072636e-10
consistent O 0 5.109242806611292e-09
with O 0 5.690004578617902e-10
autosomal O 0 2.4796875663923856e-07
codominant O 0 3.469868659067288e-07
inheritance O 0 4.140363785154477e-08
of O 0 8.590384403817097e-09
the O 0 1.746778721667397e-08
gene O 0 2.2432745083733607e-07
determining O 0 5.5581924243597314e-05
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0002030550967901945

Normal O 0 0.0002455585927236825
hemolytic O 1 0.7454180717468262
titers O 0 5.7698511227499694e-05
were O 0 7.701505921886564e-08
restored O 0 8.613407231905512e-08
to O 0 1.6750030251699854e-09
both O 0 1.712581365609367e-08
homozygous O 0 3.138305328320712e-05
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 6.794001365051372e-06
C5D B-Disease 1 1.0
) O 0 1.850237829614798e-08
sera O 0 1.4741867460088542e-07
by O 0 2.603787185861961e-10
addition O 0 1.2296681450862934e-09
of O 0 6.844908195802191e-09
highly O 0 1.173604857740429e-07
purified O 0 4.669676343382889e-07
human O 0 1.3365413451538188e-06
C5 O 0 0.055647727102041245
. O 0 1.0030094017565716e-05

In O 0 6.75923104154208e-07
specific O 0 1.0812832442752551e-06
C5 O 0 0.1533653736114502
titrations O 0 1.1046841791539919e-05
, O 0 6.912119321356158e-09
however O 0 6.464949464657366e-09
, O 0 5.38051325715827e-10
it O 0 7.923022654621192e-11
was O 0 1.6411054737375252e-09
noted O 0 4.0714606686087507e-10
that O 0 8.760440983746065e-11
when O 0 2.904230467226654e-10
limited O 0 5.556732851630386e-10
amounts O 0 1.8891133102272306e-09
of O 0 2.5190773911276665e-08
C5 O 0 1.62485521286726e-05
were O 0 2.745658633784842e-08
assayed O 0 1.3215785088505072e-07
in O 0 8.853555111265621e-10
the O 0 9.834258962726494e-10
presence O 0 1.084754175373348e-09
of O 0 5.360746069271727e-09
low O 0 1.3561391654093313e-07
dilutions O 0 1.3176422726246528e-06
of O 0 4.6567524947249694e-08
either O 0 5.279379706735199e-07
C5D B-Disease 1 1.0
serum O 0 8.853824056131998e-07
, O 0 8.6081479722111e-09
curving O 0 5.1084466434758724e-08
rather O 0 3.4921314728819652e-09
than O 0 7.489533992988129e-10
linear O 0 2.7390990808839888e-08
dose O 0 3.076869248275216e-08
- O 0 4.111598173039965e-09
response O 0 3.870149201112838e-10
plots O 0 5.732917696121831e-09
were O 0 1.543385308444556e-09
consistently O 0 4.114893314977053e-09
obtained O 0 4.319558044585392e-09
, O 0 4.612205617426923e-10
suggesting O 0 2.9022881875562234e-09
some O 0 7.747761321397206e-10
inhibitory O 0 8.840689247335831e-08
effect O 0 2.457728669469361e-07
. O 0 6.378515990945743e-07

Further O 0 3.9614104707652587e-07
studies O 0 3.076070953511589e-08
suggested O 0 1.340569255603441e-08
that O 0 1.6744408082303153e-09
low O 0 1.912655989144696e-07
dilutions O 0 2.180389128625393e-05
of O 0 1.8379819266556296e-06
C5D B-Disease 1 1.0
serum O 0 9.906541720283712e-08
contain O 0 2.2662225429570526e-09
a O 0 7.565542636811529e-10
factor O 0 3.4387583891515305e-09
( O 0 2.802373333388175e-10
or O 0 5.682174175625221e-10
factors O 0 4.3843351171801714e-09
) O 0 1.0030614117084724e-09
interfering O 0 1.1007174727239999e-08
at O 0 1.2173935637349587e-08
some O 0 3.0506980275291085e-10
step O 0 1.560239226705562e-08
in O 0 2.8131605933623405e-09
the O 0 1.902899704475658e-08
hemolytic O 0 5.9569643781287596e-05
assay O 0 1.8188345620728796e-06
of O 0 1.5215816802083282e-06
C5 O 1 0.9429076313972473
, O 0 6.565517907120011e-09
rather O 0 4.927917629515832e-09
than O 0 8.920290062164327e-10
a O 0 3.628998879179335e-09
true O 0 2.105687855191718e-07
C5 O 0 0.0002037816448137164
inhibitor O 0 3.5091441077383934e-06
or O 0 2.4423076183666126e-07
inactivator O 0 1.1279069440206513e-05
. O 0 2.7162654987478163e-06

Of O 0 1.5718188706159708e-06
clinical O 0 6.194537490955554e-06
interest O 0 7.465209961310393e-08
are O 0 4.156725186277299e-09
( O 0 1.5245142925834898e-09
a O 0 8.171818777213957e-10
) O 0 2.367061269215043e-10
the O 0 7.870551432809236e-10
documentation O 0 2.2851310177429696e-08
of O 0 5.8483117015839525e-08
membranous O 1 0.9999958276748657
glomerulonephritis B-Disease 1 1.0
, O 0 0.0002956108364742249
vasculitis B-Disease 1 1.0
, O 0 1.4821212971583009e-05
and O 0 0.0011973936343565583
arthritis B-Disease 1 1.0
in O 0 2.669508774033602e-07
an O 0 2.9154150205101814e-09
individual O 0 1.0436382424927615e-08
lacking O 0 0.0002499402326066047
C5 O 1 0.9994012117385864
( O 0 5.676933589882083e-09
and O 0 1.310118902253521e-09
its O 0 6.930783169600829e-10
biologic O 0 3.2959778906160864e-08
functions O 0 3.2873874733496677e-09
) O 0 2.468655835308198e-10
, O 0 2.1185887766339562e-10
and O 0 9.011901225264296e-10
( O 0 1.4955123806004167e-09
b O 0 2.315156422127984e-08
) O 0 6.387140816244141e-10
a O 0 6.881032410532839e-10
remarkable O 0 5.780151912659903e-09
propensity O 0 4.4224002238024696e-08
to O 0 1.0913957737557212e-08
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 1.2807864990804774e-08
the O 0 9.702742609363213e-09
proband O 0 2.0619809504296427e-07
, O 0 2.8911925631369684e-10
even O 0 1.9500982773035247e-10
during O 0 1.4881256227283757e-09
periods O 0 3.996919684112754e-09
of O 0 1.318466558153375e-09
low O 0 1.648321479308379e-08
- O 0 3.0893576585810933e-09
dose O 0 1.0977863951211475e-08
or O 0 3.5607157222727892e-09
alternate O 0 1.2641451974104712e-07
- O 0 1.336213557578958e-07
day O 0 5.972162142597881e-08
corticosteroid O 0 4.637837719201343e-06
therapy O 0 1.5944563074299367e-06
. O 0 6.224752837624692e-07

Other O 0 7.831878434672035e-08
observations O 0 7.128191015226548e-08
indicate O 0 6.585333167663521e-09
that O 0 8.875790102891301e-10
the O 0 8.951910324128676e-09
C5D B-Disease 1 0.9999998807907104
state O 0 2.6639754846513597e-09
is O 0 2.5681615167805205e-10
compatible O 0 1.579576647259273e-08
with O 0 4.2763867447170867e-10
normal O 0 5.598693952890699e-09
coagulation O 0 1.372731706084096e-08
function O 0 9.069326623034613e-09
and O 0 1.069298205536029e-09
the O 0 8.175435328716674e-10
capacity O 0 6.566081012238101e-09
to O 0 1.3225972539387953e-09
mount O 0 5.723458116335678e-07
a O 0 2.0879470241652598e-07
neutrophilic O 0 0.013714692555367947
leukocytosis O 0 0.0004775289271492511
during O 0 2.9199802611401537e-06
pyogenic B-Disease 0 8.644241461297497e-05
infection I-Disease 0 3.930900220439071e-06
. O 0 2.3541781501990044e-07
. O 0 2.252489366583177e-06

Susceptibility O 0 0.00769296707585454
to O 0 0.00016322173178195953
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 5.901429176446982e-05
twins O 0 5.439294454845367e-06
: O 0 1.3659716691094559e-09
the O 0 1.0166054664750845e-09
role O 0 1.959520989913699e-09
of O 0 4.156059496551734e-09
genes O 0 4.723502478043429e-09
, O 0 4.855710944440261e-09
HLA O 0 4.847108243666298e-07
, O 0 6.404064389897712e-09
and O 0 1.7793835738189046e-08
the O 0 1.4618932198118273e-07
environment O 0 2.096293655995396e-06
. O 0 2.0793954718101304e-06

OBJECTIVE O 0 5.169943506189156e-06
To O 0 1.2906644641930143e-08
determine O 0 2.8154703457516916e-08
the O 0 1.5649653795080098e-09
relative O 0 5.4714867303573556e-08
effects O 0 3.748117194390943e-07
of O 0 3.1305727787867e-08
genetic O 0 3.8229494236929895e-08
and O 0 1.4238007439715261e-09
environmental O 0 3.7000873476245033e-09
factors O 0 3.30636562573261e-09
in O 0 7.885171404709013e-10
susceptibility O 0 9.041571047418984e-07
to O 0 2.9412651656457456e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 4.307508788770065e-06
AS B-Disease 1 0.9999796152114868
) O 0 2.5705947592769007e-08
. O 0 2.694484919629758e-07

METHODS O 0 6.992482667556033e-05
Twins O 0 1.3611211215902586e-05
with O 0 3.622822708493345e-09
AS B-Disease 1 0.9908580183982849
were O 0 4.325700242446828e-09
identified O 0 1.311323938324449e-09
from O 0 1.8620073538588855e-10
the O 0 2.0125008326488114e-09
Royal O 0 5.696263656318479e-07
National O 0 6.10381812293781e-06
Hospital O 0 2.6922993129119277e-05
for O 0 1.3698134182504873e-07
Rheumatic B-Disease 1 0.999998927116394
Diseases I-Disease 1 0.9999990463256836
database O 0 2.0291934106353438e-06
. O 0 8.10772689874284e-06

Clinical O 0 3.102649498032406e-05
and O 0 1.1630522323002879e-07
radiographic O 0 4.529716079559876e-06
examinations O 0 2.823725480993744e-06
were O 0 1.2933555559868637e-08
performed O 0 9.898921682349737e-10
to O 0 5.272531300448691e-10
establish O 0 1.9802582684746994e-08
diagnoses O 0 9.260963452106807e-06
, O 0 2.1375381464849852e-08
and O 0 2.3611077892837784e-07
disease O 0 0.0016478582983836532
severity O 0 9.986131772166118e-06
was O 0 1.2622911071957787e-07
assessed O 0 2.3153859274316346e-08
using O 0 1.6176759931596507e-09
a O 0 7.26130655603896e-10
combination O 0 7.976480809190889e-09
of O 0 1.957314488265638e-08
validated O 0 2.372791385596429e-07
scoring O 0 2.1080667522710428e-07
systems O 0 1.1052489981011604e-06
. O 0 8.409952556576172e-07

HLA O 0 0.00036784561234526336
typing O 0 9.399261216458399e-06
for O 0 2.428814980248717e-07
HLA O 0 6.313448466244154e-06
- O 0 4.74176545139926e-07
B27 O 0 7.622050475220021e-07
, O 0 1.6501207511510074e-08
HLA O 0 5.143271550878126e-07
- O 0 4.498447836454034e-08
B60 O 0 1.1740570471374667e-07
, O 0 2.206046012531715e-09
and O 0 1.3432311263272823e-08
HLA O 0 1.7128839999713819e-06
- O 0 3.2769290214673674e-07
DR1 O 0 2.0464296540012583e-05
was O 0 3.746633581158676e-08
performed O 0 2.062569226524147e-09
by O 0 1.86195503459885e-09
polymerase O 0 2.8396637929972712e-08
chain O 0 9.882079154976964e-09
reaction O 0 7.172403115873749e-09
with O 0 2.120546627182307e-09
sequence O 0 1.8266462120664073e-08
- O 0 9.107758991433457e-09
specific O 0 1.2182315156650247e-09
primers O 0 4.985637858112568e-08
, O 0 7.458983430908006e-10
and O 0 2.374274332694881e-09
zygosity O 0 3.011889191384398e-07
was O 0 2.8515936278949994e-08
assessed O 0 7.695778236893602e-08
using O 0 1.689526030190791e-08
microsatellite O 0 3.1041784041008214e-06
markers O 0 3.939303041988751e-06
. O 0 4.99504130857531e-06

Genetic O 0 1.0613390259095468e-05
and O 0 8.008757390598475e-08
environmental O 0 5.6575874651798586e-08
variance O 0 2.774041796271831e-08
components O 0 5.8903935951093445e-08
were O 0 1.6760743903887487e-08
assessed O 0 4.8395236262877006e-08
with O 0 2.942092958146958e-10
the O 0 1.985468900400633e-09
program O 0 3.5557476962821966e-09
Mx O 0 4.182359418791748e-07
, O 0 3.120727010141877e-10
using O 0 2.277665972494347e-10
data O 0 3.0558694463778124e-10
from O 0 2.3213210867401024e-11
this O 0 3.686276978109859e-11
and O 0 1.404565491691656e-10
previous O 0 8.60835625005052e-10
studies O 0 1.3177626767557626e-09
of O 0 2.6752489112880085e-09
twins O 0 1.3757308181538974e-07
with O 0 5.029868521688741e-09
AS B-Disease 1 0.9999685287475586
. O 0 3.210880777260172e-06

RESULTS O 0 1.4291225852502976e-05
Six O 0 9.448756941310421e-07
of O 0 1.6562827909183397e-07
8 O 0 9.290510206483305e-06
monozygotic O 0 0.00027982896426692605
( O 0 3.154100625124556e-07
MZ O 1 0.604944109916687
) O 0 4.791066743337069e-08
twin O 0 1.8552117353465292e-06
pairs O 0 6.852395983969473e-08
were O 0 5.528210635930009e-07
disease O 0 7.939527131384239e-05
concordant O 0 1.018408056552289e-05
, O 0 1.1929139454025517e-08
compared O 0 3.462940156850891e-09
with O 0 6.08377070943078e-10
4 O 0 6.56033805057632e-08
of O 0 2.0772649378386632e-08
15 O 0 5.8104088651589336e-08
B27 O 0 3.953126679334673e-07
- O 0 5.2243457560052775e-08
positive O 0 2.5839655748427504e-08
dizygotic O 0 4.460744094103575e-06
( O 0 3.2409200656502435e-08
DZ O 0 4.228216766932746e-06
) O 0 1.6989913476095353e-08
twin O 0 1.8151473568650545e-07
pairs O 0 5.864651431153334e-09
( O 0 4.6430210787207216e-09
27 O 0 3.547403792936166e-08
% O 0 1.7045246325508856e-09
) O 0 8.304464893527097e-10
and O 0 4.633616601523727e-09
4 O 0 1.7539406371724908e-07
of O 0 2.547408826103492e-07
32 O 0 7.72216390032554e-06
DZ O 0 0.0004421263583935797
twin O 0 2.308094508407521e-06
pairs O 0 8.44181258230492e-09
overall O 0 4.82395847711814e-08
( O 0 2.3738759846736457e-09
12 O 0 1.3745316884694603e-08
. O 0 1.2984912034497142e-09
5 O 0 1.4369376799550082e-08
% O 0 2.56790810837515e-09
) O 0 5.666862090691893e-09
. O 0 5.528833071366535e-07

Nonsignificant O 0 0.00010057809413410723
increases O 0 1.0700458119572431e-07
in O 0 3.574488260937869e-09
similarity O 0 1.1912382191781035e-08
with O 0 4.163769606879697e-10
regard O 0 2.932615039696884e-09
to O 0 7.170293248037751e-10
age O 0 1.9236939863276348e-07
at O 0 7.411643991872552e-07
disease O 0 3.7405109765131783e-07
onset O 0 3.3477869010312133e-07
and O 0 2.351066452632722e-09
all O 0 7.353854192260201e-10
of O 0 2.2880954908544027e-09
the O 0 4.377249673837014e-09
disease O 0 4.794467400870417e-08
severity O 0 3.9097429294088215e-08
scores O 0 1.8133645696138956e-08
assessed O 0 3.833237016692692e-08
were O 0 5.413063774994953e-09
noted O 0 1.2982838804020957e-08
in O 0 2.8755271941349747e-08
disease O 0 0.00022435796563513577
- O 0 4.5964483433635905e-05
concordant O 0 0.004084187094122171
MZ O 1 0.9999936819076538
twins O 0 8.3716913650278e-06
compared O 0 7.083465902724129e-08
with O 0 4.2049720150316716e-08
concordant O 0 0.00022543675731867552
DZ O 0 0.07831160724163055
twins O 0 0.00010025015217252076
. O 0 6.985226718825288e-06

HLA O 0 0.0009561276528984308
- O 0 9.89279396890197e-06
B27 O 0 1.1392439773771912e-06
and O 0 1.39846410007749e-08
B60 O 0 2.135313650342141e-07
were O 0 4.815149168280186e-09
associated O 0 8.544548180111633e-09
with O 0 5.842497041719241e-10
the O 0 1.2749661770783405e-08
disease O 0 1.7282046371747128e-07
in O 0 4.0211136642653855e-09
probands O 0 3.936339908250375e-06
, O 0 5.271175940180228e-09
and O 0 2.419800804176475e-09
the O 0 3.830392003578709e-09
rate O 0 1.6656500179124123e-08
of O 0 9.012678603426139e-09
disease O 0 7.384348066352686e-08
concordance O 0 3.124738512383374e-08
was O 0 1.0319713972251066e-08
significantly O 0 3.970705098055305e-09
increased O 0 1.1054007487132367e-08
among O 0 5.048940820984171e-08
DZ O 0 2.2902266209712252e-05
twin O 0 5.826983624501736e-07
pairs O 0 2.8778026628373254e-09
in O 0 1.7559976805969768e-09
which O 0 2.2977522107225923e-09
the O 0 2.5195099340180604e-08
co O 0 4.3414405581643223e-07
- O 0 9.451644444880003e-08
twin O 0 1.2027935269998125e-07
was O 0 1.0950761186734326e-08
positive O 0 8.069331314253247e-10
for O 0 9.220510466256826e-10
both O 0 1.4174283968770851e-08
B27 O 0 1.6195297121157637e-06
and O 0 4.7468603270317544e-07
DR1 O 0 0.0015294207260012627
. O 0 8.564867130189668e-06

Additive O 0 4.305151378503069e-06
genetic O 0 3.035144118257449e-07
effects O 0 2.0514089271728153e-07
were O 0 1.3980720581230344e-08
estimated O 0 1.5852893442414029e-09
to O 0 3.198348252908545e-10
contribute O 0 1.340967670238058e-09
97 O 0 1.3823402866819379e-08
% O 0 2.851171798656793e-10
of O 0 5.694597016159264e-10
the O 0 7.512511168705771e-10
population O 0 9.178674487131389e-11
variance O 0 1.3935141929266592e-08
. O 0 1.4375686419043632e-07

CONCLUSION O 0 7.825829925423022e-06
Susceptibility O 0 2.6185450678894995e-06
to O 0 4.880337201029761e-08
AS B-Disease 1 0.9999964237213135
is O 0 2.3079202993159242e-09
largely O 0 4.5047303665057825e-09
genetically O 0 2.750972560860987e-09
determined O 0 3.5311618518107935e-08
, O 0 4.088520633160897e-09
and O 0 9.813746260078915e-09
the O 0 1.3974055690368914e-08
environmental O 0 2.5908450496103796e-08
trigger O 0 6.423419307566292e-08
for O 0 4.859574520565957e-09
the O 0 1.5334073566464212e-07
disease O 0 3.360336677360465e-06
is O 0 1.2155553230641658e-09
probably O 0 2.778606322806354e-08
ubiquitous O 0 2.4831805944813823e-07
. O 0 5.700236442862661e-07

HLA O 0 0.001536775380373001
- O 0 1.2493650501710363e-05
B27 O 0 1.3605803133032168e-06
accounts O 0 3.1037630243702097e-09
for O 0 8.005801577226634e-10
a O 0 8.799280193372283e-10
minority O 0 1.508328906218992e-09
of O 0 3.889228050724114e-09
the O 0 3.666198900020845e-09
overall O 0 1.5620436499830248e-08
genetic O 0 1.3878749705042992e-08
susceptibility O 0 3.4642898327774674e-08
to O 0 3.324617381395001e-08
AS B-Disease 1 1.0
. O 0 4.86657845613081e-05

Cell O 0 0.0002123203594237566
cycle O 0 6.359653525578324e-06
- O 0 6.594599426534842e-07
dependent O 0 1.706058299077995e-07
colocalization O 0 2.0258521544747055e-06
of O 0 1.8911012489297718e-07
BARD1 O 0 3.747456503333524e-05
and O 0 9.854509386286736e-08
BRCA1 O 0 5.3786308740200184e-08
proteins O 0 1.8703980586565194e-09
in O 0 3.989136132531712e-09
discrete O 0 2.461693213717808e-07
nuclear O 0 1.685969550635491e-06
domains O 0 3.648298616099055e-06
. O 0 3.485230990918353e-06

Germ O 0 0.002633491763845086
- O 0 0.00011170525976922363
line O 0 8.501146453454567e-07
mutations O 0 1.214038718444499e-07
of O 0 1.060890681969795e-07
the O 0 1.3356211070458812e-07
BRCA1 O 0 3.1335602557192033e-07
gene O 0 4.8251912687646836e-08
predispose O 0 2.1198344768436073e-07
women O 0 8.851973376522437e-09
to O 0 2.0627504149217657e-09
early O 0 7.921490032458678e-05
- O 1 0.9999476671218872
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 3.246706910431385e-06
compromising O 0 1.1716511835402343e-05
the O 0 5.925291191033466e-08
genes O 0 6.6538912157909635e-09
presumptive O 0 2.5249394752790977e-07
function O 0 7.740943885892193e-08
as O 0 6.7653300739323186e-09
a O 0 1.5759473726006945e-08
tumor B-Disease 0 1.9650522062875098e-06
suppressor O 0 2.107116779370699e-05
. O 0 7.526776698796311e-06

Although O 0 3.6264512459638354e-07
the O 0 8.66260378984407e-08
biochemical O 0 3.9960073650036065e-07
properties O 0 4.861023512603424e-07
of O 0 2.269951266953285e-07
BRCA1 O 0 8.613210411567707e-08
polypeptides O 0 2.4728290526354613e-08
are O 0 3.1434518876771733e-10
not O 0 2.1220182555570233e-10
understood O 0 6.424764720236453e-09
, O 0 3.2879879374725363e-10
their O 0 4.700473898999746e-10
expression O 0 6.756071257996155e-09
pattern O 0 4.688712706979459e-08
and O 0 1.153869977343902e-08
subcellular O 0 8.575260039833665e-07
localization O 0 1.577083253323508e-06
suggest O 0 2.619795758107557e-08
a O 0 5.046714157685983e-09
role O 0 3.0384132543304077e-08
in O 0 4.855241186874082e-08
cell O 0 2.4979375666589476e-05
- O 0 6.783423032175051e-06
cycle O 0 1.276030161534436e-06
regulation O 0 3.441182570895762e-06
. O 0 1.3427569456325728e-06

When O 0 4.3939080569543876e-06
resting O 0 1.421512115484802e-05
cells O 0 1.6883349474028364e-07
are O 0 2.9562696735041527e-09
induced O 0 3.269941828420997e-08
to O 0 1.0587752896640268e-09
proliferate O 0 6.124536611196163e-08
, O 0 2.9974396298371175e-09
the O 0 1.1105529829080751e-08
steady O 0 5.049672680002004e-08
- O 0 5.764792643248029e-09
state O 0 2.658968600854905e-10
levels O 0 3.145630422807244e-09
of O 0 1.868216026323921e-09
BRCA1 O 0 3.563406236750666e-09
increase O 0 4.810409848232666e-10
in O 0 9.819977053737716e-10
late O 0 3.826269221463008e-07
G1 O 0 1.2580994734889828e-06
and O 0 1.4033666451140903e-09
reach O 0 9.549146362530792e-09
a O 0 1.102259061802613e-09
maximum O 0 5.294909399822245e-08
during O 0 6.768623705966093e-08
S O 0 1.6403041627199855e-06
phase O 0 9.18823843676364e-06
. O 0 2.429316054985975e-06

Moreover O 0 3.46602291756426e-06
, O 0 6.027848797884872e-08
in O 0 2.285654154832173e-08
S O 0 9.223559231941181e-07
phase O 0 7.063490556902252e-06
cells O 0 5.959168092317668e-08
, O 0 5.8455098539411665e-09
BRCA1 O 0 4.132111897092727e-08
polypeptides O 0 1.8421600245233094e-08
are O 0 2.107345631330304e-09
hyperphosphorylated O 0 2.3598110487910162e-07
and O 0 5.209308095999177e-09
accumulate O 0 8.294780862172502e-09
into O 0 6.196196888907934e-09
discrete O 0 4.4974140678277763e-07
subnuclear O 0 1.4006230912855244e-06
foci O 0 6.56298016110668e-06
termed O 0 1.3925172197559732e-06
" O 0 1.3809615211357595e-06
BRCA1 O 0 4.351099960331339e-06
nuclear O 0 2.4786904759821482e-05
dots O 0 4.926970723317936e-05
. O 0 6.93035326548852e-06

" O 0 2.8208505682414398e-05
BRCA1 O 0 2.4261638827738352e-05
associates O 0 3.85286375603755e-06
in O 0 1.266679419131833e-07
vivo O 0 9.493892321188468e-07
with O 0 1.2397624260529483e-08
a O 0 8.160362341413929e-08
structurally O 0 7.451413239323301e-06
related O 0 1.0569805453997105e-05
protein O 0 1.9136688933940604e-05
termed O 0 5.48040188732557e-05
BARD1 O 0 0.0045168111100792885
. O 0 1.3255423255031928e-05

Here O 0 1.668725644776714e-06
we O 0 4.2625149632158355e-08
show O 0 4.3519503556410655e-09
that O 0 5.064387242903479e-10
the O 0 3.471014586864385e-09
steady O 0 3.601178377721226e-08
- O 0 6.6564682654757235e-09
state O 0 5.396721403094773e-10
levels O 0 1.2592954234946774e-08
of O 0 1.6500736776947633e-08
BARD1 O 0 3.878210918628611e-06
, O 0 1.0904567249170327e-09
unlike O 0 5.473986264270536e-10
those O 0 1.2046054431724684e-10
of O 0 6.777506333932592e-10
BRCA1 O 0 1.905441138205788e-09
, O 0 3.0223420988129135e-10
remain O 0 2.036922852610701e-09
relatively O 0 1.538148386437399e-09
constant O 0 1.4557627103783943e-08
during O 0 7.224386422421958e-08
cell O 0 2.2916838133824058e-06
cycle O 0 7.424080195050919e-07
progression O 0 3.2559876217419514e-06
. O 0 7.308603926503565e-07

However O 0 2.1083938008814584e-06
, O 0 9.41431039791496e-08
immunostaining O 0 4.874249043496093e-06
revealed O 0 3.9753791725161136e-07
that O 0 2.2684034206577053e-08
BARD1 O 0 1.8750084564089775e-05
resides O 0 2.412470792023669e-07
within O 0 8.859544919914697e-08
BRCA1 O 0 2.497823174962832e-07
nuclear O 0 1.94706944967038e-06
dots O 0 3.313852516839688e-07
during O 0 1.1413870026899531e-07
S O 0 3.925821090433601e-07
phase O 0 1.1369376125003328e-06
of O 0 2.8220938474987634e-08
the O 0 7.812017699393436e-09
cell O 0 2.16765734251112e-08
cycle O 0 1.000982075005652e-09
, O 0 3.052087402255488e-11
but O 0 8.594062961275739e-11
not O 0 1.495069484880318e-10
during O 0 2.952533773026289e-09
the O 0 1.7396565965555055e-08
G1 O 0 5.9979320212733e-06
phase O 0 3.7862635053897975e-06
. O 0 9.328919645668066e-07

Nevertheless O 0 1.9045837689191103e-05
, O 0 3.4115902280973387e-07
BARD1 O 0 1.161263480753405e-05
polypeptides O 0 1.1808169375626676e-07
are O 0 8.678603946599139e-10
found O 0 1.8587260619540302e-09
exclusively O 0 3.5214342553047118e-09
in O 0 1.464557142227818e-09
the O 0 3.6251732726810815e-09
nuclear O 0 9.544689305585052e-08
fractions O 0 1.01325554169307e-07
of O 0 3.266345061092579e-08
both O 0 3.1168813308113386e-08
G1 O 0 2.2845483726996463e-06
- O 0 5.121119173168154e-08
and O 0 1.3040266644281928e-08
S O 0 4.7356334675896505e-07
- O 0 2.165178614177421e-07
phase O 0 1.2445527772797504e-06
cells O 0 4.026757096653455e-07
. O 0 3.6518386536954495e-07

Therefore O 0 1.316675138696155e-06
, O 0 2.3029260276530295e-08
progression O 0 6.805362318118569e-08
to O 0 2.4277340138212367e-09
S O 0 1.8174580418417463e-07
phase O 0 2.985806304423022e-06
is O 0 7.36332828044084e-10
accompanied O 0 9.978252668574328e-10
by O 0 2.1580268128040814e-10
the O 0 7.208936225744367e-10
aggregation O 0 3.5396294784106885e-09
of O 0 3.3060123527661744e-09
nuclear O 0 2.248198285315084e-07
BARD1 O 0 1.1449631529103499e-05
polypeptides O 0 2.4303372470058093e-07
into O 0 3.9228901016485906e-08
BRCA1 O 0 7.565836881440191e-07
nuclear O 0 5.5925238484633155e-06
dots O 0 1.3907673746871296e-05
. O 0 4.8592341954645235e-06

This O 0 8.456494811071025e-07
cell O 0 3.998472493549343e-06
cycle O 0 5.24621441400086e-07
- O 0 1.664623283659239e-07
dependent O 0 5.2572225683888973e-08
colocalization O 0 8.636798156658188e-07
of O 0 1.1410921274546126e-07
BARD1 O 0 3.079650559811853e-05
and O 0 3.896439793038553e-08
BRCA1 O 0 8.053885380832071e-08
indicates O 0 1.3352003058741957e-08
a O 0 1.9811261520175094e-09
role O 0 6.636400318171809e-09
for O 0 6.953163378398131e-09
BARD1 O 0 6.8003278101969045e-06
in O 0 1.4488188071482e-07
BRCA1 O 0 1.3774095350527205e-05
- O 0 2.6977582820109092e-05
mediated O 0 4.3424181058071554e-05
tumor B-Disease 0 2.2054360670153983e-05
suppression O 0 0.00014143710723146796
. O 0 9.269084330298938e-06

Ethnic O 0 1.2382190561766038e-06
differences O 0 1.134419449044799e-06
in O 0 8.794137329459772e-08
the O 0 1.718891411428558e-07
HFE O 0 0.0001339538866886869
codon O 0 9.04164062376367e-06
282 O 0 4.408043878356693e-06
( O 0 4.7302211214628187e-07
Cys O 0 0.026278898119926453
/ O 0 0.00010969409777317196
Tyr O 0 0.00039678358007222414
) O 0 5.352763992050313e-07
polymorphism O 0 1.6775471522123553e-05
. O 0 5.5811005950090475e-06

Recent O 0 1.1109453623703303e-07
studies O 0 1.292314966150343e-08
have O 0 1.3977060620007364e-09
shown O 0 1.94136760001129e-08
that O 0 2.447056601795339e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.00020715613209176809
HH B-Disease 1 0.9999881982803345
) O 0 2.8021984732617966e-09
is O 0 2.4583654556487033e-10
likely O 0 1.6374941402830245e-09
to O 0 8.735250855984589e-10
be O 0 1.9241988002960397e-09
caused O 0 1.7974898014472274e-08
by O 0 2.7509148292637065e-09
homozygosity O 0 3.530125241013593e-07
for O 0 4.155694455221237e-09
a O 0 6.799611540486694e-09
Cys282Tyr O 0 7.633514655935869e-07
mutation O 0 8.675348439624031e-09
in O 0 3.4517697589109275e-09
the O 0 2.8952291231121308e-08
HFE O 0 4.49214712716639e-06
gene O 0 3.336547749199781e-08
located O 0 5.055647989138379e-08
4 O 0 1.5916001530058566e-06
. O 0 2.4504083739884663e-06

5 O 0 8.208071085391566e-05
Mb O 0 0.0018733525648713112
telomeric O 0 0.0001533908798592165
to O 0 1.2366718920020503e-06
HLA O 0 0.00020141087588854134
- O 0 6.852383194200229e-06
A O 0 9.239194582733035e-07
. O 0 1.9371659618627746e-06

Population O 0 9.525734867565916e-09
studies O 0 1.3412776667109938e-08
of O 0 5.122229751464147e-09
this O 0 9.436306180887755e-10
polymorphism O 0 3.6144662374226755e-08
are O 0 4.5270281967546566e-10
facilitated O 0 4.305755307854042e-09
by O 0 2.398181375706798e-10
the O 0 7.983341210326955e-10
fact O 0 7.778114818890458e-10
that O 0 2.079022926038121e-10
the O 0 5.731004115716587e-09
Cys282Tyr O 0 4.868427822657395e-06
mutation O 0 1.353802900894152e-07
creates O 0 5.355280663366102e-08
a O 0 2.6401012931387413e-08
Rsal O 0 4.952531071467092e-06
restriction O 0 1.6036123895446508e-07
site O 0 5.273637952996069e-07
. O 0 1.411690391250886e-06

We O 0 3.398153580747021e-07
have O 0 7.1760708486579006e-09
studied O 0 7.45168122762152e-08
the O 0 1.9195042000319518e-08
codon O 0 3.117217772796721e-07
282 O 0 1.0330919621992507e-06
( O 0 2.796556657358451e-07
Cys O 0 0.0224427692592144
/ O 0 1.7422356904717162e-05
Tyr O 0 1.6781601516413502e-05
) O 0 3.2461213717027704e-09
polymorphism O 0 6.897475035572143e-09
in O 0 2.3603569099250876e-10
different O 0 5.047944284797268e-10
ethnic O 0 2.6355919668930028e-09
groups O 0 8.408034268825304e-09
. O 0 3.9067694501682126e-07

In O 0 5.923601520407829e-07
agreement O 0 4.2291338786526467e-07
with O 0 1.6840276728657955e-08
previous O 0 9.550753077292029e-08
observations O 0 1.0790658677706233e-07
the O 0 2.491453621189521e-08
Tyr O 0 5.152705853106454e-06
allele O 0 2.2036337554709462e-07
appeared O 0 1.607382671409141e-08
to O 0 1.256231341173475e-09
be O 0 1.334812593789536e-09
rare O 0 2.689235722996841e-09
or O 0 2.7040383265841683e-09
absent O 0 2.016844113938987e-08
in O 0 2.131454568399249e-09
Asiatic O 0 6.319854861658314e-08
( O 0 1.2948309091598276e-09
Indian O 0 2.8653095451858235e-09
, O 0 1.0875259581766272e-09
Chinese O 0 4.791923302605028e-09
) O 0 2.5727810992748346e-09
populations O 0 1.3281113986352011e-08
. O 0 5.369553264245042e-07

The O 0 6.587710004168912e-07
highest O 0 1.6214413562920527e-06
allele O 0 2.0892237273528735e-07
frequency O 0 9.584001503526451e-08
( O 0 1.8330706952340847e-09
7 O 0 8.791433359078837e-09
. O 0 3.92733318088645e-10
5 O 0 3.142722082571936e-09
% O 0 2.2537768873398534e-10
) O 0 2.1549995121716847e-10
was O 0 3.1539213463105398e-09
found O 0 1.653979952997986e-09
in O 0 1.0539402239828632e-08
Swedes O 0 1.0092846423503943e-05
. O 0 6.325574759102892e-06

Saamis O 0 0.00010925585957011208
( O 0 9.067998263390109e-08
2 O 0 2.1960202900572767e-07
% O 0 4.543795117939453e-09
) O 0 1.8141248503411589e-09
and O 0 7.835774695763575e-09
Mordvinians O 0 9.95279833659879e-07
( O 0 1.7240974203858173e-09
1 O 0 1.373637825707874e-08
. O 0 1.1260375964994296e-09
8 O 0 1.0516149728800883e-08
% O 0 4.362419592229827e-10
) O 0 2.9381955202190113e-10
had O 0 1.621395240292145e-09
significantly O 0 8.927800720925916e-09
lower O 0 3.474553622595522e-08
frequencies O 0 9.008042667346672e-08
of O 0 2.6804496400245625e-08
the O 0 6.544877351188916e-08
Tyr O 0 2.0629875507438555e-05
allele O 0 2.810847945511341e-06
. O 0 1.153537368736579e-06

Comparisons O 0 6.720908913848689e-07
with O 0 3.262951508986589e-08
allele O 0 5.744434474763693e-07
frequencies O 0 5.371115321395337e-07
based O 0 5.184052742635004e-09
on O 0 2.039691970878721e-08
prevalence O 0 7.55741567104451e-08
estimates O 0 5.234507050033699e-09
of O 0 1.372888824846541e-08
HH B-Disease 1 0.5917049646377563
showed O 0 6.342037295326008e-08
some O 0 3.170616436065643e-09
disagreements O 0 2.778888017473946e-07
with O 0 2.036794510829054e-09
the O 0 9.999463479459791e-09
RFLP O 0 7.849837402318371e-07
data O 0 1.0022605856363498e-08
, O 0 1.3202180459970236e-09
particularly O 0 2.792855280375761e-09
in O 0 8.043964605519704e-09
Finns O 0 6.0758256950066425e-06
. O 0 2.8620938792300876e-06

The O 0 2.881643695218372e-06
newly O 0 1.0785390259115957e-05
described O 0 1.186209146908368e-06
HFE O 0 0.0005058664828538895
marker O 0 2.1418288724817103e-06
provides O 0 9.350848984013282e-09
a O 0 1.8667734025257232e-09
new O 0 2.969499313110191e-09
approach O 0 4.0749745799928405e-09
to O 0 6.554828901883525e-10
the O 0 6.968215449099091e-10
screening O 0 2.1928647786495503e-09
of O 0 2.4609752014015385e-09
HH B-Disease 0 3.5695851693162695e-05
as O 0 9.624495644899866e-10
well O 0 2.3090594714059165e-10
as O 0 1.265962612517768e-10
studies O 0 6.460655899154233e-10
of O 0 5.333044006405885e-10
the O 0 1.2959279205304597e-09
relationship O 0 3.2094411572813897e-09
between O 0 1.710208330507612e-08
the O 0 5.297172478435641e-08
HFE O 0 4.315859769121744e-05
Tyr O 0 1.3155657143215649e-05
allele O 0 6.706599151584669e-07
and O 0 5.004463687896532e-08
different O 0 6.319004910437798e-07
disorders O 1 0.9991311430931091
including O 0 6.308741376415128e-06
cancer B-Disease 1 0.9997407793998718

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.99989914894104
associated O 0 2.250189709229744e-06
with O 0 2.4964673883687283e-08
a O 0 6.810491015585285e-08
missense O 0 1.9269343738415046e-06
mutation O 0 2.2946923650124518e-07
encoding O 0 7.466760507668369e-07
Gly23 O 0 3.485974593786523e-05
- O 0 8.672687727084849e-06
- O 0 1.7104385960919899e-06
> O 0 1.090091245714575e-06
Val O 0 8.24460812509642e-07
in O 0 3.4180374086645315e-08
neurophysin O 0 4.494032054935815e-06
II O 0 0.0007947012200020254
. O 0 6.382942046911921e-06

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 2.905155997723341e-05
ADNDI B-Disease 1 0.9999929666519165
) O 0 9.943019563252165e-08
is O 0 2.513777186408106e-09
an O 0 5.045222462030097e-09
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 8.84024120750837e-05
by O 0 2.896315720590792e-07
progressive O 1 0.9999985694885254
degeneration O 1 1.0
of O 0 9.833826879912522e-06
the O 0 6.194840693751757e-07
magnocellular O 0 2.11611004488077e-05
neurons O 0 2.8328105372565915e-07
of O 0 3.699031125847796e-08
the O 0 8.765283610046026e-08
hypothalamus O 0 2.0114279664085188e-07
leading O 0 1.2187275899577799e-07
to O 0 5.3457158699643514e-09
decreased O 0 3.9281239594401995e-08
ability O 0 9.343948725870632e-09
to O 0 4.8383212991609525e-09
produce O 0 4.286672705688943e-08
the O 0 2.3535179138889362e-07
hormone O 0 1.014229496831831e-06
arginine O 0 2.2114895728009287e-06
vasopressin O 0 7.682753562221478e-07
( O 0 2.5151262406097885e-08
AVP O 0 4.48154332843842e-06
) O 0 3.728796471591522e-08
. O 0 7.286229788405763e-07

Affected O 0 7.703413871240627e-07
individuals O 0 4.553720511779602e-09
are O 0 1.5128466257507966e-09
not O 0 2.816961996998657e-09
symptomatic O 0 2.7741162966776756e-07
at O 0 1.0203069678027532e-07
birth O 0 1.9961246877642225e-08
, O 0 1.5537644504348691e-09
but O 0 6.139388109005495e-09
usually O 0 1.398902185201223e-07
develop O 0 3.2510008168173954e-05
diabetes B-Disease 1 0.993516206741333
insipidus I-Disease 0 0.0002866170834749937
at O 0 4.834310857404489e-06
1 O 0 3.0559885999537073e-06
- O 0 1.6759055370130227e-06
6 O 0 2.0613845208572457e-06
yr O 0 2.5188521249219775e-05
of O 0 5.582446505059124e-08
age O 0 5.98196663759154e-07
. O 0 9.265452831641596e-07

The O 0 4.845559260502341e-07
genetic O 0 2.8194261858516256e-07
locus O 0 6.97299412877328e-07
of O 0 4.4491486050901585e-07
the O 0 6.318576879493776e-07
disease O 0 3.299478703411296e-05
is O 0 6.287749432232204e-09
the O 0 9.416663004913062e-08
AVP O 0 1.9674240320455283e-05
- O 0 1.3154902944734204e-06
neurophysin O 0 2.2851431822346058e-06
II O 1 0.9787294864654541
( O 0 6.139238450941775e-08
NPII O 0 1.2251583939359989e-05
) O 0 6.338104263647892e-09
gene O 0 5.809607905860048e-09
, O 0 1.8659369604989706e-09
and O 0 4.838764056103173e-09
mutations O 0 9.454543814513272e-09
that O 0 7.873944829484003e-10
cause O 0 3.4272751747721486e-08
ADNDI B-Disease 0 8.356520083907526e-06
have O 0 1.6732787377904401e-09
been O 0 8.718356037107355e-10
found O 0 2.4193011483042426e-10
in O 0 3.49300227631133e-10
both O 0 2.2293356050084867e-09
the O 0 1.308311681214036e-08
signal O 0 8.543476326394739e-08
peptide O 0 1.572113639269901e-08
of O 0 2.0041779791313274e-08
the O 0 4.4529219422884125e-08
prepro O 0 1.2637110557989217e-05
- O 0 1.1550748240551911e-05
AVP O 0 4.978669676347636e-05
- O 0 1.5056584743433632e-06
NPII O 0 8.188571882783435e-06
precursor O 0 2.8159570319985505e-07
and O 0 2.981180102779035e-08
within O 0 1.052719085237186e-07
NPII O 0 1.6060630514402874e-05
itself O 0 2.6974109346156183e-07
. O 0 1.0969616823786055e-06

An O 0 1.82870337539498e-07
affected O 0 2.714401432513114e-07
girl O 0 3.137513431283878e-07
who O 0 2.0765439145975506e-08
presented O 0 1.6817159576021368e-07
at O 0 1.9889365887593158e-07
9 O 0 9.329723127393663e-08
months O 0 5.480528919576955e-09
of O 0 2.927618591996861e-09
age O 0 1.6774080791037704e-08
and O 0 1.8339902929653817e-09
her O 0 9.66212776454256e-10
similarly O 0 5.6127542613637615e-09
affected O 0 1.8476951524348806e-08
younger O 0 6.518254735965456e-08
brother O 0 6.234657234926999e-08
and O 0 5.845465000930972e-09
father O 0 1.5547612974842195e-08
were O 0 7.966278303683794e-09
all O 0 1.0543337314317114e-09
found O 0 4.520074037284161e-10
to O 0 3.2291314067123267e-10
have O 0 8.80220063503856e-10
a O 0 2.98530378195494e-09
novel O 0 5.7098404226962884e-08
missense O 0 1.1309521141811274e-06
mutation O 0 1.1836219471206277e-07
( O 0 1.405510285934497e-08
G1758 O 0 7.028415325294191e-07
- O 0 9.86515942713595e-07
- O 0 3.959378602758079e-07
> O 0 3.976861933097098e-07
T O 0 2.1366133751143934e-07
) O 0 1.6273966618740587e-09
encoding O 0 4.1915672710501894e-08
the O 0 1.5106184747537554e-08
amino O 0 2.0020957336441825e-08
acid O 0 9.733178707449497e-09
substitution O 0 6.252889050983867e-08
Gly23 O 0 8.338401130458806e-06
- O 0 2.0424540707608685e-06
- O 0 1.3279792483444908e-06
> O 0 1.732473151605518e-06
Val O 0 3.869559350277996e-06
within O 0 1.1819519158962066e-06
NPII O 0 0.00013456081796903163
. O 0 4.495549546845723e-06

The O 0 1.036571688928234e-06
mutation O 0 2.9091771125422383e-07
was O 0 1.2644706259834493e-07
confirmed O 0 3.0487058211292606e-08
by O 0 2.611423077780728e-09
restriction O 0 1.2046163533341314e-07
endonuclease O 0 4.062531843374018e-06
analysis O 0 1.7050040241883835e-06
. O 0 5.7731917877390515e-06

A O 0 0.00020108296303078532
T1 O 0 0.002566884970292449
- O 0 1.1043028280255385e-05
weighted O 0 7.503703045586008e-07
magnetic O 0 1.48555920986837e-06
resonance O 0 1.4196871234162245e-06
imaging O 0 4.419316155690467e-06
of O 0 2.8206684987708286e-07
the O 0 5.908272555643634e-07
fathers O 0 3.422691588639282e-05
pituitary O 0 5.200103623792529e-05
gland O 0 4.0773120417725295e-06
demonstrates O 0 3.098211323049327e-07
an O 0 6.838503452399891e-08
attenuated O 0 8.647812501294538e-05
posterior O 0 0.0413227304816246
pituitary O 1 0.9957183003425598
bright O 1 0.9985552430152893
spot O 0 0.16999517381191254
. O 0 4.9739239329937845e-05

This O 0 1.0996477328717447e-07
mutation O 0 1.5390948249205394e-07
may O 0 2.40365611858806e-08
be O 0 4.453335922249835e-09
valuable O 0 1.4274559312354995e-08
for O 0 6.304426425352005e-10
developing O 0 9.858886151903334e-09
models O 0 1.9957514751922645e-08
of O 0 2.2682780098648436e-08
dominantly B-Disease 0 7.45044817449525e-05
inherited I-Disease 0 0.14774423837661743
neurodegeneration I-Disease 1 1.0
, O 0 5.0930331063625545e-09
as O 0 1.063158450165247e-09
the O 0 7.354907238799058e-10
early O 0 6.48780229539625e-09
age O 0 1.5226754968011846e-08
of O 0 6.6658065733804506e-09
onset O 0 3.654887404991314e-05
of O 0 1.5803171038442088e-07
symptoms O 0 1.225545247507398e-06
suggests O 0 5.440482730989515e-09
that O 0 3.818995675253234e-10
this O 0 2.680518584874392e-10
mutation O 0 7.316963479553351e-09
may O 0 4.700027922410754e-09
be O 0 2.2681858613537997e-09
particularly O 0 3.837595130562477e-09
deleterious O 0 5.30340003024321e-07
to O 0 1.740688837514881e-08
the O 0 9.898741382130538e-08
magnocellular O 0 7.317828931263648e-06
neuron O 0 1.650385684115463e-06
. O 0 9.8100819911906e-08
. O 0 1.5361370060418267e-06

Frequent O 0 3.422288955334807e-06
inactivation O 0 0.00010267534526064992
of O 0 8.041109686018899e-05
PTEN O 1 0.9992357492446899
/ O 1 0.9976619482040405
MMAC1 O 1 0.919682502746582
in O 0 3.624519422373851e-06
primary O 1 0.9999998807907104
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0025828222278505564

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 5.902820248593343e-06
the O 0 1.3090834727336187e-07
most O 0 3.554052385723594e-09
common O 0 4.3557559337159546e-08
male B-Disease 0 1.656342263345323e-08
cancer I-Disease 0 7.167521243189867e-09
in O 0 1.0170185804625476e-09
the O 0 3.084412281140203e-09
Western O 0 6.920037520785627e-08
world O 0 1.1310622660687386e-08
, O 0 2.4010696209053606e-10
yet O 0 3.074648591283591e-10
many O 0 2.956159622646837e-11
of O 0 1.3704229417932368e-10
the O 0 2.0646070963969976e-10
major O 0 1.0017363605285823e-09
genetic O 0 2.937535770186628e-09
events O 0 7.476959607011224e-10
involved O 0 6.641006078389466e-10
in O 0 4.4949782784797776e-10
the O 0 2.461660431052337e-09
progression O 0 1.8166798554375418e-07
of O 0 9.118240384964338e-09
this O 0 2.3189823394886844e-09
often O 0 6.997803581043627e-08
fatal O 0 3.156888487865217e-05
cancer B-Disease 0 1.0869043762795627e-06
remain O 0 1.5193428737347858e-07
to O 0 3.778526291853268e-08
be O 0 2.9481864771696564e-07
elucidated O 0 5.8539826568448916e-05
. O 0 3.3808962598413927e-06

Numerous O 0 7.785110938129947e-07
cytogenetic O 0 3.783776264754124e-05
and O 0 1.860729810232442e-07
allelotype O 0 7.153058504627552e-06
studies O 0 5.949060621901481e-08
have O 0 4.001786457763501e-09
reported O 0 1.3203596438415843e-08
frequent O 0 4.95813434753245e-09
loss O 0 2.2296178769920516e-07
of O 0 9.260223805540591e-07
heterozygosity O 0 0.16103531420230865
on O 0 7.840991747798398e-05
chromosomal O 0 0.0010279214475303888
arm O 0 3.162773646181449e-05
10q O 0 5.080303890281357e-05
in O 0 2.442182449158281e-06
sporadic B-Disease 1 0.9999997615814209
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.015926692634820938

Deletion O 0 3.601363641791977e-05
mapping O 0 1.2287495110285818e-06
studies O 0 8.310493626595417e-08
have O 0 1.0280658102601592e-08
unambiguously O 0 1.4367491019129375e-07
identified O 0 5.360840305002057e-08
a O 0 7.785391886727666e-09
region O 0 1.8287900971358795e-08
of O 0 2.6599533953231003e-07
chromosome O 0 2.0260519306702918e-07
10q23 O 0 1.3872137571979692e-07
to O 0 1.569428254022398e-09
be O 0 1.6802700342211097e-09
the O 0 2.361132844796998e-09
minimal O 0 6.453014123053435e-08
area O 0 2.1697006857834822e-08
of O 0 3.827384986720972e-08
loss O 0 1.7122976032624138e-06
. O 0 2.804453970384202e-06

A O 0 2.7567837150854757e-06
new O 0 4.743258159578545e-07
tumor B-Disease 0 1.7930643707586569e-06
suppressor O 0 3.533675680955639e-06
gene O 0 1.7890215531224385e-07
, O 0 1.2055575382419192e-07
PTEN O 0 0.00014020325033925474
/ O 0 5.471978147397749e-05
MMAC1 O 0 0.0002452834160067141
, O 0 1.917074676782704e-08
was O 0 1.1772569763479623e-07
isolated O 0 2.6316952173033314e-08
recently O 0 2.921099806485472e-08
at O 0 3.039781404368114e-08
this O 0 1.0466238986595044e-09
region O 0 8.680082430601033e-09
of O 0 1.8454024086622667e-08
chromosome O 0 1.1874909944253886e-07
10q23 O 0 1.497113402137984e-07
and O 0 3.999069964066848e-09
found O 0 6.363709004197915e-10
to O 0 1.5588783042197463e-10
be O 0 2.66337452092813e-10
inactivated O 0 6.715524580869214e-09
by O 0 2.0787810361966308e-10
mutation O 0 7.31960181354907e-09
in O 0 1.2659615578058947e-08
three O 0 8.2344149632263e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.00038110039895400405
lines O 0 9.543392707200837e-07
. O 0 2.350696831854293e-06

We O 0 6.180870514072012e-06
screened O 0 1.079031699191546e-05
80 O 0 5.8704572438728064e-06
prostate B-Disease 1 0.962835967540741
tumors I-Disease 1 1.0
by O 0 2.6989283696821076e-08
microsatellite O 0 1.3894052699470194e-06
analysis O 0 5.2563603247790525e-08
and O 0 1.9399426065547232e-08
found O 0 2.640534368936187e-08
chromosome O 0 9.097345099462473e-08
10q23 O 0 3.471937475296727e-07
to O 0 5.1442401449719455e-09
be O 0 6.42664010896965e-09
deleted O 0 3.57023814956392e-08
in O 0 2.926781261791689e-09
23 O 0 9.811841295004342e-08
cases O 0 7.381545685802848e-08
. O 0 6.561037935171044e-07

We O 0 2.577778559498256e-07
then O 0 1.9755690416900507e-08
proceeded O 0 2.7574090566417908e-08
with O 0 2.907722396194856e-10
sequence O 0 1.940304361625067e-09
analysis O 0 3.760858291457225e-09
of O 0 3.170193219048656e-09
the O 0 1.4290114869197623e-08
entire O 0 3.807239465913881e-07
PTEN O 0 6.577438034582883e-05
/ O 0 2.304473855474498e-05
MMAC1 O 0 5.9138121287105605e-05
coding O 0 1.3679377843800467e-06
region O 0 5.579423145718465e-08
and O 0 7.78070141649323e-09
tested O 0 2.2017971446075535e-08
for O 0 2.9976567894607342e-09
homozygous O 0 1.8107725097138427e-08
deletion O 0 2.207351812444358e-08
with O 0 8.692735420368081e-10
new O 0 8.318513877725309e-09
intragenic O 0 1.4966894923418295e-07
markers O 0 5.2909898684561085e-09
in O 0 6.585279543891431e-10
these O 0 5.347242648667816e-10
23 O 0 9.600170436385724e-09
cases O 0 1.594541498839419e-09
with O 0 1.5319647772571443e-09
10q23 O 0 9.187600653604022e-07
loss O 0 6.00285943619383e-07
of O 0 1.0020809213528992e-06
heterozygosity O 0 0.0009114604908972979
. O 0 2.3348995455307886e-05

The O 0 1.893779568717946e-07
identification O 0 1.1225925078406362e-07
of O 0 7.912100841167558e-08
the O 0 4.796104491333608e-08
second O 0 1.3201965032294538e-07
mutational O 0 8.392935342271812e-07
event O 0 4.9569926829917677e-08
in O 0 5.375510259142402e-09
10 O 0 2.9399025436305237e-08
( O 0 4.966520528171259e-09
43 O 0 1.1003903921391611e-07
% O 0 6.799822216407847e-08
) O 0 4.2070053041243227e-07
tumors B-Disease 1 1.0
establishes O 0 6.825368473073468e-05
PTEN O 0 0.03275316581130028
/ O 0 7.058338087517768e-05
MMAC1 O 0 3.038088107132353e-05
as O 0 1.6466056962372022e-08
a O 0 4.375830364722333e-09
main O 0 2.1951676032472278e-08
inactivation O 0 1.744628406186166e-07
target O 0 1.4558682259746547e-08
of O 0 2.582950564544717e-08
10q O 0 1.2419882295944262e-06
loss O 0 5.115788894727302e-07
in O 0 2.2909293306838663e-07
sporadic B-Disease 1 0.9999955892562866
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.5996608757122885e-06
. O 0 9.344972568214871e-06

Risk O 0 1.1608493878156878e-05
reversals O 0 4.792657364305342e-06
in O 0 3.0469792022813635e-08
predictive O 0 1.5609408592354157e-06
testing O 0 5.340419306776312e-07
for O 0 9.705214552013786e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 5.737293395213783e-05

The O 0 4.933854711453023e-07
first O 0 1.0798028426961537e-07
predictive O 0 1.186165036415332e-06
testing O 0 2.5938274461623223e-07
for O 0 3.719704579907557e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 2.608392968284079e-08
HD B-Disease 0 1.1411063496780116e-05
) O 0 1.7705937827017237e-09
was O 0 2.507628549253127e-09
based O 0 1.5235367134547317e-10
on O 0 3.785290303426336e-09
analysis O 0 2.76134448640164e-09
of O 0 5.790204316014069e-09
linked O 0 7.614539043743207e-08
polymorphic O 0 2.568762340615649e-07
DNA O 0 5.270133485169026e-08
markers O 0 2.2189897919133728e-08
to O 0 2.9494042763644757e-09
estimate O 0 2.2976392344276064e-08
the O 0 5.858345808462673e-09
likelihood O 0 6.469454660873453e-08
of O 0 7.836346327394494e-08
inheriting O 0 3.4937963278025563e-07
the O 0 2.2230906893128122e-08
mutation O 0 1.5916009843408574e-08
for O 0 1.7942973329354572e-08
HD B-Disease 0 0.0001432649150956422
. O 0 2.9338082185859093e-06

Limits O 0 3.7526345408878115e-07
to O 0 9.902985986798285e-09
accuracy O 0 9.798506539482332e-08
included O 0 7.847949845540825e-09
recombination O 0 6.782746808653428e-09
between O 0 5.743720166151434e-09
the O 0 4.745255743898724e-09
DNA O 0 1.3823086675301965e-08
markers O 0 9.545559898072042e-09
and O 0 2.515480046483276e-09
the O 0 7.036735638621394e-09
mutation O 0 1.6016322490486345e-08
, O 0 3.250594904358195e-09
pedigree O 0 2.2702474566926867e-08
structure O 0 3.089441591441755e-08
, O 0 5.429988680916153e-10
and O 0 3.8722833273219237e-10
whether O 0 4.908085049493138e-10
DNA O 0 1.329687249196354e-09
samples O 0 2.930192477546001e-10
were O 0 5.246058587538016e-10
available O 0 7.691955961064423e-10
from O 0 1.5341519166156559e-09
family O 0 5.972364824913257e-09
members O 0 2.124393638780475e-08
. O 0 8.888595175449154e-07

With O 0 3.225084910241094e-08
direct O 0 2.525899667205067e-08
tests O 0 2.1908675762460916e-08
for O 0 1.5481173010201132e-09
the O 0 6.911381689178597e-09
HD B-Disease 0 1.0321039553673472e-05
mutation O 0 6.166239074900659e-09
, O 0 2.6388802254473376e-10
we O 0 3.5930103337022956e-10
have O 0 1.6755868914586358e-10
assessed O 0 9.501419206969786e-09
the O 0 4.714157397778251e-10
accuracy O 0 9.03071217805973e-09
of O 0 1.322193687869344e-09
results O 0 2.9278699464896363e-09
obtained O 0 2.2943580368917083e-09
by O 0 3.5114924856749496e-10
linkage O 0 4.3138195238157095e-09
approaches O 0 3.0077023094321476e-09
when O 0 6.384400785819366e-10
requested O 0 1.33216493392041e-09
to O 0 4.423509614159826e-10
do O 0 4.753741289498237e-10
so O 0 2.3293900142107304e-10
by O 0 1.9087795233296845e-10
the O 0 1.2646986791153836e-09
test O 0 3.300671025385782e-08
individuals O 0 8.762856218424986e-09
. O 0 4.2183469872725254e-07

For O 0 1.0100716707484025e-07
six O 0 6.196846591421945e-09
such O 0 1.8651602484709429e-10
individuals O 0 2.41741016093755e-10
, O 0 2.5816279669577114e-10
there O 0 3.9084865899319254e-10
was O 0 2.7731725804613916e-09
significant O 0 5.6174132012642986e-09
disparity O 0 9.567362724283157e-08
between O 0 2.4670061549159072e-08
the O 0 4.121470098539248e-08
tests O 0 2.2457618342741625e-07
. O 0 8.14216946309898e-07

Three O 0 1.4118506896920735e-06
went O 0 3.4766654266604746e-07
from O 0 8.562167863601644e-09
a O 0 8.010341723263537e-09
decreased O 0 9.464795169833451e-08
risk O 0 5.147812398575979e-09
to O 0 9.475245033030433e-10
an O 0 2.5304106032741913e-10
increased O 0 2.0605559480912916e-09
risk O 0 8.37656433105849e-09
, O 0 6.725814905017558e-10
while O 0 1.058411913668067e-09
in O 0 5.639084199593469e-10
another O 0 1.2874773469562228e-09
three O 0 4.6178835755306125e-10
the O 0 1.051762787973587e-09
risk O 0 1.3229082718169138e-08
was O 0 6.765706928035797e-08
decreased O 0 4.881733843831171e-07
. O 0 8.549407084501581e-07

Knowledge O 0 9.913751455314923e-06
of O 0 2.9067447826491843e-07
the O 0 1.3495844441990812e-08
potential O 0 8.805697504499221e-09
reasons O 0 4.963963018411732e-09
for O 0 2.9883959196119747e-10
these O 0 1.0675653416836184e-10
changes O 0 9.639964382301969e-10
in O 0 4.5738957066276953e-10
results O 0 1.032455720917369e-08
and O 0 1.226159840328478e-09
impact O 0 1.1260489429787413e-08
of O 0 1.6028477434204547e-09
these O 0 5.553765780597075e-10
risk O 0 1.8337664720036173e-09
reversals O 0 8.850318700126536e-09
on O 0 4.692298105624104e-09
both O 0 1.3733489900857876e-09
patients O 0 1.4534757841744295e-09
and O 0 2.3782267266625468e-09
the O 0 6.652520756489366e-09
counseling O 0 7.960323955558124e-09
team O 0 1.4408285675671095e-09
can O 0 2.2074927996662552e-10
assist O 0 2.2574049296508747e-09
in O 0 5.984448492313277e-10
the O 0 4.566454325782843e-09
development O 0 2.152655831366701e-08
of O 0 2.847146296502956e-09
strategies O 0 2.7251594758581632e-08
for O 0 5.921477752579563e-10
the O 0 1.7846816247057973e-09
prevention O 0 1.2175004115988486e-08
and O 0 2.711438018554446e-10
, O 0 1.724968223815182e-10
where O 0 2.0328697059035505e-10
necessary O 0 1.2113876124431044e-08
, O 0 1.3622535321999862e-09
management O 0 1.250570846877963e-08
of O 0 3.019059446884853e-09
a O 0 1.9526300576444555e-09
risk O 0 9.58025125896711e-09
reversal O 0 2.594380887899206e-08
in O 0 1.4731271757995046e-09
any O 0 4.11096312546988e-09
predictive O 0 6.324195567231072e-08
testing O 0 9.503594355919631e-09
program O 0 4.630268612970667e-09
. O 0 1.6044941375525923e-08
. O 0 4.3999236254421703e-07

A O 0 1.6982806982923648e-06
novel O 0 7.25401775980572e-07
common O 0 6.98199073667638e-07
missense O 0 6.586763447558042e-06
mutation O 0 2.7728151508199517e-07
G301C O 0 6.513452035505907e-07
in O 0 1.484848866084576e-08
the O 0 4.8237374983273185e-08
N O 0 1.8058767636830453e-06
- O 0 7.466141482836974e-07
acetylgalactosamine O 0 1.386152234772453e-06
- O 0 5.089520414003346e-07
6 O 0 1.4034376363269985e-06
- O 0 2.9806290058331797e-07
sulfate O 0 3.9551667896375875e-07
sulfatase O 0 4.519183676165994e-06
gene O 0 2.0256686994457596e-08
in O 0 2.858433312269426e-08
mucopolysaccharidosis B-Disease 0 1.7319302060059272e-05
IVA I-Disease 0 0.009298356249928474
. O 0 2.12829345400678e-05

Mucopolysaccharidosis B-Disease 0 0.010140304453670979
IVA I-Disease 1 0.9999982118606567
( O 0 7.110519800335169e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 3.4099736012649373e-07
is O 0 1.7404797603148836e-08
an O 0 5.8038846617591844e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.00012837685062550008
by O 0 1.8851844174605503e-07
a O 0 4.999435077479575e-06
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 5.546738520934014e-06
N O 0 0.0002844124101102352
- O 0 0.00015547021757811308
acetylgalactosamine O 0 6.666488479822874e-05
- O 0 4.619791525328765e-06
6 O 0 5.3279327403288335e-06
- O 0 7.982812917362025e-07
sulfate O 0 1.2681094858635333e-06
sulfatase O 0 2.521639908081852e-05
( O 0 4.1095777447708315e-08
GALNS O 0 1.1143531992274802e-05
) O 0 8.620737901310349e-08
. O 0 7.128986112547864e-07

In O 0 2.6543634135123284e-07
previous O 0 1.7183816680699238e-07
studies O 0 2.068590276849136e-08
, O 0 1.0426149943398855e-09
we O 0 1.056779885821868e-09
have O 0 2.750184247002352e-10
found O 0 4.070692116719954e-10
two O 0 3.8780706423935385e-10
common O 0 1.6584499329397318e-09
mutations O 0 5.601011654476906e-09
in O 0 1.7787277206693375e-09
Caucasians O 0 7.318892869534466e-08
and O 0 9.589099292384162e-09
Japanese O 0 1.9042001042635093e-07
, O 0 2.0696676372722322e-08
respectively O 0 4.280749124063732e-07
. O 0 1.2471762147470145e-06

To O 0 5.61437843771273e-07
characterize O 0 3.184860815963475e-06
the O 0 8.132642648206456e-08
mutational O 0 2.418716803731513e-06
spectrum O 0 1.2672207105879352e-07
in O 0 7.577269367509132e-10
various O 0 2.5940169456895035e-10
ethnic O 0 4.4963416323540173e-10
groups O 0 8.569445153483457e-11
, O 0 1.1386326603801677e-10
mutations O 0 2.3185656172763913e-10
in O 0 3.1378868947662397e-10
the O 0 3.908779522276973e-09
GALNS O 0 3.8834599536130554e-07
gene O 0 1.923090797717464e-09
in O 0 3.2418212558837922e-09
Colombian O 0 6.990879342083645e-07
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
patients O 0 8.055729239231368e-08
were O 0 1.7654890882567997e-08
investigated O 0 1.2594436782364937e-07
, O 0 9.016010715789946e-10
and O 0 1.9953698693342403e-09
genetic O 0 1.341863686832312e-08
backgrounds O 0 5.2383050785920204e-08
were O 0 1.3849476232508096e-08
extensively O 0 3.1257263444217642e-09
analyzed O 0 2.9859588135394688e-09
to O 0 2.154415812416488e-10
identify O 0 3.3641265329009684e-09
racial O 0 4.085433769063229e-09
origin O 0 9.485081609028612e-10
, O 0 2.351231431774181e-10
based O 0 2.8436283883159774e-10
on O 0 8.556355624023126e-09
mitochondrial O 0 3.053419561638293e-08
DNA O 0 2.0171942338720328e-08
( O 0 1.9211552348963323e-09
mtDNA O 0 1.7913224681365136e-08
) O 0 1.243338143552819e-08
lineages O 0 3.6228806266080937e-07
. O 0 2.6162560970988125e-06

Three O 0 7.259983476615162e-07
novel O 0 5.054235998613876e-07
missense O 0 8.480129508825485e-06
mutations O 0 4.6144103293954686e-07
never O 0 6.994427081963295e-08
identified O 0 3.802674086728075e-08
previously O 0 9.285975544059966e-09
in O 0 4.5768633327725183e-10
other O 0 2.9397034806422084e-10
populations O 0 2.4798876840925743e-10
and O 0 3.81697118356783e-10
found O 0 2.564196632803828e-10
in O 0 5.49866097099283e-10
16 O 0 9.63610879978205e-09
out O 0 1.5405912101584818e-09
of O 0 1.0590929022669116e-08
19 O 0 2.975897359647206e-07
Colombian O 0 3.2731795727158897e-06
MPS B-Disease 1 0.9999984502792358
IVA I-Disease 1 1.0
unrelated O 0 1.369357960356865e-06
alleles O 0 1.610312381217227e-07
account O 0 1.7582506117719277e-08
for O 0 1.8973654647425064e-08
84 O 0 1.5062042848512647e-06
. O 0 3.27054294757545e-06

2 O 0 2.7345583930582507e-06
% O 0 1.552929695947114e-08
of O 0 2.4164997114439757e-08
the O 0 1.7511451844143266e-08
alleles O 0 3.8814786051943884e-08
in O 0 3.463231035283343e-09
this O 0 3.5392646591247967e-09
study O 0 2.1947155204316005e-08
. O 0 2.3464853882160241e-07

The O 0 2.456421498209238e-06
G301C O 0 6.218141152203316e-06
and O 0 8.509762494668394e-08
S162F O 0 1.1808207318608765e-06
mutations O 0 7.045978378528162e-08
account O 0 1.1534363686394045e-08
for O 0 2.863868431290939e-08
68 O 0 1.331517410108063e-06
. O 0 2.9103414362907642e-06

4 O 0 4.1906264414137695e-06
% O 0 6.961539611438639e-08
and O 0 8.378997051750048e-08
10 O 0 4.586817397012055e-07
. O 0 1.5299644928745693e-06

5 O 0 8.677749292473891e-07
% O 0 1.4997093344959467e-08
of O 0 1.0203844880152246e-08
mutations O 0 1.7456461165465953e-08
, O 0 3.707321116763751e-09
respectively O 0 2.2058491921939094e-08
, O 0 9.37606214890252e-10
whereas O 0 4.284455457082004e-09
the O 0 2.9833910897281157e-09
remaining O 0 6.58101626527241e-08
F69V O 0 1.533481963633676e-06
is O 0 2.4758706196337243e-10
limited O 0 5.525681578966157e-10
to O 0 4.0489098185325645e-10
a O 0 3.302734974397481e-09
single O 0 2.7678263236907696e-08
allele O 0 2.30376440413238e-06
. O 0 2.1782834664918482e-06

The O 0 2.105996372847585e-06
skewed O 0 2.377913915552199e-06
prevalence O 0 7.021648684713e-07
of O 0 2.466935633549383e-08
G301C O 0 1.7505983862520225e-07
in O 0 1.6633253663300707e-09
only O 0 1.4209817766897004e-09
Colombian O 0 3.538956150350714e-08
patients O 0 1.8676102886416857e-09
and O 0 2.981053404127465e-09
haplotype O 0 4.1407744788557466e-08
analysis O 0 2.521436170965785e-09
by O 0 2.293048806389919e-10
restriction O 0 2.456388870086812e-09
fragment O 0 5.113622947305885e-08
length O 0 1.148529804595455e-08
polymorphisms O 0 1.586596987124267e-08
in O 0 2.9047193539355476e-09
the O 0 2.2823344991707017e-08
GALNS O 0 3.5586101603257703e-06
gene O 0 1.0268820460623829e-08
suggest O 0 3.099657419625146e-09
that O 0 4.15867423830818e-10
G301C O 0 3.457549979657415e-08
originated O 0 1.3520005115452705e-09
from O 0 6.115181694354987e-10
a O 0 1.8396484335880814e-09
common O 0 2.277959332275259e-08
ancestor O 0 4.6289727606563247e-07
. O 0 1.734794409458118e-06

Investigation O 0 8.411954695475288e-06
of O 0 3.171849414229655e-07
the O 0 3.429445882829896e-08
genetic O 0 2.127515941197089e-08
background O 0 6.0681979441312706e-09
by O 0 1.1540850497482324e-09
means O 0 2.778203622710862e-08
of O 0 4.710665635343503e-08
mtDNA O 0 3.738938048059026e-08
lineages O 0 9.938465161951626e-09
indicate O 0 4.101580408644168e-09
that O 0 3.341238119514145e-10
all O 0 1.0522885895980494e-09
our O 0 2.0338519757245876e-09
patients O 0 1.707784608173668e-10
are O 0 6.998581575379248e-11
probably O 0 2.6920121687368237e-09
of O 0 1.1401202648642084e-08
native O 0 1.9276086504760315e-08
American O 0 3.4034431450891134e-07
descent O 0 5.299672920955345e-05

Low O 0 7.209449449874228e-06
frequency O 0 1.6045178199419752e-06
of O 0 3.0979808229858463e-07
BRCA1 O 0 7.633718723809579e-07
germline O 0 1.2553382475744002e-06
mutations O 0 1.8318727867949747e-08
in O 0 5.859977392219662e-09
45 O 0 1.3934190690179094e-07
German O 1 1.0
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.7218233046587557e-06
. O 0 1.026974950946169e-05

In O 0 1.282992485585055e-07
this O 0 3.8366656518462605e-09
study O 0 2.8330080503735644e-09
we O 0 2.3568136331419964e-09
investigated O 0 4.2627753771284915e-08
45 O 0 4.606627257430773e-08
German O 1 0.9999974966049194
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.036889850704938e-08
for O 0 1.475554611829466e-08
germline O 0 6.568106414306385e-07
mutations O 0 1.5140827258619538e-08
in O 0 1.4859283581358795e-08
the O 0 1.3133626453054603e-07
BRCA1 O 0 1.0832866337295854e-06
gene O 0 7.712661727055092e-07
. O 0 3.917121375707211e-06

We O 0 4.03056105824362e-07
identified O 0 2.2993847892394115e-07
four O 0 6.528755847057255e-08
germline O 0 5.43092892257846e-06
mutations O 0 3.25993511296474e-07
in O 0 7.136884505598573e-08
three O 0 6.936170962035249e-07
breast B-Disease 0 0.003830455709248781
cancer I-Disease 0 6.703111284878105e-05
families O 0 2.71239759541686e-08
and O 0 3.090559346219379e-07
in O 0 6.783423032175051e-06
one O 1 0.9999984502792358
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.7025862462105579e-06
. O 0 8.54366799529771e-09
among O 0 4.593751212755848e-10
these O 0 2.592968340042745e-10
were O 0 1.5561963939703105e-09
one O 0 1.2354348655208014e-09
frameshift O 0 1.375048839236115e-07
mutation O 0 1.0491266522194564e-08
, O 0 1.4082519594893483e-09
one O 0 1.6932417690185275e-09
nonsense O 0 9.95746276544196e-08
mutation O 0 1.3982347724095234e-08
, O 0 1.964337137394523e-09
one O 0 1.4385603819278003e-09
novel O 0 6.545075148522983e-09
splice O 0 1.5315745827138016e-07
site O 0 3.293062533771263e-08
mutation O 0 1.884299294374614e-08
, O 0 5.67433566800446e-09
and O 0 2.2198026528030823e-08
one O 0 5.83989603342161e-08
missense O 0 1.1873989933519624e-05
mutation O 0 8.91759009391535e-06
. O 0 1.5665480532334186e-05

The O 0 1.6029149492169381e-06
missense O 0 5.3576077334582806e-06
mutation O 0 1.409254224427059e-07
was O 0 1.6083065190741763e-07
also O 0 5.158034444008308e-09
found O 0 5.7351816629136465e-09
in O 0 1.512322356234108e-08
2 O 0 4.5250703806232195e-06
. O 0 4.616999376594322e-06

8 O 0 4.789016202266794e-06
% O 0 3.273099125067347e-08
of O 0 2.115614883280159e-08
the O 0 5.798626023789666e-09
general O 0 4.85701701080643e-09
population O 0 8.203750873070348e-11
, O 0 1.401873062079062e-10
suggesting O 0 6.109096006845505e-10
that O 0 1.1546612971313763e-10
it O 0 2.733490933604088e-10
is O 0 6.79320433238928e-10
not O 0 1.698139229233675e-08
disease O 0 7.638583383595687e-07
associated O 0 7.604791107951314e-07
. O 0 3.7062668525322806e-06

The O 0 9.015947171064909e-07
average O 0 6.700149413063627e-08
age O 0 2.6347495918344066e-07
of O 0 1.2995218412470422e-07
disease O 0 4.897588041785639e-06
onset O 0 1.7374104572809301e-06
in O 0 2.67154165456418e-09
those O 0 2.6630913030345482e-09
families O 0 1.7967485277381456e-09
harbouring O 0 3.5525505381883704e-07
causative O 0 6.807400865227464e-08
mutations O 0 4.62393430211705e-08
was O 0 1.5245419149323425e-07
between O 0 2.3105558000224846e-07
32 O 0 2.9241434731375193e-06
. O 0 5.656272151099984e-06

3 O 0 1.1884547348017804e-05
and O 0 8.870617307366047e-07
37 O 0 4.811589860764798e-06
. O 0 3.5258528896520147e-06

4 O 0 2.2483407065010397e-06
years O 0 4.690466326451315e-08
, O 0 2.0770301034644945e-09
whereas O 0 6.149021292145562e-09
the O 0 2.9494606756941266e-09
family O 0 2.159246559330086e-09
harbouring O 0 1.8674495549930725e-07
the O 0 1.1542529598784768e-08
missense O 0 3.880612950979412e-07
mutation O 0 4.2993480775521675e-08
had O 0 8.311234367397446e-09
an O 0 5.704696159902767e-10
average O 0 2.9987661243069397e-09
age O 0 1.813745065248895e-08
of O 0 3.597498832164092e-08
onset O 0 1.4322813512990251e-05
of O 0 9.750440312927822e-07
51 O 0 2.378784984102822e-06
. O 0 2.9191614885348827e-06

2 O 0 4.015863305539824e-05
years O 0 3.5676491734193405e-06
. O 0 7.178405212471262e-06

These O 0 1.0380362880368921e-07
findings O 0 1.3752402594491286e-07
show O 0 1.1028947533020528e-08
that O 0 2.8130746621002345e-09
BRCA1 O 0 2.11617830814248e-07
is O 0 8.832645725931343e-09
implicated O 0 1.2222031386954768e-07
in O 0 2.8408271290913945e-09
a O 0 2.733059778492475e-09
small O 0 2.330031279029754e-09
fraction O 0 6.21914537646262e-08
of O 1 0.9611078500747681
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.8693574688199988e-08
suggesting O 0 1.0273327077925387e-08
the O 0 2.8359816717227204e-09
involvement O 0 1.1440500102821716e-08
of O 0 5.11777686895698e-09
another O 0 2.13528772441407e-09
susceptibility O 0 3.79782498782788e-08
gene O 0 1.0061894073487565e-07
( O 0 9.740146111880676e-08
s O 0 1.012875418382464e-05
) O 0 3.492411224215175e-06

Paternal O 0 0.00015246259863488376
transmission O 1 0.9999992847442627
of O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9999994039535522

We O 0 2.329231620024075e-06
report O 0 2.987327363257464e-08
a O 0 1.7343383396095646e-09
rare O 0 3.002011084163314e-09
case O 0 1.4855825902770903e-08
of O 0 8.904726200853474e-08
paternally O 1 0.9999161958694458
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.994322657585144
DM B-Disease 1 1.0
) O 0 5.888640544071677e-07
. O 0 1.952636921487283e-06

The O 0 4.423878635861911e-06
proband O 0 1.9351411538082175e-05
is O 0 4.892572125214656e-09
a O 0 4.789574958863341e-09
23 O 0 3.6533286618123384e-08
year O 0 6.061604107543417e-09
old O 0 1.2584690693984157e-06
, O 0 2.9680239777007955e-07
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 1.1551133866305463e-05
who O 0 4.790052798853139e-07
suffers O 1 0.8173468708992004
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 1 0.9999994039535522

He O 0 5.509466063813306e-06
presented O 0 5.915121619182173e-06
with O 0 2.388156019605958e-07
respiratory O 1 0.9993199110031128
and O 0 1.042484200297622e-06
feeding O 0 1.5796571233295253e-06
difficulties O 0 9.45629108173307e-06
at O 0 4.460127911443124e-06
birth O 0 1.731168367768987e-06
. O 0 3.0423186672123848e-06

His O 0 7.920728421595413e-06
two O 0 1.7926472537510563e-06
sibs O 0 0.012637658976018429
suffer O 0 5.170574695512187e-06
from O 0 5.304169121700397e-07
childhood O 0 0.10516814142465591
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 0.003117650980129838

Their O 0 1.991324154460017e-07
late O 0 2.1458281480590813e-06
father O 0 1.0968700792091113e-07
had O 0 6.811112118754181e-09
the O 0 3.3087188544556057e-09
adult O 0 6.54398846222648e-09
type O 0 3.153832750513175e-08
of O 0 1.2198991043987917e-06
DM B-Disease 1 1.0
, O 0 2.7294511539821542e-08
with O 0 4.139122378177262e-09
onset O 0 3.311035925435135e-06
around O 0 1.1169897895513259e-08
30 O 0 1.7939004948175352e-08
years O 0 2.250784802981798e-08
. O 0 2.903215374772117e-07

Only O 0 1.0475414313759757e-07
six O 0 1.55300075022069e-08
other O 0 5.927150437123885e-10
cases O 0 7.058306716878349e-10
of O 0 1.5997141389334502e-09
paternal O 0 3.950266318497597e-07
transmission O 1 0.9998741149902344
of O 1 0.999847412109375
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 1.194823289552005e-05
been O 0 1.0208111689280486e-07
reported O 0 6.760972581787428e-08
recently O 0 2.285872682250556e-07
. O 0 1.46139859680261e-06

We O 0 4.430454794146499e-07
review O 0 1.1515683695506596e-07
the O 0 1.0023542884596282e-08
sex O 0 1.2975510443880012e-08
related O 0 1.2783045733044673e-08
effects O 0 7.600116447292748e-08
on O 0 2.1217174150933715e-07
transmission O 1 0.9726008176803589
of O 0 0.15710724890232086
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.7244696617126465

Decreased O 0 4.875081231148215e-06
fertility O 0 4.1809477124843397e-07
of O 0 2.1115392101478392e-08
males O 0 1.6282264425626636e-08
with O 0 3.094476674903035e-09
adult O 0 1.279826506106474e-06
onset O 1 0.9999188184738159
DM B-Disease 1 1.0
and O 0 1.5704345059930347e-06
contraction O 0 1.622562990633014e-07
of O 0 9.610742424115415e-09
the O 0 2.1428723240290992e-09
repeat O 0 1.2014126582471363e-08
upon O 0 9.178263482567672e-09
male O 0 1.421589868044748e-08
transmission O 0 9.142952173135654e-09
contribute O 0 1.2351704381519113e-10
to O 0 2.8039881527774924e-10
the O 0 1.2718324171601125e-09
almost O 0 1.8749770624992834e-09
absent O 0 5.826497506689066e-09
occurrence O 0 2.7869806462632596e-09
of O 0 1.8216940178561458e-09
paternal O 0 1.366902040444984e-07
transmission O 0 0.000422833050834015
of O 0 0.0005201561725698411
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.5188350677490234

Also O 0 3.22875933989053e-07
the O 0 9.876939799369211e-08
fathers O 0 3.734213009920495e-07
of O 0 2.8080103575689463e-08
the O 0 2.4128061326678107e-08
reported O 0 2.1746420486579154e-07
congenitally O 0 2.2313877707347274e-05
affected O 0 6.294398957606973e-08
children O 0 6.425316723124297e-09
showed O 0 2.2662584697741295e-08
, O 0 8.279100960351116e-09
on O 0 1.0251212501088958e-07
average O 0 2.8455518830128312e-08
, O 0 6.301315913503913e-09
shorter O 0 4.124726444842963e-07
CTG O 0 1.9407369109103456e-05
repeat O 0 2.5662012603788753e-07
lengths O 0 7.916445952105278e-07
and O 0 3.929215619535853e-09
hence O 0 2.5661710978397423e-08
less O 0 1.1419832190995294e-08
severe O 0 9.341312647848099e-07
clinical O 0 5.763586614193628e-06
symptoms O 0 1.5198949654404714e-07
than O 0 1.4870871201111413e-09
the O 0 3.4654710212578266e-09
mothers O 0 2.0036305947712663e-09
of O 0 2.8738478263790057e-09
children O 0 1.1868225513467223e-08
with O 0 2.3900014411992743e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.2390763908624649

We O 0 4.368036172763823e-07
conclude O 0 3.350974964178022e-07
that O 0 1.900802182319694e-09
paternal O 0 2.6938656105812697e-07
transmission O 1 0.5572223663330078
of O 1 0.9991769194602966
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 7.056495405777241e-07
rare O 0 9.901569342218863e-09
and O 0 8.594428502206597e-10
preferentially O 0 2.1223756085930745e-09
occurs O 0 1.1915284314767405e-09
with O 0 2.0062221328664975e-10
onset O 0 5.271179475130339e-07
of O 0 2.416799986804108e-07
DM B-Disease 1 1.0
past O 0 1.5744811676654535e-08
30 O 0 2.0747337181603598e-09
years O 0 3.7261552177092483e-10
in O 0 1.9644484650083172e-10
the O 0 1.0955539808676917e-09
father O 0 1.3238043550245493e-08
. O 0 1.8716336924740062e-08
. O 0 4.35196966463991e-07

The O 0 5.541958671528846e-06
RB1 O 0 9.04757616808638e-05
gene O 0 1.251363528353977e-07
mutation O 0 7.459858153424648e-08
in O 0 1.9868489076202422e-08
a O 0 4.698489064480782e-08
child O 0 6.484998721134616e-06
with O 0 1.2144827223892207e-06
ectopic B-Disease 1 0.9999816417694092
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 1 0.6088667511940002

The O 0 6.324802143353736e-06
RB1 O 0 0.00022848010121379048
gene O 0 4.991395030629064e-07
mutation O 0 3.203987830602273e-07
was O 0 2.884767980049219e-07
investigated O 0 5.489779368872405e-07
in O 0 1.1426739554565302e-08
a O 0 4.302391332089428e-08
child O 0 2.452178023304441e-06
with O 0 3.3282853451055416e-07
ectopic B-Disease 0 0.34401798248291016
intracranial I-Disease 1 0.9996569156646729
retinoblastoma I-Disease 0 0.05407341569662094
using O 0 4.9978250871163254e-08
DNA O 0 1.5513251128140837e-08
obtained O 0 1.0777613468349045e-08
from O 0 9.449111493253781e-10
both O 0 4.076840198763421e-09
the O 0 5.992838225665764e-08
pineal B-Disease 0 8.047023584367707e-05
and I-Disease 0 3.2823118090163916e-07
retinal I-Disease 0 0.21985341608524323
tumours I-Disease 1 1.0
of O 0 2.154485810024198e-05
the O 0 1.2611410511453869e-06
patient O 0 7.815834806024213e-07
. O 0 2.154230742235086e-06

A O 0 3.6810527035413543e-06
nonsense O 0 4.542629085335648e-06
mutation O 0 9.35172579374921e-08
in O 0 2.06604315877712e-08
exon O 0 2.176943212361948e-07
17 O 0 2.6854755219574145e-07
( O 0 1.7376239114241798e-08
codon O 0 2.9411430091386137e-07
556 O 0 1.0061952337991897e-07
) O 0 1.7920152028949587e-09
of O 0 2.580006253083411e-08
the O 0 1.2082750799891073e-07
RB1 O 0 2.1568705051322468e-05
gene O 0 2.888543981782732e-08
was O 0 2.533296061812962e-08
found O 0 6.297011800882046e-10
to O 0 1.9450833999012929e-10
be O 0 8.175528587450742e-10
present O 0 5.777804457096636e-09
homozygously O 0 3.834853714579367e-07
in O 0 4.932327879458853e-09
both O 0 1.0789336535310667e-08
the O 0 7.699082260614887e-08
retinal B-Disease 0 8.718264325580094e-06
and I-Disease 0 3.7130203622837143e-07
the I-Disease 0 3.6941489724995336e-06
pineal I-Disease 1 0.9857563376426697
tumours I-Disease 1 1.0
. O 0 5.250591493677348e-05

The O 0 1.937868603363313e-07
same O 0 1.1622457662952002e-08
mutation O 0 1.4724368391227927e-08
was O 0 2.3866391529736575e-08
present O 0 3.6970539962766225e-09
heterozygously O 0 8.91640254963022e-08
in O 0 1.5028899236213533e-09
the O 0 2.4596988890124294e-09
DNA O 0 5.999606145223879e-09
from O 0 7.375726140956829e-10
the O 0 4.050703772406905e-09
constitutional O 0 1.7062730250927416e-07
cells O 0 2.258387787890115e-08
of O 0 1.007300820532464e-08
the O 0 5.590968132906937e-09
patient O 0 6.753069659026778e-09
, O 0 1.3622353245423824e-09
proving O 0 4.251350915751573e-08
it O 0 3.0666655326250236e-10
to O 0 3.8135217206303196e-10
be O 0 3.3490301643013254e-09
of O 0 3.752583666027931e-08
germline O 0 7.285428637260338e-06
origin O 0 5.46924809441407e-07
. O 0 2.8281262984819477e-06

The O 0 1.9541909068720997e-07
initial O 0 7.875559759895623e-08
mutation O 0 1.1844887737311183e-08
was O 0 1.0726201260524704e-08
shown O 0 8.132851614384151e-10
to O 0 6.244433858881848e-10
have O 0 8.049853561509224e-10
occurred O 0 2.513217545185853e-08
in O 0 1.356360468385276e-09
the O 0 1.2226830214956408e-08
paternally O 0 7.135910209399299e-07
derived O 0 1.683469861291087e-07
RB1 O 0 5.725247319787741e-05
allele O 0 1.2486883861129172e-05
. O 0 3.827630280284211e-06

The O 0 1.6956123261024914e-07
mutation O 0 2.1427467800094746e-08
is O 0 7.419310166234538e-10
in O 0 6.68676336523788e-10
an O 0 4.098270334207399e-10
area O 0 4.025556776809935e-09
of O 0 1.0310545306424501e-08
the O 0 8.467129219980052e-09
gene O 0 2.9865852013699623e-09
that O 0 2.0070154427287434e-09
encodes O 0 8.521826799778864e-09
the O 0 8.252583505452549e-09
protein O 0 2.0184604210271573e-08
- O 0 2.3699366025198287e-08
binding O 0 3.333138565153604e-08
region O 0 2.219510619738685e-08
known O 0 6.138978214664803e-09
as O 0 1.4209817766897004e-09
the O 0 2.26787433277309e-09
pocket O 0 2.1392149562871055e-07
region O 0 4.144533605199285e-09
and O 0 1.7154115905526623e-09
has O 0 1.9116649929706853e-10
been O 0 2.323772146928249e-10
detected O 0 6.130503327206327e-10
in O 0 1.0413942624909467e-10
other O 0 1.5835478761605515e-10
cases O 0 1.7239953908898542e-09
of O 0 9.893961205875712e-09
retinoblastoma B-Disease 0 7.1243698585021775e-06
. O 0 2.2880887229348446e-07
. O 0 1.8260316210216843e-06

Low O 0 7.788610673742369e-06
levels O 0 3.402089987503132e-07
of O 0 6.770832072788835e-08
beta O 0 8.015134085326281e-07
hexosaminidase O 0 7.607381462548801e-07
A O 0 9.335309414382209e-09
in O 0 1.3252411390496377e-09
healthy O 0 6.8871681691007325e-09
individuals O 0 1.0115259324594561e-10
with O 0 3.8783812272846774e-10
apparent O 0 7.95849587120756e-07
deficiency O 0 0.0007678947295062244
of O 0 1.9619326394604286e-06
this O 0 3.254809044506146e-08
enzyme O 0 2.7545686975827266e-07
. O 0 6.510259709102684e-07

Appreciable O 0 6.712974573019892e-05
beta O 0 3.26550543832127e-05
hexosaminidase O 0 3.517373988870531e-05
A O 0 1.0985236258420628e-06
( O 0 4.813893639266098e-08
hex O 0 1.8571855662230519e-06
A O 0 8.185085675904702e-08
) O 0 1.865737564443748e-09
activity O 0 1.151216544315048e-08
has O 0 7.073711616456535e-10
been O 0 1.6898766830308887e-09
detected O 0 1.581608621847863e-08
in O 0 4.2708318659379074e-08
cultured O 0 0.003453090088441968
skin O 1 0.999972939491272
fibroblasts O 0 0.005538800731301308
and O 0 1.2043735296174418e-05
melanoma B-Disease 1 0.9995766282081604
tissue O 0 4.6250193008745555e-07
from O 0 5.279889858655906e-09
healthy O 0 2.974880786155154e-08
individuals O 0 2.0253267118963691e-10
previously O 0 2.0270940481736943e-09
reported O 0 2.6728619317850644e-09
as O 0 2.6737285718780868e-09
having O 0 1.4188692887273646e-07
deficiency B-Disease 0 0.00030875782249495387
of I-Disease 0 8.964539119915571e-07
hex I-Disease 0 4.755487680085935e-06
A I-Disease 0 1.776941616071781e-08
activity O 0 4.600022585066199e-09
indistinguishable O 0 2.1796420224262647e-09
from O 0 4.199795372583637e-11
that O 0 3.1800978517182443e-11
of O 0 1.015092343514823e-09
patients O 0 2.1770576452695423e-09
with O 0 1.34253753003577e-07
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.0308194760000333e-06
TSD B-Disease 0 0.0005286307423375547
) O 0 1.148729751321298e-07
. O 0 7.519448104176263e-07

Identification O 0 3.07888217321306e-06
and O 0 2.4491626504641317e-07
quantitation O 0 0.00015905984037090093
of O 0 1.3892905371903908e-05
hex O 0 3.3697673643473536e-05
A O 0 2.2328140403260477e-07
, O 0 5.174529693618979e-09
amounting O 0 4.034844280909056e-08
to O 0 2.0256416988218007e-08
3 O 0 1.4427564565266948e-06
. O 0 2.5735193958098534e-06

5 O 0 7.739121429040097e-06
% O 0 3.3720880310283974e-07
- O 0 2.6273203275195556e-06
6 O 0 5.374085048970301e-06
. O 0 3.379941745151882e-06

9 O 0 2.0293173292884603e-06
% O 0 1.328144350054572e-08
of O 0 1.2028434248634312e-08
total O 0 5.084589194126465e-09
beta O 0 1.8263818901687046e-07
hexosaminidase O 0 2.434113639537827e-07
activity O 0 4.355828586710686e-09
, O 0 2.019355793692057e-10
has O 0 5.942497188771156e-11
been O 0 1.6759736654048396e-10
obtained O 0 3.715540097815051e-09
by O 0 3.692022687573626e-09
cellulose O 0 1.1634987231445848e-06
acetate O 0 1.4016744387390645e-07
gel O 0 4.6524559138561017e-07
electrophoresis O 0 1.381484224793894e-07
, O 0 3.64490730930811e-08
DEAE O 0 1.0485521670489106e-05
- O 0 1.0275060731146368e-06
cellulose O 0 1.6473335335831507e-06
ion O 0 7.193269084382337e-06
- O 0 7.629075753357029e-07
exchange O 0 1.3484527983109729e-07
chromatography O 0 6.874649898236385e-07
, O 0 4.750789095453456e-09
radial O 0 2.4594473302386177e-07
immunodiffusion O 0 1.2163164910816704e-06
, O 0 1.7427851162210573e-08
and O 0 9.048699212144129e-08
radioimmunoassay O 0 1.1387051017663907e-05
. O 0 3.819513040070888e-06

Previous O 0 4.171412729192525e-05
family O 0 9.962534619489816e-08
studies O 0 2.1564366292636805e-08
suggested O 0 9.489212970947847e-09
that O 0 3.212177190903276e-10
these O 0 2.8719668310195345e-10
individuals O 0 7.343212149457656e-11
may O 0 9.796685684904105e-10
be O 0 2.1395274441005085e-09
compound O 0 1.9134070328163943e-08
heterozygotes O 0 2.993110825855183e-08
for O 0 8.484293823052269e-10
the O 0 2.9621791686196275e-09
common O 0 1.37750006956594e-08
mutant O 0 4.1879752643581014e-07
TSD B-Disease 0 5.195272933633532e-06
gene O 0 1.0171277153858682e-08
and O 0 4.941716369444293e-09
a O 0 2.801503695692986e-09
rare O 0 2.0790524857261516e-08
( O 0 1.0507267944603882e-08
allelic O 0 1.0253750133415451e-06
) O 0 2.0572898051796074e-08
mutant O 0 1.0243203405480017e-06
gene O 0 6.535920533679018e-07
. O 0 1.9269380118203117e-06

Thus O 0 6.375931320690142e-07
, O 0 1.6927938162325518e-08
the O 0 1.338134758555043e-08
postulated O 0 1.919001419992128e-07
rate O 0 1.1858880988313558e-08
mutant O 0 1.3783226116004244e-08
gene O 0 1.936599769436498e-09
appears O 0 3.077665677864161e-09
to O 0 8.146778807116561e-10
code O 0 8.257428629754315e-10
for O 0 2.8576560562321163e-10
the O 0 4.5937773029969264e-10
expression O 0 5.745886544339385e-10
of O 0 1.3512476693122721e-09
low O 0 7.068993834735693e-09
amounts O 0 5.546654691102049e-09
of O 0 3.41749633037125e-08
hex O 0 2.446567350489204e-06
A O 0 5.048868843005039e-07
. O 0 1.254869061995123e-06

Heterozygotes O 0 4.123240796616301e-05
for O 0 9.837119563371743e-08
the O 0 4.178603774107614e-08
rare O 0 1.519753745071739e-08
mutant O 0 5.2866244715232824e-08
may O 0 5.741299435868541e-09
be O 0 2.5415369808712285e-09
indistinguishable O 0 6.210608471945989e-09
from O 0 4.845614465232018e-10
heterozygotes O 0 3.285552452325646e-08
for O 0 1.4269297965441297e-09
the O 0 1.4972483697306416e-08
common O 0 2.3896939183032373e-07
TSD B-Disease 0 5.596043774858117e-05
mutant O 0 1.1107109457952902e-05
. O 0 5.779631464974955e-06

However O 0 3.612337309277791e-07
, O 0 1.1965485491316485e-08
direct O 0 1.300383001279215e-08
visualization O 0 3.6738066455654916e-07
and O 0 3.498680101188256e-08
quantitation O 0 4.683571387431584e-05
of O 0 1.8780472146318061e-06
hex O 0 9.952277650882024e-06
A O 0 5.814433023942911e-08
by O 0 1.4809194981424412e-09
the O 0 3.098327372441645e-09
methods O 0 1.0955716334137833e-07
described O 0 1.9676042128935478e-08
may O 0 9.338568141004089e-09
prevent O 0 2.3196518483814543e-08
false O 0 3.3763518558771466e-07
- O 0 3.339862360007828e-07
positive O 0 3.69962371848942e-08
prenatal O 0 5.151469508746231e-07
diagnosis O 0 8.263745030490099e-07
of O 0 1.203431452267978e-07
TSD B-Disease 0 0.0001053385203704238
in O 0 5.530410263077101e-08
fetuses O 0 4.119863490359421e-07
having O 0 2.376640928503093e-08
the O 0 2.6989336987526258e-08
incomplete O 0 1.764639364409959e-06
hex B-Disease 0 8.121563587337732e-05
A I-Disease 0 1.574645580149081e-06
deficiency I-Disease 0 6.512622348964214e-05
of O 0 1.4163155981350428e-07
the O 0 8.869194267902003e-09
type O 0 2.705180577322608e-07
described O 0 2.2302810265273365e-08
in O 0 7.2911352511084715e-09
the O 0 6.295528010014095e-08
four O 0 3.3991420878010103e-07
healthy O 0 1.5338242747020558e-06
individuals O 0 3.8424869330810907e-07

The O 0 4.06666777053033e-06
tumor B-Disease 0 1.3433137610263657e-05
suppressor O 0 1.1750079465855379e-05
gene O 0 8.137713507494482e-07
Smad4 O 0 0.0001815146388253197
/ O 0 2.4111370294122025e-05
Dpc4 O 0 1.9332650481374003e-05
is O 0 1.5011423215582909e-09
required O 0 3.0301705589153016e-09
for O 0 1.3123598874287268e-09
gastrulation O 0 3.0384370575120556e-07
and O 0 3.876098109145687e-09
later O 0 2.4711551915856944e-08
for O 0 3.8626288834109346e-09
anterior O 0 4.0197511452788603e-07
development O 0 2.314945106718369e-07
of O 0 8.366301784690222e-08
the O 0 1.0454994736619483e-07
mouse O 0 2.5130049152721767e-07
embryo O 0 3.269212811574107e-07
. O 0 8.026968316698913e-07

Mutations O 0 3.2852256026671967e-06
in O 0 2.0257273547485966e-07
the O 0 6.396546723408392e-07
SMAD4 O 1 0.8147186636924744
/ O 0 0.00167913269251585
DPC4 O 0 0.00039873141213320196
tumor B-Disease 0 3.2296511562890373e-06
suppressor O 0 1.638603066567157e-06
gene O 0 2.3484995281819465e-08
, O 0 8.839690757156404e-09
a O 0 1.1653155773672097e-08
key O 0 4.0581613802714855e-07
signal O 0 3.439088800405443e-07
transducer O 0 2.3482135702579399e-07
in O 0 7.816668201598986e-09
most O 0 8.213042690385919e-09
TGFbeta O 0 9.551693437970243e-06
- O 0 3.2302872909895086e-07
related O 0 3.4944317661711466e-08
pathways O 0 1.1707337321809064e-08
, O 0 2.258290776602223e-10
are O 0 4.378564524842865e-11
involved O 0 3.0377322879360236e-10
in O 0 4.1372652526128206e-10
50 O 0 5.149737525300679e-09
% O 0 1.664652771182773e-08
of O 0 1.6545003518331214e-06
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999997615814209
. O 0 0.0005257272277958691

Homozygous O 0 0.0001535621122457087
Smad4 O 0 0.00025056395679712296
mutant O 0 1.1130956409033388e-05
mice O 0 2.4419939563813386e-06
die O 0 1.2625550880329683e-06
before O 0 7.290358894351812e-07
day O 0 2.844065818408126e-07
7 O 0 3.1582928841089597e-06
. O 0 1.9366025298950262e-06

5 O 0 7.382055173366098e-06
of O 0 2.705766064536874e-06
embryogenesis O 0 6.389649934135377e-05
. O 0 8.171268746082205e-06

Mutant O 0 3.384354386071209e-06
embryos O 0 2.0161158431619697e-07
have O 0 9.477382434397441e-09
reduced O 0 4.037384826460766e-08
size O 0 1.2517282321766743e-08
, O 0 1.7490048298540728e-09
fail O 0 7.90329224287234e-08
to O 0 9.717911808593271e-09
gastrulate O 0 2.901653260778403e-06
or O 0 2.5721003993339764e-08
express O 0 5.949693182571991e-09
a O 0 2.6102577876940813e-09
mesodermal O 0 2.1866142674298317e-07
marker O 0 1.0995177035511006e-07
, O 0 3.513785928888069e-09
and O 0 8.273323359730966e-09
show O 0 1.2839080909543554e-07
abnormal O 0 1.3116743957652943e-06
visceral O 0 1.1447404176578857e-05
endoderm O 0 0.0013663844438269734
development O 0 1.1452153557911515e-05
. O 0 2.7431360649643466e-06

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 1.865142803580966e-05
the O 0 7.05884417584457e-07
Smad4 O 0 0.0006146673113107681
- O 0 2.058602831311873e-06
deficient O 0 1.41383381446758e-07
embryos O 0 7.595345685729171e-09
results O 0 2.650318009500552e-08
from O 0 2.7083741915845394e-09
reduced O 0 4.886494053835122e-08
cell O 0 3.3922077591341804e-08
proliferation O 0 2.4717207836033595e-08
rather O 0 1.7438083199650123e-09
than O 0 4.35723901404117e-10
increased O 0 6.067445212920575e-09
apoptosis O 0 4.881533754996781e-07
. O 0 1.393070903077387e-07

Aggregation O 0 9.062782737601083e-06
of O 0 1.1607235137489624e-06
mutant O 0 3.816491243924247e-06
Smad4 O 0 6.591987767023966e-05
ES O 0 2.8005068088532425e-05
cells O 0 5.8989382267782275e-08
with O 0 6.104533323281203e-09
wild O 0 1.0679151074555193e-07
- O 0 2.45684503852317e-07
type O 0 2.0404370388860116e-06
tetraploid O 0 0.004223233554512262
morulae O 0 0.0004533920146059245
rescues O 0 4.189148057776038e-06
the O 0 3.6825937854700896e-07
gastrulation B-Disease 0 8.545660239178687e-05
defect I-Disease 0 2.0218210920575075e-05
. O 0 1.2280324881430715e-05

These O 0 2.491791804004606e-07
results O 0 3.237158239244309e-07
indicate O 0 4.919599305708289e-08
that O 0 4.0372674092736816e-09
Smad4 O 0 6.876794031995814e-07
is O 0 7.262123680185084e-10
initially O 0 2.2268622501542268e-09
required O 0 6.140755126615716e-10
for O 0 1.2276708816205684e-10
the O 0 7.9401518693345e-10
differentiation O 0 1.4892962418855404e-08
of O 0 5.094461297261432e-09
the O 0 6.845390920773298e-09
visceral O 0 1.1214497419587133e-07
endoderm O 0 1.2324204590186127e-06
and O 0 4.016690535735279e-09
that O 0 6.350140968613971e-10
the O 0 7.671535406927887e-09
gastrulation B-Disease 0 1.2101195352443028e-06
defect I-Disease 0 8.900260439759222e-08
in O 0 7.159049797422767e-09
the O 0 2.0943678791240927e-08
epiblast O 0 7.192213161033578e-06
is O 0 3.7656171514299785e-09
secondary O 0 2.061377415429888e-07
and O 0 3.0952691076890915e-08
non O 0 5.9199865063419566e-06
- O 0 3.988418484368594e-06
cell O 0 6.934663815627573e-06
autonomous O 0 6.877207283650932e-07
. O 0 2.1790751816297416e-06

Rescued O 0 1.929844256665092e-05
embryos O 0 6.412947186618112e-07
show O 0 3.8030410109968216e-07
severe O 0 6.520924216601998e-05
anterior O 0 0.07633603364229202
truncations O 1 0.9988923668861389
, O 0 1.5333679925788601e-07
indicating O 0 2.989679046550009e-07
a O 0 1.6565506300025845e-08
second O 0 4.679957044118055e-08
important O 0 1.4300529649347027e-08
role O 0 1.608416155818304e-08
for O 0 1.0667380756501643e-08
Smad4 O 0 4.168830855633132e-06
in O 0 7.813063973571843e-08
anterior O 0 1.0313699931430165e-05
patterning O 0 2.020113606704399e-05
during O 0 2.3559350665891543e-06
embryogenesis O 0 1.7732290871208534e-05
. O 0 3.6026704037794843e-06

Prevalence O 0 5.4637715948047116e-05
of O 0 1.0597576647342066e-06
p16 O 0 2.8533590921142604e-06
and O 0 6.440736228796595e-07
CDK4 O 0 0.0016088408883661032
germline O 0 9.951570245902985e-05
mutations O 0 5.536927574212314e-07
in O 0 1.0380482251548528e-07
48 O 0 8.881638677848969e-06
melanoma B-Disease 1 0.9999988079071045
- O 0 0.005472593009471893
prone O 0 4.425843872013502e-05
families O 0 2.1287497986577364e-08
in O 0 9.319195015677906e-08
France O 0 6.846980249974877e-05
. O 0 0.00010498503979761153

The O 0 8.454950148006901e-06
French O 0 0.001577993854880333
Familial B-Disease 1 0.9991662502288818
Melanoma I-Disease 1 0.9999997615814209
Study O 0 3.6560866192303365e-06
Group O 0 6.541308152918646e-07
. O 0 5.64923720958177e-06

Germline O 0 0.0003551022964529693
mutations O 0 8.514810474480328e-07
in O 0 6.284886211460616e-08
the O 0 7.541920865605789e-08
p16 O 0 3.077439032495022e-07
and O 0 6.442192557187809e-08
CDK4 O 0 4.624711436918005e-06
genes O 0 7.374238997215343e-09
have O 0 6.936469731932959e-10
been O 0 2.029070467202132e-09
reported O 0 2.4188040459449667e-09
in O 0 7.440738025721316e-10
a O 0 2.700482060191689e-09
subset O 0 1.733776144874355e-07
of O 0 2.4158228484338906e-07
melanoma B-Disease 0 0.20316068828105927
pedigrees O 0 1.9853038679684687e-07
, O 0 1.9178161281274697e-09
but O 0 8.497443859667442e-10
their O 0 7.954400471632539e-10
prevalence O 0 1.8632562159837107e-08
is O 0 6.172646421775951e-11
not O 0 2.4455046321314455e-10
well O 0 1.8979509075478518e-09
known O 0 2.9220471375879242e-08
. O 0 9.906331115416833e-07

We O 0 5.297687835081888e-07
searched O 0 1.4857701557957625e-07
for O 0 1.893983858636261e-09
such O 0 3.660594938281747e-09
germline O 0 2.327508582311566e-06
mutations O 0 7.93358978512515e-08
in O 0 1.7227703708044828e-08
48 O 0 1.0404590966572869e-06
French O 1 0.998516857624054
melanoma B-Disease 1 1.0
- O 0 0.1163431778550148
prone O 0 4.2636434045562055e-06
families O 0 1.52748313997364e-09
selected O 0 3.593471520346725e-09
according O 0 4.42069242323484e-10
to O 0 1.9340404278089807e-10
two O 0 3.158253936152988e-10
major O 0 2.038088808831162e-09
criteria O 0 2.6335934322219146e-08
families O 0 1.7018306208704814e-10
with O 0 1.2221805512080408e-10
at O 0 6.1938569828612344e-09
least O 0 7.439092675198822e-10
three O 0 5.906903854935308e-10
affected O 0 1.4143625159945827e-09
members O 0 1.0572819286736035e-09
( O 0 1.3458024694656956e-09
n O 0 3.5646447571480167e-08
= O 0 5.897363308804415e-08
20 O 0 8.65645510828017e-09
) O 0 2.3584850739055696e-10
or O 0 2.8496768833541353e-10
families O 0 3.707260887164665e-11
with O 0 4.606664702477836e-11
two O 0 2.530212706020052e-10
affected O 0 9.934613132145387e-10
members O 0 1.0475999928649671e-10
, O 0 1.7212181679937544e-10
one O 0 2.1461066257444372e-10
of O 0 8.352246672060915e-10
them O 0 5.925635537806784e-10
affected O 0 1.4416862148536325e-09
before O 0 1.147830719361309e-09
the O 0 6.460052492940349e-10
age O 0 1.6614798425962363e-09
of O 0 1.2082878031449695e-09
50 O 0 1.4301178019593408e-09
( O 0 6.070949853942409e-10
n O 0 1.4241680723614536e-08
= O 0 3.9714642241506226e-08
28 O 0 2.5518554380710157e-08
) O 0 6.471324032197856e-10
, O 0 3.384216795687678e-10
and O 0 4.856440249945138e-10
one O 0 2.2460910908961296e-10
additional O 0 2.0148669399588925e-09
minor O 0 1.0038451137006632e-07
criterion O 0 3.984111572208349e-06
. O 0 1.2804222251361352e-06

Sixteen O 0 2.35032584896544e-05
different O 0 3.3418061207157734e-07
p16 O 0 1.938694367709104e-06
germline O 0 3.1391316497320076e-06
mutations O 0 2.9281114422019527e-08
were O 0 5.360541344145986e-09
found O 0 6.081415371284038e-10
in O 0 6.225334692189222e-10
21 O 0 2.296600776219293e-08
families O 0 9.041893900274545e-10
, O 0 2.870933046850155e-09
while O 0 1.2658552428490566e-08
one O 0 2.6094228999795632e-08
germline O 0 2.965267185572884e-06
mutation O 0 6.405581132185034e-08
, O 0 1.5117340268488988e-08
Arg24His O 0 2.5345343601657078e-06
, O 0 8.713572086094246e-09
was O 0 5.205219011372719e-08
detected O 0 2.5579955931220866e-08
in O 0 5.461661789496475e-09
the O 0 8.529310946414626e-08
CDK4 O 0 6.408071203622967e-05
gene O 0 1.0989260772475973e-06
. O 0 3.446454002187238e-06

The O 0 8.323261795339931e-07
frequency O 0 8.27320718599367e-07
of O 0 9.805965817122342e-08
p16 O 0 6.343476854908658e-08
gene O 0 3.6957568116946504e-09
mutation O 0 2.4489179573095043e-09
in O 0 9.136323364522525e-10
our O 0 1.306657559929647e-09
sample O 0 2.944602339738367e-10
( O 0 4.481751914031662e-10
44 O 0 1.9185844024605103e-09
% O 0 7.996324158376922e-10
) O 0 5.277249748303348e-10
is O 0 2.840072343968103e-10
among O 0 7.350896003011087e-10
the O 0 1.7809581587258094e-09
highest O 0 2.991912140259956e-08
rates O 0 6.122957696419462e-09
yet O 0 2.3572450658093658e-09
reported O 0 2.048064606796629e-09
and O 0 1.0727136956489858e-09
the O 0 6.032435440062045e-09
CDK4 O 0 1.3165042673790595e-06
mutation O 0 3.2246216807862993e-09
is O 0 1.2413867156446656e-10
the O 0 4.670758224634142e-10
second O 0 2.1211370437868027e-09
mutation O 0 8.625170577758468e-10
detected O 0 1.3803187481897794e-09
in O 0 5.695194316146512e-10
this O 0 1.4876148091147456e-09
gene O 0 2.7235850907914028e-08
worldwide O 0 4.784501328458646e-08
. O 0 1.2156995126133552e-06

In O 0 1.4583800975742633e-06
summary O 0 2.7646912712953053e-05
, O 0 3.1221947693893526e-08
our O 0 3.163140505080264e-08
results O 0 5.5204722571033926e-08
show O 0 1.1255615106620098e-08
frequent O 0 3.960705541317111e-09
involvement O 0 3.96569639349309e-08
of O 0 4.637810135932341e-08
the O 0 4.919186480378812e-08
p16 O 0 2.2972675139953935e-07
gene O 0 4.4510795049745866e-08
in O 0 2.374248531111789e-08
familial B-Disease 0 6.152277364890324e-06
melanoma I-Disease 0 0.0010358854196965694
and O 0 4.131623398961892e-08
confirm O 0 7.181043315540592e-08
the O 0 1.1525237653131626e-08
role O 0 3.116251434676087e-08
of O 0 8.524008876520384e-08
the O 0 1.3362580375542166e-07
CDK4 O 0 0.000494510808493942
gene O 0 1.4889772614878893e-07
as O 0 3.904809631194439e-08
a O 0 1.2766859924795426e-07
melanoma B-Disease 1 0.5175814628601074
- O 0 1.1739405636035372e-05
predisposing O 0 1.3518369996745605e-06
gene O 0 1.4181942731283925e-07
. O 0 2.1792779136831086e-07
. O 0 2.545794131947332e-06

Progression O 0 0.00013676391972694546
of O 0 1.2410810086294077e-05
somatic O 0 8.776824688538909e-05
CTG O 0 4.4146188884042203e-05
repeat O 0 2.202188369437863e-07
length O 0 9.290882729828809e-09
heterogeneity O 0 3.0634474512680754e-08
in O 0 1.041108643740074e-09
the O 0 2.071684823690134e-09
blood O 0 1.424442430675299e-08
cells O 0 1.1448737495811656e-06
of O 0 0.0001891755237011239
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 3.3466643799329177e-05
. O 0 5.708795015380019e-06

The O 0 8.587751665345422e-08
genetic O 0 7.152351599870599e-08
basis O 0 2.701421806250437e-07
of O 0 0.00025798994465731084
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.8488455414772034
DM B-Disease 1 1.0
) O 0 8.83028672404862e-09
is O 0 2.9064581297255643e-10
the O 0 9.915550602812573e-10
expansion O 0 7.244612909573789e-09
of O 0 4.255258811980411e-09
an O 0 1.4825926042405513e-09
unstable O 0 3.480802490685164e-07
CTG O 0 2.5312058369308943e-06
repeat O 0 3.70494781520847e-08
in O 0 2.3318096342705985e-09
the O 0 9.798409195127533e-09
34 O 0 6.209734237927478e-08
UTR O 0 4.035955953440862e-06
of O 0 1.6595842566857755e-07
the O 0 7.175942755566211e-07
DM B-Disease 1 1.0
protein O 0 2.4468093329232943e-07
kinase O 0 1.314796378437677e-07
gene O 0 7.935675228054606e-09
on O 0 4.122303209896927e-08
chromosome O 0 1.7139807084731729e-07
19 O 0 1.284223117181682e-06
. O 0 3.3379408250766573e-06

One O 0 1.4736680498117494e-07
of O 0 9.566942793526323e-08
the O 0 2.264257936701597e-08
principal O 0 7.864196760465347e-08
features O 0 1.0788225424107623e-08
of O 0 4.092611050054984e-08
the O 0 4.998011036150274e-07
DM B-Disease 1 1.0
mutation O 0 1.3519296260255942e-07
is O 0 9.457694627457158e-10
an O 0 3.0518154670033937e-10
extraordinarily O 0 1.7841548682895336e-08
high O 0 1.2446650998754194e-07
level O 0 2.7335308914189227e-06
of O 0 1.9081448954239022e-07
somatic O 0 7.025177183095366e-06
mosaicism O 0 2.630737526487792e-06
, O 0 6.033986088560539e-10
due O 0 6.932346696686409e-09
to O 0 4.700241307276087e-10
an O 0 2.1042600995002658e-10
extremely O 0 2.794102060832415e-09
high O 0 2.5294770722439353e-08
degree O 0 1.3967066081477242e-07
of O 0 1.6081401099654613e-08
somatic O 0 3.3698765378176176e-07
instability O 0 2.2415738598624557e-08
both O 0 2.5333770636848385e-09
within O 0 3.4356375522293092e-09
and O 0 1.766030433003607e-09
between O 0 8.505588233731487e-09
different O 0 2.641340479669907e-08
tissues O 0 6.688637768093031e-07
. O 0 7.685670766477415e-07

This O 0 1.533196751779542e-07
instability O 0 4.0424751546197513e-07
appears O 0 1.6617310194533275e-08
to O 0 7.408690883003999e-10
be O 0 7.376021460281379e-10
biased O 0 1.1321477977332961e-08
towards O 0 1.508472680100681e-09
further O 0 5.830007587803721e-10
expansion O 0 1.3941807708306442e-09
and O 0 2.3113243263761518e-10
continuous O 0 2.3922845926449554e-09
throughout O 0 2.931332954148047e-10
the O 0 8.518946104096869e-10
life O 0 3.903591616616353e-10
of O 0 1.6260709445603538e-10
an O 0 3.754024174851267e-11
individual O 0 6.424843990160412e-11
, O 0 7.177240052280709e-11
features O 0 1.3378041729961154e-10
that O 0 2.5668280001500676e-11
could O 0 2.0084350849103316e-10
be O 0 4.4679504540567905e-10
associated O 0 1.5227705763010135e-09
with O 0 2.4551322086452387e-10
the O 0 6.698523513648524e-09
progressive O 0 3.379252348167938e-06
nature O 0 7.324004513975524e-08
of O 0 8.915671401155123e-08
the O 0 2.1447200992952276e-07
disease O 0 9.696171218820382e-06
. O 0 1.680827267591667e-06

Although O 0 3.734220399564947e-07
increasing O 0 1.555598458935492e-07
measured O 0 1.094830111014744e-07
allele O 0 1.3820783806295367e-07
size O 0 3.892242972369786e-08
between O 0 1.2132328031100315e-08
patients O 0 7.96009658188268e-09
clearly O 0 9.457338912000068e-09
correlates O 0 1.3972456081035034e-08
with O 0 1.4069624632018218e-10
an O 0 4.97615837424803e-11
increased O 0 1.0546374884512488e-09
severity O 0 1.758050132139033e-07
of O 0 2.2518456432862877e-08
symptoms O 0 6.068859903507473e-08
and O 0 8.632148329468237e-10
an O 0 1.062561982845267e-10
earlier O 0 1.7625442216839815e-09
age O 0 3.36065686390441e-09
of O 0 1.096785440246606e-09
onset O 0 1.8471807194941903e-08
, O 0 9.065945216768512e-11
this O 0 4.336509276670064e-11
correlation O 0 3.8696029713847224e-10
is O 0 3.095984926759776e-11
not O 0 1.0112847365073563e-10
precise O 0 8.215017999191332e-09
and O 0 2.7014608328101986e-09
measured O 0 7.552527492293848e-09
allele O 0 1.3761974670956079e-08
length O 0 1.2250073178066145e-09
cannot O 0 6.475126546057197e-10
be O 0 2.2367625807095948e-10
used O 0 1.3033041312837668e-10
as O 0 1.841595903551152e-10
an O 0 5.3075304567995474e-11
accurate O 0 1.6629993382366592e-08
predictor O 0 3.127950094494736e-07
of O 0 1.867180188241946e-08
age O 0 3.405271229439677e-07
of O 0 4.2318370674365724e-07
onset O 0 0.0004320470616221428
. O 0 7.255689524754416e-06

In O 0 1.4827338645773125e-07
order O 0 6.82372771620976e-08
to O 0 6.56403997822963e-09
further O 0 3.310848128990074e-08
characterize O 0 2.974907147290651e-07
the O 0 7.083641406779861e-08
dynamics O 0 3.4780391615640838e-06
of O 0 4.950613856635755e-06
DM B-Disease 1 1.0
CTG O 0 0.0014575417153537273
repeat O 0 1.0777098395919893e-06
somatic O 0 1.134830654336838e-06
instability O 0 6.86796681748092e-08
, O 0 1.692815554399374e-09
we O 0 2.187626080285554e-09
have O 0 4.4220666017835697e-10
studied O 0 1.656234793756539e-08
repeat O 0 4.217467708400591e-09
length O 0 7.414500680091862e-10
changes O 0 5.405921266188329e-10
over O 0 4.1993811206175735e-10
time O 0 5.278921189066921e-10
in O 0 6.805758734351741e-10
111 O 0 2.9955378977319924e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 1.555989470602981e-08
with O 0 9.35517885380932e-10
varying O 0 2.842741864128584e-08
clinical O 0 3.255970568716293e-07
severity O 0 6.782062769161712e-07
and O 0 5.018505788711991e-08
CTG O 0 2.229133997388999e-06
repeat O 0 1.7368881444213002e-08
size O 0 3.329311715205563e-09
over O 0 1.0466677524689771e-09
time O 0 8.225345404788698e-10
intervals O 0 3.6739689068809867e-09
of O 0 9.357213892613458e-10
1 O 0 1.4044652552058778e-08
- O 0 1.1365573371335813e-08
7 O 0 4.9960807047000344e-08
years O 0 3.1842784409263913e-08
. O 0 2.011322521866532e-07

We O 0 1.2411103966769588e-07
have O 0 1.8922940991927817e-09
found O 0 9.931222511028182e-10
a O 0 5.238859346334834e-10
direct O 0 2.240213348159159e-09
progression O 0 9.93558799677885e-08
of O 0 2.0371569320332128e-08
the O 0 8.570664178364495e-09
size O 0 1.2667054960502355e-08
heterogeneity O 0 9.596988803650675e-08
over O 0 7.514664446262032e-09
time O 0 7.607045660051881e-09
related O 0 8.572854426347476e-09
to O 0 8.429981712687606e-10
initial O 0 3.77972249054892e-08
CTG O 0 2.617169457153068e-06
repeat O 0 2.8197479906566514e-08
size O 0 6.313237932431548e-09
and O 0 1.7257029139017277e-09
the O 0 1.2986670627768149e-09
time O 0 1.965664075953555e-09
interval O 0 1.0325994281856765e-08
and O 0 2.565414825017598e-10
always O 0 7.709405336342456e-10
biased O 0 1.966924934038161e-08
towards O 0 5.563098426364377e-09
further O 0 1.181181374931839e-08
expansion O 0 1.2537405780221889e-07
. O 0 5.754512812927715e-07

Attempts O 0 1.961498355740332e-06
to O 0 7.764663223497337e-08
mathematically O 0 1.345867076452123e-06
model O 0 1.04234757714039e-07
the O 0 1.274864036560075e-08
dynamics O 0 1.6548082726330904e-07
have O 0 1.1005699684929482e-09
proved O 0 4.589867330651032e-08
only O 0 1.1192498039491738e-09
partially O 0 8.636006576523414e-09
successful O 0 1.2573844188068506e-09
suggesting O 0 1.6039487515939754e-09
that O 0 6.60658819318094e-11
individual O 0 7.425719761311456e-11
specific O 0 8.849335153549021e-10
genetic O 0 1.3001176135674086e-08
and O 0 4.703113010151583e-09
/ O 0 2.7768905397351773e-07
or O 0 4.071493808766036e-09
environmental O 0 3.7488474546876205e-09
factors O 0 6.24508000868218e-09
also O 0 9.42750988386365e-10
play O 0 4.221918370461708e-09
a O 0 1.1833545254802402e-09
role O 0 8.529567274706551e-09
in O 0 1.4238041856629025e-08
somatic O 0 3.092129645665409e-06
mosaicism O 0 1.1898995580850169e-05
. O 0 1.5006612841261813e-07
. O 0 1.1935736665691365e-06

Aspartylglucosaminuria B-Disease 1 0.9999958276748657
among O 0 1.6976523511402775e-06
Palestinian O 0 3.205845132470131e-05
Arabs O 0 2.5185854610754177e-05
. O 0 6.493749424407724e-06

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9772157669067383
AGU B-Disease 1 1.0
) O 0 1.1296353363832168e-07
is O 0 3.1855404980518642e-09
a O 0 7.148583947014231e-09
rare O 0 1.4419105127672083e-06
disorder B-Disease 1 0.9998666048049927
of I-Disease 0 0.06275250017642975
glycoprotein I-Disease 0 0.004692834336310625
metabolism I-Disease 0 0.0001299128489335999
caused O 0 8.437791620963253e-08
by O 0 9.036863701794573e-09
the O 0 3.5438776535556826e-07
deficiency B-Disease 0 0.22737134993076324
of I-Disease 0 1.692938712949399e-05
the I-Disease 0 1.652699552323611e-06
lysosomal I-Disease 0 5.652045729220845e-05
enzyme I-Disease 0 2.6640637429409253e-07
aspartylglucosaminidase I-Disease 0 2.40823737840401e-06
( O 0 2.2576125857654006e-08
AGA O 0 5.697411779692629e-06
) O 0 9.775992992899774e-08
. O 0 2.0636073259083787e-06

AGU B-Disease 1 1.0
is O 0 1.0974838460242609e-06
inherited O 0 3.989509423263371e-05
as O 0 1.4420766092371196e-07
an O 0 1.8382884547918366e-08
autosomal O 0 0.0981086865067482
recessive O 0 0.011825534515082836
trait O 0 6.897542789374711e-06
and O 0 1.71980644836367e-07
occurs O 0 2.8591420786483468e-08
with O 0 7.88270559937132e-10
a O 0 3.714909269092459e-09
high O 0 1.488603942334521e-07
frequency O 0 3.7324898016777297e-07
in O 0 3.46574213772044e-09
Finland O 0 3.993081065800652e-08
because O 0 4.785456475531191e-09
of O 0 1.3305784030137602e-08
a O 0 5.725235396880635e-09
founder O 0 1.5084266635767563e-07
effect O 0 3.9474340951528575e-07
. O 0 6.398084337888577e-07

While O 0 8.663080279802671e-07
very O 0 5.785890522247428e-08
few O 0 3.465677522740407e-08
patients O 0 1.4996148323120906e-08
with O 0 9.281566626384574e-09
AGU B-Disease 1 1.0
have O 0 1.568073670910053e-08
been O 0 5.430758065472219e-09
reported O 0 7.58181162296978e-09
from O 0 1.6823608062210837e-09
non O 0 2.5237332579308713e-07
- O 0 1.29454562625142e-07
Finnish O 0 3.1197245675684826e-07
origin O 0 2.5043362938959035e-08
, O 0 5.121722157497288e-09
we O 0 1.747071820545898e-08
diagnosed O 0 1.45796161632461e-06
the O 0 1.284211226248999e-08
disorder O 0 2.046799210120298e-07
in O 0 3.6564082872558856e-09
8 O 0 6.46789999336761e-08
patients O 0 7.771026599989739e-10
originating O 0 1.5202776815215202e-09
from O 0 2.625316630755492e-09
3 O 0 9.709874149166353e-08
unrelated O 0 1.5051941915089628e-08
families O 0 1.6570958494277477e-10
, O 0 1.2473132249279928e-10
all O 0 2.8545946162417124e-10
Palestinian O 0 2.7139915204088538e-08
Arabs O 0 1.772682978185003e-08
from O 0 7.730638351688413e-10
the O 0 1.2932117599007142e-09
region O 0 9.852869631288286e-09
of O 0 4.049261193017628e-08
Jerusalem O 0 9.667953236203175e-06
. O 0 5.5227433222171385e-06

The O 0 7.11284428689396e-07
clinical O 0 3.438208295847289e-05
diagnosis O 1 0.9997814297676086
of O 1 0.8559527397155762
AGU B-Disease 1 1.0
is O 0 1.0581180731605855e-07
often O 0 2.336858484497384e-09
difficult O 0 5.245951228971535e-09
, O 0 3.3507666086229904e-10
in O 0 1.3884031424549192e-10
particular O 0 3.175262830446002e-10
early O 0 1.5590137181220598e-08
in O 0 6.640879512964659e-10
the O 0 1.9280084195827385e-09
course O 0 1.406813687765407e-08
of O 0 3.2909195368802102e-09
the O 0 1.0644393810821384e-08
disease O 0 1.2565271845232928e-07
, O 0 4.008277598721577e-10
and O 0 5.308869455156184e-10
most O 0 2.1082452450471578e-10
of O 0 1.5653833784767812e-09
the O 0 1.4628875888433868e-09
patients O 0 1.1665047816578067e-09
are O 0 8.524960182221264e-10
diagnosed O 0 2.8290029874256106e-08
after O 0 5.067616548615206e-09
the O 0 2.1231487679074235e-09
age O 0 4.102831852037525e-09
of O 0 6.3087002288853e-09
5 O 0 4.545305642977837e-08
years O 0 6.06524892532434e-08
. O 0 6.998797630330955e-07

However O 0 8.855960800246976e-07
, O 0 1.8798193224256465e-08
since O 0 1.458772924678442e-08
these O 0 1.231865387474329e-09
patients O 0 8.016329267057642e-10
excrete O 0 1.6019439996739493e-08
early O 0 1.0000836603296648e-08
large O 0 7.92659438086929e-10
amounts O 0 5.061511210158187e-09
of O 0 9.972245251788081e-09
aspartylglucosamine O 0 3.472331115972338e-07
in O 0 5.41618305760494e-09
urine O 0 1.74303771416362e-08
, O 0 1.490790380032081e-09
biochemical O 0 1.9409345242138443e-08
screening O 0 9.754030472208797e-09
is O 0 6.805446761681821e-10
easy O 0 7.212323183125591e-09
by O 0 4.072860715353954e-09
urine O 0 2.581241709265214e-08
chromatography O 0 4.778003130923025e-07
. O 0 1.204317783276565e-07
. O 0 6.905052032379899e-07

Detection O 0 8.75211935635889e-06
of O 0 3.563527286587487e-07
heterozygous O 0 7.669110146935054e-08
carriers O 0 2.1977777819870425e-08
of O 0 2.902847029417899e-07
the O 0 0.0006005993345752358
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 5.68441282666754e-05
ATM O 0 2.8015592761221342e-05
) O 0 5.540099490275452e-09
gene O 0 2.9828848280288867e-09
by O 0 6.106419814244646e-09
G2 O 0 9.598087672202382e-06
phase O 0 4.50512061433983e-06
chromosomal O 0 2.2822662231192226e-06
radiosensitivity O 0 3.3376859391864855e-06
of O 0 2.111239609803306e-07
peripheral O 0 9.59564476943342e-06
blood O 0 2.5409358386241365e-06
lymphocytes O 0 1.336410059593618e-05
. O 0 5.425094514066586e-06

In O 0 0.0502086766064167
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.0373668146712589e-08
patients O 0 7.023966408503668e-10
, O 0 9.097210484920737e-11
mutations O 0 2.3936572168814507e-10
in O 0 9.536741535365323e-11
a O 0 2.789712905126862e-10
single O 0 4.055030755623079e-10
gene O 0 1.6472112562837538e-09
, O 0 1.343194555580851e-09
ATM O 0 1.425904088137031e-07
, O 0 7.010595437506595e-10
result O 0 4.950329479669335e-09
in O 0 5.663328916938326e-09
an O 0 8.949658081292e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 4.338052804087056e-06
embraces O 0 5.497365691553568e-07
a O 0 9.882777263214848e-09
variety O 0 3.3971417678912985e-08
of O 0 3.230416112387502e-08
clinical O 0 6.586641916328517e-07
features O 0 2.2346240413639862e-08
and O 0 9.196716277415362e-09
manifests O 0 3.048781493930619e-08
extreme O 0 2.1929751881089032e-07
radiosensitivity O 0 1.5062350939842872e-05
and O 0 2.6284746823534988e-08
a O 0 8.566610532056984e-09
strong O 0 4.144899534708202e-08
pre O 0 1.4534923138853628e-05
- O 0 1.050301875693549e-06
disposition O 0 2.8915706025145482e-06
to O 0 1.1390361720486908e-07
malignancy B-Disease 0 9.447990305488929e-05
. O 0 3.0348510335898027e-06

Heterozygotes O 0 1.188970600196626e-05
for O 0 4.718083701504838e-08
the O 0 3.726819741700638e-08
ATM O 0 3.5309435020280944e-07
gene O 0 2.2292592216643925e-09
have O 0 8.623064484680754e-10
no O 0 2.3886006506046442e-09
clinical O 0 5.38138067440741e-08
expression O 0 3.1127584065870906e-08
of O 0 5.83469613957277e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 3.3779653563215106e-07
may O 0 3.3643854635556636e-07
be O 0 8.787547756128333e-08
cancer B-Disease 0 5.512843017640989e-07
prone O 0 2.480817506977928e-08
with O 0 2.677187083133248e-10
a O 0 8.871338663674067e-10
moderate O 0 4.226222927172785e-08
increase O 0 1.4067862430522382e-09
in O 0 2.7100122146350714e-09
in O 0 1.270785521256812e-08
vitro O 0 8.240049282903783e-07
radiosensitivity O 0 6.473888333857758e-06
. O 0 1.279338448512135e-06

We O 0 1.1718550467776367e-06
performed O 0 1.4162115746785275e-07
a O 0 1.5080685500379332e-07
blind O 0 1.3554218867284362e-06
chromosomal O 0 6.869328444736311e-06
analysis O 0 9.14764541448676e-07
on O 0 2.152316710635205e-06
G2 O 0 3.6055145756108686e-05
- O 0 2.47136085818056e-07
phase O 0 6.03025796408474e-07
lymphocytes O 0 2.55906922319582e-08
from O 0 2.0742429995834755e-09
7 O 0 3.5301621892358526e-07
unrelated O 0 1.5850806676098728e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.1566263797012653e-07
, O 0 1.0620240686876059e-08
13 O 0 1.2242644231719169e-07
obligate O 0 4.465816800802713e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 2.750528437900357e-06
( O 0 2.5304263129299898e-09
parents O 0 3.958512961865779e-10
of O 0 6.827236553874627e-10
the O 0 7.234860488480876e-10
patients O 0 1.2528592052696297e-10
) O 0 1.7948979802451248e-10
, O 0 4.766961270163961e-10
and O 0 2.921499486774337e-09
14 O 0 7.340016594525878e-08
normal O 0 2.2210690175938907e-08
controls O 0 1.913257463570517e-08
following O 0 1.1140132372133849e-08
X O 0 3.836470909845957e-07
- O 0 1.6123722801353324e-08
irradiation O 0 6.939649743742393e-09
with O 0 3.701617345974739e-10
1 O 0 3.2844560848843685e-08
Gy O 0 6.74376565257262e-07
in O 0 4.06616046388919e-10
order O 0 2.0654351562399142e-09
to O 0 5.171310601959078e-10
evaluate O 0 1.3424985567667136e-08
this O 0 6.974145705385126e-10
cytogenetic O 0 1.8671308055218105e-07
method O 0 2.252794928381263e-08
as O 0 1.9021659802831437e-09
a O 0 1.1355946183400079e-09
tool O 0 4.85346340894921e-08
for O 0 2.2162689461424634e-09
detection O 0 1.3362057416088646e-07
of O 0 6.696673438000289e-08
ATM O 0 4.961456397722941e-06
carriers O 0 2.542891763823718e-07
. O 0 4.2481428863538895e-06

Both O 0 6.0018792282789946e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 0.0005325992242433131
and O 0 8.321406852473956e-08
heterozygotes O 0 7.294364650078933e-07
showed O 0 2.37929853597052e-08
significantly O 0 5.580548467776225e-09
increased O 0 3.173036278170116e-09
levels O 0 2.5599332431625044e-08
of O 0 1.0021707907981181e-08
radiation O 0 0.00010001554619520903
- O 0 1.8934107401946676e-06
induced O 0 9.069586894838721e-07
chromatid O 0 8.143684340211621e-07
damage O 0 5.618862886080933e-08
relative O 0 1.0529898730737841e-08
to O 0 4.5732156950251124e-10
that O 0 3.7819902765079405e-10
of O 0 9.417091106911357e-09
normal O 0 1.5127383790058957e-07
controls O 0 5.006259016226977e-07
. O 0 1.3511873930838192e-06

These O 0 3.6399538316800317e-07
results O 0 7.41524274872063e-07
show O 0 4.709317735773766e-08
that O 0 4.286261567898464e-09
the O 0 5.913831202519759e-08
G2 O 0 2.0048099031555466e-05
- O 0 6.448929070757004e-07
phase O 0 6.873810889373999e-06
chromosomal O 0 8.19601893908839e-07
radiosensitivity O 0 8.908988888833846e-07
assay O 0 3.1114996801306916e-08
can O 0 3.5395733566367937e-10
be O 0 2.4290064404297596e-10
used O 0 1.5317944135340156e-10
for O 0 2.881667959808709e-10
the O 0 7.252157763204536e-10
detection O 0 1.0347508805352845e-07
of O 0 3.222985185402649e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.00010060879139928147
. O 0 5.499744020198705e-06

In O 0 5.962493219158205e-07
combination O 0 1.3683030601896462e-06
with O 0 3.8180235861773326e-08
molecular O 0 1.0767199455585796e-05
genetic O 0 1.523524417734734e-07
analyses O 0 2.897168016602336e-08
, O 0 6.44433728602678e-10
this O 0 1.0488735574520902e-10
test O 0 1.4331924536037377e-09
may O 0 4.266788866669202e-10
be O 0 1.322367076950215e-10
of O 0 1.311823566441106e-10
value O 0 1.7105947214268724e-10
in O 0 7.305772653509734e-11
studies O 0 3.248820101831029e-10
of O 0 5.559987470427075e-10
familial B-Disease 0 1.8162030102075732e-08
and I-Disease 0 1.2686978578813068e-08
sporadic I-Disease 0 3.0672297270939453e-06
cancers I-Disease 0 0.0009423693991266191
aimed O 0 2.7663543278322322e-06
at O 0 3.9441454191546654e-07
determination O 0 5.1501430675671145e-08
of O 0 1.7592904910657126e-08
the O 0 2.5036903661401766e-09
potential O 0 1.1816275957698963e-08
involvement O 0 3.178101692924429e-08
of O 0 1.5037055334232718e-07
ATM O 0 6.964660315134097e-06
mutations O 0 1.0737974776020565e-07
in O 0 1.0964952501524294e-08
tumor B-Disease 0 4.113289378437912e-06
risk O 0 2.5886973276101344e-07
or O 0 4.7493507793205936e-08
development O 0 1.3299319334691972e-07
. O 0 3.195656361754118e-08
. O 0 8.805271249912039e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 6.300702352746157e-06
identification O 0 2.7555381620913977e-07
and O 0 1.7107661065551838e-08
detection O 0 5.639013807012816e-07
of O 0 2.3477343802369433e-07
founder O 0 2.355252036068123e-06
- O 0 2.0513326148829947e-07
effect O 0 4.3492310197734696e-08
mutations O 0 5.91904170121893e-09
in O 0 1.135194049872723e-09
the O 0 4.685081211874831e-09
ATM O 0 4.014325938328511e-08
gene O 0 6.687605469402058e-10
in O 0 4.413068244168983e-10
ethnic O 0 6.403551022771126e-09
populations O 0 2.4745698823380735e-08
. O 0 5.513926453204476e-07

To O 0 3.1554546353618207e-07
facilitate O 0 1.5198239111668954e-07
the O 0 2.4919906138620718e-08
evaluation O 0 1.062997228018503e-07
of O 0 1.1140072331272677e-07
ATM O 0 1.0399528946436476e-05
heterozygotes O 0 3.5489273386701825e-07
for O 0 3.361201761364896e-09
susceptibility O 0 1.776462852376426e-07
to O 0 5.300353045356587e-09
other O 0 2.5041263285174864e-08
diseases O 1 0.9864031076431274
, O 0 6.500023297384416e-10
such O 0 1.0139351580562561e-09
as O 0 1.461943384128972e-07
breast B-Disease 0 1.5742007235530764e-05
cancer I-Disease 0 1.763928167974882e-07
, O 0 1.916847125471577e-09
we O 0 2.2861237347626684e-09
have O 0 3.8694628057278635e-10
attempted O 0 4.4826942158238126e-09
to O 0 6.554503051425797e-10
define O 0 5.473864028715525e-09
the O 0 1.0284476603672488e-09
most O 0 1.290505619033766e-10
common O 0 3.781680246728314e-10
mutations O 0 3.1389044141683087e-10
and O 0 2.2524446197103032e-10
their O 0 5.803535985116071e-10
frequencies O 0 5.979821793289375e-08
in O 0 1.551281485490108e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.953036367893219
A B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
T I-Disease 1 0.9999994039535522
) O 0 3.074315690909657e-09
homozygotes O 0 3.4603736764893256e-08
from O 0 3.8912442712479844e-10
10 O 0 1.6007886127766824e-09
ethnic O 0 1.875692490216352e-09
populations O 0 1.0154723284472311e-08
. O 0 2.8493218451330904e-07

Both O 0 3.932059655653575e-07
genomic O 0 4.501125658862293e-07
mutations O 0 6.31958911867514e-08
and O 0 5.185258888928956e-09
their O 0 3.59878726818863e-09
effects O 0 4.587923996268728e-08
on O 0 4.2200124283908735e-08
cDNA O 0 6.977212052561299e-08
were O 0 6.250301964882965e-08
characterized O 0 4.0764618347566284e-07
. O 0 1.4172871942719212e-06

Protein O 0 1.735393743729219e-05
- O 0 2.17727642848331e-06
truncation O 0 1.4335192872749758e-06
testing O 0 8.826721398236259e-08
of O 0 3.339145138170352e-08
the O 0 1.93745783860777e-08
entire O 0 6.46670343940059e-08
ATM O 0 1.4481585708381317e-07
cDNA O 0 2.4380693020020772e-08
detected O 0 1.6712890626990884e-08
92 O 0 7.779843258504116e-08
( O 0 2.0681749646200842e-09
66 O 0 1.7318170009161804e-08
% O 0 2.8728941448008527e-09
) O 0 1.4047591978538776e-09
truncating O 0 2.1679514361494512e-07
mutations O 0 1.5224722815787572e-08
in O 0 1.0796089355835647e-08
140 O 0 4.8408068664684833e-08
mutant O 0 4.131328523726552e-07
alleles O 0 6.021368221809098e-07
screened O 0 1.165343292086618e-06
. O 0 2.639178319441271e-06

The O 0 8.17744239611784e-06
haplotyping O 0 0.00012153666466474533
of O 0 7.905762799964577e-07
patients O 0 3.8094761123375065e-08
with O 0 3.5454943425605734e-09
identical O 0 7.856959882701631e-07
mutations O 0 1.314054145495902e-07
indicates O 0 2.6089301385923136e-08
that O 0 5.098035882333818e-10
almost O 0 1.2115602965323546e-09
all O 0 1.46299278247497e-10
of O 0 1.982141811796012e-10
these O 0 3.8415826075777204e-11
represent O 0 1.8618688535365635e-10
common O 0 9.622568297729117e-10
ancestry O 0 4.129665220897749e-10
and O 0 3.772933909740317e-10
that O 0 1.6701595662027557e-10
very O 0 2.257185105491999e-09
few O 0 9.458095640013653e-09
spontaneously O 0 5.967971361542368e-08
recurring O 0 4.1731716748927283e-08
ATM O 0 6.017510258971015e-07
mutations O 0 9.068119766197924e-08
exist O 0 2.853087721632619e-07
. O 0 1.6468842432004749e-06

Assays O 0 7.905847269285005e-06
requiring O 0 1.7461498202919756e-07
minimal O 0 1.1730755034022877e-07
amounts O 0 6.0100515675287625e-09
of O 0 7.1649375321669595e-09
genomic O 0 9.549766311067742e-09
DNA O 0 9.204805806461991e-09
were O 0 1.0228273783496888e-09
designed O 0 1.9497607972596143e-09
to O 0 4.3349901446276817e-10
allow O 0 1.438228314221135e-09
rapid O 0 4.966757227720109e-09
screening O 0 1.89837101594037e-09
for O 0 3.430070671939234e-10
common O 0 5.126902014040979e-09
ethnic O 0 1.596547960502903e-08
mutations O 0 2.912182992531598e-07
. O 0 4.469523844363721e-07

These O 0 1.5178900980572507e-07
rapid O 0 2.093443924877647e-07
assays O 0 2.1884834211505222e-07
detected O 0 2.4439030354983515e-08
mutations O 0 8.232208692504628e-09
in O 0 3.3863367665531996e-09
76 O 0 4.588099145053093e-08
% O 0 2.7813091829642644e-09
of O 0 3.28684386374789e-08
Costa O 0 1.3232941000751453e-06
Rican O 0 2.722258614085149e-07
patients O 0 4.852600099525262e-09
( O 0 8.873538570597361e-10
3 O 0 2.3697921847087855e-08
) O 0 5.57349333352164e-10
, O 0 5.840859462757919e-10
50 O 0 1.6125006885303605e-09
% O 0 5.786525147932764e-10
of O 0 5.424619420324461e-09
Norwegian O 0 2.3863802312007465e-07
patients O 0 2.5527497893307327e-09
( O 0 9.289000679757464e-10
1 O 0 2.2460845627847448e-08
) O 0 5.096616462196835e-10
, O 0 2.774059870702672e-10
25 O 0 8.770728032736486e-10
% O 0 2.7289279169728786e-10
of O 0 2.6455944102110607e-09
Polish O 0 2.3201633325697912e-07
patients O 0 3.6591569774202526e-09
( O 0 8.099785286930228e-10
4 O 0 2.245258023947372e-08
) O 0 3.0272401252418035e-10
, O 0 2.872772020268144e-10
and O 0 4.824063370989506e-10
14 O 0 4.593797342522521e-09
% O 0 2.614097827091655e-10
of O 0 1.412836403424933e-09
Italian O 0 1.4485922861240397e-07
patients O 0 2.0175587867043987e-09
( O 0 4.137249709490476e-10
1 O 0 2.3020170658583083e-08
) O 0 6.964734344805379e-10
, O 0 2.0057935867789922e-10
as O 0 3.136355064548013e-10
well O 0 4.191962332811272e-10
as O 0 2.367779028400463e-10
in O 0 1.6444605399623669e-10
patients O 0 3.158482642096061e-10
of O 0 5.834593252984632e-09
Amish O 0 1.0430331940369797e-06
/ O 0 4.655123007069051e-07
Mennonite O 0 1.1325461173328222e-06
and O 0 1.7835866117366095e-08
Irish O 0 2.3329879184075253e-07
English O 0 1.8079102801493718e-06
backgrounds O 0 5.362913725548424e-06
. O 0 3.1139959446591092e-06

Additional O 0 1.6205927977352985e-07
mutations O 0 1.0129193128705083e-07
were O 0 2.4778241680678548e-08
observed O 0 1.1448445746964353e-08
in O 0 1.6970214122835614e-09
Japanese O 0 4.3241264791049616e-08
, O 0 3.1763547347907206e-09
Utah O 0 2.4995834735364042e-08
Mormon O 0 1.1291287016490514e-08
, O 0 1.1993400717003055e-09
and O 0 4.246242912842035e-09
African O 0 6.44750315359488e-08
American O 0 2.5115163282407593e-08
patients O 0 7.664971946041987e-08
. O 0 1.410574668625486e-06

These O 0 1.8067055407300359e-07
assays O 0 5.75514377487707e-07
should O 0 2.547677802056114e-08
facilitate O 0 3.5918969132353595e-08
screening O 0 3.729457986878515e-08
for O 0 1.8439457960539585e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999978542327881
T I-Disease 1 0.9999997615814209
heterozygotes O 0 1.2016585060337093e-07
in O 0 6.672239427629734e-10
the O 0 7.752107289427101e-10
populations O 0 1.842066638113593e-10
studied O 0 7.751149944112967e-09
. O 0 5.202714703500533e-09
. O 0 1.5996820934560674e-07

The O 0 3.3645912481006235e-05
von B-Disease 1 0.9999955892562866
Hippel I-Disease 1 0.9999994039535522
- I-Disease 1 0.9999839067459106
Lindau I-Disease 1 0.9366666674613953
tumor I-Disease 0 4.9322778068017215e-05
suppressor O 0 4.624504072126001e-06
gene O 0 2.0619568275037636e-08
is O 0 1.223428913732505e-09
required O 0 7.435762228169551e-09
for O 0 5.978473716083954e-09
cell O 0 2.469155617745855e-07
cycle O 0 3.2199707789004606e-08
exit O 0 4.448499169029674e-08
upon O 0 4.624727978352894e-08
serum O 0 1.3221003314356494e-07
withdrawal O 0 5.893921866118035e-07
. O 0 1.9871538370352937e-06

The O 0 8.948241543293989e-07
inactivation O 0 7.010680747043807e-06
of O 0 4.647480125186121e-07
the O 0 5.797102744509175e-07
von B-Disease 1 0.9999934434890747
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 0.9999998807907104
( I-Disease 0 6.819955160608515e-06
VHL I-Disease 0 0.2762157917022705
) I-Disease 0 2.856635319403722e-07
tumor I-Disease 0 2.241221591248177e-05
suppressor O 0 3.593720248318277e-05
gene O 0 3.8105233102214697e-07
predisposes O 0 5.564496063925617e-07
affected O 0 2.7715136852179967e-08
individuals O 0 7.838177884522679e-10
to O 0 3.500594258909473e-09
the O 0 1.9556097186068655e-07
human O 1 0.9999401569366455
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
and O 0 7.900248277792343e-08
is O 0 1.2794332260313013e-09
associated O 0 1.3890613992373346e-08
with O 0 1.8964140480193237e-08
sporadic B-Disease 1 0.9941348433494568
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 2.7345004127710126e-05
RCC B-Disease 1 0.9997041821479797
) O 0 8.445036314697063e-08
and O 0 1.9802322981377074e-07
brain B-Disease 0 0.00025332538643851876
hemangioblastomas I-Disease 0 5.760505155194551e-05
. O 0 5.5530153986182995e-06

VHL O 0 0.016079260036349297
- O 0 9.620933269616216e-05
negative O 0 5.291242359817261e-06
786 O 0 2.8315396775724366e-05
- O 0 1.2698577847913839e-05
0 O 0 2.525679292375571e-06
RCC B-Disease 0 4.0400700527243316e-05
cells O 0 1.2392321480092505e-07
are O 0 5.132176017497159e-09
tumorigenic O 0 1.180162257696793e-06
in O 0 3.652715818702745e-08
nude O 0 9.295102358919394e-07
mice O 0 1.7769076876561485e-08
which O 0 8.822723662760268e-10
is O 0 3.8478323305390916e-10
suppressed O 0 9.730691807874337e-09
by O 0 3.4319422304029956e-10
the O 0 2.203560445224184e-09
reintroduction O 0 1.3710067037209228e-07
of O 0 9.606493733826937e-08
VHL B-Disease 0 0.00021571110119111836
. O 0 6.492609827546403e-06

Remarkably O 0 1.6088562915683724e-05
, O 0 6.260226115273326e-09
this O 0 8.061777356793698e-10
occurs O 0 2.6779647388508465e-09
without O 0 5.726961127550112e-09
affecting O 0 9.86339987463225e-09
the O 0 2.850037095214475e-09
growth O 0 5.626870969166475e-09
rate O 0 9.742669782042412e-09
and O 0 3.135483206406775e-09
cell O 0 3.1444326253904364e-08
cycle O 0 4.70009986486275e-09
profile O 0 3.076744192753722e-09
of O 0 1.2093346324348886e-09
these O 0 4.176679002654282e-10
cells O 0 1.8359153086677793e-09
in O 0 1.7543638763939384e-09
culture O 0 7.919317823734673e-08
. O 0 2.4711275159461366e-07

The O 0 5.941541985521326e-06
786 O 0 2.08655656024348e-05
- O 0 2.841037257894641e-06
0 O 0 4.880225787928794e-07
cell O 0 5.656378903040604e-07
line O 0 9.924489319246277e-08
, O 0 5.739755781775102e-09
like O 0 3.029523298891945e-09
many O 0 2.513072416832074e-09
cancer B-Disease 0 1.9445584698019047e-08
cells O 0 9.58774570847254e-09
, O 0 6.140614683403101e-10
fails O 0 7.88353649028295e-09
to O 0 2.844682267522103e-09
exit O 0 1.084916476656872e-07
the O 0 2.6981460621300357e-08
cell O 0 1.0315645226910419e-07
cycle O 0 1.8750425212488153e-08
upon O 0 1.774959912381746e-08
serum O 0 1.341177267022431e-07
withdrawal O 0 5.574529495788738e-07
. O 0 3.096449972872506e-06

Here O 0 2.1155699414521223e-06
, O 0 8.171386234323563e-09
it O 0 3.636112522187318e-10
is O 0 7.02140498520798e-11
shown O 0 1.1732093074812155e-10
that O 0 7.178088679005157e-11
reintroduction O 0 1.5643573547663436e-08
of O 0 4.703023304131193e-09
the O 0 1.135095040183387e-08
wild O 0 4.812691045685824e-08
- O 0 1.5058868996220554e-07
type O 0 1.3615214129458764e-06
VHL B-Disease 0 0.00014313642168417573
gene O 0 2.1211670286902518e-07
restores O 0 4.680090910369472e-07
the O 0 3.133709114422345e-08
ability O 0 5.31167039241609e-08
of O 0 8.412431498072692e-07
VHL O 1 0.9870469570159912
- O 0 0.0018379557877779007
negative O 0 1.744174187479075e-05
RCC B-Disease 1 0.9419122934341431
cancer I-Disease 0 4.481649398258014e-07
cells O 0 7.740335483674698e-09
to O 0 3.576070106703355e-09
exit O 0 9.034006609454082e-08
the O 0 4.887910876050228e-08
cell O 0 2.1592872201381397e-07
cycle O 0 3.743097920505534e-08
and O 0 1.0604169098371585e-08
enter O 0 2.8664268825195904e-07
G0 O 0 0.0014554522931575775
/ O 0 6.489236056950176e-06
quiescence O 0 6.0855504671053495e-06
in O 0 5.335593300515029e-08
low O 0 1.1948446854148642e-06
serum O 0 1.3190893923820113e-06
. O 0 1.95759093912784e-06

Both O 0 2.12954000744503e-05
VHL O 0 0.2113913893699646
- O 0 2.6313538910471834e-05
positive O 0 9.484511309665322e-08
and O 0 1.664680411295194e-07
VHL O 0 0.0002716413582675159
- O 0 1.549340254314302e-06
negative O 0 1.4744975374014757e-07
RCC B-Disease 0 8.223530130635481e-06
cells O 0 1.4257091507374753e-08
exit O 0 3.5999764946836876e-08
the O 0 2.728210990454727e-09
cell O 0 2.4136530996088368e-08
cycle O 0 4.437471723406361e-09
by O 0 1.1424663437509253e-09
contact O 0 2.057726078419364e-07
inhibition O 0 8.396198609261774e-06
. O 0 3.903755441569956e-06

The O 0 8.64178582560271e-06
cyclin O 0 5.338288610801101e-05
- O 0 4.149470441916492e-06
dependent O 0 3.0532163464158657e-07
kinase O 0 6.254881554923486e-07
inhibitor O 0 6.19184618244617e-07
, O 0 8.059013900663103e-09
p27 O 0 2.5210871967829007e-07
, O 0 2.1231691960110766e-09
accumulates O 0 8.397905482127044e-09
upon O 0 2.2703283697467214e-09
serum O 0 1.828374118773013e-09
withdrawal O 0 1.455178977316507e-09
, O 0 3.055531383466814e-10
only O 0 1.4153790639515051e-10
in O 0 1.1711635827804656e-10
the O 0 3.7995237511800894e-10
presence O 0 1.210220701430842e-09
of O 0 1.2675101856984838e-08
VHL B-Disease 0 4.630404419003753e-06
, O 0 1.462558296694283e-09
as O 0 5.597666219436803e-10
a O 0 2.840240542756334e-10
result O 0 2.3232680224083424e-09
of O 0 5.177688500168642e-09
the O 0 4.303521983217706e-09
stabilization O 0 3.8069995156320147e-08
of O 0 1.7511752048449125e-08
the O 0 5.7222802496426084e-08
protein O 0 2.927537252617185e-07
. O 0 6.255430093915493e-07

We O 0 4.7604879682694445e-07
propose O 0 1.209538709190383e-07
that O 0 7.079758446160156e-10
the O 0 3.3827536327635244e-09
loss O 0 5.430895555491588e-08
of O 0 9.517420096472051e-08
wild O 0 7.859878081717397e-08
- O 0 2.315377827244447e-07
type O 0 2.961056452477351e-06
VHL B-Disease 0 0.0021192319691181183
gene O 0 1.2524738224328757e-07
results O 0 2.0607936335181876e-07
in O 0 7.2608536960672154e-09
a O 0 1.162041751712195e-08
specific O 0 7.024294035318235e-08
cellular O 0 1.0775926284622983e-06
defect O 0 1.0754823875913644e-07
in O 0 1.5217697324487744e-08
serum O 0 3.175284746248508e-07
- O 0 5.187022793506912e-07
dependent O 0 2.4037294821255273e-08
growth O 0 4.803133002440063e-09
control O 0 8.961221986680812e-09
, O 0 5.300956895659681e-10
which O 0 4.974822775949406e-10
may O 0 1.1264956967238504e-08
initiate O 0 1.8741455676263286e-07
tumor B-Disease 0 1.7168383692478528e-06
formation O 0 1.9868316485371906e-06
. O 0 3.8888179005880374e-06

This O 0 7.117173339565852e-08
is O 0 4.404593578755112e-09
corrected O 0 3.919135593832834e-08
by O 0 5.267635772021606e-10
the O 0 2.765745632515859e-09
reintroduction O 0 2.652310548967307e-08
of O 0 1.4701917905313167e-08
wild O 0 1.3209107407874399e-07
- O 0 5.865917955816258e-07
type O 0 3.394198211026378e-05
VHL B-Disease 1 0.9999860525131226
, O 0 1.1438719411671627e-06
implicating O 0 0.00033201847691088915
VHL B-Disease 0 0.00015772190818097442
as O 0 1.9262305528400248e-08
the O 0 9.791907729095328e-09
first O 0 4.427681776775216e-09
tumor B-Disease 0 1.976601637920794e-08
suppressor O 0 9.524429600560325e-08
involved O 0 8.629041481356126e-09
in O 0 6.257181883739804e-09
the O 0 3.3705891411273114e-08
regulation O 0 1.8143788338420563e-07
of O 0 8.367961612520958e-08
cell O 0 3.604442895266402e-07
cycle O 0 1.805626759221468e-08
exit O 0 2.7004421809806445e-08
, O 0 6.361063342730233e-10
which O 0 5.19959741929199e-10
is O 0 2.6783109063899246e-10
consistent O 0 4.118018370746768e-09
with O 0 1.4578786788899123e-10
its O 0 9.837936021384053e-10
gatekeeper O 0 2.2265320254177823e-08
function O 0 4.692807920037012e-09
in O 0 1.360687673646055e-09
the O 0 1.1357945695067428e-08
kidney O 0 7.259062613229617e-07
. O 0 8.649807625715766e-08
. O 0 1.2973600860277656e-06

Piebaldism B-Disease 1 1.0
with O 1 0.8533071279525757
deafness B-Disease 1 1.0
: O 0 4.86363887830521e-07
molecular O 0 4.7198753350130573e-07
evidence O 0 9.990030491735524e-08
for O 0 3.737224751887425e-09
an O 0 3.8337839569635435e-09
expanded O 0 7.748846542199317e-07
syndrome O 1 0.7354064583778381
. O 0 1.3629941349790897e-05

In O 0 2.59476763631028e-07
a O 0 6.32383390097857e-08
South O 0 7.69463269989501e-07
African O 0 4.725518465420464e-06
girl O 0 6.100194696045946e-07
of O 0 1.433229215308529e-07
Xhosa O 0 4.45349314759369e-06
stock O 0 1.370021873725591e-08
with O 0 7.849099148415917e-10
severe O 0 8.018529342734837e-07
piebaldism B-Disease 0 8.817946945782751e-05
and O 0 1.9713284018507693e-06
profound O 1 0.9999998807907104
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 1.083135066437535e-05
identified O 0 5.7629488736665735e-08
a O 0 4.316387247627063e-09
novel O 0 1.863696930115566e-08
missense O 0 6.148062539068633e-07
substitution O 0 1.7019047504618356e-07
at O 0 2.006442940682973e-07
a O 0 8.015906161062958e-09
highly O 0 3.2685449014024925e-08
conserved O 0 7.167550819531243e-08
residue O 0 1.3850895186351408e-07
in O 0 5.3002517930167414e-09
the O 0 1.9298454390082043e-08
intracellular O 0 9.48527087984985e-08
kinase O 0 1.1985190440100268e-07
domain O 0 2.6941965103333132e-08
of O 0 1.1848051428842155e-08
the O 0 2.860456760345187e-08
KIT O 0 1.2647962648770772e-05
proto O 0 6.975592987146229e-05
- O 0 4.0049676499620546e-06
oncogene O 0 4.25264215664356e-06
, O 0 6.27814031872731e-08
R796G O 0 9.272470379073638e-06
. O 0 3.836379164567916e-06

Though O 0 2.410661636531586e-06
auditory B-Disease 0 0.000249322853051126
anomalies I-Disease 0 8.793750566837844e-06
have O 0 5.770182998077189e-09
been O 0 4.824765476030279e-09
observed O 0 2.8034454757630556e-08
in O 0 1.2529415727158266e-08
mice O 0 9.900327313516755e-08
with O 0 9.781621734816781e-09
dominant O 0 0.4740171432495117
white O 0 5.3479029702430125e-06
spotting O 0 7.962004019645974e-06
( O 0 2.472710924905641e-08
W O 0 3.801727871177718e-06
) O 0 2.140956301133201e-09
due O 0 3.6352908239223325e-08
to O 0 6.513765971050134e-09
KIT O 0 0.0007051863940432668
mutations O 0 8.206974598579109e-06
, O 0 5.439800361273228e-07
deafness B-Disease 1 1.0
is O 0 2.2354116335776553e-09
not O 0 1.078673927956686e-09
typical O 0 1.017836126493421e-08
in O 0 4.9068611396307915e-09
human O 0 1.1903392760359566e-07
piebaldism B-Disease 0 8.547812285542022e-06
. O 0 1.9242056623625103e-06

Thus O 0 5.359449914976722e-07
, O 0 1.0579078058015057e-08
the O 0 8.175923049691391e-09
occurrence O 0 2.458687617945543e-07
of O 0 3.306919461465441e-05
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 2.0543391201499617e-06
this O 0 2.2241211539153483e-08
patient O 0 3.201378717676562e-08
extends O 0 6.4633836061034344e-09
considerably O 0 8.051209476889198e-09
the O 0 4.591081737004288e-09
phenotypic O 0 2.9625039132952224e-07
range O 0 5.0725315503541424e-08
of O 0 1.9235981696397175e-08
piebaldism B-Disease 0 5.492188392963726e-07
due O 0 1.5487965754346078e-07
to O 0 1.3070795112923861e-08
KIT O 0 2.4049345483945217e-06
gene O 0 8.392620820529828e-09
mutation O 0 5.580421014172998e-09
in O 0 1.4443284346299379e-09
humans O 0 9.145044721492468e-09
and O 0 5.5105595642146454e-09
tightens O 0 2.3692226847060738e-08
the O 0 1.7070623803405738e-09
clinical O 0 1.1714685221875243e-08
similarity O 0 5.310938355762573e-09
between O 0 1.2176538000119308e-08
piebaldism B-Disease 0 5.500816655512608e-07
and O 0 2.8176498911847148e-09
the O 0 2.081761873995447e-09
various O 0 1.356670886742961e-09
forms O 0 3.0419737839793015e-08
of O 0 3.2684550888006925e-07
Waardenburg B-Disease 1 0.9999995231628418
syndrome I-Disease 0 0.014728322625160217
. O 0 2.124383939872132e-07
. O 0 1.8883308712247526e-06

Cycloheximide O 0 0.00013436503650154918
facilitates O 0 4.915364684165979e-07
the O 0 1.3020184930212508e-08
identification O 0 5.101114908256932e-08
of O 0 5.122457480410958e-08
aberrant O 0 2.324772623296667e-07
transcripts O 0 4.758150282668794e-07
resulting O 0 2.6152575216542573e-08
from O 0 6.4883338701804405e-09
a O 0 7.424934445054987e-09
novel O 0 8.030569631500839e-08
splice O 0 5.479608716996154e-06
- O 0 6.189112582433154e-07
site O 0 4.4360184858760476e-08
mutation O 0 1.4769061529307237e-08
in O 0 8.078282043300078e-09
COL17A1 O 0 3.35584300046321e-05
in O 0 1.3524835473788244e-08
a O 0 8.98273189164911e-09
patient O 0 1.0727370636232081e-07
with O 0 7.803949131357513e-08
generalized O 1 0.9990092515945435
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999997615814209
bullosa I-Disease 1 0.9995492100715637
. O 0 0.0001424598303856328

Patients O 0 1.332570354861673e-05
with O 0 4.629149543688982e-07
generalized O 1 0.9986536502838135
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9995443224906921
often O 0 4.050759727647346e-08
show O 0 1.998090048971335e-08
decreased O 0 1.8591984840554687e-08
expression O 0 7.0359704729128225e-09
of O 0 9.549820489951344e-09
type O 0 2.5861555741357733e-07
XVII O 0 0.0002632664400152862
collagen O 0 4.4919318042957457e-07
, O 0 2.078640193303727e-08
a O 0 3.291423311679864e-08
transmembrane O 0 4.4288242406764766e-07
hemidesmosomal O 0 1.1491234772620373e-06
protein O 0 2.5630550126720664e-08
encoded O 0 8.413183927302725e-09
by O 0 1.7954132403019685e-08
COL17A1 O 0 2.1447156541398726e-05
. O 0 2.3400812096951995e-06

This O 0 2.36487551319442e-07
report O 0 1.175399191311044e-07
documents O 0 1.7662139839558222e-07
a O 0 2.3333678100811994e-08
novel O 0 1.1066268967852011e-07
splice O 0 4.775657544087153e-06
- O 0 3.199725142621901e-07
site O 0 2.7264228208423447e-08
mutation O 0 1.2868764720508352e-08
in O 0 5.961598326109652e-09
COL17A1 O 0 3.7975554732838646e-05
in O 0 9.224438102251042e-09
a O 0 7.413726965666001e-09
patient O 0 5.554555215780965e-08
with O 0 2.530123666133477e-08
generalized O 1 0.9996558427810669
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999207258224487
, O 0 6.500253135754974e-08
and O 0 1.1602102389929314e-08
applies O 0 8.535165463285921e-09
a O 0 1.4079027943481037e-09
new O 0 2.387730679842548e-09
methodology O 0 8.24855383996237e-09
to O 0 8.193152822855154e-10
define O 0 1.4346975163448406e-08
and O 0 3.788720892572428e-09
characterize O 0 3.3568849033827064e-08
the O 0 5.976330097468008e-09
resulting O 0 1.6654626122658556e-08
mRNA O 0 2.344297769241166e-07
splice O 0 3.765938572541927e-06
variants O 0 2.2826277472631773e-06
. O 0 2.875469817809062e-06

Mutational O 0 0.00039371801540255547
analysis O 0 4.402783361001639e-06
of O 0 2.696011506486684e-06
COL17A1 O 0 0.010228171944618225
identified O 0 2.0179695638944395e-06
a O 0 2.7135317282045435e-07
maternally O 0 4.1534572119417135e-06
inherited O 0 2.1997664589434862e-05
G O 0 0.00010351686069043353
- O 0 8.318474283441901e-05
to O 0 6.172678581606306e-07
- O 1 0.7227054834365845
T O 0 0.001044685486704111
transversion O 0 1.476851412007818e-05
at O 0 1.1735433247395122e-07
the O 0 2.8655500194929573e-09
- O 0 2.9581932459166183e-09
1 O 0 5.9530984586331215e-09
position O 0 2.09099901837817e-08
of O 0 2.236944141031927e-08
exon O 0 3.4440444096617284e-07
32 O 0 4.5638964252248115e-07
. O 0 1.1325926152494503e-06

This O 0 4.5670878989767516e-07
acceptor O 0 1.1996503417321946e-06
splice O 0 1.3592842151410878e-05
- O 0 7.341387799897348e-07
site O 0 6.855402290284474e-08
mutation O 0 1.1927273391165727e-08
led O 0 1.0862390986687842e-08
to O 0 2.3031005991214215e-09
the O 0 8.941637652526424e-09
formation O 0 1.6081561682312895e-07
of O 0 2.812454624745442e-07
aberrant O 0 6.024733920639846e-07
transcripts O 0 6.533290957122517e-07
present O 0 1.9736820178195558e-08
at O 0 2.1191168286804896e-07
extremely O 0 2.153769429469321e-07
low O 0 5.692957984138047e-06
levels O 0 4.892527613264974e-06
. O 0 3.148188625345938e-06

Based O 0 7.404501616292691e-07
on O 0 4.0484320606992696e-07
our O 0 5.208575970527818e-08
recent O 0 5.31518429269795e-09
finding O 0 1.779980784988311e-08
that O 0 1.627803336567979e-09
cycloheximide O 0 1.2011295211777906e-06
stabilized O 0 1.1364313650119584e-06
mutant O 0 4.041530701215379e-07
COL17A1 O 0 6.5863555391842965e-06
transcripts O 0 2.1544884987179103e-07
in O 0 1.0103410552630976e-08
keratinocytes O 0 2.939286787295714e-07
homozygous O 0 1.1129092314376976e-07
for O 0 4.214717463923989e-09
a O 0 2.016198052956497e-08
frameshift O 0 1.4538600225932896e-06
mutation O 0 7.861677175924342e-08
, O 0 1.10136850750564e-08
the O 0 1.2945698735222777e-08
effects O 0 3.927382294932613e-07
of O 0 2.200737583279988e-07
the O 0 1.0679273287905744e-07
splice O 0 1.1021439831893076e-06
- O 0 5.4937185467451854e-08
site O 0 1.326802401280247e-08
mutation O 0 4.330579006506241e-09
on O 0 1.962435725033629e-08
splicing O 0 5.305210848405295e-08
of O 0 2.626249617776466e-08
COL17A1 O 0 3.956640739488648e-06
transcripts O 0 3.0595063549299084e-07
were O 0 4.5229398004664745e-09
determined O 0 1.6410279357614854e-08
using O 0 1.0824460439096129e-08
reverse O 0 1.6159104632151866e-07
transcriptase O 0 3.5898978012482985e-07
polymerase O 0 7.415285097067681e-08
chain O 0 8.790058458885142e-09
reaction O 0 7.317479955304407e-09
of O 0 2.615980854159261e-08
total O 0 8.738804346819506e-09
RNA O 0 2.5304517592417142e-08
from O 0 3.409311055690978e-09
keratinocytes O 0 3.5941042142439983e-07
incubated O 0 6.15654585089942e-08
for O 0 2.4785269392424425e-09
2 O 0 3.356252022967965e-07
. O 0 7.763920848447015e-07

5 O 0 3.035404233742156e-06
h O 0 4.302211209505913e-07
in O 0 4.543483367314138e-09
the O 0 1.5015202414758733e-09
presence O 0 9.080018958940173e-10
or O 0 2.121841369273625e-09
absence O 0 2.78947069887181e-08
of O 0 3.579668472752928e-08
10 O 0 1.536417073566554e-07
microg O 0 3.5594521250459366e-06
cycloheximide O 0 4.347325557318982e-06
per O 0 2.8511701088973496e-07
ml O 0 8.281098416773602e-06
. O 0 2.04015668714419e-06

Using O 0 9.135582246244667e-08
this O 0 3.5183727042920054e-09
approach O 0 2.783422736740704e-08
, O 0 1.7934957963205989e-09
an O 0 1.5869018321623685e-09
abnormally O 0 1.403231379981662e-07
spliced O 0 4.7544807557642343e-07
transcript O 0 2.939923149369861e-07
was O 0 1.7531304408180404e-08
identified O 0 2.7782975919876662e-09
that O 0 1.398251930906369e-10
contains O 0 6.102876537461555e-10
an O 0 3.598510656122045e-10
extra O 0 1.3469408699506857e-08
264 O 0 2.5388830593442435e-08
bases O 0 4.232230566003636e-09
upstream O 0 1.097740298661165e-08
from O 0 2.7489899245836114e-09
exon O 0 9.579304105500341e-08
32 O 0 3.336624132543875e-08
, O 0 1.3869904114116594e-09
resulting O 0 8.975744592021329e-09
in O 0 4.483942550592701e-09
a O 0 3.053704844546701e-08
premature O 0 1.4220014463717234e-06
termination O 0 2.4052992557699326e-06
codon O 0 2.827551952577778e-06
27 O 0 3.0034502742637414e-06
bp O 0 1.4430950159294298e-06
downstream O 0 2.8197487722536607e-07
from O 0 1.8057438211371846e-08
the O 0 1.2692913742284873e-07
cryptic O 0 2.733369456109358e-06
splice O 0 1.7260285858355928e-06
site O 0 5.628397730106371e-07
. O 0 2.0642942217818927e-06

Three O 0 3.147481208998215e-07
other O 0 1.3740964810438072e-08
splice O 0 3.2367384505960217e-07
variants O 0 3.4750769373204093e-08
, O 0 9.415900281695144e-10
including O 0 2.1796449367617043e-10
one O 0 3.1558089474970075e-10
derived O 0 8.411784047090975e-10
from O 0 7.512109267970857e-10
the O 0 5.896640509206463e-09
skipping O 0 5.386309709365378e-08
of O 0 1.538023042257919e-08
exon O 0 4.155879196332535e-08
32 O 0 2.4421231259452725e-08
, O 0 1.8983601357547286e-09
were O 0 1.2957456441142767e-08
also O 0 1.4368034761957915e-08
identified O 0 4.170419174442941e-07
. O 0 2.8541076062538195e-06

These O 0 1.2609075383807067e-07
results O 0 3.868552482799714e-07
indicate O 0 5.678745296222587e-08
the O 0 9.385173527221014e-09
usefulness O 0 1.3169297119475232e-07
of O 0 1.0979119835496931e-08
cycloheximide O 0 1.9031180897854938e-07
treatment O 0 5.45678879859679e-09
in O 0 1.8614507713010653e-09
evaluating O 0 5.2396639915741616e-08
the O 0 1.207532829283764e-08
abnormal O 0 8.649791283232844e-08
processing O 0 4.711465351192601e-08
of O 0 2.2255811416016513e-08
mRNA O 0 9.78136469598212e-08
due O 0 1.82017430461201e-07
to O 0 1.2683011085812268e-08
splice O 0 1.3983194548927713e-06
- O 0 5.387748558405292e-08
site O 0 5.574931183360832e-09
mutations O 0 4.034388378926224e-09
, O 0 4.2671471911504e-10
because O 0 1.7709518296271654e-09
( O 0 3.909964796378063e-09
i O 0 5.2602317168748414e-08
) O 0 8.917520943896307e-09
aberrant O 0 2.62101849557439e-07
splicing O 0 1.8187584771567344e-07
often O 0 7.782600341954549e-09
generates O 0 1.3506171292476665e-08
a O 0 1.2424562711998988e-08
premature O 0 2.6280591214344895e-07
termination O 0 5.710700179406558e-07
codon O 0 3.3002785926328215e-07
, O 0 2.0962822588899144e-08
( O 0 9.60432888774676e-09
ii O 0 4.847320269618649e-06
) O 0 3.421514094270606e-08
transcripts O 0 5.130476097292558e-07
with O 0 3.6036915673776093e-09
premature O 0 3.1097115993361513e-07
termination O 0 3.563184520771756e-07
codons O 0 9.459002825451535e-08
can O 0 1.0794360072452491e-08
occur O 0 7.036013727201862e-08
at O 0 3.1895308438834036e-07
low O 0 8.171263061740319e-07
or O 0 1.8862699846522446e-08
undetectable O 0 1.6182144690901623e-07
levels O 0 7.872416496468304e-09
due O 0 1.6360900190193206e-08
to O 0 3.215635979714193e-09
nonsense O 0 1.5047757528918737e-07
- O 0 1.585281239613323e-08
mediated O 0 2.8426660136915416e-08
mRNA O 0 4.348913673624111e-09
decay O 0 1.4064408304648168e-08
, O 0 1.002179242370893e-10
and O 0 1.4622145161347078e-10
( O 0 1.39390624043223e-10
iii O 0 4.5341707277657406e-08
) O 0 2.890161443502848e-10
the O 0 4.837488187803274e-10
levels O 0 6.212266701055569e-09
of O 0 2.7076099140543874e-09
these O 0 1.2963036200019928e-09
transcripts O 0 1.1245529840664403e-08
can O 0 2.328563730724653e-10
be O 0 3.631981659868444e-10
increased O 0 9.582603599511685e-10
by O 0 5.273710357300843e-09
cycloheximide O 0 3.8776229303039145e-06
. O 0 9.259658781957114e-07

A O 0 2.877271981560625e-06
deletion O 0 1.2413286185619654e-06
mutation O 0 9.491913033343735e-08
in O 0 2.0374951503754346e-08
COL17A1 O 0 1.2278275789867621e-05
in O 0 1.79091248497798e-08
five O 0 1.598263210667028e-08
Austrian O 0 3.148442146994057e-07
families O 0 1.2541515381769841e-08
with O 0 4.574075163077396e-08
generalized O 1 0.9719518423080444
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9991887211799622
represents O 0 4.566173288367281e-07
propagation O 0 3.1001966362964595e-06
of O 0 6.006158059790323e-08
an O 0 8.225176983955862e-09
ancestral O 0 5.391092940953968e-07
allele O 0 6.272327482292894e-06
. O 0 5.53158815819188e-06

Patients O 0 7.911225111456588e-06
with O 0 4.061750473738357e-07
generalized O 1 0.9998464584350586
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999955892562866
, O 0 1.0454815679850071e-07
a O 0 1.1597721893963353e-08
usually O 0 1.4246326784927987e-08
nonlethal O 0 3.4653983220778173e-06
form O 0 9.036305073095718e-07
of O 0 2.6858782803174108e-05
junctional B-Disease 1 0.9999991655349731
epidermolysis I-Disease 1 0.9999996423721313
bullosa I-Disease 1 0.999426007270813
, O 0 6.412549424794634e-08
have O 0 1.4358911393230755e-08
generalized O 0 1.9890173916792264e-06
blistering B-Disease 0 1.7611759176361375e-05
, O 0 1.11762471988186e-06
nail B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 4.8529669584240764e-05
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 8.947627975430805e-06
and O 0 0.011682450771331787
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 0 0.034269824624061584

Skin B-Disease 1 0.999998927116394
fragility I-Disease 0 0.00018079657456837595
in O 0 4.9017288006325543e-08
most O 0 1.889423284495706e-09
cases O 0 1.7312513644895944e-09
is O 0 1.2493990564355073e-10
due O 0 4.78086814581502e-09
to O 0 8.495855685630715e-10
mutations O 0 2.053094361187391e-09
in O 0 6.578061428896831e-10
the O 0 4.097779893186271e-09
gene O 0 4.058080982360934e-09
encoding O 0 5.7592348667867554e-08
type O 0 3.3449816783104325e-07
XVII O 0 9.071290696738288e-05
collagen O 0 1.4495611821985221e-06
( O 0 4.375958084779086e-08
COL17A1 O 0 1.264788988919463e-05
) O 0 7.166936200064811e-08
. O 0 1.1042733376598335e-06

Recently O 0 2.5002782422234304e-06
, O 0 3.32823404392002e-08
we O 0 1.1337361272012458e-08
reported O 0 5.4939670590670175e-09
five O 0 2.9553961500283776e-09
Austrian O 0 9.615200724510942e-08
families O 0 4.836512967898443e-09
with O 0 1.9616461344185154e-08
generalized O 0 0.09821324795484543
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.999935507774353
who O 0 2.099139493338953e-07
share O 0 4.819056442784131e-08
the O 0 5.276973169543453e-08
same O 0 1.8107695609614893e-07
COL17A1 O 0 6.690325972158462e-05
mutation O 0 1.6491412679897621e-06
. O 0 2.6888271804637043e-06

Affected O 0 7.034429359009664e-07
individuals O 0 3.403061166196153e-09
in O 0 4.023814170750484e-09
three O 0 6.829998233648382e-10
families O 0 2.0660843869091394e-10
are O 0 1.3040900304073233e-10
homozygous O 0 2.13282924654834e-09
for O 0 1.8889187991533163e-09
4003delTC O 0 1.7473360003350535e-07
, O 0 1.4108921808642094e-09
whereas O 0 3.799322634279179e-09
those O 0 7.155483428000764e-10
in O 0 5.482512777099657e-10
two O 0 8.691724007192647e-10
others O 0 1.6171115557739313e-09
are O 0 8.358717606959942e-10
compound O 0 6.392497198248748e-08
heterozygotes O 0 1.55877955876349e-06
. O 0 2.4279358967760345e-06

To O 0 7.564914739077722e-08
determine O 0 1.144384427220757e-07
if O 0 6.8231007510632935e-09
the O 0 6.3361103030956656e-09
occurrence O 0 2.6595953883656875e-08
of O 0 5.214258358421375e-09
4003delTC O 0 6.079553571680663e-08
in O 0 2.9805119483583553e-10
these O 0 3.2441574426833597e-10
unrelated O 0 4.319343993586244e-09
families O 0 1.7462338519624865e-10
signifies O 0 2.4419120059349098e-09
propagation O 0 2.991672332086637e-08
of O 0 4.747754189793341e-09
an O 0 1.0563224739357224e-09
ancestral O 0 3.778626833650378e-08
allele O 0 3.930027787646395e-07
or O 0 5.229968635944715e-08
a O 0 4.031351963362795e-08
mutational O 0 4.501457169681089e-06
hot O 0 4.088986315764487e-06
spot O 0 5.071287432656391e-06
, O 0 1.5138576614504018e-08
haplotypes O 0 7.33212459635979e-08
were O 0 4.241524020898169e-09
determined O 0 1.0966437535842033e-08
for O 0 2.70776467914402e-09
polymorphisms O 0 1.716944275642618e-08
both O 0 7.59993934451586e-09
within O 0 5.591429896867339e-08
and O 0 1.359861272476337e-07
flanking O 0 1.9266701201559044e-05
COL17A1 O 0 0.0010460279881954193
. O 0 1.0356910024711397e-05

Five O 0 6.650850082223769e-06
intragenic O 0 1.5318944861064665e-05
polymorphisms O 0 2.002613825879962e-07
were O 0 1.7941125918241596e-08
chosen O 0 2.6694495502965765e-08
based O 0 7.148011960111944e-09
on O 0 1.5666124397739623e-07
their O 0 2.788402468922868e-07
informativeness O 0 7.711051148362458e-05
. O 0 6.8897061282768846e-06

One O 0 1.4946583348773856e-07
of O 0 1.893934253871521e-08
these O 0 7.31998905934006e-10
, O 0 1.971926510968558e-10
not O 0 2.266601906164567e-10
previously O 0 5.7891553773004034e-09
reported O 0 7.455558836966247e-09
, O 0 2.3133983617640297e-09
was O 0 6.045464573389836e-08
2988 O 0 5.866756964678643e-07
A O 0 3.893297417789654e-08
or O 0 1.2312553643312185e-08
C O 0 1.3150098538972088e-06
that O 0 1.4635238576587994e-09
introduces O 0 4.239081530243993e-09
a O 0 4.260299613090268e-10
new O 0 4.4147602240585115e-10
restriction O 0 1.318192444088595e-09
site O 0 2.4032333900692038e-09
for O 0 1.3499906748037915e-09
Eco0109 O 0 5.860393343937176e-07
I O 0 2.2740275653632125e-06
. O 0 1.6595414535913733e-06

All O 0 3.355413582539768e-07
the O 0 6.370272132016908e-08
4003delTC O 0 6.663476028734294e-07
alleles O 0 5.4569891716482744e-08
showed O 0 1.765088342153831e-08
the O 0 3.500220335794779e-09
same O 0 1.9006136664501128e-09
haplotype O 0 3.697352113363195e-08
for O 0 1.1124265952844326e-09
these O 0 3.3429161661047146e-09
five O 0 2.3016175632051272e-08
polymorphic O 0 1.1478168744361028e-06
markers O 0 1.8041193925455445e-06
. O 0 4.31041007686872e-06

Fourteen O 0 2.267486161144916e-05
microsatellite O 0 2.03992585738888e-05
polymorphisms O 0 6.802104621783656e-07
were O 0 7.914273680853512e-08
selected O 0 1.5237242578791665e-08
based O 0 4.4170955781908106e-09
on O 0 2.4382226015973174e-08
their O 0 1.3690318212411512e-08
high O 0 7.947695053189818e-07
heterozygosity O 0 1.382297568852664e-06
and O 0 7.719119565763322e-09
their O 0 3.969084616528562e-09
location O 0 2.885273353570028e-08
within O 0 2.96792670440027e-08
10q23 O 0 6.491455906143528e-07
- O 0 3.088476319135225e-07
q25 O 0 1.6722256077628117e-06
near O 0 1.1958455843341653e-06
COL17A1 O 0 0.0002053476928267628
. O 0 9.820106242841575e-06

Three O 0 4.179345012289559e-07
families O 0 2.484804717539646e-08
shared O 0 2.2838898416921438e-07
microsatellite O 0 2.5384981199749745e-05
polymorphisms O 0 4.801999693881953e-06
covering O 0 1.8836346953321481e-06
at O 0 4.233742743053881e-07
most O 0 1.466849530729064e-09
19 O 0 6.982297406921134e-08
cM O 0 3.727424484623043e-07
, O 0 2.94312729742785e-09
whereas O 0 5.4417177430821084e-09
the O 0 3.996828201735525e-09
others O 0 1.2232165280678942e-09
shared O 0 6.312090294890993e-10
smaller O 0 5.981493078621725e-10
regions O 0 2.1800037330876876e-09
consistent O 0 1.8680673008475424e-08
with O 0 9.975112957860688e-10
cross O 0 1.624187895288287e-08
- O 0 3.0072108359036065e-08
over O 0 1.8463026663084747e-09
events O 0 5.641440092851724e-10
during O 0 5.89519766336366e-10
passage O 0 6.296458909815783e-10
of O 0 1.9910348370011377e-10
this O 0 3.853691671329429e-11
mutation O 0 5.66358515641241e-10
through O 0 4.087138683050995e-10
several O 0 2.0840580372549766e-09
generations O 0 6.283495679326734e-08
. O 0 6.633770226471825e-07

These O 0 3.017023857410095e-07
results O 0 2.5187657115566253e-07
indicate O 0 4.633522010522029e-08
that O 0 5.7600226810450295e-09
4003delTC O 0 3.118195763818221e-07
occurs O 0 1.0143805795337357e-08
on O 0 8.229696923933716e-09
a O 0 1.7080459269180892e-09
single O 0 4.657043195521737e-09
ancestral O 0 1.0097480895865374e-07
allele O 0 3.248975986025471e-07
. O 0 9.244485710269146e-08
. O 0 1.1865123497045715e-06

The O 0 5.748864168708678e-06
haptoglobin O 0 0.0001279572898056358
- O 0 6.142627626104513e-06
gene O 0 6.729272428174227e-08
deletion O 0 1.886511569182403e-07
responsible O 0 7.101728272118635e-08
for O 0 6.529603524541017e-08
anhaptoglobinemia B-Disease 0 3.542773629305884e-05
. O 0 1.1875099517055787e-05

We O 0 2.8894677939206304e-07
have O 0 5.916964695984461e-09
found O 0 7.338627483477467e-09
an O 0 1.3932477394007492e-09
allelic O 0 7.530478569606203e-07
deletion O 0 5.727275151912181e-07
of O 0 2.4006237708817935e-07
the O 0 2.955277409455448e-07
haptoglobin O 0 3.1876399589236826e-05
( O 0 3.410919191537687e-08
Hp O 0 4.5854574182158103e-07
) O 0 1.2991203668377693e-09
gene O 0 1.7335478608160315e-09
from O 0 1.2209112609795625e-09
an O 0 8.160370157384023e-10
individual O 0 2.1606925137973576e-09
with O 0 1.623859624544366e-08
anhaptoglobinemia B-Disease 0 1.3011072951485403e-05
. O 0 4.1018433876161e-06

The O 0 7.247680969157955e-06
Hp O 0 1.1591137990762945e-05
gene O 0 3.891285516033349e-08
cluster O 0 1.7993255596593372e-07
consists O 0 2.632167017679876e-08
of O 0 3.9999186185468716e-08
coding O 0 3.56847550619932e-07
regions O 0 2.0397697753082866e-08
of O 0 1.738881110213697e-07
the O 0 1.369759843328211e-07
alpha O 0 4.108602524866001e-07
chain O 0 9.916235832463371e-09
and O 0 2.5559556693366403e-09
beta O 0 8.896849834627574e-08
chain O 0 7.520084110979042e-09
of O 0 1.0823097973400309e-08
the O 0 2.4142055465858903e-08
haptoglobin O 0 8.187706157514185e-07
gene O 0 1.6129076740867276e-08
( O 0 3.8904079957546855e-09
Hp O 0 2.822907561039756e-07
) O 0 1.4812048254597698e-09
and O 0 2.076637972692197e-09
of O 0 1.3554921629577166e-08
the O 0 1.7489155013095115e-08
alpha O 0 2.1711998954287992e-07
chain O 0 3.9970795562283e-09
and O 0 6.523302342742454e-09
beta O 0 2.0752696627823752e-07
chain O 0 1.0842561515289617e-08
of O 0 1.2317532771533024e-08
the O 0 2.4646123364391315e-08
haptoglobin O 0 3.5118225696351146e-06
- O 0 3.188071104887058e-07
related O 0 6.950939024363834e-08
gene O 0 2.1791651150238067e-08
( O 0 8.403673312784576e-09
Hpr O 0 6.836395982645627e-07
) O 0 4.254390173485945e-09
, O 0 1.2705424490278006e-09
in O 0 2.493553585836139e-09
tandem O 0 1.2535755899989454e-07
from O 0 7.5585937509004e-09
the O 0 3.361177647320801e-08
5 O 0 7.286966479114199e-07
side O 0 3.7406612136692274e-06
. O 0 4.398561486596009e-06

Southern O 0 6.422129899874562e-06
blot O 0 7.939998795336578e-06
and O 0 7.351042796699403e-08
PCR O 0 9.201825434956845e-08
analyses O 0 1.5099846706334574e-08
have O 0 7.560854164978537e-10
indicated O 0 4.305344525334931e-09
that O 0 2.718205660556805e-10
the O 0 1.0562962726723413e-09
individual O 0 2.121840203539449e-10
with O 0 4.4343054228512813e-10
anhaptoglobinemia B-Disease 0 8.529197259576904e-08
was O 0 7.574353588779559e-09
homozygous O 0 3.1158693403199322e-09
for O 0 4.468402314827813e-10
the O 0 9.17164399982795e-10
gene O 0 1.454962483826705e-09
deletion O 0 9.087421481979163e-09
and O 0 7.538979995835859e-10
that O 0 2.4690233191293487e-10
the O 0 1.4048797680743519e-09
gene O 0 1.7654478989825861e-09
deletion O 0 1.4989428365197455e-08
was O 0 1.7392983053809985e-08
included O 0 3.4876783683301937e-09
at O 0 1.894309953343054e-08
least O 0 1.4528936942426185e-09
from O 0 1.2968799367740758e-09
the O 0 1.0789645621400723e-08
promoter O 0 1.3051994756096974e-06
region O 0 1.0663824667744848e-07
of O 0 4.1498839209452854e-07
Hp O 0 4.512258328759344e-06
to O 0 3.794493963482637e-08
Hpr O 0 1.6294835631924798e-06
alpha O 0 1.1574280023296524e-07
but O 0 7.336552476644442e-10
not O 0 6.238897731769555e-10
to O 0 3.4351657074438435e-09
Hpr O 0 1.1835920759040164e-06
beta O 0 1.11246527012554e-06
( O 0 2.6912331918538257e-08
Hpdel O 0 3.566914301700308e-06
) O 0 7.215848540909064e-08
. O 0 1.2351114264674834e-06

In O 0 1.0131376626532074e-07
addition O 0 1.135731686474628e-08
, O 0 2.1929820182009507e-09
we O 0 1.5426112609517872e-09
found O 0 6.517602568756331e-10
seven O 0 1.5883007131733962e-09
individuals O 0 1.3126195963497622e-10
with O 0 2.443369395699335e-10
hypohaptoglobinemia B-Disease 0 1.413587114029724e-07
in O 0 1.6027774663029959e-09
three O 0 1.2269365523565057e-09
families O 0 1.5727028013223787e-10
, O 0 2.125201958858014e-10
and O 0 4.928817354254988e-10
the O 0 1.9901209569184175e-09
genotypes O 0 1.6753784848333453e-07
of O 0 4.429643496450808e-08
six O 0 2.2145545841567582e-08
of O 0 1.1060883764457685e-08
the O 0 6.272512731442248e-09
seven O 0 4.219189442267179e-09
individuals O 0 1.8900424281209638e-10
were O 0 2.274485044750918e-09
found O 0 1.2146793570977366e-09
to O 0 2.2709825131528305e-09
be O 0 6.378174788324031e-08
Hp2 O 0 0.00049555953592062
/ O 0 0.00012062179303029552
Hpdel O 0 0.00023406617401633412
. O 0 5.422456979431445e-06

The O 0 6.885515517751628e-07
phenotypes O 0 8.111431952784187e-07
and O 0 1.5012060927688253e-08
genotypes O 0 1.9108473736650922e-07
in O 0 2.7516964262730426e-09
one O 0 4.3879133659885383e-10
of O 0 1.937538129936911e-09
these O 0 4.4054737635690344e-10
three O 0 1.7782052497139489e-09
families O 0 3.3364175311412225e-10
showed O 0 2.91676660602036e-09
the O 0 2.1153232498960506e-09
father O 0 6.7865904007646805e-09
to O 0 1.569853358418527e-09
be O 0 1.7328378731917837e-08
hypohaptoglobinemic B-Disease 0 2.2394813186110696e-06
( O 0 2.6899810379177325e-08
Hp2 O 0 3.4104295991710387e-06
) O 0 8.99857699465656e-09
and O 0 2.4618872274118075e-08
Hp2 O 0 3.4518183383625e-05
/ O 0 3.663380994112231e-06
Hpdel O 0 8.541920578863937e-06
, O 0 1.2181415876000301e-08
the O 0 5.798714397542426e-09
mother O 0 4.394264063733999e-09
to O 0 1.4589056629432662e-09
be O 0 2.077324268157099e-08
Hp2 O 0 6.0017714531568345e-06
- O 0 3.3720303349582537e-07
1 O 0 2.8568479137902614e-07
and O 0 5.4409323269055676e-08
Hp1 O 0 3.657628258224577e-05
/ O 0 1.2233709867359721e-06
Hp2 O 0 2.2456449642049847e-06
, O 0 1.1550012057881531e-09
one O 0 5.129843771989329e-10
of O 0 8.067684298396216e-10
the O 0 6.237255711916134e-10
two O 0 8.465671497148719e-10
children O 0 1.823824286040221e-10
to O 0 5.929151614125772e-10
be O 0 1.224589851744895e-08
hypohaptoglobinemic B-Disease 0 1.6629951460345183e-06
( O 0 4.728850200308443e-08
Hp2 O 0 6.880021828692406e-06
) O 0 1.4969343098414356e-08
and O 0 5.1607727868940856e-08
Hp2 O 0 7.323375029955059e-05
/ O 0 6.819987902417779e-06
Hpdel O 0 3.027185084647499e-05
, O 0 1.1698318758135429e-08
and O 0 6.6039991253319386e-09
the O 0 5.228190769202001e-09
other O 0 9.723413185724894e-10
child O 0 3.6793548208180482e-09
to O 0 5.830964044939435e-10
be O 0 9.047574245357737e-09
Hp1 O 0 9.432268598175142e-06
and O 0 2.763272277661599e-07
Hp1 O 0 0.006351470481604338
/ O 0 6.193326407810673e-05
Hpdel O 0 7.272730726981536e-05
, O 0 1.5675951203775185e-08
showing O 0 3.163937023487051e-08
an O 0 2.729152903668819e-09
anomalous O 0 3.921495590475388e-07
inheritance O 0 4.941553584103531e-07
of O 0 6.198397954904067e-07
Hp O 0 1.4988640032242984e-05
phenotypes O 0 1.861180294326914e-06
in O 0 2.065767290559961e-08
the O 0 5.7294116118100646e-08
child O 0 1.6735482688545744e-07
with O 0 5.6011323579241434e-08
Hp1 O 0 0.0002131647925125435
. O 0 2.067414970952086e-05

The O 0 3.1870483780949144e-06
Hp2 O 0 0.0026952812913805246
/ O 0 5.651657556882128e-05
Hpdel O 0 4.255296880728565e-05
individuals O 0 5.713497674975088e-09
had O 0 6.436024602152202e-09
an O 0 5.184248030865035e-10
extremely O 0 2.080460781428428e-08
low O 0 3.6870002873001795e-07
level O 0 2.906527697632555e-06
of O 0 2.268700427521253e-07
Hp O 0 2.5740005185070913e-06
( O 0 2.6617963388986254e-09
mean O 0 8.352123437305181e-09
+ O 0 1.8341241414532305e-08
/ O 0 3.3347983929843394e-08
- O 0 1.0621375778896436e-08
SD O 0 1.9450747856808448e-07
= O 0 3.40688828259772e-08
0 O 0 1.1296608981581358e-08
. O 0 3.1471367734070554e-09
049 O 0 3.7922336559859104e-07
+ O 0 5.272848113690998e-08
/ O 0 7.34647329636573e-08
- O 0 1.6392418089594685e-08
0 O 0 1.6212723608077795e-08
. O 0 8.443229226884341e-09
043 O 0 2.1041514628450386e-06
mg O 0 2.1476910205819877e-06
/ O 0 3.369513024154003e-07
ml O 0 1.1111466591273711e-07
; O 0 1.1733418681103558e-09
n O 0 1.5511181672422936e-08
= O 0 1.7222642867409377e-08
6 O 0 2.4542874399458015e-08
) O 0 1.730768445229458e-10
, O 0 1.0903689062757849e-10
compared O 0 4.115503493551387e-10
with O 0 6.214239539614752e-11
the O 0 1.2998837561895016e-09
level O 0 6.097378957292676e-08
( O 0 2.7742400043884174e-10
1 O 0 1.8359749276442017e-09
. O 0 5.147672288430272e-10
64 O 0 3.317369712263485e-09
+ O 0 1.2319906872448882e-08
/ O 0 1.4623024569004883e-08
- O 0 4.153935417861021e-09
1 O 0 6.501911453682396e-09
. O 0 2.0100188180549594e-09
07 O 0 2.1810078010275902e-07
mg O 0 7.880831844886416e-07
/ O 0 8.786575733665813e-08
ml O 0 3.079182064880115e-08
) O 0 1.4209920740082538e-10
obtained O 0 1.895957391084835e-09
from O 0 1.3305980761657565e-09
52 O 0 5.230946342749121e-08
healthy O 0 2.2606158722737746e-08
volunteers O 0 1.5258153851505085e-08
having O 0 3.583200225421024e-08
phenotype O 0 6.143151267679059e-07
Hp2 O 0 3.1729705369798467e-06
, O 0 5.0321138367337426e-09
whereas O 0 2.0298264402640598e-08
the O 0 1.2995250209257847e-08
serum O 0 6.000764329883168e-08
Hp O 0 3.017956089479412e-07
level O 0 1.0860696875170106e-07
of O 0 3.428195061161432e-09
an O 0 1.6991354157003258e-10
individual O 0 1.836149010614463e-10
with O 0 1.904957969145471e-09
Hp1 O 0 9.083350960281678e-06
/ O 0 1.479193429076986e-06
Hpdel O 0 7.5085163189214654e-06
was O 0 5.803839826512558e-07
0 O 0 1.451780349270848e-06
. O 0 1.4469273992290255e-06

50 O 0 9.304022569267545e-06
mg O 0 0.0002259437314933166
/ O 0 1.5160504517552909e-05
ml O 0 2.820103190970258e-06
, O 0 1.4211065657576682e-09
which O 0 2.2446820791000022e-10
was O 0 3.0468616518675162e-09
approximately O 0 5.303363859177068e-10
half O 0 1.0944845030280703e-09
the O 0 6.111788297680221e-10
level O 0 3.0269486472889184e-08
of O 0 7.544708857665228e-09
Hp O 0 1.3652669395014527e-07
in O 0 1.195359367045512e-09
control O 0 2.6471504099845333e-08
sera O 0 5.01319618706475e-07
from O 0 1.0961016538857393e-09
the O 0 6.5750294098165796e-09
Hp1 O 0 5.767148536506284e-07
phenotype O 0 3.076880972230356e-08
( O 0 4.497559547012031e-10
1 O 0 5.434934280401649e-09
. O 0 2.299654910942195e-09
26 O 0 3.610821153188226e-08
+ O 0 4.0104151111108877e-08
/ O 0 4.3209936961829953e-08
- O 0 9.09003983196044e-09
0 O 0 1.0674402695087792e-08
. O 0 1.987901621092192e-09
33 O 0 2.813274768698193e-08
mg O 0 8.270178000202577e-07
/ O 0 1.292160192178926e-07
ml O 0 7.215999886511781e-08
; O 0 1.0990029997159922e-09
n O 0 1.4881094578811371e-08
= O 0 2.7631108068248977e-08
9 O 0 6.01022591695255e-08
) O 0 1.184165099310519e-09
, O 0 1.2229108836692149e-09
showing O 0 1.083239187238405e-08
a O 0 1.5192320290680073e-08
gene O 0 9.241964704642669e-08
- O 0 2.780568593152566e-07
dosage O 0 2.6405000426166225e-06
effect O 0 2.5274114250350976e-06
. O 0 2.4250107344414573e-06

The O 0 2.0100472397643898e-07
other O 0 1.8114700850446752e-08
allele O 0 2.759638277893828e-07
( O 0 1.1386186216100214e-08
Hp2 O 0 1.4925471987226047e-06
) O 0 2.544903399126497e-09
of O 0 6.049869050173129e-09
individuals O 0 8.666395934220361e-10
with O 0 7.69445396286983e-09
Hp2 O 0 0.0002580192231107503
/ O 0 1.4566436220775358e-05
Hpdel O 0 9.609243534214329e-06
was O 0 1.8070599239194962e-08
found O 0 2.467638871017641e-10
to O 0 1.7104577476612093e-10
have O 0 2.358318540451876e-10
, O 0 2.443667490581447e-10
in O 0 1.9927293148924718e-10
all O 0 6.032386257182054e-10
exons O 0 1.8355100550593306e-08
, O 0 2.494598971836126e-10
no O 0 3.9205075297310543e-10
mutation O 0 5.741372932632771e-10
, O 0 4.369281325633523e-10
by O 0 9.284235602535773e-10
DNA O 0 8.993227140763338e-08
sequencing O 0 3.9303424159697897e-07
. O 0 9.982884421333438e-07

On O 0 7.681185820729297e-07
the O 0 1.2325522824596646e-08
basis O 0 2.2270121746714722e-08
of O 0 3.2916287473483408e-09
the O 0 1.0936623828783354e-09
present O 0 8.671720563846463e-10
study O 0 6.058133439346136e-10
, O 0 2.9517890909325217e-10
the O 0 1.1214187356500815e-09
mechanism O 0 4.329127634150609e-08
of O 0 1.444106079162566e-08
anhaptoglobinemia B-Disease 0 7.647818733858003e-07
and O 0 5.371266986742285e-09
the O 0 8.489768887898208e-09
mechanism O 0 1.73533919678448e-07
of O 0 2.1782176062856706e-08
anomalous O 0 3.341436354276084e-07
inheritance O 0 1.5147725207498297e-07
of O 0 6.043620004447803e-08
Hp O 0 1.7305625306107686e-06
phenotypes O 0 7.666732244615559e-07
were O 0 6.429830534671055e-08
well O 0 5.3048665904498193e-08
explained O 0 1.5726286619610619e-06
. O 0 2.0095924355700845e-06

However O 0 1.1192951205885038e-06
, O 0 4.146006205019148e-08
the O 0 1.370424307367557e-08
mechanism O 0 1.8461139461578568e-07
of O 0 5.53148638005041e-08
hypohaptoglobinemia B-Disease 0 2.5211165848304518e-06
remains O 0 1.381765059704776e-06
unknown O 0 2.291366945428308e-05

ATM O 0 3.92265610571485e-05
mutations O 0 8.235665518441238e-07
and O 0 1.1164406288344253e-07
phenotypes O 0 6.353339995257556e-05
in O 0 6.302007386693731e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 3.199846787538263e-07
in O 0 7.425416281847674e-09
the O 0 8.846032351073063e-09
British O 0 3.8056853668422264e-08
Isles O 0 3.632241885043186e-07
: O 0 5.174351613845829e-09
expression O 0 5.2059707655871534e-09
of O 0 8.729775125004835e-09
mutant O 0 5.783165590855788e-08
ATM O 0 2.8286854103498627e-07
and O 0 3.817912208603502e-09
the O 0 2.329133552692042e-09
risk O 0 1.76318390998631e-08
of O 0 2.8873000701423734e-07
leukemia B-Disease 1 1.0
, O 1 0.994380533695221
lymphoma B-Disease 1 1.0
, O 1 0.999998927116394
and O 1 0.9999997615814209
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999983310699463
. O 1 0.9854551553726196

We O 0 5.23127596352424e-07
report O 0 3.0774149450962796e-08
the O 0 3.862194564163701e-09
spectrum O 0 4.740174119888252e-08
of O 0 1.8956004765868784e-08
59 O 0 7.02350391179607e-08
ATM O 0 3.496329554764088e-07
mutations O 0 7.195754392341769e-08
observed O 0 3.1231093089445494e-07
in O 0 4.419252945808694e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.853857037469879e-09
patients O 0 5.881204412361285e-10
in O 0 6.243706662800719e-10
the O 0 4.290555910557714e-09
British O 0 8.772308746074486e-08
Isles O 0 8.478560630464926e-06
. O 0 1.9012655911865295e-06

Of O 0 8.391562914766837e-06
51 O 0 4.035159236082109e-06
ATM O 0 4.171185082668671e-06
mutations O 0 7.524764811250861e-08
identified O 0 3.823576477657298e-08
in O 0 4.833838218587516e-09
families O 0 2.7423809889626227e-09
native O 0 1.951230288455008e-09
to O 0 2.23902585361202e-09
the O 0 1.1615433059830593e-08
British O 0 1.1107229624940373e-07
Isles O 0 1.8758939859253587e-06
, O 0 9.019024638234896e-09
11 O 0 3.5130970132968287e-08
were O 0 1.6661964252762118e-08
founder O 0 1.1684140588386072e-07
mutations O 0 1.3556369360401277e-08
, O 0 2.4762967232305755e-09
and O 0 4.719503898797939e-09
2 O 0 5.695580540532319e-08
of O 0 7.407026991756993e-09
these O 0 1.7487613579447725e-09
11 O 0 2.1580001785537206e-08
conferred O 0 2.036254471704524e-07
a O 0 6.70845778927287e-09
milder O 0 1.7339498015189747e-07
clinical O 0 6.81085552400873e-08
phenotype O 0 2.8950083219569933e-08
with O 0 3.418412497513401e-10
respect O 0 3.2081863832189583e-09
to O 0 2.892909245488795e-09
both O 0 1.8021212611074588e-07
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 6.318718988040928e-06
cellular O 0 5.7456795730104204e-06
features O 0 3.925705129859125e-07
. O 0 1.5654013623134233e-06

We O 0 6.623182002840622e-07
report O 0 3.3324138115631285e-08
, O 0 1.4132892633966776e-09
in O 0 1.5129361097265814e-09
two O 0 1.3160728506989017e-08
A B-Disease 1 0.9999972581863403
- I-Disease 1 0.9999991655349731
T I-Disease 1 1.0
families O 0 9.50167322599782e-09
, O 0 1.397964743965474e-09
an O 0 9.228604547217856e-10
ATM O 0 2.652822388427012e-07
mutation O 0 1.8427291692546532e-08
( O 0 4.9811585967063365e-09
7271T O 0 2.579246825007431e-07
- O 0 4.462674780825182e-07
- O 0 2.8041094424224866e-07
> O 0 7.839575033585788e-08
G O 0 3.7458473656215574e-08
) O 0 9.101618764217889e-11
that O 0 2.6462226507262265e-11
may O 0 2.921258512866842e-10
be O 0 8.178538957182013e-10
associated O 0 1.59760416007515e-09
with O 0 8.956035218998792e-11
an O 0 1.0432550656691575e-10
increased O 0 4.8011088438215666e-09
risk O 0 2.4372053530896665e-07
of O 0 7.504721907025669e-06
breast B-Disease 0 0.3145659267902374
cancer I-Disease 0 1.0929830978056998e-06
in O 0 8.7508462698338e-09
both O 0 2.9494900743998187e-08
homozygotes O 0 1.0807656281031086e-06
and O 0 2.5072280251947632e-08
heterozygotes O 0 6.778429906262318e-08
( O 0 1.2617085154431606e-09
relative O 0 1.4291640759722668e-08
risk O 0 5.028343075252906e-09
12 O 0 5.939897018691909e-09
. O 0 8.439296483864211e-10
7 O 0 1.229903379140751e-08
; O 0 1.825934625721004e-09
P O 0 3.581075702641101e-07
= O 0 3.8829295334608105e-08
. O 0 3.3278642064260566e-09
0025 O 0 4.228573402542679e-07
) O 0 1.5579657008935044e-10
, O 0 3.844265183960971e-11
although O 0 1.5401380171198298e-10
there O 0 6.266219765294068e-10
is O 0 2.357162798283241e-10
a O 0 7.647397159971092e-10
less O 0 2.460760484268576e-08
severe O 1 0.7919819355010986
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 3.225721911803703e-07
in O 0 5.36338140566528e-10
terms O 0 1.514963154924942e-09
of O 0 4.957858013021621e-10
the O 0 3.2262134630478556e-10
degree O 0 7.123406930986675e-08
of O 0 1.4322182551040896e-07
cerebellar B-Disease 1 0.9999996423721313
degeneration I-Disease 1 0.9999998807907104
. O 0 3.449841096880846e-05

This O 0 3.1671973488300864e-07
mutation O 0 3.2903099622672016e-07
( O 0 2.6110658524203245e-08
7271T O 0 6.782793775528262e-07
- O 0 2.1872482136586768e-07
- O 0 1.0129405580983075e-07
> O 0 7.739910756754398e-08
G O 0 7.300378257468765e-08
) O 0 6.200508995135579e-10
also O 0 1.6158496762841423e-10
allows O 0 7.583134814526105e-11
expression O 0 3.0515009963316686e-10
of O 0 8.565952391847986e-10
full O 0 7.315373196092878e-09
- O 0 1.3248147467948002e-08
length O 0 3.789768943107674e-09
ATM O 0 1.0061894073487565e-07
protein O 0 8.26099277873027e-09
at O 0 1.8019076009068158e-08
a O 0 9.310801019069004e-10
level O 0 1.6148037573771035e-08
comparable O 0 4.925380547859959e-09
with O 0 1.1953862899538592e-10
that O 0 1.35788699728856e-10
in O 0 6.230074234281346e-10
unaffected O 0 3.563353345725773e-08
individuals O 0 6.034840627222593e-09
. O 0 4.076228776739299e-07

In O 0 6.032655619492289e-08
addition O 0 1.864408005758378e-08
, O 0 2.3593096365459587e-09
we O 0 2.061177228895872e-09
have O 0 7.469304619256434e-10
studied O 0 8.639617732342231e-08
18 O 0 4.2200045413665066e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 3.1472165318291445e-08
, O 0 3.444323160017859e-10
in O 0 4.3243700287298736e-10
15 O 0 3.995669572987026e-09
families O 0 2.4192459147087675e-10
, O 0 3.578661256220528e-10
who O 0 9.944773893266756e-10
developed O 0 4.5676193849431e-07
leukemia B-Disease 1 1.0
, O 0 1.990667988138739e-05
lymphoma B-Disease 1 1.0
, O 0 0.00012246842379681766
preleukemic O 1 0.9925392270088196
T O 1 0.8683432936668396
- O 0 2.351684270252008e-05
cell O 0 1.1983252079517115e-06
proliferation O 0 1.1248821465414949e-06
, O 0 8.044792387806865e-09
or O 0 3.0770749503972183e-07
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 6.005230375194515e-07
mostly O 0 1.1149761114381818e-08
in O 0 1.500484714256345e-08
childhood O 0 1.5431968449775013e-06
. O 0 2.4354608285648283e-06

A O 0 3.7841628000023775e-06
wide O 0 9.336360449196945e-07
variety O 0 1.2152945316756814e-07
of O 0 2.0368040054563608e-07
ATM O 0 2.0830038920394145e-06
mutation O 0 1.7180646239012276e-08
types O 0 9.733382988486028e-09
, O 0 2.4187949421161647e-09
including O 0 7.751386199572607e-09
missense O 0 6.125355298536306e-07
mutations O 0 7.302690363530928e-08
and O 0 5.8482225284706146e-08
in O 0 1.0022742458204448e-07
- O 0 3.23100675814203e-06
frame O 0 4.486897523747757e-06
deletions O 0 3.861953246087069e-08
, O 0 1.5914121131999082e-09
were O 0 4.742152004411082e-09
seen O 0 8.640635762446891e-09
in O 0 2.6130673180801978e-09
these O 0 1.768873225671541e-08
patients O 0 5.643598299798214e-08
. O 0 1.8463973674442968e-06

We O 0 1.671675562420205e-07
also O 0 1.3313190549979481e-09
show O 0 5.062339436534558e-10
that O 0 8.1464626711103e-11
25 O 0 1.971987684257215e-09
% O 0 4.522350827151911e-10
of O 0 6.032930155441818e-09
all O 0 5.092093502412354e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.6491460996803653e-07
carried O 0 2.6664725538694256e-08
in O 0 1.671180882567569e-08
- O 0 2.890440669034433e-07
frame O 0 1.0069215932162479e-06
deletions O 0 6.850174116834751e-08
or O 0 5.5231232920505136e-09
missense O 0 8.820460806191477e-08
mutations O 0 4.3304799746124445e-09
, O 0 5.324080065705061e-10
many O 0 9.245706977800694e-11
of O 0 4.857579893879915e-10
which O 0 1.2557203887819668e-10
were O 0 1.7078309877405218e-09
also O 0 2.6647919981748203e-10
associated O 0 1.505555236036571e-09
with O 0 4.107582884937955e-10
expression O 0 1.3341463933613795e-08
of O 0 1.0879813316932996e-07
mutant O 0 1.3765040876023704e-06
ATM O 0 9.439278983336408e-06
protein O 0 7.976496476658212e-07
. O 0 1.5738979755042237e-06

The O 0 3.294462203484727e-06
DMPK O 0 0.00010820183524629101
gene O 0 2.3968081563907617e-07
of O 0 6.862007921881741e-07
severely O 1 0.9999421834945679
affected O 1 0.9999996423721313
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.040946122258901596
is O 0 4.8831491739065314e-08
hypermethylated O 0 1.9326762412674725e-06
proximal O 0 8.541062470612815e-07
to O 0 3.764899059177651e-09
the O 0 9.204595308176522e-09
largely O 0 4.3791725801156645e-08
expanded O 0 2.181265728040671e-07
CTG O 0 2.7821313778986223e-05
repeat O 0 1.359131715616968e-06
. O 0 1.624893229745794e-06

Using O 0 4.627768703358015e-06
methylation O 0 9.427151780982967e-06
- O 0 8.800076102488674e-06
sensitive O 0 5.653747052747349e-07
restriction O 0 2.437255552933948e-08
enzymes O 0 1.764422030703372e-08
, O 0 9.664523625829702e-10
we O 0 1.115043612998079e-09
characterized O 0 1.7452890244129549e-09
the O 0 9.005732271027966e-10
methylation O 0 1.5771622230431603e-08
pattern O 0 1.7014071929111196e-08
on O 0 1.4213187071732136e-08
the O 0 5.271065361966976e-09
5 O 0 2.995069436906306e-08
side O 0 4.7277499248821186e-08
of O 0 4.057394420442506e-08
the O 0 4.6309072132544316e-08
CTG O 0 3.051800376852043e-06
repeat O 0 2.2079159833765516e-08
in O 0 3.1499112207455937e-09
the O 0 6.246652528574259e-09
DMPK O 0 5.325009624357335e-07
gene O 0 2.8980342570150697e-09
of O 0 2.962891265667622e-09
normal O 0 8.59721982493511e-09
individuals O 0 1.6388744528139654e-10
and O 0 8.027958298129079e-10
of O 0 2.946008548221357e-09
patients O 0 4.3632790713843406e-09
affected O 0 3.607103948866097e-08
with O 0 2.5964187443605624e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 2.4281666810566094e-07
showing O 0 3.8866641460799656e-08
expansions O 0 4.481362836372682e-08
of O 0 9.468601902540286e-09
the O 0 2.0174674375539325e-08
repetitive O 0 2.4357274241992855e-07
sequence O 0 6.530823526418317e-08
. O 0 4.949557705913321e-07

The O 0 1.5833703628231888e-06
gene O 0 1.9198452605451166e-07
segment O 0 1.0043007847571062e-07
analyzed O 0 1.2941038107783243e-07
corresponds O 0 2.6063588620672817e-08
to O 0 7.248386335589885e-09
the O 0 2.1837793795498328e-08
genomic O 0 3.848824121632788e-07
SacI O 0 1.4071717487240676e-05
- O 0 5.03676403695863e-07
HindIII O 0 1.8867468725147774e-06
fragment O 0 1.3965534151338943e-07
carrying O 0 7.044419447765904e-08
exons O 0 7.576884968329978e-07
11 O 0 5.510708547262766e-07
- O 0 5.611589699583419e-07
15 O 0 5.900828341509623e-07
. O 0 2.9203422400314594e-06

There O 0 3.6153357996226987e-07
is O 0 1.585166309325814e-08
constitutive O 0 9.224439168065146e-07
methylation O 0 2.073285685355586e-07
in O 0 3.984157359582241e-08
intron O 0 9.700004284241004e-07
12 O 0 5.25524797012622e-07
at O 0 8.313854493735562e-08
restriction O 0 7.935144985538045e-09
sites O 0 5.6655107272263194e-09
of O 0 1.2942192206821801e-08
SacII O 0 2.096335720125353e-06
and O 0 2.2120300258166026e-08
HhaI O 0 1.9655844880617224e-06
, O 0 5.237502875843347e-09
localized O 0 4.924565644159884e-08
1 O 0 1.3149266919754155e-07
, O 0 5.41550138066782e-09
159 O 0 3.643134505182388e-08
- O 0 3.029536443932557e-08
1 O 0 1.0332106370469774e-07
, O 0 1.865994825323014e-08
232 O 0 1.3637352935802483e-07
bp O 0 2.421561760002078e-07
upstream O 0 7.293141379705048e-08
of O 0 4.9547811187267143e-08
the O 0 1.4418139926419826e-07
CTG O 0 3.5708108043763787e-05
repeat O 0 2.668885201728699e-07
, O 0 2.5235580292104487e-09
whereas O 0 1.8418111480400512e-09
most O 0 2.7673960345531157e-10
, O 0 9.326241168228222e-11
if O 0 8.60935420177178e-11
not O 0 1.5439380329773655e-10
all O 0 2.537375032307665e-10
, O 0 1.8407039781287438e-10
of O 0 5.387670864998029e-10
the O 0 6.389906936909995e-10
other O 0 9.968165876061974e-11
sites O 0 1.489767087470284e-09
of O 0 6.418249043349533e-09
SacII O 0 2.902151436501299e-06
, O 0 1.7012515840519882e-08
HhaI O 0 3.6024644032295328e-06
, O 0 7.376686372850827e-09
and O 0 5.548771220276194e-09
HpaII O 0 3.5687480703927577e-07
in O 0 1.1534667665458187e-09
this O 0 8.246316407500842e-10
region O 0 7.1060206607853615e-09
are O 0 2.307849911176163e-09
unmethylated O 0 2.580723048595246e-07
, O 0 1.2586824915672423e-09
in O 0 6.153370590844531e-10
normal O 0 7.918015576535709e-09
individuals O 0 1.7385835826555507e-10
and O 0 6.337484426133244e-10
most O 0 2.5683477566929014e-10
of O 0 3.39996009124377e-09
the O 0 8.785901783880945e-09
patients O 0 1.6959511128789018e-08
. O 0 5.607988668998587e-07

In O 0 1.7717913181058975e-07
a O 0 1.3881079397037865e-08
number O 0 9.009637480517085e-09
of O 0 4.642341622229651e-08
young O 0 8.256118917415733e-07
and O 0 9.844364257105553e-08
severely O 0 4.209897088003345e-05
affected O 0 2.8388459583084114e-08
patients O 0 1.6543963976545228e-09
, O 0 4.769307726526506e-10
however O 0 3.7187515289360817e-09
, O 0 7.78532849299296e-10
complete O 0 2.0123551713879806e-09
methylation O 0 4.578454504411411e-09
of O 0 1.2479325350867043e-09
these O 0 1.591623777219553e-10
restriction O 0 3.840427142964842e-10
sites O 0 1.1212369921409504e-09
was O 0 3.495470135561618e-09
found O 0 6.926659801287371e-10
in O 0 1.7665356955021139e-09
the O 0 2.2414711864371384e-08
mutated O 0 6.860175858491857e-07
allele O 0 6.4419000409543514e-06
. O 0 6.752184162905905e-06

In O 0 8.357035596873175e-08
most O 0 3.523483504963565e-09
of O 0 6.557432818965481e-09
these O 0 1.392881143758018e-09
patients O 0 6.887926895515761e-10
, O 0 2.3266281956590973e-10
the O 0 7.931010292949736e-10
onset O 0 8.914911973079143e-07
of O 0 5.950967363332893e-08
the O 0 6.155836445032037e-07
disease O 1 0.9687427282333374
was O 0 9.390058403369039e-05
congenital O 1 1.0
. O 0 0.00017058024241123348

Preliminary O 0 2.8911381377838552e-05
in O 0 1.4514163240164635e-06
vivo O 0 1.712936682451982e-05
footprinting O 0 1.5699008145020343e-05
data O 0 1.0232420066813575e-07
gave O 0 2.696818590663952e-08
evidence O 0 6.2191688243729e-08
for O 0 3.442669704867285e-09
protein O 0 1.4178204388315407e-08
- O 0 3.148885951986813e-08
DNA O 0 1.2095913604071029e-08
contact O 0 4.781880225124269e-09
in O 0 3.040446561186627e-09
normal O 0 2.8870459800600656e-08
genes O 0 9.80280212559137e-09
at O 0 3.2151348250408773e-08
an O 0 1.3355460071196035e-09
Sp1 O 0 4.866287781624123e-07
consensus O 0 8.184585453818727e-08
binding O 0 3.8314169614750426e-08
site O 0 5.265973612722519e-08
upstream O 0 1.503200230956736e-08
of O 0 8.71752892095401e-09
the O 0 1.803231342023537e-08
CTG O 0 2.8168562948849285e-06
repeat O 0 3.13197041634794e-08
and O 0 9.790875887816242e-10
for O 0 2.8779054139782545e-10
a O 0 1.9228074688015795e-10
significant O 0 6.36741159798504e-10
reduction O 0 5.809075886986648e-09
of O 0 3.3695464196625835e-09
this O 0 3.456155361902802e-10
interaction O 0 2.3983792729609377e-09
in O 0 5.358739563199322e-10
cells O 0 1.1849242698147577e-09
with O 0 1.9406659612641874e-10
a O 0 3.3808895683051787e-09
hypermethylated O 0 6.88887155320117e-07
DMPK O 0 2.5356659989483887e-06
gene O 0 1.5086719429291406e-08
. O 0 2.845541047236111e-08
. O 0 5.185885356695508e-07

The O 0 0.0010258302791044116
hemochromatosis B-Disease 1 1.0
gene O 0 4.407193330280279e-07
product O 0 3.30501173095854e-08
complexes O 0 3.852308338991861e-08
with O 0 3.84330167690905e-09
the O 0 2.7759682552641607e-08
transferrin O 0 2.5968171257773065e-07
receptor O 0 7.207678009990559e-08
and O 0 5.4143236560832975e-09
lowers O 0 2.0956827384566168e-08
its O 0 4.3337167188184367e-10
affinity O 0 2.1739496869344066e-09
for O 0 1.0028490260438616e-09
ligand O 0 4.086394511659819e-08
binding O 0 2.0119382782013417e-07
. O 0 4.944636771142541e-07

We O 0 7.896675811025489e-07
recently O 0 9.726593219738788e-08
reported O 0 9.944040257892084e-09
the O 0 3.1847930959116866e-09
positional O 0 1.767093493754146e-07
cloning O 0 2.3683643490812756e-08
of O 0 2.364729301262969e-09
a O 0 1.4965395589427999e-09
candidate O 0 6.75446329978513e-08
gene O 0 3.7562793409051665e-07
for O 0 2.7105672870675335e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9423157572746277
HFE O 1 0.9949819445610046
. O 0 2.955218769784551e-05

The O 0 4.4253539499550243e-07
gene O 0 1.1508038966212553e-08
product O 0 5.565772731586094e-09
, O 0 1.7668356777633676e-09
a O 0 2.242085850312492e-09
member O 0 9.855068761055463e-09
of O 0 3.810857052144456e-08
the O 0 4.597261948902087e-08
major O 0 1.9543904272723012e-07
histocompatibility O 0 2.985454375448171e-05
complex O 0 5.364848902900121e-07
class O 0 1.066748609446222e-07
I O 0 1.1467544709375943e-06
- O 0 4.4485922501280584e-08
like O 0 9.764318242844183e-10
family O 0 6.347343761703428e-10
, O 0 2.7993604656550986e-10
was O 0 5.221633347929355e-09
found O 0 5.200479491485055e-10
to O 0 1.1108617359312234e-09
have O 0 5.9200355728705745e-09
a O 0 1.1482977235743874e-08
mutation O 0 1.2227907575379504e-07
, O 0 1.0118302640194088e-07
Cys O 0 0.001080215908586979
- O 0 1.8439495761413127e-05
282 O 0 1.6723755607017665e-06
- O 0 4.735055426863255e-06
- O 0 3.851787369058002e-06
> O 0 1.393682396155782e-06
Tyr O 0 1.0208495950791985e-05
( O 0 2.7825559634209185e-09
C282Y O 0 5.24560341830238e-08
) O 0 2.4325208514142105e-10
, O 0 1.236896141065813e-10
in O 0 5.047559037407723e-10
85 O 0 8.257810435452484e-09
% O 0 3.1676183898099453e-09
of O 0 4.490654958999585e-08
patient O 0 2.492290889222204e-07
chromosomes O 0 2.628545644256519e-06
. O 0 5.4280135373119265e-06

This O 0 1.7050433598342352e-07
mutation O 0 2.4030748591030715e-07
eliminates O 0 3.8258241374933277e-07
the O 0 2.1383455006684926e-08
ability O 0 3.3893879702873164e-08
of O 0 9.802656819601907e-08
HFE O 0 2.3102827981347218e-05
to O 0 2.980583246880997e-08
associate O 0 1.894903363108824e-07
with O 0 5.232480226879943e-09
beta2 O 0 3.0898597742634593e-06
- O 0 2.3766692720528226e-06
microglobulin O 0 4.508498932409566e-06
( O 0 1.1351469986209395e-08
beta2m O 0 9.011081374410423e-07
) O 0 5.329365837525302e-09
and O 0 9.296945435721682e-09
prevents O 0 2.17099227484141e-08
cell O 0 7.002542474765505e-07
- O 0 2.0298077174629725e-07
surface O 0 4.253816712207481e-07
expression O 0 1.305743580815033e-06
. O 0 2.2469262148661073e-06

A O 0 2.4395869786530966e-06
second O 0 3.892963889029488e-07
mutation O 0 4.45717063257689e-08
that O 0 8.126726513957294e-10
has O 0 2.2622570483576965e-10
no O 0 7.770566967657544e-10
effect O 0 2.7219597242833515e-08
on O 0 7.771063792461064e-08
beta2m O 0 3.3522578632982913e-06
association O 0 1.2523706516276434e-08
, O 0 1.6921860579444115e-09
H63D O 0 7.273351343428658e-07
, O 0 5.261400204403799e-10
was O 0 2.2151280809623586e-09
found O 0 1.818318967616861e-10
in O 0 4.0731620853939887e-10
eight O 0 1.9176809029630704e-09
out O 0 1.0568685926415355e-09
of O 0 4.588875501809753e-09
nine O 0 2.3083703837301073e-08
patients O 0 7.022305514858829e-10
heterozygous O 0 3.7069607383699577e-09
for O 0 5.5552096256406e-09
the O 0 6.460108181727264e-08
C282Y O 0 2.5955298497137846e-06
mutant O 0 8.857498869474512e-06
. O 0 5.03987666888861e-06

In O 0 1.409330820933974e-07
this O 0 7.35440508492502e-09
report O 0 6.748511527376877e-09
, O 0 1.0888481227766533e-09
we O 0 3.305747675597104e-09
demonstrate O 0 1.4126081637755306e-08
in O 0 2.0195116690047143e-08
cultured O 0 1.3330318324733526e-06
293 O 0 3.366914427260781e-07
cells O 0 2.9062792350487143e-07
overexpressing O 0 3.76620437236852e-06
wild O 0 2.4025203515520843e-07
- O 0 1.3110437180330337e-07
type O 0 1.3469362158957665e-07
or O 0 3.1688287549513916e-08
mutant O 0 1.868787649073056e-07
HFE O 0 9.057934562406444e-07
proteins O 0 2.929197995271693e-10
that O 0 8.296022202536335e-11
both O 0 8.858825895075029e-10
the O 0 7.83229392453677e-09
wild O 0 3.587166119700669e-08
- O 0 2.8021251097243294e-08
type O 0 6.439096722488102e-08
and O 0 2.0032193503993767e-07
H63D O 0 0.00016954148304648697
HFE O 0 2.5665254725026898e-05
proteins O 0 1.4940477299774102e-08
form O 0 1.9952945962131707e-08
stable O 0 1.0750762413636039e-07
complexes O 0 1.8806513679692216e-08
with O 0 2.1498112179330064e-09
the O 0 1.8391862255384694e-08
transferrin O 0 8.629232297607814e-07
receptor O 0 3.680101201553043e-07
( O 0 1.5033119638019343e-08
TfR O 0 1.8410678421787452e-06
) O 0 2.6793353313792068e-08
. O 0 7.065262366268144e-07

The O 0 1.795170760487963e-06
C282Y O 0 4.145194907323457e-06
mutation O 0 7.846187344284772e-08
nearly O 0 7.942049684572794e-09
completely O 0 8.994973654807836e-09
prevents O 0 3.201023002219472e-09
the O 0 8.292518671737525e-09
association O 0 7.025953152606235e-09
of O 0 1.4377602219894925e-08
the O 0 2.9425955005990545e-08
mutant O 0 7.542381013081467e-07
HFE O 0 8.260622053057887e-06
protein O 0 8.45569019247705e-08
with O 0 7.553246916813805e-09
the O 0 1.5111436368897557e-07
TfR O 0 3.776454468606971e-05
. O 0 3.710383225552505e-06

Studies O 0 3.974935225414811e-06
on O 0 1.5393576404676423e-06
cell O 0 3.089898200414609e-06
- O 0 2.991889687109506e-07
associated O 0 3.81739724275576e-08
transferrin O 0 6.671189112239517e-07
at O 0 3.270029651503137e-07
37 O 0 2.909095364600489e-08
degrees O 0 1.5949004250614962e-07
C O 0 1.6318693951689056e-07
suggest O 0 2.8785658301444528e-09
that O 0 2.7907026689533154e-10
the O 0 7.841007843012449e-09
overexpressed O 0 5.221904757490847e-07
wild O 0 3.459529196447875e-08
- O 0 7.557934367241614e-08
type O 0 1.115599914669474e-07
HFE O 0 4.229713340464514e-06
protein O 0 2.927681563846818e-08
decreases O 0 7.46737072176984e-09
the O 0 9.98402138741028e-10
affinity O 0 3.458841213443975e-09
of O 0 8.18297429816539e-09
the O 0 1.886363598657681e-08
TfR O 0 9.99424855763209e-07
for O 0 2.4655809838236564e-08
transferrin O 0 7.507255759264808e-06
. O 0 2.9509303658414865e-06

The O 0 2.6758205422083847e-05
overexpressed O 0 0.00022405845811590552
H63D O 0 8.458617958240211e-05
protein O 0 1.9289917219111885e-08
does O 0 2.6591412405352344e-10
not O 0 1.6015695714077793e-10
have O 0 5.516727005772104e-11
this O 0 2.6226115029670538e-11
effect O 0 1.3174912272262418e-09
, O 0 1.2124751203046458e-10
providing O 0 2.432404833108137e-10
the O 0 9.714232890312147e-11
first O 0 1.0696422914069359e-10
direct O 0 2.3550417171946947e-10
evidence O 0 3.7166101307661847e-09
for O 0 1.5771245420737046e-10
a O 0 4.011199150610878e-10
functional O 0 3.01644753619712e-08
consequence O 0 6.540247454722703e-08
of O 0 3.068581833076678e-08
the O 0 7.624159792385399e-08
H63D O 0 3.4617711207829416e-05
mutation O 0 1.255474671779666e-06
. O 0 1.941366008395562e-06

Addition O 0 1.8587076056064689e-06
of O 0 3.313986553621362e-06
soluble O 0 3.754975841729902e-05
wild O 0 5.363044692785479e-07
- O 0 7.77834259224619e-07
type O 0 8.494213034282438e-06
HFE O 1 0.999995231628418
/ O 0 0.0041730511002242565
beta2m O 0 1.873322980827652e-05
heterodimers O 0 2.5201165954058524e-06
to O 0 1.73941785419629e-08
cultured O 0 8.95061660344254e-08
cells O 0 1.0054542975979075e-08
also O 0 8.598478040688917e-10
decreased O 0 3.463653586166515e-09
the O 0 4.1023134889073276e-10
apparent O 0 7.318219363838807e-09
affinity O 0 6.23646201347583e-09
of O 0 2.433502466203663e-08
the O 0 1.2093698487092297e-08
TfR O 0 1.2726343356916914e-07
for O 0 3.509584289851375e-10
its O 0 2.3841162377635783e-10
ligand O 0 5.0183119881808125e-09
under O 0 8.603798562489828e-09
steady O 0 5.5474192350857265e-08
- O 0 4.458630797898877e-09
state O 0 1.5229557892570966e-10
conditions O 0 2.883093319638874e-09
, O 0 1.3899398298988785e-10
both O 0 2.3866686404971915e-10
in O 0 8.538629248100449e-10
293 O 0 6.340498348578194e-09
cells O 0 2.2210424610591417e-09
and O 0 2.6405533315454477e-09
in O 0 1.712234976025684e-08
HeLa O 0 2.734258487180341e-06
cells O 0 5.048349294156651e-07
. O 0 1.0278088211634895e-06

Furthermore O 0 1.0017647582571954e-06
, O 0 2.4713436630463548e-08
at O 0 3.370389833889931e-08
4 O 0 3.3856085934758084e-08
degrees O 0 2.3858885356276005e-07
C O 0 5.412962309492286e-07
, O 0 2.0812653822588345e-09
the O 0 4.357789684661384e-09
added O 0 3.016062422034338e-08
soluble O 0 1.8227064302323015e-08
complex O 0 2.6344322279214794e-08
of O 0 3.282783822555757e-08
HFE O 0 0.00010096246842294931
/ O 0 3.1267561553249834e-06
beta2m O 0 2.8964004741283134e-06
inhibited O 0 2.442503443944588e-07
binding O 0 1.1918898223939323e-07
of O 0 7.393127532395738e-08
transferrin O 0 1.5726435549368034e-06
to O 0 1.210513715932393e-07
HeLa O 0 1.092736238206271e-05
cell O 0 1.7709918438413297e-06
TfR O 0 2.0326431240391685e-06
in O 0 3.362240486026735e-09
a O 0 4.556379273878974e-09
concentration O 0 4.844958993999171e-07
- O 0 2.2799596877121076e-07
dependent O 0 7.38308045811209e-08
manner O 0 1.3849615925209946e-06
. O 0 1.6532386553080869e-06

Scatchard O 0 4.2275016312487423e-05
plots O 0 1.1112628044429584e-06
of O 0 1.6840702699028043e-07
these O 0 9.66362545540278e-09
data O 0 1.566083085435821e-08
indicate O 0 7.899732423766181e-09
that O 0 1.8646846289271934e-09
the O 0 1.4772584044919768e-08
added O 0 3.632962020105879e-08
heterodimer O 0 8.55897113183346e-08
substantially O 0 1.672099081417855e-08
reduced O 0 8.164469100790939e-09
the O 0 1.2496330636935227e-09
affinity O 0 4.276454301788135e-09
of O 0 1.882560773935893e-08
TfR O 0 4.348609365933953e-07
for O 0 8.013643082449562e-09
transferrin O 0 3.0787762170803035e-06
. O 0 1.6095921182568418e-06

These O 0 2.500516416148457e-07
results O 0 4.3032821395172505e-07
establish O 0 1.0109351222808982e-07
a O 0 6.760415338646908e-09
molecular O 0 1.0595034893867705e-07
link O 0 8.677751139885004e-08
between O 0 1.0272174932879352e-07
HFE O 0 0.0006133447168394923
and O 0 4.606346593050148e-08
a O 0 1.5027644906240312e-08
key O 0 2.2589333070754947e-07
protein O 0 3.6725836594087014e-08
involved O 0 9.677662227147721e-09
in O 0 5.464777519392783e-09
iron O 0 2.296352704433957e-06
transport O 0 2.965290946121968e-07
, O 0 6.520640472018613e-09
the O 0 1.4898475342306483e-08
TfR O 0 1.8177229321736377e-06
, O 0 1.8059324036201474e-09
and O 0 9.291428182400807e-10
raise O 0 1.796313431334795e-09
the O 0 9.837524128641917e-10
possibility O 0 4.658269325830133e-09
that O 0 2.0626390873079714e-10
alterations O 0 6.760363824298565e-09
in O 0 1.9685518493073317e-10
this O 0 1.2815819239175852e-10
regulatory O 0 5.277856374164003e-09
mechanism O 0 2.5653147162074674e-08
may O 0 1.2905481128200336e-09
play O 0 1.8504133780794518e-09
a O 0 2.3282618888398332e-10
role O 0 1.4217518273795804e-09
in O 0 8.963559339214555e-10
the O 0 6.8873782232969916e-09
pathogenesis O 0 0.00024806498549878597
of O 0 7.397768786177039e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 1.259151758858934e-05
. O 0 2.6135553525818978e-06

Genomic O 0 2.967207819892792e-06
organization O 0 2.4127331244017114e-07
of O 0 1.7802635454700066e-07
the O 0 5.19212051131035e-07
UBE3A O 0 0.001786760869435966
/ O 0 0.0007746487972326577
E6 O 0 0.00022871048713568598
- O 0 8.483527381031308e-06
AP O 0 9.97440565697616e-06
gene O 0 1.78270251893764e-08
and O 0 1.441087604803215e-08
related O 0 2.47940391773227e-07
pseudogenes O 0 6.1551590988528915e-06
. O 0 2.7250248422205914e-06

The O 0 8.931191587180365e-06
UBE3A O 0 0.00010359408042859286
gene O 0 2.3489683087518642e-07
encodes O 0 1.2973387697456928e-07
the O 0 2.10786978982469e-07
E6 O 0 4.3427407945273444e-05
- O 0 5.82860411668662e-05
AP O 0 0.04435991123318672
ubiquitin O 0 3.12311458401382e-05
- O 0 8.705262189323548e-06
protein O 0 9.309263759860187e-08
ligase O 0 4.2490892582236484e-08
and O 0 3.3753160266769555e-09
has O 0 7.978819827059169e-10
recently O 0 7.316740546770006e-09
been O 0 7.653511158167703e-10
shown O 0 5.716928597188087e-10
to O 0 6.744171887618222e-10
be O 0 2.5040343132332055e-09
mutated O 0 4.541414853065362e-07
in O 0 1.8478945094102528e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 1.1586643040573108e-06
who O 0 2.2380408637445726e-08
lack O 0 9.612879239284666e-07
15q11 O 0 6.032234978192719e-06
- O 0 1.603931877980358e-06
q13 O 0 1.0318935892428271e-06
deletions O 0 1.8392184131243994e-07
or O 0 2.240954088961189e-08
chromosome O 0 3.0689804475514393e-07
15 O 0 5.737596211474738e-07
paternal O 0 1.7916518117999658e-05
uniparental B-Disease 0 0.0036528559867292643
disomy I-Disease 0 0.00169112510047853
. O 0 7.308716885745525e-05

Previous O 0 7.474515314243035e-06
UBE3A O 0 5.398595749284141e-05
cDNA O 0 2.6116541107512603e-07
analysis O 0 3.253077096587731e-08
has O 0 2.0770420938731604e-09
shown O 0 3.824829342136127e-09
a O 0 6.330457047454274e-09
coding O 0 1.7695927567729086e-07
region O 0 1.153201001358184e-08
of O 0 2.3446908414825884e-08
approximately O 0 1.2795827508682578e-08
2 O 0 3.7150817888687016e-07
. O 0 5.135233891451207e-07

6 O 0 6.793570355512202e-05
kb O 0 0.00010058443149318919
and O 0 1.6166535488082445e-07
a O 0 5.563186178392243e-08
3 O 0 8.934769653023977e-07
- O 0 1.3055903309577843e-06
untranslated O 0 3.821405698545277e-05
region O 0 1.0504165715019553e-07
( O 0 1.1555504109139747e-08
UTR O 0 5.832192982779816e-06
) O 0 3.0612554713371765e-09
of O 0 1.772412616674046e-08
< O 0 4.509598738877685e-07
50 O 0 3.9417155761611866e-08
bp O 0 8.603194601164432e-08
, O 0 1.8627008824267932e-09
whereas O 0 6.030859367456287e-09
Northern O 0 1.6259516399941276e-08
analysis O 0 1.2276112570930309e-08
has O 0 1.1847276493170966e-09
indicated O 0 1.0930477856163634e-08
mRNA O 0 1.0680695439191368e-08
sizes O 0 1.6235373934136987e-08
of O 0 8.653946004244517e-09
5 O 0 9.748881524274111e-08
- O 0 2.0407607337347144e-07
8 O 0 5.878708861928317e-07
kb O 0 4.269458804628812e-05
. O 0 2.056632411040482e-06

We O 0 3.149390863654844e-07
have O 0 9.441946779986665e-09
analyzed O 0 2.7336504615504964e-08
additional O 0 3.857798969164605e-09
cDNA O 0 2.9388038669253547e-08
clones O 0 2.6054642887629598e-08
and O 0 2.770677243191244e-09
provide O 0 9.324894190143596e-10
evidence O 0 3.088167943587905e-09
for O 0 1.5527060193143427e-10
an O 0 1.1612518585613074e-10
additional O 0 2.6043993628377393e-09
0 O 0 2.2891842377248395e-07
. O 0 5.016419777348347e-07

5 O 0 1.5017713849374559e-05
kb O 0 3.970744728576392e-05
of O 0 1.1843000038425089e-06
5 O 0 2.966036618090584e-06
- O 0 1.8541894633017364e-06
UTR O 0 1.6438072634628043e-05
and O 0 4.645078632847799e-08
> O 0 1.5113857898541028e-07
2 O 0 1.1310540060094354e-07
kb O 0 9.562971854393254e-07
of O 0 5.941667069464529e-08
3 O 0 9.72468001236848e-07
- O 0 1.0597830168990185e-06
UTR O 0 0.0001002771095954813
. O 0 1.8082240558214835e-06

We O 0 2.3760703982134146e-07
have O 0 5.145819770291382e-09
established O 0 1.228431134592256e-08
the O 0 3.5962828270896807e-09
genomic O 0 9.207246520759327e-09
organization O 0 8.651701577377935e-09
of O 0 2.229779028084522e-08
UBE3A O 0 4.156508111918811e-06
and O 0 1.5060757974083572e-08
the O 0 1.5413796461416496e-08
sequence O 0 1.0598062871736147e-08
of O 0 6.603031721397201e-08
intron O 0 2.042169626292889e-06
- O 0 6.633582870563259e-06
exon O 0 3.2882251161936438e-06
borders O 0 3.266183910000109e-07
. O 0 4.90261618324439e-06

We O 0 7.780643045407487e-07
have O 0 2.032654755623753e-08
also O 0 6.8359580218668725e-09
mapped O 0 2.055760006669516e-08
two O 0 2.9474136464813228e-09
highly O 0 1.8801205925456088e-08
homologous O 0 2.857364655994843e-08
processed O 0 2.997006731675356e-08
pseudogenes O 0 2.259394449311003e-07
, O 0 8.252803773700634e-09
UBE3AP1 O 0 3.322156999274739e-06
and O 0 2.81668395274437e-08
UBE3AP2 O 0 1.7870381725515472e-06
, O 0 1.892965562078075e-09
to O 0 8.649981286801278e-10
chromosomes O 0 3.596797082394687e-09
2 O 0 1.1155504964222018e-08
and O 0 1.1340642869228645e-09
21 O 0 9.273868784021033e-09
, O 0 1.9824103469900933e-10
respectively O 0 1.6979830874674917e-09
, O 0 8.961366371185164e-11
and O 0 1.668465643422934e-10
determined O 0 3.822306027245759e-09
their O 0 1.568862706413654e-09
genomic O 0 2.2755710205046853e-08
organization O 0 8.430680509263766e-08
. O 0 7.237806016746617e-07

These O 0 8.92753178050043e-08
results O 0 1.0418645501886203e-07
will O 0 1.6414654080421087e-09
form O 0 4.77564321421653e-10
the O 0 2.5931662372968844e-10
basis O 0 4.6080642079893153e-10
for O 0 1.539579227993748e-11
studies O 0 1.650399261698965e-10
of O 0 4.0102426934751634e-10
mutation O 0 1.8205303931040362e-09
and O 0 1.0655626603295332e-08
imprinting O 0 1.6932141306824633e-06
of O 0 1.0349418744226568e-06
UBE3A O 0 0.0006725536659359932
. O 0 2.1478432245203294e-05

Mutation O 0 1.2245205653016455e-05
spectrum O 0 7.65926597523503e-06
and O 0 2.86626573142712e-07
genotype O 0 1.7608635971555486e-05
- O 0 4.193937002128223e-06
phenotype O 0 3.643246486717544e-07
analyses O 0 5.4532954152364255e-08
in O 0 1.4999411490634884e-08
Cowden B-Disease 1 0.9870718121528625
disease I-Disease 0 0.0649583712220192
and O 0 2.5986157652369e-06
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
, O 0 7.9348147608016e-08
two O 0 5.046625801696791e-07
hamartoma B-Disease 1 0.9897659420967102
syndromes I-Disease 0 0.0017657802673056722
with O 0 3.2996754271152895e-06
germline O 1 0.9828975796699524
PTEN O 0 0.002459609182551503
mutation O 0 4.0969949623104185e-05
. O 0 3.0461356800515205e-05

The O 0 6.039594882167876e-05
tumour B-Disease 1 1.0
suppressor O 0 0.0017189948121085763
gene O 0 1.707225010250113e-06
PTEN O 0 1.3414637578534894e-05
, O 0 2.1734699373610056e-08
which O 0 4.347826987327608e-09
maps O 0 2.1984821074738647e-08
to O 0 3.6209524267860616e-08
10q23 O 0 8.823269126878586e-06
. O 0 3.109766794295865e-06

3 O 0 4.5178690015745815e-06
and O 0 8.669413631423595e-08
encodes O 0 4.04826536737346e-08
a O 0 7.93509968843864e-09
403 O 0 1.692964879396186e-08
amino O 0 4.1052061305890675e-08
acid O 0 5.8553993653731595e-08
dual O 0 1.3739623909714282e-06
specificity O 0 2.5216206267941743e-05
phosphatase O 0 0.05759250745177269
( O 0 3.369786156781629e-07
protein O 0 4.121903032228147e-07
tyrosine O 0 6.659117843810236e-07
phosphatase O 0 3.740985619060666e-07
; O 0 2.2797141951969024e-09
PTPase O 0 3.325195336856268e-07
) O 0 5.305791916931923e-10
, O 0 1.775317115537689e-10
was O 0 2.6876769698702674e-09
shown O 0 8.153727137916178e-10
recently O 0 3.368428203032181e-09
to O 0 7.713685246102386e-10
play O 0 1.4299303074949421e-08
a O 0 3.846631013715296e-09
broad O 0 3.8185184791927895e-08
role O 0 5.407071768104288e-08
in O 0 1.990342113344923e-08
human O 0 3.612547629927576e-07
malignancy B-Disease 0 3.1793453672435135e-05
. O 0 2.5103656753344694e-06

Somatic O 0 0.0013621184043586254
PTEN O 0 0.00015577916929032654
deletions O 0 1.6639216937619494e-06
and O 0 2.4800320019835453e-08
mutations O 0 2.16394369090267e-08
were O 0 1.1675938438315825e-08
observed O 0 1.9377644377982506e-08
in O 0 6.922978634804622e-09
sporadic B-Disease 0 0.007239908911287785
breast I-Disease 1 1.0
, I-Disease 0 0.09144693613052368
brain I-Disease 1 1.0
, I-Disease 1 0.9763875007629395
prostate I-Disease 1 1.0
and I-Disease 1 0.9999996423721313
kidney I-Disease 1 1.0
cancer I-Disease 1 0.9999960660934448
cell O 0 0.15787672996520996
lines O 0 2.5451601004533586e-07
and O 0 2.2156108059334656e-08
in O 0 1.6720727025187898e-09
several O 0 3.6494476329806957e-09
primary O 0 1.4571646715921815e-05
tumours B-Disease 1 1.0
such O 0 1.1502359598125622e-07
as O 0 8.396374141739216e-06
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9999953508377075
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 1 0.9999402761459351

In O 0 1.1702585567263668e-07
addition O 0 6.447293543487831e-08
, O 0 2.8571141896804875e-08
PTEN O 0 2.421655153739266e-06
was O 0 6.086259674020766e-08
identified O 0 7.012765479430527e-09
as O 0 1.6267511782075417e-09
the O 0 3.5611773530064283e-09
susceptibility O 0 3.7604365843435517e-08
gene O 0 1.4658293245872756e-08
for O 0 1.0143883066859871e-08
two O 0 9.367280995320471e-07
hamartoma B-Disease 1 0.9999998807907104
syndromes I-Disease 1 0.9999997615814209
Cowden B-Disease 1 0.9999996423721313
disease I-Disease 1 0.8219282627105713
( O 0 2.9668401069216088e-08
CD B-Disease 0 2.0244424376869574e-06
; O 0 6.565795729329693e-08
MIM O 0 1.6277102986350656e-05
158350 O 0 1.9235430954722688e-06
) O 0 1.4025911987403106e-08
and O 0 5.8424920013067094e-08
Bannayan B-Disease 0 0.0001069132486009039
- I-Disease 0 0.000322688661981374
Zonana I-Disease 0 0.4245162904262543
( I-Disease 0 2.4543581389480096e-07
BZS I-Disease 0 7.898356125224382e-05
) I-Disease 0 9.66681881209297e-08
or I-Disease 0 2.9307526006050466e-07
Ruvalcaba I-Disease 0 0.00013624702114611864
- I-Disease 0 2.566419971117284e-05
Riley I-Disease 0 0.00016501038044225425
- I-Disease 1 0.5666887164115906
Smith I-Disease 1 0.9666529893875122
syndrome I-Disease 1 0.9999990463256836
( O 0 1.4747887462362996e-06
MIM O 0 0.00027920029242523015
153480 O 0 2.3071937903296202e-05
) O 0 3.003633821663243e-07
. O 0 3.724620910361409e-06

Constitutive O 0 2.49632794293575e-05
DNA O 0 5.832287683915638e-07
from O 0 1.3772057272376514e-08
37 O 0 5.740700714795821e-08
CD B-Disease 0 1.9956397068199294e-07
families O 0 3.4639511259371147e-09
and O 0 1.285259987326981e-08
seven O 0 8.342908586200792e-08
BZS B-Disease 0 8.738307769817766e-06
families O 0 8.96246987736049e-09
was O 0 6.64712018760838e-08
screened O 0 2.2088812556830817e-07
for O 0 1.4892117405906902e-07
germline O 0 0.0003549609682522714
PTEN O 0 0.00024186036898754537
mutations O 0 2.4570854293415323e-05
. O 0 1.1747703865694348e-05

PTEN O 0 0.00018166146764997393
mutations O 0 5.904707336412685e-07
were O 0 9.655964561261499e-08
identified O 0 2.7880773245669843e-08
in O 0 6.312503408878456e-09
30 O 0 3.346643495660828e-08
of O 0 2.854390679374319e-08
37 O 0 2.3045394925702567e-07
( O 0 8.368995274565805e-09
81 O 0 5.171848371787746e-08
% O 0 2.5463502417721884e-09
) O 0 1.6003702807410036e-09
CD B-Disease 0 8.473078594306571e-08
families O 0 7.509932120619567e-10
, O 0 3.591872910213567e-10
including O 0 1.185916920221075e-09
missense O 0 2.4664564080012497e-07
and O 0 1.3670669929410906e-08
nonsense O 0 4.686611987381184e-07
point O 0 7.42182280077941e-08
mutations O 0 3.238973533825629e-08
, O 0 4.132535647016766e-09
deletions O 0 4.901270145296621e-08
, O 0 7.616249853015233e-09
insertions O 0 1.0109795312018832e-07
, O 0 1.8154167946704547e-08
a O 0 4.6958280819353604e-08
deletion O 0 4.484142664296087e-06
/ O 0 1.0823183401953429e-05
insertion O 0 5.628671146951092e-07
and O 0 7.692350436627748e-07
splice O 0 2.898268576245755e-05
site O 0 1.4239745951272198e-06
mutations O 0 4.493303549679695e-06
. O 0 1.0103824024554342e-05

These O 0 6.351201164989106e-08
mutations O 0 8.303870657755397e-08
were O 0 4.3157388773806815e-08
scattered O 0 3.2533066018913814e-08
over O 0 6.437694377581238e-09
the O 0 6.10685102486741e-09
entire O 0 1.6557768489633418e-08
length O 0 5.908078914984571e-09
of O 0 1.219317802281239e-08
PTEN O 0 3.3898155038514233e-07
, O 0 5.93460502962273e-10
with O 0 8.60564397520136e-11
the O 0 4.0570732884326333e-10
exception O 0 5.31010457827108e-10
of O 0 8.681418361966564e-10
the O 0 5.176442052778896e-10
first O 0 9.628919883652998e-10
, O 0 6.087728654513569e-10
fourth O 0 1.4047331298172594e-08
and O 0 7.40620764716482e-09
last O 0 2.575714290742326e-07
exons O 0 8.403728315897752e-06
. O 0 3.565234237612458e-06

A O 0 7.337114766414743e-06
hot O 0 9.601686542737298e-06
spot O 0 9.023998245538678e-06
for O 0 1.3934349851751904e-07
PTEN O 0 3.893479060934624e-06
mutation O 0 3.341617471619429e-08
in O 0 6.728025248037284e-09
CD B-Disease 0 2.536908993988618e-07
was O 0 7.328196005573773e-08
identified O 0 1.3195743164828855e-08
in O 0 3.81750453470886e-09
exon O 0 3.801883607934542e-08
5 O 0 1.2340789723452872e-08
that O 0 1.9334836509621312e-10
contains O 0 5.314644280218772e-10
the O 0 2.4321600289312073e-09
PTPase O 0 4.868488190368225e-07
core O 0 1.0395559968401358e-07
motif O 0 1.1165893099018831e-08
, O 0 2.42407732775618e-10
with O 0 7.251158007370861e-11
13 O 0 2.490748940431331e-09
of O 0 1.869969956658224e-09
30 O 0 4.1512429049817e-09
( O 0 7.2829581254652e-10
43 O 0 4.361905947547484e-09
% O 0 6.288561893441624e-10
) O 0 6.878868030746332e-10
CD B-Disease 0 7.526860201778618e-08
mutations O 0 1.1940316291259023e-08
identified O 0 9.65441415701207e-09
in O 0 4.385740215440137e-09
this O 0 1.3985093971768947e-08
exon O 0 2.4121886781358626e-06
. O 0 1.5864054603298428e-06

Seven O 0 1.2525327974799438e-06
of O 0 1.3485635008692043e-07
30 O 0 1.320063063303678e-07
( O 0 3.5981695400977287e-09
23 O 0 2.2560112000746813e-08
% O 0 6.471077007574877e-10
) O 0 2.9050892247362015e-10
were O 0 1.521812453830762e-09
within O 0 3.1145739320947996e-09
the O 0 2.711935787047537e-09
core O 0 4.861152902435606e-08
motif O 0 9.834770331451637e-09
, O 0 2.0518875487596233e-10
the O 0 2.2706868330057972e-10
majority O 0 2.860699177542614e-10
( O 0 4.2283393453246276e-10
five O 0 1.1610973293940674e-09
of O 0 1.7626349269050934e-09
seven O 0 1.4920932267514786e-09
) O 0 1.1166521179939437e-10
of O 0 3.687889438275249e-10
which O 0 6.495772253423127e-10
were O 0 2.5690116700616272e-08
missense O 0 1.4406913351194817e-06
mutations O 0 3.6112280099587224e-07
, O 0 1.7046685840682585e-08
possibly O 0 3.579505118977977e-07
pointing O 0 1.4212947974101553e-07
to O 0 4.661051544729844e-09
the O 0 8.552031971476026e-09
functional O 0 6.67484201244406e-08
significance O 0 5.8121269574940015e-08
of O 0 1.044637887304134e-08
this O 0 3.715773688739432e-09
region O 0 9.748621465632823e-08
. O 0 1.1403320741010248e-06

Germline O 0 0.0037188297137618065
PTEN O 0 6.105058855609968e-05
mutations O 0 4.02384728204197e-07
were O 0 4.8823761034100244e-08
identified O 0 2.2455106218899346e-08
in O 0 3.3216498440680198e-09
four O 0 9.041484894112273e-09
of O 0 3.567529205383835e-08
seven O 0 7.080939212755766e-08
( O 0 1.0655727855635178e-08
57 O 0 7.707221527653019e-08
% O 0 1.3657533770583541e-08
) O 0 3.384956315244381e-08
BZS B-Disease 0 1.9531918951543048e-05
families O 0 3.5670119302722014e-08
studied O 0 1.7827503597800387e-06
. O 0 3.0431253890128573e-06

Interestingly O 0 3.920582003047457e-06
, O 0 2.268472520938758e-08
none O 0 1.8383410349542828e-08
of O 0 5.21220044902293e-09
these O 0 7.932099421736893e-10
mutations O 0 8.905384873969524e-09
was O 0 1.928454551602954e-08
observed O 0 1.2613676325656797e-08
in O 0 6.312672162778199e-09
the O 0 7.992063189021792e-08
PTPase O 0 2.5058374376385473e-05
core O 0 1.7964681319426745e-05
motif O 0 5.205355591897387e-06
. O 0 2.773143023659941e-06

It O 0 8.450708577356636e-08
is O 0 2.7671862579126127e-09
also O 0 1.1122482934666778e-09
worthy O 0 4.493216820833368e-08
of O 0 7.210466446139208e-09
note O 0 5.368891109469587e-09
that O 0 3.154533301241713e-10
a O 0 7.490562614620444e-10
single O 0 2.83577605841856e-09
nonsense O 0 6.6973889545352e-08
point O 0 4.2751352680170385e-08
mutation O 0 9.422552516014093e-09
, O 0 2.659609199540114e-09
R233X O 0 7.257644085711945e-08
, O 0 1.0488220292259598e-09
was O 0 4.248989604604958e-09
observed O 0 2.7086997089753595e-09
in O 0 8.997285694256618e-10
the O 0 5.856938045667448e-09
germline O 0 3.273274558068806e-07
DNA O 0 1.4140799642348156e-08
from O 0 1.5380369200457267e-09
two O 0 1.8950463420708274e-09
unrelated O 0 2.578205737790995e-08
CD B-Disease 0 1.4650836988039373e-07
families O 0 3.209214671784366e-09
and O 0 9.578040582880476e-09
one O 0 3.417692084894952e-08
BZS B-Disease 0 6.406672764569521e-05
family O 0 9.009775681079191e-07
. O 0 6.161825240269536e-06

Genotype O 0 0.00012710872397292405
- O 0 7.052915407257387e-06
phenotype O 0 1.6081055775885034e-07
studies O 0 7.612575458892934e-09
were O 0 2.116118169581682e-09
not O 0 1.4866582964678798e-10
performed O 0 3.887490607201727e-10
on O 0 3.081201516152987e-09
this O 0 2.5542240544851325e-10
small O 0 1.4888467125828697e-09
group O 0 6.0520619626913685e-09
of O 0 1.1502480390390701e-07
BZS B-Disease 0 7.576959615107626e-05
families O 0 1.4669991799109994e-07
. O 0 2.7496603252075147e-06

However O 0 2.489711505404557e-06
, O 0 1.7966763721233292e-07
genotype O 0 1.7804311482905177e-06
- O 0 7.268435524565575e-07
phenotype O 0 1.9131230999391846e-07
analysis O 0 4.516794760434095e-08
inthe O 0 3.997967041868833e-07
group O 0 3.302243811731387e-09
of O 0 1.0590423649148306e-08
CD B-Disease 0 9.318196703134163e-07
families O 0 2.8552660236158545e-09
revealed O 0 3.300192830124615e-08
two O 0 1.4457119945632257e-09
possible O 0 8.3157543073753e-09
associations O 0 3.4093825540537637e-09
worthy O 0 3.9200028112418295e-08
of O 0 1.6129076740867276e-08
follow O 0 1.2688817108141848e-08
- O 0 1.344674327441453e-08
up O 0 2.525903042283062e-09
in O 0 1.5156221833123595e-09
independent O 0 3.436819184798878e-08
analyses O 0 3.182199463935831e-07
. O 0 1.7315679770035786e-06

The O 0 2.548446502714796e-07
first O 0 7.029642290490301e-08
was O 0 1.0352918167200187e-07
an O 0 2.3266026882851065e-09
association O 0 4.47171233375343e-09
noted O 0 7.675501123571848e-09
in O 0 2.7150566239697582e-09
the O 0 1.3533815845789832e-08
group O 0 2.6867235103367193e-09
of O 0 8.931990258531641e-09
CD B-Disease 0 5.454883648781106e-06
families O 0 5.824052795588841e-09
with O 0 1.4568493611477606e-07
breast B-Disease 1 0.9998944997787476
disease I-Disease 1 0.9115155935287476
. O 0 5.6074164604069665e-05

A O 0 6.477331453424995e-07
correlation O 0 2.4758026029303437e-07
was O 0 1.0181122434005374e-07
observed O 0 1.3154379807645e-08
between O 0 5.930794966246822e-09
the O 0 3.676976501054696e-09
presence O 0 1.1073908012804168e-08
/ O 0 9.156687497124949e-07
absence O 0 2.2443445857334154e-07
of O 0 9.764438857473579e-08
a O 0 4.2832891011812535e-08
PTEN O 0 1.6136481235662359e-06
mutation O 0 1.8442447569100295e-08
and O 0 2.0968569103274604e-09
the O 0 1.4692099759017196e-09
type O 0 7.466235274478095e-08
of O 0 4.2380489162496815e-07
breast O 0 0.0015175669686868787
involvement O 0 1.1744343282771297e-05
( O 0 6.228736992852646e-07
unaffected O 0 2.9979848477523774e-05
versus O 1 0.6415640711784363
benign O 1 0.9643151164054871
versus O 0 0.002336155856028199
malignant O 0 0.0023329518735408783
) O 0 4.2884514073193714e-07
. O 0 3.5295836369186873e-06

Specifically O 0 4.431705633578531e-07
and O 0 1.757734224838714e-08
more O 0 6.625064941090386e-10
directly O 0 1.7010495234615064e-09
, O 0 7.772316124032841e-10
an O 0 5.154982551935916e-10
association O 0 3.299272188783675e-09
was O 0 3.3115803432792745e-08
also O 0 1.6072438935310629e-09
observed O 0 6.332086854854424e-09
between O 0 1.4635629375092662e-09
the O 0 9.034343273484069e-10
presence O 0 1.1495089324853325e-09
of O 0 1.0666241223589168e-08
a O 0 5.476801234749473e-08
PTEN O 0 0.0008933813660405576
mutation O 0 0.00010622182890074328
and O 0 7.901203935034573e-05
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9999953508377075
. O 0 0.00040052749682217836

Secondly O 0 1.5863231965340674e-05
, O 0 3.8427756976489036e-08
there O 0 1.343074895743257e-08
appeared O 0 2.0174057979716054e-08
to O 0 2.298869983263785e-09
be O 0 4.987623203334124e-09
an O 0 6.177445666111225e-09
interdependent O 0 9.918119758367538e-06
association O 0 3.607530629778921e-08
between O 0 8.626790304333554e-08
mutations O 0 1.0449751641772309e-07
upstream O 0 1.8637893006712147e-08
and O 0 3.863071196263945e-09
within O 0 1.4496281508513675e-08
the O 0 1.497442703168872e-08
PTPase O 0 2.802451263050898e-06
core O 0 6.631973974435823e-07
motif O 0 4.799152009127283e-08
, O 0 1.5888037552258538e-09
the O 0 2.062325421547939e-09
core O 0 5.326929652937906e-08
motif O 0 2.87173262947249e-09
containing O 0 3.259166547753267e-10
the O 0 2.9955293801009475e-10
majority O 0 4.509060624879879e-10
of O 0 3.647548041385562e-09
missense O 0 1.138032814651524e-07
mutations O 0 1.5729684221810203e-08
, O 0 1.5231133021487153e-09
and O 0 1.9494668102026935e-09
the O 0 4.523482921570121e-09
involvement O 0 1.808763450128481e-08
of O 0 2.151038813735795e-08
all O 0 2.8909290517020736e-09
major O 0 2.52722980320641e-08
organ O 0 4.3963056668872014e-05
systems O 1 0.9950201511383057
( O 0 2.546717041695956e-06
central O 0 0.002542357426136732
nervous O 0 0.00045634328853338957
system O 1 0.5667393803596497
, O 0 1.1129958693345543e-05
thyroid O 1 1.0
, O 0 9.166490053758025e-05
breast O 1 1.0
, O 0 0.00030288848211057484
skin O 1 1.0
and O 1 0.9990804195404053
gastrointestinal O 1 0.9999998807907104
tract O 0 0.06869787722826004
) O 0 2.4845808184181806e-06
. O 0 3.170807030983269e-05

However O 0 7.008288207543956e-07
, O 0 1.0394147764714035e-08
these O 0 7.877114516219308e-10
observations O 0 7.414745262224187e-09
would O 0 5.489942389580449e-10
need O 0 1.1656440257468148e-09
to O 0 4.733474723295217e-10
be O 0 8.971923204370569e-10
confirmed O 0 2.233608853430269e-09
by O 0 1.661814991171795e-10
studying O 0 1.597503573869119e-09
a O 0 1.0594494725957304e-10
larger O 0 5.124660695798866e-10
number O 0 8.642428439564753e-10
of O 0 3.852681285110293e-09
CD B-Disease 0 3.180097110089264e-07
families O 0 1.728358789421236e-08
. O 0 3.251204532261909e-07

Molecular O 1 0.999984860420227
defects O 1 0.999994158744812
leading O 0 5.112080543767661e-06
to O 0 1.8092810805114823e-08
human O 0 1.6610536590633274e-07
complement B-Disease 0 6.606832812394714e-06
component I-Disease 1 0.9999992847442627
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.45359573267001e-08
an O 0 1.1506978703224036e-09
African O 0 5.4687532724528864e-08
- O 0 2.5235017631075607e-08
American O 0 1.2414519190429019e-08
family O 0 2.5180638019151047e-08
. O 0 6.253139872569591e-07

Complement B-Disease 0 6.0339651099639013e-05
component I-Disease 1 0.999761164188385
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 4.263478672328347e-07
C6D B-Disease 0 8.7065200204961e-05
) O 0 1.0533152128289203e-08
was O 0 7.085195363742969e-08
diagnosed O 0 2.7320092499394377e-07
in O 0 5.95123728075464e-09
a O 0 1.2569101315307307e-08
16 O 0 1.983305537578417e-07
- O 0 1.0599037381098242e-07
year O 0 1.653551784386309e-08
- O 0 6.066071023269615e-08
old O 0 5.283192194838193e-07
African O 0 6.958419476177369e-07
- O 0 2.2332137916691863e-08
American O 0 2.2697179691277825e-09
male O 0 6.890981296692189e-08
with O 0 1.48750274320264e-07
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.00013080010830890387

The O 0 2.900743822920049e-07
patients O 0 6.149527820298317e-08
father O 0 4.752060078772047e-08
and O 0 1.3788405972547935e-08
two O 0 2.464950910052721e-08
brothers O 0 1.7170859223369916e-07
also O 0 5.792657020720071e-09
had O 0 5.3448008685563764e-08
C6D B-Disease 0 7.786561036482453e-05
, O 0 3.5855911573179355e-09
but O 0 1.3650339747428575e-09
gave O 0 5.6674891446562015e-09
no O 0 2.1390418325495375e-09
history O 0 8.596711786879041e-09
of O 0 2.7844317074254832e-08
meningitis B-Disease 1 1.0
or O 0 1.4642735379766236e-07
other O 0 4.8050690537593255e-08
neisserial B-Disease 0 5.5032563977874815e-05
infection I-Disease 0 0.00013475098239723593
. O 0 3.9579012991453055e-06

By O 0 3.324726094433572e-07
using O 0 1.9799509232143464e-07
exon O 0 9.550057029628078e-07
- O 0 1.563332006071505e-07
specific O 0 2.6542489095504607e-08
polymerase O 0 9.712356074942363e-08
chain O 0 1.4912689749735364e-08
reaction O 0 6.770286997692665e-09
( O 0 3.946272641996984e-09
PCR O 0 3.917880064818746e-08
) O 0 4.323613467249743e-09
/ O 0 4.3304655861220454e-08
single O 0 1.299180585334625e-08
- O 0 6.835529831050735e-08
strand O 0 4.0129478406925045e-08
conformation O 0 1.0284698426232808e-08
polymorphism O 0 1.1012844858271365e-08
as O 0 2.3211585431504034e-10
a O 0 1.1307332153931426e-10
screening O 0 4.991141944188371e-10
step O 0 3.4268614612642523e-09
and O 0 1.3762020412144693e-09
nucleotide O 0 2.883120853169885e-09
sequencing O 0 1.5527275021298692e-09
of O 0 2.0877422013398927e-09
target O 0 1.3869354553719404e-08
exons O 0 9.165076875206069e-08
, O 0 2.1400050620457023e-09
we O 0 1.4687504545918273e-09
determined O 0 4.17025747267985e-09
that O 0 1.9959627006738145e-10
the O 0 3.4910792034992255e-09
proband O 0 4.594076017383486e-07
was O 0 2.7471672936485447e-08
a O 0 2.514064956216089e-09
compound O 0 3.601686771048662e-08
heterozygote O 0 2.2515497732911172e-07
for O 0 1.0553604212759637e-08
two O 0 1.151636510599019e-07
C6 O 0 0.00031592597952112556
gene O 0 9.479932714384631e-07
mutations O 0 2.0032396150782006e-06
. O 0 3.647216772151296e-06

The O 0 5.910899290029192e-07
first O 0 9.868296757531425e-08
, O 0 1.2436512264457633e-08
1195delC O 0 2.4026530809351243e-07
located O 0 7.76888153808386e-09
in O 0 2.9787912136924888e-09
exon O 0 1.4008031712364755e-07
7 O 0 1.0613764089839606e-07
, O 0 1.5660821528484803e-09
is O 0 2.490990191894582e-10
a O 0 4.774823869624356e-10
novel O 0 1.7625475523530554e-09
mutation O 0 2.5230766365069712e-09
, O 0 7.023523984628355e-10
while O 0 1.5960751609256363e-09
the O 0 2.260196474423992e-09
second O 0 7.20101089868308e-09
, O 0 2.159510126276132e-09
1936delG O 0 5.515388679100397e-08
in O 0 3.55505580529325e-09
exon O 0 3.6759335131364423e-08
12 O 0 2.1530253135892963e-08
, O 0 1.5070836800745724e-09
has O 0 4.778276108119428e-10
been O 0 1.31500832445397e-09
described O 0 2.722970737778496e-09
before O 0 6.089090565097877e-09
to O 0 2.0276971213206707e-09
cause O 0 7.967983606249618e-08
C6D B-Disease 0 2.6040663215098903e-05
in O 0 1.3987201619158895e-08
an O 0 3.990034080914029e-09
unrelated O 0 1.3445568924908002e-07
African O 0 8.157037996170402e-07
- O 0 2.5393924829586467e-07
American O 0 3.4267131354681624e-08
individual O 0 8.404896334468503e-08
. O 0 2.550927092670463e-06

Both O 0 3.27754463569363e-07
mutations O 0 2.7200556473871984e-07
result O 0 5.0068791779267485e-08
in O 0 2.6992371005007953e-08
premature O 0 1.3596710459751193e-06
termination O 0 2.0029722236358793e-06
codons O 0 1.4723883623446454e-06
and O 0 3.8568305171793327e-07
C6 O 0 0.00030275050085037947
null O 0 4.805615026270971e-05
alleles O 0 9.256002158508636e-06
. O 0 6.955082881177077e-06

Allele O 0 3.052300598938018e-05
- O 0 6.803570613556076e-07
specific O 0 1.081290434967741e-08
PCR O 0 2.597594495057365e-08
indicated O 0 1.1139325017950341e-08
that O 0 5.394117930102027e-10
the O 0 5.360193622294673e-09
probands O 0 7.39973643248959e-07
two O 0 1.577637576133384e-08
brothers O 0 7.419104974815127e-08
also O 0 5.0123616368580315e-09
inherited O 0 1.242911906729205e-07
the O 0 3.1480929862937046e-08
1195delC O 0 2.488243922016409e-07
mutation O 0 7.903892651484057e-09
from O 0 1.1730219018346588e-09
their O 0 2.4078399274429785e-09
heterozygous O 0 1.823836726089212e-08
mother O 0 5.2565880537258636e-09
and O 0 5.728119312209401e-09
the O 0 1.5825319721329834e-08
1936delG O 0 2.572366213371424e-07
mutation O 0 1.0349359591543816e-08
from O 0 2.8962992004721855e-09
their O 0 9.841056858306274e-09
homozygous O 0 1.238137059544897e-07
father O 0 2.349548680058433e-07
. O 0 1.6555974013954255e-07
. O 0 3.2184132123802556e-06

PAX6 O 0 0.012870663776993752
mutations O 0 0.00013263609434943646
reviewed O 0 0.00010216064401902258
. O 0 1.5717989299446344e-05

Mutations O 0 2.8645843030972173e-06
in O 0 2.0769665809439175e-07
PAX6 O 0 0.0008433408220298588
are O 0 1.757935308432934e-08
responsible O 0 9.463802541631594e-08
for O 0 7.616424824163914e-09
human O 0 9.80868435362936e-07
aniridia B-Disease 1 1.0
and O 0 9.327498418087998e-08
have O 0 2.7003688174431772e-09
also O 0 1.1306583447279195e-09
been O 0 4.901359318409959e-10
found O 0 3.3580729863480485e-10
in O 0 3.2179231501672234e-10
patients O 0 6.473854785582489e-10
with O 0 4.862606317601603e-09
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 1.4100717180554057e-06
with O 0 0.15065059065818787
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 1.2262699783605058e-05
with O 0 1.4055578958505066e-06
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 4.4076887917299246e-08
and O 0 2.2668810828463393e-08
with O 0 5.493760468766595e-08
isolated B-Disease 0 0.00047802081098780036
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.0015388049650937319

No O 0 1.0471314908500062e-06
locus O 0 6.032265105204715e-07
other O 0 4.678455400863868e-09
than O 0 5.723018947634273e-09
chromosome O 0 7.320959838352792e-08
11p13 O 0 2.562388772275881e-07
has O 0 1.8127033207804288e-09
been O 0 9.599805395055228e-09
implicated O 0 1.7143648278761248e-07
in O 0 3.8358628273726936e-08
aniridia B-Disease 1 1.0
, O 0 6.252543016671552e-08
and O 0 6.01583494130864e-08
PAX6 O 0 0.0002737529866863042
is O 0 6.878162928103393e-09
clearly O 0 1.0226797186874137e-08
the O 0 6.175242983630369e-09
major O 0 6.559334408962059e-09
, O 0 3.920851421312932e-10
if O 0 2.0258174304732535e-10
not O 0 2.746362859351592e-10
only O 0 9.457694627457158e-10
, O 0 5.002619207772341e-09
gene O 0 5.2163105834779344e-08
responsible O 0 2.6436467237545003e-07
. O 0 2.474257144058356e-06

Twenty O 0 1.7275109712500125e-05
- O 0 1.487914346398611e-06
eight O 0 4.190128422010275e-08
percent O 0 7.870555762679032e-09
of O 0 2.357623785087526e-08
identified O 0 3.059278697037371e-07
PAX6 O 0 1.7230124285561033e-05
mutations O 0 1.8868803408622625e-07
are O 0 2.0643179610146944e-08
C O 0 8.025252463994548e-05
- O 0 1.765925480867736e-05
T O 0 1.56859050548519e-06
changes O 0 5.823489601652909e-08
at O 0 1.518030643410384e-07
CpG O 0 1.2725007536573685e-07
dinucleotides O 0 9.889531327189616e-08
, O 0 3.208613097438473e-10
20 O 0 1.429539597808116e-09
% O 0 3.523004388217288e-10
are O 0 4.3475759103905887e-10
splicing O 0 1.2174173491530382e-07
errors O 0 3.4208883903374954e-07
, O 0 1.6683486814272896e-09
and O 0 6.522651307960814e-10
more O 0 4.006700873859792e-11
than O 0 6.619302328481069e-11
30 O 0 7.950957670033176e-10
% O 0 2.92521146194602e-10
are O 0 7.009111624434183e-10
deletion O 0 4.173792333972415e-08
or O 0 1.2646728109189098e-08
insertion O 0 9.440257286996712e-08
events O 0 1.0395182670208669e-07
. O 0 1.4766690128453774e-06

There O 0 3.047985615012294e-07
is O 0 9.462156391748522e-09
a O 0 9.351116325717612e-09
noticeably O 0 1.409459855494788e-07
elevated O 0 5.058108172306675e-07
level O 0 1.709437782437817e-07
of O 0 5.6130859960035195e-09
mutation O 0 1.787533010499942e-09
in O 0 1.0279573858795743e-09
the O 0 3.996766917424566e-09
paired O 0 8.70636185368312e-09
domain O 0 2.839039447977143e-09
compared O 0 5.785763534937871e-10
with O 0 4.805639219895852e-11
the O 0 4.426750355168707e-10
rest O 0 2.1439312547499867e-09
of O 0 1.9955943564298195e-09
the O 0 8.056616707108333e-09
gene O 0 2.709977486858861e-08
. O 0 4.633367325368454e-07

Increased O 0 2.0843839365625172e-07
mutation O 0 5.1507619502899615e-08
in O 0 1.0501296721088238e-08
the O 0 1.182890319029184e-08
homeodomain O 0 2.8694191200884234e-07
is O 0 5.134023761677042e-10
accounted O 0 1.424284135076448e-09
for O 0 2.0390482358134676e-10
by O 0 8.587595079490029e-10
the O 0 2.3213512889697085e-08
hypermutable O 0 3.6914725569658913e-06
CpG O 0 5.2525242608680855e-06
dinucleotide O 0 2.4033504359977087e-06
in O 0 8.04806532528346e-08
codon O 0 2.5756801278475905e-06
240 O 0 1.5661539691791404e-06
. O 0 1.926954610098619e-06

Very O 0 6.130217116151471e-07
nearly O 0 1.812237471199296e-08
all O 0 1.2114054204204194e-09
mutations O 0 3.4453364605724346e-09
appear O 0 3.5670917331032115e-09
to O 0 1.2593860398979473e-09
cause O 0 2.205542060096377e-08
loss O 0 4.044159140903503e-08
of O 0 2.698506307297066e-08
function O 0 2.1964785545947052e-08
of O 0 1.3027712242319467e-08
the O 0 5.567100114234336e-09
mutant O 0 4.295381117458419e-08
allele O 0 3.130172743226467e-08
, O 0 5.919681966837231e-10
and O 0 2.7321045426020873e-10
more O 0 3.594324837763452e-11
than O 0 9.634096298505312e-11
80 O 0 7.230721577045074e-10
% O 0 3.563866701750129e-10
of O 0 2.0475958706356323e-09
exonic O 0 2.3015677186322137e-07
substitutions O 0 1.9402682127633852e-08
result O 0 9.686526247776328e-09
in O 0 8.998096490131502e-09
nonsense O 0 9.839818631007802e-07
codons O 0 2.652594503160799e-06
. O 0 1.8081550479109865e-06

In O 0 5.518124339687347e-07
a O 0 3.350117694367327e-08
gene O 0 8.641047877233632e-09
with O 0 9.771491393806286e-10
such O 0 2.591125314310716e-09
extraordinarily O 0 1.601730730271811e-07
high O 0 2.1616135370550182e-07
sequence O 0 6.3175864539744e-09
conservation O 0 1.4904663059311929e-09
throughout O 0 2.466970794312573e-10
evolution O 0 5.2993422983149685e-09
, O 0 2.2195929816337667e-10
there O 0 2.1084785306602072e-10
are O 0 5.222756116474159e-10
presumed O 0 1.1564812751885256e-07
undiscovered O 0 1.3187146805648808e-06
missense O 0 1.0275755357724847e-06
mutations O 0 7.444620564456272e-08
, O 0 1.9702357523243563e-09
these O 0 1.643354341496206e-09
are O 0 1.281782902040618e-09
hypothesized O 0 1.8892116315782914e-08
to O 0 6.824034670671608e-10
exist O 0 6.235117755437614e-09
in O 0 2.5522823854373655e-09
as O 0 1.4205517651078026e-08
- O 0 5.9042399414011015e-08
yet O 0 2.23570264523687e-08
unidentified O 0 1.8649028277195612e-07
phenotypes O 0 2.0212773677030782e-07
. O 0 7.175717087193334e-08
. O 0 1.430643010280619e-06

Genetic O 0 5.5049595175660215e-06
heterogeneity O 0 2.0603035864041885e-06
and O 0 9.325613348210027e-08
penetrance O 0 4.793151219928404e-06
analysis O 0 6.460452794954108e-08
of O 0 5.4134591920274033e-08
the O 0 9.392948641107068e-08
BRCA1 O 0 1.26477846151829e-06
and O 0 1.4642458836533478e-06
BRCA2 O 0 6.288271379162325e-06
genes O 0 1.162472813120985e-06
in O 0 9.898964208332472e-07
breast B-Disease 1 0.9678842425346375
cancer I-Disease 0 0.0005993956001475453
families O 0 7.966856969687797e-07
. O 0 1.2366751434456091e-05

The O 1 0.9157714247703552
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.0012754714116454124
Consortium O 0 1.1995384738838766e-05
. O 0 7.063523753458867e-06

The O 0 6.020529781380901e-07
contribution O 0 2.4434237388959446e-07
of O 0 3.9906453253024665e-07
BRCA1 O 0 2.9197046842455165e-06
and O 0 2.0905320070596645e-06
BRCA2 O 0 0.00045335007598623633
to O 0 0.0002538335684221238
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 1 0.9960307478904724
assessed O 0 2.83579402093892e-06
by O 0 5.518605572518709e-09
linkage O 0 5.0038433840882135e-08
and O 0 2.7525470791545104e-09
mutation O 0 2.6369797456737842e-09
analysis O 0 8.775162263496838e-10
in O 0 5.56904078408138e-10
237 O 0 4.236996087314537e-09
families O 0 2.7149102410639614e-10
, O 0 1.5871916281273712e-10
each O 0 8.253487476794774e-11
with O 0 1.9486963431791793e-10
at O 0 1.7569297128261496e-08
least O 0 1.6754375664618237e-09
four O 0 1.576105912448611e-09
cases O 0 2.8592879175448616e-09
of O 0 1.3566345558047033e-07
breast B-Disease 0 0.00012582979979924858
cancer I-Disease 0 6.657930384790234e-07
, O 0 3.498458189810094e-09
collected O 0 4.4980335012212436e-09
by O 0 3.5409259968588458e-09
the O 0 9.841713790592621e-07
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 4.221241397317499e-05
Consortium O 0 2.238992237835191e-06
. O 0 2.1752132397523383e-06

Families O 0 7.255761858004917e-08
were O 0 1.961096174341037e-08
included O 0 2.071700588857084e-09
without O 0 2.146983923978496e-09
regard O 0 5.177560158386996e-09
to O 0 7.716878802632721e-10
the O 0 3.3594582671270246e-09
occurrence O 0 2.2303495939013374e-07
of O 0 4.245720901963068e-06
ovarian B-Disease 1 0.9999995231628418
or I-Disease 0 0.0003676412452477962
other I-Disease 0 2.7026042062061606e-06
cancers I-Disease 1 0.9997249245643616
. O 0 2.172501990571618e-05

Overall O 0 0.0002566102775745094
, O 0 1.5345410702138906e-06
disease O 0 0.00046485179336741567
was O 0 7.581553518321016e-07
linked O 0 1.36894755087269e-07
to O 0 6.115161710340544e-09
BRCA1 O 0 5.361954791283097e-08
in O 0 4.314140156225221e-09
an O 0 5.286870941034749e-10
estimated O 0 1.6303511873871912e-09
52 O 0 6.771940341820937e-09
% O 0 6.626594273306807e-10
of O 0 1.9354104985325193e-09
families O 0 3.0089974956126753e-10
, O 0 3.096476686170746e-10
to O 0 6.464686563845135e-10
BRCA2 O 0 1.6208334230327637e-08
in O 0 4.153602795042843e-09
32 O 0 2.359693418441111e-08
% O 0 9.585126026223634e-10
of O 0 2.3456376840869098e-09
families O 0 1.9793272576507093e-10
, O 0 1.355351247900316e-10
and O 0 1.552747513899888e-10
to O 0 1.529683602008447e-10
neither O 0 1.7980581468179935e-09
gene O 0 6.083317738436733e-10
in O 0 7.466798290778343e-10
16 O 0 8.836723353056186e-09
% O 0 8.136265550184874e-10
( O 0 3.6260081048844484e-10
95 O 0 1.315929765155488e-08
% O 0 4.7787618306927016e-09
confidence O 0 2.073273748237625e-07
interval O 0 6.530625000777945e-07
[ O 0 2.4788741370684875e-07
CI O 0 2.9845136850781273e-06
] O 0 5.642113265480475e-08
6 O 0 4.576405387979321e-08
% O 0 2.4666801934358773e-09
- O 0 7.390219991521008e-09
28 O 0 1.1950181288966633e-08
% O 0 1.0366503211400868e-09
) O 0 8.86215545392588e-10
, O 0 9.57847356986008e-10
suggesting O 0 2.5437886463919313e-08
other O 0 2.0372462827822346e-08
predisposition O 0 1.3766235724688158e-06
genes O 0 9.824591415963368e-07
. O 0 2.543323944337317e-06

The O 0 2.4219914962486655e-07
majority O 0 3.198436715479147e-08
( O 0 8.621835689837098e-09
81 O 0 3.86284462194908e-08
% O 0 4.229704586578009e-09
) O 0 2.4824160504977044e-09
of O 0 7.90543381867792e-08
the O 0 0.009634990245103836
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.857302223129409e-08
were O 0 9.9789998486699e-09
due O 0 7.641396848612203e-08
to O 0 4.720430712978896e-09
BRCA1 O 0 5.693038929166505e-08
, O 0 1.1420697720865292e-09
with O 0 1.8153561986977707e-10
most O 0 1.8774382049002725e-10
others O 0 7.798838241868111e-10
( O 0 2.383302166730772e-10
14 O 0 3.5148717270061525e-09
% O 0 3.375642820824254e-10
) O 0 5.870814945296843e-10
due O 0 4.6034127620941945e-08
to O 0 1.109850416014524e-07
BRCA2 O 0 1.5726745914435014e-05
. O 0 7.090580766089261e-06

Conversely O 0 2.686861307665822e-06
, O 0 1.7330725299302685e-08
the O 0 3.3722145076353627e-09
majority O 0 1.2511165436990268e-09
of O 0 8.07578626194072e-09
families O 0 6.666934782018075e-10
with O 0 1.6400383273662555e-09
male B-Disease 0 1.2150401744293049e-05
and I-Disease 0 0.0024552340619266033
female I-Disease 1 0.9974537491798401
breast I-Disease 1 0.9995026588439941
cancer I-Disease 0 0.29412713646888733
were O 0 1.5246656403178349e-05
due O 0 0.0016539444914087653
to O 0 4.281590406662872e-07
BRCA2 O 0 2.79699929706112e-06
( O 0 4.306972556378241e-08
76 O 0 2.528086326947232e-07
% O 0 1.0833672625665258e-08
) O 0 2.3358969869491375e-08
. O 0 6.240367156351567e-07

The O 0 1.1003501185768982e-06
largest O 0 5.997355145836991e-08
proportion O 0 3.599791398301022e-08
( O 0 4.80391149082493e-09
67 O 0 1.7360999748916583e-08
% O 0 1.2797676252063184e-09
) O 0 4.720275281755448e-10
of O 0 2.5007409476529574e-09
families O 0 1.4327325437157867e-10
due O 0 3.6982035211963193e-09
to O 0 5.511818224057663e-10
other O 0 3.6302916228692084e-10
genes O 0 1.0691533214313154e-09
was O 0 1.9185697475165853e-09
found O 0 1.4794025726683202e-10
in O 0 2.0239868114835247e-10
families O 0 1.1600409521861366e-10
with O 0 1.254772397096815e-10
four O 0 1.870876120690923e-09
or O 0 3.0478553014745557e-09
five O 0 4.349170357187404e-09
cases O 0 7.797191337033382e-09
of O 0 6.833026304775558e-07
female O 0 0.0005521404091268778
breast B-Disease 0 0.020836832001805305
cancer I-Disease 0 4.039554187329486e-05
only O 0 1.1610258070504642e-06
. O 0 1.5968538718880154e-05

These O 0 7.349416364377248e-08
estimates O 0 2.3041783592248066e-08
were O 0 4.921398844004443e-09
not O 0 8.44018188672635e-10
substantially O 0 1.0035231312599535e-08
affected O 0 1.0726501908919772e-09
either O 0 1.4599941255966087e-09
by O 0 5.888028398182144e-10
changing O 0 4.781661289143813e-09
the O 0 6.414256348286074e-10
assumed O 0 1.0002629835526022e-08
penetrance O 0 7.010922331573965e-08
model O 0 4.5170338580646785e-09
for O 0 6.559081056067839e-10
BRCA1 O 0 5.526611612793886e-09
or O 0 4.613807114139945e-10
by O 0 1.4364456846216456e-10
including O 0 6.110587591479089e-10
or O 0 6.407583352796564e-09
excluding O 0 6.043412525968961e-08
BRCA1 O 0 1.8403606816264073e-07
mutation O 0 1.2545395122742775e-07
data O 0 5.139000904819113e-07
. O 0 1.143406279879855e-06

Among O 0 2.4085537120299705e-07
those O 0 1.9256868100114843e-08
families O 0 5.329081620430998e-09
with O 0 3.2196068033840675e-09
disease O 0 2.840387764990737e-07
due O 0 2.2978217373292864e-07
to O 0 9.129986544564872e-09
BRCA1 O 0 2.7107633471246118e-08
that O 0 7.532081069960839e-10
were O 0 2.0760557717380834e-09
tested O 0 1.0280319928668291e-09
by O 0 1.111081643356826e-10
one O 0 1.781657044119811e-10
of O 0 5.861215401914421e-10
the O 0 4.5484579991317275e-10
standard O 0 4.365801498096289e-09
screening O 0 7.604400997784921e-10
methods O 0 4.949262333298066e-09
, O 0 3.315875074516583e-10
mutations O 0 1.7670850338546984e-09
were O 0 2.776485708011478e-09
detected O 0 4.80684470005599e-09
in O 0 2.0843045067664434e-09
the O 0 1.1688952028521271e-08
coding O 0 1.0007442341475326e-07
sequence O 0 6.494797588629808e-09
or O 0 9.376973642005737e-10
splice O 0 1.2777414681863775e-08
sites O 0 8.166053944158591e-10
in O 0 2.0318231819249633e-10
an O 0 4.282678031652942e-11
estimated O 0 4.667062847296677e-10
63 O 0 6.638426253147145e-09
% O 0 1.7945018804255142e-09
( O 0 1.2340759525386602e-09
95 O 0 6.03166654400411e-08
% O 0 2.05325978441806e-08
CI O 0 3.3549220006534597e-06
51 O 0 1.31298193650764e-07
% O 0 9.272789647241098e-09
- O 0 6.543005071080188e-08
77 O 0 1.616073141974539e-08
% O 0 2.9482511987311e-09
) O 0 1.1399180266380426e-08
. O 0 4.843859073844214e-07

The O 0 5.505739295585954e-07
estimated O 0 4.890074478680617e-08
sensitivity O 0 5.2912447756625625e-08
was O 0 1.948943761931332e-08
identical O 0 2.0272949985411515e-09
for O 0 2.0182006066349345e-10
direct O 0 3.8157116355463927e-10
sequencing O 0 1.5761449922990778e-09
and O 0 9.32695698452335e-10
other O 0 2.8679121300001498e-09
techniques O 0 6.945835480109963e-07
. O 0 2.9472752771653177e-07

The O 0 2.884844207073911e-06
penetrance O 0 0.00015120592433959246
of O 0 2.5581625777704176e-06
BRCA2 O 0 3.110900024694274e-06
was O 0 2.0830047731124068e-07
estimated O 0 3.46377282411936e-09
by O 0 1.0036201869567662e-09
maximizing O 0 8.248149185874354e-08
the O 0 1.0622063228993284e-08
LOD O 0 4.9235795813729055e-06
score O 0 6.972742028210632e-08
in O 0 2.453009706471221e-08
BRCA2 O 0 1.731837301122141e-06
- O 0 6.728682251377904e-07
mutation O 0 9.436761594372456e-09
families O 0 2.8271443519578554e-10
, O 0 3.331762365998969e-10
over O 0 1.5209186132736363e-09
all O 0 6.792815754330661e-10
possible O 0 1.5699111344247285e-08
penetrance O 0 1.1743151162590948e-06
functions O 0 1.7804332230753062e-07
. O 0 3.7501908423109853e-07

The O 0 8.064889698289335e-07
estimated O 0 7.462163154059454e-08
cumulative O 0 9.15832060854882e-07
risk O 0 7.429782158396847e-07
of O 0 2.0406491785252e-06
breast B-Disease 0 2.787381708913017e-05
cancer I-Disease 0 8.090079290923313e-07
reached O 0 7.358926268352661e-07
28 O 0 2.2229215801417013e-07
% O 0 6.238187300056097e-09
( O 0 2.1852408771394494e-09
95 O 0 4.740852332929535e-08
% O 0 7.204994822984645e-09
CI O 0 1.1751900501622004e-06
9 O 0 1.2312135311276506e-07
% O 0 1.9111410232142134e-09
- O 0 3.4020293249170663e-09
44 O 0 8.60774895805605e-10
% O 0 1.1243760089652e-10
) O 0 3.7832653676517225e-11
by O 0 5.1523160737865226e-11
age O 0 9.984231219561934e-10
50 O 0 3.938014359050612e-10
years O 0 1.817230393941216e-10
and O 0 3.14821585467584e-10
84 O 0 3.1619924456549597e-09
% O 0 3.2757505041836055e-10
( O 0 4.0565625858413057e-10
95 O 0 9.795419586566823e-09
% O 0 4.987157353752991e-09
CI O 0 8.426017075180425e-07
43 O 0 3.764893463653607e-08
% O 0 2.452858582913109e-09
- O 0 8.863157319183301e-09
95 O 0 6.837235666523611e-09
% O 0 2.5637272860201676e-10
) O 0 8.345825419642239e-11
by O 0 1.3496088968611986e-10
age O 0 1.4268598746980388e-08
70 O 0 2.3613502264652197e-08
years O 0 4.779311169045286e-08
. O 0 2.5920965640580107e-07

The O 0 1.20633221740718e-05
corresponding O 1 0.9999285936355591
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 9.418093213753309e-06
were O 0 1.1704812550306087e-06
0 O 0 3.2797659059724538e-06
. O 0 3.0889436857250985e-06

4 O 0 3.155962076561991e-06
% O 0 5.737394914717697e-08
( O 0 9.93096094248358e-09
95 O 0 1.1272119593286334e-07
% O 0 1.1358811669026636e-08
CI O 0 1.3827378779751598e-06
0 O 0 6.475651304072017e-08
% O 0 1.5225671834429022e-09
- O 0 4.192900249222475e-09
1 O 0 3.967790096481849e-09
% O 0 9.230078507060924e-11
) O 0 3.4889521827174974e-11
by O 0 3.220414213078726e-11
age O 0 5.673412850626391e-10
50 O 0 2.2953854095231208e-10
years O 0 8.69973051931261e-11
and O 0 1.2506888580343656e-10
27 O 0 1.7085282077999864e-09
% O 0 1.2044630570695603e-10
( O 0 1.2951167915886685e-10
95 O 0 4.999004321604161e-09
% O 0 1.6933257018791892e-09
CI O 0 2.1650527060046443e-07
0 O 0 2.6143448295101734e-08
% O 0 1.5124773655728063e-09
- O 0 4.766900207897606e-09
47 O 0 2.582968949838005e-09
% O 0 2.139677324208833e-10
) O 0 5.105876832445233e-11
by O 0 1.1876705174884705e-10
age O 0 2.3985727182207484e-08
70 O 0 1.933382343111134e-08
years O 0 4.029906719438259e-08
. O 0 4.953769803250907e-07

The O 0 1.9663043531181756e-06
lifetime O 0 2.4171848053811118e-05
risk O 0 0.0005684840143658221
of O 1 0.9286618232727051
breast B-Disease 1 0.9999990463256836
cancer I-Disease 0 0.009098801761865616
appears O 0 1.9431871578490245e-07
similar O 0 7.2082246838078845e-09
to O 0 5.369546141054116e-09
the O 0 1.3315761826504513e-08
risk O 0 2.2687322243086783e-08
in O 0 6.871750279913158e-09
BRCA1 O 0 3.1375908093878024e-08
carriers O 0 1.9323120881153955e-09
, O 0 5.912437761601552e-10
but O 0 6.198758728537257e-10
there O 0 2.463340642577805e-10
was O 0 1.3513894447925168e-09
some O 0 4.044168472328025e-11
suggestion O 0 5.640377942484065e-09
of O 0 4.253148944144414e-09
a O 0 4.366367267749638e-09
lower O 0 8.046868060773704e-08
risk O 0 3.755705790808861e-08
in O 0 1.8461099315913998e-08
BRCA2 O 0 3.371631578374945e-07
carriers O 0 1.4309753382235613e-08
< O 0 2.7391837420509546e-07
50 O 0 1.2599490339937347e-08
years O 0 6.833089649660451e-09
of O 0 1.7074475167078162e-08
age O 0 2.452741227898514e-07
. O 0 5.019434183850535e-07

Eye B-Disease 1 0.9999970197677612
movement I-Disease 0 0.00033456392702646554
abnormalities I-Disease 0 0.04104379564523697
correlate O 0 2.2179240488640062e-07
with O 0 3.112994084730758e-09
genotype O 0 1.049623961080215e-06
in O 0 1.1656372578272567e-07
autosomal O 1 0.9999971389770508
dominant O 1 1.0
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 0.9999991655349731
. O 0 3.0165972930262797e-05

We O 0 2.012632194237085e-06
compared O 0 4.957116175319243e-07
horizontal O 0 6.099587699281983e-05
eye O 0 0.0009113489650189877
movements O 0 2.2444289697887143e-06
( O 0 1.24837399084754e-07
visually O 0 7.125689904796673e-08
guided O 0 1.6449679662855488e-07
saccades O 0 2.5284844014095142e-06
, O 0 1.248447389912144e-08
antisaccades O 0 4.1515545490256045e-07
, O 0 3.2687055284696953e-09
and O 0 7.179068894913598e-09
smooth O 0 3.9782115379694005e-08
pursuit O 0 2.9030868375912178e-08
) O 0 7.02284119746821e-10
in O 0 2.6834753863447247e-10
control O 0 1.2050571207566918e-08
subjects O 0 3.3603836868678627e-07
( O 0 4.946506759750946e-09
n O 0 5.1843819903751864e-08
= O 0 9.873812700789131e-08
14 O 0 2.0906043118884554e-08
) O 0 9.52954604116485e-10
and O 0 8.319827604630348e-10
patients O 0 3.6908520684164614e-10
with O 0 5.855815138344767e-11
three O 0 2.0976800851890687e-10
forms O 0 4.250010565698403e-09
of O 0 4.023324962076913e-08
autosomal O 0 0.06113465502858162
dominant O 0 0.19907410442829132
cerebellar B-Disease 1 0.9999998807907104
ataxias I-Disease 0 0.0031673519406467676
type I-Disease 0 5.1264349167468026e-05
I I-Disease 0 2.322478758287616e-05
spinocerebellar B-Disease 0 3.0018898542039096e-05
ataxias I-Disease 0 3.1568774829793256e-06
1 I-Disease 0 1.6968822080798418e-07
and I-Disease 0 1.4754928834292969e-08
2 I-Disease 0 2.0022490332394227e-07
( O 0 5.414499071321188e-09
SCA1 B-Disease 0 9.40639210966765e-07
, O 0 7.812613667113055e-09
n O 0 3.5325090408377946e-08
= O 0 5.149661674863637e-08
11 O 0 1.9650052252018213e-08
; O 0 1.2978423891141233e-09
SCA2 B-Disease 0 2.9182717753428733e-07
, O 0 2.78058220892774e-09
n O 0 3.16186756776915e-08
= O 0 6.22370208702705e-08
10 O 0 1.2930101433994423e-08
) O 0 2.146418820458962e-09
and O 0 5.2155545660070857e-08
SCA3 B-Disease 1 1.0
/ O 0 1.9686645828187466e-05
Machado B-Disease 0 1.179184550892387e-06
- I-Disease 0 2.634430416037503e-07
Joseph I-Disease 0 8.65925812831847e-06
disease I-Disease 0 5.281285666569602e-06
( O 0 3.108812762775415e-08
MJD B-Disease 1 1.0
) O 0 2.2888038131441135e-08
( O 0 7.320229755691798e-09
n O 0 1.3454508973609336e-07
= O 0 4.562151616482879e-07
16 O 0 3.858412469526229e-07
) O 0 5.777366141046514e-08
. O 0 1.0254570952383801e-06

In O 0 2.9482187073881505e-06
SCA1 B-Disease 0 0.0001497355697210878
, O 0 1.613991571502993e-07
saccade O 0 3.156437969664694e-06
amplitude O 0 4.5965566641825717e-07
was O 0 2.461530357322772e-08
significantly O 0 3.3111620112435958e-09
increased O 0 1.0494364266477874e-09
, O 0 7.038262195280254e-10
resulting O 0 9.197891337464625e-09
in O 0 1.6862552243424034e-08
hypermetria B-Disease 0 6.559400844707852e-06
. O 0 9.92384343589947e-07

The O 0 5.412939572124742e-06
smooth O 0 6.21633262198884e-06
pursuit O 0 2.815346761053661e-06
gain O 0 2.041129846475087e-06
was O 0 3.0335172596096527e-06
decreased O 0 2.769469119812129e-06
. O 0 1.4499746612273157e-06

In O 0 6.5715921664377674e-06
SCA2 B-Disease 0 0.0004150440508965403
, O 0 7.471448384421819e-07
saccade O 0 1.5524832633673213e-05
velocity O 0 5.3498979468713515e-06
was O 0 1.469668291065318e-06
markedly O 0 3.482334022919531e-06
decreased O 0 3.1288409445551224e-06
. O 0 1.69603902122617e-06

The O 0 4.0803516299092735e-07
percentage O 0 1.9278317608950601e-07
of O 0 4.8267285279735006e-08
errors O 0 9.55611653807864e-07
in O 0 1.6752402132169664e-08
antisaccades O 0 1.921711373142898e-06
was O 0 4.3420197215482403e-08
greatly O 0 4.582700885435997e-09
increased O 0 1.2261737181162857e-09
and O 0 9.42547706550556e-10
was O 0 2.9264686229879544e-09
significantly O 0 1.19872711756841e-09
correlated O 0 1.3320810010597484e-09
with O 0 1.3446627145086154e-10
age O 0 7.058811490878725e-08
at O 0 4.636134462998598e-07
disease O 0 1.9353008156031137e-06
onset O 0 5.56796931050485e-06
. O 0 8.908563700060768e-07

In O 0 8.426307829267898e-08
addition O 0 1.4478596987999026e-08
, O 0 3.0970985775979898e-09
a O 0 1.1777567809900802e-09
correlation O 0 1.1428069157659593e-08
between O 0 1.3385176522717757e-08
smooth O 0 9.956417557077657e-08
pursuit O 0 2.8420911846183117e-08
gain O 0 2.0395207300794027e-08
and O 0 1.2702057183844317e-09
the O 0 8.412249230538293e-10
number O 0 1.1971619251482934e-09
of O 0 1.3116348007713441e-08
trinucleotide O 0 6.81566916682641e-07
repeats O 0 9.223209929132281e-08
was O 0 8.45851388930896e-08
found O 0 7.829309112139526e-08
. O 0 9.962313924916089e-07

In O 0 2.2817202989244834e-05
SCA3 B-Disease 1 1.0
, O 0 4.6873101382516325e-06
gaze B-Disease 0 0.12385048717260361
- I-Disease 0 5.505172521225177e-05
evoked I-Disease 0 1.9535270894266432e-06
nystagmus I-Disease 0 1.2437919394869823e-05
was O 0 3.424478478564197e-08
often O 0 1.208142696995651e-09
present O 0 2.0862058747184165e-09
as O 0 2.5349431442833747e-09
was O 0 7.317385097849183e-08
saccade O 0 1.1329425433359575e-06
hypometria O 0 1.78172888354311e-06
and O 0 5.973141270487758e-08
smooth O 0 4.24365453000064e-07
pursuit O 0 8.076426638581324e-07
gain O 0 8.667493034408835e-07
was O 0 9.377685614708753e-07
markedly O 0 8.239687758759828e-07
decreased O 0 4.841868417315709e-07
. O 0 9.349262199975783e-07

Three O 0 5.603813519883261e-07
major O 0 1.6243947698058037e-07
criteria O 0 4.837631308873824e-07
, O 0 3.9991483902213076e-08
saccade O 0 9.613676184017095e-07
amplitude O 0 3.0072166623540397e-07
, O 0 8.225051750798684e-09
saccade O 0 2.6338528869018774e-07
velocity O 0 1.626583525649039e-07
, O 0 4.092734151583954e-09
and O 0 1.3287567712794157e-09
presence O 0 6.988597256452067e-09
of O 0 6.217022132659622e-07
gaze B-Disease 1 0.8302776217460632
- I-Disease 0 0.00032852223375812173
evoked I-Disease 0 2.4169737571355654e-06
nystagmus I-Disease 0 3.25613041241013e-06
, O 0 2.5886655041773565e-09
permitted O 0 6.256537510296312e-09
the O 0 2.71140843111084e-09
correct O 0 4.353272586854473e-08
assignment O 0 2.6753367521337168e-08
of O 0 6.96107216313635e-09
90 O 0 9.469865780431519e-09
% O 0 1.0438646613764035e-09
of O 0 5.097522848274139e-09
the O 0 6.703456900680749e-09
SCA1 B-Disease 0 1.1192971669515828e-06
, O 0 9.170559867044403e-10
90 O 0 2.6127682239973637e-09
% O 0 3.1181682236258723e-10
of O 0 2.1374635394977304e-09
the O 0 8.083245184309362e-09
SCA2 B-Disease 0 1.6981041426333832e-06
, O 0 1.6382375456203135e-09
and O 0 9.801395250974565e-10
93 O 0 6.4190568416222504e-09
% O 0 6.446586597874671e-10
of O 0 4.340436010608073e-09
the O 0 5.7781459616990105e-09
patients O 0 9.665634514988142e-09
with O 0 6.079527548052965e-09
SCA3 B-Disease 1 1.0
to O 0 6.680150654858608e-09
their O 0 2.9016518077185083e-09
genetically O 0 8.604749801577327e-09
confirmed O 0 9.778786669301098e-09
patient O 0 6.451190248668581e-09
group O 0 1.0099397984575376e-09
and O 0 1.6500979471700816e-09
, O 0 5.777713307786314e-10
therefore O 0 4.2940109246103475e-09
, O 0 9.154569324820727e-10
may O 0 5.0188093680958445e-09
help O 0 1.664040105708864e-08
orient O 0 1.8751230754787684e-06
diagnoses O 0 3.128513981209835e-07
of O 0 2.0959705082645996e-08
SCA1 B-Disease 0 2.159041514460114e-06
, O 0 4.497493044652856e-09
SCA2 B-Disease 0 1.8889883222072967e-06
, O 0 2.8912050531459954e-09
and O 0 1.7097482540862075e-08
SCA3 B-Disease 1 1.0
at O 0 2.9753837793577986e-07
early O 0 6.116563611158199e-08
clinical O 0 1.6069634511950426e-07
stages O 0 1.8894644426836749e-07
of O 0 6.54349250339692e-08
the O 0 1.1632885588142017e-07
diseases O 0 9.3212875071913e-06
. O 0 8.443409882374908e-08
. O 0 2.226227934443159e-06

Genetic O 0 5.828923121953267e-07
basis O 0 1.578383148626017e-07
and O 0 7.208389884993949e-09
molecular O 0 4.352658606876503e-07
mechanism O 0 1.026470727083506e-05
for O 0 7.216261224129994e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.9218981266021729

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 0.9999732971191406
causes O 0 5.852747563039884e-06
more O 0 5.309135353570582e-09
than O 0 2.5094752942322884e-09
300 O 0 5.2881850010066955e-09
, O 0 1.5217718196680607e-09
000 O 0 2.6739748193449486e-08
sudden O 0 1.2407441296602428e-08
deaths O 0 3.493903610873872e-09
each O 0 3.8899533594261015e-10
year O 0 1.6354246845651232e-09
in O 0 1.922547898658422e-09
the O 0 3.143107463188244e-08
USA O 0 2.128299740888906e-07
alone O 0 1.7718522826726257e-07
. O 0 1.2411356919983518e-06

In O 0 5.21230276717688e-07
approximately O 0 6.814649111674953e-08
5 O 0 1.693446876060989e-07
- O 0 5.623161669632282e-08
12 O 0 1.3879967397656401e-08
% O 0 3.053096109262299e-10
of O 0 3.2305852437630733e-10
these O 0 1.275660549415747e-10
cases O 0 1.9675872042768106e-10
, O 0 1.5561772356842418e-11
there O 0 2.1619477041934232e-11
are O 0 6.423631071506009e-11
no O 0 2.064962423276029e-09
demonstrable O 0 1.3407247024588287e-05
cardiac O 0 0.004170060623437166
or O 0 2.701653329495457e-06
non O 1 0.9999727010726929
- O 1 0.9912083148956299
cardiac O 0 0.021271347999572754
causes O 0 1.0995554333703694e-07
to O 0 2.6311770540132784e-09
account O 0 6.04970407103167e-10
for O 0 4.734413416862537e-10
the O 0 3.2200859756414957e-09
episode O 0 4.8545256703391715e-09
, O 0 1.305842239895938e-10
which O 0 3.314912233598477e-11
is O 0 3.4155556855042235e-11
therefore O 0 7.38115846221632e-10
classified O 0 3.3101137386637447e-09
as O 0 1.226997969894228e-08
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.0002829519798979163
IVF B-Disease 1 1.0
) O 0 7.338168188653071e-07
. O 0 7.639379873580765e-06

A O 0 1.0910845276157488e-06
distinct O 0 2.8941093432877096e-07
group O 0 5.0139227880663384e-08
of O 0 1.384834831696935e-06
IVF B-Disease 1 1.0
patients O 0 6.975123056918164e-08
has O 0 9.580702897693527e-10
been O 0 1.1313249226319044e-09
found O 0 3.015121763372264e-10
to O 0 1.9640214454774707e-10
present O 0 6.469522140228889e-10
with O 0 4.868942471425441e-10
a O 0 4.864573188712029e-09
characteristic O 0 2.308983994225855e-06
electrocardiographic O 0 1.9787155906669796e-05
pattern O 0 8.549328413209878e-06
. O 0 1.9850381249852944e-06

Because O 0 2.550199269535369e-07
of O 0 2.3298929363591014e-07
the O 0 2.1746600964434037e-08
small O 0 2.073740734687135e-09
size O 0 3.963607220214271e-09
of O 0 5.896775512326258e-09
most O 0 4.851292700891463e-10
pedigrees O 0 1.9102856185782002e-08
and O 0 2.2509898389699856e-09
the O 0 2.710229596303293e-09
high O 0 2.568032471117476e-07
incidence O 0 2.2331590798785328e-07
of O 0 5.659916091360628e-09
sudden B-Disease 0 1.3471695758937585e-08
death I-Disease 0 7.086465814154508e-08
, O 0 4.5044362684265593e-10
however O 0 2.0988417670508852e-09
, O 0 4.2661219001871586e-10
molecular O 0 5.695262483840224e-09
genetic O 0 8.33267510547131e-10
studies O 0 1.7374010008452956e-09
of O 0 1.0946625828012202e-08
IVF B-Disease 1 0.9940112233161926
have O 0 2.0056798444301194e-09
not O 0 5.659837598592787e-10
yet O 0 6.771061933363853e-09
been O 0 8.713805677018627e-09
done O 0 1.0417572582355206e-07
. O 0 7.672195465602272e-07

Because O 0 5.527021585294278e-06
IVF B-Disease 1 1.0
causes O 0 0.00015050855290610343
cardiac O 1 0.9999204874038696
rhythm O 1 0.9997871518135071
disturbance O 1 0.7937496900558472
, O 0 3.6255343616176106e-08
we O 0 4.7630582145075095e-08
investigated O 0 1.3167588974738464e-07
whether O 0 1.626785994801594e-08
malfunction O 0 3.2625584935885854e-06
of O 0 6.28184224638062e-08
ion O 0 1.3355104783840943e-05
channels O 0 6.703369876959187e-07
could O 0 3.753170574327669e-08
cause O 0 1.366561832583102e-07
the O 0 9.168570791473485e-09
disorder O 0 1.6883664244460306e-08
by O 0 2.8916666283684833e-10
studying O 0 2.2506077002049096e-09
mutations O 0 1.4501888578877242e-09
in O 0 9.517721055729567e-10
the O 0 1.9008684404298037e-08
cardiac O 0 5.170107897356502e-07
sodium O 0 2.545470749737433e-07
channel O 0 7.806634698681592e-07
gene O 0 2.200668376417525e-07
SCN5A O 0 2.81873199128313e-05
. O 0 2.8078768536943244e-06

We O 0 6.219103738658305e-07
have O 0 1.0999283261980963e-08
now O 0 5.91723559040247e-09
identified O 0 3.417985183773453e-08
a O 0 1.65581148792171e-08
missense O 0 1.5853996728765196e-06
mutation O 0 1.7561968945756234e-07
, O 0 2.4995262748461755e-08
a O 0 4.2041456538299826e-08
splice O 0 3.582791350709158e-06
- O 0 3.246946960189234e-07
donor O 0 8.739254653278294e-09
mutation O 0 3.782491830861545e-08
, O 0 3.4147318306310126e-09
and O 0 7.020849679406638e-09
a O 0 1.1738819694073754e-08
frameshift O 0 5.325939582689898e-07
mutation O 0 1.7004275321141904e-08
in O 0 4.393711172667736e-09
the O 0 9.027405489803186e-09
coding O 0 7.401537516216194e-08
region O 0 5.7711737611043645e-09
of O 0 2.1704870789562847e-08
SCN5A O 0 4.147274466959061e-06
in O 0 5.862045515669934e-09
three O 0 4.8270965891106243e-08
IVF B-Disease 0 0.03783278539776802
families O 0 3.8384609268860004e-08
. O 0 1.1628841320998617e-06

We O 0 3.919390678674972e-07
show O 0 1.298591012499628e-08
that O 0 6.132795937752178e-10
sodium O 0 5.686318527153844e-09
channels O 0 6.575932243180205e-09
with O 0 4.5939002601969037e-10
the O 0 4.644996387526135e-09
missense O 0 3.701081539020379e-07
mutation O 0 3.656396074802615e-08
recover O 0 7.221851916483502e-08
from O 0 5.751042753132651e-09
inactivation O 0 4.2125418531213654e-07
more O 0 1.1350901329976182e-09
rapidly O 0 8.303264742437477e-09
than O 0 3.6602301745070065e-10
normal O 0 1.38827671580799e-09
and O 0 1.8188150985309903e-10
that O 0 1.0778650888498831e-10
the O 0 2.3691220096822008e-09
frameshift O 0 2.3416119176999928e-07
mutation O 0 5.322285723252662e-09
causes O 0 2.7426212412251516e-09
the O 0 1.9663315420359595e-09
sodium O 0 8.700087761326358e-09
channel O 0 7.71343877659092e-09
to O 0 7.898748877188666e-10
be O 0 6.254807338734736e-09
non O 0 2.040651878587596e-07
- O 0 1.9601506551225611e-07
functional O 0 8.318453410538496e-07
. O 0 6.133983561085188e-07

Our O 0 8.829632065499027e-07
results O 0 1.3826651468207274e-07
indicate O 0 2.0681483192674932e-08
that O 0 1.0825011997894762e-09
mutations O 0 6.541817310079523e-09
in O 0 5.964464033780814e-09
cardiac O 0 9.478793003836472e-07
ion O 0 0.00018250489665661007
- O 0 0.05546420440077782
channel O 0 3.3281648370575567e-07
genes O 0 2.260549969435033e-09
contribute O 0 2.1598632604646895e-10
to O 0 2.5435920036898096e-10
the O 0 8.095831227628025e-10
risk O 0 3.820425309442044e-09
of O 0 1.2074637290027113e-08
developing O 0 1.3589113905254635e-06
IVF B-Disease 1 0.9015887379646301
. O 0 6.98834625723066e-08
. O 0 4.7471274911004e-07

Molecular O 0 1.323846936429618e-05
heterogeneity O 0 3.700749857671326e-06
in O 0 2.655348225744092e-07
mucopolysaccharidosis B-Disease 0 2.9343198548303917e-05
IVA I-Disease 0 0.00030631752451881766
in O 0 6.784055983644066e-08
Australia O 0 4.281900700675578e-08
and O 0 5.598074892532168e-09
Northern O 0 3.827677375056737e-08
Ireland O 0 1.5595838931403705e-07
: O 0 7.758087505749245e-09
nine O 0 8.224424696834376e-09
novel O 0 5.022275928467934e-09
mutations O 0 7.836253423931794e-09
including O 0 2.116207209468257e-09
T312S O 0 3.4914546631625853e-07
, O 0 4.0370364828845595e-09
a O 0 2.308629065694845e-09
common O 0 1.3116547847857873e-08
allele O 0 1.281082688819879e-07
that O 0 1.8130040801977998e-09
confers O 0 2.369478551145221e-07
a O 0 8.336784418361276e-08
mild O 0 1.3227389899839181e-05
phenotype O 0 4.702909791376442e-05
. O 0 3.2727675716159865e-06

Mucopolysaccharidosis B-Disease 0 0.025388725101947784
IVA I-Disease 1 0.9999985694885254
( O 0 4.779673326993361e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 3.5745998161473835e-07
is O 0 1.1848277026160758e-08
an O 0 3.431651052210327e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 4.668645851779729e-05
by O 0 3.984484635566332e-07
a O 0 6.277904958551517e-06
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999998807907104
in O 0 2.6396339762868593e-06
N O 0 0.00012411856732796878
- O 0 6.862229201942682e-05
acetylgalactosamine O 0 1.7956561350729316e-05
- O 0 2.616964820845169e-06
6 O 0 4.847800937568536e-06
- O 0 8.669915700920683e-07
sulfate O 0 9.044538273883518e-07
sulfatase O 0 2.0385741663631052e-05
( O 0 1.7504707017224064e-08
GALNS O 0 8.853968211042229e-06
) O 0 6.752878789484384e-08
. O 0 5.626272354675166e-07

Previous O 0 1.5866656895013875e-06
studies O 0 1.214300482388353e-07
of O 0 3.564726469562629e-08
patients O 0 2.743531846149949e-09
from O 0 1.7501627924687568e-09
a O 0 5.2839199682352955e-09
British O 0 1.3696461564904894e-07
- O 0 1.4581576124328421e-06
Irish O 0 4.991147051214284e-08
population O 0 2.869355031354104e-10
showed O 0 2.700858203752432e-09
that O 0 3.8635702970246655e-10
the O 0 4.850610579865133e-09
I113F O 0 1.2529612547496072e-07
mutation O 0 4.981357992761559e-09
is O 0 1.9762265435208093e-10
the O 0 3.639026580071203e-10
most O 0 1.1032722652126736e-10
common O 0 1.2372789459647038e-09
single O 0 1.4500616263291022e-09
mutation O 0 2.993025205455524e-08
among O 0 4.724829238966777e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 1.684447511252074e-06
and O 0 1.9057983635661913e-08
produces O 0 1.9135493189992303e-08
a O 0 7.548134561830011e-09
severe O 0 4.664602784032468e-06
clinical O 0 1.809889727155678e-05
phenotype O 0 1.385140603815671e-05
. O 0 2.5979418296628864e-06

We O 0 6.973878612370754e-07
studied O 0 2.8693423814729613e-07
mutations O 0 2.123283593391534e-08
in O 0 3.7853697953948995e-09
the O 0 1.944818173171825e-08
GALNS O 0 1.366386186418822e-06
gene O 0 2.9995728123566323e-09
from O 0 1.7528787310538974e-09
23 O 0 4.2612061434965653e-08
additional O 0 7.382446653991792e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 3.500982970194855e-08
( O 0 1.495529478034996e-09
15 O 0 3.6515992452024193e-09
from O 0 3.6211422749232725e-10
Australia O 0 1.7217280934289647e-09
, O 0 2.5830612648825024e-10
8 O 0 3.2774267744173358e-09
from O 0 1.4057044417370435e-10
Northern O 0 3.350717037164941e-09
Ireland O 0 1.315995046269336e-08
) O 0 6.097350402356483e-10
, O 0 2.0403979894556556e-10
with O 0 7.357119774509258e-11
various O 0 1.5473763381734784e-09
clinical O 0 7.218298492261965e-07
phenotypes O 0 7.339690910157515e-06
( O 0 6.671543317793294e-09
severe O 0 8.150428243425267e-07
, O 0 5.796138236036086e-09
16 O 0 3.6039132567111665e-08
cases O 0 1.1556424706071766e-09
; O 0 4.187303836999945e-10
intermediate O 0 4.1539692574588116e-08
, O 0 8.550151697761521e-10
4 O 0 9.631956565669952e-09
cases O 0 8.250690131106353e-10
; O 0 4.412605281167714e-10
mild O 0 3.631285494520853e-08
, O 0 1.5601253622321565e-09
3 O 0 3.32075806852572e-08
cases O 0 6.752734815762551e-09
) O 0 4.853173862784388e-09
. O 0 3.6613585052691633e-07

We O 0 3.524171461322112e-07
found O 0 1.3956261923908642e-08
two O 0 4.270137576867228e-09
common O 0 7.037876503801499e-09
mutations O 0 6.298071397736749e-09
that O 0 3.8950612180066457e-10
together O 0 1.0846983311552094e-09
accounted O 0 2.90100987676567e-09
for O 0 6.574837341233319e-10
32 O 0 1.4390989733215065e-08
% O 0 7.32679195092345e-10
of O 0 4.279636645065921e-09
the O 0 4.669451048044948e-09
44 O 0 6.671568630878255e-09
unrelated O 0 1.5502989114679622e-08
alleles O 0 9.917787480162588e-09
in O 0 1.5747747550420854e-09
these O 0 5.097260835640327e-09
patients O 0 2.964899614710248e-08
. O 0 5.326269274519291e-07

One O 0 5.28173131897347e-07
is O 0 8.722334854383007e-09
the O 0 2.3714244790085104e-08
T312S O 0 8.715169883544149e-07
mutation O 0 3.8733208640451267e-08
, O 0 1.3623783212679541e-09
a O 0 1.196068688535945e-09
novel O 0 5.6076392418447085e-09
mutation O 0 8.048291810780484e-09
found O 0 1.794317028291914e-09
exclusively O 0 6.109390771058543e-09
in O 0 1.4456851715749508e-08
milder O 0 1.3015429431106895e-05
patients O 0 8.600682122050785e-07
. O 0 4.381146482046461e-06

The O 0 8.795778398962284e-07
other O 0 1.2430606766145047e-08
is O 0 1.4347569798900395e-09
the O 0 2.588774083989165e-09
previously O 0 1.8633095066888927e-08
described O 0 2.1382067671993354e-08
I113F O 0 1.8683010694076074e-07
that O 0 1.4249227353602123e-09
produces O 0 1.2778486713216353e-08
a O 0 2.194133585931013e-08
severe O 0 1.0586229109321721e-05
phenotype O 0 0.00012435679673217237
. O 0 1.2749250345223118e-05

The O 0 6.633687803514476e-07
I113F O 0 3.834155450022081e-06
and O 0 5.670292324566617e-08
T312S O 0 8.83482925928547e-07
mutations O 0 2.7953243275646855e-08
accounted O 0 6.734945490194377e-09
for O 0 1.4342316223547869e-09
8 O 0 3.560819195058684e-08
( O 0 9.075240003930674e-10
18 O 0 4.137235887213819e-09
% O 0 1.774267677223662e-10
) O 0 1.229442381234236e-10
and O 0 1.056366771834405e-09
6 O 0 4.770531703002234e-08
( O 0 6.241278605045864e-10
14 O 0 3.507986789941242e-09
% O 0 3.572046269884055e-10
) O 0 4.312262491534824e-10
of O 0 2.8845785760012177e-09
44 O 0 1.0545072370859998e-08
unrelated O 0 5.6919638780073e-08
alleles O 0 7.806837487578377e-08
, O 0 3.177440888180172e-08
respectively O 0 1.1172921858815243e-06
. O 0 2.8198771815368673e-06

The O 0 8.644527156320692e-07
relatively O 0 1.4244062640500488e-07
high O 0 4.4826452949564555e-07
residual O 0 4.019500465801684e-06
GALNS O 0 9.861756552709267e-06
activity O 0 3.996105846226783e-08
seen O 0 6.171851918423954e-09
when O 0 1.3125576181494125e-09
the O 0 2.0120711763382815e-09
T312S O 0 2.2580561420681988e-08
mutant O 0 1.505602043039289e-08
cDNA O 0 4.524468977251672e-08
is O 0 2.5479438559017353e-09
overexpressed O 0 1.9310573406983167e-07
in O 0 4.655045238166622e-09
mutant O 0 9.97666305124767e-08
cells O 0 1.925584136586167e-08
provides O 0 5.688072790555054e-10
an O 0 5.1454219357482955e-11
explanation O 0 1.391940895878463e-09
for O 0 4.218503601993717e-10
the O 0 4.014829357856797e-09
mild O 0 2.384110047159993e-07
phenotype O 0 1.6418677262208803e-07
in O 0 1.2652222602937968e-09
patients O 0 5.560973903584454e-10
with O 0 3.154876082600566e-10
this O 0 2.4605808501831916e-09
mutation O 0 1.7142227193289727e-07
. O 0 6.339678861877474e-07

The O 0 2.202087472369385e-07
distribution O 0 2.011864808082464e-08
and O 0 3.1574904912901047e-09
relative O 0 2.5217694599177776e-08
frequencies O 0 5.850152717812307e-08
of O 0 4.5603614218237e-09
the O 0 2.8441287103220247e-09
I113F O 0 5.180961437645237e-08
and O 0 2.1312349662849783e-09
T312S O 0 5.6246637569756786e-08
mutations O 0 3.3593368087281306e-09
in O 0 1.2014075290167625e-09
Australia O 0 5.491903376508844e-09
corresponded O 0 1.520376269326107e-09
to O 0 3.1989338955540347e-10
those O 0 1.6170519090419333e-10
observed O 0 1.1389894583047067e-09
in O 0 4.3287848305872956e-10
Northern O 0 1.8600816886760185e-08
Ireland O 0 8.811010587805868e-08
and O 0 7.378966326854197e-09
are O 0 3.8818001590890105e-10
unique O 0 3.1842145586935544e-10
to O 0 1.3021016209702196e-10
these O 0 1.4654392976876096e-10
two O 0 1.3499899809144011e-10
populations O 0 1.4717137231112787e-10
, O 0 3.1932203409246185e-11
suggesting O 0 2.4568047596318365e-10
that O 0 3.5340872589495476e-11
both O 0 1.3682080468591096e-10
mutations O 0 1.3323834258116563e-09
were O 0 1.0796289418024685e-09
probably O 0 9.476962548049528e-10
introduced O 0 1.0043306186702239e-09
to O 0 1.7938713015031027e-10
Australia O 0 8.132510220804079e-10
by O 0 3.059088538037713e-10
Irish O 0 1.0466482791571252e-08
migrants O 0 2.2718185110903732e-09
during O 0 1.8334307405609707e-09
the O 0 2.3758011113983457e-09
19th O 0 1.1532828381177751e-07
century O 0 4.376124991267716e-07
. O 0 7.128448942239629e-07

Haplotype O 0 4.0812999941408634e-05
analysis O 0 4.746045760839479e-07
using O 0 2.211769043469758e-07
6 O 0 2.9473162612703163e-06
RFLPs O 0 9.211444194079377e-06
provides O 0 7.2829071662283695e-09
additional O 0 3.214244204130523e-09
data O 0 2.4558921563055947e-09
that O 0 1.1486820522543795e-10
the O 0 1.1468941352177353e-09
I113F O 0 3.193273911961114e-08
mutation O 0 1.8792305489512273e-09
originated O 0 1.227252521829314e-09
from O 0 2.43071202055134e-10
a O 0 9.092827046863761e-10
common O 0 8.322958322537488e-09
ancestor O 0 2.616907295305282e-07
. O 0 1.0277108231093735e-06

The O 0 3.0644645221400424e-07
other O 0 1.0861541888118609e-08
9 O 0 1.5434736155839346e-07
novel O 0 2.0950311707679248e-08
mutations O 0 1.9251910288176077e-08
identified O 0 6.9771695088149954e-09
in O 0 7.583948469225277e-10
these O 0 9.013242374678043e-10
23 O 0 3.738167819733462e-08
patients O 0 3.17401704919007e-09
were O 0 6.942522556840913e-09
each O 0 8.883224711375703e-10
limited O 0 3.109973167880753e-09
to O 0 3.097074596780658e-09
a O 0 1.0138388795155606e-08
single O 0 4.084828120198836e-08
family O 0 9.085917440643243e-08
. O 0 9.322018854618364e-07

These O 0 1.9786220661899279e-07
data O 0 5.60239321600875e-08
provide O 0 1.7404058194614436e-09
further O 0 1.4167330641967624e-09
evidence O 0 1.0892143187390957e-08
for O 0 6.773616112454306e-10
extensive O 0 1.0062159105928004e-08
allelic O 0 3.132917925086076e-07
heterogeneity O 0 3.351006796492584e-07
in O 0 9.83496164508324e-08
MPS B-Disease 1 0.9999953508377075
IVA I-Disease 1 1.0
in O 0 7.473644103583865e-08
British O 0 7.484555908376933e-07
- O 0 2.8760209715983365e-06
Irish O 0 8.273295293292904e-08
patients O 0 1.7400739737993831e-09
and O 0 5.109688783200284e-10
provide O 0 3.7706171518436804e-10
evidence O 0 3.5474021498060893e-09
for O 0 2.943103261099367e-10
their O 0 1.1375803632418524e-09
transmission O 0 4.7347075593506815e-08
to O 0 4.24258989051296e-10
Australia O 0 2.0925061683385593e-09
by O 0 4.0805570034052607e-10
British O 0 1.5510352113778936e-08
- O 0 3.342165655340068e-08
Irish O 0 1.3003135457267945e-08
migrants O 0 6.75519551407433e-09
. O 0 8.512469840127324e-09
. O 0 2.963317626836215e-07

Identification O 0 5.334246907295892e-06
of O 0 2.1009750525990967e-06
constitutional O 0 0.0001698594423942268
WT1 O 0 0.001964298076927662
mutations O 0 7.676177347093471e-07
, O 0 8.42196623551672e-09
in O 0 2.105678298391922e-09
patients O 0 4.393752917053462e-09
with O 0 3.354208244488177e-09
isolated O 0 3.6360995636641746e-06
diffuse B-Disease 1 0.9999997615814209
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 7.095418652625085e-08
and O 0 8.110301763508687e-09
analysis O 0 1.4519913271726637e-08
of O 0 4.640748230144709e-08
genotype O 0 4.252301550877746e-06
/ O 0 2.4651328658364946e-06
phenotype O 0 8.586522426412557e-08
correlations O 0 3.653872582276563e-08
by O 0 2.2593033000006812e-10
use O 0 1.487030387714583e-09
of O 0 8.82634676457883e-09
a O 0 8.765247194730819e-09
computerized O 0 3.2683709605407785e-07
mutation O 0 1.3463839820815338e-07
database O 0 3.0162152597768e-07
. O 0 1.912040943352622e-06

Constitutional O 0 9.629628038965166e-06
mutations O 0 5.215246119405492e-07
of O 0 3.361268170465337e-07
the O 0 3.0944551099310047e-07
WT1 O 0 1.404975319019286e-05
gene O 0 5.4742528732276696e-08
, O 0 1.21335537173195e-08
encoding O 0 2.8337399271549657e-07
a O 0 6.952185316322357e-08
zinc O 0 3.926958470401587e-06
- O 0 1.015560428641038e-05
finger O 0 7.525367209382239e-07
transcription O 0 1.243892597813101e-07
factor O 0 4.403688791398963e-08
involved O 0 6.608321445611409e-09
in O 0 6.33052898990627e-09
renal O 1 0.9999959468841553
and O 0 4.695784355135402e-06
gonadal O 1 0.999994158744812
development O 0 3.895610279869288e-05
, O 0 1.8674715107636075e-09
are O 0 3.4782896007889974e-10
found O 0 7.399116319639631e-10
in O 0 7.410499991422625e-10
most O 0 1.0591832966255765e-09
patients O 0 9.926658384173948e-10
with O 0 4.739593162383926e-09
Denys B-Disease 1 0.9999992847442627
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 4.107158929400612e-06
DDS B-Disease 1 1.0
) O 0 1.553089745698344e-08
, O 0 2.8065203494520574e-09
or O 0 9.674344170207405e-08
diffuse B-Disease 1 0.9958733916282654
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 3.515317303026677e-06
DMS B-Disease 0 0.002710690489038825
) O 0 9.777443743530512e-09
associated O 0 5.677857117802887e-08
with O 0 3.854976782236008e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 0.03396882861852646
/ O 1 0.9997199177742004
or O 0 1.2821065865864512e-05
Wilms B-Disease 1 0.999834418296814
tumor I-Disease 0 4.26556434831582e-05
( O 0 1.5639166406344884e-07
WT B-Disease 1 0.9999998807907104
) O 0 4.435790685874963e-07
. O 0 2.7975754619546933e-06

Most O 0 1.97223002373903e-07
mutations O 0 1.555306312184257e-06
in O 0 4.0680112078916864e-07
DDS B-Disease 1 1.0
patients O 0 5.093415325063688e-07
lie O 0 3.8676225244671514e-07
in O 0 4.583489854326217e-08
exon O 0 3.669496493330371e-07
8 O 0 3.3036636182259826e-07
or O 0 2.7555794090972086e-08
exon O 0 1.4159968486637808e-07
9 O 0 3.3691051726236765e-07
, O 0 2.302530788256263e-08
encoding O 0 9.097437327909574e-07
zinc O 0 1.6008769989639404e-06
finger O 0 3.6981743960495805e-06
2 O 0 5.619287094305037e-06
or O 0 2.201277027324977e-07
zinc O 0 1.166970264421252e-06
finger O 0 9.645248155720765e-07
3 O 0 6.735911597388622e-07
, O 0 5.660693247477866e-09
respectively O 0 3.0105965720395034e-08
, O 0 1.022813722606486e-09
with O 0 2.53323556576035e-10
a O 0 2.63896193786195e-09
hot O 0 1.798930924223896e-07
spot O 0 7.922080271782761e-07
( O 0 4.84653206456187e-09
R394W O 0 1.2083511080618337e-07
) O 0 1.6259910085025808e-09
in O 0 5.3253117471285805e-09
exon O 0 6.166130219753541e-07
9 O 0 2.578004796305322e-06
. O 0 2.185251787523157e-06

We O 0 7.424038130920962e-07
analyzed O 0 9.929070898806458e-08
a O 0 3.4906861845485082e-09
series O 0 6.445827871459642e-09
of O 0 6.456803980370296e-09
24 O 0 2.5883903020940124e-08
patients O 0 1.0740403011411104e-09
, O 0 5.265214930716411e-10
10 O 0 6.414969000445581e-09
with O 0 2.630920814539195e-09
isolated B-Disease 0 5.476471187648713e-07
DMS I-Disease 1 0.8999858498573303
( O 0 9.685643220791462e-08
IDMS B-Disease 0 1.2832490938308183e-05
) O 0 3.7660763396729635e-09
, O 0 1.962775497688085e-09
10 O 0 9.092935293608662e-09
with O 0 3.184495334096482e-09
DDS B-Disease 1 1.0
, O 0 2.990661274182571e-09
and O 0 3.6259961699869336e-09
4 O 0 1.110250593683304e-07
with O 0 1.6144127812367515e-08
urogenital B-Disease 1 0.9981696605682373
abnormalities I-Disease 1 0.9999668598175049
and O 0 8.509650797350332e-06
/ O 0 0.35068878531455994
or O 0 0.00012040220462949947
WT B-Disease 1 1.0
. O 0 6.532450788654387e-05

We O 0 1.3011991541134194e-05
report O 0 1.4372604937307187e-06
WT1 O 0 3.351339910295792e-05
heterozygous O 0 2.0018194391013822e-07
mutations O 0 6.834331145455508e-08
in O 0 6.196515744960607e-09
16 O 0 5.4453341391536014e-08
patients O 0 2.2864072857231577e-09
, O 0 1.6410428571589364e-09
4 O 0 7.636428733803768e-08
of O 0 4.937949782402029e-08
whom O 0 1.215741889382116e-07
presented O 0 8.162352855833888e-07
with O 0 2.3582362018714775e-07
IDMS B-Disease 0 0.001545425970107317
. O 0 1.6313981177518144e-05

One O 0 1.6859839888638817e-06
male O 0 9.586484566170839e-07
and O 0 9.17222919838423e-08
two O 0 5.681052783756968e-08
female O 0 4.198544445443986e-07
IDMS B-Disease 0 0.0006654536118730903
patients O 0 1.40202743637019e-07
with O 0 1.8433642878790124e-07
WT1 O 1 0.9997003078460693
mutations O 0 0.00045688130194321275
underwent O 0 8.438187069259584e-05
normal O 0 2.781364855763968e-05
puberty O 0 0.0006792910280637443
. O 0 3.1523948109679623e-06

Two O 0 2.6242673811793793e-06
mutations O 0 1.983735955946031e-06
associated O 0 3.9206466340147017e-07
with O 0 1.7562127752057677e-08
IDMS B-Disease 0 4.768796497955918e-05
are O 0 1.3798607811921215e-09
different O 0 7.411121161204903e-10
from O 0 3.0516872362440495e-10
those O 0 4.766097516650802e-10
described O 0 7.623938813594577e-09
in O 0 2.8587603395635597e-08
DDS B-Disease 1 1.0
patients O 0 9.415636554876983e-07
. O 0 2.9040174922556616e-06

No O 0 5.3564222071145196e-06
WT1 O 0 8.30745484563522e-05
mutations O 0 2.2646558761607594e-07
were O 0 3.823868155450327e-08
detected O 0 1.9161571884751538e-08
in O 0 3.49901885243753e-09
the O 0 1.645572922370775e-08
six O 0 6.193020851696929e-08
other O 0 9.155708191599388e-09
IDMS B-Disease 0 0.0006465158658102155
patients O 0 1.2790289716235748e-08
, O 0 1.5491244953480532e-09
suggesting O 0 1.6180903728013618e-08
genetic O 0 5.195250807332741e-08
heterogeneity O 0 1.5747731652027142e-07
of O 0 9.112922327858541e-08
this O 0 4.802549113946952e-08
disease O 0 2.434076122881379e-05
. O 0 1.5176325405263924e-06

We O 0 3.459342224232387e-06
analyzed O 0 4.824270945391618e-06
genotype O 0 6.723231308569666e-06
/ O 0 2.3222316940518795e-06
phenotype O 0 2.833018584169622e-07
correlations O 0 1.7749641756381607e-07
, O 0 1.286348250140179e-09
on O 0 3.130792070038524e-09
the O 0 4.4443304592078903e-10
basis O 0 1.3886263250384445e-09
of O 0 8.457941014228254e-10
the O 0 8.463895695420831e-10
constitution O 0 3.93834698186879e-09
of O 0 9.653419397182006e-09
a O 0 2.5005657988685925e-08
WT1 O 0 5.697612778021721e-06
mutation O 0 5.629589949762703e-08
database O 0 2.440986790475108e-08
of O 0 3.477523691230999e-08
84 O 0 5.979205752737471e-07
germ O 0 5.957526445854455e-05
- O 0 0.001116930041462183
line O 0 3.2513578389625764e-06
mutations O 0 1.378909644245141e-07
, O 0 1.5666558050853041e-09
to O 0 5.758262200394881e-10
compare O 0 1.4384670121714294e-09
the O 0 6.818050013457366e-10
distribution O 0 8.433214127023803e-10
and O 0 2.892477646287972e-10
type O 0 4.298763567334163e-09
of O 0 3.951695859427673e-09
mutations O 0 2.9766558107269248e-09
, O 0 2.111891495015783e-10
according O 0 2.0040231973883493e-10
to O 0 2.2866895876827442e-10
the O 0 1.6918149103872793e-09
different O 0 2.744663696319094e-08
symptoms O 0 1.6809299268061295e-06
. O 0 7.20128753073368e-07

This O 0 5.8890456955396076e-08
demonstrated O 0 1.153220168248481e-07
( O 0 7.219218556286933e-09
1 O 0 4.275877074633172e-08
) O 0 1.6885524090071158e-09
the O 0 3.4507952051399116e-09
association O 0 2.127344300717482e-09
between O 0 2.728876902224897e-09
mutations O 0 2.9766331621772224e-09
in O 0 1.9045836019415674e-09
exons O 0 6.436370370010991e-08
8 O 0 3.127063763486149e-08
and O 0 2.932855514004018e-09
9 O 0 1.0055563137711943e-07
and O 0 3.057312625287523e-08
DMS B-Disease 0 4.324516794440569e-06
; O 0 3.8839278460045534e-09
( O 0 3.3386404751922782e-09
2 O 0 6.60050147871516e-08
) O 0 2.160362999603649e-09
among O 0 2.483486305493443e-09
patients O 0 2.3691490991240016e-09
with O 0 3.3969587143189983e-09
DMS B-Disease 0 3.775799268623814e-05
, O 0 2.00061367472415e-09
a O 0 1.156806761493101e-09
higher O 0 6.39293418203124e-09
frequency O 0 1.9653651150974838e-08
of O 0 4.180515045248967e-09
exon O 0 4.5882920574058517e-08
8 O 0 2.3327892506586068e-08
mutations O 0 8.007317475744458e-09
among O 0 3.4076272914518313e-09
46 O 0 4.844824985639207e-08
, O 0 1.908337310396746e-08
XY O 0 0.00015805673319846392
patients O 0 2.2471988714301006e-08
with O 0 4.595550162633799e-09
female O 0 4.302210854234545e-08
phenotype O 0 9.689856028671784e-08
than O 0 2.7867255170122007e-09
among O 0 3.2980516095904022e-09
46 O 0 1.2743734600917378e-07
, O 0 6.97956821227308e-08
XY O 0 0.006300813518464565
patients O 0 1.662568038796053e-08
with O 0 2.1402091210376284e-09
sexual O 0 6.719204748151242e-08
ambiguity O 0 1.0604133393599113e-07
or O 0 6.430529708723043e-08
male O 0 2.3689560535444798e-08
phenotype O 0 1.5772585015838558e-08
; O 0 1.7199260904376956e-09
and O 0 1.0859574572918973e-08
( O 0 1.5805462494355993e-09
3 O 0 2.8221476711109972e-08
) O 0 1.6378744194245343e-10
statistically O 0 2.6213625714532895e-10
significant O 0 1.0015066553847873e-10
evidence O 0 2.525233577799213e-09
that O 0 2.438155233264183e-10
mutations O 0 3.1433273761649616e-09
in O 0 2.9240303511812726e-09
exons O 0 1.0505808489824631e-07
8 O 0 9.457306759941275e-08
and O 0 9.881796714239499e-09
9 O 0 1.521810872873175e-07
preferentially O 0 8.138104590216244e-08
affect O 0 8.809850982061107e-08
amino O 0 9.5363876795318e-09
acids O 0 4.131666397899636e-10
with O 0 9.314685828210045e-11
different O 0 5.544187331452122e-10
functions O 0 6.025500987050236e-09
. O 0 4.012264742669913e-09
. O 0 8.689179509246969e-08

The O 0 3.711151293828152e-06
185delAG O 0 1.1933942005271092e-05
BRCA1 O 0 6.170712936182099e-07
mutation O 0 5.4092172518949155e-08
originated O 0 1.0645124781660797e-08
before O 0 1.8923310918239622e-08
the O 0 1.6126883162215222e-09
dispersion O 0 2.9529857670240744e-08
of O 0 2.0780008824772267e-09
Jews O 0 3.7859977375376275e-09
in O 0 8.205209844902583e-10
the O 0 1.409358962867202e-09
diaspora O 0 1.2264965709718467e-09
and O 0 1.0894464219646238e-09
is O 0 2.818169864138298e-10
not O 0 1.0439681341622986e-09
limited O 0 1.671254246105036e-08
to O 0 6.43587938498058e-08
Ashkenazim O 0 0.00021405033476185054
. O 0 1.7932434275280684e-05

The O 0 1.428953510185238e-06
185delAG O 0 3.3507974421809195e-06
mutation O 0 1.248195502512317e-07
in O 0 1.5640173600672824e-08
BRCA1 O 0 8.589683631043954e-08
is O 0 1.429697804589125e-09
detected O 0 3.788511726554589e-09
in O 0 1.3030240220146538e-09
Ashkenazi O 0 8.485984892558918e-08
Jews O 0 1.1817447465034547e-08
both O 0 2.919388064626105e-09
in O 0 2.59730708052075e-08
familial B-Disease 1 0.9993708729743958
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 0.031705956906080246
in O 0 2.492290889222204e-07
the O 0 1.2238652402629668e-07
general O 0 6.30336174367585e-08
population O 0 2.1054453736013556e-09
. O 0 2.519375925658096e-07

All O 0 2.1110213310748804e-06
tested O 0 3.363267069289577e-06
Ashkenazi O 0 3.040848014279618e-06
mutation O 0 4.582790325002861e-08
carriers O 0 7.0271055641057956e-09
share O 0 7.27230142771873e-09
the O 0 4.142257647998804e-09
same O 0 7.0203407531721496e-09
allelic O 0 1.5378565194623661e-06
pattern O 0 3.3779781460907543e-07
at O 0 2.2953709333251027e-07
the O 0 4.0572626147650226e-08
BRCA1 O 0 6.093775937188184e-07
locus O 0 1.661666829022579e-06
. O 0 2.964113491543685e-06

Our O 0 2.3691379738011165e-06
previous O 0 2.395446188074857e-07
study O 0 1.7336379443122496e-08
showed O 0 2.224391781879831e-09
that O 0 1.9369827963799935e-10
this O 0 5.94315763269293e-10
Ashkenazi O 0 1.6063351893080835e-07
mutation O 0 6.009363673342705e-09
also O 0 1.1556203771689866e-09
occurs O 0 1.2273203564561186e-09
in O 0 5.655941825999378e-10
Iraqi O 0 5.215494525145914e-08
Jews O 0 1.8810066393371017e-08
with O 0 1.0681789897049043e-09
a O 0 4.751803839297963e-09
similar O 0 4.431840849861146e-08
allelic O 0 4.667635221267119e-05
pattern O 0 4.1268791392212734e-05
. O 0 6.496326022897847e-06

We O 0 8.314043498103274e-07
extended O 0 7.980486316228053e-08
our O 0 9.115526999892154e-09
analysis O 0 1.421610829055453e-09
to O 0 2.3490034917195146e-10
other O 0 6.005785868623548e-10
non O 0 6.044288625162153e-08
- O 0 5.03624484338161e-08
Ashkenazi O 0 1.0907697856055165e-07
subsets O 0 3.063991016460932e-08
354 O 0 1.4953647209381415e-08
of O 0 1.7742042279778047e-09
Moroccan O 0 1.2699234730462194e-07
origin O 0 1.804845162212132e-08
, O 0 7.0647212524477254e-09
200 O 0 2.6716294954098885e-08
Yemenites O 0 2.2635729237663327e-06
and O 0 1.3751688676677531e-08
150 O 0 2.0788542443028746e-08
Iranian O 0 3.606485563523165e-07
Jews O 0 9.055844429894933e-07
. O 0 2.5926156013156287e-06

Heteroduplex O 0 4.6086195652605966e-05
analysis O 0 1.4281673088589741e-07
complemented O 0 3.680563764874023e-08
by O 0 6.93400947771039e-10
direct O 0 2.607575710911192e-09
DNA O 0 1.458272169685415e-08
sequencing O 0 1.4185860486293222e-08
of O 0 6.424446308272991e-09
abnormally O 0 6.116610506978759e-08
migrating O 0 5.671652480998546e-09
bands O 0 3.867193854034667e-08
were O 0 5.98251403971517e-08
employed O 0 3.3444078439970326e-07
. O 0 9.638076789997285e-07

Four O 0 2.575611404154188e-07
of O 0 8.720559208086343e-08
Moroccan O 0 1.0754306458693463e-06
origin O 0 8.618103564117519e-09
( O 0 4.875698733641798e-10
1 O 0 2.7893471976625506e-09
. O 0 2.4080773486367946e-10
1 O 0 3.6591989438505834e-09
% O 0 2.4342008964062245e-10
) O 0 2.0698276426145412e-10
and O 0 6.710758060357591e-10
none O 0 6.056126711229126e-09
of O 0 7.401689039454595e-09
the O 0 1.1520864262593022e-08
Yemenites O 0 9.524989650344651e-07
or O 0 4.054328872626911e-09
Iranians O 0 2.209129235097862e-08
was O 0 1.9931039929588223e-08
a O 0 1.8394975542790348e-09
carrier O 0 2.196087756090037e-09
of O 0 2.5297376637922753e-08
the O 0 3.543021875884733e-08
185delAG O 0 3.461593223619275e-06
mutation O 0 7.99801512130216e-07
. O 0 1.5157767165874247e-06

BRCA1 O 0 9.377281094202772e-05
allelic O 0 4.0419588913209736e-05
patterns O 0 4.412824523569725e-07
were O 0 1.6205643049715945e-08
determined O 0 2.1905918856646167e-08
for O 0 9.018985558384429e-10
four O 0 2.186829384243083e-09
of O 0 1.5525083441048082e-09
these O 0 2.1749439749196853e-10
individuals O 0 7.929917139604115e-11
and O 0 4.741498860205695e-10
for O 0 7.597905637979352e-10
12 O 0 1.0784316550882522e-08
additional O 0 4.451730539756227e-09
non O 0 4.4445093294598337e-07
- O 0 2.847224891411315e-07
Ashkenazi O 0 1.900707502500154e-07
185delAG O 0 1.3057767489499383e-07
mutation O 0 5.465162988826933e-09
carriers O 0 3.918804836189338e-09
who O 0 6.575069022574098e-08
had O 0 0.005691430997103453
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9925951361656189

Six O 0 1.0999232472386211e-05
non O 0 6.288805889198557e-05
- O 0 6.805563771195011e-06
Ashkenazi O 0 7.849837402318371e-07
individuals O 0 3.3340017413507894e-09
shared O 0 9.361841968313911e-09
the O 0 5.800738556160923e-09
common O 0 2.4149610311496872e-08
Ashkenazi O 0 1.2531397715065395e-06
haplotype O 0 3.256132004025858e-07
, O 0 5.615955700477571e-09
four O 0 1.056476151006791e-08
had O 0 1.094032242576759e-08
a O 0 5.397125413253434e-09
closely O 0 7.571378191073563e-09
related O 0 3.435849293964566e-08
pattern O 0 1.065063202076999e-07
, O 0 1.0344657352945319e-09
and O 0 3.1887865681312633e-09
the O 0 8.098568926584448e-09
rest O 0 1.566806062669457e-08
( O 0 1.7534070861913165e-09
n O 0 2.72239066845259e-08
= O 0 9.045041338140436e-08
6 O 0 3.611337717757124e-08
) O 0 4.900302386090516e-10
displayed O 0 1.0454272114657215e-08
a O 0 1.0545635475978088e-08
distinct O 0 1.2443932462247176e-07
BRCA1 O 0 4.095269105164334e-06
allelic O 0 2.9275806809891947e-05
pattern O 0 8.630527190689463e-06
. O 0 5.904255885980092e-06

We O 0 8.274083143078315e-07
conclude O 0 6.627952302551421e-07
that O 0 4.4206944771474355e-09
the O 0 1.82698762785094e-08
185delAG O 0 5.568020924329176e-07
BRCA1 O 0 2.3756035716360202e-07
mutation O 0 1.376940517161529e-08
occurs O 0 2.0801582678586783e-09
in O 0 5.621075271911025e-10
some O 0 7.869365714618937e-10
non O 0 1.8290977266133268e-07
- O 0 1.7889531989112584e-07
Ashkenazi O 0 1.4323178731956432e-07
populations O 0 6.812680974910279e-10
at O 0 9.7839354396001e-09
rates O 0 1.651971559546439e-09
comparable O 0 9.362998154571756e-10
with O 0 1.0328643496038126e-10
that O 0 3.936662662518131e-10
of O 0 2.616390126775059e-08
Ashkenazim O 0 3.932278195861727e-05
. O 0 2.1400037439889275e-06

The O 0 5.855008566868491e-07
majority O 0 1.993537246391952e-08
of O 0 6.861576906658229e-08
Jewish O 0 2.0307525971929863e-07
185delAG O 0 9.45376825711719e-07
mutation O 0 3.1422139556980255e-08
carriers O 0 3.836329476314404e-09
have O 0 2.42058550981028e-09
a O 0 1.101881164089491e-08
common O 0 2.2361980711593787e-07
allelic O 0 6.976131408009678e-05
pattern O 0 1.8595906112750527e-06
, O 0 9.808001522060295e-09
supporting O 0 2.6509146877629064e-08
the O 0 1.5000038544599192e-08
founder O 0 8.82493651488403e-08
effect O 0 3.735630471624063e-08
notion O 0 1.2584214559296925e-08
, O 0 5.477108766527294e-10
but O 0 4.757514937558938e-10
dating O 0 4.87369300472551e-09
the O 0 9.682716850534234e-10
mutations O 0 1.0424520135998705e-09
origin O 0 1.05104291936442e-09
to O 0 7.808885205129457e-10
an O 0 3.9411704455538654e-10
earlier O 0 9.368111619778574e-09
date O 0 1.3638198481658037e-07
than O 0 4.674593157005802e-09
currently O 0 1.6780704825691828e-08
estimated O 0 7.55963611709376e-08
. O 0 1.6627684544801014e-06

However O 0 2.3337022980740585e-07
, O 0 4.162850508748761e-09
the O 0 2.7421662718296602e-09
different O 0 3.495603584369178e-09
allelic O 0 6.425883043448266e-07
pattern O 0 2.7671040925270063e-07
at O 0 1.9199733003461006e-07
the O 0 1.7802660678967186e-08
BRCA1 O 0 3.98814101743028e-08
locus O 0 2.7774406774483396e-08
even O 0 1.288017692502308e-09
in O 0 5.278175674305885e-10
some O 0 3.1566096958535184e-10
Jewish O 0 7.529872725342557e-09
mutation O 0 5.417339909996599e-09
carriers O 0 1.2236482938021709e-09
, O 0 1.1967488111608304e-09
might O 0 2.665591525286004e-09
suggest O 0 3.647847135468396e-09
that O 0 3.931162617654138e-10
the O 0 3.165045558972679e-09
mutation O 0 7.399374002403647e-09
arose O 0 1.496246326837536e-08
independently O 0 2.3820867056656425e-08
. O 0 2.651688468802149e-08
. O 0 8.906779953576915e-07

Crystal O 0 0.0003206300607416779
structure O 0 2.245909308840055e-05
of O 0 2.4119419322232716e-05
the O 0 7.443865615641698e-05
hemochromatosis B-Disease 1 1.0
protein O 0 4.443739271664526e-06
HFE O 0 8.590130892116576e-05
and O 0 1.921727665887829e-08
characterization O 0 5.581935624832113e-08
of O 0 2.1576420650148975e-08
its O 0 4.144849796716699e-09
interaction O 0 2.9094227471659906e-08
with O 0 1.5370112294021965e-08
transferrin O 0 2.4586738618381787e-06
receptor O 0 1.950768137248815e-06
. O 0 1.3811853705192334e-06

HFE O 0 0.01631220057606697
is O 0 4.819948458134604e-07
an O 0 9.414507928795501e-08
MHC O 0 2.1139883756404743e-05
- O 0 0.00017837075574789196
related O 0 2.0905699784634635e-06
protein O 0 4.7051070595216515e-08
that O 0 6.63343602269606e-10
is O 0 2.2510487918125932e-10
mutated O 0 6.736101454407617e-09
in O 0 3.3403539934084847e-09
the O 0 7.527377476890251e-08
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.06722770631313324

HFE O 0 0.0006122884806245565
binds O 0 1.3056128409516532e-06
to O 0 1.2618998823654692e-07
transferrin O 0 4.907790298602777e-06
receptor O 0 1.0341191227780655e-06
( O 0 3.5705241430150636e-08
TfR O 0 1.3473669469021843e-06
) O 0 2.5185860064169674e-09
and O 0 2.103293983424237e-09
reduces O 0 9.308728010637424e-09
its O 0 2.4958946021058637e-09
affinity O 0 7.200846141586226e-09
for O 0 6.2139973167063545e-09
iron O 0 9.145052899839357e-06
- O 0 6.475639224845509e-07
loaded O 0 8.539436180399207e-08
transferrin O 0 7.687854690630047e-07
, O 0 3.165681405903342e-08
implicating O 0 4.066020210302668e-06
HFE O 0 0.0001616476511117071
in O 0 7.947225526550028e-07
iron O 1 0.5427103042602539
metabolism O 0 0.15212540328502655
. O 0 4.313963017921196e-06

The O 0 7.636902410013136e-06
2 O 0 3.661998198367655e-05
. O 0 7.249146619869862e-06

6 O 0 0.0004710414505098015
A O 0 5.499974577105604e-06
crystal O 0 0.00011791987344622612
structure O 0 1.5506277122767642e-05
of O 0 1.8975196098836022e-06
HFE O 0 0.0005138568230904639
reveals O 0 1.1160318535985425e-07
the O 0 5.107167577733662e-09
locations O 0 2.716591573914684e-08
of O 0 2.982792466355022e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 0.0008146663312800229
and O 0 2.3975812837306876e-06
a O 0 2.0630314168101904e-07
patch O 0 1.656262065807823e-05
of O 0 1.080058154911967e-05
histidines O 0 1.998992775043007e-05
that O 0 2.334479720644822e-09
could O 0 6.8599250724332705e-09
be O 0 6.054463153049028e-09
involved O 0 1.3371473706058623e-08
in O 0 1.1087096574158295e-08
pH O 0 2.018391933233943e-05
- O 0 1.088365820578474e-06
dependent O 0 9.038246417958362e-08
interactions O 0 3.545158904216805e-07
. O 0 8.919087690628658e-07

We O 0 6.194680963744759e-07
also O 0 1.4468272802048432e-08
demonstrate O 0 3.5466459991084776e-08
that O 0 1.3592487135838383e-08
soluble O 0 6.29481974101509e-07
TfR O 0 3.236236807424575e-06
and O 0 4.166713196696037e-08
HFE O 0 6.2996214182931e-06
bind O 0 8.291146258443405e-08
tightly O 0 1.294614833113883e-07
at O 0 1.6694961857410817e-07
the O 0 1.304325181195054e-08
basic O 0 9.934829847679794e-08
pH O 0 5.669486426995718e-07
of O 0 4.7449049134229426e-08
the O 0 1.1846332803600035e-08
cell O 0 1.4096769973548362e-08
surface O 0 1.1086672913052098e-08
, O 0 4.079482862628936e-10
but O 0 5.411801562438256e-10
not O 0 3.117842872768506e-09
at O 0 6.934016028026235e-08
the O 0 3.7643406614051855e-08
acidic O 0 1.4040574569662567e-06
pH O 0 7.199706942628836e-06
of O 0 1.1245109590163338e-06
intracellular O 0 2.506674036339973e-06
vesicles O 0 1.016308397083776e-05
. O 0 4.127451120439218e-06

TfR O 0 0.0011763015063479543
HFE O 0 0.00030661176424473524
stoichiometry O 0 4.674167939811014e-06
( O 0 8.612487079062703e-08
2 O 0 7.25533254808397e-07
1 O 0 2.0975666359390743e-07
) O 0 8.371357829162207e-09
differs O 0 4.023555177923299e-08
from O 0 1.694140649988185e-08
TfR O 0 1.2119998018533806e-06
transferrin O 0 1.4393218350505776e-07
stoichiometry O 0 9.230372199908743e-08
( O 0 1.8663284251374535e-09
2 O 0 2.295996459622529e-08
2 O 0 2.9547154056785985e-08
) O 0 5.059878072088964e-10
, O 0 3.3617772454697104e-10
implying O 0 2.354315409291985e-09
a O 0 4.929174846068918e-10
different O 0 4.2806791444860437e-10
mode O 0 4.1972150199853786e-08
of O 0 2.4656217068041997e-09
binding O 0 1.0681183937322203e-08
for O 0 5.7231832606419175e-09
HFE O 0 7.0062292252259795e-06
and O 0 1.8881992858155172e-08
transferrin O 0 2.545711197399214e-07
to O 0 1.0804535044428576e-08
TfR O 0 1.0649347359503736e-06
, O 0 2.1299102481719956e-09
consistent O 0 1.6620417042645386e-08
with O 0 9.443850146340083e-10
our O 0 1.6152043258443882e-08
demonstration O 0 5.0089617786852614e-08
that O 0 2.0261816668920574e-09
HFE O 0 5.597785275313072e-06
, O 0 1.187338849462094e-08
transferrin O 0 2.0402158895649336e-07
, O 0 2.991488390335917e-09
and O 0 6.1268363715782925e-09
TfR O 0 4.3882741351808363e-07
form O 0 1.8083115449485376e-08
a O 0 2.825465372779945e-08
ternary O 0 1.592527837601665e-06
complex O 0 2.7151620543008903e-06
. O 0 1.7891561583383009e-06

Identification O 0 9.918506975736818e-07
of O 0 2.2867011750804522e-07
three O 0 1.5514613593836657e-08
novel O 0 1.0295277519389856e-08
mutations O 0 2.5070844955621396e-08
and O 0 6.528007023831606e-09
a O 0 4.251721641423956e-09
high O 0 7.056428330542985e-08
frequency O 0 1.1182265780007583e-07
of O 0 1.9167528009234047e-08
the O 0 1.6464298369101016e-08
Arg778Leu O 0 2.4133114493452013e-06
mutation O 0 3.0122162542056685e-08
in O 0 3.2858455956130683e-09
Korean O 0 1.8366172582773288e-07
patients O 0 1.6693075366447374e-08
with O 0 1.3421682432124271e-08
Wilson B-Disease 0 1.5797017113072798e-05
disease I-Disease 0 0.00012308338773436844
. O 0 3.0461796995950863e-06

Four O 0 7.64023934607394e-06
mutations O 0 2.466607384121744e-06
- O 0 3.3788589917094214e-06
- O 0 7.460945425918908e-07
R778L O 0 5.160792397873593e-07
, O 0 7.743540031412977e-09
A874V O 0 2.4024055278459855e-07
, O 0 5.693741922385698e-09
L1083F O 0 1.9640876303128607e-07
, O 0 4.80249173762104e-09
and O 0 9.574258719169393e-09
2304delC O 0 6.327658184090978e-07
- O 0 8.985220034674057e-08
- O 0 3.7971222610622135e-08
in O 0 1.0309680220643713e-08
the O 0 5.2154451424257786e-08
copper O 0 7.25302129467309e-07
- O 0 2.2432595869759098e-07
transporting O 0 3.9640930538098473e-08
enzyme O 0 2.4470281800859084e-08
, O 0 9.555376934144988e-09
P O 0 6.765384569007438e-06
- O 0 3.8980758176876407e-07
type O 0 4.645902436095639e-07
ATPase O 0 6.551261776621686e-06
( O 0 8.180680133307305e-09
ATP7B O 0 1.0317606893295306e-06
) O 0 3.4427730111197263e-10
, O 0 1.3751359773106486e-10
were O 0 1.4001796388996013e-09
identified O 0 6.510300742945674e-09
in O 0 1.9194483780182736e-09
Korean O 0 1.6091594545741827e-07
Patients O 0 5.73584095775459e-08
with O 0 2.3781735691841277e-08
Wilson B-Disease 0 0.0001845113147282973
disease I-Disease 0 0.0213624257594347
. O 0 6.222875072126044e-06

Arg778Leu O 0 0.00032294963602907956
, O 0 1.0299974917415966e-07
the O 0 1.2527839210463299e-08
most O 0 9.049399007921011e-10
frequently O 0 2.1021751006600198e-09
reported O 0 2.8211128988431255e-09
mutation O 0 7.753083175465747e-10
of O 0 1.5843432121798173e-09
this O 0 2.1560807306197916e-10
enzyme O 0 9.33108590395193e-10
, O 0 2.46765774480906e-10
was O 0 1.7979346900176552e-09
found O 0 5.596652030703808e-10
in O 0 7.53905216033246e-10
six O 0 4.767818584383576e-09
of O 0 1.2133184235096905e-08
eight O 0 2.9175806659509362e-08
unrelated O 0 2.1883534984112885e-08
patients O 0 1.1692201651314349e-09
studied O 0 1.8187751749110248e-08
, O 0 8.891548053391318e-10
an O 0 3.8211742103833046e-10
allele O 0 1.6345149234098244e-08
frequency O 0 6.170359512225332e-08
of O 0 6.925662177081904e-08
37 O 0 5.918310534980264e-07
. O 0 1.111215169657953e-06

5 O 0 2.0229060737619875e-06
% O 0 3.285640204353513e-08
, O 0 2.8086142300765005e-09
which O 0 1.1220134821243732e-09
is O 0 2.4821308897138294e-10
considerably O 0 2.9243649724008947e-09
higher O 0 1.0746920020565653e-09
than O 0 4.264671601972303e-11
those O 0 1.9437101234087706e-11
in O 0 3.8371888999577664e-11
other O 0 1.4082567056927786e-10
Asian O 0 1.3285395894513385e-08
populations O 0 5.27469623534671e-09
. O 0 8.70945555675462e-08

The O 0 2.1776241965199006e-07
novel O 0 8.573201881745263e-08
single O 0 4.6723933166958886e-08
nucleotide O 0 8.615839419690019e-08
deletion O 0 9.674602807763222e-08
, O 0 5.8644271661023595e-09
2304delC O 0 3.4594538078636106e-07
, O 0 7.838854010344676e-09
was O 0 3.375195234411876e-08
found O 0 4.134372399988706e-09
in O 0 4.213415394360709e-09
one O 0 2.0568895919836905e-08
patient O 0 2.6366097927166265e-07
. O 0 2.6898378564510494e-06

Since O 0 5.137570155966387e-07
a O 0 2.988923242241981e-08
mutation O 0 5.421043169917539e-08
at O 0 2.8162335752313084e-07
cDNA O 0 4.023409871933836e-07
nucleotide O 0 6.882403340568999e-07
2302 O 0 5.570434223045595e-05
( O 0 2.0772727538087565e-08
2302insC O 0 7.910047088444117e-07
) O 0 3.6988454521491576e-09
had O 0 4.8579438249873874e-09
been O 0 3.595274744583321e-09
previously O 0 1.506636060355504e-08
described O 0 3.0473266132702292e-09
, O 0 5.885592013754604e-10
this O 0 2.4414126276184334e-10
region O 0 3.0491114078046166e-09
of O 0 1.712035846423987e-08
the O 0 4.4311139646424635e-08
ATP7B O 0 1.4780915080336854e-05
gene O 0 2.1742661004964248e-08
may O 0 1.7843658994820544e-08
be O 0 1.2216503364470555e-08
susceptible O 0 2.6137846020901634e-07
to O 0 3.3348364070207026e-08
gene O 0 1.2477247537390213e-06
rearrangements O 0 0.0004270344215910882
causing O 0 0.0037457961589097977
Wilson B-Disease 0 0.02540445700287819
disease I-Disease 1 0.9042829871177673
. O 0 1.265351238544099e-05

Disruption O 0 6.942293111933395e-05
of O 0 3.435473900026409e-06
splicing O 0 2.4833798306644894e-06
regulated O 0 8.525212535914761e-08
by O 0 3.6468175146353587e-09
a O 0 1.7468252622165892e-08
CUG O 0 8.309141776408069e-06
- O 0 3.0260630978773406e-07
binding O 0 2.457135792610643e-07
protein O 0 9.499517545918934e-07
in O 0 6.2744658180236e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 8.803579839877784e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.999896764755249
DM B-Disease 1 1.0
) O 0 1.0536471961586358e-07
is O 0 1.668892912753961e-09
caused O 0 8.474108526002055e-09
by O 0 3.1356628404921594e-09
a O 0 1.0742539302555087e-08
CTG O 0 1.3042104001215193e-06
expansion O 0 1.181397646377036e-08
in O 0 8.772768622655747e-10
the O 0 1.259763293681715e-09
3 O 0 2.8141817765003907e-08
untranslated O 0 8.250735277215426e-07
region O 0 9.899379094235883e-09
of O 0 3.456554154013247e-08
the O 0 1.9304130205455294e-07
DM B-Disease 1 1.0
gene O 0 1.929070776895969e-06
. O 0 3.1156621389527572e-06

One O 0 4.5267998416420596e-07
model O 0 1.0732534292401397e-06
of O 0 4.677753622672753e-06
DM B-Disease 1 1.0
pathogenesis O 0 0.00026601055287756026
suggests O 0 1.070559907390134e-08
that O 0 5.274231051899392e-10
RNAs O 0 1.675451244409487e-08
from O 0 1.6065451191593638e-09
the O 0 4.42106573572687e-09
expanded O 0 1.1490294049565364e-08
allele O 0 6.546912345584133e-08
create O 0 6.778841044052797e-09
a O 0 4.432895384098856e-09
gain O 0 6.685353781676895e-08
- O 0 6.730466139970304e-08
of O 0 2.8168990695576213e-08
- O 0 1.937114113559346e-08
function O 0 4.048294144354259e-09
mutation O 0 3.4556146832898094e-10
by O 0 9.83526662889922e-11
the O 0 2.6558666377241025e-10
inappropriate O 0 1.738265975603781e-09
binding O 0 2.127165776855122e-09
of O 0 2.6075706038852786e-09
proteins O 0 2.0086496355098404e-10
to O 0 1.57537549672071e-09
the O 0 2.172976643066704e-08
CUG O 0 2.6958861781167798e-05
repeats O 0 3.058440597669687e-06
. O 0 1.639877154957503e-06

Data O 0 6.413175469788257e-06
presented O 0 2.2872691261e-06
here O 0 8.118879435414783e-08
indicate O 0 2.103403318187702e-08
that O 0 9.301872050393456e-10
the O 0 1.0376874470807707e-08
conserved O 0 1.1001763766671502e-07
heterogeneous O 0 2.637001728089672e-07
nuclear O 0 1.924906655403902e-06
ribonucleoprotein O 0 6.652143838437041e-06
, O 0 9.39432922564265e-08
CUG O 0 1.0703948646550998e-05
- O 0 2.304209800740864e-07
binding O 0 2.217365704382246e-07
protein O 0 1.050300326710385e-07
( O 0 1.4425286742891785e-08
CUG O 0 8.857397006067913e-06
- O 0 2.8047057298863365e-07
BP O 0 1.7691523623852845e-07
) O 0 9.738373440981718e-10
, O 0 1.234141899786323e-09
may O 0 3.060830877643639e-08
mediate O 0 5.321445541994763e-07
the O 0 2.1743039724242408e-07
trans O 0 1.8571346060980432e-07
- O 0 1.3290849665281712e-07
dominant O 0 1.211787719057611e-07
effect O 0 4.836607914171509e-08
of O 0 1.0235441827433078e-08
the O 0 1.1082634365777722e-08
RNA O 0 1.1033790769943153e-07
. O 0 2.060125581238026e-07

CUG O 1 0.5123745203018188
- O 0 0.0006133096758276224
BP O 0 6.033155841578264e-06
was O 0 1.229301176408626e-07
found O 0 1.3893071137971447e-09
to O 0 4.772965911392646e-10
bind O 0 2.060705606155011e-09
to O 0 3.3462397297512325e-09
the O 0 2.3450395403301627e-08
human O 0 1.080628635463654e-06
cardiac O 0 0.0014182876329869032
troponin O 0 0.000419819523813203
T O 0 2.43069607677171e-05
( O 0 2.0529466127072737e-08
cTNT O 0 3.7070975622555125e-07
) O 0 2.2047166314820288e-09
pre O 0 1.8668352197437343e-07
- O 0 3.9564863385521676e-08
messenger O 0 3.762402300822032e-08
RNA O 0 1.898853696502556e-08
and O 0 3.086589428491493e-09
regulate O 0 4.264383068885991e-09
its O 0 1.4251428925859955e-09
alternative O 0 1.935135287567391e-07
splicing O 0 2.3309360130951973e-06
. O 0 1.0355599897593493e-06

Splicing O 0 7.96525455371011e-06
of O 0 1.4755258916920866e-06
cTNT O 0 1.7139302144641988e-05
was O 0 1.5514723372689332e-06
disrupted O 0 8.418775905738585e-06
in O 0 1.1253038110226044e-06
DM B-Disease 1 1.0
striated O 0 9.141123155131936e-05
muscle O 0 1.6109020180010702e-06
and O 0 1.875629607184237e-07
in O 0 2.0176635473490023e-08
normal O 0 5.282693038566322e-08
cells O 0 2.350076933055334e-08
expressing O 0 3.508301205101816e-09
transcripts O 0 2.6836417532649648e-08
that O 0 4.043469170600389e-10
contain O 0 1.9130384387722188e-08
CUG O 0 1.7692986148176715e-05
repeats O 0 2.3102527393348282e-06
. O 0 9.422939228898031e-07

Altered O 0 4.857825388171477e-06
expression O 0 6.121191518104752e-07
of O 0 4.095309975582495e-07
genes O 0 1.042910326987112e-07
regulated O 0 1.4247147817059158e-07
posttranscriptionally O 0 1.2094503745174734e-06
by O 0 5.8015711346115495e-08
CUG O 0 0.0005072392523288727
- O 0 8.747946594667155e-06
BP O 0 3.593028168324963e-07
therefore O 0 2.0911786080546335e-08
may O 0 1.2274051996996604e-08
contribute O 0 1.6654244205938085e-08
to O 0 4.584224200243625e-08
DM B-Disease 1 1.0
pathogenesis O 0 0.0004959364305250347
. O 0 1.0586752807739686e-07
. O 0 5.388657200455782e-07

Identification O 0 2.6770064778247615e-06
of O 0 2.619326551211998e-07
a O 0 1.820851025513548e-08
novel O 0 5.481827969333608e-08
nonsense O 0 4.4254468889448617e-07
mutation O 0 2.451232283817717e-08
and O 0 5.402872815807314e-09
a O 0 7.426492754092351e-09
missense O 0 2.3456306053049047e-07
substitution O 0 6.379537609291219e-08
in O 0 1.9691322350468e-08
the O 0 7.107284005769543e-08
vasopressin O 0 3.7155564314161893e-07
- O 0 8.876865109641585e-08
neurophysin O 0 1.1450262604739692e-07
II O 0 2.9557468224084005e-06
gene O 0 1.4511517543169816e-09
in O 0 5.687758042327573e-10
two O 0 1.6141562531046816e-09
Spanish O 0 3.194556938979076e-07
kindreds O 0 6.587034022231819e-06
with O 0 8.46329015757874e-08
familial B-Disease 0 0.030774427577853203
neurohypophyseal I-Disease 1 0.9999972581863403
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999833106994629
. O 0 0.0006266338750720024

Familial B-Disease 1 0.9999988079071045
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 1 0.9742687940597534
FNDI B-Disease 1 1.0
) O 0 8.177585186786018e-07
is O 0 6.135080443669949e-09
an O 0 6.8869843161678546e-09
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 6.391624629031867e-05
by O 0 2.685045217276638e-07
deficiency O 1 0.9811120629310608
in O 0 7.921521500975359e-07
the O 0 2.6460445951670408e-05
antidiuretic O 0 0.00040918501326814294
hormone O 0 2.5401823222637177e-06
arginine O 0 2.463478267600294e-06
vasopressin O 0 4.594465679019777e-07
( O 0 1.9193979738929556e-08
AVP O 0 1.2456856666176463e-06
) O 0 1.885463118966868e-09
encoded O 0 3.475605581115815e-09
by O 0 4.001297959632666e-09
the O 0 8.972735798806752e-08
AVP O 0 1.71537740243366e-05
- O 0 1.326292135672702e-06
neurophysin O 0 6.370640221575741e-06
II O 1 0.999614953994751
( O 0 7.139769877539948e-07
AVP O 0 4.5460685214493424e-05
- O 0 1.315372401222703e-06
NPII O 0 1.0857401321118232e-05
) O 0 1.9637276693629246e-08
gene O 0 4.433413280935383e-08
on O 0 6.451550120800675e-07
chromosome O 0 4.465141046239296e-06
20p13 O 0 6.686766573693603e-05
. O 0 1.5483416063943878e-05

In O 0 1.2223046041981434e-07
this O 0 8.45442915675676e-09
study O 0 3.649266666627682e-09
, O 0 4.711954715297395e-10
we O 0 1.774414060129459e-09
analyzed O 0 6.915416239650085e-09
two O 0 4.797462982431e-10
families O 0 2.147416827691373e-10
with O 0 1.1414318379365795e-09
FNDI B-Disease 1 0.9999929666519165
using O 0 2.099034901448249e-08
direct O 0 2.3804879845101823e-08
automated O 0 8.953212216056272e-08
fluorescent O 0 4.575226952852063e-08
, O 0 1.1060899973713845e-09
solid O 0 3.76403157531513e-08
phase O 0 7.772575827402761e-08
, O 0 5.373928524399219e-10
single O 0 7.054309358878186e-10
- O 0 2.580373914540246e-09
stranded O 0 1.4391531300006477e-09
DNA O 0 1.2047003394854983e-09
sequencing O 0 4.267588948891898e-09
of O 0 9.518124954865925e-09
PCR O 0 6.348584520310396e-07
- O 0 1.8597289681565599e-06
amplified O 0 3.269916078352253e-06
AVP O 0 4.2735155147966e-05
- O 0 1.2898397017124807e-06
NPII O 0 1.9354436517460272e-05
DNA O 0 1.381921833853994e-06
. O 0 8.348008577740984e-07

In O 0 1.7995229484313313e-07
one O 0 8.09595945838737e-09
of O 0 9.889093988135755e-09
the O 0 3.1232532116121092e-09
families O 0 3.249322200193916e-10
, O 0 4.553926957751031e-10
affected O 0 1.6099469535291178e-09
individuals O 0 4.1216230428631206e-10
presented O 0 1.1158079793460729e-08
a O 0 2.283382816159474e-09
novel O 0 1.1047810666298119e-08
nonsense O 0 1.3313099600509304e-07
mutation O 0 7.690228898127316e-09
in O 0 2.539293442183066e-09
exon O 0 1.9345035795481635e-08
3 O 0 3.663390657493437e-08
of O 0 8.425983466509024e-09
the O 0 1.878349031869675e-09
gene O 0 1.0112795045813527e-09
, O 0 8.352087355056881e-10
consisting O 0 2.1926014337481092e-09
in O 0 1.0548506512719769e-09
a O 0 7.256506062702783e-09
G O 0 3.3265465049225895e-07
to O 0 6.602314783776819e-08
T O 0 1.1183497008460108e-05
transition O 0 2.728132358242874e-06
at O 0 7.363489089584618e-07
nucleotide O 0 6.445117151088198e-08
2101 O 0 9.789705472940113e-07
, O 0 1.0061521615867264e-09
which O 0 2.1377601078231834e-10
produces O 0 4.180305268608464e-10
a O 0 3.6344902087925846e-10
stop O 0 1.335581645278694e-09
signal O 0 1.963667628501753e-08
in O 0 5.653916890224764e-09
codon O 0 1.699138039157333e-07
82 O 0 2.22784109382701e-07
( O 0 2.9780316879168822e-08
Glu O 0 2.172443964809645e-05
) O 0 1.580107067411518e-08
of O 0 2.1049289955499262e-07
NPII O 0 0.00020161722204647958
. O 0 1.0941596883640159e-05

The O 0 2.047126145043876e-06
premature O 0 7.373351763817482e-06
termination O 0 1.1124355978608946e-06
eliminates O 0 4.159488469213102e-07
part O 0 1.3510267571348322e-08
of O 0 4.689392696377581e-08
the O 0 3.431696882216784e-08
C O 0 4.177984919806477e-06
- O 0 1.2879550581601507e-07
terminal O 0 3.0945844997631866e-08
domain O 0 1.1385947296105314e-08
of O 0 2.1172901654153975e-08
NPII O 0 6.156057224870892e-06
, O 0 2.0776640408115554e-09
including O 0 1.5418611942763505e-09
a O 0 3.099805079287421e-09
cysteine O 0 2.5378664503250548e-08
residue O 0 3.702489692614108e-08
in O 0 8.247480476342162e-10
position O 0 1.6278661973956332e-08
85 O 0 7.2999291056419224e-09
, O 0 2.007830013361911e-10
which O 0 7.303375265665935e-11
could O 0 5.870691710541109e-10
be O 0 9.931070410473808e-10
involved O 0 1.176997721508144e-09
in O 0 9.179432214345695e-10
the O 0 1.1220311790793858e-08
correct O 0 8.278731797872751e-07
folding O 0 2.613577635202091e-06
of O 0 1.3176041591123067e-07
the O 0 3.7289390775185893e-07
prohormone O 0 0.00019411391986068338
. O 0 6.4301520978915505e-06

In O 0 2.8135787033534143e-07
the O 0 6.148918174631035e-08
second O 0 2.6594639734867087e-07
family O 0 5.320895279936622e-09
, O 0 9.193010797048373e-10
a O 0 1.9536992024171695e-09
G279A O 0 6.378199657319783e-08
substitution O 0 5.2457334476230244e-08
at O 0 6.978542899105378e-08
position O 0 6.760185300436206e-08
- O 0 9.778525544845706e-09
1 O 0 5.724700713471975e-09
of O 0 1.7384815809151632e-09
the O 0 1.2042661312605674e-09
signal O 0 1.2586855113738693e-08
peptide O 0 1.995666742971025e-09
was O 0 1.3777041729667872e-09
observed O 0 9.235753273273417e-10
in O 0 3.6636527145361697e-10
all O 0 1.1451497528014443e-09
affected O 0 4.763782701644459e-09
individuals O 0 1.7647845407253726e-09
. O 0 4.060697165186866e-07

This O 0 3.5669989983944106e-07
missense O 0 9.189053344016429e-06
mutation O 0 3.3802601251409214e-07
, O 0 3.5908488627001134e-08
which O 0 3.2288330231722284e-08
replaces O 0 6.718340591760352e-05
Ala O 0 6.95975249982439e-05
with O 0 2.715975000455728e-08
Thr O 0 1.2988905837119091e-05
, O 0 5.4220126166626414e-09
is O 0 7.275683389096343e-10
frequent O 0 3.147424987304248e-09
among O 0 3.476502286048344e-08
FNDI B-Disease 1 1.0
patients O 0 3.1194272764878406e-07
and O 0 2.587970726608546e-08
is O 0 1.3709361423863697e-09
thought O 0 3.4256262271270543e-09
to O 0 1.2915355451781352e-09
reduce O 0 1.198389476542161e-08
the O 0 5.8812297254462464e-09
efficiency O 0 6.766725846318877e-08
of O 0 7.351937281185883e-09
cleavage O 0 1.2750025923935482e-08
by O 0 1.6165379035371075e-09
signal O 0 1.2517369896158925e-07
peptidases O 0 1.3026131000515306e-06
. O 0 8.891947089750829e-08
. O 0 1.0958136726912926e-06

Genetic O 0 1.082072685676394e-05
heterogeneity O 0 2.014905294345226e-05
of O 0 1.6802388927317224e-05
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 0.9999995231628418
, O 0 1.1035112379431666e-08
due O 0 3.611951342463726e-07
to O 0 1.3890587347020755e-08
TWIST O 0 6.836938609922072e-06
and O 0 2.88997227926302e-07
FGFR O 0 0.00015269522555172443
mutations O 0 1.5700810536145582e-06
. O 0 1.8873100771088502e-06

Thirty O 0 0.0004410332185216248
- O 0 5.6735865655355155e-05
two O 0 2.606627269585715e-08
unrelated O 0 9.243551346571621e-08
patients O 0 2.6419688659018448e-09
with O 0 7.121688794242687e-10
features O 0 2.17099227484141e-08
of O 0 1.1727896662705461e-06
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.200785331751831e-08
a O 0 2.0090693553243e-08
common O 0 1.470491156396747e-06
autosomal B-Disease 1 0.9998123049736023
dominant I-Disease 1 0.9998440742492676
condition I-Disease 0 0.41729187965393066
of O 0 0.0014086550800129771
craniosynostosis B-Disease 1 0.9999997615814209
and O 0 0.0005191066884435713
limb B-Disease 1 0.9999886751174927
anomalies I-Disease 0 0.0003818138793576509
, O 0 2.0366636377389113e-08
were O 0 2.765420070716118e-08
screened O 0 1.800481896907513e-08
for O 0 2.470625926065395e-09
mutations O 0 3.802644954475909e-08
in O 0 1.4179502905165009e-08
TWIST O 0 6.631773430854082e-06
, O 0 3.8463834783897255e-08
FGFR2 O 0 1.529842302261386e-05
, O 0 2.2874857563692785e-08
and O 0 1.4207175524916238e-07
FGFR3 O 0 8.595531835453585e-05
. O 0 4.953655206918484e-06

Nine O 0 3.694191264003166e-06
novel O 0 1.0957304397152257e-07
and O 0 2.2068087801585534e-08
three O 0 7.619083142174077e-09
recurrent O 0 1.070578576900516e-07
TWIST O 0 6.615221650463354e-07
mutations O 0 2.3302723306528605e-08
were O 0 1.0132686689701131e-08
found O 0 3.21795545765724e-09
in O 0 1.1590026716135071e-08
12 O 0 5.859935185981158e-07
families O 0 1.0093533120425491e-07
. O 0 2.7564551601244602e-06

Seven O 0 1.4614375913879485e-06
families O 0 1.1323444404354177e-08
were O 0 6.979818056862541e-09
found O 0 2.8649598249330666e-09
to O 0 1.4768604117421091e-09
have O 0 4.1106025250314815e-09
the O 0 3.055167141496895e-08
FGFR3 O 0 1.629278813197743e-05
P250R O 0 6.539611945299839e-07
mutation O 0 8.982801169565846e-09
, O 0 1.3248999675141704e-09
and O 0 1.329925614079741e-09
one O 0 3.959925165553102e-10
individual O 0 2.899061268823999e-10
was O 0 3.791851277412661e-09
found O 0 5.001949410221584e-10
to O 0 4.6338885506536087e-10
have O 0 1.2890917222563303e-09
an O 0 3.883550370176181e-09
FGFR2 O 0 8.230482308135834e-06
VV269 O 0 6.227612630027579e-06
- O 0 1.7447612208343344e-06
270 O 0 3.398805006327166e-07
deletion O 0 1.6390499695262406e-06
. O 0 2.4684522941242903e-06

To O 0 1.5401373332224466e-07
date O 0 2.1414857656054664e-06
, O 0 1.9835582065752533e-08
our O 0 1.4803017478470792e-08
detection O 0 4.1484106816369604e-08
rate O 0 3.955247240838844e-09
for O 0 4.528073194176585e-10
TWIST O 0 2.5083454602281563e-07
or O 0 2.865529680207146e-08
FGFR O 0 1.622661898181832e-06
mutations O 0 1.2908540902856203e-08
is O 0 3.356798727871535e-10
68 O 0 8.511950255751799e-09
% O 0 1.0639699121739454e-09
in O 0 3.372883528030002e-09
our O 0 9.019372271268367e-08
Saethre B-Disease 1 0.9995854496955872
- I-Disease 1 0.9999847412109375
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 0.9999902248382568
patients O 0 1.3165498913281226e-08
, O 0 9.205433637582416e-10
including O 0 1.1593159765510563e-09
our O 0 3.098707068716067e-08
five O 0 6.131840368794883e-09
patients O 0 6.031086186020218e-10
elsewhere O 0 6.084214465573723e-09
reported O 0 1.0524496829589225e-08
with O 0 9.903155628876448e-09
TWIST O 0 1.8826303858077154e-05
mutations O 0 4.846964202442905e-06
. O 0 2.960226538561983e-06

More O 0 2.3434209239781012e-08
than O 0 4.30173274779122e-09
35 O 0 7.278518232567421e-09
different O 0 8.83489892355982e-10
TWIST O 0 1.0011451223590484e-07
mutations O 0 3.9221026426616845e-09
are O 0 1.4705521522717646e-10
now O 0 1.1438088670656654e-10
known O 0 2.3586782527118544e-10
in O 0 4.739880155035792e-10
the O 0 3.373173074194824e-09
literature O 0 9.800936595638632e-08
. O 0 3.2651030323904706e-07

The O 0 8.592885478719836e-07
most O 0 9.03165986443355e-09
common O 0 1.3456621594798435e-08
phenotypic O 0 3.59798320914706e-07
features O 0 2.08019486080957e-08
, O 0 9.598866146376395e-10
present O 0 9.511313958654455e-10
in O 0 3.0248389903952955e-10
more O 0 7.036486671108122e-11
than O 0 1.9186566224682622e-10
a O 0 5.712514350442177e-10
third O 0 6.327933732563906e-09
of O 0 4.2080823270396195e-09
our O 0 8.674239104777826e-09
patients O 0 6.750001113609017e-10
with O 0 8.875840618038922e-10
TWIST O 0 5.421057949206443e-07
mutations O 0 7.969244819605592e-08
, O 0 5.872565100872862e-09
are O 0 8.751197100309582e-09
coronal B-Disease 0 3.1584513635607436e-05
synostosis I-Disease 0 1.0074901183543261e-05
, O 0 4.855602142583848e-08
brachycephaly B-Disease 0 3.7647500903403852e-06
, O 0 4.228940042594331e-08
low B-Disease 0 0.00033878913382068276
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 0.023587381467223167
facial B-Disease 1 1.0
asymmetry I-Disease 1 0.9999979734420776
, O 0 2.8595484309335006e-06
ptosis B-Disease 1 0.9999738931655884
, O 0 8.205153108065133e-07
hypertelorism B-Disease 0 0.008773011155426502
, O 0 2.0980226622668852e-07
broad B-Disease 0 4.3180829379707575e-05
great I-Disease 0 0.0073549444787204266
toes I-Disease 0 0.0061751543544232845
, O 0 8.307577559207857e-08
and O 0 4.852079769079864e-07
clinodactyly B-Disease 0 0.00010068297706311569
. O 0 1.0428489986225031e-05

Significant O 0 2.3032565877656452e-05
intra O 0 0.0409715473651886
- O 0 3.692428799695335e-05
and O 0 7.521607869875879e-08
interfamilial O 0 1.4220572666090447e-05
phenotypic O 0 1.2501313904067501e-05
variability O 0 3.100339256434381e-07
is O 0 3.4353606070958165e-10
present O 0 3.6823719073986183e-10
for O 0 2.529802756168209e-10
either O 0 8.400804496488945e-09
TWIST O 0 1.121748596233374e-06
mutations O 0 1.2821350026115397e-07
or O 0 7.676866431438611e-08
FGFR O 0 2.0651486920542084e-05
mutations O 0 1.4492267155219452e-06
. O 0 2.747681264736457e-06

The O 0 9.203490662912372e-07
overlap O 0 1.6151618353887898e-07
in O 0 9.242048903956857e-09
clinical O 0 1.3714786462060147e-07
features O 0 7.416103287027909e-09
and O 0 2.5585504825897942e-09
the O 0 9.094404673781753e-10
presence O 0 4.739635905970374e-10
, O 0 1.8204149299094752e-10
in O 0 1.4717024821031544e-10
the O 0 3.4812630556046997e-10
same O 0 2.9191474237855175e-10
genes O 0 7.564128767789668e-10
, O 0 3.480672139399843e-10
of O 0 1.2444858477067555e-09
mutations O 0 3.3030880253193118e-09
for O 0 5.379261480698005e-10
more O 0 1.6640162858738705e-10
than O 0 5.417740145396976e-10
one O 0 2.0929651345369393e-09
craniosynostotic B-Disease 0 2.2465223992185201e-07
condition I-Disease 0 7.549808600515462e-08
- O 0 9.83591430525621e-09
such O 0 6.446967959483629e-10
as O 0 9.071593254361687e-09
Saethre B-Disease 0 6.468654646596406e-06
- I-Disease 0 3.266984265337669e-07
Chotzen I-Disease 0 3.3184553558385232e-06
, I-Disease 0 1.267222593526185e-08
Crouzon I-Disease 0 4.8736628741608e-06
, I-Disease 0 1.6227820864855858e-08
and I-Disease 0 5.914879963597741e-08
Pfeiffer I-Disease 0 0.000151861910126172
syndromes I-Disease 0 1.548864383948967e-05
- O 0 2.786666470910859e-07
support O 0 8.749945656916225e-09
the O 0 1.21405463460178e-08
hypothesis O 0 3.141519044902452e-08
that O 0 8.055259792527636e-10
TWIST O 0 2.263956417891677e-07
and O 0 1.3570002899143674e-08
FGFRs O 0 1.1228061111978604e-06
are O 0 7.784689559642288e-10
components O 0 1.011497996472599e-08
of O 0 2.7671334112966406e-09
the O 0 1.635611868167075e-09
same O 0 1.1215364192906918e-09
molecular O 0 3.670034587344162e-08
pathway O 0 5.009475056994006e-09
involved O 0 5.870434138799396e-10
in O 0 2.854409486552356e-10
the O 0 2.7738655816733626e-09
modulation O 0 1.2811233318643644e-06
of O 0 7.875241863075644e-07
craniofacial O 1 0.9999996423721313
and O 0 1.7714002751745284e-05
limb O 1 0.999721109867096
development O 0 3.014906042153598e-06
in O 0 1.1506853248022253e-08
humans O 0 3.308524654244138e-08
. O 0 2.7674515123976562e-08
. O 0 6.33666218163853e-07

Mutation O 0 1.787215524018393e-06
analysis O 0 3.297380999356392e-07
of O 0 7.290337862286833e-07
UBE3A O 1 0.9993528723716736
in O 0 0.09498684853315353
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.00019022406195290387
. O 0 3.217563789803535e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.011166468262672424
AS B-Disease 1 1.0
) O 0 5.4900521462286633e-08
is O 0 2.549256361561447e-09
caused O 0 3.4111273805592646e-08
by O 0 2.380260966106107e-08
chromosome O 0 6.329988195830083e-07
15q11 O 0 3.071755145356292e-06
- O 0 6.361972850754682e-07
q13 O 0 8.134742301990627e-07
deletions O 0 9.87626123105656e-08
of O 0 1.0187470422806655e-08
maternal O 0 2.294311052253306e-08
origin O 0 1.2597975107553339e-08
, O 0 5.592482477112526e-09
by O 0 1.2174679042686876e-08
paternal O 0 4.508124675339786e-06
uniparental B-Disease 1 0.9965699911117554
disomy I-Disease 1 0.9998817443847656
( O 0 2.618444705149159e-05
UPD B-Disease 1 1.0
) O 0 9.390637956130377e-08
15 O 0 1.99952424395633e-07
, O 0 7.844343841156842e-09
by O 0 1.8170554838548014e-08
imprinting O 0 9.58524615271017e-05
defects O 0 0.00014264658966567367
, O 0 6.513505290683952e-09
and O 0 7.998464113256887e-09
by O 0 2.2523556353348795e-09
mutations O 0 2.1742245337463828e-08
in O 0 2.3492658485224638e-08
the O 0 4.07664089152604e-07
UBE3A O 0 0.0001602710981387645
gene O 0 2.2130402612674516e-06
. O 0 8.985578460851684e-06

UBE3A O 0 0.005726351868361235
encodes O 0 2.121784200426191e-05
a O 0 2.1425112208817154e-06
ubiquitin O 0 1.5861658539506607e-05
- O 0 1.5469939171453007e-05
protein O 0 3.78254298993852e-07
ligase O 0 3.3223108175661764e-07
and O 0 8.749666591256755e-08
shows O 0 2.774397103166848e-07
brain O 0 0.00016278185648843646
- O 0 1.1405844588807668e-06
specific O 0 1.0467345390452465e-07
imprinting O 0 1.0738302080426365e-05
. O 0 2.637158104334958e-06

Here O 0 4.933195668854751e-06
we O 0 5.583068514170009e-07
describe O 0 1.8633185163707822e-06
UBE3A O 0 0.0002446383296046406
coding O 0 2.4608165404060856e-05
- O 0 1.7641984868532745e-06
region O 0 2.7103496336167154e-08
mutations O 0 3.688083083375204e-08
detected O 0 9.024720526440433e-09
by O 0 2.570549328950733e-09
SSCP O 0 9.145499575424765e-07
analysis O 0 5.312144057967316e-09
in O 0 1.1263597832211758e-09
13 O 0 1.9893363401024544e-08
AS B-Disease 0 0.16393277049064636
individuals O 0 4.6201387160493823e-10
or O 0 3.325713260338148e-09
families O 0 3.948019244859324e-09
. O 0 1.7161330845283373e-07

Two O 0 5.898904191781185e-07
identical O 0 1.5626970935045392e-06
de O 0 3.130897312075831e-05
novo O 0 7.605287009937456e-06
5 O 0 5.354460881790146e-06
- O 0 1.000636984826997e-06
bp O 0 2.9709946147704613e-07
duplications O 0 6.289083103183657e-07
in O 0 1.8937139856234353e-08
exon O 0 2.0495122043939773e-07
16 O 0 4.7612690678988656e-08
were O 0 3.548466054326127e-08
found O 0 1.1077778339085853e-07
. O 0 2.2033868845028337e-06

Among O 0 1.3256038755571353e-07
the O 0 1.0835656816254868e-08
other O 0 1.0740014433352485e-09
11 O 0 5.3336166594419865e-09
unique O 0 6.330682644772878e-10
mutations O 0 1.6478365338912226e-09
, O 0 7.132672785736816e-10
8 O 0 2.4150068611561437e-08
were O 0 1.2359235412873204e-08
small O 0 6.420698195341856e-09
deletions O 0 1.6746021458402538e-07
or O 0 2.56588741365249e-08
insertions O 0 1.362319750342067e-07
predicted O 0 8.518417615732687e-08
to O 0 4.659566954501315e-09
cause O 0 1.3335248638668418e-07
frameshifts O 0 5.323798177414574e-06
, O 0 6.067248925489821e-09
1 O 0 1.3470761928147112e-07
was O 0 2.2296470447713546e-08
a O 0 7.539167068415509e-10
mutation O 0 5.808097891524255e-10
to O 0 2.590729020202076e-10
a O 0 1.1095234730973402e-09
stop O 0 6.1442966270419674e-09
codon O 0 3.0866324607359275e-08
, O 0 2.0168431369427253e-09
1 O 0 2.1748714829072924e-08
was O 0 9.924675303807362e-09
a O 0 2.6728310675849798e-09
missense O 0 1.0590327548243295e-07
mutation O 0 5.257851487527887e-09
, O 0 7.368034515842226e-10
and O 0 1.601561216979519e-09
1 O 0 6.760352988521845e-08
was O 0 4.0149767954744675e-08
predicted O 0 6.611337255435501e-08
to O 0 3.986580399129025e-09
cause O 0 2.201230309140101e-08
insertion O 0 5.3019935108977734e-08
of O 0 1.0504966496682755e-07
an O 0 1.149785777698753e-08
isoleucine O 0 1.1508519719427568e-06
in O 0 9.467897577053463e-09
the O 0 3.3809943289497824e-08
hect O 0 5.673894065694185e-07
domain O 0 3.2328696164540816e-08
of O 0 1.599904209115266e-08
the O 0 1.61190509828657e-08
UBE3A O 0 1.1078196848757216e-06
protein O 0 5.257721369389401e-09
, O 0 3.932572600895412e-10
which O 0 1.6163119453960206e-10
functions O 0 2.8452462608186124e-09
in O 0 2.0940993383788964e-09
E2 O 0 4.87930435610906e-07
binding O 0 1.454073270679146e-07
and O 0 5.12905664606933e-08
ubiquitin O 0 1.2103826065867906e-06
transfer O 0 2.1095943338877987e-06
. O 0 2.2103740775492042e-06

Eight O 0 1.3340352325030835e-06
of O 0 6.308967215318262e-08
the O 0 6.756922132922227e-09
cases O 0 2.014509670189568e-09
were O 0 4.805799758145213e-09
familial O 0 2.3960213368923178e-08
, O 0 4.659415520080756e-09
and O 0 9.64114654777859e-09
five O 0 2.432880563674189e-08
were O 0 8.410331986397068e-08
sporadic O 0 3.457923867244972e-06
. O 0 8.583862836530898e-06

In O 0 3.579054350666411e-07
two O 0 3.178222840460876e-08
familial O 0 2.469789137649059e-07
cases O 0 1.7953311726159882e-08
and O 0 2.84352119628295e-09
one O 0 1.2288710049546125e-09
sporadic O 0 6.740344815625576e-08
case O 0 1.3294068423874705e-07
, O 0 1.4168742623610342e-08
mosaicism O 0 2.458352810208453e-06
for O 0 3.5803921605293e-08
UBE3A O 0 1.5715650079073384e-05
mutations O 0 7.293920134543441e-08
was O 0 2.7114044343079513e-08
detected O 0 5.1133275391634925e-09
in O 0 7.82506226482127e-10
the O 0 2.539124022149508e-09
mother O 0 3.378169299850242e-09
of O 0 1.6000598179743974e-08
three O 0 2.0695333446951736e-08
AS B-Disease 1 0.9999996423721313
sons O 0 2.004986527026631e-06
, O 0 1.9718524590928155e-09
in O 0 8.094611647635475e-10
the O 0 2.623895101194762e-09
maternal O 0 2.326550507802949e-08
grandfather O 0 3.072259602276972e-08
of O 0 7.605235197161164e-08
two O 0 2.3507537250111454e-08
AS B-Disease 1 1.0
first O 0 1.9470977008495538e-07
cousins O 0 6.169264565869526e-08
, O 0 1.2506632396380724e-09
and O 0 1.8365176046586384e-09
in O 0 2.6569928479602822e-09
the O 0 1.769696744702287e-08
mother O 0 6.105302041703453e-09
of O 0 2.192711257009705e-08
an O 0 9.928347921572822e-09
AS B-Disease 1 1.0
daughter O 0 0.00011793247540481389
. O 0 5.695085201296024e-05

The O 0 2.761494215519633e-07
frequencies O 0 1.6196642604882072e-07
with O 0 4.0441860971185406e-10
which O 0 2.5277768767040243e-10
we O 0 5.358126164978216e-10
detected O 0 6.366039917438115e-10
mutations O 0 7.869094820200928e-10
were O 0 1.8959755987424387e-09
5 O 0 9.854768556749605e-09
( O 0 7.45106309985033e-10
14 O 0 3.4294442841087402e-09
% O 0 2.322185915781816e-10
) O 0 1.1455489334899482e-10
of O 0 5.719971718498584e-10
35 O 0 4.244064655267721e-09
in O 0 3.2472219357870813e-10
sporadic O 0 1.2660944292974818e-08
cases O 0 8.65470084487896e-10
and O 0 1.4564590644638997e-09
8 O 0 3.423452810125127e-08
( O 0 4.834112554696901e-10
80 O 0 8.392744832441679e-10
% O 0 1.8145945857028778e-10
) O 0 1.4932854952576236e-10
of O 0 1.5899921379514126e-09
10 O 0 4.696712352370014e-09
in O 0 1.514778302791342e-09
familial O 0 6.91167443278573e-08
cases O 0 1.2152129080789109e-08
. O 0 4.150500032551463e-08
. O 0 1.0472792837390443e-06

The O 0 0.0004193611675873399
hemochromatosis B-Disease 1 1.0
845 O 0 0.00010606140131130815
G O 0 2.7590785975917242e-05
- O 0 1.0345242117182352e-05
- O 0 1.0636659908414003e-06
> O 0 2.269176349045665e-07
A O 0 2.0874644235391315e-08
and O 0 2.8927329420724845e-09
187 O 0 7.186233386136109e-09
C O 0 2.6094508598362154e-07
- O 0 8.932505579650751e-08
- O 0 8.08085829362426e-08
> O 0 1.9203505985387892e-07
G O 0 1.7176067501623038e-07
mutations O 0 3.342701049291463e-08
: O 0 1.6212405862248147e-09
prevalence O 0 4.0941728229881846e-08
in O 0 1.9242356597004573e-09
non O 0 1.351248926084736e-07
- O 0 8.806776463643473e-08
Caucasian O 0 5.986166229376977e-08
populations O 0 5.0870266221636484e-08
. O 0 7.612396188960702e-07

Hemochromatosis B-Disease 1 0.9999814033508301
, O 0 8.821274377623922e-07
the O 0 1.1079253454227e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 4.952730705554131e-07
leads O 0 1.8450543848302914e-07
, O 0 3.225365974302008e-09
if O 0 8.521533700900363e-09
untreated O 0 3.1087229217519052e-06
, O 0 3.399655224001208e-09
to O 0 1.6624918330876426e-08
progressive O 1 0.9999544620513916
iron B-Disease 1 0.9999997615814209
overload I-Disease 1 0.9976420402526855
and O 0 3.040297087864019e-06
premature B-Disease 0 1.826091465773061e-05
death I-Disease 0 1.98129109776346e-05
. O 0 4.033531695313286e-06

The O 0 0.00011993823136435822
hemochromatosis B-Disease 1 1.0
gene O 0 3.1791616947884904e-06
, O 0 1.229260107038499e-07
HFE O 0 0.0011788314441218972
, O 0 3.366926648595836e-08
recently O 0 1.9912913984398983e-08
has O 0 6.26618423815728e-10
been O 0 1.7892179959844157e-09
identified O 0 6.0135834090147e-09
, O 0 5.981664052967517e-10
and O 0 1.3673793208823781e-09
characterization O 0 2.2843336111577628e-08
of O 0 1.0213658363511513e-08
this O 0 8.480216528994333e-10
gene O 0 2.250689412619522e-09
has O 0 2.839530832687842e-10
shown O 0 2.1033771946399327e-10
that O 0 5.1773280107525466e-11
it O 0 4.2090577551112673e-11
contains O 0 1.168145163932266e-10
two O 0 1.0044795550889773e-10
mutations O 0 2.766388229602512e-10
that O 0 6.27934162999999e-11
result O 0 2.6180859702407133e-09
in O 0 8.091852521374676e-09
amino O 0 2.713442803781163e-08
acid O 0 7.17749415457547e-09
substitutions O 0 2.956254263608571e-08
- O 0 4.69250664991705e-08
cDNA O 0 4.4446995417501967e-08
nucleotides O 0 3.563115669180661e-08
845 O 0 1.4959360328248295e-07
G O 0 2.6927435214929574e-07
- O 0 2.0082596563497646e-07
- O 0 1.0286860430142042e-07
> O 0 8.538556528492336e-08
A O 0 2.797617959515719e-08
( O 0 1.886035105869155e-09
C282Y O 0 5.7526477803548914e-08
) O 0 5.203635300432552e-10
and O 0 2.1057424692827453e-09
187 O 0 1.0708927078439956e-08
C O 0 3.8898980392332305e-07
- O 0 1.2775177538060234e-07
- O 0 1.3125087150456238e-07
> O 0 2.2628684348546813e-07
G O 0 6.221815169737965e-07
( O 0 1.603591570642493e-08
H63D O 0 6.857638254587073e-06
) O 0 2.086751926810848e-08
. O 0 2.0352059948436363e-07

Although O 0 7.543551328126341e-05
hemochromatosis B-Disease 1 1.0
is O 0 4.007792497873197e-08
common O 0 2.68661217717181e-08
in O 0 5.84040504847394e-09
Caucasians O 0 2.5784129320527427e-07
, O 0 1.0603906197559354e-08
affecting O 0 6.063039847958862e-08
> O 0 1.931667128474146e-07
= O 0 2.2461966864284477e-07
1 O 0 1.7500842375284265e-07
/ O 0 6.188935230966308e-08
300 O 0 2.1447899012372318e-09
individuals O 0 8.695831554828004e-11
of O 0 6.311103306622101e-10
northern O 0 2.1749784195890243e-09
European O 0 1.7317047351639303e-08
origin O 0 4.7299302252667985e-09
, O 0 1.933859739011723e-10
it O 0 1.7097000898358417e-11
has O 0 7.524232972788703e-12
not O 0 2.3572336790844695e-11
been O 0 6.884796899253587e-11
recognized O 0 1.4879404652834438e-10
in O 0 2.6999658064852383e-10
other O 0 4.4955872358087845e-10
populations O 0 9.107289145049435e-09
. O 0 3.814930096268654e-07

The O 0 2.8412273422873113e-07
present O 0 1.954740191933979e-08
study O 0 2.2720394454722737e-09
used O 0 8.159420916697968e-10
PCR O 0 2.1270938788120475e-08
and O 0 4.866113734180999e-09
restriction O 0 2.145265831643428e-08
- O 0 1.975410590659976e-08
enzyme O 0 2.64097632651783e-09
digestion O 0 2.5105859613461234e-09
to O 0 4.2746250983327627e-10
analyze O 0 5.288447013640507e-09
the O 0 1.504447233457995e-09
frequency O 0 3.184047869808637e-08
of O 0 6.193361379303042e-09
the O 0 1.5215984916494563e-08
845 O 0 1.0339420697391688e-07
G O 0 2.7500303190208797e-07
- O 0 2.4203657744692464e-07
- O 0 9.485741969683659e-08
> O 0 3.9617347624698596e-08
A O 0 1.0996535237950411e-08
and O 0 2.745662364134205e-09
187 O 0 8.158740349983873e-09
C O 0 1.0100061587081655e-07
- O 0 2.3478859745296177e-08
- O 0 3.168031170730501e-08
> O 0 1.246777401320287e-07
G O 0 1.8846881744138955e-07
mutations O 0 5.506286271383942e-08
in O 0 3.262341508047939e-08
HLA O 0 1.1917550182261039e-06
- O 0 8.104552762233652e-08
typed O 0 8.900290282554124e-09
samples O 0 4.4138509514013435e-10
from O 0 2.546280963855452e-10
non O 0 2.1903913349774484e-08
- O 0 9.907255460461784e-09
Caucasian O 0 6.846252453840407e-09
populations O 0 8.112850391484017e-10
, O 0 4.658116115052735e-10
comprising O 0 1.60106938817961e-09
Australian O 0 4.7445791295785966e-08
Aboriginal O 0 4.725595204035926e-08
, O 0 1.390996096084507e-09
Chinese O 0 5.087179122398311e-09
, O 0 5.127664959303502e-09
and O 0 4.8239858330134666e-08
Pacific O 0 2.2981184883974493e-06
Islanders O 0 2.3685081032454036e-05
. O 0 3.900090177921811e-06

Results O 0 1.9697858078870922e-05
showed O 0 4.1234284253732767e-07
that O 0 1.445293662527547e-08
the O 0 4.87346305533265e-08
845 O 0 4.1449004584137583e-07
G O 0 1.6927473325267783e-06
- O 0 5.686451459041564e-06
- O 0 1.926291361087351e-06
> O 0 1.141051839681495e-07
A O 0 8.536060747132979e-09
mutation O 0 1.902340063253405e-09
was O 0 9.82162462470626e-10
present O 0 1.7913719119189153e-10
in O 0 5.378601730665622e-11
these O 0 1.0603854599944285e-10
populations O 0 9.892687363732833e-11
( O 0 7.235077120748556e-11
allele O 0 2.9443008031648787e-09
frequency O 0 3.711941420903031e-09
0 O 0 9.94344717675233e-10
. O 0 1.0893668606071216e-10
32 O 0 8.119507288739669e-10
% O 0 6.920687634082157e-11
) O 0 8.040688947996699e-11
, O 0 8.82219713949084e-11
and O 0 2.2912038932787482e-10
, O 0 1.0628822127989324e-10
furthermore O 0 2.372444463105694e-10
, O 0 8.440934062825534e-11
it O 0 5.551105061729622e-11
was O 0 7.44041539491036e-09
always O 0 2.767798656932996e-09
seen O 0 4.1671084360928035e-09
in O 0 6.361997595405455e-10
conjunction O 0 4.81110973282739e-09
with O 0 6.44118181014619e-09
HLA O 0 3.0073824746068567e-06
haplotypes O 0 9.408046253156499e-08
common O 0 1.4543556581259054e-08
in O 0 6.633085192220278e-09
Caucasians O 0 1.322315910101679e-07
, O 0 2.736121551549786e-09
suggesting O 0 1.2902018120541925e-08
that O 0 2.410302846200807e-09
845 O 0 1.5566446620596253e-07
G O 0 1.199198550239089e-06
- O 0 7.436306987074204e-06
- O 0 3.7231366150081158e-06
> O 0 1.2677912764047505e-07
A O 0 6.457050449881763e-09
may O 0 2.533855347763847e-09
have O 0 2.364592965875545e-10
been O 0 2.1981905184986772e-10
introduced O 0 4.220016280864769e-10
into O 0 4.34468884480399e-11
these O 0 2.0705295117329214e-11
populations O 0 3.547844656948129e-11
by O 0 2.9778979282468754e-10
Caucasian O 0 9.21870721981577e-08
admixture O 0 4.170580268691992e-06
. O 0 3.1702120395493694e-06

187 O 0 3.656951321318047e-06
C O 0 7.3192663876398e-06
- O 0 9.900030590870301e-07
- O 0 2.363874500588281e-07
> O 0 1.8520391620313603e-07
G O 0 1.196542172010595e-07
was O 0 1.5247097806536658e-08
present O 0 1.6327038609986744e-09
at O 0 3.7077314551936524e-09
an O 0 6.238882327425088e-11
allele O 0 4.837333644758246e-09
frequency O 0 2.6505507122465133e-08
of O 0 1.8198370810296183e-08
2 O 0 5.590330260929477e-07
. O 0 1.0711327149692806e-06

68 O 0 2.4388637029915117e-06
% O 0 1.644938940614793e-08
in O 0 3.8027230253590005e-09
the O 0 3.6519334223328315e-09
two O 0 1.2081864397828213e-09
populations O 0 7.697518733529307e-10
analyzed O 0 9.189947469678827e-09
( O 0 2.9690292446815647e-09
Australian O 0 1.4037077278317156e-07
Aboriginal O 0 1.0903454494837206e-07
and O 0 6.202617530703947e-09
Chinese O 0 2.2994454340619086e-08
) O 0 2.4120286212792053e-08
. O 0 4.88017008137831e-07

In O 0 3.6529391422845947e-07
the O 0 1.2224339229760517e-07
Australian O 0 7.970078854668827e-07
Aboriginal O 0 9.008849843894495e-08
samples O 0 2.927077025205449e-09
, O 0 1.793215465006881e-09
187 O 0 9.858302618681591e-09
C O 0 3.2154451901078573e-07
- O 0 1.7552508779772324e-07
- O 0 1.971748559981279e-07
> O 0 1.5425538890667667e-07
G O 0 1.028175944384202e-07
was O 0 9.283407820248613e-09
found O 0 4.055696056770586e-10
to O 0 1.2356252132583734e-10
be O 0 6.301000277098012e-10
associated O 0 7.760395881462046e-09
with O 0 4.828484279073564e-09
HLA O 0 9.068065992323682e-06
haplotypes O 0 1.8108661947735527e-07
common O 0 1.0892266644191295e-08
in O 0 2.1284238815866274e-09
Caucasians O 0 1.1376823039199735e-07
, O 0 9.826759406195151e-10
suggesting O 0 2.1603010491588748e-09
that O 0 6.731625673550568e-11
it O 0 9.343530116279197e-11
was O 0 2.2143085143255803e-09
introduced O 0 4.5455030850405365e-09
by O 0 2.2124213572283224e-09
recent O 0 4.033605449649258e-08
admixture O 0 4.479381459532306e-06
. O 0 2.229882511528558e-06

In O 0 2.3277740979210648e-07
the O 0 3.873136478205197e-08
Chinese O 0 8.61807070151599e-09
samples O 0 4.127257646757698e-09
analyzed O 0 1.577781993944427e-08
, O 0 1.475537025896756e-09
187 O 0 6.545336717067585e-09
C O 0 1.5294274646748818e-07
- O 0 4.899410654957137e-08
- O 0 3.053064290270413e-08
> O 0 3.846698959364403e-08
G O 0 3.839303275299244e-08
was O 0 6.308338740268482e-09
present O 0 1.2379753888680511e-09
in O 0 1.2878899058321736e-09
association O 0 9.652659782588557e-10
with O 0 2.8607646807010667e-10
a O 0 9.202169026778506e-10
wide O 0 8.838476617256674e-09
variety O 0 8.078774982323011e-09
of O 0 3.317681063208511e-08
HLA O 0 3.2017076136980904e-06
haplotypes O 0 4.777069406713963e-08
, O 0 4.1253431226628834e-10
showing O 0 9.013809143532114e-10
this O 0 1.2382959935219873e-10
mutation O 0 2.3624152634127427e-10
to O 0 1.715708408678296e-10
be O 0 3.755315225451028e-10
widespread O 0 3.288704641946083e-09
and O 0 2.1807855521416286e-09
likely O 0 9.645909848643441e-09
to O 0 3.295511197265455e-09
predate O 0 1.6693719828708709e-07
the O 0 9.388664068410435e-09
more O 0 1.3943112220360376e-09
genetically O 0 1.4997866060184606e-08
restricted O 0 1.32893234194853e-08
845 O 0 2.367922178336812e-07
G O 0 6.024641834301292e-07
- O 0 1.3044254956184886e-06
- O 0 3.091992084591766e-07
> O 0 1.6271420122393465e-07
A O 0 4.2493969232282325e-08
mutation O 0 1.799579649741645e-07
. O 0 3.837359656699846e-07

Genotype O 0 0.00013654003851115704
- O 0 9.020909601531457e-06
phenotype O 0 1.4905187981639756e-06
correlations O 0 2.879078238038346e-06
in O 0 3.905286973804323e-07
attenuated B-Disease 1 0.9998942613601685
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 1.0
. O 0 0.0015725819393992424

Germ O 1 0.959983229637146
- O 0 0.03187425062060356
line O 0 4.733741207019193e-06
mutations O 0 3.511021589019947e-07
of O 0 1.8421148695324518e-07
the O 0 7.375732735681595e-08
tumor B-Disease 0 1.5497303138545249e-06
suppressor O 0 6.811868843215052e-06
APC O 0 1.1002662176906597e-06
are O 0 1.5508696549204615e-08
implicated O 0 8.453125133200956e-07
in O 0 5.310196797836397e-07
attenuated B-Disease 1 0.9999992847442627
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.9987723231315613
AAPC B-Disease 1 1.0
) O 0 4.735773373454322e-08
, O 0 2.4600506076666306e-09
a O 0 2.4288362432400845e-09
variant O 0 6.8785916482738685e-06
of O 0 0.008134408853948116
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 4.4119253288954496e-05
FAP B-Disease 0 4.63655887870118e-05
) O 0 5.961686042610381e-07
. O 0 6.316182862065034e-06

AAPC B-Disease 1 0.9999998807907104
is O 0 5.765873112295594e-08
recognized O 0 1.1783236608664538e-08
by O 0 1.870369414902484e-09
the O 0 3.0911260218147163e-09
occurrence O 0 3.2643210801097666e-08
of O 0 4.151252497308633e-08
< O 0 2.272518713652971e-06
100 O 0 2.266470886524985e-07
colonic B-Disease 0 1.857394636317622e-05
adenomas I-Disease 0 6.279784884100081e-06
and O 0 8.308841614734774e-09
a O 0 7.2153509833583485e-09
later O 0 2.34941410326428e-07
onset O 1 0.9997387528419495
of O 1 0.9999997615814209
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 4.26952091459043e-08
age O 0 1.3787727937142336e-07
> O 0 1.237930433717338e-07
40 O 0 1.0859635857229932e-08
years O 0 4.9135016055856795e-09
) O 0 8.623743497082614e-09
. O 0 2.038442090679382e-07

The O 0 9.962808462660178e-07
aim O 0 1.3678190953214653e-06
of O 0 6.972928190407401e-08
this O 0 2.5000921333173665e-09
study O 0 3.3846641045442993e-09
was O 0 1.2064876209194608e-08
to O 0 1.4338868981056407e-09
assess O 0 2.2007691313774558e-07
genotype O 0 1.974011183847324e-06
- O 0 2.5384556465724017e-06
phenotype O 0 1.2442003480828134e-06
correlations O 0 2.078578518194263e-06
in O 0 4.252376868407737e-07
AAPC B-Disease 1 0.9999995231628418
families O 0 3.1956659540810506e-07
. O 0 1.7676104562269757e-06

By O 0 9.61556452239165e-07
protein O 0 8.288551498480956e-07
- O 0 8.598549356975127e-07
truncation O 0 4.594540769176092e-06
test O 0 1.6104164615171612e-06
( O 0 5.2624493207531486e-08
PTT O 0 1.3242989780337666e-06
) O 0 2.056959047536111e-09
assay O 0 2.7629106114090973e-08
, O 0 1.2268873694765148e-09
the O 0 3.273347592980258e-09
entire O 0 4.344289550317626e-08
coding O 0 1.441943311419891e-07
region O 0 2.821964706356539e-08
of O 0 3.3782097119683385e-08
the O 0 5.07218338441362e-08
APC B-Disease 0 1.2956782313722215e-07
gene O 0 6.4628413731782075e-09
was O 0 1.2581478081585828e-08
screened O 0 6.072481628649484e-09
in O 0 1.4899120825973e-09
affected O 0 4.137457043640325e-09
individuals O 0 9.6720842446274e-10
from O 0 1.581638819914133e-08
11 O 0 1.8654895029612817e-05
AAPC B-Disease 1 1.0
kindreds O 0 4.044129673275165e-05
, O 0 1.140912075925371e-08
and O 0 5.222659194004109e-09
their O 0 7.479288299805376e-09
phenotypic O 0 2.078578518194263e-06
differences O 0 1.4137948483039509e-06
were O 0 9.290210414292233e-07
examined O 0 8.320981578435749e-06
. O 0 3.3909000194398686e-06

Five O 0 8.251480721810367e-06
novel O 0 2.101339987348183e-06
germ O 0 9.597035386832431e-05
- O 0 1.697760308161378e-05
line O 0 9.506214269094926e-07
APC B-Disease 0 4.837396545553929e-07
mutations O 0 8.681261220999659e-08
were O 0 2.1986162224152395e-08
identified O 0 4.359246830176744e-08
in O 0 2.3427954687349484e-08
seven O 0 6.995880994509207e-07
kindreds O 0 7.368002843577415e-05
. O 0 1.8185819499194622e-05

Mutations O 0 2.324210527149262e-06
were O 0 2.6772110572892416e-07
located O 0 2.0152906898829315e-08
in O 0 1.97360194853502e-09
three O 0 1.2125266346529884e-09
different O 0 1.2402868732053207e-09
regions O 0 5.04222086306072e-09
of O 0 1.9123307382074017e-08
the O 0 3.433608597447346e-08
APC B-Disease 0 2.7962789417301792e-08
gene O 0 2.4449273716697917e-09
( O 0 7.185694816946864e-10
1 O 0 1.5029078426209708e-08
) O 0 8.004412688222828e-10
at O 0 8.52044568233623e-09
the O 0 1.5113296170099488e-09
5 O 0 1.0398847116732668e-08
end O 0 1.6637956790077624e-08
spanning O 0 2.985072100614161e-08
exons O 0 2.1078209400116066e-08
4 O 0 5.8890874399253335e-09
and O 0 4.738532899395409e-10
5 O 0 5.556926474525881e-09
, O 0 7.261556356219501e-10
( O 0 2.750372984916538e-10
2 O 0 9.43224520710828e-09
) O 0 5.219937815326148e-10
within O 0 4.514079776640756e-09
exon O 0 1.5196523150962093e-08
9 O 0 2.3821050021410883e-08
, O 0 1.0291305585496957e-09
and O 0 2.222093176129647e-09
( O 0 1.1216990669637994e-09
3 O 0 2.5745398701815247e-08
) O 0 1.9633781267458517e-09
at O 0 2.1501568525650328e-08
the O 0 4.124857344578459e-09
3 O 0 5.994827034783157e-08
distal O 0 3.2879540867725154e-07
end O 0 9.294272018678384e-08
of O 0 3.87024172709971e-08
the O 0 4.2826112434113384e-08
gene O 0 2.760806978585606e-07
. O 0 1.3933315585745731e-06

Variability O 0 1.1404416000004858e-05
in O 0 2.6593973245780944e-08
the O 0 2.3840502905159155e-08
number O 0 7.973989113452262e-08
of O 0 0.46823447942733765
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 1.173718374047894e-06
most O 0 4.36126329494968e-10
apparent O 0 3.3404432553396646e-09
in O 0 7.483536568209104e-10
individuals O 0 2.056067677225215e-10
with O 0 2.801042731093162e-10
mutations O 0 6.388630957587793e-09
in O 0 3.6182099538706325e-09
region O 0 2.9422251301980396e-08
1 O 0 7.424147497658851e-06
, O 0 3.325765618455989e-08
and O 0 5.79425034175074e-07
upper O 1 0.9999152421951294
- O 0 0.1288476586341858
gastrointestinal O 0 2.042179949057754e-05
manifestations O 0 2.0918960217386484e-05
were O 0 1.747785027816917e-08
more O 0 5.180393336523537e-10
severe O 0 6.206158076338397e-08
in O 0 9.73702185547154e-09
them O 0 4.660893537788979e-08
. O 0 1.0286324823027826e-06

In O 0 2.0418295321178448e-07
individuals O 0 1.003660976550691e-08
with O 0 1.953300632351329e-09
mutations O 0 7.702045223823006e-09
in O 0 2.6075110959311587e-09
either O 0 1.0172791498064271e-08
region O 0 1.4334474940369546e-08
2 O 0 2.5931620939445565e-07
or O 0 7.497799714428766e-09
region O 0 8.747409019349561e-09
3 O 0 5.065734853815229e-08
, O 0 7.868239948471967e-10
the O 0 1.5741951076009286e-09
average O 0 2.087622741342443e-09
number O 0 1.5301045985793849e-09
of O 0 1.8655105904485936e-08
adenomas B-Disease 0 2.460341647747555e-06
tended O 0 2.4566711331885926e-08
to O 0 1.6434233973683376e-09
be O 0 3.086601418900159e-09
lower O 0 7.60986029746391e-09
than O 0 1.3309400803684923e-10
those O 0 3.637907683429198e-11
in O 0 2.555592196196166e-11
individuals O 0 9.742153264657993e-12
with O 0 2.368225060500606e-11
mutations O 0 7.16597226002591e-10
in O 0 2.0087492780263005e-10
region O 0 1.2259773196632295e-09
1 O 0 1.4485777910522302e-08
, O 0 2.3531290804790217e-10
although O 0 6.960749754369999e-10
age O 0 1.4129880376856363e-08
at O 0 8.006340479482787e-09
diagnosis O 0 2.7796559720627556e-08
was O 0 7.83253195635325e-09
similar O 0 1.2941328009219433e-08
. O 0 5.709218839911046e-07

In O 0 3.38716358783131e-06
all O 0 4.473311037145322e-06
AAPC B-Disease 1 1.0
kindreds O 0 0.00014200144505593926
, O 0 3.67445416316059e-08
a O 0 2.0742479733826258e-08
predominance O 0 7.865049269639712e-07
of O 0 7.0394894464698154e-06
right O 1 0.9999936819076538
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9999871253967285
rectal B-Disease 1 1.0
polyp I-Disease 1 0.6049588322639465
sparing O 0 1.6177683619389427e-06
was O 0 4.561459832075343e-07
observed O 0 7.939793817968166e-07
. O 0 1.7788290733733447e-06

No O 0 5.595526454271749e-05
desmoid B-Disease 0 0.10103364288806915
tumors I-Disease 1 1.0
were O 0 3.4293813655494887e-07
found O 0 2.1727238674884575e-08
in O 0 1.166084917514354e-08
these O 0 4.4110443297995516e-08
kindreds O 0 4.3221407395321876e-05
. O 0 4.4250095925235655e-06

Our O 0 3.982345333497506e-06
data O 0 1.898464745409001e-07
suggest O 0 3.4842756235775596e-08
that O 0 2.490174288993785e-09
, O 0 8.405757867535613e-09
in O 0 5.355076382329571e-08
AAPC B-Disease 1 1.0
families O 0 5.945473002810786e-09
, O 0 1.443783093080242e-09
the O 0 1.4908899670373899e-09
location O 0 1.1362343066423364e-08
of O 0 3.0797814076777286e-08
the O 0 7.92273198158e-08
APC B-Disease 0 7.797661396580224e-07
mutation O 0 7.681084923660819e-08
may O 0 6.579384859151105e-08
partially O 0 2.3152276185101073e-07
predict O 0 5.613635067902578e-08
specific O 0 3.729137887376055e-08
phenotypic O 0 1.4395361176866572e-05
expression O 0 2.942014361906331e-06
. O 0 5.196135134610813e-06

This O 0 4.4889766570577194e-08
should O 0 1.6800816737827517e-08
help O 0 5.619663401290609e-09
in O 0 1.4135157488937011e-09
the O 0 2.51284726360268e-09
design O 0 1.0157496888041351e-07
of O 0 4.824666532954325e-08
tailored O 0 2.670244612090755e-07
clinical O 0 1.8651888922249782e-06
- O 0 4.237038808696525e-07
management O 0 4.3820133299732333e-08
protocols O 0 9.059648675702192e-08
in O 0 6.245648442870788e-10
this O 0 3.003120530031822e-10
subset O 0 8.65873417410512e-09
of O 0 5.681613401975483e-09
FAP B-Disease 0 1.0262949956540979e-07
patients O 0 3.8479885944298076e-09
. O 0 3.271301807217242e-08
. O 0 8.411661269747128e-07

Wilms B-Disease 1 0.9967765212059021
' I-Disease 0 1.5421348507516086e-05
tumor I-Disease 0 1.941706614161376e-06
1 O 0 3.0645221613667673e-06
and O 0 2.74712874670513e-07
Dax O 0 0.0003026500344276428
- O 0 7.251500164784375e-07
1 O 0 2.569818491338083e-07
modulate O 0 1.0428546204366285e-07
the O 0 1.4228322520182246e-08
orphan O 0 2.233976381660341e-08
nuclear O 0 2.2258235787830927e-07
receptor O 0 3.929319234430295e-07
SF O 0 2.811059675877914e-05
- O 0 8.603949908092545e-08
1 O 0 2.1787993631505742e-08
in O 0 1.114784153877224e-09
sex O 0 6.8912942019494494e-09
- O 0 1.8753205655031024e-09
specific O 0 8.791193883972426e-10
gene O 0 6.153103804251714e-09
expression O 0 8.384689209606222e-08
. O 0 8.251026883954182e-07

Products O 0 3.843366357614286e-06
of O 0 2.006132035603514e-06
steroidogenic O 0 1.643775794946123e-05
factor O 0 2.814877575474384e-07
1 O 0 9.476099762650847e-07
( O 0 2.3492791711987593e-08
SF O 0 1.4274934983404819e-05
- O 0 1.8306997162653715e-07
1 O 0 1.0519162430000506e-07
) O 0 3.5573417545009534e-09
and O 0 1.6847346628878768e-08
Wilms B-Disease 0 2.803306961141061e-05
tumor I-Disease 0 5.796886739517504e-07
1 O 0 9.455590088691679e-07
( O 0 1.8709199522959352e-08
WT1 O 0 1.5530592918366892e-06
) O 0 1.7679616659549424e-09
genes O 0 1.578142394542681e-09
are O 0 2.3365631651728336e-10
essential O 0 3.612803611829918e-09
for O 0 1.098317881087496e-09
mammalian O 0 3.1321977189691097e-07
gonadogenesis O 0 2.778071745979105e-07
prior O 0 5.190229401819124e-08
to O 0 8.26851209723145e-09
sexual O 0 1.6163312466233037e-07
differentiation O 0 2.0194327134959167e-06
. O 0 2.0859120013483334e-06

In O 0 8.398899922212877e-07
males O 0 9.468439543525164e-07
, O 0 1.302289689419922e-07
SF O 0 0.0006147284875623882
- O 0 4.566780262393877e-06
1 O 0 5.488470833370229e-07
participates O 0 1.3714415381116396e-08
in O 0 7.250194333785487e-10
sexual O 0 3.615912680388078e-09
development O 0 2.5469575337666583e-09
by O 0 2.5807861403492893e-10
regulating O 0 2.9417690505795235e-09
expression O 0 1.4786474267225458e-09
of O 0 1.2592618503504127e-08
the O 0 6.185712919659636e-08
polypeptide O 0 3.163181418130989e-06
hormone O 0 5.703417400582111e-07
Mullerian O 0 8.50595097290352e-06
inhibiting O 0 3.7347828651945747e-07
substance O 0 7.597187163810304e-07
( O 0 1.407920251494943e-07
MIS O 0 4.493373489822261e-05
) O 0 1.0031961750200935e-07
. O 0 1.2213565696583828e-06

Here O 0 3.7552440517174546e-06
, O 0 5.407515146771402e-08
we O 0 4.0060651684825643e-08
show O 0 3.6448515317033525e-08
that O 0 2.3796436821044153e-08
WT1 O 0 0.00012284278636798263
- O 0 4.9021735321730375e-05
KTS O 0 0.0003534065617714077
isoforms O 0 6.440910965466173e-06
associate O 0 1.6570475054322742e-06
and O 0 4.829923838656214e-08
synergize O 0 2.229304300271906e-06
with O 0 2.7766143162466506e-08
SF O 0 0.00019970626453869045
- O 0 7.340435672631429e-07
1 O 0 1.3565026790729462e-07
to O 0 2.391610642860087e-08
promote O 0 6.483796255452035e-07
MIS O 0 0.00017625439795665443
expression O 0 1.446936948923394e-06
. O 0 2.0374016003188444e-06

In O 0 5.824778099849937e-07
contrast O 0 6.776722898393928e-07
, O 0 2.3697791107224475e-07
WT1 O 0 0.00010044554073829204
missense O 0 3.1515889986621914e-06
mutations O 0 2.2390106835246115e-07
, O 0 1.171765795504598e-08
associated O 0 6.227192983487839e-08
with O 0 1.820246708916784e-08
male B-Disease 0 1.814165784708166e-06
pseudohermaphroditism I-Disease 1 1.0
in O 0 3.2573666430835146e-06
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.994510168718989e-07
fail O 0 5.175281330593862e-06
to O 0 7.985023131595881e-08
synergize O 0 1.2118762242607772e-05
with O 0 1.9662279271415173e-07
SF O 1 0.9993103742599487
- O 0 9.595946903573349e-05
1 O 0 1.0750884939625394e-05
. O 0 2.188463668062468e-06

Additionally O 0 6.00337989453692e-06
, O 0 7.360442566550773e-08
the O 0 3.362819356311775e-08
X O 0 1.9292849174235016e-05
- O 0 6.617614872084232e-06
linked O 0 4.061212166561745e-07
, O 0 4.480941839801744e-09
candidate O 0 6.089999260439072e-08
dosage O 0 4.395085397845833e-06
- O 0 4.256880856701173e-07
sensitive O 0 1.2235116741976526e-07
sex O 0 2.079175409619438e-08
- O 0 2.830049972146753e-08
reversal O 0 5.0828269593239384e-08
gene O 0 1.3901640727453923e-08
, O 0 3.47522259858124e-08
Dax O 0 7.400853064609692e-05
- O 0 6.859233963041333e-07
1 O 0 5.628134545077046e-07
, O 0 2.0944838752257056e-08
antagonizes O 0 1.0180378922086675e-06
synergy O 0 5.915816814194841e-07
between O 0 1.864943754981141e-07
SF O 0 0.00025068485410884023
- O 0 4.484518285607919e-07
1 O 0 7.975160087880795e-08
and O 0 9.879591367223384e-09
WT1 O 0 2.1817493234266294e-06
, O 0 9.62620316791174e-10
most O 0 1.957275175268336e-10
likely O 0 9.226580055532452e-10
through O 0 2.2616875039460638e-10
a O 0 5.968648908449836e-10
direct O 0 2.18017426334427e-09
interaction O 0 1.8979374516447933e-08
with O 0 1.4395024727775763e-08
SF O 0 0.001150633324868977
- O 0 3.98337851947872e-06
1 O 0 1.297383619203174e-06
. O 0 1.2181832289570593e-06

We O 0 1.4928376685929834e-06
propose O 0 8.672073477100639e-07
that O 0 1.923759462840735e-08
WT1 O 0 2.2829213776276447e-05
and O 0 3.6318331808615767e-07
Dax O 0 0.0013755712425336242
- O 0 5.407683829616872e-07
1 O 0 5.1872994788482174e-08
functionally O 0 1.688759354578906e-08
oppose O 0 4.928669472548108e-09
each O 0 5.829006721747021e-10
other O 0 9.086186802953478e-10
in O 0 5.58939028394434e-09
testis O 0 8.290417099487968e-07
development O 0 3.6549806736729806e-08
by O 0 5.535092828523602e-09
modulating O 0 3.8361122278729454e-07
SF O 0 3.318956441944465e-05
- O 0 5.686624717782252e-07
1 O 0 6.79643051171297e-07
- O 0 2.1529295679556526e-07
mediated O 0 1.9673432234412758e-06
transactivation O 0 4.393413291836623e-06
. O 0 5.881479836489234e-08
. O 0 5.198660346650286e-07

A O 0 1.1525781701493543e-05
mouse O 0 1.2506910707088537e-06
model O 0 1.9415474525885656e-06
for O 0 3.0953929126553703e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999997615814209
- O 1 0.9998941421508789
centre O 0 0.0006571151898242533
mutations O 0 3.7155461996007944e-06
. O 0 2.9853536034352146e-06

Imprinting O 0 0.0001299812429351732
in O 0 6.324726200546138e-07
the O 0 3.8325103446368303e-07
15q11 O 0 1.0396733159723226e-05
- O 0 1.7342518958685105e-06
q13 O 0 1.3373766023505596e-06
region O 0 2.2114312159260407e-08
involves O 0 1.2493573287031268e-08
an O 0 1.2313321473556016e-09
imprinting O 0 3.287452443601069e-07
centre O 0 1.591511318110861e-05
( O 0 3.7845843792183587e-08
IC O 0 2.5961289793485776e-06
) O 0 3.2915850045611705e-09
, O 0 1.1615337580650476e-09
mapping O 0 4.831948618999604e-09
in O 0 5.501850086631066e-10
part O 0 1.8206588459079853e-09
to O 0 1.725380394113074e-09
the O 0 1.783181957648594e-08
promoter O 0 5.466155812428042e-07
and O 0 2.8456820899691593e-08
first O 0 4.755832350156197e-08
exon O 0 6.410483024410496e-07
of O 0 4.5338245513448783e-07
SNRPN O 0 0.0002612055104691535
. O 0 9.621870958653744e-06

Deletion O 0 3.2220897992374375e-05
of O 0 9.085308079193055e-07
this O 0 6.565958443616182e-08
IC O 0 1.6392079487559386e-05
abolishes O 0 1.2521458074843395e-06
local O 0 3.614121624195832e-08
paternally O 0 5.213873777165645e-08
derived O 0 2.2634321084069597e-09
gene O 0 1.661825455023802e-09
expression O 0 2.8188915646154555e-09
and O 0 3.799148995398127e-09
results O 0 1.010399230949588e-07
in O 0 1.2830503237637458e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9960291385650635
PWS B-Disease 1 1.0
) O 0 6.779094974262989e-07
. O 0 2.1557023046625545e-06

We O 0 6.15236785961315e-07
have O 0 9.692403324379484e-09
created O 0 1.1111377595796057e-08
two O 0 3.771223333615126e-09
deletion O 0 3.1270758427126566e-08
mutations O 0 3.037567353203485e-08
in O 0 1.0825162988226111e-08
mice O 0 9.365327713339866e-08
to O 0 1.647142866545437e-08
understand O 0 2.1009991542086937e-06
PWS B-Disease 1 1.0
and O 0 1.2914074432046618e-07
the O 0 1.2096582402421063e-08
mechanism O 0 6.989120038269903e-08
of O 0 5.299999106256337e-09
this O 0 3.905872514309294e-09
IC O 0 7.239950718940236e-06
. O 0 7.965497275108646e-07

Mice O 0 0.000529471377376467
harbouring O 0 0.00018716620979830623
an O 0 1.3189406899982714e-07
intragenic O 0 8.69342329679057e-06
deletion O 0 5.087244971946348e-07
in O 0 3.353435928943327e-08
Snrpn O 0 0.00013539807696361095
are O 0 4.726046043401766e-08
phenotypically O 0 4.582013389153872e-06
normal O 0 1.6029929383876151e-07
, O 0 1.900352541994721e-09
suggesting O 0 4.089971472609477e-09
that O 0 1.5120438234816902e-10
mutations O 0 5.265800240294993e-09
of O 0 5.2736099931394165e-09
SNRPN O 0 6.719806719956978e-07
are O 0 2.9439622961646705e-10
not O 0 1.7783741146359944e-10
sufficient O 0 8.333665313386973e-09
to O 0 1.7772906701907232e-08
induce O 0 7.740168257441837e-06
PWS B-Disease 1 1.0
. O 0 7.20155076123774e-05

Mice O 0 8.540153430658393e-06
with O 0 2.3417410233150804e-08
a O 0 1.1878236172435663e-08
larger O 0 3.529949665903587e-08
deletion O 0 3.5806692721962463e-07
involving O 0 5.103080624735412e-08
both O 0 1.6211547659850112e-08
Snrpn O 0 6.666421086265473e-06
and O 0 4.228359529179215e-08
the O 0 8.440044751978348e-08
putative O 0 1.3798155123367906e-05
PWS O 1 1.0
- O 0 0.000683746300637722
IC O 0 3.835150710074231e-05
lack O 0 4.879657922174374e-07
expression O 0 4.6070315562474207e-08
of O 0 2.0743824435953684e-08
the O 0 1.4271756221262422e-08
imprinted O 0 7.561582293647007e-08
genes O 0 3.331816600393722e-08
Zfp127 O 0 6.218645012268098e-06
( O 0 2.5459387487103413e-08
mouse O 0 2.578004796305322e-07
homologue O 0 1.648729266889859e-06
of O 0 3.187986123975861e-07
ZNF127 O 0 0.00016348029021173716
) O 0 1.3429716716473195e-07
, O 0 1.302515784118441e-07
Ndn O 0 4.6770950575591996e-05
and O 0 2.2843580893550097e-07
Ipw O 0 1.6474639778607525e-05
, O 0 9.954041146897907e-09
and O 0 6.1952278862520416e-09
manifest O 0 7.198555351806135e-08
several O 0 1.7371631244600394e-08
phenotypes O 0 6.604061127291061e-06
common O 0 1.4709246443089796e-06
to O 0 4.841397185373353e-06
PWS B-Disease 1 1.0
infants O 1 0.9999758005142212
. O 0 8.064476423896849e-05

These O 0 6.758832427067318e-08
data O 0 2.2892930218176843e-08
demonstrate O 0 1.0247924286943544e-08
that O 0 6.094664772859915e-10
both O 0 1.5663780272845429e-09
the O 0 2.6449789025662085e-09
position O 0 5.782768397466498e-08
of O 0 8.878368262799086e-09
the O 0 9.065141526320986e-09
IC O 0 2.824582736593584e-07
and O 0 5.349854448333247e-10
its O 0 1.524182030587795e-10
role O 0 6.472088975861823e-10
in O 0 2.186190256603382e-10
the O 0 7.889730535559636e-10
coordinate O 0 1.49004553140486e-09
expression O 0 2.318009562074508e-09
of O 0 3.1962399393847818e-09
genes O 0 6.452712808524552e-10
is O 0 1.6309351091869928e-10
conserved O 0 4.595532843154615e-09
between O 0 1.3283115052331596e-08
mouse O 0 2.6298787147993608e-08
and O 0 1.5937662301013233e-09
human O 0 1.1162011315235532e-09
, O 0 8.71535899005238e-11
and O 0 1.2460814324821712e-10
indicate O 0 8.725609124127232e-10
that O 0 6.304847199878338e-10
the O 0 1.058949550269972e-08
mouse O 0 3.743876320072559e-08
is O 0 2.3806537297055286e-10
a O 0 2.5638494105528764e-10
suitable O 0 6.661815543651528e-09
model O 0 3.202201614982414e-09
system O 0 1.2258627446470882e-09
in O 0 2.5462662534003755e-10
which O 0 2.130746273865114e-10
to O 0 3.7012995446339403e-10
investigate O 0 7.09912528762402e-09
the O 0 1.992065179479141e-09
molecular O 0 3.050730157383441e-08
mechanisms O 0 6.497661786397657e-08
of O 0 7.762735343419536e-09
imprinting O 0 6.019243414812081e-08
in O 0 8.309186672050828e-10
this O 0 5.5534693510495e-10
region O 0 4.078458015754904e-09
of O 0 8.391981332067644e-09
the O 0 1.2194201204351884e-08
genome O 0 5.124907609399543e-09
. O 0 8.619369218365591e-09
. O 0 4.4896020767737355e-07

Mutations O 0 8.485343414577073e-07
of O 0 3.5626950989353645e-07
the O 0 2.4835901513142744e-07
ATM O 0 2.770150786091108e-06
gene O 0 2.428518008912306e-08
detected O 0 6.174161626404384e-08
in O 0 7.823398107120738e-08
Japanese O 1 0.9999972581863403
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.00782383605837822
: O 0 7.044914429599203e-09
possible O 0 1.1765426854992711e-08
preponderance O 0 9.020988755992221e-08
of O 0 3.417188532139903e-09
the O 0 1.9997821176787056e-09
two O 0 1.553936312959081e-09
founder O 0 4.2371436137500496e-08
mutations O 0 2.9542363222390122e-08
4612del165 O 0 3.4256973435731197e-07
and O 0 1.1483496820119399e-07
7883del5 O 0 1.3043101716903038e-05
. O 0 4.137232735956786e-06

The O 0 7.39059260013164e-06
ATM O 0 0.005364623852074146
( O 0 6.154877155495342e-06
A O 1 1.0
- O 1 1.0
T O 1 1.0
, O 0 1.1898552365607884e-08
mutated O 0 9.403324341406005e-09
) O 0 7.524471046238546e-10
gene O 0 2.5621251786844823e-09
on O 0 2.403789167715331e-08
human O 0 5.429942717682934e-08
chromosome O 0 5.458695682136749e-07
11q22 O 0 6.908326213306282e-06
. O 0 3.2178484161704546e-06

3 O 0 7.810790521034505e-06
has O 0 1.2432386675698126e-08
recently O 0 1.5025381827626916e-08
been O 0 1.5886462145786595e-09
identified O 0 1.8800767609405966e-09
as O 0 3.947994431374724e-10
the O 0 6.219140202823326e-10
gene O 0 1.5946205467187724e-09
responsible O 0 1.7182899547663055e-09
for O 0 3.018746919103421e-10
the O 0 8.71791083767448e-09
human O 0 0.00028857123106718063
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 7.902355605438061e-07
. O 0 1.448968305339804e-06

In O 0 1.0052782783986913e-07
order O 0 4.5510834212336704e-08
to O 0 3.987508101488402e-09
define O 0 4.1701319730691466e-08
the O 0 6.280557851567892e-09
types O 0 1.7154196996216342e-07
of O 0 1.3124927136232145e-06
disease O 0 0.035156361758708954
- O 0 1.489912165197893e-06
causing O 0 4.283623979972617e-07
ATM O 0 8.503338904120028e-06
mutations O 0 5.413190606873286e-08
in O 0 8.434682285951567e-09
Japanese O 0 2.0279851014493033e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.3000803988916232e-08
as O 0 6.788321571526978e-10
well O 0 1.3542761356788446e-10
as O 0 7.995527157023119e-11
to O 0 8.878545815216299e-11
look O 0 1.3905823159632291e-09
for O 0 1.55152196645858e-10
possible O 0 4.3110475189678255e-09
mutational O 0 2.775836662749498e-07
hotspots O 0 3.498366396570418e-08
, O 0 1.6741182884416617e-09
reverse O 0 2.613237981563543e-08
- O 0 9.774068665535651e-09
transcribed O 0 2.2872841398680066e-09
RNA O 0 1.254344628165427e-09
derived O 0 6.343229275174167e-10
from O 0 4.8033871324904e-10
ten O 0 9.244041976330664e-09
patients O 0 1.0191040233920035e-09
belonging O 0 3.819041083374941e-09
to O 0 2.197374060486368e-09
eight O 0 3.838951556645043e-08
unrelated O 0 1.8115846955879533e-07
Japanese O 0 1.1237328180868644e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 9.401656342333808e-09
was O 0 1.8080426045230524e-08
analyzed O 0 2.7491051657335674e-09
for O 0 1.2182356512457915e-10
mutations O 0 5.268218639109534e-10
by O 0 2.835974788339968e-10
the O 0 1.014902495377612e-09
restriction O 0 4.534047359783244e-09
endonuclease O 0 1.6153373394445225e-07
fingerprinting O 0 8.583248245486175e-08
method O 0 1.7639550264902937e-07
. O 0 9.342862199446245e-07

As O 0 2.3893545630926383e-07
has O 0 7.272121571588741e-09
been O 0 2.6654696227979002e-09
reported O 0 8.408848617413867e-10
by O 0 1.6937641567071893e-10
others O 0 1.034742069805361e-09
, O 0 3.690373562292848e-10
mutations O 0 1.7676109465014633e-09
that O 0 2.455722569738583e-10
lead O 0 8.698478382029862e-09
to O 0 1.2794851400599327e-08
exon O 0 6.268604124670674e-07
skipping O 0 4.4554201394930715e-07
or O 0 2.8809125751649844e-08
premature O 0 8.781449167827304e-08
protein O 0 1.8441355109644064e-08
truncation O 0 2.5595775809961197e-07
were O 0 1.708141361689286e-08
also O 0 2.261541842685233e-09
predominant O 0 9.296097402966552e-08
in O 0 7.779335398083731e-09
our O 0 8.459094402724077e-08
mutants O 0 1.6937131022132235e-06
. O 0 9.451514983993548e-07

Six O 0 5.43766361715825e-07
different O 0 1.2725366538290928e-08
mutations O 0 1.1209339234596882e-08
were O 0 5.88909854215558e-09
identified O 0 1.0195207345020663e-08
on O 0 1.5723715662829818e-08
12 O 0 2.8492884496245097e-08
of O 0 2.523453446201529e-08
the O 0 4.118672336517193e-08
16 O 0 5.354990548767091e-07
alleles O 0 1.844457869992766e-06
examined O 0 1.0338851097912993e-05
. O 0 4.94541473017307e-06

Four O 0 1.0661888154572807e-06
were O 0 2.0031964709232852e-07
deletions O 0 7.255228524627455e-07
involving O 0 2.1151998907953384e-07
a O 0 1.6295746974037684e-08
loss O 0 1.8730180784132244e-07
of O 0 3.539412318787072e-07
a O 0 5.34918598305012e-08
single O 0 6.00852985144229e-08
exon O 0 7.853820989112137e-07
exon O 0 3.865749533815688e-07
7 O 0 4.2070254835380183e-07
, O 0 2.1000721162067748e-08
exon O 0 2.5026537286976236e-07
16 O 0 2.4614419658064435e-07
, O 0 4.016133203776917e-08
exon O 0 5.362251727092371e-07
33 O 0 3.3210181982212816e-07
or O 0 1.2159043194515107e-07
exon O 0 1.6845342543092556e-06
35 O 0 2.112527681674692e-06
. O 0 2.900463641708484e-06

The O 0 4.773808655045286e-07
others O 0 7.461181183998633e-08
were O 0 4.047662827133536e-08
minute O 0 1.4295504513484047e-07
deletions O 0 6.991239587250675e-08
, O 0 6.0052620654005295e-09
4649delA O 0 2.375891341444003e-07
in O 0 1.511416769517382e-08
exon O 0 2.059779831142805e-07
33 O 0 4.547473508864641e-08
and O 0 2.0980502668521694e-08
7883del5 O 0 4.843947181143449e-07
in O 0 9.234845776973089e-08
exon O 0 2.9632826681336155e-06
55 O 0 2.4815710730763385e-06
. O 0 8.360042556887493e-06

The O 0 1.1762440408347175e-06
mutations O 0 4.807346840607352e-07
4612del165 O 0 1.0530850431678118e-06
and O 0 1.2951922201409616e-08
7883del5 O 0 3.489786877253209e-07
were O 0 4.202804770869761e-09
found O 0 8.183251298810035e-10
in O 0 2.2233598295784418e-10
more O 0 6.278060016295939e-11
than O 0 1.4745543674976602e-10
two O 0 2.5546187387703867e-10
unrelated O 0 1.8110892785472288e-09
families O 0 4.4930476006399545e-11
; O 0 1.7682304231936286e-10
44 O 0 9.745247941950197e-10
% O 0 6.269734731390031e-10
( O 0 6.314835876430891e-10
7 O 0 3.8658665602042674e-08
of O 0 1.67391487337909e-08
16 O 0 5.2990014154374876e-08
) O 0 7.581258953948122e-10
of O 0 1.6990034934494247e-09
the O 0 1.265120785909346e-09
mutant O 0 9.665911626655088e-09
alleles O 0 6.34394625720347e-09
had O 0 1.7952275221944092e-09
one O 0 4.696889543964744e-10
of O 0 1.365679791476282e-09
the O 0 5.632111221842706e-09
two O 0 1.533558702249138e-08
mutations O 0 5.779988896392751e-07
. O 0 3.354368573127431e-06

The O 0 7.232341658891528e-07
4612del165 O 0 1.2083435194654157e-06
mutations O 0 3.24941211715668e-08
in O 0 2.0509927090017754e-09
three O 0 4.910210571473783e-10
different O 0 2.2980839453623503e-10
families O 0 1.8423478020945794e-10
were O 0 1.643909341986216e-09
all O 0 5.646499934286453e-10
ascribed O 0 6.0672946666784355e-09
to O 0 1.7068767510508565e-09
the O 0 7.28651938786129e-09
same O 0 2.8342256541691313e-08
T O 0 3.3310718663415173e-06
- O 0 7.486841013815138e-07
- O 0 1.7535860763473465e-07
> O 0 3.8386147593882924e-08
A O 0 4.322475266604897e-09
substitution O 0 8.744740043198362e-09
at O 0 1.1498998198078425e-08
the O 0 1.3175717183955271e-09
splice O 0 4.990252477909962e-08
donor O 0 1.7410963781827604e-09
site O 0 1.4078337606804325e-08
in O 0 1.4634659706302955e-08
intron O 0 3.5816876788885565e-06
33 O 0 5.7791799008555245e-06
. O 0 8.25678671390051e-06

Microsatellite O 0 0.00023705187777522951
genotyping O 0 3.205307439202443e-05
around O 0 2.6530500463195494e-07
the O 0 8.158759357002054e-08
ATM O 0 2.4874473183444934e-06
locus O 0 3.3947588917726534e-07
also O 0 2.9287245961739927e-09
indicated O 0 7.055766193531099e-09
that O 0 5.006855485767403e-10
a O 0 1.395141113746945e-09
common O 0 4.388225338658458e-09
haplotype O 0 1.2215225808631658e-07
was O 0 1.2166763596610508e-08
shared O 0 4.164992795097078e-10
by O 0 1.1605897493049966e-10
the O 0 2.7431742988248686e-10
mutant O 0 3.2783835646199577e-09
alleles O 0 3.807578696779501e-09
in O 0 1.2278588146230618e-09
both O 0 1.04642081666384e-08
mutations O 0 6.449157012866635e-07
. O 0 1.807020794331038e-06

This O 0 7.244423017027657e-08
suggests O 0 3.050095997991775e-08
that O 0 5.052760432278092e-10
these O 0 7.26919191507136e-10
two O 0 1.7009165187431563e-09
founder O 0 3.97117645434264e-08
mutations O 0 6.645267447424885e-09
may O 0 3.360458133983002e-09
be O 0 3.221959588017853e-09
predominant O 0 8.612076385361433e-08
among O 0 2.7823279236116605e-09
Japanese O 0 5.997972607474367e-08
ATM O 0 4.846446586270758e-07
mutant O 0 9.115119041780417e-07
alleles O 0 1.6654790897518978e-06
. O 0 2.0285335722292075e-06

W474C O 0 0.0001009908810374327
amino O 0 2.8559102247527335e-06
acid O 0 1.2385433478812047e-07
substitution O 0 9.79503127496173e-08
affects O 0 1.7589012912822e-08
early O 0 1.2856939513028465e-08
processing O 0 7.306559801634194e-09
of O 0 3.1594424854120007e-09
the O 0 4.079531379375112e-09
alpha O 0 3.197948927891048e-08
- O 0 2.479434879631981e-09
subunit O 0 6.646889261219258e-09
of O 0 3.3497582485608746e-09
beta O 0 9.915444820762787e-08
- O 0 2.1169590525005333e-08
hexosaminidase O 0 5.74277052578509e-08
A O 0 2.7807043334604487e-09
and O 0 7.744924146457777e-10
is O 0 2.411221222686777e-10
associated O 0 6.739880209494231e-09
with O 0 6.270599151037004e-09
subacute O 0 6.578140892088413e-05
G B-Disease 0 2.6276127755409107e-05
( I-Disease 0 6.591707091274657e-08
M2 I-Disease 0 5.251071797829354e-06
) I-Disease 0 1.2710987107311666e-07
gangliosidosis I-Disease 0 1.64982247952139e-05
. O 0 4.317013008403592e-06

Mutations O 0 1.2644214848478441e-06
in O 0 9.847707360677305e-08
the O 0 2.3341519295172475e-07
HEXA O 0 1.9387796783121303e-05
gene O 0 1.4855060292973121e-08
, O 0 6.88978252227912e-09
encoding O 0 2.3700588158703795e-08
the O 0 2.484131833568881e-08
alpha O 0 5.8297910499049976e-08
- O 0 5.6527094116631815e-09
subunit O 0 7.2522996497070835e-09
of O 0 6.243245920245499e-09
beta O 0 2.2761032880680432e-07
- O 0 4.297987032941819e-08
hexosaminidase O 0 2.0352662488676287e-07
A O 0 3.745976329128098e-08
( O 0 6.236937633019579e-09
Hex O 0 1.562734382787312e-06
A O 0 2.55762966361317e-08
) O 0 1.2640282154308125e-09
, O 0 8.656104721893598e-10
that O 0 9.79962000435819e-10
abolish O 0 2.9953238822599815e-07
Hex O 0 2.7982398478343384e-06
A O 0 7.649460798120344e-08
enzyme O 0 6.84859386979042e-08
activity O 0 1.7135427299308503e-07
cause O 0 0.0008150439825840294
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 2.6403968149679713e-06
TSD B-Disease 1 0.8347156047821045
) O 0 1.4968229322676052e-08
, O 0 2.8529412166022894e-09
the O 0 2.1804872574193723e-08
fatal O 0 3.007973646163009e-06
infantile B-Disease 0 1.1205553391846479e-06
form I-Disease 0 1.0941703720845908e-07
of I-Disease 0 4.21022286900552e-06
G I-Disease 0 3.084685158682987e-05
( I-Disease 0 3.382497482107283e-08
M2 I-Disease 0 1.5035521983008948e-06
) I-Disease 0 1.6883438647141702e-08
gangliosidosis I-Disease 0 2.980725639645243e-07
, I-Disease 0 4.146605281363236e-09
Type I-Disease 0 2.23497849560772e-07
1 I-Disease 0 1.3974555486129248e-06
. O 0 1.6800292996776989e-06

Less O 0 1.5430823623319156e-05
severe O 1 0.9231509566307068
, O 0 1.9833103124256013e-06
subacute O 1 0.9999986886978149
( O 0 1.6465889984829118e-06
juvenile O 0 0.010643086396157742
- O 0 4.0231361708720215e-06
onset O 0 0.41164183616638184
) O 0 5.5770613016647985e-08
and O 0 9.109288612307864e-07
chronic O 1 0.9999984502792358
( O 0 6.377809995683492e-07
adult O 0 1.2215790775371715e-05
- O 0 5.425200697573018e-07
onset O 0 1.542399445497722e-06
) O 0 6.249556983028981e-10
variants O 0 1.3287321465327295e-08
are O 0 2.332097570612035e-10
characterized O 0 7.3752198792576e-10
by O 0 1.6948985270826e-10
a O 0 5.49081169420873e-10
broad O 0 8.4964275615107e-09
spectrum O 0 2.5298341199686547e-08
of O 0 1.0823236751278387e-09
clinical O 0 1.4796580849463226e-08
manifestations O 0 4.2479303630216236e-08
and O 0 8.090026981655285e-10
are O 0 2.079328237369893e-10
associated O 0 2.3903050649920488e-09
with O 0 3.004942683570988e-10
residual O 0 4.123400856315129e-07
levels O 0 5.014023258809175e-07
of O 0 2.8272157237552165e-07
Hex O 0 4.147500021645101e-06
A O 0 6.840904376304024e-08
enzyme O 0 7.021428416464914e-08
activity O 0 3.04260083794361e-07
. O 0 6.343645964079769e-07

We O 0 2.5724273200466996e-06
identified O 0 7.591914936710964e-07
a O 0 1.2663666382195515e-07
1422 O 0 4.5918262912891805e-05
G O 0 1.6074896848294884e-05
- O 0 1.164019795396598e-05
- O 0 4.079443442606134e-06
> O 0 1.107475213757425e-06
C O 0 2.288106770720333e-06
( O 0 4.495006145077696e-09
amino O 0 3.157954342469793e-09
acid O 0 4.323149060958542e-10
W474C O 0 1.7617005632075688e-09
) O 0 1.3652618098547453e-11
substitution O 0 5.248220191766961e-10
in O 0 1.1826996326735895e-10
the O 0 3.6816977244669147e-10
first O 0 1.6713935790946266e-09
position O 0 2.9435049953008274e-08
of O 0 6.849779410345036e-09
exon O 0 5.297121674630034e-08
13 O 0 7.471506791034699e-08
of O 0 1.2519340941707924e-07
HEXA O 0 0.00018243477097712457
of O 0 3.633149674442393e-07
a O 0 9.090892660879035e-08
non O 0 3.856973762594862e-06
- O 0 1.645917109271977e-06
Jewish O 0 4.6406643150476157e-07
proband O 0 3.668950739665888e-05
who O 0 3.608273857480526e-08
manifested O 0 3.9714342392471735e-07
a O 0 4.673730558124589e-08
subacute O 0 7.99713143351255e-06
variant O 0 4.003711183031555e-06
of O 0 3.284108970547095e-05
G B-Disease 0 0.011994709260761738
( I-Disease 0 2.815817481405247e-07
M2 I-Disease 0 1.184451684821397e-05
) I-Disease 0 1.59489275119995e-07
gangliosidosis I-Disease 0 1.7429802028345875e-05
. O 0 3.041956006200053e-06

On O 0 1.490074737375835e-05
the O 0 4.4298252532826154e-07
second O 0 4.6861291025379614e-07
maternally O 0 1.5392914747280884e-06
inherited O 0 1.1428023753978778e-06
allele O 0 4.1445957776886644e-07
, O 0 4.306214940186237e-09
we O 0 4.062588931930122e-09
identified O 0 1.6031421523621248e-08
the O 0 2.649944086385858e-08
common O 0 0.0007334767142310739
infantile O 1 1.0
disease O 1 0.9998421669006348
- O 0 0.0001404025824740529
causing O 0 4.0739421820035204e-05
4 O 0 0.003982756286859512
- O 0 2.13674757105764e-05
bp O 0 4.2138637468269735e-07
insertion O 0 3.669894610425217e-08
, O 0 1.9810364904060407e-08
+ O 0 2.7471415364743734e-07
TATC O 0 1.072045779437758e-05
1278 O 0 8.462840014544781e-06
, O 0 1.6934007973645748e-08
in O 0 3.581505580996236e-08
exon O 0 1.3140057717464515e-06
11 O 0 1.2248266330061597e-06
. O 0 1.8080033896694658e-06

Pulse O 0 0.0009105590870603919
- O 0 3.885066325892694e-05
chase O 0 8.452810789094656e-07
analysis O 0 4.058354363678518e-08
using O 0 3.657693525838113e-08
proband O 0 2.64643654190877e-06
fibroblasts O 0 3.316925756280398e-07
revealed O 0 7.2411076246226e-08
that O 0 7.669278545563429e-10
the O 0 4.045345392000854e-09
W474C O 0 1.2149075701017864e-07
- O 0 1.2871194776664652e-08
containing O 0 6.7123488989295765e-09
alpha O 0 9.094932806874567e-08
- O 0 1.4883932308862313e-08
subunit O 0 2.7985946005060214e-08
precursor O 0 1.9279175589304032e-08
was O 0 9.023120028928133e-09
normally O 0 1.238020241878246e-09
synthesized O 0 3.984998997452749e-09
, O 0 1.91386489989398e-10
but O 0 3.386257385606939e-10
not O 0 3.5271932596891986e-10
phosphorylated O 0 1.3058883752137262e-08
or O 0 1.1314910119963884e-09
secreted O 0 8.526537254027744e-10
, O 0 5.975084316212076e-10
and O 0 2.797728271275446e-09
the O 0 2.3880735611214732e-08
mature O 0 4.067204315560957e-07
lysosomal O 0 7.444733682859805e-07
alpha O 0 3.747148582533555e-07
- O 0 3.7381109763146014e-08
subunit O 0 6.74658338084555e-08
was O 0 2.4941780196741092e-08
not O 0 7.204266960769701e-09
detected O 0 2.9930825462543e-07
. O 0 8.173032597369456e-07

When O 0 7.521951488342893e-07
the O 0 1.5736817715605866e-07
W474C O 0 6.649066222053079e-07
- O 0 3.440872475835022e-08
containing O 0 9.534823597334707e-09
alpha O 0 1.159319253929425e-07
- O 0 2.2973805968717897e-08
subunit O 0 1.5629025540420116e-07
was O 0 1.617461578007351e-07
transiently O 0 5.86143301006814e-07
co O 0 1.347383431493654e-07
- O 0 1.776541580511548e-08
expressed O 0 8.392248562749671e-10
with O 0 3.7314820677814e-10
the O 0 3.8924490297631564e-09
beta O 0 3.6902150668538525e-08
- O 0 2.025323908583232e-09
subunit O 0 5.741770614520192e-09
to O 0 2.9226740472232393e-10
produce O 0 3.130427916886447e-09
Hex O 0 1.6518155234734877e-06
A O 0 1.0560574992268812e-07
( O 0 7.852442251987668e-09
alphabeta O 0 3.673992239328072e-07
) O 0 2.079356908879504e-09
in O 0 5.157326121718597e-09
COS O 0 1.1694312433974119e-06
- O 0 1.803039282322061e-07
7 O 0 7.802996293548858e-08
cells O 0 6.702203680930552e-09
, O 0 6.124029061638225e-10
the O 0 2.3390926973121395e-09
mature O 0 1.472186905715489e-08
alpha O 0 2.3146927929929006e-08
- O 0 2.3687287686868785e-09
subunit O 0 8.09009303992525e-09
was O 0 1.6511367828542234e-09
present O 0 1.9154609842697568e-10
, O 0 1.0048244875049406e-10
but O 0 1.696745383084064e-10
its O 0 2.2651411302199165e-10
level O 0 2.778558716443058e-08
was O 0 4.8124499940627175e-09
much O 0 6.126891216595709e-10
lower O 0 2.209262994767869e-09
than O 0 7.246747646405538e-11
that O 0 2.7620947196105305e-11
from O 0 2.387333386533186e-10
normal O 0 9.907198617042923e-09
alpha O 0 4.159249300528245e-08
- O 0 6.663569696030436e-09
subunit O 0 1.4831165628947929e-08
transfections O 0 2.8513976957356135e-08
, O 0 8.65826299545347e-11
although O 0 1.4353090938001856e-10
higher O 0 1.2469045795882039e-09
than O 0 1.0230025160318235e-10
in O 0 2.197712567486576e-10
those O 0 4.6307432888248456e-10
cells O 0 2.5786224266965974e-09
transfected O 0 2.284285649523099e-08
with O 0 1.4815940141410522e-10
an O 0 3.135445791890845e-10
alpha O 0 3.9152876496473255e-08
- O 0 1.6790982826364598e-08
subunit O 0 8.990500077743491e-08
associated O 0 5.5343782889849535e-08
with O 0 6.022217746703973e-08
infantile O 0 0.0017659224104136229
TSD B-Disease 0 0.002261050743982196
. O 0 1.1492350495245773e-05

Furthermore O 0 9.898134294417105e-07
, O 0 1.4186048780118199e-08
the O 0 6.340171943008954e-09
precursor O 0 4.7654392432150416e-08
level O 0 9.169553294441357e-08
of O 0 7.202095808622744e-09
the O 0 6.237461214197992e-09
W474C O 0 9.599789763115041e-08
alpha O 0 9.456115890316141e-08
- O 0 5.599238850351185e-09
subunit O 0 1.1479057704377738e-08
was O 0 4.814056264734745e-09
found O 0 2.1081486556440154e-10
to O 0 3.5186262237196786e-10
accumulate O 0 2.648937069693602e-09
in O 0 1.0345013734536224e-09
comparison O 0 3.203771470339234e-09
to O 0 1.3462287951071517e-09
the O 0 9.201014172788291e-09
normal O 0 6.830082810438398e-08
alpha O 0 3.1105776088224957e-07
- O 0 4.19462224954259e-08
subunit O 0 1.1207847450123154e-07
precursor O 0 7.787206612874797e-08
levels O 0 1.993705325276096e-07
. O 0 1.6422968940332794e-07

We O 0 1.8470700524630956e-06
conclude O 0 2.484334345354e-06
that O 0 9.57210488650162e-09
the O 0 5.984408346648706e-08
1422 O 0 1.6770993170212023e-05
G O 0 3.5833481888403185e-06
- O 0 2.0740048967127223e-06
- O 0 8.343089916706958e-07
> O 0 1.4476020737674844e-07
C O 0 1.5445439771610836e-07
mutation O 0 2.3487043421255294e-09
is O 0 5.694018520574495e-11
the O 0 4.226033412102481e-10
cause O 0 8.415783625537188e-09
of O 0 5.0396277373465637e-08
Hex B-Disease 0 0.0001442794018657878
A I-Disease 0 1.5735822671558708e-05
enzyme I-Disease 1 0.9999997615814209
deficiency I-Disease 1 1.0
in O 0 4.6917904228394036e-08
the O 0 2.5560382255207514e-07
proband O 0 2.423680416541174e-05
. O 0 3.2641114557918627e-06

The O 0 9.36241349336342e-07
resulting O 0 5.109313860884868e-07
W474C O 0 1.9174460703652585e-06
substitution O 0 6.57746454635344e-07
clearly O 0 9.878879581037836e-08
interferes O 0 2.728435966048437e-08
with O 0 4.59377114125914e-09
alpha O 0 2.6254892304677924e-07
- O 0 3.512628410362595e-08
subunit O 0 4.9673658963911294e-08
processing O 0 3.2573164165938806e-09
, O 0 5.5862085790447935e-11
but O 0 8.939139706232169e-11
because O 0 9.73238920010111e-11
the O 0 2.936962895105921e-10
base O 0 1.1256339194076759e-09
substitution O 0 1.1906815977624774e-08
falls O 0 1.807508098750077e-08
at O 0 1.0823758778144565e-08
the O 0 1.6602381691654955e-09
first O 0 1.7702426191590348e-09
position O 0 2.6813699705030558e-08
of O 0 1.4044062801588097e-08
exon O 0 8.952529384487207e-08
13 O 0 4.3599534649274574e-08
, O 0 7.98882826558156e-09
aberrant O 0 9.578939597076896e-08
splicing O 0 1.848048185593143e-07
may O 0 2.3789718639477542e-08
also O 0 7.462089612886302e-09
contribute O 0 1.8856727734828382e-08
to O 0 2.1407204897627707e-08
Hex B-Disease 0 0.0004278194101061672
A I-Disease 0 4.848513071920024e-06
deficiency I-Disease 0 7.803233893355355e-05
in O 0 9.67932312079256e-09
this O 0 4.401730091529998e-09
proband O 0 3.9842643673182465e-07
. O 0 3.890773214720866e-08
. O 0 3.9836260157244396e-07

Two O 0 5.60431601570599e-07
frequent O 0 2.15483979104647e-07
missense O 0 4.3859417928615585e-05
mutations O 0 4.5793636672897264e-05
in O 0 3.588137769838795e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.35788577795028687

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 2.1446946902869968e-06
an O 0 8.397287274419796e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 9.796225640457124e-06
by O 0 9.668326583778253e-09
early O 0 0.0031369926873594522
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999984502792358
goiter B-Disease 1 1.0
. O 1 0.7730348706245422

A O 0 1.1132357258247794e-06
century O 0 2.3923001890580053e-07
after O 0 1.042786568206111e-08
its O 0 3.189228880984274e-10
recognition O 0 5.149305426499495e-09
as O 0 1.8489044961711443e-08
a O 0 1.7342037139655986e-08
syndrome O 0 2.0728546701320738e-07
by O 0 3.3787104225524445e-09
Vaughan O 0 3.4952499845530838e-06
Pendred O 0 1.7420612493879162e-05
, O 0 8.143395291426714e-09
the O 0 1.5403157860305328e-08
disease O 0 4.1951743412482756e-08
gene O 0 1.3975760992934738e-08
( O 0 1.525416593040063e-08
PDS O 0 8.530336344847456e-06
) O 0 1.492612078379807e-08
was O 0 9.299751724256566e-08
mapped O 0 8.476246904365325e-08
to O 0 2.29260521678043e-08
chromosome O 0 1.0801577445818111e-06
7q22 O 0 1.4627379641751759e-05
- O 0 2.007547846005764e-05
q31 O 0 3.571859997464344e-05
. O 0 7.508938779210439e-06

1 O 0 4.266921678208746e-06
and O 0 3.4693155015474986e-08
, O 0 6.203256130987711e-09
recently O 0 9.121892574626145e-09
, O 0 6.210060243816429e-10
found O 0 3.822602789860241e-10
to O 0 1.1907355101925532e-09
encode O 0 2.996058157123116e-08
a O 0 4.9323212181207055e-08
putative O 0 5.822656476084376e-06
sulfate O 0 1.88424874068005e-05
transporter O 0 9.536634024698287e-05
. O 0 6.5441995502624195e-06

We O 0 6.642075618401577e-07
performed O 0 5.971546812588713e-08
mutation O 0 1.558876938645426e-08
analysis O 0 1.2202879595690774e-08
of O 0 1.4708565032606202e-08
the O 0 2.6773429695481354e-08
PDS B-Disease 0 4.822560185857583e-06
gene O 0 1.2589111975103151e-08
in O 0 1.7630518156508401e-09
patients O 0 1.2862844123162631e-09
from O 0 1.2836155471873667e-09
14 O 0 3.990637154061005e-08
Pendred B-Disease 0 1.3188617913328926e-06
families O 0 1.5521885998737162e-09
originating O 0 1.994570730801115e-09
from O 0 5.309294670574616e-10
seven O 0 2.3665431836406015e-09
countries O 0 2.7310781414158214e-10
and O 0 2.135145171777708e-09
identified O 0 1.2587166864364008e-08
all O 0 7.325537509927926e-09
mutations O 0 4.3499613866515574e-07
. O 0 9.259057947019755e-07

The O 0 5.890196348445897e-07
mutations O 0 2.6152281407121336e-07
include O 0 1.2419256734119699e-08
three O 0 8.876352985964786e-09
single O 0 6.225824744632291e-09
base O 0 1.735742394259887e-08
deletions O 0 9.28612138295648e-08
, O 0 1.6849080353154022e-08
one O 0 8.16946954529385e-09
splice O 0 1.9764929959364963e-07
site O 0 2.479360539098252e-08
mutation O 0 1.9088032487957207e-08
and O 0 2.6524775265102107e-08
10 O 0 2.854171157196106e-07
missense O 0 1.537542812002357e-05
mutations O 0 1.7182279407279566e-05
. O 0 2.9140854167053476e-05

One O 0 1.3161979950382374e-06
missense O 0 4.786171757586999e-06
mutation O 0 2.188704684158438e-07
( O 0 2.873443705198042e-08
L236P O 0 4.224385463658109e-07
) O 0 5.180573303675828e-09
was O 0 1.9066090928276935e-08
found O 0 1.3395692333162401e-09
in O 0 8.762233716375079e-10
a O 0 7.779494270998555e-10
homozygous O 0 6.317441680891989e-09
state O 0 8.48851877677248e-10
in O 0 2.158431433585406e-09
two O 0 8.274869678359664e-09
consanguineous O 0 5.871268626833626e-07
families O 0 1.2208017929893344e-09
and O 0 9.871732320476667e-10
in O 0 1.5874467296228545e-09
a O 0 1.2209415700681348e-09
heterozygous O 0 4.192092450949758e-09
state O 0 1.174246366808518e-09
in O 0 2.142316546382972e-09
five O 0 5.55725510054117e-09
additional O 0 1.2574784769014968e-08
non O 0 1.61755542649189e-06
- O 0 4.11282644563471e-06
consanguineous O 0 1.113663620344596e-05
families O 0 6.618806480673811e-08
. O 0 7.804751476214733e-07

Another O 0 4.5380479605228174e-06
missense O 0 1.4822825505689252e-05
mutation O 0 5.204385615797946e-07
( O 0 3.561790506978468e-08
T416P O 0 4.017742867290508e-07
) O 0 3.626196676265181e-09
was O 0 8.050933253400672e-09
found O 0 6.52212950313924e-10
in O 0 2.754457217868378e-10
a O 0 6.779651839927681e-10
homozygous O 0 4.392386898643963e-09
state O 0 8.250752858707244e-10
in O 0 1.2057416176602942e-09
one O 0 1.2540695148999248e-09
family O 0 5.416809778502341e-10
and O 0 7.28790527926293e-10
in O 0 4.904603945199426e-10
a O 0 7.702526394481879e-10
heterozygous O 0 2.683558486538118e-09
state O 0 1.3162203549299534e-09
in O 0 5.828398208507224e-09
four O 0 2.8753298408901173e-08
families O 0 2.269026566636967e-08
. O 0 7.643851631655707e-07

Pendred B-Disease 0 0.001254639239050448
patients O 0 6.169966013658268e-07
in O 0 7.509093791213672e-08
three O 0 6.184556866628554e-08
non O 0 4.831499154533958e-06
- O 0 1.5918400322334492e-06
consanguineous O 0 1.432436988579866e-06
families O 0 9.529472766445224e-10
were O 0 2.342123828213971e-09
shown O 0 5.820818271828898e-10
to O 0 4.978079060080631e-10
be O 0 2.8665230189517388e-09
compound O 0 4.534862441119003e-08
heterozygotes O 0 2.2695012091844546e-07
for O 0 2.1608503431025383e-08
L236P O 0 1.4731272131029982e-06
and O 0 1.2299085483391536e-07
T416P O 0 9.268085705116391e-06
. O 0 1.8555249425844522e-06

In O 0 2.3500462020820123e-07
total O 0 2.9050310601519413e-08
, O 0 2.2243193953386253e-09
one O 0 3.682884552880239e-10
or O 0 2.3200874554873963e-10
both O 0 2.6302371392006307e-10
of O 0 3.9169795185145517e-10
these O 0 9.934551098433886e-11
mutations O 0 8.259853911951609e-10
were O 0 1.0954975815380408e-09
found O 0 4.602846159773577e-10
in O 0 1.224000678590187e-09
nine O 0 9.174500270603403e-09
of O 0 5.61610624671971e-09
the O 0 1.2447809005777799e-08
14 O 0 7.7215531746333e-08
families O 0 5.776360723075413e-09
analyzed O 0 1.9947208329540445e-07
. O 0 1.0578795581750455e-06

The O 0 1.0220755797263337e-07
identification O 0 5.316434226187994e-08
of O 0 4.3467014876341636e-08
two O 0 7.974213289685395e-09
frequent O 0 1.3215842642466669e-08
PDS B-Disease 0 2.4789553208393045e-05
mutations O 0 1.8509443577841012e-07
will O 0 1.3303652401930322e-08
facilitate O 0 3.000181081347364e-08
the O 0 9.161822411840603e-09
molecular O 0 1.4070438965063659e-06
diagnosis O 0 0.0012128695379942656
of O 0 5.850633897352964e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00019720738055184484

Insertional O 0 0.00011535784869920462
mutation O 0 4.689553634307231e-07
by O 0 2.8496145887402236e-08
transposable O 0 1.5318653368012747e-06
element O 0 3.2874118005565833e-07
, O 0 2.576858548763994e-08
L1 O 0 2.5012534479174064e-06
, O 0 4.273698284151806e-09
in O 0 7.51318829372849e-09
the O 0 1.6456237972306553e-07
DMD B-Disease 1 1.0
gene O 0 9.042971527151167e-08
results O 0 1.4889390342887054e-07
in O 0 3.104966594946745e-08
X B-Disease 1 0.9991324543952942
- I-Disease 1 0.9999134540557861
linked I-Disease 0 0.26061728596687317
dilated I-Disease 0 0.15627728402614594
cardiomyopathy I-Disease 1 1.0
. O 0 0.0010630417382344604

X B-Disease 1 0.9999957084655762
- I-Disease 1 0.9999996423721313
linked I-Disease 1 0.9995456337928772
dilated I-Disease 1 0.9999439716339111
cardiomyopathy I-Disease 1 1.0
( O 0 0.0003253979666624218
XLDCM B-Disease 1 0.9999867677688599
) O 0 3.341923360267174e-08
is O 0 1.2079053313129862e-09
a O 0 1.809273175723547e-09
clinical O 0 1.1615868089620562e-07
phenotype O 0 3.0934518235881114e-07
of O 0 1.4551304161614098e-07
dystrophinopathy B-Disease 0 3.2987693430186482e-06
which O 0 2.8131390550356628e-09
is O 0 5.516698764473915e-10
characterized O 0 1.454241171927606e-09
by O 0 4.86776341457329e-10
preferential O 0 1.5571956168969336e-07
myocardial B-Disease 0 0.0001630459591979161
involvement I-Disease 0 8.848651589232759e-08
without O 0 5.45000666818396e-09
any O 0 1.8840935478436904e-09
overt O 0 1.4888305699400917e-08
clinical O 0 1.8232876186630165e-07
signs O 0 7.791818461555522e-07
of O 0 0.0018335634376853704
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 1 0.5884455442428589

To O 0 7.013142777623216e-08
date O 0 3.5710661450139014e-07
, O 0 1.3216037153540583e-09
several O 0 1.3419296784888957e-09
mutations O 0 1.8729801709582716e-08
in O 0 7.952341896100279e-09
the O 0 3.826425654551713e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 0 0.037515927106142044
, O 0 9.918942851072643e-06
DMD O 1 1.0
, O 0 1.3321732161841737e-08
have O 0 9.108692133885654e-10
been O 0 1.394369619767133e-09
identified O 0 5.7505387118794715e-09
in O 0 1.4303114248548354e-09
patients O 0 2.4246518126602723e-09
with O 0 2.750877969859289e-09
XLDCM B-Disease 0 0.0003705201088450849
, O 0 2.9624223074620204e-09
but O 0 9.185299743030839e-10
a O 0 4.205665538048464e-10
pathogenic O 0 1.0800722982651223e-08
correlation O 0 5.208791176158911e-09
of O 0 2.1058430554887764e-09
these O 0 2.5233271028213267e-09
cardiospecific O 0 3.8605472241215466e-07
mutations O 0 3.9927538608708346e-08
in O 0 1.67320930444248e-08
DMD O 1 1.0
with O 0 1.3578210555920123e-08
the O 0 5.484076481820921e-08
XLDCM B-Disease 0 4.0659899241290987e-05
phenotype O 0 2.670662411219382e-07
has O 0 1.4423958694109729e-09
remained O 0 3.1520766441417436e-08
to O 0 1.875706923115672e-09
be O 0 2.1785002246588192e-08
elucidated O 0 1.4734175238118041e-05
. O 0 1.6212590026043472e-06

We O 0 1.4355057373904856e-06
report O 0 3.4891037614670495e-08
here O 0 5.715764750391372e-09
the O 0 1.0906876513061547e-09
identification O 0 4.929233465844618e-09
of O 0 5.628352450770535e-09
a O 0 6.667179697217307e-09
unique O 0 5.7472188785823164e-08
de O 0 1.1957922652072739e-05
novo O 0 8.683554369781632e-06
L1 O 0 9.681700248620473e-06
insertion O 0 1.8362423759299418e-07
in O 0 2.445758973124157e-08
the O 0 3.244135982072294e-08
muscle O 0 1.2314623631937138e-07
exon O 0 4.258618844232842e-07
1 O 0 2.501212748029502e-07
in O 0 2.8562313403313055e-08
DMD O 1 1.0
in O 0 1.4876468057423153e-08
three O 0 7.093873932717543e-09
XLDCM B-Disease 0 1.6780148826001096e-06
patients O 0 7.312495609035352e-10
from O 0 4.735443148717877e-10
two O 0 9.794948185870567e-10
unrelated O 0 2.0034633507748367e-08
Japanese O 0 1.0729253574481845e-07
families O 0 4.388520835618692e-08
. O 0 1.215497832163237e-06

The O 0 5.856985012542282e-07
insertion O 0 3.8360022358574497e-07
was O 0 2.3885294808678736e-07
a O 0 8.29321500361857e-09
5 O 0 6.581430511687358e-08
- O 0 2.65063171411839e-08
truncated O 0 4.278202325735947e-08
form O 0 8.51310311134057e-09
of O 0 4.627401750667559e-08
human O 0 4.211561588363111e-08
L1 O 0 2.6547252218733774e-06
inversely O 0 2.903796882947063e-07
integrated O 0 1.000509541881911e-07
in O 0 2.0826751434555035e-09
the O 0 4.395547037461256e-09
5 O 0 4.3131056060019546e-08
- O 0 2.8920281280875315e-08
untranslated O 0 1.5785727782713366e-06
region O 0 7.131819579342391e-09
in O 0 2.7296838123191947e-09
the O 0 7.020688919112672e-09
muscle O 0 1.4914141033273154e-08
exon O 0 2.1101582703408894e-08
1 O 0 6.549745634742976e-09
, O 0 4.392801747354902e-11
which O 0 2.844234396615075e-11
affected O 0 1.8857070072098026e-10
the O 0 3.5835928668959127e-10
transcription O 0 1.8499475284983191e-09
or O 0 8.288798536426611e-10
the O 0 1.3692114109176146e-09
stability O 0 2.8833259335669936e-08
of O 0 3.9414880248500594e-09
the O 0 2.3407038529654756e-09
muscle O 0 6.127712559589327e-09
form O 0 2.6282439336000607e-08
of O 0 1.2222335499245673e-07
dystrophin O 0 8.313916737279214e-07
transcripts O 0 9.90078063978217e-08
but O 0 4.58780596845898e-10
not O 0 1.0503710401454924e-10
that O 0 1.248622316651904e-10
of O 0 6.929650187004199e-09
the O 0 5.329836483269901e-08
brain O 0 0.000371605739928782
or O 0 5.577406341217284e-07
Purkinje O 0 0.00019263042486272752
cell O 0 1.293020886805607e-06
form O 0 5.3657402077078586e-08
, O 0 3.902395295796168e-09
probably O 0 1.1440937086604208e-08
due O 0 2.6439360922836386e-08
to O 0 9.297437819633103e-10
its O 0 7.408634261629743e-10
unique O 0 1.4310591600619205e-09
site O 0 8.967547593385916e-09
of O 0 1.8151986580505763e-08
integration O 0 1.244600298377918e-06
. O 0 1.566504920447187e-06

We O 0 5.42232498901285e-07
speculate O 0 1.4685248572732235e-07
that O 0 5.499877775427819e-10
this O 0 2.6117155660365654e-10
insertion O 0 2.952883049189836e-09
of O 0 3.932731917899446e-09
an O 0 1.7153590770035976e-09
L1 O 0 1.6446886093035573e-06
sequence O 0 5.780154666013004e-08
in O 0 7.335034268862728e-08
DMD O 1 1.0
is O 0 5.323118390521131e-09
responsible O 0 5.550337522919335e-09
for O 0 2.3124707704269554e-10
some O 0 7.84914008788995e-11
of O 0 2.7435825833421745e-10
the O 0 2.0651348686673288e-10
population O 0 1.7434973603736026e-11
of O 0 4.917906082368972e-10
Japanese O 0 1.5502484629337232e-08
patients O 0 2.5674378179019186e-09
with O 0 3.1949294321265143e-09
XLDCM B-Disease 0 1.0948976523650344e-05
. O 0 1.3248859431769233e-07
. O 0 1.5373872201962513e-06

Severe O 1 0.9669131636619568
early O 1 0.9999697208404541
- O 1 1.0
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 3.412236401345581e-05
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9999929666519165
red O 1 0.9999924898147583
hair O 1 0.9999711513519287
pigmentation O 0 0.25939658284187317
caused O 0 4.643944748750073e-07
by O 0 7.08120992953809e-08
POMC O 0 0.0001327181962551549
mutations O 0 3.372445007698843e-07
in O 0 3.156961980721462e-08
humans O 0 5.161654144103522e-07
. O 0 1.5596701814502012e-06

Sequential O 0 2.1970245143165812e-05
cleavage O 0 2.3590173441334628e-06
of O 0 1.043563543134951e-06
the O 0 1.9806215334483568e-07
precursor O 0 2.680802992927056e-07
protein O 0 6.842013533514546e-08
pre O 0 1.9623255411715945e-06
- O 0 1.5942678146529943e-06
pro O 0 0.00010956916958093643
- O 0 2.514970583433751e-05
opiomelanocortin O 0 1.6998403225443326e-05
( O 0 3.913100599106656e-08
POMC O 0 3.5334871881786967e-06
) O 0 2.9585598415593495e-09
generates O 0 4.058452685029579e-09
the O 0 1.5818740095596695e-08
melanocortin O 0 7.714839739492163e-06
peptides O 0 1.9956303276558174e-07
adrenocorticotrophin O 0 3.833387381746434e-06
( O 0 6.101020488813447e-08
ACTH O 0 4.3828254092659336e-06
) O 0 7.077024122281728e-08
, O 0 1.5258946461926826e-07
melanocyte O 0 0.0003485514025669545
- O 0 0.00024766201386228204
stimulating O 0 2.6931544198305346e-05
hormones O 0 2.4673573761901935e-07
( O 0 1.052353315600385e-08
MSH O 0 2.1636853944073664e-06
) O 0 1.6641503730596696e-09
alpha O 0 2.9159952674717715e-08
, O 0 4.440568468488948e-10
beta O 0 7.116152556108091e-09
and O 0 1.0295388985781528e-09
gamma O 0 1.2026415419086334e-08
as O 0 4.6415135623867343e-10
well O 0 2.5932550551388545e-10
as O 0 4.2759301654982096e-10
the O 0 2.384949571165862e-09
opioid O 0 7.332894114142618e-08
- O 0 2.0700111846849722e-08
receptor O 0 2.3416248495777836e-08
ligand O 0 2.9842840376659296e-07
beta O 0 1.972953441509162e-06
- O 0 1.0912573316090857e-06
endorphin O 0 1.3805565686197951e-05
. O 0 7.980103191584931e-07

While O 0 7.955802061587747e-07
a O 0 2.554952871491878e-08
few O 0 1.3607585280794865e-08
cases O 0 1.3814283050805898e-08
of O 0 5.345208720086703e-08
isolated O 0 6.115728410804877e-06
ACTH B-Disease 1 0.7490159869194031
deficiency I-Disease 1 0.9987112283706665
have O 0 5.380498180329596e-08
been O 0 6.389742424062206e-08
reported O 0 1.7966763721233292e-07
( O 0 4.4058143799929894e-08
OMIM O 0 4.3646876292768866e-05
201400 O 0 4.0517757042835e-06
) O 0 1.4219314614649647e-08
, O 0 8.775919546621935e-09
an O 0 1.2710908769975049e-08
inherited O 0 0.008889091201126575
POMC O 1 0.9999980926513672
defect O 0 0.0003674020990729332
has O 0 1.1889546236432125e-08
not O 0 5.540162550943251e-09
been O 0 7.2473773649051054e-09
described O 0 1.6141941117098213e-08
so O 0 6.20648732407858e-09
far O 0 5.702504779492301e-08
. O 0 7.925880822767795e-07

Recent O 0 8.835469316181843e-07
studies O 0 1.0824464879988227e-07
in O 0 8.826414266138727e-09
animal O 0 1.3938040055450074e-08
models O 0 8.606427570612141e-08
elucidated O 0 1.1519126701386995e-06
a O 0 5.1920086008294675e-09
central O 0 1.3654096520099301e-08
role O 0 1.8906932908180352e-08
of O 0 5.8316814488534874e-08
alpha O 0 1.137448407462216e-06
- O 0 2.6213658088636294e-07
MSH O 0 7.078150247252779e-06
in O 0 3.289507555237492e-09
the O 0 6.422069542821873e-09
regulation O 0 1.4308197293644298e-08
of O 0 1.824110529291545e-09
food O 0 4.3813069838805063e-10
intake O 0 8.001512230570995e-10
by O 0 1.1008990247196593e-10
activation O 0 6.734585777934399e-09
of O 0 3.3332021587284544e-08
the O 0 4.270131626071816e-08
brain O 0 1.889516283881676e-06
melanocortin O 0 6.538703473779606e-06
- O 0 2.0517337873116048e-07
4 O 0 3.4452204999979585e-07
- O 0 6.516415140822573e-08
receptor O 0 8.077206814505189e-08
( O 0 1.265613924772424e-08
MC4 O 0 6.917120117577724e-06
- O 0 1.1847807002141053e-07
R O 0 3.215686916746563e-08
; O 0 1.6819116099853204e-09
refs O 0 1.1509754926919413e-07
3 O 0 2.5617598709004596e-08
- O 0 5.660261592765892e-09
5 O 0 5.835750993554711e-09
) O 0 3.8119801759606275e-10
and O 0 8.159981024213891e-10
the O 0 3.707688822629507e-09
linkage O 0 1.5867611580233643e-07
of O 0 8.181838495602278e-08
human O 0 1.4095513733991538e-06
obesity B-Disease 1 0.9992571473121643
to O 0 2.160762679892514e-09
chromosome O 0 1.6260385038435743e-08
2 O 0 1.087545697942005e-07
in O 0 1.1488694440231484e-08
close O 0 5.0432241494036134e-08
proximity O 0 3.188283415056503e-08
to O 0 4.293732036586562e-09
the O 0 2.4514756447047148e-08
POMC O 0 5.665703611157369e-06
locus O 0 9.25593610645592e-08
, O 0 1.42038303341252e-09
led O 0 1.4086012356528954e-09
to O 0 4.121293029069051e-10
the O 0 7.124976719730114e-10
proposal O 0 2.5190087793447447e-09
of O 0 6.836309740521074e-09
an O 0 1.3956468203346617e-09
association O 0 1.0333186750699497e-08
of O 0 2.751622787400265e-07
POMC O 1 0.6837451457977295
with O 0 7.40426116863091e-07
human O 0 0.04540032520890236
obesity B-Disease 1 1.0
. O 0 1.7393902453477494e-05

The O 0 7.170032176873065e-07
dual O 0 1.7052789189619943e-06
role O 0 1.1476560075607267e-06
of O 0 5.9906087699346244e-06
alpha O 0 0.0006292702164500952
- O 0 0.00031263759592548013
MSH O 0 0.4318420886993408
in O 0 1.2416656147706817e-07
regulating O 0 2.2363985863194102e-07
food O 0 1.0243664583242662e-08
intake O 0 7.077280628209337e-08
and O 0 3.8473963570595515e-08
influencing O 0 3.16753976221662e-05
hair O 0 0.22792713344097137
pigmentation O 0 0.0001252352521987632
predicts O 0 4.216954962998898e-08
that O 0 2.2203169858237004e-10
the O 0 1.8422714465060608e-09
phenotype O 0 4.968787692405385e-08
associated O 0 6.682367548194179e-09
with O 0 1.541073268995774e-09
a O 0 7.362546128319991e-09
defect O 0 3.2130512295225344e-07
in O 0 7.658205447569344e-08
POMC O 0 0.0002122450532624498
function O 0 2.536139618314337e-07
would O 0 1.082972644894653e-08
include O 0 5.473511777154272e-08
obesity B-Disease 1 1.0
, O 0 1.2757859657597237e-08
alteration O 0 1.6474938320243382e-06
in O 0 1.3849798108367395e-07
pigmentation O 1 0.9999160766601562
and O 0 2.1947083951090463e-05
ACTH B-Disease 1 0.99620121717453
deficiency I-Disease 1 0.9999083280563354
. O 0 2.417115683783777e-05

The O 0 3.6573419492924586e-07
observation O 0 7.496785769944836e-07
of O 0 3.784649393878681e-08
these O 0 9.14666653528684e-09
symptoms O 0 5.855466156390321e-07
in O 0 9.458421601493683e-09
two O 0 2.97286710804201e-08
probands O 0 3.3268936476815725e-06
prompted O 0 3.4080446909001694e-08
us O 0 1.8175535521081088e-09
to O 0 4.613032733580269e-10
search O 0 2.3915911473437745e-09
for O 0 8.422219033299427e-10
mutations O 0 3.0282304663842297e-08
within O 0 2.1076603573533248e-08
their O 0 9.974113623911762e-08
POMC O 0 2.596465674287174e-05
genes O 0 4.4723418568537454e-07
. O 0 2.2846966203360353e-06

Patient O 0 3.8137695810291916e-06
1 O 0 1.5502654377996805e-06
was O 0 8.531751660711961e-08
found O 0 1.5472877423761133e-09
to O 0 4.720185353690454e-10
be O 0 1.723436504619258e-09
a O 0 1.9849237808955422e-09
compound O 0 1.9843037435407496e-08
heterozygote O 0 7.960024106523633e-08
for O 0 1.2683101235921868e-09
two O 0 1.3510209617706437e-09
mutations O 0 7.930348822071664e-09
in O 0 5.0293982312155094e-09
exon O 0 6.856187440007488e-08
3 O 0 2.042139044533542e-07
( O 0 2.5404029990738763e-09
G7013T O 0 8.897816172748207e-08
, O 0 2.1775019565239973e-09
C7133delta O 0 2.0081715490505303e-07
) O 0 8.143546392780365e-10
which O 0 3.8476050123747996e-10
interfere O 0 4.266107911377048e-09
with O 0 5.402530089959612e-10
appropriate O 0 1.4706545314879804e-08
synthesis O 0 7.622560360687203e-08
of O 0 3.5972107070847414e-08
ACTH O 0 1.746615794218087e-06
and O 0 2.0313491688739305e-07
alpha O 0 1.4346544958243612e-05
- O 0 7.6292885751172435e-06
MSH O 0 0.0002584261819720268
. O 0 2.0956999833288137e-06

Patient O 0 4.080579856236e-06
2 O 0 1.7110716044044239e-06
was O 0 1.461877872088735e-07
homozygous O 0 1.106788971583228e-08
for O 0 1.078525824205201e-09
a O 0 1.869114196750843e-09
mutation O 0 3.5296043865429283e-09
in O 0 7.419130199082247e-09
exon O 0 1.3826756628532166e-07
2 O 0 3.8131042856548447e-07
( O 0 7.279295832773869e-09
C3804A O 0 1.790171921811634e-07
) O 0 2.44790920866933e-09
which O 0 5.018876425566532e-09
abolishes O 0 5.610756943497108e-06
POMC O 0 6.499506707768887e-05
translation O 0 5.770951702288585e-06
. O 0 5.111232439958258e-06

These O 0 4.351637272748121e-08
findings O 0 4.614876658592948e-08
represent O 0 2.2306330116350637e-09
the O 0 1.0291895113923033e-09
first O 0 9.200062933700792e-10
examples O 0 1.972055407861717e-09
of O 0 5.5156594847005636e-09
a O 0 1.885191025507993e-08
genetic B-Disease 1 0.9999998807907104
defect I-Disease 1 0.9999940395355225
within O 0 1.1327336579824987e-07
the O 0 7.866236728659715e-08
POMC O 0 3.1375063826999394e-06
gene O 0 4.9573780636080755e-09
and O 0 2.6649003004308724e-09
define O 0 2.9639327436825624e-08
a O 0 9.776773168823638e-09
new O 0 2.789766995192622e-07
monogenic B-Disease 1 0.9999998807907104
endocrine I-Disease 1 0.9999998807907104
disorder I-Disease 0 0.00015279994113370776
resulting O 0 1.2468713350699545e-07
in O 0 2.7205270924923752e-08
early O 0 0.017833612859249115
- O 1 0.9999953508377075
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.004449277184903622
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9999741315841675
red O 1 0.9998669624328613
hair O 1 0.9771426916122437
pigmentation O 0 0.0038061209488660097
. O 0 9.094808888221451e-07
. O 0 4.7213429752446245e-06

A O 0 3.4369156765023945e-06
European O 0 3.986741830885876e-06
multicenter O 0 0.00011630597145995125
study O 0 5.62701814033062e-07
of O 0 4.9230722652282566e-05
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.8587967076655332e-07
classification O 0 6.867337987159772e-08
of O 0 2.4034269685557774e-08
105 O 0 4.299553069131434e-08
mutations O 0 6.625751503008814e-09
and O 0 1.409256933371239e-09
a O 0 9.78717884514424e-10
general O 0 2.7877833375100636e-09
system O 0 5.4191899856448345e-09
for O 0 1.0474486833444985e-09
genotype O 0 4.4106240437713495e-08
- O 0 2.7217465614626235e-08
based O 0 2.9055615691220282e-09
prediction O 0 3.073526215757738e-07
of O 0 1.5958725896325632e-07
metabolic O 0 0.028360264375805855
phenotype O 0 1.0099971404997632e-05
. O 0 2.506382543288055e-06

Phenylketonuria B-Disease 1 0.9874934554100037
( O 0 1.0768931133497972e-06
PKU B-Disease 0 0.00011517122766235843
) O 0 5.926455415306009e-08
and O 0 2.343399359006071e-07
mild B-Disease 1 0.999943733215332
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.002446645637974143
MHP B-Disease 1 1.0
) O 0 9.733125949651367e-08
are O 0 3.054456598761135e-08
allelic B-Disease 0 0.00027953454991802573
disorders I-Disease 0 7.841548722353764e-06
caused O 0 1.3143945487570363e-08
by O 0 1.045877495720049e-09
mutations O 0 1.7982741962185855e-09
in O 0 2.177236169131902e-09
the O 0 1.6687058845832325e-08
gene O 0 3.669180870247146e-08
encoding O 0 1.8577683249532129e-06
phenylalanine O 0 7.729590834060218e-06
hydroxylase O 0 0.00010822381591424346
( O 0 3.7905016370132216e-07
PAH O 0 4.5314391172723845e-05
) O 0 9.650569410268872e-08
. O 0 1.676453848631354e-06

Previous O 0 1.5584583934469265e-06
studies O 0 5.242802814109382e-08
have O 0 1.1706214886331168e-09
suggested O 0 2.658660624987874e-09
that O 0 1.8412447955196143e-10
the O 0 1.7711139221887606e-09
highly O 0 4.1729965261083635e-08
variable O 0 2.552696287239087e-06
metabolic O 0 0.26468443870544434
phenotypes O 0 4.243950024829246e-05
of O 0 6.402690632967278e-05
PAH B-Disease 1 1.0
deficiency I-Disease 1 0.9967265129089355
correlate O 0 1.6069342336777481e-06
with O 0 2.9527447509281046e-07
PAH O 0 0.4179181456565857
genotypes O 0 5.411058009485714e-05
. O 0 4.462676315597491e-06

We O 0 4.458947842067573e-07
identified O 0 8.103346260668332e-08
both O 0 1.858092524287258e-08
causative O 0 1.8340583096687624e-07
mutations O 0 8.144409235910643e-08
in O 0 2.1718744136478563e-08
686 O 0 7.807997235431685e-07
patients O 0 7.428178072643732e-09
from O 0 1.1343721517675931e-08
seven O 0 9.521050969851785e-08
European O 0 5.140609005138685e-07
centers O 0 4.4452721681409457e-07
. O 0 8.072045147855533e-07

On O 0 4.557146553452185e-07
the O 0 1.0077389589469021e-08
basis O 0 9.189842664625303e-09
of O 0 2.9213600427624442e-09
the O 0 1.8153709646639982e-09
phenotypic O 0 4.18343660157916e-07
characteristics O 0 2.107934307105097e-07
of O 0 8.507458204576324e-08
297 O 0 2.983023534852691e-07
functionally O 0 2.544990138630965e-07
hemizygous O 0 2.2058877391373244e-07
patients O 0 3.535641557306235e-09
, O 0 7.079731245696053e-10
105 O 0 9.325805905291418e-09
of O 0 2.634998885753248e-09
the O 0 1.3673271404002207e-09
mutations O 0 1.210892608405345e-09
were O 0 9.895825270334058e-10
assigned O 0 8.709978849275046e-10
to O 0 3.016329686023056e-10
one O 0 5.833478144978699e-10
of O 0 3.990810348852847e-09
four O 0 9.772017861564564e-09
arbitrary O 0 9.949583557045116e-08
phenotype O 0 6.293493015618878e-07
categories O 0 5.745990279137914e-07
. O 0 1.922246838148567e-06

We O 0 1.2527011676866096e-06
proposed O 0 2.1369086766753753e-07
and O 0 1.6923449308592353e-08
tested O 0 3.426085726232486e-08
a O 0 1.5362073835234469e-09
simple O 0 2.1544170891729664e-09
model O 0 2.53711962550085e-09
for O 0 2.858730197008441e-10
correlation O 0 4.443917678287335e-09
between O 0 2.270679200222503e-09
genotype O 0 2.0786323773336335e-08
and O 0 3.623237487815345e-09
phenotypic O 0 9.299251928496233e-07
outcome O 0 2.1078669760754565e-06
. O 0 1.3221914514360833e-06

The O 0 1.0817628890436026e-06
observed O 0 1.015667862702685e-06
phenotype O 0 1.3823397466694587e-06
matched O 0 1.7121493556260248e-07
the O 0 2.5514612644883528e-08
predicted O 0 1.1642075037343602e-07
phenotype O 0 6.73208404577963e-08
in O 0 2.405113441739104e-09
79 O 0 1.023253304310856e-08
% O 0 3.7818750908691356e-10
of O 0 1.0508985903712187e-09
the O 0 7.141576219282797e-10
cases O 0 4.976369871734221e-10
, O 0 8.908145748831586e-11
and O 0 1.565024360106193e-10
in O 0 1.8312489025174017e-10
only O 0 5.446242345996666e-10
5 O 0 8.759212910547376e-09
of O 0 3.2719740250541918e-09
184 O 0 5.347551290668662e-09
patients O 0 9.058326866373534e-10
was O 0 6.318586542874982e-09
the O 0 3.914412349814711e-09
observed O 0 1.0575910813770406e-08
phenotype O 0 1.2656380832254399e-08
more O 0 1.0590333471283131e-10
than O 0 7.516004485452754e-11
one O 0 8.371413284802287e-11
category O 0 1.8624665143462948e-09
away O 0 2.0265449318657147e-09
from O 0 4.1292713692797633e-10
that O 0 5.926087398577806e-10
expected O 0 1.3054206249307754e-07
. O 0 9.011511110657011e-07

Among O 0 3.7245177963995957e-07
the O 0 4.4446231584061024e-08
seven O 0 1.6032766225748674e-08
contributing O 0 3.2942542027569743e-09
centers O 0 4.248916329885333e-09
, O 0 2.3813800931193896e-10
the O 0 5.980135275862608e-10
proportion O 0 1.586835218780891e-09
of O 0 1.3006650201319303e-09
patients O 0 2.371132457046343e-10
for O 0 1.518037084924373e-10
whom O 0 3.809728532644385e-09
the O 0 3.8330671969788455e-09
observed O 0 1.1525282062052611e-08
phenotype O 0 2.0291993862997515e-08
did O 0 2.6826065813168043e-09
not O 0 1.6746067865724967e-09
match O 0 3.05560774904734e-07
the O 0 2.0514983489761107e-08
predicted O 0 4.9792042489116284e-08
phenotype O 0 3.7456690193948816e-08
was O 0 1.0870723876621469e-08
4 O 0 1.7534414809006194e-08
% O 0 1.1264886801143348e-09
- O 0 9.416570634357413e-09
23 O 0 2.692840261886431e-08
% O 0 6.572972832685764e-09
( O 0 1.0856260779235072e-08
P O 0 6.507983016490471e-06
< O 0 7.384543891930662e-07
. O 0 3.3823681633293745e-08
0001 O 0 2.9707824069191702e-05
) O 0 2.0347521445529537e-09
, O 0 2.832077350412021e-10
suggesting O 0 1.4181903429388854e-09
that O 0 2.5386723279119394e-10
differences O 0 1.1133949762154316e-08
in O 0 7.458029749329853e-10
methods O 0 5.537268421562658e-09
used O 0 4.679880927227487e-10
for O 0 5.110243894712596e-10
mutation O 0 1.1775957098336676e-08
detection O 0 2.420956946025399e-07
or O 0 1.6198505647935235e-08
phenotype O 0 2.6642314310265647e-07
classification O 0 2.8607621160858798e-08
may O 0 3.910710866250611e-09
account O 0 3.0344374235546923e-10
for O 0 1.0602135835924287e-10
a O 0 2.2198765048386804e-10
considerable O 0 2.2344697203635633e-09
proportion O 0 7.647955158063269e-09
of O 0 2.4976865020676087e-08
genotype O 0 2.386968162682024e-06
- O 0 2.660313612068421e-06
phenotype O 0 2.8021252092003124e-06
inconsistencies O 0 6.985480013099732e-06
. O 0 2.577886789367767e-06

Our O 0 1.6103796269817394e-06
data O 0 8.901211856482405e-08
indicate O 0 2.7641176458814698e-08
that O 0 4.388803098720473e-09
the O 0 1.0389216242856492e-07
PAH O 0 0.0003954372077714652
- O 0 1.8293140158220922e-07
mutation O 0 1.6454347218086696e-08
genotype O 0 4.0524291478050145e-08
is O 0 5.635804600778727e-10
the O 0 1.6700966165572595e-09
main O 0 3.3462988824339845e-08
determinant O 0 3.693063774790062e-07
of O 0 1.462694996234859e-07
metabolic O 0 0.00035363115603104234
phenotype O 0 4.3060325083388307e-07
in O 0 9.157874458765036e-09
most O 0 1.0559926266751063e-08
patients O 0 2.94414604695703e-07
with O 0 6.172588655317668e-06
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0001768761285347864

In O 0 2.4861020619937335e-07
the O 0 2.4659335906562774e-08
present O 0 4.234022910054591e-09
study O 0 9.098429787357531e-10
, O 0 2.0607672512884534e-10
the O 0 5.853897366847605e-10
classification O 0 7.168409865698777e-09
of O 0 3.3697215684469484e-08
105 O 0 6.892137776048912e-07
PAH O 0 7.905877282610163e-05
mutations O 0 1.919405434591681e-08
may O 0 2.056692371965596e-09
allow O 0 2.365460050057777e-09
the O 0 3.519366353899045e-09
prediction O 0 5.802224123385713e-08
of O 0 4.295944044940825e-09
the O 0 3.669850867638047e-09
biochemical O 0 7.588079142806237e-08
phenotype O 0 6.384650674817749e-08
in O 0 6.9863981266848896e-09
> O 0 1.7977440336380823e-07
10 O 0 3.018197247683929e-08
, O 0 4.1648675619399e-09
000 O 0 2.7071981989479355e-08
genotypes O 0 4.875378323276891e-08
, O 0 1.1742486982768696e-09
which O 0 3.6376246459468575e-10
may O 0 1.0481541190543453e-09
be O 0 5.397102209592219e-10
useful O 0 3.356678490717968e-09
for O 0 4.6332790382130895e-10
the O 0 4.445070533876105e-09
management O 0 4.6820819221693455e-08
of O 0 7.169725080302669e-08
hyperphenylalaninemia B-Disease 1 0.9999933242797852
in O 0 1.8338658946959185e-07
newborns O 0 2.144529162251274e-06
. O 0 2.4523465071979444e-06

Somatic O 0 0.00020498422964010388
instability O 0 9.399628652317915e-06
of O 0 2.5525987439323217e-06
the O 0 1.3455589851218974e-06
CTG O 0 0.00018157853628508747
repeat O 0 1.2799766864191042e-06
in O 0 6.156264475976059e-08
mice O 0 2.3217171474243514e-07
transgenic O 0 1.306651284949112e-07
for O 0 9.209969675794127e-09
the O 0 3.582267527235672e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 1.7200341062562075e-06
is O 0 1.5901832073339506e-09
age O 0 3.2845859365693286e-09
dependent O 0 5.055430518652315e-10
but O 0 2.1772725289359585e-10
not O 0 2.545562372002763e-10
correlated O 0 1.4523063862625918e-09
to O 0 2.2692059342688253e-10
the O 0 2.2021444667785772e-09
relative O 0 1.3696096345938713e-07
intertissue O 0 1.8309455072085257e-06
transcription O 0 2.1407434758202726e-07
levels O 0 3.003665369760711e-07
and O 0 1.3230349793502683e-07
proliferative O 0 0.0006603118381462991
capacities O 0 3.821992504526861e-05
. O 0 2.1752236989414087e-06

A O 0 2.4755321646807715e-05
( O 0 1.0644859003150486e-06
CTG O 0 6.705245323246345e-05
) O 0 5.7255881813489395e-08
nexpansion O 0 1.1637772558970028e-06
in O 0 6.46096776080185e-09
the O 0 1.73775962508671e-08
3 O 0 3.0243234050431056e-07
- O 0 1.9801662176632817e-07
untranslated O 0 7.256796834553825e-06
region O 0 5.295384042369733e-08
( O 0 1.3538901555421035e-08
UTR O 0 3.928966634703102e-06
) O 0 5.093849342330259e-09
of O 0 2.6327043656237947e-08
the O 0 2.5137217107840115e-07
DM O 1 1.0
protein O 0 7.760752396279713e-07
kinase O 0 2.1943100136923022e-07
gene O 0 1.4458092501001829e-08
( O 0 3.844430551680489e-09
DMPK O 0 1.7334913309241529e-06
) O 0 2.003462284960733e-09
is O 0 3.742473275725189e-10
responsible O 0 8.274333218594165e-09
for O 0 2.5777534773396837e-08
causing O 1 0.9998975992202759
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9941242337226868
DM B-Disease 1 1.0
) O 0 7.088465849847125e-07
. O 0 1.9175849956809543e-06

Major O 0 1.408668867952656e-05
instability O 0 1.3286925423017237e-05
, O 0 2.6144546083628484e-08
with O 0 1.2294946172275445e-09
very O 0 1.6588643791948243e-09
large O 0 7.177640704014721e-10
expansions O 0 1.993297793490001e-08
between O 0 4.02743793870286e-09
generations O 0 4.720763779886283e-09
and O 0 5.052114837589272e-10
high O 0 7.1019692349238994e-09
levels O 0 4.350298787869633e-09
of O 0 5.1391695343738775e-09
somatic O 0 6.148578677311889e-07
mosaicism O 0 9.152872166851012e-07
, O 0 9.288788072048249e-10
is O 0 3.3125879816964243e-10
observed O 0 4.566488964741211e-09
in O 0 5.402862601755487e-09
patients O 0 3.205460430422136e-08
. O 0 7.425701937791018e-07

There O 0 3.199407387910469e-07
is O 0 4.920901464089411e-09
a O 0 3.692867789339971e-09
good O 0 1.416223138761552e-08
correlation O 0 4.329986680318143e-08
between O 0 1.2174029784262075e-08
repeat O 0 3.3896984774628436e-08
size O 0 1.9144072993526606e-08
( O 0 9.256916344568822e-10
at O 0 5.899059019043307e-09
least O 0 3.97640226301732e-10
in O 0 6.786367023892126e-10
leucocytes O 0 1.5217064230910182e-07
) O 0 6.009590047817426e-10
, O 0 4.1794681604478967e-10
clinical O 0 1.3704347878729095e-08
severity O 0 3.798266945409523e-08
and O 0 9.35698629689341e-09
age O 0 1.7384020623012475e-07
of O 0 3.109367412434949e-07
onset O 0 0.00020574338850565255
. O 0 5.525888354895869e-06

The O 0 1.152722143160645e-05
trinucleotide O 0 0.00019271198834758252
repeat O 0 4.87788975078729e-06
instability O 0 5.2799209697695915e-06
mechanisms O 0 0.00030996030545793474
involved O 0 1.4683428162243217e-07
in O 0 9.330559436193653e-08
DM B-Disease 1 1.0
and O 0 1.2130358300055377e-06
other O 0 8.340999357869805e-08
human O 0 9.021661389851943e-05
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 2.057225945151231e-09
unknown O 0 2.700638503938535e-07
. O 0 1.0054084214061731e-06

We O 0 1.3717759657083661e-06
studied O 0 1.6411896694989991e-06
somatic O 0 1.8025904182650265e-06
instability O 0 2.751042984527885e-07
by O 0 1.9579491805643556e-08
measuring O 0 3.852257577818818e-06
the O 0 9.519671095858939e-08
CTG O 0 7.034737336653052e-06
repeat O 0 8.599356249305856e-08
length O 0 5.824241977592237e-09
at O 0 7.1133303691794936e-09
several O 0 3.0461336231191183e-10
ages O 0 2.9089550768190975e-09
in O 0 2.829949885541083e-10
various O 0 8.39575520217295e-10
tissues O 0 1.4700375139398147e-08
of O 0 3.06672127692309e-08
transgenic O 0 8.985237087699716e-08
mice O 0 2.436600254895893e-08
carrying O 0 1.3954957189810102e-08
a O 0 1.45425307351843e-08
( O 0 2.0879939555129567e-08
CTG O 0 7.587654181406833e-06
) O 0 1.045265829446862e-08
55expansion O 0 4.945518981003261e-07
surrounded O 0 3.182645258448247e-08
by O 0 2.5139881287827848e-09
45 O 0 1.9163032050073525e-08
kb O 0 2.116629730153363e-06
of O 0 2.2755239115213044e-07
the O 0 3.1525883059657644e-07
human O 0 1.1580033060454298e-05
DM B-Disease 1 1.0
region O 0 1.19322720593118e-07
, O 0 3.519715408017987e-09
using O 0 6.850576550476717e-09
small O 0 3.031588136082064e-08
- O 0 3.018445511315804e-07
pool O 0 3.5345686910659424e-07
PCR O 0 7.979570568750205e-07
. O 0 8.321451900883403e-07

These O 0 2.8087049486202886e-07
mice O 0 4.6826180266634765e-08
have O 0 7.475148278146548e-10
been O 0 6.623612769374176e-10
shown O 0 3.161894357450734e-10
to O 0 5.583047912871564e-10
reproduce O 0 1.9874855539114833e-08
the O 0 4.107867379588015e-09
intergenerational O 0 7.882697872219069e-08
and O 0 4.81451545297773e-09
somatic O 0 3.415659648453584e-07
instability O 0 3.0860911692798254e-07
of O 0 9.920041321720419e-08
the O 0 1.423867104222154e-07
55 O 0 3.541090336511843e-07
CTG O 0 9.937775757862255e-06
repeat O 0 6.752544123855841e-08
suggesting O 0 9.819307145164657e-09
that O 0 3.900785805477369e-10
surrounding O 0 6.0249494282516025e-09
sequences O 0 3.931082570574063e-09
and O 0 3.049943186894666e-09
the O 0 4.311203394280483e-09
chromatin O 0 4.9921560218990635e-08
environment O 0 2.7258405310703893e-08
are O 0 5.427711058381135e-10
involved O 0 3.5987597346576194e-09
in O 0 3.6072951292709377e-09
instability O 0 9.158731586467184e-07
mechanisms O 0 0.003250369569286704
. O 0 8.400138540309854e-06

As O 0 2.8289929332458996e-07
observed O 0 7.445358818358727e-08
in O 0 2.8466033974439142e-09
some O 0 1.5136664144321799e-09
of O 0 9.343557039187544e-09
the O 0 9.412529422547777e-09
tissues O 0 1.4375576995462325e-07
of O 0 4.790669549947779e-07
DM B-Disease 1 1.0
patients O 0 1.1619198936330122e-08
, O 0 2.856855030319849e-10
there O 0 2.430392276320248e-10
is O 0 9.570196718433621e-11
a O 0 2.006482341387894e-10
tendency O 0 1.3142235077978626e-09
for O 0 1.0500349478803628e-09
repeat O 0 2.003669763439575e-08
length O 0 8.427413433764741e-09
and O 0 7.570482907226506e-09
somatic O 0 5.543494694393303e-07
mosaicism O 0 2.727458650042536e-07
to O 0 5.171162387185291e-10
increase O 0 7.922161537887717e-11
with O 0 5.099822994458769e-11
the O 0 6.861046730755049e-10
age O 0 1.0888383528140366e-08
of O 0 5.724755336444787e-09
the O 0 9.215434637610542e-09
mouse O 0 1.6718590245545784e-07
. O 0 3.194980422449589e-07

Furthermore O 0 1.8297760107088834e-06
, O 0 9.76557146259438e-09
we O 0 4.597505043335559e-09
observed O 0 2.669173104763445e-09
no O 0 3.1027788671700307e-10
correlation O 0 2.6347575232676945e-09
between O 0 5.59004043054756e-09
the O 0 8.427139874811473e-09
somatic O 0 5.553230835175782e-07
mutation O 0 6.276788155901158e-08
rate O 0 6.295407928291752e-08
and O 0 2.149000799533951e-08
tissue O 0 3.8930380696911016e-07
proliferation O 0 1.4527263374475297e-06
capacity O 0 2.075858674288611e-06
. O 0 1.1549244618436205e-06

The O 0 6.111810307629639e-06
somatic O 0 3.997339808847755e-05
mutation O 0 3.616104606862791e-07
rates O 0 2.397566412071228e-08
in O 0 1.4305624462807032e-09
different O 0 1.0560444740903563e-09
tissues O 0 1.10303348677121e-08
were O 0 4.0555745428605405e-09
also O 0 4.047273072238511e-10
not O 0 3.4706884588509013e-10
correlated O 0 3.1644420417364927e-09
to O 0 3.859195740751886e-10
the O 0 5.6040465601370215e-09
relative O 0 5.128264888298872e-07
inter O 0 0.002915956312790513
- O 0 2.3758414613439527e-07
tissue O 0 1.537439509036176e-08
difference O 0 7.991785011540742e-09
in O 0 3.9234845927715867e-10
transcriptional O 0 7.728857553956914e-09
levels O 0 4.026585731509158e-09
of O 0 9.36076660629226e-10
the O 0 8.370236170840428e-10
three O 0 5.077366305172859e-10
genes O 0 1.6849361905713067e-09
( O 0 1.3583046909459995e-09
DMAHP O 0 1.0346399221816682e-06
, O 0 1.0066248279372303e-08
DMPK O 0 2.1291411940183025e-06
and O 0 1.5554968868514152e-08
59 O 0 6.070434466209917e-08
) O 0 1.8002784818449413e-09
surrounding O 0 2.6582867462821014e-08
the O 0 1.608864153013201e-08
repeat O 0 1.0470620281921583e-07
. O 0 7.613159880293097e-08
. O 0 1.1491914619909949e-06

A O 0 2.1132570964255137e-06
novel O 0 8.200835281968466e-07
missense O 0 5.424370101536624e-06
mutation O 0 1.6075550490768364e-07
in O 0 1.4136835702061035e-08
patients O 0 7.525522427442866e-09
from O 0 8.314581023682877e-09
a O 0 3.0881455614917286e-08
retinoblastoma B-Disease 0 0.0016645343275740743
pedigree O 0 1.3956097291156766e-06
showing O 0 1.0355130086736608e-07
only O 0 1.1716719150456356e-08
mild O 0 2.7606728281170945e-07
expression O 0 3.494258393743621e-08
of O 0 3.2348186351782715e-08
the O 0 4.0249521049418036e-08
tumor B-Disease 0 1.261516331396706e-06
phenotype O 0 2.9238253773655742e-06
. O 0 1.5315163182094693e-06

We O 0 7.753933317644623e-08
have O 0 1.348613665186349e-09
used O 0 3.9504146620572556e-09
single O 0 9.013435331439723e-09
strand O 0 2.850848623836555e-08
conformation O 0 8.675910656563701e-09
polymorphism O 0 6.600007651513806e-09
analysis O 0 7.111929378744719e-10
to O 0 1.2362688650568998e-10
study O 0 3.2427716067928714e-10
the O 0 5.128327207337691e-10
27 O 0 1.836886553974182e-08
exons O 0 4.378788176495618e-08
of O 0 7.116749856095339e-09
the O 0 1.1881045480777175e-08
RB1 O 0 4.918464355796459e-07
gene O 0 1.7257391071723305e-09
in O 0 8.70904848238041e-10
individuals O 0 2.7636878896508676e-10
from O 0 6.81535772262265e-10
a O 0 1.8579958682707343e-09
family O 0 3.221148681120667e-09
showing O 0 5.592229612716437e-08
mild O 0 1.4315738781078835e-06
expression O 0 3.1763931929162936e-07
of O 0 6.156094514153665e-07
the O 0 5.205815227782296e-07
retinoblastoma B-Disease 0 0.0011791897704824805
phenotype O 0 2.954227056761738e-05
. O 0 4.948169134877389e-06

In O 0 1.0324423982410735e-07
this O 0 5.389225510299411e-09
family O 0 2.416922662007437e-09
affected O 0 1.167695717896322e-09
individuals O 0 1.307621788626534e-10
developed O 0 2.566420853611362e-08
unilateral B-Disease 0 1.7376030882587656e-05
tumors I-Disease 1 1.0
and O 0 4.954169980919687e-06
, O 0 6.502792082585529e-09
as O 0 1.0634485514415815e-09
a O 0 5.233705691054524e-10
result O 0 6.048853862239412e-09
of O 0 1.4990972019290894e-08
linkage O 0 8.374652082920875e-08
analysis O 0 1.2886130384970329e-08
, O 0 1.3225922579351845e-09
unaffected O 0 9.866843342365428e-09
mutation O 0 1.3021146383351834e-09
carriers O 0 1.0791718629832303e-09
were O 0 6.867544755095878e-09
also O 0 2.523755426864227e-09
identified O 0 1.2652397352042044e-08
within O 0 2.5165034500673755e-08
the O 0 4.271630515972902e-08
pedigree O 0 1.5842207403693465e-06
. O 0 2.3031998352962546e-06

A O 0 1.3494862969309906e-06
single O 0 6.621458226163668e-08
band O 0 8.147888763687661e-08
shift O 0 6.11983139719996e-08
using O 0 2.0145142443084296e-08
SSCP O 0 6.855009360151598e-06
was O 0 7.889767061897146e-08
identified O 0 2.8858346823312786e-08
in O 0 3.7088769833104607e-09
exon O 0 3.67168730974754e-08
21 O 0 9.225264996359783e-09
which O 0 2.6914717676795874e-10
resulted O 0 9.955805957417851e-09
in O 0 1.9001278328545368e-09
a O 0 1.7334164326143764e-08
missense O 0 1.5508658179896884e-06
mutation O 0 1.197233814309584e-07
converting O 0 9.389569868289982e-07
a O 0 3.1555057944387954e-07
cys O 0 0.00015052908565849066
- O 0 2.003907684411388e-05
- O 0 9.39772780839121e-06
> O 0 2.9608561362692853e-06
arg O 0 2.007921921176603e-06
at O 0 9.631004616039718e-08
nucleotide O 0 8.395631745372611e-09
position O 0 7.669783030905819e-08
28 O 0 8.26745889526137e-08
in O 0 1.3684288369120168e-08
the O 0 1.1512982922567971e-07
exon O 0 3.4025581499008695e-06
. O 0 1.9036314142795163e-06

The O 0 6.375511247824761e-07
mutation O 0 2.1251986481729546e-07
destroyed O 0 9.906558489092276e-07
an O 0 1.9063728373680533e-08
NdeI O 0 5.5525706557091326e-06
restriction O 0 2.0375189535570826e-07
enzyme O 0 3.8086412246229884e-07
site O 0 6.628685582654725e-07
. O 0 2.0346910787338857e-06

Analysis O 0 3.332980043069256e-07
of O 0 1.0147137885496704e-07
all O 0 1.2551206296507189e-08
family O 0 4.590083868549755e-09
members O 0 1.1424249324321067e-09
demonstrated O 0 1.1407989219947012e-08
that O 0 1.1490792761748025e-09
the O 0 3.268862869276745e-08
missense O 0 1.0992238458129577e-05
mutation O 0 5.762723503721645e-06
co O 0 4.302959860069677e-05
- O 0 0.006216724403202534
segregated O 0 6.524200557578297e-07
with O 0 1.009401007223687e-08
patients O 0 2.0044500104177132e-07
with O 0 4.614339843556081e-07
tumors B-Disease 1 1.0
or O 1 0.6743537187576294
who O 0 4.834597078229308e-08
, O 0 8.724992950348565e-10
as O 0 6.0129612400317e-10
a O 0 4.880015835873053e-10
result O 0 6.798444918132418e-09
of O 0 2.176025049038799e-08
linkage O 0 1.208639304195458e-07
analysis O 0 3.0881690094020087e-08
had O 0 1.130050897302226e-08
been O 0 7.676204560880251e-09
predicted O 0 4.512962803460141e-08
to O 0 2.0185479954193397e-09
carry O 0 1.2680349215088427e-08
the O 0 4.853241009072917e-08
predisposing O 0 5.84583040108555e-06
mutation O 0 2.1614744127873564e-06
. O 0 2.8475881208578357e-06

These O 0 8.298930254113657e-08
observations O 0 1.9059334022131225e-07
point O 0 3.365925138609782e-08
to O 0 1.614048561471293e-09
another O 0 2.9313902416561177e-09
region O 0 8.352076363848937e-09
of O 0 2.0314919524366815e-08
the O 0 3.620192856601534e-08
RB1 O 0 9.523509447717515e-07
gene O 0 3.0867544076329523e-09
where O 0 1.24413934710077e-09
mutations O 0 1.929535198286203e-09
only O 0 3.022053718382267e-10
modify O 0 2.9789843924987736e-09
the O 0 7.554756820127295e-10
function O 0 2.334381576929445e-09
of O 0 8.935496231821105e-10
the O 0 6.582441813840489e-10
gene O 0 1.12430365017957e-09
and O 0 1.1395631105415305e-09
raise O 0 2.023609502188606e-09
important O 0 1.7725333423257439e-09
questions O 0 7.84361020578217e-09
for O 0 3.599993636527188e-10
genetic O 0 8.665127282370122e-09
counseling O 0 1.8321024697343091e-09
in O 0 2.950162614201446e-10
families O 0 1.976215302512685e-10
with O 0 1.4401134451613729e-10
these O 0 8.915850280288851e-10
distinctive O 0 3.869702780434636e-08
phenotypes O 0 3.455750743341923e-07
. O 0 7.431638948673935e-08
. O 0 1.416977738699643e-06

Maternal B-Disease 0 0.0004747180500999093
disomy I-Disease 0 0.30311375856399536
and O 1 0.5565252304077148
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 1 0.9999376535415649
with O 0 1.3300790158154996e-07
gamete O 0 1.9685573988681426e-06
complementation O 0 3.4052848150167847e-06
in O 0 2.6023287968968134e-09
a O 0 3.119734692802467e-09
case O 0 1.6633896038342755e-08
of O 0 2.5690459537486277e-08
familial O 0 6.574943967052604e-08
translocation O 0 7.135673030234102e-08
( O 0 3.882602239713151e-09
3 O 0 2.541111676634955e-08
; O 0 1.3992851322086608e-09
15 O 0 1.6559726034870437e-08
) O 0 2.005867250076676e-09
( O 0 9.823086788429691e-10
p25 O 0 3.908692036702632e-08
; O 0 4.3739423194466553e-10
q11 O 0 1.4999239184021462e-08
. O 0 1.9082380120494236e-09
2 O 0 7.525238743255613e-08
) O 0 2.354033767915098e-08
. O 0 6.812465471739415e-07

Maternal B-Disease 0 0.02417593263089657
uniparental I-Disease 1 0.999718964099884
disomy I-Disease 1 0.999539852142334
( I-Disease 0 3.0835701181786135e-05
UPD I-Disease 1 1.0
) I-Disease 0 8.372287396696265e-08
for I-Disease 0 1.683054762224856e-08
chromosome I-Disease 0 2.044602354089875e-07
15 I-Disease 0 5.982171558116534e-08
is O 0 2.775215168782097e-09
responsible O 0 6.271675179192471e-09
for O 0 4.660284380619828e-10
an O 0 1.3688920830201567e-10
estimated O 0 3.152025307429085e-10
30 O 0 1.1433666236015938e-09
% O 0 3.474688869964382e-10
of O 0 1.0814570350348163e-09
cases O 0 5.2600181987827455e-09
of O 0 7.0506157499039546e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0008927409653551877
PWS B-Disease 1 1.0
) O 0 3.471844820523984e-07
. O 0 1.2723785403068177e-06

We O 0 1.2680950476351427e-06
report O 0 4.6230169914451835e-08
on O 0 8.837853116006045e-09
an O 0 3.269502169001015e-10
unusual O 0 2.9954165814416456e-09
case O 0 2.3833639062331713e-08
of O 0 3.568856143942867e-08
maternal B-Disease 0 4.885776547780551e-07
disomy I-Disease 0 5.19620016348199e-06
15 I-Disease 0 2.3619725197931984e-07
in O 0 4.7261181634894456e-08
PWS B-Disease 1 1.0
that O 0 5.722528229057389e-09
is O 0 5.929728374987064e-10
most O 0 8.595145428724749e-11
consistent O 0 1.3616119343140554e-09
with O 0 1.9629128877873825e-10
adjacent O 0 4.012608911807547e-09
- O 0 8.829799114096204e-09
1 O 0 2.3956282291237585e-08
segregation O 0 3.006361737334373e-08
of O 0 1.9737298462274566e-09
a O 0 1.6000315516961905e-09
paternal O 0 2.2853621217677755e-08
t O 0 6.381813477673859e-08
( O 0 1.4328371822358577e-09
3 O 0 1.4330237441129157e-08
; O 0 1.2419296702148586e-09
15 O 0 1.24893322350772e-08
) O 0 1.400414562091612e-09
( O 0 6.011390274451855e-10
p25 O 0 4.579102963475634e-08
; O 0 1.0662716265485983e-09
q11 O 0 2.8648027949884636e-08
. O 0 6.810679797908392e-10
2 O 0 1.4121528835175923e-08
) O 0 5.886086063000562e-10
with O 0 1.1921581499763079e-09
simultaneous O 0 1.2155842910033243e-07
maternal O 0 2.280547505506547e-06
meiotic O 0 3.446276605245657e-05
nondisjunction O 0 3.2460135116707534e-05
for O 0 2.3326832376824314e-07
chromosome O 0 1.282313974115823e-06
15 O 0 2.796684839267982e-06
. O 0 6.835660769866081e-06

The O 0 8.870329111232422e-07
patient O 0 2.2409459177197277e-07
( O 0 1.0897960756039993e-08
J O 0 3.669891839308548e-07
. O 0 4.601023118055991e-09
B O 0 4.274923526281782e-08
. O 0 5.84138293291403e-10
) O 0 3.3111730024515396e-10
, O 0 1.4496820410769828e-10
a O 0 9.11667019654061e-10
17 O 0 1.7720138245636008e-08
- O 0 3.870049880561055e-08
year O 0 1.5149725030028094e-08
- O 0 3.163502810821228e-07
old O 0 1.03422269148723e-06
white O 0 7.554994141401039e-08
male O 0 2.035405444189564e-08
with O 0 5.540226499789469e-09
PWS B-Disease 1 1.0
, O 0 2.175402613602273e-08
was O 0 3.235991030692276e-08
found O 0 1.7272275831814454e-09
to O 0 7.549527669681311e-10
have O 0 2.459243919616938e-09
47 O 0 6.153728548952131e-08
chromosomes O 0 1.5930041286082997e-08
with O 0 1.8263036638543895e-09
a O 0 8.705282716903184e-09
supernumerary O 0 2.5338479190395446e-06
, O 0 4.4208632310471785e-09
paternal O 0 2.928809905711205e-08
der O 0 4.298358180676587e-05
( O 0 6.30606544760326e-09
15 O 0 1.6310051975665374e-08
) O 0 6.692913445682791e-10
consisting O 0 4.216036408877244e-09
of O 0 1.050718712036769e-08
the O 0 4.163384659250369e-08
short O 0 1.7159564436042274e-07
arm O 0 1.374628141093126e-06
and O 0 1.318560833851734e-07
the O 0 5.652743766404456e-07
proximal O 0 0.13384538888931274
long O 0 1.6745602806622628e-06
arm O 0 3.4543841138656717e-06
of O 0 2.7809608127427055e-06
chromosome O 0 2.256772404507501e-06
15 O 0 3.826849024335388e-06
, O 0 1.972532857053011e-07
and O 0 3.4401818993501365e-06
distal O 1 0.9884228110313416
chromosome O 0 0.46934792399406433
arm O 1 0.9684427976608276
3p O 1 0.9991714954376221
. O 0 0.00021438326803036034

The O 0 5.33436877958593e-06
t O 0 1.1420135024309275e-06
( O 0 7.824782599641367e-09
3 O 0 3.4222907174807915e-08
; O 0 8.152234443059569e-10
15 O 0 3.547571125750437e-09
) O 0 2.3293725281980926e-10
was O 0 2.704992674296136e-09
present O 0 4.269833930869993e-10
in O 0 1.6976291206116656e-10
the O 0 4.301697886788247e-10
balanced O 0 1.891810486043255e-09
state O 0 7.3473033213034e-11
in O 0 1.3943476928623966e-10
the O 0 1.949719719007703e-09
patients O 0 2.1073536249360814e-09
father O 0 1.974484042932545e-08
and O 0 1.8664467305029575e-08
a O 0 7.74188961827349e-08
sister O 0 4.013371835753787e-06
. O 0 2.004584348469507e-05

Fluorescent O 0 2.207784382335376e-05
in O 0 1.2523580039669469e-07
situ O 0 1.4612467111874139e-06
hybridization O 0 2.6447834144960325e-08
analysis O 0 1.4137267356773009e-08
demonstrated O 0 2.972946688828415e-08
that O 0 2.2319905923495753e-09
the O 0 5.0618716329609015e-08
PWS B-Disease 1 1.0
critical O 0 7.932860626169713e-07
region O 0 5.361443555784717e-08
resided O 0 5.5217043382072006e-08
on O 0 1.4480309395992208e-08
the O 0 2.6520816653885504e-09
derivative O 0 1.117842263198554e-08
chromosome O 0 5.870000929775188e-09
3 O 0 9.072943285559631e-09
and O 0 3.398817061128767e-10
that O 0 6.087202963911409e-11
there O 0 4.0085984531756935e-10
was O 0 4.464110858748427e-09
no O 0 1.2966003826164751e-09
deletion O 0 1.8556026049054708e-08
of O 0 1.1227163199123424e-08
the O 0 8.501959314344276e-08
PWS B-Disease 1 1.0
region O 0 3.290206507244875e-07
on O 0 3.5063303016613645e-07
the O 0 3.227915712500362e-08
normal O 0 4.4430382928339895e-08
pair O 0 1.8863204331864836e-08
of O 0 1.1579376568704447e-08
15s O 0 2.1277242012729403e-06
present O 0 1.2576488295223953e-08
in O 0 3.795956260432831e-08
J O 0 2.6072095351992175e-05
. O 0 4.9884861255122814e-06

B O 0 0.0006788981845602393
. O 0 4.2077936086570844e-05

Methylation O 0 8.205527592508588e-06
analysis O 0 1.1769038792408537e-06
at O 0 1.671595782681834e-06
exon O 0 5.889993985874753e-07
alpha O 0 3.2677726835572685e-07
of O 0 6.325112167360203e-08
the O 0 2.0606357509223017e-08
small O 0 1.0280265527740085e-08
nuclear O 0 3.322771590319462e-06
ribonucleoprotein O 0 1.4534437468682881e-05
- O 0 1.5586426798108732e-06
associated O 0 3.3308322144876e-07
polypeptide O 0 9.80264417194121e-07
N O 0 1.988844815059565e-06
( O 0 8.310617083395755e-09
SNRPN O 0 1.819315116335929e-06
) O 0 1.579386066374866e-09
gene O 0 2.9073354834707743e-09
showed O 0 5.0664952233603344e-09
a O 0 3.6493712496366015e-09
pattern O 0 3.646381330213444e-08
characteristic O 0 4.8202515756656794e-08
of O 0 9.839443038117679e-09
only O 0 1.01702635202372e-09
the O 0 3.3415776812262266e-09
maternal O 0 2.6285647436452564e-08
chromosome O 0 2.7887367082257697e-08
15 O 0 6.039851285777331e-08
in O 0 6.126722240651361e-08
J O 0 9.210904681822285e-05
. O 0 1.3621884136227891e-05

B O 0 0.0005776026519015431
. O 0 4.5778873754898086e-05

Maternal B-Disease 0 9.498742292635143e-05
disomy I-Disease 0 7.5596894021146e-05
was O 0 8.903561479201016e-07
confirmed O 0 9.117825783278022e-08
by O 0 9.872414885592207e-09
polymerase O 0 8.180870736396173e-08
chain O 0 1.2389302916915312e-08
reaction O 0 6.1023213149269395e-09
analysis O 0 1.7998123880147432e-08
of O 0 1.7290380682766227e-08
microsatellite O 0 6.844792324045557e-07
repeats O 0 1.2901874413273617e-07
at O 0 1.28854338754536e-07
the O 0 1.1878416472654862e-08
gamma O 0 5.279293873172719e-07
- O 0 2.1473869082910824e-07
aminobutyric O 0 7.914740649539453e-07
acid O 0 3.4639988655271736e-08
receptor O 0 7.184934247561614e-08
beta3 O 0 1.078449145097693e-06
subunit O 0 1.9539449169769796e-07
( O 0 1.0728348875943539e-08
GABRB3 O 0 2.846895768016111e-06
) O 0 1.9802582684746994e-08
locus O 0 2.132085455741617e-06
. O 0 3.2786433621367905e-06

A O 0 9.945834790414665e-06
niece O 0 7.711140824540053e-06
( O 0 2.7103910227310735e-08
B O 0 1.1147405842848457e-07
. O 0 1.3687753153135418e-09
B O 0 2.117516295641053e-08
. O 0 5.545678916085706e-10
) O 0 9.617443647025326e-11
with O 0 1.0250220117136166e-10
45 O 0 1.0990219845297133e-09
chromosomes O 0 1.5451289137047297e-09
and O 0 4.5118050961967526e-10
the O 0 9.200484263338637e-10
derivative O 0 5.489955601234442e-09
3 O 0 5.992446983071886e-09
but O 0 5.246478806952837e-10
without O 0 2.3930513126657615e-09
the O 0 3.793124481177301e-09
der O 0 5.4407105380960274e-06
( O 0 3.0294193820168402e-09
15 O 0 1.622893464059416e-08
) O 0 9.96933091634844e-10
demonstrated O 0 1.2687753070395047e-08
a O 0 4.9488657616336695e-09
phenotype O 0 1.2205457267100428e-07
consistent O 0 1.4074767129557131e-08
with O 0 1.901083873656617e-10
that O 0 2.3751520195069986e-10
reported O 0 1.848332265019792e-09
for O 0 1.4506259526925191e-09
haploinsufficiency O 0 2.773084872842446e-07
of O 0 1.1945913058752922e-07
distal O 0 6.4194541664619464e-06
3 O 0 1.0493544323253445e-05
p O 0 3.390924393897876e-05
. O 0 4.336642177804606e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
associated O 0 8.694882126292214e-06
with O 0 1.1590428528052144e-07
unbalanced O 0 0.00011727229139069095
segregation O 0 5.710793629987165e-06
of O 0 2.2965357970861078e-07
non O 0 2.0400912035256624e-05
- O 0 8.754506779951043e-06
Robertsonian O 0 4.4498567149275914e-05
translocations O 0 8.534743756172247e-07
has O 0 1.880973377055284e-09
been O 0 2.9683553393056172e-09
reported O 0 3.877843379740398e-09
previously O 0 2.9986690908145874e-09
but O 0 5.628843502414327e-10
has O 0 5.483126799821214e-11
not O 0 1.2719943154326785e-10
, O 0 9.196478994999424e-11
to O 0 1.718164499564523e-10
our O 0 1.1607940164637398e-09
knowledge O 0 9.971409475895143e-09
, O 0 3.153570737879363e-10
been O 0 4.767925498860848e-10
observed O 0 1.3867206272166754e-09
in O 0 5.08087349970765e-10
a O 0 3.0976183840181193e-09
case O 0 1.1571719227276844e-07
of O 0 1.1108136277471203e-06
PWS B-Disease 1 1.0
. O 0 5.1832510507665575e-05

Furthermore O 0 8.175828952516895e-06
, O 0 6.521500495182408e-08
our O 0 2.362764917052118e-08
findings O 0 9.931207856084256e-09
are O 0 3.495214950799408e-10
best O 0 2.198430548716601e-09
interpreted O 0 4.120768615223369e-09
as O 0 2.6467503744243004e-09
true O 0 6.472713209859648e-08
gamete O 0 1.253850996363326e-06
complementation O 0 2.7612516078079352e-06
resulting O 0 1.5657610674679745e-07
in O 0 1.0667750416359922e-07
maternal B-Disease 0 0.00011544083099579439
UPD I-Disease 1 1.0
15 I-Disease 0 0.00023655178665649146
and O 0 0.0002733156434260309
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9985700845718384
- I-Disease 1 0.9999954700469971
Jampel I-Disease 1 0.9999985694885254
syndrome I-Disease 1 0.9612011313438416
type I-Disease 0 3.922218456864357e-05
2 I-Disease 0 0.00019244903523940593
and O 0 1.1258125596214086e-06
Stuve B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.9999947547912598
: O 0 6.0992260131342846e-09
a O 0 1.3675330867712887e-09
case O 0 3.5727840685950696e-09
for O 0 6.702264854219209e-10
" O 0 2.2491841278338143e-08
lumping O 0 8.560293451864709e-08
" O 0 2.9187503969296813e-07
. O 0 9.429924716641835e-07

Recent O 0 3.8855532125126047e-07
studies O 0 9.076875784330696e-08
demonstrated O 0 1.1323437121291136e-07
the O 0 1.3899095208103063e-08
existence O 0 2.8471587754097527e-08
of O 0 1.5890469384771677e-08
a O 0 4.030973332902477e-09
genetically O 0 2.4471496828937234e-08
distinct O 0 6.4632974527967235e-09
, O 0 4.689343358066367e-10
usually O 0 1.6362725063778782e-10
lethal O 0 4.2909160669069024e-09
form O 0 3.962987271677321e-09
of O 0 1.9592977906768283e-08
the O 0 5.709688011279468e-08
Schwartz B-Disease 0 0.00013235815276857466
- I-Disease 0 0.009611266665160656
Jampel I-Disease 1 0.9999654293060303
syndrome I-Disease 1 0.964047372341156
( O 0 6.524785334249827e-08
SJS B-Disease 0 0.00023203613818623126
) O 0 2.7503022081987183e-08
of O 0 2.7814758141175844e-07
myotonia B-Disease 1 0.9999641180038452
and O 0 0.00010626226139720529
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 0.9999994039535522
, O 0 7.235584575937537e-08
which O 0 1.593295984037013e-08
we O 0 3.36972796333157e-08
called O 0 8.003198104233888e-08
SJS B-Disease 0 3.209853093721904e-05
type I-Disease 0 1.9913957203243626e-06
2 I-Disease 0 7.921129508758895e-06
. O 0 1.986952838706202e-06

This O 0 2.815444304360426e-07
disorder O 0 0.15218240022659302
is O 0 5.249374268601059e-09
reminiscent O 0 2.528382765376591e-07
of O 0 6.017716458472933e-08
another O 0 1.2612448863080772e-08
rare O 0 2.509639429604249e-08
condition O 0 4.4021692247042665e-07
, O 0 1.2863194065459993e-08
the O 0 7.993251927018719e-08
Stuve B-Disease 1 0.993236243724823
- I-Disease 1 0.9999958276748657
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.5098082712938776e-06
SWS B-Disease 0 0.0003854904498439282
) O 0 5.232969613189198e-09
, O 0 2.3081625499798974e-09
which O 0 7.021103698434672e-09
comprises O 0 5.116198664723015e-08
campomelia B-Disease 0 1.2322559541644296e-06
at O 0 2.474957625508978e-07
birth O 0 2.669486036666058e-07
with O 0 1.1812076650130621e-07
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 9.709019650472328e-07
contractures B-Disease 0 0.09303358197212219
, O 0 3.033456508205745e-08
and O 0 2.538796017859113e-08
early B-Disease 0 3.861453308218188e-07
death I-Disease 0 4.232509581925115e-06
. O 0 1.7532393030705862e-06

To O 0 1.415423014350381e-07
test O 0 8.987808541860431e-08
for O 0 1.8931172185432388e-09
possible O 0 3.061076014887476e-08
nosologic O 0 7.261326686602843e-07
identity O 0 1.8251764544174875e-08
between O 0 1.9744087254025544e-08
these O 0 1.782630931757012e-08
disorders O 0 3.9060614653863013e-07
, O 0 4.3723494269620744e-10
we O 0 9.49869627397959e-10
reviewed O 0 4.158041466695295e-09
the O 0 3.91458948589829e-10
literature O 0 9.76450476031232e-10
and O 0 1.838479368743151e-10
obtained O 0 2.0376609288774716e-09
a O 0 5.097588462454894e-10
follow O 0 1.6800488777946043e-09
- O 0 4.796385955074811e-09
up O 0 1.0402789740737717e-09
of O 0 1.2198917431760492e-09
the O 0 3.196835574037493e-10
only O 0 2.7251878531586726e-10
two O 0 3.046644880821958e-10
surviving O 0 1.0219698864943894e-08
patients O 0 4.5004427962069826e-10
, O 0 4.2423389801093947e-10
one O 0 6.989460121786806e-10
with O 0 2.7454947204574864e-09
SJS B-Disease 0 5.52627352590207e-06
type I-Disease 0 3.9062479118001647e-07
2 I-Disease 0 4.888554485660279e-07
at O 0 2.1504561686924717e-08
age O 0 3.0838003262090297e-09
10 O 0 5.478289488713983e-10
years O 0 2.8459723466767173e-10
and O 0 2.6609472958405433e-10
another O 0 7.704113458295581e-10
with O 0 1.940319016568992e-09
SWS B-Disease 0 3.489241862553172e-06
at O 0 5.410599968058705e-08
age O 0 4.2123886601075355e-08
7 O 0 2.0380632292926748e-07
years O 0 1.3093831796595623e-07
. O 0 5.630512873722182e-07

Patients O 0 3.398442686375347e-06
reported O 0 2.3261385706518922e-07
as O 0 1.2998102150163504e-08
having O 0 8.454271238633737e-08
either O 0 1.505368572907173e-06
neonatal O 1 0.9999998807907104
SJS B-Disease 1 1.0
or O 0 0.017142193391919136
SWS B-Disease 0 0.09779869019985199
presented O 0 8.68222116423567e-08
a O 0 2.092933382158435e-09
combination O 0 8.57758131189712e-09
of O 0 1.4712605356237418e-08
a O 0 7.36032745862758e-09
severe O 0 8.355802492587827e-06
, O 0 1.0756711077419823e-07
prenatal O 1 0.6635010838508606
- O 0 0.11646082997322083
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 1.055499296853668e-06
with O 0 3.181851207045838e-05
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 1.0
respiratory O 1 1.0
and O 1 0.9996635913848877
feeding O 0 0.02881750464439392
difficulties O 0 0.02190612070262432
, O 0 8.123774364321434e-08
tendency O 0 5.1558831870579525e-08
to O 0 1.2424089312901287e-08
hyperthermia B-Disease 0 0.12997056543827057
, O 0 1.0152360729875909e-08
and O 0 2.153722755693366e-09
frequent O 0 1.8477047669662738e-09
death O 0 8.860203593030747e-08
in O 0 5.438843597715959e-09
infancy O 0 1.1260424344072817e-06
) O 0 8.828666131499574e-10
with O 0 3.8702302473936356e-10
a O 0 5.055172724865997e-09
distinct O 0 2.3606033039413887e-07
campomelic B-Disease 0 0.006332077085971832
- I-Disease 1 0.8797961473464966
metaphyseal I-Disease 1 0.7672155499458313
skeletal I-Disease 1 0.999996542930603
dysplasia I-Disease 1 0.999996542930603
. O 0 6.821010174462572e-05

The O 0 3.799219996380998e-07
similarity O 0 3.6137259940005606e-07
of O 0 2.966552301586489e-07
the O 0 4.067832293230822e-08
clinical O 0 9.565125083099701e-07
and O 0 2.109566743513369e-08
radiographic O 0 5.456965300254524e-05
findings O 0 5.902973043703241e-07
is O 0 2.3540998039806027e-09
so O 0 5.044854534119736e-10
extensive O 0 1.6871036789822824e-09
that O 0 4.72585193200814e-10
these O 0 1.8086046438270387e-08
disorders O 0 9.36215201363666e-06
appear O 0 6.662755680508781e-09
to O 0 9.884130180992656e-10
be O 0 1.651451864148612e-09
a O 0 2.6654696227979002e-09
single O 0 1.5828156563202356e-08
entity O 0 7.791647362864751e-07
. O 0 2.4795365334284725e-06

The O 0 4.030340278404765e-06
follow O 0 1.127065274886263e-06
- O 0 1.3031635717197787e-06
up O 0 8.19698620091458e-09
observation O 0 6.574354927124659e-08
of O 0 5.202377195701047e-09
an O 0 1.2504050572736958e-10
identical O 0 3.842810514242956e-09
and O 0 1.924485015791788e-09
unique O 0 6.937518559624323e-09
pattern O 0 1.2603799177668407e-06
of O 0 2.5075134544749744e-05
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 0.9999979734420776
in O 0 5.24047365502156e-08
the O 0 5.496664101656279e-08
two O 0 2.8276150310091452e-09
patients O 0 9.603481343489761e-10
( O 0 4.3355438683612135e-10
one O 0 8.117230221316163e-10
with O 0 8.174156906903818e-10
SJS B-Disease 0 8.856129056766804e-07
type I-Disease 0 3.036067397488296e-08
2 I-Disease 0 1.146825141518093e-07
, O 0 1.047964159894832e-09
one O 0 6.352212089666409e-10
with O 0 1.6638267430479914e-09
SWS B-Disease 0 2.5861088488454698e-06
) O 0 3.2679323691553464e-09
surviving O 0 8.443361565468877e-08
beyond O 0 1.2507788937909936e-07
infancy O 0 3.0921952998141933e-07
adds O 0 5.772692990291262e-09
to O 0 3.984434726600483e-10
the O 0 5.281317605465574e-10
evidence O 0 2.7304389860205447e-09
in O 0 8.513569849100122e-10
favor O 0 1.6209229514174694e-08
of O 0 3.8396837709342435e-08
identity O 0 2.784899777452665e-07
. O 0 2.194629360019462e-06

The O 0 1.110375137614028e-06
hypothesis O 0 1.3159043419364025e-06
that O 0 3.91756600492954e-08
SWS B-Disease 0 2.673983726708684e-05
and O 0 7.11611463088957e-08
SJS B-Disease 0 5.4817348427604884e-05
type I-Disease 0 1.929847257997608e-06
2 I-Disease 0 3.3292997159151128e-06
are O 0 1.4469894171753594e-09
the O 0 2.4301847201257942e-09
same O 0 7.434457494071012e-09
disorder O 0 8.393969608277985e-08
should O 0 5.639450018080083e-10
be O 0 1.3145393662483684e-09
testable O 0 2.569094981197395e-08
by O 0 2.2223380080621524e-10
molecular O 0 6.813801967098243e-09
methods O 0 4.8871559243934826e-08
. O 0 1.9092984970825455e-08
. O 0 3.6948992487850774e-07

A O 0 4.660458671423839e-06
mouse O 0 6.453371383940976e-07
model O 0 2.4185291636058537e-07
of O 0 1.565014571269785e-07
severe O 1 0.9996840953826904
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9996092915534973
defects O 1 0.999976396560669
in O 0 1.038899426930584e-06
hemostasis O 0 0.45562803745269775
and O 0 1.092737238650443e-05
thrombosis B-Disease 1 0.8691068291664124
. O 0 0.00010852072591660544

von B-Disease 1 0.9956381916999817
Willebrand I-Disease 1 0.999893307685852
factor I-Disease 0 0.002580091590061784
( I-Disease 0 2.6767770577862393e-06
vWf I-Disease 1 0.5021976828575134
) I-Disease 0 1.0324278264306486e-05
deficiency I-Disease 1 0.9999992847442627
causes O 1 0.9098066091537476
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.0005897045484744012
humans O 0 3.6048855690751225e-05
. O 0 2.6521593099460006e-06

We O 0 1.1975059805990895e-06
generated O 0 7.818743341658774e-08
a O 0 1.1714037739807281e-08
mouse O 0 1.6658532331348397e-08
model O 0 7.847591021459266e-09
for O 0 4.0375119914060065e-10
this O 0 3.7622122084357557e-10
disease O 0 9.663970734763438e-10
by O 0 1.4836526451844634e-10
using O 0 1.939371996328987e-09
gene O 0 1.5033322142699035e-08
targeting O 0 1.9393105787912646e-07
. O 0 1.220699800796865e-06

vWf B-Disease 0 0.03133523464202881
- I-Disease 1 0.9999468326568604
deficient I-Disease 0 0.19113357365131378
mice O 0 2.5241620278393384e-06
appeared O 0 2.918088171099953e-07
normal O 0 1.69942310890292e-07
at O 0 3.519609492741438e-08
birth O 0 1.4274416093584819e-09
; O 0 1.8912613142241241e-10
they O 0 6.080858594437188e-10
were O 0 4.800248198932877e-09
viable O 0 2.420855196305638e-07
and O 0 6.710994426839534e-08
fertile O 0 4.666400400310522e-06
. O 0 2.9031978101556888e-06

Neither O 0 5.206335481489077e-05
vWf O 0 0.00020772615971509367
nor O 0 4.550210360321216e-05
vWf O 0 0.00019469595281407237
propolypeptide O 0 0.00010224172729067504
( O 0 3.4953725958075665e-07
von B-Disease 0 0.00031771862995810807
Willebrand I-Disease 0 0.00015337990771513432
antigen O 0 1.333541717940534e-06
II O 0 0.08007055521011353
) O 0 9.12279762843582e-09
were O 0 7.864178641625585e-09
detectable O 0 7.438744376031536e-08
in O 0 1.156784668054911e-09
plasma O 0 5.571692085482027e-08
, O 0 1.477023836571334e-09
platelets O 0 2.0710617221197936e-08
, O 0 1.249227943311837e-09
or O 0 1.1639156305420784e-09
endothelial O 0 4.071338821631798e-09
cells O 0 3.283972205281316e-09
of O 0 5.045607043285827e-09
the O 0 1.697478602125102e-08
homozygous O 0 4.5520516778196907e-07
mutant O 0 7.726510375505313e-06
mice O 0 4.6947275222919416e-06
. O 0 3.403992650419241e-06

The O 0 4.720227025245549e-06
mutant O 0 7.150194142013788e-05
mice O 0 1.9082019207417034e-05
exhibited O 0 5.830574536958011e-06
defects O 0 0.001777424942702055
in O 0 8.761021774716937e-08
hemostasis O 0 0.008569715544581413
with O 0 2.0803973654892616e-08
a O 0 2.7147681436190396e-08
highly O 0 7.085146535246167e-06
prolonged O 0 0.1045900210738182
bleeding O 1 0.7014399170875549
time O 0 5.319730576047732e-07
and O 0 3.474692533700363e-08
spontaneous O 0 1.9189465660929272e-07
bleeding O 0 4.039673342504102e-07
events O 0 4.878948356434876e-09
in O 0 1.574744667998118e-09
approximately O 0 8.298922660188168e-10
10 O 0 2.974907431507745e-09
% O 0 3.183639352144496e-09
of O 0 1.3389676212227641e-07
neonates O 0 1.0771400411613286e-05
. O 0 6.511646006401861e-06

As O 0 2.5852432372630574e-07
in O 0 4.055638314071075e-08
the O 0 6.685315412369164e-08
human O 0 2.1687455387109367e-07
disease O 0 8.038507814944751e-08
, O 0 4.903135120137847e-10
the O 0 1.2044154562573794e-09
factor O 0 8.56576143348775e-09
VIII O 0 1.0368384209868964e-05
level O 0 4.90195304791996e-07
in O 0 9.848186710570417e-10
these O 0 1.1082672557449769e-09
mice O 0 6.3952021456259445e-09
was O 0 3.0433477959945776e-09
reduced O 0 3.5967835376737867e-09
strongly O 0 4.431413569427889e-10
as O 0 2.8341523572450456e-10
a O 0 1.2347982358829057e-10
result O 0 7.660126977171444e-10
of O 0 8.281592633885282e-10
the O 0 5.353713028455331e-10
lack O 0 6.447352429717057e-09
of O 0 1.6132390978640387e-09
protection O 0 5.365932143064356e-09
provided O 0 2.8678410757265738e-09
by O 0 1.358828871644846e-08
vWf O 0 1.4640986591984984e-05
. O 0 6.59796114632627e-06

Defective O 1 0.7547596096992493
thrombosis B-Disease 0 0.034019164741039276
in O 0 7.041625167403254e-07
mutant O 0 2.4498779112036573e-06
mice O 0 1.1806074695641655e-07
was O 0 3.377958535111247e-08
also O 0 7.883442232348159e-10
evident O 0 7.101481624971484e-09
in O 0 5.681263792745028e-10
an O 0 1.9813366225474027e-10
in O 0 1.3945611332388808e-09
vivo O 0 1.1433568403163008e-07
model O 0 2.2984399095093977e-07
of O 0 3.5515515719453106e-06
vascular B-Disease 1 0.9999998807907104
injury I-Disease 1 1.0
. O 0 0.0017324191285297275

In O 0 8.444360588555355e-08
this O 0 6.69853639223561e-09
model O 0 6.740602742638657e-08
, O 0 1.0371967285038863e-08
the O 0 4.897709970919095e-08
exteriorized O 0 4.45648402092047e-06
mesentery O 0 5.680051344825188e-06
was O 0 3.566495649920398e-07
superfused O 0 3.2461653063364793e-06
with O 0 2.9753744357208234e-08
ferric O 0 6.322763510979712e-06
chloride O 0 3.745508934116515e-07
and O 0 1.0916875936572978e-07
the O 0 2.7939703883816946e-08
accumulation O 0 1.8032902460163314e-07
of O 0 6.594159174255765e-08
fluorescently O 0 5.037830419496458e-07
labeled O 0 2.0157980173962642e-08
platelets O 0 4.8933401330941706e-08
was O 0 2.2433702895341412e-08
observed O 0 9.234419451331632e-09
by O 0 6.843980937532024e-09
intravital O 0 3.6852886751148617e-06
microscopy O 0 1.7675363778835163e-05
. O 0 2.7288685942039592e-06

We O 0 8.845257752909674e-07
conclude O 0 8.057294280661154e-07
that O 0 2.7476949604476886e-09
these O 0 5.134750846735869e-09
mice O 0 6.041349820407049e-08
very O 0 1.553617146043962e-08
closely O 0 1.1607718164441394e-07
mimic O 0 4.990605157217942e-05
severe O 0 0.2987896800041199
human O 1 0.9831673502922058
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 1.8360693502472714e-05
will O 0 1.4653011248810799e-08
be O 0 2.1018262685856826e-09
very O 0 5.285953896816409e-10
useful O 0 1.61611557469854e-09
for O 0 2.0045851090166877e-10
investigating O 0 4.703740952294311e-09
the O 0 6.29445384703331e-10
role O 0 2.07356287695859e-09
of O 0 5.301091121623358e-09
vWf O 0 2.601390463041753e-07
in O 0 9.09942432514299e-09
normal O 0 2.3376470892344514e-07
physiology O 0 1.1920675433430006e-06
and O 0 5.165102567872282e-09
in O 0 5.456080920396289e-09
disease O 0 2.117160846637489e-08
models O 0 2.4238717699631707e-08
. O 0 3.034399753687467e-08
. O 0 5.010203949495917e-07

Oral O 0 0.00036688215914182365
contraceptives O 0 2.9265449484228157e-05
and O 0 5.2726267796288084e-08
the O 0 4.235252504258824e-08
risk O 0 3.2240134260064224e-06
of O 1 0.998353123664856
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9999521970748901

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 1 0.9923381209373474
Study O 0 4.145214461459545e-06
Group O 0 1.088005660676572e-06
. O 0 4.927421741740545e-06

BACKGROUND O 0 4.5978555135661736e-05
Women O 0 4.214799957935611e-07
with O 0 2.466868265216249e-09
mutations O 0 3.8501393184731114e-09
in O 0 1.2215587430475239e-09
either O 0 9.680911183806984e-09
the O 0 5.17577589675966e-08
BRCA1 O 0 9.441914272656504e-08
or O 0 1.2051859066275483e-08
the O 0 6.1929830152962495e-09
BRCA2 O 0 7.422615055929782e-08
gene O 0 5.084404453015168e-09
have O 0 1.1267766719669225e-09
a O 0 1.2143271943543255e-09
high O 0 7.245804312105975e-08
lifetime O 0 2.2927456200250163e-07
risk O 0 4.841157078772085e-06
of O 1 0.9990966320037842
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.01138617005199194

Oral O 0 0.4378594160079956
contraceptives O 1 0.9967657327651978
protect O 0 0.00047064918908290565
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 6.582506102859043e-06
general O 0 7.841038609512907e-07
, O 0 1.565299778683027e-09
but O 0 3.386916025416298e-10
it O 0 5.509366227118839e-11
is O 0 1.8121759301492624e-11
not O 0 3.900969824943701e-11
known O 0 4.683560206331094e-10
whether O 0 6.865498169972284e-10
they O 0 6.87847390157259e-10
also O 0 5.309233608308261e-10
protect O 0 1.6719994277991646e-09
against O 0 5.407762415643447e-08
hereditary B-Disease 1 0.9999958276748657
forms I-Disease 1 0.9998471736907959
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.008310582488775253

METHODS O 0 3.8226617107284255e-06
We O 0 1.3889956562707084e-07
enrolled O 0 1.3459219871947425e-07
207 O 0 4.030484035411064e-07
women O 0 2.458185690557002e-07
with O 0 2.9508021270885365e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.826352894975571e-06
161 O 0 8.526513539663938e-08
of O 0 3.744290211216139e-08
their O 0 8.77391528320004e-08
sisters O 0 3.5842461443280627e-07
as O 0 1.1132378574529866e-08
controls O 0 1.1444510050750978e-07
in O 0 1.3845594004635586e-08
a O 0 1.6896807508715028e-08
case O 0 2.9228618814158835e-07
- O 0 3.4582302532726317e-07
control O 0 2.67840619017079e-07
study O 0 1.5136561160034034e-07
. O 0 5.596059509116458e-07

All O 0 9.813671795200207e-07
the O 0 4.811323250919486e-08
patients O 0 6.464456525634432e-09
carried O 0 4.612797699365956e-09
a O 0 2.0566415237510682e-09
pathogenic O 0 2.1207584666171897e-07
mutation O 0 2.481214878002902e-08
in O 0 6.02913363678681e-09
either O 0 4.829611199852479e-08
BRCA1 O 0 2.8229669624124654e-07
( O 0 1.0074776568558264e-08
179 O 0 3.774362866693082e-08
women O 0 7.991342698687731e-09
) O 0 1.6772856437086148e-09
or O 0 1.518027126223842e-08
BRCA2 O 0 6.683045512545505e-07
( O 0 1.5594181945743912e-08
28 O 0 5.347212663764367e-07
women O 0 1.8360218234647618e-07
) O 0 6.216382786305985e-08
. O 0 1.6440878880530363e-06

The O 0 1.378241904603783e-06
control O 0 3.827057298622094e-06
women O 0 6.570832056240761e-08
were O 0 1.098362378826323e-08
enrolled O 0 4.188072999511405e-09
regardless O 0 6.912435956962781e-09
of O 0 2.0293764446677187e-09
whether O 0 5.926878987594364e-10
or O 0 4.6065351533286503e-10
not O 0 1.8737034146454334e-10
they O 0 4.511891416036917e-10
had O 0 3.092163858298136e-09
either O 0 2.8483048808425337e-08
mutation O 0 5.636529749608599e-07
. O 0 1.9829585653496906e-06

Lifetime O 0 2.231902544735931e-05
histories O 0 3.2690243187971646e-06
of O 0 9.671371117292438e-07
oral O 0 4.890559011982987e-06
- O 0 2.0739639694511425e-07
contraceptive O 0 1.9133523210257408e-08
use O 0 1.0835320418678407e-09
were O 0 2.0294539382348376e-09
obtained O 0 5.7228013439214465e-09
by O 0 1.2039766961180476e-09
interview O 0 7.866352902397011e-09
or O 0 9.012588453316539e-10
by O 0 2.54844811919952e-10
written O 0 2.983697178216005e-10
questionnaire O 0 6.90697610217228e-10
and O 0 3.355953570594039e-10
were O 0 1.5525438712415962e-09
compared O 0 2.0728154748184124e-09
between O 0 2.1259409788143557e-09
patients O 0 1.6121255441703397e-09
and O 0 1.894099543875427e-09
control O 0 4.747276989292004e-07
women O 0 2.4788498365069245e-08
, O 0 1.1576520853040506e-09
after O 0 8.353032043828534e-09
adjustment O 0 1.4299084583058175e-08
for O 0 2.136679860820223e-10
year O 0 5.128953928235092e-10
of O 0 2.635149431995387e-09
birth O 0 1.2930250647968933e-08
and O 0 4.270237496939444e-08
parity O 0 2.842733920260798e-06
. O 0 1.3772512374998769e-06

RESULTS O 0 5.839051664224826e-05
The O 0 8.642928150948137e-07
adjusted O 0 5.867423169547692e-07
odds O 0 5.529038844542811e-07
ratio O 0 2.2579372398467967e-06
for O 0 1.9354272808413953e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 2.448882412409148e-07
with O 0 5.569953942519135e-10
any O 0 6.342285030491723e-10
past O 0 6.491078230475011e-10
use O 0 2.3833568452147347e-10
of O 0 1.6614609688048176e-09
oral O 0 4.0884447827238546e-08
contraceptives O 0 3.1130493738373843e-08
was O 0 2.513768748713119e-08
0 O 0 2.951058490907599e-07
. O 0 5.106181788505637e-07

5 O 0 4.6346281123987865e-06
( O 0 5.452567819475007e-08
95 O 0 2.1808538974710245e-07
percent O 0 3.4119864267267985e-08
confidence O 0 1.7772457283626864e-07
interval O 0 2.9349163099823272e-08
, O 0 3.9701728016261484e-10
0 O 0 7.437162552470511e-10
. O 0 7.145332936442372e-11
3 O 0 9.70782898512823e-10
to O 0 1.4688421312580857e-10
0 O 0 3.489101896292368e-09
. O 0 6.675524022448087e-10
8 O 0 5.797998525736148e-08
) O 0 1.5922173801641293e-08
. O 0 3.450123244874703e-07

The O 0 1.5833719544389169e-06
risk O 0 4.730198952529463e-07
decreased O 0 8.443828392046271e-08
with O 0 5.640773403925436e-10
increasing O 0 1.6874287522838927e-09
duration O 0 1.603778265746314e-08
of O 0 2.18723816836075e-09
use O 0 3.6951997017808935e-09
( O 0 2.5988069474180975e-09
P O 0 2.2278005928910716e-07
for O 0 6.516682748980429e-10
trend O 0 6.7020504701531536e-09
, O 0 2.462241521783426e-10
< O 0 4.4202055349273905e-09
0 O 0 2.130901677332986e-09
. O 0 3.212942967234511e-10
001 O 0 3.001852277861872e-08
) O 0 5.534073893587177e-11
; O 0 3.0563458014443157e-11
use O 0 2.2972689028843973e-10
for O 0 4.3451553466411497e-10
six O 0 1.7614183445147091e-09
or O 0 1.9833709674621502e-10
more O 0 3.114647775803725e-11
years O 0 1.1360078155941977e-10
was O 0 2.286071332235906e-09
associated O 0 1.7852093137094016e-09
with O 0 1.363087143158026e-10
a O 0 9.141324919248461e-10
60 O 0 6.021893650398624e-09
percent O 0 3.5341112258890917e-09
reduction O 0 2.4590056213469325e-08
in O 0 2.4447329494137193e-08
risk O 0 1.1094033425251837e-06
. O 0 2.310058789589675e-06

Oral O 0 0.017034081742167473
- O 0 4.913054726785049e-05
contraceptive O 0 2.6607856398186414e-06
use O 0 1.020491851022598e-07
protected O 0 0.00045244587818160653
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 9.542941370455083e-08
for O 0 3.6614049570005136e-09
carriers O 0 1.3902853313041419e-09
of O 0 4.856389779206438e-08
the O 0 9.269717082815987e-08
BRCA1 O 0 1.8840376014850335e-07
mutation O 0 2.5668221326213825e-08
( O 0 1.6401009439448444e-09
odds O 0 4.6382705676251135e-08
ratio O 0 5.869440933281567e-09
, O 0 3.363675449286063e-10
0 O 0 1.533797866493103e-09
. O 0 1.0909763370481329e-10
5 O 0 1.5393312180478347e-09
; O 0 1.5442030987244948e-10
95 O 0 3.8477607766651545e-09
percent O 0 1.0788075988088508e-09
confidence O 0 2.1318623311117335e-08
interval O 0 8.515165461631113e-09
, O 0 2.0604724870754154e-10
0 O 0 4.22039458936041e-10
. O 0 6.143142244896538e-11
3 O 0 4.933859432121324e-10
to O 0 1.137423627506351e-10
0 O 0 1.8877159835284374e-09
. O 0 4.0943717860564277e-10
9 O 0 1.2953848660401945e-08
) O 0 2.820094713307242e-10
and O 0 3.2771940716713743e-10
for O 0 3.379250212987017e-10
carriers O 0 9.475082940468837e-10
of O 0 2.9678304258595745e-08
the O 0 1.4229277667254792e-07
BRCA2 O 0 1.2042572734571877e-06
mutation O 0 5.7950021670194474e-08
( O 0 2.5495869859781806e-09
odds O 0 4.8003236940985516e-08
ratio O 0 1.0027616070829026e-08
, O 0 5.473296815772244e-10
0 O 0 4.003176012901122e-09
. O 0 3.807038850833777e-10
4 O 0 4.6126920061340115e-09
; O 0 7.084459130446419e-10
95 O 0 1.2170407792666538e-08
percent O 0 3.6392366897786133e-09
confidence O 0 5.211288467421582e-08
interval O 0 2.985516189824011e-08
, O 0 4.236363482235106e-10
0 O 0 1.181735154176522e-09
. O 0 9.84844497620152e-11
2 O 0 6.604827795797519e-10
to O 0 1.68782696152725e-10
1 O 0 2.4233388629113506e-09
. O 0 8.877568125065238e-10
1 O 0 3.087179578642463e-08
) O 0 1.8083357034015535e-08
. O 0 4.4301339130470296e-07

CONCLUSIONS O 0 0.0008286458905786276
Oral O 1 0.6496774554252625
- O 0 4.241117858327925e-05
contraceptive O 0 6.051400873730017e-07
use O 0 7.995474504696176e-09
may O 0 1.7655228390367483e-08
reduce O 0 3.645365964644043e-08
the O 0 3.569006068460112e-08
risk O 0 2.466483238094952e-05
of O 1 0.9993352293968201
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.8818504088358168e-07
women O 0 4.833432765138923e-09
with O 0 2.8685234743086596e-10
pathogenic O 0 4.279214138591669e-08
mutations O 0 5.8173252881488224e-09
in O 0 2.3172757046552306e-09
the O 0 1.6081125764344506e-08
BRCA1 O 0 1.0634641967044445e-06
or O 0 1.0899353810600587e-06
BRCA2 O 0 3.8836402382003143e-05
gene O 0 3.0387836886802688e-05

A O 0 3.361657263667439e-06
Japanese O 0 4.092833023605635e-06
family O 0 1.2228514378875843e-07
with O 0 9.747598284093328e-08
adrenoleukodystrophy B-Disease 1 1.0
with O 0 4.898130612218665e-08
a O 0 8.322135869320846e-08
codon O 0 8.052807061176281e-07
291 O 0 2.310093378810052e-07
deletion O 0 2.0330449501670955e-07
: O 0 8.159238618077325e-09
a O 0 5.0234447712682595e-09
clinical O 0 1.885331784023947e-07
, O 0 4.732393144024627e-09
biochemical O 0 7.539309763160418e-07
, O 0 3.340189991263287e-08
pathological O 0 1.3913497241446748e-05
, O 0 3.0823080976460915e-08
and O 0 1.3160696710201591e-07
genetic O 0 1.3300578984853928e-06
report O 0 7.567085731352563e-07
. O 0 3.889986601279816e-06

We O 0 5.002832494938048e-07
report O 0 2.7508376021501135e-08
a O 0 2.5536117664870517e-09
Japanese O 0 4.709057677132478e-08
family O 0 1.7430044962907232e-08
with O 0 3.102028074408736e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.06753906607627869
ALD B-Disease 1 1.0
) O 0 1.981826258656838e-08
with O 0 1.5871560732350076e-09
a O 0 3.826668315554116e-09
three O 0 3.527733216657225e-09
base O 0 3.311694385388364e-08
pair O 0 1.2427732087871846e-07
deletion O 0 3.0788390859015635e-07
( O 0 1.012312456083464e-08
delGAG O 0 4.2602272287695087e-07
291 O 0 5.870943908803383e-08
) O 0 2.8903723858775265e-09
in O 0 1.7214761172112958e-08
the O 0 5.987000122331665e-07
ALD B-Disease 1 1.0
gene O 0 1.0261722309223842e-05
. O 0 1.358656936645275e-05

A O 0 6.872749054309679e-07
variety O 0 7.452960204545889e-08
of O 0 3.547917870605488e-08
phenotypes O 0 1.896132459933142e-07
were O 0 1.389448289756956e-08
observed O 0 1.1361087182137908e-08
within O 0 5.873852959581427e-09
this O 0 3.759890176979752e-09
family O 0 1.5746612902489687e-08
. O 0 5.14630414727435e-07

While O 0 1.1570190281418036e-06
the O 0 1.675362426567517e-07
proband O 0 1.3507169569493271e-05
( O 0 8.550091301628981e-09
patient O 0 7.41242622837035e-09
1 O 0 7.943613411498518e-08
) O 0 3.0629669911519386e-09
was O 0 1.3412649657595921e-08
classified O 0 4.733296421477462e-09
as O 0 1.4319246899319182e-09
having O 0 4.394851149669421e-09
a O 0 1.348418265934015e-09
rare O 0 3.477992782663364e-09
intermediate O 0 9.475252937818368e-08
type O 0 1.0942121519974535e-07
of O 0 8.791587902123865e-08
adult O 0 1.0909523098234786e-06
cerebral O 0 4.771794920088723e-05
and O 0 5.15420197189087e-07
cerebello O 1 0.9214275479316711
- O 0 0.017699021846055984
brain O 0 8.253902342403308e-05
stem O 0 1.9980087984095007e-07
forms O 0 2.7499927668372948e-08
, O 0 1.2472185506595679e-09
his O 0 4.5579962026920384e-09
younger O 0 1.2727932130474073e-07
brother O 0 3.17526968274251e-07
( O 0 4.290563904163491e-09
patient O 0 5.156499671699066e-09
2 O 0 9.914613485761947e-08
) O 0 3.6663247993118375e-09
and O 0 9.497107100742141e-09
nephew O 0 5.028335181123111e-06
( O 0 9.111772669712082e-09
patient O 0 2.1213445222656446e-08
3 O 0 7.370992989308434e-07
) O 0 1.2176259112095522e-08
had O 0 6.532854968099855e-08
a O 0 2.14041477875071e-07
childhood O 0 0.001003527664579451
ALD B-Disease 1 1.0
type O 0 0.15858964622020721
. O 0 6.825322634540498e-05

Another O 0 4.887052909907652e-06
nephew O 0 7.81628186814487e-05
( O 0 1.442031276610578e-07
patient O 0 5.1311310755863815e-08
4 O 0 5.02755483466899e-07
) O 0 5.442880368633496e-09
of O 0 2.8599163925946414e-08
patient O 0 2.783295371955319e-08
1 O 0 4.2059224369950243e-07
was O 0 1.4477650722710678e-07
classified O 0 1.1161208846033333e-08
as O 0 1.3737236903565986e-09
having O 0 9.28581567194442e-09
an O 0 1.9310300025665583e-09
adolescent O 0 1.7821983533394814e-07
form O 0 1.3518778985144309e-07
. O 0 3.426312332521775e-06

The O 0 4.614019417203963e-06
tau O 0 7.753592399240006e-06
level O 0 8.763108212406223e-07
in O 0 1.1413365363921457e-08
the O 0 2.0425455105055335e-08
cerebrospinal O 0 1.7965887764148647e-06
fluid O 0 1.2040597994200652e-06
( O 0 3.208010568300779e-08
CSF O 0 2.1144223865121603e-06
) O 0 1.7872807678287472e-09
in O 0 1.579907205062625e-09
patient O 0 5.3228030871821375e-09
1 O 0 6.391546492068301e-08
was O 0 2.5031663852814745e-08
as O 0 1.5202573644401696e-09
high O 0 1.0394444416306214e-08
as O 0 1.4804103776189237e-10
that O 0 4.57524643171503e-11
of O 0 2.24526108816292e-09
patients O 0 2.6075954728810302e-09
with O 0 1.0369909375640418e-08
Alzheimers B-Disease 1 1.0
disease I-Disease 0 0.00012283178512006998
( O 0 1.051278086805496e-08
AD B-Disease 0 1.1597609272939735e-06
) O 0 3.954215443968678e-08
. O 0 5.396051392381196e-07

His O 0 5.202752799959853e-05
brain O 0 2.6431138394400477e-05
magnetic O 0 6.621775355597492e-06
resonance O 0 3.772836862481199e-06
image O 0 1.2106758049412747e-06
( O 0 4.2995203841655893e-08
MRI O 0 2.277480780321639e-05
) O 0 2.0762270125374016e-08
showed O 0 1.9390628835935786e-07
abnormalities B-Disease 0 9.930309715855401e-06
in I-Disease 0 1.660432147332358e-08
the I-Disease 0 1.289818385430408e-07
bilateral I-Disease 0 0.029821617528796196
cerebellar I-Disease 1 1.0
hemispheres I-Disease 1 0.9999994039535522
and O 0 0.004644252359867096
brain O 0 0.09939297288656235
stem O 0 2.021024840814789e-07
, O 0 4.893204175182575e-10
but O 0 4.5364495493416257e-10
not O 0 3.265638037763807e-10
in O 0 9.170577075501285e-10
the O 0 1.5941621356319047e-08
cerebral O 0 9.818680700846016e-05
white O 0 3.3444294444962e-08
matter O 0 1.194749188471178e-08
, O 0 2.936010601306549e-10
where O 0 3.8693595549865734e-10
marked O 0 1.5487582327722293e-09
reductions O 0 1.2456192521881349e-08
of O 0 2.3500454915392766e-08
the O 0 4.96251750803367e-08
cerebral O 0 4.066625024279347e-06
blood O 0 3.612433374655666e-08
flow O 0 2.0963861757650193e-08
and O 0 3.424093009130047e-08
oxygen O 0 7.55277511643726e-08
metabolism O 0 8.374457820536918e-07
were O 0 1.2983234931596144e-08
clearly O 0 8.974528675764759e-09
demonstrated O 0 3.429158468293281e-08
by O 0 6.690670240061536e-09
positron O 0 1.8088881859057437e-07
emission O 0 2.2328055138132186e-07
tomography O 0 9.866730579233263e-07
( O 0 1.3782095464875965e-08
PET O 0 1.3958477040887374e-07
) O 0 2.5069411435652e-08
. O 0 8.07877654551703e-07

In O 0 1.468090715661674e-07
patients O 0 1.1531856358715231e-08
2 O 0 6.035349287003555e-08
and O 0 6.175337574632067e-09
3 O 0 1.1226610752146371e-07
, O 0 7.819303537992539e-10
the O 0 1.96618143988303e-09
autopsy O 0 9.322181426796305e-08
findings O 0 3.894091804568234e-08
showed O 0 9.215244034521675e-08
massive O 0 8.387202797166537e-06
demyelination B-Disease 1 1.0
of I-Disease 1 0.9628031253814697
the I-Disease 0 0.000301449210382998
cerebral I-Disease 1 0.9997163414955139
white I-Disease 0 3.8891343479008356e-07
matter I-Disease 0 3.603535247975742e-08
with O 0 3.208527610265577e-10
sparing O 0 9.216189589267287e-09
of O 0 2.0196850414322398e-08
the O 0 1.2836386531489552e-07
U O 0 0.35905367136001587
- O 0 0.01426042802631855
fibers O 0 1.453711661270063e-06
, O 0 3.0484890167770118e-09
compatible O 0 9.897797070834713e-08
with O 0 5.719426043881981e-10
the O 0 5.732819108317244e-09
findings O 0 2.6251427698298357e-08
of O 0 1.3811865073876106e-07
childhood O 0 6.951654358999804e-05
ALD B-Disease 1 1.0
. O 0 6.042273889761418e-05

Oleic O 0 0.003940817900002003
and O 0 5.2905183110851794e-05
erucic O 0 0.014603829011321068
acids O 0 3.1423214750248007e-06
( O 0 8.709156418262864e-08
Lorenzos O 0 3.3802580219344236e-06
Oil O 0 8.684937569114481e-08
) O 0 8.290379494013678e-10
were O 0 7.995531459137339e-10
administered O 0 7.175477989562751e-10
to O 0 2.6226928961925466e-10
patients O 0 5.321968421512224e-10
1 O 0 1.7782637584673466e-08
and O 0 2.7375364197723684e-09
4 O 0 2.3843504948217742e-08
, O 0 1.4044664042867083e-10
but O 0 5.298700020417435e-11
sufficient O 0 7.333530449571413e-10
effectiveness O 0 3.2792839554929287e-09
was O 0 2.853834057958693e-09
not O 0 1.572409535910424e-09
obtained O 0 8.708724408279522e-08
. O 0 5.991083753542625e-07

The O 0 9.660806199462968e-07
findings O 0 2.4269394316434045e-07
in O 0 4.762183536399789e-09
this O 0 8.130773831993565e-10
family O 0 5.921499957040055e-10
suggest O 0 1.095392998529121e-09
that O 0 2.26365551303509e-10
delGAG291 O 0 3.19066195686446e-08
is O 0 1.5861958968521606e-10
part O 0 7.248285860406156e-10
of O 0 1.4817304050396274e-09
the O 0 1.337292165892734e-09
cause O 0 1.3410909716071728e-08
of O 0 5.5196405668311854e-08
Japanese O 0 1.1891010217368603e-05
ALD B-Disease 1 1.0
with O 0 5.1765063346920215e-08
phenotypic O 0 1.968794094864279e-05
variations O 0 3.126836418232415e-06
. O 0 3.2714942790335044e-06

Moreover O 0 9.934335594152799e-07
, O 0 8.181428867715113e-09
although O 0 3.025844685922152e-09
the O 0 2.0492367802660283e-09
scale O 0 6.519224626799769e-08
of O 0 9.740439566030545e-09
the O 0 2.9542124302395223e-09
study O 0 1.3649193997267162e-09
is O 0 1.3598983050755464e-10
limited O 0 1.391136761341727e-09
, O 0 8.9387691692977e-10
there O 0 1.514896652565767e-09
is O 0 3.425324190953205e-10
a O 0 1.5016118348754048e-09
possibility O 0 6.854853040749731e-08
that O 0 1.0343124579037521e-08
PET O 0 3.424773069582443e-07
can O 0 4.05283877569218e-08
detect O 0 1.0391698879175237e-06
an O 0 2.1521222137721452e-08
insidious B-Disease 0 1.298501683777431e-05
lesion I-Disease 0 3.654001920949668e-05
which O 0 3.372497614506642e-09
is O 0 8.091724512659937e-10
undetectable O 0 1.6793544332927013e-08
by O 0 9.57673829127259e-10
computed O 0 6.791034223851966e-08
tomogram O 0 9.183745532936882e-07
( O 0 6.713603895036613e-09
CT O 0 3.787892410400673e-06
) O 0 3.508173973543194e-09
or O 0 1.686875306106117e-09
MRI O 0 2.5164848693748354e-07
analysis O 0 2.6215087878256327e-09
, O 0 2.2108213870719595e-10
and O 0 1.2147921557570385e-10
that O 0 6.57620138899695e-11
the O 0 4.946334453137524e-10
higher O 0 1.0199291189394444e-08
level O 0 4.702792466559913e-08
of O 0 4.353453153527198e-09
tau O 0 3.9316393696253726e-08
reflects O 0 5.329393593100917e-10
the O 0 3.2905100866287285e-10
process O 0 6.055179468944516e-09
of O 0 1.5537178654767558e-08
neuronal B-Disease 0 1.4576567082258407e-05
degeneration I-Disease 1 0.8471031188964844
in O 0 2.125400214936235e-06
ALD B-Disease 1 1.0
. O 0 6.584310904145241e-05

Lorenzos O 0 0.0001706960902083665
Oil O 0 3.4442678042978514e-07
should O 0 3.8594034634797936e-09
be O 0 5.794432711425657e-10
given O 0 5.489690924065371e-10
in O 0 2.7598318075305883e-10
the O 0 8.39966318721963e-10
early O 0 1.3813887811409131e-08
stage O 0 2.988022629324405e-08
. O 0 1.908304625430901e-08
. O 0 4.649421896374406e-07

Nonsense O 0 2.591100928839296e-05
mutation O 0 3.904311256519577e-07
in O 0 4.006897924568875e-08
exon O 0 6.703702410959522e-07
4 O 0 4.5913560597909964e-07
of O 0 7.684675296104615e-08
human O 0 6.424424014994656e-08
complement O 0 1.2397273962960753e-07
C9 O 0 0.00027035357197746634
gene O 0 9.704835157720026e-09
is O 0 2.7551141923432e-10
the O 0 6.993994272619375e-10
major O 0 1.8006630631006715e-09
cause O 0 3.634792022921829e-08
of O 0 9.833441794171449e-08
Japanese O 0 4.242393970343983e-06
complement B-Disease 0 0.0004407850210554898
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.9999587535858154
. O 0 1.8536346033215523e-05

Deficiency B-Disease 1 0.9999630451202393
of I-Disease 0 0.0005878485389985144
the I-Disease 0 6.075141754990909e-06
ninth I-Disease 0 1.9935694126616e-06
component I-Disease 0 7.566155346694359e-08
of I-Disease 0 2.2883062555933975e-08
human I-Disease 0 3.634563228160914e-08
complement I-Disease 0 1.2927382897487405e-07
( O 0 3.467429721126791e-08
C9 O 0 0.40425875782966614
) O 0 6.553281473031802e-09
is O 0 4.0195469175330345e-10
the O 0 1.108478531186563e-09
most O 0 6.535441077204496e-10
common O 0 7.891563882367336e-07
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 7.2790182770177125e-09
Japan O 0 4.9516324374110354e-09
but O 0 8.989909927592521e-10
is O 0 3.943153442653724e-11
rare O 0 2.0188511973273648e-10
in O 0 1.5503059946908593e-10
other O 0 4.4647557873034316e-10
countries O 0 5.551523685198845e-09
. O 0 2.9449941507664334e-07

We O 0 3.4789573533089424e-07
studied O 0 1.587325613172652e-07
the O 0 2.125519094064998e-09
molecular O 0 3.1491261154315e-08
basis O 0 5.1222130537098565e-08
of O 0 1.9660929240217229e-07
C9 B-Disease 1 0.9999986886978149
deficiency I-Disease 0 0.05146322026848793
in O 0 4.8053617973664586e-08
four O 0 1.1292261348216925e-07
Japanese O 0 5.213204985921038e-06
C9 B-Disease 1 0.9999998807907104
- I-Disease 0 0.0004903035005554557
deficient I-Disease 0 1.2437397344911005e-05
patients O 0 3.241513368834603e-08
who O 0 5.06280528611569e-09
had O 0 7.790534795049098e-08
suffered O 0 4.390583126223646e-05
from O 0 4.3982305214740336e-05
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.00035927959834225476

Direct O 0 2.6834788968699286e-07
sequencing O 0 1.356599739210651e-07
of O 0 1.0613197787279205e-07
amplified O 0 4.493997209920053e-07
C9 O 0 2.2985695977695286e-05
cDNA O 0 1.2368224133751937e-07
and O 0 1.4781744717140555e-08
DNA O 0 7.628116804880847e-08
revealed O 0 1.0622493107348419e-07
a O 0 1.373182101360726e-08
nonsense O 0 4.41764143488399e-07
substitution O 0 8.481419513373112e-07
( O 0 9.217846042020028e-08
CGA O 0 2.8610133995243814e-06
- O 0 1.540376729280979e-06
- O 0 7.871712455198576e-07
> O 0 5.562458795793646e-07
TGA O 0 8.80072946074506e-07
) O 0 4.173774659221863e-09
at O 0 5.144036663295992e-08
codon O 0 4.4606320415141454e-08
95 O 0 3.4539315407755566e-08
in O 0 5.109895617749771e-09
exon O 0 6.264516372311846e-08
4 O 0 6.860189927238025e-08
in O 0 4.8820854026132565e-09
the O 0 4.7085723764439535e-08
four O 0 2.2337468408295535e-07
C9 B-Disease 1 0.5798810720443726
- I-Disease 0 4.382909082778497e-06
deficient I-Disease 0 9.659589750299347e-07
individuals O 0 1.6747801367955617e-08
. O 0 6.543604058606434e-07

An O 0 1.242363623532583e-06
allele O 0 5.075186891190242e-06
- O 0 2.2378203539119568e-06
specific O 0 9.351511209843011e-08
polymerase O 0 4.105496316242352e-07
chain O 0 1.9233045378541647e-08
reaction O 0 4.23325552389997e-09
system O 0 1.625331513821493e-08
designed O 0 1.1403355593131437e-08
to O 0 8.721083299967347e-10
detect O 0 7.871485685484458e-09
exclusively O 0 1.050952658232518e-09
only O 0 2.057472248129244e-10
one O 0 1.1740688976580316e-10
of O 0 4.939037512308175e-10
the O 0 4.11271017242143e-10
normal O 0 1.2852643394012375e-09
and O 0 1.5670555131297448e-10
mutant O 0 6.577424382925301e-09
alleles O 0 4.490687377511904e-09
indicated O 0 1.249473524644884e-09
that O 0 9.52739623305554e-11
all O 0 2.3422122574778825e-10
the O 0 4.376780049497597e-10
four O 0 4.269695430547671e-10
patients O 0 8.449890093187307e-11
were O 0 3.8537303903574127e-10
homozygous O 0 1.4941067272289388e-09
for O 0 4.0291034397732517e-10
the O 0 2.4839743595350683e-09
mutation O 0 2.2444304192958953e-09
in O 0 2.2990673809175632e-09
exon O 0 2.972861423700124e-08
4 O 0 3.115692592814412e-08
and O 0 9.430278780087065e-10
that O 0 1.3050853453488998e-10
the O 0 1.17255216647294e-09
parents O 0 7.127233248027665e-10
of O 0 2.868886017637351e-09
patient O 0 6.793013707095952e-09
2 O 0 7.550355718421997e-08
were O 0 8.170797372031302e-08
heterozygous O 0 7.180864827205369e-07
. O 0 3.668960971481283e-06

The O 0 1.2655941645789426e-06
common O 0 4.3987196818306984e-07
mutation O 0 3.5448917401481594e-07
at O 0 3.468822740160249e-07
codon O 0 2.3067602228366013e-07
95 O 0 1.208565407750939e-07
in O 0 1.2502727742003117e-08
exon O 0 1.6461794416500197e-07
4 O 0 4.8356390891513e-08
might O 0 2.6817115195143515e-09
be O 0 1.048346076615303e-09
responsible O 0 1.928166515341445e-09
for O 0 3.980735185926676e-10
most O 0 1.072910094102042e-09
Japanese O 0 5.670702307725151e-07
C9 B-Disease 1 0.999994158744812
deficiency I-Disease 0 0.0002839948865585029
. O 0 1.5527496088907355e-07
. O 0 1.2772061381838284e-06

BRCA1 O 0 1.3722966514251311e-06
required O 0 1.1004996025576474e-07
for O 0 3.899934242213021e-08
transcription O 0 1.0670065648810123e-06
- O 0 1.309999333898304e-06
coupled O 0 1.074134956979833e-06
repair O 0 2.773042524495395e-06
of O 0 6.808243711020623e-07
oxidative O 0 2.9912278478150256e-05
DNA O 0 1.8577117089080275e-06
damage O 0 2.7012154532712884e-05
. O 0 8.031861398194451e-06

The O 0 0.00036339412326924503
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.9994503855705261
gene O 0 3.409461714909412e-05
BRCA1 O 0 1.4643794202129357e-05
encodes O 0 7.70558131080179e-07
a O 0 9.286705449085275e-08
zinc O 0 2.1095963802508777e-06
finger O 0 7.622646194249683e-07
protein O 0 1.1571145819289086e-07
of O 0 1.1389774101644434e-07
unknown O 0 5.781201934951241e-07
function O 0 6.994980594754452e-07
. O 0 1.0458090855536284e-06

Association O 0 2.8985170956730144e-06
of O 0 1.784994310582988e-06
the O 0 2.2950864320137043e-07
BRCA1 O 0 1.0313775788972634e-07
protein O 0 1.0766251001825822e-08
with O 0 1.5553003329671355e-09
the O 0 2.4643254548095683e-08
DNA O 0 1.4415857663152565e-07
repair O 0 2.0299664527101413e-07
protein O 0 7.821771674798583e-08
Rad51 O 0 2.1587325136351865e-06
and O 0 3.5832463662899272e-09
changes O 0 3.0105431481075584e-09
in O 0 3.2633776236856704e-10
the O 0 6.579542466411681e-10
phosphorylation O 0 5.405861980278814e-09
and O 0 4.899482597409133e-09
cellular O 0 7.072854657508287e-08
localization O 0 1.8212335817224812e-07
of O 0 2.227581319402816e-08
the O 0 6.951148101563831e-09
protein O 0 1.0287856788693261e-08
after O 0 2.456460279631756e-08
exposure O 0 3.6192677299595744e-08
to O 0 3.8629384135902e-09
DNA O 0 5.474925615089887e-07
- O 0 2.459461541093333e-07
damaging O 0 6.93935987783334e-07
agents O 0 2.0003696477033373e-09
are O 0 1.672346289227633e-10
consistent O 0 2.475730065398807e-09
with O 0 8.117226335535577e-11
a O 0 3.0790733851482344e-10
role O 0 2.819106503793023e-09
for O 0 3.949314653084457e-09
BRCA1 O 0 1.64408021419149e-07
in O 0 4.3021945117516225e-08
DNA O 0 1.1178165095770964e-06
repair O 0 7.937530426715966e-06
. O 0 6.557531378348358e-06

Here O 0 1.397438268213591e-06
, O 0 1.000530058803406e-08
it O 0 5.545181536170674e-10
is O 0 2.1529288074528807e-10
shown O 0 1.8335111207079535e-09
that O 0 2.1737507349683938e-09
mouse O 0 1.6024854687657353e-07
embryonic O 0 1.788567800531382e-07
stem O 0 1.1467977856227662e-07
cells O 0 3.0790001659397603e-08
deficient B-Disease 0 4.9491706732851526e-08
in I-Disease 0 3.6513905232737898e-09
BRCA1 I-Disease 0 3.4076418131689934e-08
are O 0 1.7151497999634557e-09
defective O 0 4.912698159387219e-08
in O 0 3.14561265923885e-09
the O 0 2.398173437612172e-09
ability O 0 1.848247555003013e-09
to O 0 4.944919473892639e-10
carry O 0 3.827127947886311e-09
out O 0 3.176330309884179e-09
transcription O 0 1.8340442409225943e-07
- O 0 4.0958917679745355e-07
coupled O 0 4.733289529212925e-07
repair O 0 1.1554101320143673e-06
of O 0 2.7069947350355505e-07
oxidative O 0 5.429256361821899e-06
DNA O 0 4.1789704141592665e-07
damage O 0 4.068169346282957e-06
, O 0 2.2045160363859395e-08
and O 0 5.5771675278037947e-08
are O 0 3.353461508481814e-08
hypersensitive O 0 2.9774407721561147e-06
to O 0 5.921156542854078e-08
ionizing O 0 2.746886275417637e-05
radiation O 0 2.4086593839456327e-05
and O 0 7.578981353617564e-08
hydrogen O 0 3.538042108175432e-07
peroxide O 0 2.4457238396280445e-05
. O 0 2.8921720058860956e-06

These O 0 2.0251169985385786e-07
results O 0 4.21403257178099e-07
suggest O 0 6.693277043723356e-08
that O 0 5.993761931222252e-09
BRCA1 O 0 8.785000460420633e-08
participates O 0 5.59072255157389e-09
, O 0 8.459118405745869e-10
directly O 0 1.3292587031088487e-09
or O 0 9.91573934072676e-10
indirectly O 0 1.5731955738118586e-09
, O 0 6.826989529251648e-10
in O 0 1.6859167395466557e-09
transcription O 0 1.2281456918117328e-07
- O 0 1.4524586333664047e-07
coupled O 0 1.550018566831568e-07
repair O 0 3.096506588917691e-07
of O 0 8.450724919839558e-08
oxidative O 0 1.3546969057642855e-06
DNA O 0 1.22533208468667e-07
damage O 0 3.202417531156243e-07
. O 0 1.1786971754190745e-07
. O 0 2.886275296987151e-06

Truncation O 0 7.999991794349626e-05
mutations O 0 1.1921607665499323e-06
in O 0 7.201686003099894e-08
the O 0 1.1360700824525338e-07
transactivation O 0 1.9440860342001542e-05
region O 0 3.9512835314781114e-07
of O 0 7.849515668567619e-07
PAX6 O 0 0.0001745581248542294
result O 0 7.9280960108008e-07
in O 0 1.197202976754852e-07
dominant O 0 2.9467988497344777e-05
- O 0 4.926999395138409e-07
negative O 0 1.0595116606282318e-07
mutants O 0 2.607796659503947e-06
. O 0 9.884587370834197e-07

PAX6 O 0 0.0006878800340928137
is O 0 7.357551368158965e-08
a O 0 1.7262864915323917e-08
transcription O 0 3.4346239630167474e-08
factor O 0 1.5075299231170902e-08
with O 0 9.119800470358541e-10
two O 0 3.170441242872357e-09
DNA O 0 3.4133076809439444e-08
- O 0 2.8260528139867347e-08
binding O 0 6.444379607728479e-08
domains O 0 2.14143568655345e-07
( O 0 3.329470921187294e-09
paired O 0 7.74912578549447e-09
box O 0 1.9641245074808467e-08
and O 0 8.35947044919294e-09
homeobox O 0 3.124897034467722e-07
) O 0 5.25058618805474e-09
and O 0 2.0992873217551278e-08
a O 0 9.306175030587838e-08
proline O 0 2.020866077145911e-06
- O 0 5.49582227904466e-06
serine O 0 8.454910130240023e-06
- O 0 6.5651965996949e-06
threonine O 0 2.401418714725878e-05
( O 0 1.55942174728807e-07
PST O 0 0.0035869001876562834
) O 0 1.1891592066604062e-07
- O 0 5.084776262265223e-07
rich O 0 3.100206242834247e-07
transactivation O 0 3.227141860406846e-05
domain O 0 2.7126491204398917e-06
. O 0 3.5556386137614027e-06

PAX6 O 1 0.9997647404670715
regulates O 0 3.403471419005655e-05
eye O 0 0.0015585989458486438
development O 0 8.480012638756307e-07
in O 0 9.100170395015539e-09
animals O 0 4.605940073787451e-09
ranging O 0 5.016218551645579e-08
from O 0 2.453785175049461e-09
jellyfish O 0 4.863895952667008e-09
to O 0 3.77215814140186e-09
Drosophila O 0 1.361241857011919e-07
to O 0 1.3755046879282418e-08
humans O 0 5.061972956355021e-07
. O 0 1.1451631962700048e-06

Heterozygous O 0 4.031670414406108e-06
mutations O 0 5.050559366281959e-07
in O 0 5.5350326988445886e-08
the O 0 9.829430069885348e-08
human O 0 2.3593744913341652e-07
PAX6 O 0 1.2000488823105115e-05
gene O 0 1.939572591425076e-08
result O 0 1.4482519183900422e-08
in O 0 5.1625321795256696e-09
various O 0 2.82850116661848e-08
phenotypes O 0 1.5860211988183437e-06
, O 0 1.0476568945705367e-08
including O 0 2.8456224043793554e-08
aniridia B-Disease 1 1.0
, O 0 2.3219306513055926e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 6.691885801046737e-08
autosomal B-Disease 0 0.0016340112779289484
dominant I-Disease 1 0.8220064043998718
keratitis I-Disease 1 0.9999974966049194
, O 0 3.4564922657409625e-07
and O 0 2.015503923757933e-06
familial B-Disease 1 0.9976061582565308
foveal I-Disease 1 0.9999971389770508
dysplasia I-Disease 1 1.0
. O 0 0.2718585133552551

It O 0 2.1959506213420354e-08
is O 0 1.2619347788955793e-09
believed O 0 4.9665391799180725e-09
that O 0 3.11266595831583e-10
the O 0 1.9732706579844717e-09
mutated O 0 2.21334683914165e-08
allele O 0 2.029743768616754e-07
of O 0 7.75888935322655e-08
PAX6 O 0 1.4511889276036527e-05
produces O 0 1.7677468377996775e-08
an O 0 1.1317996539972341e-09
inactive O 0 2.6466457470064597e-08
protein O 0 2.9730204076372502e-08
and O 0 5.674338510175403e-08
aniridia B-Disease 1 1.0
is O 0 4.755448479443203e-09
caused O 0 2.2316426040447368e-08
due O 0 1.3102174989398918e-07
to O 0 3.143796689641931e-08
genetic O 0 5.948379566689255e-07
haploinsufficiency O 0 1.5159030226641335e-05
. O 0 4.1009202504938e-06

However O 0 4.183216901765263e-07
, O 0 1.552920814162917e-08
several O 0 5.856826579275776e-09
truncation O 0 2.242429673060542e-07
mutations O 0 1.664303539428147e-08
have O 0 1.2858282216754446e-09
been O 0 1.8783419264423173e-09
found O 0 4.160848332546152e-10
to O 0 7.047316064046072e-10
occur O 0 4.277204812552782e-09
in O 0 3.109635438036662e-09
the O 0 1.8853814509611766e-08
C O 0 2.0450543161132373e-05
- O 0 3.476052370388061e-07
terminal O 0 9.10192738956539e-08
half O 0 1.0667116079332573e-08
of O 0 1.5260162911090447e-08
PAX6 O 0 5.541261543839937e-06
in O 0 5.1781827714592055e-09
patients O 0 4.217861615529728e-09
with O 0 5.093820476531619e-09
Aniridia B-Disease 1 0.9999996423721313
resulting O 0 1.3554345912325516e-07
in O 0 6.1588925071021094e-09
mutant O 0 3.5734537107146025e-08
proteins O 0 8.261272221865568e-10
that O 0 5.499133370889808e-10
retain O 0 2.194749093575865e-08
the O 0 1.8245430055685574e-08
DNA O 0 3.859523545202137e-08
- O 0 8.850657096104442e-09
binding O 0 8.07116684597986e-09
domains O 0 4.845543077891534e-09
but O 0 9.658295274661555e-10
have O 0 5.709082651073061e-10
lost O 0 1.7049027078996914e-08
most O 0 4.92635487958637e-10
of O 0 2.566101331424875e-09
the O 0 1.0938110861502537e-08
transactivation O 0 3.728509227585164e-06
domain O 0 3.8968045146248187e-07
. O 0 2.5530930543027353e-06

It O 0 5.478691988969331e-08
is O 0 1.0513255821464895e-09
not O 0 8.935700512857636e-10
clear O 0 4.9149262437708785e-09
whether O 0 1.8637245080554976e-09
such O 0 1.1186224169179582e-09
mutants O 0 1.2562124993564794e-06
really O 0 5.7308216838691806e-08
behave O 0 1.9213208801716064e-08
as O 0 8.082166047529427e-09
loss O 0 4.091690186669439e-08
- O 0 4.391702645989426e-08
of O 0 4.4043776625812825e-08
- O 0 4.936415010092787e-08
function O 0 1.0590343713090533e-08
mutants O 0 2.905236051731208e-08
as O 0 9.12112274598087e-10
predicted O 0 1.5391352192750674e-08
by O 0 9.582370452676514e-09
haploinsufficiency O 0 4.4159455683256965e-06
. O 0 1.4315478438220453e-06

Contrary O 0 5.008866423850122e-07
to O 0 6.066160906925688e-09
this O 0 9.843491577399277e-10
theory O 0 5.417260240392352e-08
, O 0 2.1482537970740623e-09
our O 0 4.3380445902130305e-09
data O 0 2.8210160873953782e-09
showed O 0 7.520940537020238e-10
that O 0 9.657701027787624e-11
these O 0 2.7418353698571707e-10
mutants O 0 1.9182671451289934e-08
are O 0 6.394979545909507e-10
dominant O 0 7.023650994142372e-08
- O 0 6.8334937708414145e-09
negative O 0 4.930644337264312e-09
in O 0 2.860744308108565e-09
transient O 0 7.246274691397048e-08
transfection O 0 9.791929755920137e-08
assays O 0 1.1468071825504467e-08
when O 0 2.3031752061086763e-09
they O 0 1.4783907431592525e-09
are O 0 1.995617227024127e-09
coexpressed O 0 6.995227295192308e-07
with O 0 8.418786556774194e-09
wild O 0 2.432382473216421e-07
- O 0 1.4153043821352185e-06
type O 0 3.54073999915272e-05
PAX6 O 0 0.050037894397974014
. O 0 1.373160193907097e-05

We O 0 4.4726104420078627e-07
found O 0 1.0548814266542195e-08
that O 0 7.8337830666797e-10
the O 0 5.807846203964573e-09
dominant O 0 4.661035859498952e-07
- O 0 2.6139858277929306e-08
negative O 0 5.644456457787328e-09
effects O 0 3.8323381801319556e-08
result O 0 1.3344211957644347e-08
from O 0 1.5694792132592283e-09
the O 0 3.561605455004724e-09
enhanced O 0 1.363093815598404e-08
DNA O 0 3.861966302309838e-09
binding O 0 2.5035185036159646e-09
ability O 0 2.907069474034074e-09
of O 0 5.964396088131707e-09
these O 0 5.62285862315548e-09
mutants O 0 7.941179660519992e-07
. O 0 4.0256591660181584e-07

Kinetic O 0 7.226884918054566e-06
studies O 0 1.1635260221964927e-07
of O 0 2.6220652316055748e-08
binding O 0 8.587652899905152e-08
and O 0 1.3433900214465666e-08
dissociation O 0 4.40845369098497e-08
revealed O 0 9.898094788240996e-09
that O 0 1.757088918807881e-10
various O 0 1.5733876423951187e-09
truncation O 0 9.065525574669664e-08
mutants O 0 6.465210589112758e-08
have O 0 1.7491649240142237e-09
3 O 0 4.1285510121724656e-08
- O 0 2.3504041379851515e-08
5 O 0 5.6594981145963175e-08
- O 0 2.5906228273697707e-08
fold O 0 1.8148110569882192e-08
higher O 0 1.1505316699356172e-08
affinity O 0 1.2743285315863773e-09
to O 0 5.670805491853059e-10
various O 0 2.5873276854326832e-09
DNA O 0 4.336497383405913e-09
- O 0 7.072119556639223e-10
binding O 0 7.162966331186738e-10
sites O 0 7.065418805574097e-10
when O 0 5.622705634422687e-10
compared O 0 3.362559397590559e-10
with O 0 6.357566556536298e-11
the O 0 1.3592610370594116e-09
wild O 0 2.2857719272906252e-08
- O 0 5.634714383973005e-08
type O 0 7.425758781209879e-07
PAX6 O 0 0.0006692713941447437
. O 0 6.067892172723077e-06

These O 0 2.0645606468860933e-07
results O 0 3.9828472608860466e-07
provide O 0 3.4047036301387834e-09
a O 0 8.745970614398857e-10
new O 0 3.2773768143812276e-09
insight O 0 1.269269045423016e-08
into O 0 2.6678842468541575e-10
the O 0 4.584971569077112e-10
role O 0 1.8710046845171746e-09
of O 0 4.0108183441134315e-09
mutant O 0 3.9670433693572704e-07
PAX6 O 0 1.902195072034374e-05
in O 0 6.310989419944235e-08
causing O 0 1.755889798005228e-06
aniridia B-Disease 1 0.9999955892562866
. O 0 1.11344377273781e-06
. O 0 7.221332907647593e-06

Reversal O 0 4.0200357034336776e-05
of O 0 9.849706657405477e-06
severe O 1 0.9999966621398926
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 1 0.9988154172897339
excellent O 0 0.22074638307094574
neuropsychologic O 0 0.0008100013947114348
outcome O 0 3.664327959995717e-05
in O 0 6.713491274012995e-08
very B-Disease 0 2.426504295272025e-07
- I-Disease 0 2.573823849161272e-06
long I-Disease 0 7.285097467502055e-07
- I-Disease 0 7.751606608508155e-05
chain I-Disease 0 1.4508152162306942e-05
acyl I-Disease 0 6.221592775546014e-05
- I-Disease 1 0.9262779355049133
coenzyme I-Disease 0 0.0327945202589035
A I-Disease 0 4.5304710511118174e-05
dehydrogenase I-Disease 0 7.74009240558371e-05
deficiency I-Disease 0 0.0017120788106694818
. O 0 2.2081069346313598e-06

Very B-Disease 0 0.00011733818973880261
- I-Disease 0 0.0006349186296574771
long I-Disease 0 1.0495245987840462e-05
- I-Disease 0 0.0003300601674709469
chain I-Disease 0 6.578295142389834e-06
acyl I-Disease 0 1.3244770343590062e-05
- I-Disease 0 0.0007761184242554009
coenzyme I-Disease 0 3.7568024708889425e-05
A I-Disease 0 1.588906684446556e-06
dehydrogenase I-Disease 0 4.924067980027758e-07
( I-Disease 0 1.3117073649482336e-08
VLCAD I-Disease 0 0.0001506915141362697
) I-Disease 0 9.368955034005921e-08
deficiency I-Disease 0 0.00010994888725690544
is O 0 5.1870592265856885e-09
a O 0 4.308287770982133e-08
disorder O 0 0.00015740864910185337
of O 0 3.1673230296291877e-06
fatty O 0 2.0640035813812574e-07
acid O 0 3.78528461908445e-08
beta O 0 1.0755192647593503e-07
oxidation O 0 5.154051407885163e-09
that O 0 4.1170816755808914e-10
reportedly O 0 1.1947081546281879e-08
has O 0 5.994478802229253e-10
high O 0 3.0030491871002596e-08
rates O 0 1.585287101590893e-08
of O 0 1.5199363545548294e-08
morbidity O 0 1.537467824164196e-06
and O 0 4.6767180350570925e-08
mortality O 0 1.7441554973629536e-06
. O 0 4.1932784711207205e-07

We O 0 4.4142936417301826e-07
describe O 0 7.715679117836771e-08
the O 0 1.3606676674271512e-08
outcome O 0 2.499860727311898e-07
of O 0 2.5241755352567452e-08
a O 0 5.966330096640604e-09
5 O 0 5.030302574482448e-08
- O 0 2.932980258663065e-08
year O 0 5.8387126244952015e-09
- O 0 5.3976844327507933e-08
old O 0 5.672341671925096e-07
girl O 0 1.3961738432044513e-07
with O 0 3.017374083924551e-08
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 3.081355970380173e-08
was O 0 5.602126051940104e-08
first O 0 3.182540453394722e-09
seen O 0 6.169827759805457e-09
at O 0 9.978809778488085e-09
5 O 0 2.3483954780800786e-09
months O 0 3.764494549418629e-10
of O 0 6.175758238136098e-10
age O 0 8.30130186812994e-09
with O 0 1.0552712037537049e-09
severe O 0 5.374186366680078e-05
hypertrophic B-Disease 1 0.9999996423721313
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999935626983643
hepatomegaly B-Disease 1 1.0
, O 1 0.9999790191650391
encephalopathy B-Disease 1 0.9814777374267578
, O 0 4.132739377382677e-07
and O 0 2.7221290110901464e-06
hypotonia B-Disease 0 0.030213013291358948
. O 0 4.63005926576443e-05

Biochemical O 0 0.00012445646279957145
studies O 0 1.8220745914732106e-05
indicated O 0 0.2357543408870697
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.00023466034326702356
by O 0 1.7771347060602238e-08
a O 0 1.0733670841034382e-08
stable O 0 2.3898624590401596e-07
yet O 0 1.332692107780531e-07
inactive O 0 6.263936711548013e-07
enzyme O 0 4.668549706821068e-07
. O 0 7.584981744912511e-07

Molecular O 0 1.0325509720132686e-05
genetic O 0 3.488678714802518e-07
analysis O 0 1.1429218460534685e-07
of O 0 2.2627430951160932e-07
her O 0 2.1029065067068586e-07
VLCAD O 0 0.001306207268498838
gene O 0 8.763216783336247e-07
revealed O 0 1.5434441138495458e-06
a O 0 8.694451736346309e-08
T1372C O 0 3.090393192906049e-06
( O 0 6.42136157580353e-08
F458L O 0 2.1398955141194165e-06
) O 0 4.502095762859426e-08
missense O 0 2.5920667212631088e-06
mutation O 0 1.487020426793606e-07
and O 0 6.159811505312973e-08
a O 0 1.595011553945369e-07
1668 O 0 0.00016822329780552536
ACAG O 0 0.0011349719716235995
1669 O 0 0.000229666504310444
splice O 0 2.2491669369628653e-05
site O 0 1.463250555389095e-06
mutation O 0 4.477356924326159e-06
. O 0 7.50601020627073e-06

After O 0 1.0367408549427637e-06
initial O 0 1.1089447582435241e-07
treatment O 0 1.5834383759738557e-07
with O 0 7.184588923792035e-09
intravenous O 0 3.410360420730285e-07
glucose O 0 3.6394822018337436e-06
and O 0 7.285522229949493e-08
carnitine O 0 3.0373005301953526e-06
, O 0 2.078559990792428e-09
the O 0 2.5212536503005367e-09
patient O 0 6.9024097548719965e-09
has O 0 1.1015739431741167e-09
thrived O 0 5.568026750779609e-08
on O 0 1.9618594748749274e-08
a O 0 4.490121607858555e-09
low O 0 8.21124331196188e-07
- O 0 4.5953598259984574e-07
fat O 0 3.0134262374303944e-07
diet O 0 1.0440387399057727e-07
supplemented O 0 1.2498746038147601e-08
with O 0 1.386019854443532e-09
medium O 0 7.050991825963138e-06
- O 0 3.2430105534331233e-07
chain O 0 3.4439651130924176e-08
triglyceride O 0 3.249952271744405e-07
oil O 0 1.0700478725311768e-07
and O 0 2.7807162794601936e-08
carnitine O 0 8.56164660945069e-07
and O 0 7.637678045568919e-09
avoidance O 0 5.041637223257567e-07
of O 0 1.0051900289909099e-07
fasting O 0 4.312268629291793e-06
. O 0 1.3815410966344643e-06

Her O 0 5.281233825371601e-05
ventricular O 1 0.9972472786903381
hypertrophy O 1 0.9537714719772339
resolved O 0 0.00013783459144178778
significantly O 0 3.0128373396109964e-07
over O 0 3.791766545191422e-08
1 O 0 1.2527306125775794e-07
year O 0 4.07841094229866e-09
, O 0 1.4174303952785294e-09
and O 0 4.699167277522065e-09
cognitively O 0 7.336082603615068e-07
, O 0 7.264202017687182e-10
she O 0 4.3996042919935974e-10
is O 0 9.609559675771706e-11
in O 0 3.321825592372818e-10
the O 0 2.760296435866394e-09
superior O 0 4.103187336568226e-07
range O 0 1.1280916112355044e-07
for O 0 1.0485305956819957e-08
age O 0 8.770658155299316e-07
. O 0 1.0097439826495247e-06

Clinical O 0 9.134845640801359e-06
recognition O 0 2.883595470848377e-06
of O 1 0.9999507665634155
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.6093234239965568e-08
important O 0 4.692647159743046e-09
because O 0 2.836001988804071e-10
it O 0 8.64382523890761e-11
is O 0 6.479052017116516e-11
one O 0 3.246224677955212e-10
of O 0 1.0456382426582422e-09
the O 0 2.220805095376477e-09
few O 0 9.12398068209086e-09
directly O 0 2.9023230041502757e-08
treatable O 0 0.034875765442848206
causes O 0 1.0855768550754874e-07
of O 0 2.1541289640936157e-07
cardiomyopathy B-Disease 1 1.0
in O 0 8.462691312161041e-07
children O 0 4.985828283565752e-08
. O 0 8.117826411080387e-08
. O 0 1.5096297829586547e-06

Cloning O 0 5.317924660630524e-07
of O 0 9.252917720914411e-08
a O 0 6.224447623992546e-09
novel O 0 1.6704095884279013e-08
member O 0 2.1981927389447264e-08
of O 0 4.6404917242170995e-08
the O 0 5.0474003643330434e-08
low O 0 3.904194727510912e-06
- O 0 5.841271786266589e-07
density O 0 9.407166601249628e-08
lipoprotein O 0 7.978117537277285e-06
receptor O 0 1.868236722657457e-06
family O 0 3.33501816385251e-07
. O 0 1.8568721316114534e-06

A O 0 2.2093665847933153e-06
gene O 0 1.9552143726286886e-07
encoding O 0 6.446832117035228e-07
a O 0 5.866007768418058e-08
novel O 0 2.267763790086974e-07
transmembrane O 0 6.424443199648522e-07
protein O 0 2.224859407817803e-08
was O 0 2.519134945089263e-08
identified O 0 2.8931301798706954e-09
by O 0 4.4593090331446206e-10
DNA O 0 5.02844876848485e-09
sequence O 0 1.6730457019775713e-09
analysis O 0 2.6063473601567466e-09
within O 0 5.335152764018858e-09
the O 0 1.638428948069759e-08
insulin B-Disease 0 3.8735979615012184e-05
- I-Disease 0 0.0010849878890439868
dependent I-Disease 0 0.02513612061738968
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 1.6459249536637799e-06
IDDM B-Disease 0 4.469138730200939e-05
) O 0 1.9256978234238886e-08
locus O 0 3.249685676109948e-07
IDDM4 O 0 4.943759904563194e-06
on O 0 5.064343895355705e-07
chromosome O 0 7.1758535113986e-07
11q13 O 0 1.5778890883666463e-05
. O 0 6.111401944508543e-06

Based O 0 9.800746738619637e-07
on O 0 3.4308956742279406e-07
its O 0 2.6870630165376497e-08
chromosomal O 0 6.806367878198216e-07
position O 0 2.440890284560737e-06
, O 0 5.0605653001412065e-09
this O 0 5.068280795050839e-10
gene O 0 1.4947908466567128e-09
is O 0 2.325860615215447e-10
a O 0 4.666020902988066e-10
candidate O 0 9.809273393557305e-09
for O 0 4.750082105431375e-09
conferring O 0 4.840945280193409e-07
susceptibility O 0 5.397454970079707e-06
to O 0 7.240574859679327e-07
diabetes B-Disease 1 0.9920915365219116
. O 0 4.027303293696605e-05

The O 0 2.5589433789718896e-06
gene O 0 3.7610291769851756e-07
, O 0 7.755382824825574e-08
termed O 0 8.83001064266864e-07
low O 0 8.45211252453737e-06
- O 0 1.4981874301156495e-06
density O 0 8.04188147185414e-08
lipoprotein O 0 5.314416853252624e-07
receptor O 0 6.235833893697418e-08
related O 0 5.5872504844955984e-08
protein O 0 2.036519930470604e-08
5 O 0 5.1717698568154447e-08
( O 0 1.8952706071218017e-09
LRP5 O 0 6.46765897727164e-07
) O 0 8.858792033272778e-10
, O 0 4.788695551205535e-10
encodes O 0 1.2921318459646614e-09
a O 0 2.020042355610485e-09
protein O 0 9.027182557019842e-09
of O 0 4.956822863277921e-08
1615 O 0 1.936270564328879e-05
amino O 0 9.336327622122553e-08
acids O 0 3.823231953248296e-09
that O 0 2.4366303419398605e-10
contains O 0 1.1137555322449089e-09
conserved O 0 5.463975050190584e-09
modules O 0 5.513187684158538e-09
which O 0 1.6342045772166358e-10
are O 0 2.106372160026737e-10
characteristic O 0 1.8771679322071577e-08
of O 0 1.0026525387729635e-08
the O 0 9.759594910008218e-09
low O 0 3.3040038260878646e-07
- O 0 3.5881239313084734e-08
density O 0 6.282330655693613e-09
lipoprotein O 0 3.9268357454602665e-07
( O 0 6.21750606555338e-09
LDL O 0 4.1261037608819606e-07
) O 0 1.0404957784260205e-08
receptor O 0 1.7228794035872852e-07
family O 0 2.244632923975587e-08
. O 0 3.168623550209304e-07

These O 0 3.575244136300171e-07
modules O 0 1.6330305925293942e-06
include O 0 1.7838656773960793e-08
a O 0 1.84365731570324e-08
putative O 0 4.042355499223049e-07
signal O 0 2.5494674105175363e-07
peptide O 0 4.608736503541877e-08
for O 0 2.480139649208013e-09
protein O 0 7.751549624401832e-09
export O 0 1.846180452957924e-08
, O 0 2.7681787972966276e-09
four O 0 6.57029008976906e-09
epidermal O 0 4.4914944652418853e-08
growth O 0 2.578730562419196e-09
factor O 0 7.630455378659917e-09
( O 0 2.121011810629625e-09
EGF O 0 1.0503082847890255e-07
) O 0 7.238297183853604e-10
repeats O 0 4.410891207839995e-09
with O 0 1.7958816656005183e-09
associated O 0 5.195597552187792e-08
spacer O 0 3.210355714600155e-07
domains O 0 1.7582900113666255e-07
, O 0 1.0883585588317146e-08
three O 0 1.0785304205285229e-08
LDL O 0 1.928348467572505e-07
- O 0 1.0219274315659277e-07
receptor O 0 4.4091937212442645e-08
( O 0 4.104303563678968e-09
LDLR O 0 1.2173760524092359e-06
) O 0 1.6267014402160385e-09
repeats O 0 3.4117373370889936e-09
, O 0 5.10884057280947e-10
a O 0 1.99291272373614e-09
single O 0 2.3622016342983443e-08
transmembrane O 0 1.2841619536629878e-06
spanning O 0 5.716465238947421e-07
domain O 0 9.369151854343727e-08
, O 0 6.348352066254392e-09
and O 0 8.924923022846087e-09
a O 0 1.3041410618086502e-08
cytoplasmic O 0 6.080934440433339e-07
domain O 0 1.052911443366611e-06
. O 0 2.7442767986940453e-06

The O 0 1.4976104694142123e-06
encoded O 0 1.454744591455892e-07
protein O 0 6.050990464245842e-08
has O 0 1.2297667328908801e-09
a O 0 5.020655002851981e-10
unique O 0 1.7693514431371682e-09
organization O 0 6.455646239800217e-09
of O 0 2.2206283034620355e-08
EGF O 0 1.3642014664583257e-06
and O 0 3.453325447821953e-08
LDLR O 0 5.626161510008387e-06
repeats O 0 5.599038743753226e-08
; O 0 1.3954257749304588e-09
therefore O 0 2.3787540825992437e-08
, O 0 5.232590361003986e-09
LRP5 O 0 3.329922037664801e-06
likely O 0 2.9484832353432466e-08
represents O 0 2.979996027718812e-09
a O 0 7.537384605349473e-10
new O 0 1.125814219626875e-09
category O 0 9.042036452910907e-09
of O 0 7.965290649281087e-09
the O 0 1.7654958384127895e-08
LDLR O 0 2.0014478650409728e-05
family O 0 2.895578177231073e-07
. O 0 1.6501167010574136e-06

Both O 0 1.8220828224002616e-06
human O 0 1.141236111834587e-06
and O 0 2.5164055728055246e-07
mouse O 0 6.768610205654113e-07
LRP5 O 0 1.731139127514325e-05
cDNAs O 0 7.945831157485372e-07
have O 0 1.460005227826855e-09
been O 0 1.9871775336355313e-09
isolated O 0 3.757144373395249e-09
and O 0 2.0266841538330027e-09
the O 0 3.619286870204519e-09
encoded O 0 1.0469157984971389e-08
mature O 0 9.011492885235839e-09
proteins O 0 1.1583605602494274e-10
are O 0 1.1667111721180845e-10
95 O 0 3.0711448939513275e-09
% O 0 3.458542341405746e-10
identical O 0 6.5553069639179284e-09
, O 0 4.721805724194894e-10
indicating O 0 4.2189403082204535e-09
a O 0 1.3636808349204443e-09
high O 0 2.209137583975007e-08
degree O 0 1.402126343919008e-07
of O 0 1.4785861424115865e-08
evolutionary O 0 1.7578490485448128e-07
conservation O 0 8.908442872268552e-09
. O 0 1.7551446518382363e-08
. O 0 6.538738830386137e-07

The O 0 2.567704314060393e-06
APC B-Disease 0 1.93787923308264e-06
variants O 0 4.22958578383259e-07
I1307K O 0 1.292488377657719e-06
and O 0 1.3087285033464013e-08
E1317Q O 0 4.5494604705709207e-07
are O 0 8.342952106943358e-09
associated O 0 6.318676696537295e-06
with O 1 0.9985427856445312
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 7.685347895858285e-07
but O 0 2.095457585227223e-09
not O 0 6.562234089457775e-10
always O 0 1.1859756510190778e-09
with O 0 2.77540962434486e-10
a O 0 1.9786376981301146e-09
family O 0 6.538099839303868e-09
history O 0 1.066071391164769e-07
. O 0 8.894030543160625e-07

Classical O 0 0.08598639070987701
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0025610998272895813
FAP B-Disease 0 0.0008921377593651414
) O 0 5.9562026422099734e-08
is O 0 6.516438055825802e-09
a O 0 2.0855184246215686e-08
high O 0 0.39692792296409607
- O 1 0.999998927116394
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9688313603401184
that O 0 2.96094215812559e-09
predisposes O 0 2.5300415984474967e-08
to O 0 1.2016274641979408e-09
hundreds O 0 2.818262512249703e-09
or O 0 3.540345128172362e-09
thousands O 0 2.8837437326956206e-08
of O 0 0.00018647467368282378
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999998807907104
carcinoma I-Disease 1 1.0
and O 0 2.2417860634504905e-07
that O 0 1.7341100777557017e-09
results O 0 2.130471976613535e-08
from O 0 2.749891869768817e-09
truncating O 0 1.393392494719592e-07
mutations O 0 5.314484852192436e-09
in O 0 3.6313254625497393e-09
the O 0 2.2411720479453834e-08
APC B-Disease 0 7.118883331713732e-07
gene O 0 3.156676768867328e-07
. O 0 1.8731964246399002e-06

A O 0 1.3287659612615244e-06
variant O 0 2.4605974431324285e-06
of O 0 7.209121122286888e-07
FAP B-Disease 0 3.269852459197864e-05
is O 0 1.9046505883579812e-07
attenuated B-Disease 1 0.7694637179374695
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999477863311768
coli I-Disease 1 0.9999487400054932
, O 0 8.653586291984539e-08
which O 0 1.4563181771620748e-08
results O 0 1.8153325243019935e-07
from O 0 1.1801521537790904e-08
germ O 0 1.4699986422783695e-05
- O 0 1.3882556686439784e-06
line O 0 4.6601645209420894e-08
mutations O 0 2.4040036628036887e-09
in O 0 3.788466484966335e-10
the O 0 7.182639483183095e-10
5 O 0 2.9987490268723604e-09
and O 0 4.0519537725103305e-10
3 O 0 3.83841491924386e-09
regions O 0 1.0270186923122537e-09
of O 0 6.502742788683236e-09
the O 0 2.5915273482723933e-08
APC B-Disease 0 2.878628322378063e-07
gene O 0 1.3652903874117328e-07
. O 0 1.1083934623457026e-06

Attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999998807907104
patients O 0 4.226162673148792e-07
have O 0 8.266193951556033e-09
" O 0 1.0215590862117097e-07
multiple O 0 0.00011650911619653925
" O 1 0.9999998807907104
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 1.43419470077788e-07
typically O 0 5.424619420324461e-09
fewer O 0 1.2476707444974977e-09
than O 0 3.17357973234067e-10
100 O 0 6.60509202887738e-10
) O 0 1.017800149716308e-10
without O 0 6.812550523704886e-10
the O 0 1.2895023937531391e-09
florid O 0 1.718049134069588e-07
phenotype O 0 2.5471043940683558e-08
of O 0 5.972604188997366e-09
classical O 0 1.7984180544772244e-07
FAP B-Disease 0 1.8973187252413481e-06
. O 0 7.210056196527148e-07

Another O 0 3.565553925000131e-06
group O 0 1.2599362264609226e-07
of O 0 2.0601531502961734e-07
patients O 0 3.6397452163328126e-08
with O 0 6.009432951259441e-09
multiple O 0 9.370646694151219e-06
adenomas B-Disease 0 0.3738895356655121
has O 0 1.7308297017848417e-08
no O 0 1.1985471282116578e-08
mutations O 0 8.956436481355468e-09
in O 0 2.401546961294798e-09
the O 0 1.1849542680408831e-08
APC B-Disease 0 3.6534405722932206e-08
gene O 0 1.7988539546820448e-09
, O 0 6.544247366235822e-10
and O 0 7.367093601828856e-10
their O 0 1.447803765763922e-09
phenotype O 0 1.4411425830473945e-08
probably O 0 4.535344544365216e-09
results O 0 7.496440801446624e-09
from O 0 1.3229252138202696e-09
variation O 0 4.2461479665689694e-08
at O 0 3.0770568315574565e-08
a O 0 1.0099205915992115e-09
locus O 0 1.1464659444015979e-08
, O 0 1.0813580031410197e-09
or O 0 1.831560902942897e-09
loci O 0 1.4597164366136894e-08
, O 0 1.1156094936737304e-09
elsewhere O 0 1.0267685368603452e-08
in O 0 5.213423026617647e-09
the O 0 3.2107593028740666e-08
genome O 0 1.0216389512152091e-07
. O 0 9.220763104167418e-07

Recently O 0 1.8605592231324408e-06
, O 0 8.76951045114538e-09
however O 0 8.388459704633533e-09
, O 0 2.288951028717179e-09
a O 0 3.1839730851856984e-09
missense O 0 1.856651152820632e-07
variant O 0 6.505636065412546e-07
of O 0 1.434267346667184e-06
APC B-Disease 0 2.336666966584744e-06
( O 0 1.400244364901937e-08
I1307K O 0 2.2688151091188047e-07
) O 0 2.7416433567850618e-09
was O 0 1.4848659191102342e-08
described O 0 2.565528678388773e-09
that O 0 3.412022053783659e-10
confers O 0 1.3239962903810465e-08
an O 0 3.274057414071052e-10
increased O 0 5.857742735315696e-09
risk O 0 9.413874067831784e-06
of O 1 0.9999998807907104
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.720562295304262e-06
including O 0 8.80825101745586e-09
multiple O 0 2.761925941285881e-07
adenomas B-Disease 0 1.8022406948148273e-05
, O 0 2.046773062147622e-08
in O 0 9.460914185410729e-08
Ashkenazim O 0 0.00017412642773706466
. O 0 8.88304475665791e-06

We O 0 3.761721245609806e-07
have O 0 1.3394600095750775e-08
studied O 0 7.169697369135974e-08
a O 0 1.7176509103933313e-09
set O 0 9.57696233427896e-09
of O 0 4.365543038176156e-09
164 O 0 2.234790485999838e-08
patients O 0 3.28923155379357e-09
with O 0 6.901317295415765e-09
multiple O 1 0.9999997615814209
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999978542327881
/ I-Disease 1 1.0
or I-Disease 1 0.9930858612060547
carcinoma I-Disease 1 1.0
and O 0 7.355164939326642e-07
analyzed O 0 3.5816219678963535e-07
codons O 0 2.604595294997125e-07
1263 O 0 6.968593879719265e-06
- O 0 9.277876529267814e-07
1377 O 0 1.4565297533408739e-05
( O 0 6.085667791921878e-08
exon O 0 5.582956532634853e-07
15G O 0 2.13335670196102e-06
) O 0 4.729830749283792e-09
of O 0 4.347497295498215e-08
the O 0 9.330114636441067e-08
APC B-Disease 0 4.0664286871106015e-07
gene O 0 3.1314684179051255e-08
for O 0 1.2743146093896485e-08
germ O 0 5.598039933829568e-05
- O 0 1.9546825569705106e-05
line O 0 1.6603202084297664e-06
variants O 0 6.560389465448679e-06
. O 0 3.5147609196428675e-06

Three O 0 6.46090825284773e-07
patients O 0 1.1116974008018587e-08
with O 0 1.2502625601484851e-09
the O 0 1.041637531784545e-08
I1307K O 0 9.186393157278872e-08
allele O 0 5.850510120808394e-08
were O 0 4.293044142400504e-09
detected O 0 5.293280924689725e-09
, O 0 5.872035635512418e-10
each O 0 4.2670170175007627e-10
of O 0 1.6486831455608808e-08
Ashkenazi O 0 2.3893642264738446e-06
descent O 0 3.0818109735264443e-06
. O 0 5.0376229410176165e-06

Four O 0 1.3446147022477817e-05
patients O 0 1.4684845837109606e-06
had O 0 1.8091607500991813e-07
a O 0 7.295032844467642e-08
germ O 0 4.0319493564311415e-05
- O 0 2.036061960097868e-05
line O 0 1.8738091966952197e-06
E1317Q O 0 2.4953878892119974e-06
missense O 0 8.622346285847016e-07
variant O 0 2.6625269811120233e-07
of O 0 6.073828018315908e-08
APC O 0 2.194719783688015e-08
that O 0 2.14735132453292e-10
was O 0 3.136948922843885e-09
not O 0 2.6423452315071927e-10
present O 0 5.443552830719511e-10
in O 0 3.7918856943264245e-10
controls O 0 1.2964643802959586e-09
; O 0 3.9244948957239956e-10
one O 0 1.2351092371076788e-10
of O 0 2.641534213587704e-10
these O 0 8.849870836158402e-11
individuals O 0 5.132170383115309e-11
had O 0 4.720941415570223e-10
an O 0 1.2478700017748423e-10
unusually O 0 1.3091346895421907e-09
large O 0 1.3710355073470737e-09
number O 0 6.558670939682543e-09
of O 0 1.0139321204860607e-07
metaplastic B-Disease 0 1.1136584362247959e-05
polyps I-Disease 0 1.1936692771996604e-06
of I-Disease 0 5.9051522782738175e-08
the I-Disease 0 1.1202887861827548e-07
colorectum I-Disease 0 1.5312434697989374e-05
. O 0 2.7859700821863953e-06

There O 0 1.9037534570998105e-07
is O 0 2.8093374293547413e-09
increasing O 0 1.4815325632966392e-09
evidence O 0 5.14635978277056e-09
that O 0 1.688983120029519e-10
there O 0 3.8856076689519625e-10
exist O 0 4.674771236778952e-09
germ O 0 2.238856922076593e-07
- O 0 5.041531281335665e-08
line O 0 7.822798409051757e-09
variants O 0 9.395471955997436e-09
of O 0 5.437090777604681e-09
the O 0 6.397569141114445e-09
APC B-Disease 0 1.1332929261698155e-08
gene O 0 4.153632437997601e-10
that O 0 4.330814179498432e-11
predispose O 0 5.96708149558367e-09
to O 0 9.91729032229216e-10
the O 0 2.4641362283972512e-09
development O 0 2.5400165526434648e-08
of O 0 1.1215930584285161e-07
multiple O 1 0.9999998807907104
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
, O 0 5.163529692708835e-08
but O 0 4.95345542361747e-09
without O 0 1.3019688438475896e-08
the O 0 1.1667166788242866e-08
florid O 0 5.81805466026708e-07
phenotype O 0 6.185288725646387e-08
of O 0 7.507845012355574e-09
classical O 0 9.911984477639635e-08
FAP B-Disease 0 3.833829964605684e-07
, O 0 1.9097199377426932e-09
and O 0 1.383988368353073e-09
possibly O 0 1.4038009865657841e-08
with O 0 1.3003896848218233e-09
importance O 0 7.327773801080184e-06
for O 1 0.9998897314071655
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 1.3281625399486074e-07
in O 0 1.042985031673993e-09
the O 0 1.2086889267237666e-09
general O 0 1.3941462428945783e-09
population O 0 5.974955946674854e-11
. O 0 5.50325918169392e-09
. O 0 3.543434843322757e-07

Genomic O 0 2.313588538527256e-06
structure O 0 6.060219561732083e-07
of O 0 3.474444838502677e-07
the O 0 1.933155544975307e-06
human O 1 0.9999970197677612
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.999975323677063
CLD B-Disease 1 0.9999995231628418
) O 0 4.886755391453335e-07
gene O 0 6.834375767539314e-07
. O 0 3.0516082460962934e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999988079071045
CLD B-Disease 1 1.0
) O 0 5.507042288854791e-08
is O 0 1.0702102537507585e-09
caused O 0 3.0816542651024292e-09
by O 0 8.354939518007143e-10
mutations O 0 5.672582847893182e-09
in O 0 1.7528920537301929e-09
a O 0 2.017077838090131e-09
gene O 0 5.373849365497563e-09
which O 0 4.669308939497796e-09
encodes O 0 6.013998898879436e-08
an O 0 1.4242957924182065e-08
intestinal O 0 8.34420006867731e-06
anion O 0 8.390627044718713e-06
transporter O 0 8.001334936125204e-05
. O 0 5.972748112981208e-06

We O 0 6.668084893135529e-07
report O 0 7.904648668954906e-08
here O 0 6.350592496318086e-09
the O 0 2.3149873129568732e-09
complete O 0 4.021542654442101e-09
genomic O 0 1.5910758932591307e-08
organization O 0 7.506656629630015e-09
of O 0 2.0323872362837392e-08
the O 0 3.290645267384207e-08
human O 0 3.3036448598977586e-07
CLD B-Disease 0 4.568825170281343e-05
gene O 0 5.677294012684797e-08
which O 0 1.5048927437533166e-08
spans O 0 6.22605327293968e-08
approximately O 0 4.1147756313364425e-09
39kb O 0 1.916760794529182e-07
, O 0 2.3942565707812946e-09
and O 0 6.511604588865794e-09
comprises O 0 1.8778770538574463e-08
21 O 0 5.14452779043495e-07
exons O 0 1.368118500977289e-05
. O 0 5.231293471297249e-06

All O 0 7.448330052284291e-06
exon O 0 3.669100988190621e-05
/ O 0 1.3669330655829981e-05
intron O 0 1.969545110114268e-06
boundaries O 0 2.644459016210021e-07
conform O 0 1.589681346558791e-07
to O 0 2.9298655945808605e-08
the O 0 2.568867785157636e-07
GT O 0 0.0017397013725712895
/ O 0 8.233055268647149e-05
AG O 0 0.00013451490667648613
rule O 0 3.8701127778040245e-06
. O 0 2.8798908715543803e-06

An O 0 5.08202226967569e-08
analysis O 0 3.7624456439289133e-08
of O 0 3.760723643608799e-08
the O 0 5.3384638931675e-08
putative O 0 9.097802262658661e-07
promoter O 0 1.7516950947538135e-06
region O 0 9.708652015660846e-08
sequence O 0 7.866626816621647e-08
shows O 0 1.211131106515495e-08
a O 0 2.4539970056025595e-08
putative O 0 3.00464489555452e-06
TATA O 0 2.756914182100445e-05
box O 0 3.944991817661503e-07
and O 0 3.917940105679918e-08
predicts O 0 1.259794402130865e-07
multiple O 0 3.288304739612613e-08
transcription O 0 5.0939004125893916e-08
factor O 0 3.634507450556157e-08
binding O 0 5.9491856774229745e-08
sites O 0 1.1611570727154685e-07
. O 0 1.047199361892126e-06

The O 0 6.718223630741704e-07
genomic O 0 2.380138965918377e-07
structure O 0 1.1510523734159506e-07
was O 0 2.2277639288859064e-08
determined O 0 6.684088837971558e-09
using O 0 3.2162004170999126e-09
DNA O 0 9.997537020467462e-09
from O 0 3.3188235493142315e-10
several O 0 1.2156132767060512e-09
sources O 0 9.42839495365888e-09
including O 0 1.9169201781465972e-09
multiple O 0 1.4078231025393961e-08
large O 0 6.307535471705705e-08
- O 0 2.4190560452552745e-06
insert O 0 2.608592524211417e-07
libaries O 0 2.2072902083891677e-06
and O 0 1.0369217484651472e-08
genomic O 0 4.592327940144969e-08
DNA O 0 5.4567188101373176e-08
from O 0 2.9115710731275612e-08
Finnish O 0 3.3963679015869275e-05
CLD B-Disease 1 0.9641867876052856
patients O 0 3.1731201488582883e-07
and O 0 1.7795471762838133e-07
controls O 0 4.9010736802301835e-06
. O 0 8.70930580276763e-06

Exon O 0 8.602796151535586e-05
- O 0 1.7165403960461845e-06
specific O 0 1.8030110737754512e-08
primers O 0 1.8748856689398963e-07
developed O 0 1.436017083022989e-08
in O 0 1.1964133017627887e-09
this O 0 7.205774865681747e-10
study O 0 1.5598486946544199e-09
will O 0 5.437585937073663e-10
facilitate O 0 4.947959819645575e-09
mutation O 0 3.1802707134431785e-09
screening O 0 1.9353958435885943e-09
studies O 0 1.37873990002646e-09
of O 0 1.7810667385376178e-09
patients O 0 1.2979612940000607e-09
with O 0 7.438878957266581e-10
the O 0 5.5523418751590725e-08
disease O 0 6.324639343802119e-06
. O 0 8.844481840242224e-07

Genomic O 0 2.7826747555081965e-06
sequencing O 0 9.137896768152132e-07
of O 0 4.834785727325652e-07
a O 0 3.9541862406622386e-07
BAC O 0 0.0025466089136898518
clone O 0 6.999911420280114e-06
H O 1 1.0
_ O 0 2.713308902002609e-07
RG364P16 O 0 6.666915055575373e-07
revealed O 0 4.206600223710666e-08
the O 0 2.592138725887594e-09
presence O 0 8.693978870155661e-10
of O 0 5.503742350754237e-09
another O 0 4.92525842332725e-09
, O 0 1.4956036409330409e-09
highly O 0 7.1954504576865475e-09
homologous O 0 4.679490572812028e-09
gene O 0 3.0669653483528236e-09
3 O 0 4.347248605540699e-08
of O 0 3.834048811768298e-08
the O 0 1.3495116490958026e-07
CLD B-Disease 0 0.0003313509514555335
gene O 0 3.099617629231943e-08
, O 0 1.399293125814438e-09
with O 0 2.358961914694646e-10
a O 0 9.295629266325989e-10
similar O 0 1.9156847219647943e-09
genomic O 0 3.126503145267634e-08
structure O 0 1.6622072962491075e-07
, O 0 2.6766167060543467e-09
recently O 0 5.483582032894674e-09
identified O 0 6.791135209738286e-09
as O 0 2.7992337336968376e-09
the O 0 1.4665292269455676e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 4.794302981281362e-07
( O 0 3.7679463105178e-08
PDS B-Disease 0 3.0829016850475455e-06
) O 0 1.1498405783072485e-08
. O 0 5.287108351126335e-08
. O 0 1.247940076609666e-06

The O 0 4.865419668931281e-06
APCI1307K O 0 0.0009365477599203587
allele O 0 1.2871356375399046e-05
and O 0 2.2429259161071968e-07
cancer B-Disease 0 2.2646136130788364e-06
risk O 0 4.491940330808575e-08
in O 0 1.5064923530871965e-08
a O 0 7.813746094598173e-09
community O 0 3.5019098731936538e-09
- O 0 9.848849735760723e-09
based O 0 1.2994896270157597e-09
study O 0 2.6142585873856206e-09
of O 0 9.859450145199844e-09
Ashkenazi O 0 4.254603709341609e-07
Jews O 0 5.695166578334465e-07
. O 0 2.7857865916303126e-06

Mutations O 0 4.785865712619852e-06
in O 0 1.48054795090502e-07
APC O 0 1.1563020052562933e-06
are O 0 1.0495470270655005e-08
classically O 0 4.342583395100519e-07
associated O 0 3.976031166530447e-07
with O 0 2.0471361494855955e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.6400828957557678
FAP B-Disease 0 0.001125634298659861
) O 0 3.9310918964474695e-08
, O 0 5.921187096191716e-09
a O 0 1.268685778654799e-08
highly O 0 0.0004235951346345246
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 8.349532436113805e-05
by O 0 4.218403049094377e-08
multiple O 0 6.245128133741673e-06
intestinal O 0 0.45071932673454285
polyps B-Disease 0 1.268459982384229e-05
and O 0 1.3633017381664558e-08
, O 0 8.688939567846887e-10
without O 0 2.2481407846441925e-09
surgical O 0 3.3251191666749946e-07
intervention O 0 1.8759891418085317e-07
, O 0 6.135279395635962e-09
the O 0 2.173258550897117e-08
development O 0 1.557501127535943e-05
of O 1 0.9996659755706787
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.400574203420547e-06
CRC B-Disease 0 5.845604027854279e-05
) O 0 6.82608387592154e-08
. O 0 1.237960418620787e-06

APC B-Disease 0 6.312659388640895e-05
is O 0 1.8808923130109179e-07
a O 0 2.903624931605009e-07
tumour O 1 1.0
- O 0 5.5858708947198465e-05
suppressor O 0 1.1348761290719267e-06
gene O 0 1.1064892113665792e-08
, O 0 1.7934000950958762e-09
and O 0 1.586587927704386e-08
somatic O 0 7.575492418254726e-06
loss O 0 1.2052569218212739e-06
occurs O 0 5.743679025727033e-07
in O 0 1.1610811725404346e-06
tumours B-Disease 1 1.0
. O 0 0.00032131769694387913

The O 0 4.032445576740429e-05
germline O 0 0.0012518013827502728
T O 0 3.821201607934199e-05
- O 0 5.149529442860512e-07
to O 0 1.9818376273406102e-08
- O 0 1.5861527913330065e-07
A O 0 3.5665085107439154e-08
transversion O 0 5.400515306064335e-07
responsible O 0 1.396358406680065e-08
for O 0 2.833245860145439e-09
the O 0 1.579603825518916e-08
APC O 0 9.695069991266791e-08
I1307K O 0 1.0569199559995468e-07
allele O 0 2.7684123438120878e-08
converts O 0 2.23363549878286e-08
the O 0 3.869427889213739e-09
wild O 0 8.417854857611928e-09
- O 0 4.521041763183575e-09
type O 0 7.309124416821078e-09
sequence O 0 4.16024681371141e-09
to O 0 2.2437369739947144e-09
a O 0 2.371804441736458e-08
homopolymer O 0 6.81009769323282e-05
tract O 0 4.872682438872289e-06
( O 0 3.074569576710928e-08
A8 O 0 6.33896252111299e-06
) O 0 4.443188483804761e-09
that O 0 8.583108113136007e-10
is O 0 4.3763144219610695e-09
genetically O 0 1.921680592431585e-07
unstable O 0 1.7606183973839507e-05
and O 0 9.264799132324697e-07
prone O 0 1.2477432392188348e-05
to O 0 1.9214276392176544e-07
somatic O 0 0.00022622958931606263
mutation O 0 5.4585057114309166e-06
. O 0 6.35597871223581e-06

The O 0 1.6750219629102503e-06
I1307K O 0 3.059803020732943e-06
allele O 0 4.914924147669808e-07
was O 0 8.048142063898922e-08
found O 0 7.938929513784387e-09
in O 0 1.3541510135439694e-08
6 O 0 3.946352990169544e-06
. O 0 4.076853201695485e-06

1 O 0 4.618584625859512e-06
% O 0 8.423223363251964e-08
of O 0 1.2693543283148756e-07
unselected O 0 1.794846320990473e-05
Ashkenazi O 0 6.839474622211128e-07
Jews O 0 4.305871925680549e-08
and O 0 3.6443839057653804e-09
higher O 0 1.0734162003700476e-08
proportions O 0 2.013941902134775e-08
of O 0 4.6207603077164094e-08
Ashkenazim O 0 1.412738401995739e-05
with O 0 6.277827147016524e-09
family O 0 1.5374795880873648e-09
or O 0 3.367560896805344e-09
personal O 0 2.5539492298776167e-08
histories O 0 1.0541255335283495e-07
of O 0 8.806530900073994e-07
CRC B-Disease 0 0.00013321914593689144
( O 0 4.9165226556624475e-08
ref O 0 1.2607682720044977e-06
. O 0 1.597214982496098e-08
2 O 0 4.7626585342186445e-07
) O 0 6.218623127551837e-08
. O 0 8.679851362103363e-07

To O 0 2.792266116102837e-07
evaluate O 0 7.224310820674873e-07
the O 0 1.811411465268975e-08
role O 0 1.268845473134661e-08
of O 0 2.987498248785414e-08
I1307K O 0 3.719963501680468e-07
in O 0 7.059710593892987e-09
cancer B-Disease 0 7.181605354844578e-08
, O 0 4.0375369714240605e-09
we O 0 1.5463443858720893e-08
genotyped O 0 6.879634497636289e-07
5 O 0 1.4600763620364887e-07
, O 0 3.22134674490826e-08
081 O 0 9.328456144430675e-06
Ashkenazi O 0 7.146663847379386e-07
volunteers O 0 3.090832834118373e-08
in O 0 1.3756200623049608e-08
a O 0 4.489541538532649e-08
community O 0 7.937009627312364e-08
survey O 0 3.51434465528655e-07
. O 0 2.3782790776749607e-06

Risk O 0 0.0002712190034799278
of O 0 0.008457470685243607
developing O 1 1.0
colorectal B-Disease 1 1.0
, I-Disease 1 0.9997001886367798
breast I-Disease 1 0.9999831914901733
and I-Disease 0 4.172016360826092e-06
other I-Disease 0 1.8997162953837687e-07
cancers I-Disease 1 0.7710992097854614
were O 0 3.7810571029694984e-07
compared O 0 7.560471715351014e-08
between O 0 1.7215785419466556e-07
genotyped O 0 4.182465545454761e-06
I1307K O 0 2.805623466883844e-07
carriers O 0 2.4241617602172028e-09
and O 0 3.499826428665642e-09
non O 0 4.163789668609752e-08
- O 0 6.319394341147699e-09
carriers O 0 2.704511614659566e-10
and O 0 5.443978046137943e-10
their O 0 5.534414593277859e-10
first O 0 3.5191247693688865e-09
- O 0 7.01284585957751e-09
degree O 0 1.6270334413093224e-07
relatives O 0 7.945598667902232e-08
. O 0 3.856359853671165e-07

Sperm O 0 1.0013014843934798e-06
DNA O 0 2.81129359791521e-07
analysis O 0 1.0811671558030866e-07
in O 0 3.43442074779432e-08
a O 0 4.4132832499599317e-07
Friedreich B-Disease 1 0.9977204203605652
ataxia I-Disease 1 0.9999997615814209
premutation O 0 0.1511482298374176
carrier O 0 2.5026611183420755e-07
suggests O 0 2.211828160625373e-07
both O 0 3.6877032982829405e-08
meiotic O 0 2.748740143942996e-06
and O 0 4.7113125845044124e-08
mitotic O 0 3.326387911783968e-07
expansion O 0 5.3677158717846396e-08
in O 0 1.3235998075344924e-08
the O 0 1.1619147954888831e-07
FRDA B-Disease 0 3.27524212480057e-05
gene O 0 7.779678412589419e-07
. O 0 2.9007790089963237e-06

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 6.463398563028022e-07
usually O 0 2.5323105390384626e-08
caused O 0 8.90086759852693e-09
by O 0 4.235612138803191e-10
an O 0 1.6487128329245593e-10
expansion O 0 1.2045745734212687e-08
of O 0 7.425985870668228e-08
a O 0 1.2745435640226788e-07
GAA O 0 9.830750968831126e-06
trinucleotide O 0 1.5345952988354838e-06
repeat O 0 8.026557196672002e-08
in O 0 8.16224243749275e-09
intron O 0 1.1412095801688338e-07
1 O 0 8.734443213143095e-08
of O 0 3.087179578642463e-08
the O 0 7.211225749870209e-08
FRDA B-Disease 0 1.319558850809699e-05
gene O 0 2.2093952622981305e-07
. O 0 1.2478365079005016e-06

Occasionally O 0 4.2562778617138974e-06
, O 0 6.095530125094228e-08
a O 0 1.92007174604214e-08
fully O 0 7.473986585182502e-08
expanded O 0 1.837117657998988e-08
allele O 0 5.062672769895471e-08
has O 0 4.813227594269165e-10
been O 0 5.403900660283512e-10
found O 0 2.3733631726585713e-10
to O 0 2.366921103558184e-10
arise O 0 6.7381704660363084e-09
from O 0 8.550444796640022e-10
a O 0 1.638912672241588e-09
premutation O 0 1.3010544819280767e-07
of O 0 1.2737897847614477e-08
100 O 0 2.677169419484926e-08
or O 0 1.452603459739521e-08
less O 0 1.0778254022625333e-07
triplet O 0 1.3639317330671474e-05
repeats O 0 2.366938588238554e-06
. O 0 1.7790835045161657e-06

We O 0 7.151982686082192e-07
have O 0 8.983211507995748e-09
examined O 0 1.2723938880299102e-07
the O 0 4.527263453013575e-09
sperm O 0 3.1010232159900397e-09
DNA O 0 9.886170104778103e-09
of O 0 1.0612485112915238e-08
a O 0 2.9331143736044396e-08
premutation O 0 7.890014785516541e-06
carrier O 0 2.2688375338475453e-06
. O 0 1.5322408216889016e-05

This O 0 4.943486260344798e-07
mans O 0 4.898205952486023e-05
leucocyte O 0 5.281754056341015e-06
DNA O 0 2.2315516901016963e-07
showed O 0 3.3153977341271457e-08
one O 0 2.0754302720860096e-09
normal O 0 8.858526356902985e-09
allele O 0 1.4511220669533031e-08
and O 0 2.040476898557131e-09
one O 0 9.5509455899645e-10
allele O 0 1.4498050759925718e-08
of O 0 1.0880970791049549e-08
approximately O 0 9.13882036712721e-09
100 O 0 5.7325163282939684e-08
repeats O 0 4.022769246603275e-07
. O 0 1.1734183544831467e-06

His O 0 2.2169183466758113e-06
sperm O 0 2.5162785277643707e-07
showed O 0 3.516415603144196e-08
an O 0 8.90227336292071e-10
expanded O 0 5.130599944891401e-09
allele O 0 6.226944293530323e-08
in O 0 8.80774742029189e-09
a O 0 2.6331914426691583e-08
tight O 0 4.0498491671314696e-07
range O 0 5.865738330612658e-07
centering O 0 3.617498123276164e-07
on O 0 2.7430621329926907e-08
a O 0 1.9748935820018687e-09
size O 0 5.486134657672892e-09
of O 0 1.7432871146638718e-08
approximately O 0 3.462902498085896e-08
320 O 0 4.177336734301207e-07
trinucleotide O 0 9.464428330829833e-06
repeats O 0 3.458613264228916e-06
. O 0 3.4116658298444236e-06

His O 0 1.1327437277941499e-05
affected O 0 3.4414879337418824e-06
son O 0 1.5342455299105495e-05
has O 0 3.9790311490151e-08
repeat O 0 1.9593861111388833e-07
sizes O 0 4.4030508661307977e-07
of O 0 3.098202228102309e-07
1040 O 0 1.003707802738063e-05
and O 0 1.3237821860911936e-07
540 O 0 1.4569094446414965e-06
. O 0 1.4879611853757524e-06

These O 0 3.294080030968871e-08
data O 0 2.8714056909961982e-08
suggest O 0 2.1281518769455943e-09
that O 0 6.532110269352742e-11
expansion O 0 1.7853590827954235e-09
occurs O 0 2.6788932183663405e-10
in O 0 6.529855822723363e-11
two O 0 1.0900901709076649e-10
stages O 0 3.857092867320944e-09
, O 0 1.229932544699608e-10
the O 0 2.1525428661739454e-10
first O 0 5.124866087058422e-10
during O 0 2.0188752891669992e-09
meiosis O 0 1.0583175225065133e-08
followed O 0 1.9834061060208796e-09
by O 0 7.527600209833452e-10
a O 0 6.1842246878995866e-09
second O 0 8.49110080025639e-08
mitotic O 0 2.857057097571669e-06
expansion O 0 3.926366844098084e-06
. O 0 4.451395398064051e-06

We O 0 5.310384381118638e-07
also O 0 1.56642343540625e-08
show O 0 3.3688651868146735e-09
that O 0 5.093545585310721e-10
in O 0 7.661719592100269e-10
all O 0 1.4398120473657627e-09
informative O 0 8.712957466627813e-09
carrier O 0 1.2033752883056081e-09
father O 0 6.117658379878321e-09
to O 0 6.11209483025732e-09
affected O 0 4.521225349662927e-08
child O 0 6.86228389668031e-08
transmissions O 0 2.9470592721736466e-07
, O 0 1.4976047069126253e-09
with O 0 1.211074435181203e-10
the O 0 1.3782219809854723e-09
notable O 0 2.0311576864884273e-09
exception O 0 4.855498225708743e-09
of O 0 5.883630915803906e-09
the O 0 1.0807667649714858e-08
premutation O 0 4.2176151282546925e-07
carrier O 0 1.1397637500465407e-08
, O 0 8.934563311413513e-09
the O 0 1.1945829214710102e-08
expansion O 0 6.418802200869322e-08
size O 0 3.799129189019368e-08
decreases O 0 2.9453019578795647e-08
. O 0 2.7422775161767277e-08
. O 0 5.344913347471447e-07

The O 0 1.5005683735580533e-06
R496H O 0 3.9954916246642824e-06
mutation O 0 1.4846371243493195e-07
of O 0 7.984291983120784e-08
arylsulfatase O 0 4.62674506707117e-06
A O 0 3.7964703381021536e-08
does O 0 3.275483217990427e-09
not O 0 2.033154977709728e-08
cause O 0 4.267211625119671e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 1.9062719729845412e-05

Deficiency B-Disease 1 0.9998998641967773
of I-Disease 0 0.0001883807999547571
arylsulfatase I-Disease 1 0.5040100812911987
A I-Disease 0 1.736645572236739e-05
( O 0 2.5480795784460497e-07
ARSA O 0 3.9102305890992284e-05
) O 0 2.3830320827755713e-08
enzyme O 0 1.50343169025291e-07
activity O 0 3.9951237340574153e-07
causes O 0 4.736025948659517e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 8.835007065499667e-06
MLD B-Disease 1 0.9999998807907104
) O 0 5.301781698108243e-07
. O 0 2.6208210783806862e-06

A O 0 4.858441684518766e-07
number O 0 7.959356196352019e-08
of O 0 4.1279534457316913e-07
ARSA O 0 0.0001002498684101738
gene O 0 1.769589346167777e-07
mutations O 0 1.5173314693583961e-07
responsible O 0 5.787005363799835e-08
for O 0 3.3844528957160946e-08
MLD B-Disease 1 1.0
have O 0 2.0709943981955803e-08
been O 0 2.2802677079880596e-08
identified O 0 2.0996679950258113e-07
. O 0 9.095242603507359e-07

Recently O 0 2.149957481378806e-06
, O 0 2.9787646127488188e-08
the O 0 3.446416130259422e-08
R496H O 0 1.3091163282297202e-06
mutation O 0 1.1490880069686682e-07
of O 0 2.078531906590797e-07
ARSA O 0 9.271833550883457e-05
was O 0 1.2933141135818005e-07
proposed O 0 1.3872133663994646e-08
to O 0 1.1292293766729244e-09
be O 0 2.380314167993447e-09
a O 0 1.7961387932530215e-09
cause O 0 6.48184297347143e-08
of O 0 1.8989098862220999e-06
MLD B-Disease 1 1.0
( O 0 1.531390694253787e-07
Draghia O 0 7.558764991699718e-06
et O 0 2.6534801236266503e-06
al O 0 3.5151387578480353e-07
. O 0 1.7555655817957927e-09
, O 0 1.4717930207908125e-09
1997 O 0 2.233703533249809e-08
) O 0 2.1502799540940032e-08
. O 0 7.169410309870727e-07

We O 0 9.455093845645024e-07
have O 0 3.355438593644067e-08
investigated O 0 2.924228112988203e-07
the O 0 1.4337946829812154e-08
R496H O 0 1.851770576877243e-07
mutation O 0 8.21191559197132e-09
and O 0 1.1562024671007975e-09
found O 0 9.276182044715142e-10
this O 0 3.618415567174793e-10
mutation O 0 5.5436935042507685e-09
at O 0 1.662472826069461e-08
a O 0 6.165647992162349e-10
relatively O 0 7.924719214180698e-10
high O 0 8.961444031285737e-09
frequency O 0 9.358878116927372e-09
in O 0 1.6050893947294753e-10
an O 0 8.873669854470023e-11
African O 0 1.078879652283149e-09
American O 0 1.502009350229372e-10
population O 0 1.0423197027709108e-11
( O 0 6.525548157387817e-11
f O 0 9.790114496865954e-09
= O 0 1.5584962653747425e-08
0 O 0 6.018218812187115e-09
. O 0 7.26011584184505e-10
09 O 0 3.5536746878506165e-08
, O 0 1.9900980863241102e-09
n O 0 6.790904905074058e-08
= O 0 1.8608452023727295e-07
61 O 0 3.03209155561035e-08
subjects O 0 3.9729496847940027e-07
) O 0 3.9211844438113985e-08
. O 0 1.0259707323712064e-06

The O 0 1.0842119991139043e-05
ARSA O 0 0.00015883479500189424
enzyme O 0 1.35864411276998e-07
activity O 0 3.4922727820685395e-08
in O 0 1.623394307870285e-09
subjects O 0 2.1454784615571043e-08
with O 0 3.276662552398335e-10
and O 0 1.0174493469961021e-09
without O 0 3.315307584017546e-09
the O 0 3.1090954255574843e-09
R496H O 0 5.298152316868254e-08
mutation O 0 2.5593460684092406e-09
was O 0 3.797489878110127e-09
determined O 0 1.081005951419911e-08
and O 0 1.4736862841147058e-09
found O 0 8.430962594729863e-10
to O 0 7.718453653993151e-10
be O 0 1.1659914811446015e-08
normal O 0 4.238986832660885e-07
. O 0 1.1959938319705543e-06

It O 0 3.877445919897582e-08
is O 0 2.564794820969496e-09
therefore O 0 6.857518108915883e-09
concluded O 0 2.0400031885969838e-08
that O 0 4.0701408909882275e-10
the O 0 2.8967632736964788e-09
R496H O 0 1.142406276244401e-07
mutation O 0 1.8285565062114983e-08
of O 0 3.3081651196198436e-08
ARSA O 0 2.8866936645499663e-06
does O 0 1.812741290407871e-09
not O 0 3.790398217518032e-09
negatively O 0 8.055064171230697e-09
influence O 0 9.474888429394923e-09
the O 0 6.5053731290731776e-09
activity O 0 1.7753357894889632e-08
of O 0 2.1535635497116346e-08
ARSA O 0 9.94372931018006e-06
and O 0 4.984551438269591e-09
is O 0 2.9524366285116344e-10
not O 0 7.580188698952384e-10
a O 0 5.724078544488975e-09
cause O 0 1.761643034114968e-06
of O 0 0.00010049699631053954
MLD B-Disease 1 1.0

Down O 0 6.602884968742728e-05
- O 0 4.283557245798875e-06
regulation O 0 5.947914587522973e-07
of O 0 5.584985274253995e-07
transmembrane O 0 2.5500912670395337e-05
carbonic O 0 0.050141528248786926
anhydrases O 0 0.001050502760335803
in O 0 5.6886156016844325e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9987257122993469
lines O 0 7.62366425988148e-07
by O 0 6.285760889568337e-08
wild O 0 3.652239115581324e-07
- O 0 1.16521096060751e-06
type O 0 3.9317157643381506e-05
von B-Disease 1 0.9999998807907104
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999963045120239
Lindau I-Disease 1 0.9916748404502869
transgenes O 0 0.0003395926905795932
. O 0 7.395937245746609e-06

To O 0 1.2240384421602357e-06
discover O 0 1.2337658290562104e-06
genes O 0 1.1763053464619588e-07
involved O 0 6.819563935778206e-08
in O 0 8.336832024724572e-08
von B-Disease 1 0.9999639987945557
Hippel I-Disease 1 0.9999998807907104
- I-Disease 1 0.9999997615814209
Lindau I-Disease 1 0.9999982118606567
( O 0 1.7333755977233523e-06
VHL B-Disease 0 0.009484871290624142
) O 0 4.336607162258588e-07
- O 0 6.779840077797417e-06
mediated O 0 2.3306125513045117e-05
carcinogenesis O 0 0.01316895056515932
, O 0 3.146904248296778e-08
we O 0 4.822311439056648e-08
used O 0 1.5616647033311892e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999983310699463
lines O 0 3.901618765667081e-05
stably O 0 6.590630073333159e-05
transfected O 0 3.8310849959088955e-06
with O 0 3.062880793436307e-08
wild O 0 3.2026954954744724e-07
- O 0 2.24069481191691e-06
type O 0 0.00045096036046743393
VHL O 1 0.9999834299087524
- O 0 0.0006137399468570948
expressing O 0 1.2177034705018741e-06
transgenes O 0 6.907840725034475e-05
. O 0 3.354118916831794e-06

Large O 0 3.6948995330021717e-06
- O 0 8.733825779927429e-06
scale O 0 3.5202554045099532e-06
RNA O 0 4.234247512613365e-07
differential O 0 9.040950317285024e-07
display O 0 3.396390368948232e-08
technology O 0 5.549514980884851e-08
applied O 0 1.4717152829746283e-08
to O 0 4.207783843579449e-10
these O 0 4.873365044844036e-10
cell O 0 8.248192351345551e-09
lines O 0 1.523583925688854e-09
identified O 0 1.6347542208805521e-09
several O 0 5.261510671594749e-10
differentially O 0 2.3005203075854297e-08
expressed O 0 1.1148735268307064e-09
genes O 0 2.209937344233026e-09
, O 0 4.114647789155157e-10
including O 0 5.629186561328936e-10
an O 0 1.602856958271559e-09
alpha O 0 5.633901878354663e-07
carbonic O 0 5.600401436822722e-06
anhydrase O 0 7.682851901336107e-06
gene O 0 7.03252496236928e-08
, O 0 4.162495059745197e-08
termed O 0 3.1116774152906146e-06
CA12 O 0 0.00020517545635811985
. O 0 9.052727364178281e-06

The O 0 3.7238146433082875e-06
deduced O 0 1.9135513866785914e-06
protein O 0 4.09073805940352e-08
sequence O 0 1.1952963063777133e-08
was O 0 1.3482003957676625e-08
classified O 0 3.780030510824872e-09
as O 0 9.234802367252826e-10
a O 0 2.9276912005826716e-09
one O 0 1.0745591971783597e-08
- O 0 5.437891559267882e-07
pass O 0 4.897327130493068e-07
transmembrane O 0 2.216858592873905e-05
CA O 0 3.213451236661058e-06
possessing O 0 5.663255251420196e-07
an O 0 7.003582158660038e-09
apparently O 0 1.6309809325321112e-07
intact O 0 3.709304223775689e-07
catalytic O 0 1.1137480271372624e-07
domain O 0 8.538393103663111e-08
in O 0 2.088834527569361e-08
the O 0 6.441135269596998e-08
extracellular O 0 2.0008224055345636e-06
CA O 0 9.432071237824857e-06
module O 0 1.9551076547941193e-05
. O 0 3.982087037002202e-06

Reintroduced O 0 9.31946124183014e-05
wild O 0 4.7970156629162375e-06
- O 0 2.172642552977777e-06
type O 0 3.2293742151523475e-06
VHL B-Disease 0 0.00018248749256599694
strongly O 0 6.22659968030348e-08
inhibited O 0 4.780286744221485e-08
the O 0 4.247352691777451e-09
overexpression O 0 2.4156888045467895e-08
of O 0 5.875455677539776e-09
the O 0 3.77894204817153e-09
CA12 O 0 8.535948836652096e-07
gene O 0 3.6189000685027395e-09
in O 0 2.267139143086183e-09
the O 0 6.958261167255841e-08
parental O 0 0.0002310389536432922
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999964237213135
lines O 0 0.00015877179976087064
. O 0 3.156957609462552e-05

Similar O 0 2.592635439668811e-07
results O 0 2.764355713225086e-07
were O 0 1.777389080359626e-08
obtained O 0 1.1669036403816335e-08
with O 0 1.7496253335025358e-09
CA9 O 0 3.0082375815254636e-05
, O 0 1.2725172027217013e-08
encoding O 0 3.0981726695245015e-07
another O 0 4.487025151433954e-08
transmembrane O 0 6.483548418145801e-07
CA O 0 3.456558204106841e-07
with O 0 2.698849810300885e-09
an O 0 3.0083564528382567e-09
intact O 0 2.162933157023872e-07
catalytic O 0 6.177071441015869e-07
domain O 0 9.307503319178068e-07
. O 0 1.7960458080779063e-06

Although O 0 2.1763847257716407e-07
both O 0 4.223603866648773e-08
domains O 0 1.8881243590840313e-07
of O 0 8.335877765830446e-08
the O 0 6.353393899871662e-08
VHL B-Disease 0 4.244895080773858e-06
protein O 0 2.837454893267477e-08
contribute O 0 2.660055509196013e-09
to O 0 2.5705295669808947e-09
regulation O 0 2.1756598300726182e-08
of O 0 2.0962342972552506e-08
CA12 O 0 5.951880211796379e-06
expression O 0 1.9812556928400227e-08
, O 0 1.0905274461237013e-09
the O 0 2.346206118275518e-09
elongin O 0 6.542955333088685e-08
binding O 0 1.651345549191774e-08
domain O 0 3.392926473111402e-08
alone O 0 4.537048958752621e-09
could O 0 5.408667735906647e-09
effectively O 0 2.473801430369349e-07
regulate O 0 2.5731608843670983e-07
CA9 O 0 0.0002422422985546291
expression O 0 3.5613059026218252e-06
. O 0 5.101107944938121e-06

We O 0 8.589127901359461e-06
mapped O 0 4.1033067645912524e-06
CA12 O 0 6.962633779039606e-05
and O 0 1.045126055032597e-06
CA9 O 0 0.00012555919238366187
loci O 0 5.170048780200887e-07
to O 0 3.512809243488846e-08
chromosome O 0 1.6435645022738754e-07
bands O 0 3.7730748658759694e-07
15q22 O 0 3.639971737356973e-06
and O 0 3.007933742082969e-07
17q21 O 0 1.7402047888026573e-05
. O 0 4.254285158822313e-06

2 O 0 9.237766789738089e-06
respectively O 0 1.100366944228881e-06
, O 0 1.6388884915841118e-08
regions O 0 3.1403928346662724e-08
prone O 0 5.8071509556612e-07
to O 0 1.1074055450421838e-08
amplification O 0 1.9265139883373195e-07
in O 0 1.4851038621088719e-08
some O 0 3.060007713884261e-08
human O 0 3.0048770440771477e-06
cancers B-Disease 0 0.005248569883406162
. O 0 2.218593635916477e-06

Additional O 0 4.5745551346954016e-07
experiments O 0 2.1033376640389179e-07
are O 0 1.935580362655287e-09
needed O 0 8.789153405075467e-09
to O 0 1.1502722108147623e-09
define O 0 1.2304289143116875e-08
the O 0 4.1005323581089215e-09
role O 0 8.751698921116713e-09
of O 0 1.5960850419105554e-08
CA O 0 1.9155402242176933e-07
IX O 0 4.087816705578007e-06
and O 0 3.61259857584173e-08
CA O 0 3.787434081914398e-07
XII O 0 6.311629931587959e-06
enzymes O 0 2.307520752253822e-08
in O 0 3.2614067002612046e-09
the O 0 4.703570422037728e-09
regulation O 0 2.1715472087180387e-08
of O 0 1.341055178016859e-08
pH O 0 5.168880647943297e-07
in O 0 1.1429507118521087e-08
the O 0 1.9365858250353085e-08
extracellular O 0 1.0127106975232891e-07
microenvironment O 0 4.868168161920039e-07
and O 0 2.7016411330293977e-09
its O 0 9.399268030563235e-10
potential O 0 1.1829083490511039e-08
impact O 0 6.603258952964097e-07
on O 0 5.003074420528719e-06
cancer B-Disease 0 4.169972817180678e-05
cell O 0 9.691815648693591e-06
growth O 0 3.7816917597410793e-07
. O 0 1.1737262184396968e-06

A O 0 4.081459337612614e-06
gene O 0 5.388564545683039e-07
encoding O 0 2.3265897652891e-06
a O 0 2.1401555727607047e-07
transmembrane O 0 9.665201332609286e-07
protein O 0 4.541215758990802e-08
is O 0 1.890179401886627e-10
mutated O 0 2.1539936501113743e-09
in O 0 4.492304028769212e-10
patients O 0 6.629037763161705e-09
with O 0 1.200707657744715e-07
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.8196610808372498
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 3.140602871098963e-07
. O 0 1.8759941440293915e-06

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0009894294198602438
WFS B-Disease 1 0.9990352392196655
; O 0 1.075287059393304e-06
OMIM O 0 0.0013696977403014898
222300 O 0 1.0421321348985657e-05
) O 0 1.4736815323601604e-08
is O 0 2.2748321004684158e-09
an O 0 2.2048061154578136e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999997615814209
defined O 0 6.859665973024676e-07
by O 0 2.795526832244377e-08
young O 0 1.1660018572001718e-05
- O 0 0.00021117017604410648
onset O 1 0.9999995231628418
non O 1 0.9999997615814209
- O 1 0.9999912977218628
immune O 1 0.9999840259552002
insulin B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999985694885254
dependent I-Disease 1 0.9993209838867188
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.999977707862854
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999330043792725
. O 0 3.510488022584468e-05

Linkage O 0 1.9902467101928778e-05
to O 0 1.5308225442822732e-07
markers O 0 8.40486109154881e-07
on O 0 1.0043906968348892e-06
chromosome O 0 3.3369381071679527e-06
4p O 0 7.883954094722867e-05
was O 0 8.470822194794891e-07
confirmed O 0 1.1446408620940929e-07
in O 0 8.775952409223464e-09
five O 0 4.1244426540743007e-08
families O 0 1.1978021241532133e-08
. O 0 5.860673013557971e-07

On O 0 9.296609277953394e-07
the O 0 3.427000550004777e-08
basis O 0 8.429844911006512e-08
of O 0 9.032232384242889e-08
meiotic O 0 5.756562313763425e-05
recombinants O 0 0.0011564051965251565
and O 0 2.7581670565268723e-06
disease O 0 0.00622929260134697
- O 0 1.8863563582272036e-06
associated O 0 4.535450841558486e-07
haplotypes O 0 8.544826641809777e-07
, O 0 1.4857214125640894e-08
the O 0 9.479899887310239e-08
WFS B-Disease 0 2.886168658733368e-05
gene O 0 1.2611871547107967e-08
was O 0 2.7483883613399485e-08
localized O 0 3.30064615639003e-08
to O 0 7.817800629084104e-09
a O 0 9.999924799330984e-08
BAC O 0 0.05108639970421791
/ O 0 6.669635331491008e-05
P1 O 0 5.660190436174162e-05
contig O 0 4.545003776001977e-06
of O 0 5.183482088000346e-08
less O 0 1.0598426136709804e-08
than O 0 1.1334032379295422e-08
250 O 0 1.1867030735857043e-07
kb O 0 2.1783604097436182e-05
. O 0 2.07943890018214e-06

Mutations O 0 1.791643967408163e-06
in O 0 6.047840628298218e-08
a O 0 1.366295432347897e-08
novel O 0 2.4809594378893962e-08
gene O 0 2.8588203804247314e-08
( O 0 3.3206376315320085e-08
WFS1 O 0 4.994612481823424e-06
) O 0 2.504293483696074e-08
encoding O 0 2.5981549356401956e-07
a O 0 3.263704684286495e-08
putative O 0 4.496294820910407e-07
transmembrane O 0 2.1133931227268477e-07
protein O 0 1.5027186606175746e-08
were O 0 4.048178237070488e-09
found O 0 5.327990826309303e-10
in O 0 2.954385625031364e-10
all O 0 9.43981670609162e-10
affected O 0 2.7887192555198226e-09
individuals O 0 4.909939121944262e-10
in O 0 6.148200615285759e-09
six O 0 2.1546691186813405e-07
WFS B-Disease 0 0.00013803134788759053
families O 0 9.322298488712022e-10
, O 0 4.1197209532661816e-10
and O 0 2.752005012762737e-10
these O 0 1.7504589444605756e-10
mutations O 0 2.357451789336551e-09
were O 0 3.0107327742001644e-09
associated O 0 1.606417221466927e-08
with O 0 7.023340575784687e-09
the O 0 1.1458120070528821e-06
disease O 0 0.1195186972618103
phenotype O 0 2.0227449567755684e-05
. O 0 3.7448373859660933e-06

WFS1 O 0 0.00012912465899717063
appears O 0 2.2146396361222287e-07
to O 0 6.876352376394834e-09
function O 0 3.863220499056297e-08
in O 0 8.562364151032398e-09
survival O 0 6.582472451555077e-07
of O 0 1.468596337872441e-07
islet O 0 2.4323528577951947e-06
beta O 0 5.3959311117068864e-06
- O 0 1.0367091363150394e-06
cells O 0 6.099507743329013e-08
and O 0 4.4564817613945706e-08
neurons O 0 3.260333016896766e-07
. O 0 7.120635814317211e-08
. O 0 8.019883352972101e-07

Stable O 0 8.415334013989195e-05
interaction O 0 5.968939831291209e-07
between O 0 3.241216717242423e-08
the O 0 6.269678110015775e-09
products O 0 4.036482259550667e-09
of O 0 8.196829881512713e-09
the O 0 8.743572976754876e-09
BRCA1 O 0 7.091441744933036e-08
and O 0 4.1399690786647625e-08
BRCA2 O 0 2.796428759666014e-07
tumor B-Disease 0 1.678525762827121e-07
suppressor O 0 1.2424935391663894e-07
genes O 0 1.3746339178055678e-08
in O 0 2.1199086930323574e-08
mitotic O 0 1.4636301557402476e-06
and O 0 7.898287321950193e-07
meiotic O 0 9.28355657379143e-05
cells O 0 1.5175836779235397e-05
. O 0 1.092228831112152e-05

BRCA1 O 0 4.260438072378747e-05
and O 0 6.556740572705166e-07
BRCA2 O 0 5.204018407312105e-07
account O 0 4.524233432334768e-09
for O 0 5.653374990366444e-10
most O 0 9.089336228118583e-11
cases O 0 3.735370346369393e-10
of O 0 9.171574055777398e-10
familial O 0 2.0121335708722654e-08
, O 0 2.454220382475114e-09
early O 0 9.635410833652713e-07
onset O 1 0.9981896281242371
breast B-Disease 1 0.9999620914459229
and I-Disease 1 0.9999899864196777
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 7.618971267220331e-06
encode O 0 3.6282322923852917e-08
products O 0 9.651375698638276e-09
that O 0 4.395385444500022e-10
each O 0 1.2500550594651827e-09
interact O 0 4.622415339383679e-09
with O 0 2.2542681055170988e-09
hRAD51 O 0 1.5165749118750682e-06
. O 0 6.120928333075426e-07

Results O 0 7.928588274808135e-06
presented O 0 1.4820470823906362e-06
here O 0 6.33079721978902e-08
show O 0 4.623702754003034e-09
that O 0 1.317933651101555e-09
BRCA1 O 0 8.635087311859024e-08
and O 0 3.5682230503653045e-08
BRCA2 O 0 6.418741804736783e-07
coexist O 0 2.1206734857059928e-07
in O 0 5.341354025745204e-09
a O 0 6.716113887250685e-09
biochemical O 0 2.685526681034389e-07
complex O 0 4.6605202896898845e-07
and O 0 7.41781747137793e-08
colocalize O 0 2.7265273274679203e-06
in O 0 6.750599368388066e-08
subnuclear O 0 5.487578164320439e-06
foci O 0 4.006835752079496e-06
in O 0 2.6876270098341593e-08
somatic O 0 3.932164531761373e-07
cells O 0 2.5148622739834536e-08
and O 0 4.08566780407682e-09
on O 0 1.5658081053970818e-08
the O 0 1.3044214597357495e-09
axial O 0 7.006000668496881e-09
elements O 0 2.2135326460670512e-08
of O 0 4.044336776587443e-08
developing O 0 4.760097738198965e-07
synaptonemal O 0 5.264173978503095e-06
complexes O 0 3.539527426710265e-07
. O 0 6.514097776744165e-07

Like O 0 6.009646767779486e-06
BRCA1 O 0 1.346438057225896e-05
and O 0 2.539230308684637e-06
RAD51 O 0 0.00036027494934387505
, O 0 3.9470089063797786e-07
BRCA2 O 0 3.5431683045317186e-06
relocates O 0 9.514432122159633e-07
to O 0 7.278146796352303e-08
PCNA O 0 1.3010228940402158e-05
+ O 0 1.8571788018562074e-07
replication O 0 1.4045455465350187e-08
sites O 0 3.2857139231623478e-09
following O 0 7.33802529850891e-09
exposure O 0 3.825130079349037e-08
of O 0 3.44665274099043e-08
S O 0 9.172682098324003e-07
phase O 0 6.177269824547693e-06
cells O 0 7.006605073911487e-08
to O 0 1.4079653887222321e-08
hydroxyurea O 0 3.832371476164553e-06
or O 0 4.1106446246885753e-07
UV O 0 0.0001211933049489744
irradiation O 0 5.1636466196214315e-06
. O 0 1.3182594784666435e-06

Thus O 0 2.1949535948806442e-06
, O 0 1.050132070190557e-07
BRCA1 O 0 3.886524098106747e-07
and O 0 4.985913903965411e-08
BRCA2 O 0 2.2612590555581846e-07
participate O 0 1.9073258528123915e-08
, O 0 2.4930544295642676e-09
together O 0 5.825772086964776e-10
, O 0 2.721692038409884e-10
in O 0 4.460015134988282e-10
a O 0 1.347397637907477e-09
pathway O 0 7.258457834780074e-09
( O 0 9.750676932540614e-10
s O 0 1.2866041565473552e-08
) O 0 5.275810344151921e-10
associated O 0 2.6872974956404505e-09
with O 0 5.27882015877168e-10
the O 0 2.0672166201052278e-09
activation O 0 1.4563598327299587e-08
of O 0 2.2359030182883544e-08
double O 0 2.548421385029087e-08
- O 0 2.6933903995995934e-07
strand O 0 4.501099937215258e-08
break O 0 1.2406287908106606e-07
repair O 0 5.372016858018469e-07
and O 0 8.933425021950825e-08
/ O 0 1.1020304100384237e-06
or O 0 7.047147931871223e-08
homologous O 0 3.5390277730584785e-07
recombination O 0 1.0098518714585225e-06
. O 0 1.9690476165123982e-06

Dysfunction O 0 0.2446986585855484
of O 0 2.93538096229895e-06
this O 0 1.6176029404846304e-08
pathway O 0 4.9686928349501613e-08
may O 0 4.552469956564664e-09
be O 0 1.8155231762406743e-09
a O 0 1.1552149237203935e-09
general O 0 7.294640447241818e-09
phenomenon O 0 1.0468779620964597e-08
in O 0 4.2766967744967133e-10
the O 0 4.803790143448339e-10
majority O 0 1.878820987677443e-10
of O 0 1.2276832883628686e-09
cases O 0 3.766823741813141e-09
of O 0 4.705134415416978e-08
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00025634982739575207
. O 0 5.225944551057182e-05

A O 0 3.198646481905598e-06
novel O 0 1.3182318525650771e-06
Arg362Ser O 0 1.2514352420112118e-05
mutation O 0 8.957055541713999e-08
in O 0 1.2858214937239154e-08
the O 0 5.234210576077203e-08
sterol O 0 1.2989027027288103e-06
27 O 0 2.4526598281227052e-06
- O 0 3.2540535812586313e-06
hydroxylase O 0 3.2934945011220407e-06
gene O 0 3.542873372452959e-08
( O 0 1.1043176151304124e-08
CYP27 O 0 3.605402980610961e-06
) O 0 2.88374235601907e-09
: O 0 9.360641151090476e-10
its O 0 6.129463048232253e-10
effects O 0 1.945641692202571e-08
on O 0 3.051370356388361e-08
pre O 0 3.1712929171590076e-07
- O 0 2.9243441446169527e-08
mRNA O 0 3.2460732768413436e-08
splicing O 0 3.997714514980544e-08
and O 0 3.774807133538616e-09
enzyme O 0 4.32227160729326e-08
activity O 0 1.8077587071729795e-07
. O 0 6.207963565429964e-07

A O 0 1.0991209364874521e-06
novel O 0 2.434891257507843e-07
C O 0 1.0626197308738483e-06
to O 0 8.172321486199507e-09
A O 0 1.7397162821453094e-08
mutation O 0 1.2019857109635268e-08
in O 0 4.482300752783885e-09
the O 0 2.16901394622937e-08
sterol O 0 3.598034652441129e-07
27 O 0 5.337771540325775e-07
- O 0 3.9934741380420746e-07
hydroxylase O 0 5.528848419089627e-07
gene O 0 1.2041656560768388e-08
( O 0 4.417306520565489e-09
CYP27 O 0 2.2184706267580623e-06
) O 0 2.683783639767512e-09
was O 0 1.662970738891545e-08
identified O 0 1.5097542771513872e-08
by O 0 4.210185977626679e-09
sequencing O 0 2.0554763580094004e-07
amplified O 0 9.146781394520076e-07
CYP27 O 0 1.989922020584345e-05
gene O 0 2.5916062185160627e-08
products O 0 2.7769692323431627e-08
from O 0 6.998374768585336e-09
a O 0 6.877244551617423e-09
patient O 0 3.698311346056471e-08
with O 0 5.08803523757706e-08
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 3.072934191550303e-07
CTX B-Disease 0 7.110830483725294e-05
) O 0 7.940598578670688e-08
. O 0 1.5011910363682546e-06

The O 0 5.499809390130395e-07
mutation O 0 2.9302830739652563e-07
changed O 0 1.531757192196892e-07
the O 0 1.0937259986576464e-07
adrenodoxin O 0 4.444531896297121e-06
cofactor O 0 3.733522078164242e-07
binding O 0 1.6525751789231435e-07
residue O 0 7.74359364186239e-07
362Arg O 0 8.824219435155101e-07
to O 0 2.269983134794984e-08
362Ser O 0 7.472997367585776e-06
( O 0 1.554455195673654e-07
CGT O 0 2.502310417185072e-05
362Arg O 0 5.636080004478572e-06
to O 0 6.839260180413476e-08
AGT O 0 3.382907380000688e-05
362Ser O 0 9.431507805857109e-07
) O 0 2.9497981834936127e-09
, O 0 1.3255168074266521e-09
and O 0 3.5825558075686104e-09
was O 0 7.302676152676213e-08
responsible O 0 4.417746524154609e-08
for O 0 1.762541756988867e-08
deficiency O 0 2.7913079975405708e-05
in O 0 4.155173627395925e-08
the O 0 1.5252719265390624e-07
sterol O 0 8.279624239548866e-07
27 O 0 1.1372900416972698e-06
- O 0 1.017930230773345e-06
hydroxylase O 0 8.396897897000599e-07
activity O 0 2.599119364177227e-09
, O 0 8.170162463239095e-11
as O 0 5.5046817798443115e-11
confirmed O 0 2.836926804583584e-10
by O 0 7.573970617347214e-11
expression O 0 8.048963162643474e-10
of O 0 2.7251580991816127e-09
mutant O 0 1.2617478617471534e-08
cDNA O 0 3.186939778743181e-08
into O 0 3.916953517091315e-08
COS O 0 3.978537733928533e-06
- O 0 8.696804343344411e-07
1 O 0 5.453014182421612e-07
cells O 0 8.794822861091234e-07
. O 0 1.0187371799474931e-06

Quantitative O 0 4.8211159082711674e-06
analysis O 0 1.4161966532810766e-07
showed O 0 1.5946458375992734e-08
that O 0 1.8289661452008943e-10
the O 0 1.0229600500011315e-09
expression O 0 3.5783016549828517e-09
of O 0 1.346365507970404e-08
CYP27 O 0 6.182246465868957e-07
gene O 0 1.6811482206335882e-09
mRNA O 0 5.9096336713082565e-09
in O 0 2.0323629446039604e-09
the O 0 7.178288186082682e-09
patient O 0 1.3375809793103599e-08
represented O 0 5.863065766220643e-08
52 O 0 1.6753654108470073e-06
. O 0 4.151623670622939e-06

5 O 0 5.765949708802509e-07
% O 0 9.235141540386849e-09
of O 0 2.643910868016519e-08
the O 0 4.3263952420602436e-08
normal O 0 4.1187908550455177e-07
level O 0 1.112683821702376e-05
. O 0 1.2414469665600336e-06

As O 0 9.285607660558526e-08
the O 0 2.0215541240986568e-08
mutation O 0 1.605259392079006e-08
occurred O 0 7.191885487145555e-08
at O 0 2.583827729552013e-08
the O 0 6.51819043184787e-09
penultimate O 0 3.157887249471969e-07
nucleotide O 0 1.0327216415362273e-08
of O 0 2.3173742036419753e-08
exon O 0 2.420790679025231e-07
6 O 0 7.091014708748844e-07
( O 0 1.2093952506120331e-08
- O 0 5.914327516620688e-08
2 O 0 9.845603443636719e-08
position O 0 4.5594680386784603e-07
of O 0 1.9730917699689599e-07
exon O 0 2.689017151169537e-07
6 O 0 6.64384288029396e-07
- O 0 1.3895204631353408e-07
intron O 0 2.559294500770193e-07
6 O 0 5.979114803267294e-07
splice O 0 2.612919729472196e-07
site O 0 3.796984771042844e-08
) O 0 7.471684382309718e-10
of O 0 5.326906471481152e-09
the O 0 7.012658898020163e-09
gene O 0 9.088097385756555e-09
, O 0 4.455332103248111e-09
we O 0 6.140161268319844e-09
hypothesized O 0 1.7429048426720328e-08
that O 0 2.9513610999565287e-10
the O 0 3.1922919863092147e-09
mutation O 0 8.858577871251327e-09
may O 0 1.8561548742468403e-08
partially O 0 8.518694727399634e-08
affect O 0 2.372166285624644e-08
the O 0 1.7254338402494795e-08
normal O 0 3.233134293623152e-08
splicing O 0 2.951364130865386e-08
efficiency O 0 1.7368451565857868e-08
in O 0 1.4957063365628187e-09
exon O 0 2.6443800038578047e-08
6 O 0 1.4234402101465093e-08
and O 0 1.0877977407730555e-09
cause O 0 3.4226872447362666e-09
alternative O 0 9.387679966721407e-09
splicing O 0 1.2692496831334665e-08
elsewhere O 0 1.1237032415678527e-09
, O 0 5.353822246645379e-11
which O 0 4.9699456355911664e-11
resulted O 0 2.278232047459028e-09
in O 0 1.0643108616648078e-09
decreased O 0 3.382123026085537e-08
transcript O 0 6.490861892416433e-08
in O 0 2.443999669310415e-09
the O 0 1.0489745960740038e-08
patient O 0 1.6058696417076135e-07
. O 0 9.342719522464904e-07

Transfection O 0 0.00012401871208567172
of O 0 1.8050330936603132e-06
constructed O 0 5.3523167480307166e-06
minigenes O 0 1.2569287719088607e-05
, O 0 6.787056250345813e-09
with O 0 1.1674351485524426e-09
or O 0 6.427093968142117e-09
without O 0 1.2279226524469777e-08
the O 0 9.90551729529443e-09
mutation O 0 7.957408953984668e-09
, O 0 2.357227080196367e-09
into O 0 5.230973876280132e-09
COS O 0 8.286338015750516e-07
- O 0 1.7147213782209292e-07
1 O 0 4.899410654957137e-08
cells O 0 2.861792136599206e-09
confirmed O 0 1.4499510481158495e-09
that O 0 5.0800665757355645e-11
the O 0 7.472468754876616e-10
mutant O 0 5.259850510697106e-08
minigene O 0 5.462090939545305e-07
was O 0 2.3776609126002768e-08
responsible O 0 5.7366476013953616e-09
for O 0 7.84549203380891e-10
a O 0 2.1119408444292276e-09
mRNA O 0 3.776760593154904e-08
species O 0 3.3688587475211307e-09
alternatively O 0 7.276203461969999e-08
spliced O 0 6.697925414300698e-07
at O 0 2.5437455519750074e-07
an O 0 7.298342374895128e-09
activated O 0 4.7624044441363367e-07
cryptic O 0 9.277248409489403e-07
5 O 0 3.052412864690268e-07
splice O 0 1.8549180822446942e-06
site O 0 3.2960539897430863e-07
88 O 0 4.941539373248816e-07
bp O 0 2.2385067666164105e-07
upstream O 0 2.0553640567300135e-08
from O 0 1.5943317777100674e-09
the O 0 5.948944448164184e-09
3 O 0 6.31118126648289e-08
end O 0 8.857178812604616e-08
of O 0 7.779072319635816e-08
exon O 0 1.0617485486363876e-06
6 O 0 2.559887889219681e-06
. O 0 1.6833587324072141e-06

Our O 0 1.3464537005347665e-06
data O 0 2.4663240338895775e-08
suggest O 0 1.521887837974134e-09
that O 0 1.2067671861792917e-10
the O 0 8.553968644520182e-10
C O 0 3.91002643596039e-08
to O 0 4.4063477866451706e-10
A O 0 7.2856853883251915e-09
mutation O 0 8.789236893846919e-09
at O 0 2.7487709886031553e-08
the O 0 5.810893544122564e-09
penultimate O 0 2.5105350687226746e-07
nucleotide O 0 7.931332035582273e-09
of O 0 5.424163784795155e-09
exon O 0 3.171719242800464e-08
6 O 0 3.7405715858085387e-08
of O 0 1.0309070930247799e-08
the O 0 1.3938225684739791e-08
CYP27 O 0 2.2635426830674987e-06
gene O 0 4.400487974010048e-09
not O 0 1.090602275155561e-09
only O 0 2.7009661174304256e-09
causes O 0 6.017992149054407e-08
the O 0 3.107620827336177e-08
deficiency B-Disease 0 2.5374222332175123e-06
in I-Disease 0 1.3488690164820127e-08
the I-Disease 0 2.3489699074730197e-08
sterol I-Disease 0 2.3402546389661438e-07
27 I-Disease 0 3.8304494864860317e-07
- I-Disease 0 3.1929820920595375e-07
hydroxylase I-Disease 0 6.867068691462919e-07
activity I-Disease 0 4.597768388237e-09
, O 0 2.4155755173893567e-10
but O 0 8.053877564861978e-10
also O 0 1.2261575088601262e-09
partially O 0 1.2996167697565397e-08
leads O 0 2.897807771518046e-09
to O 0 5.754309806427216e-10
alternative O 0 3.738238874007038e-08
pre O 0 1.9932679151679622e-07
- O 0 2.1088666812829615e-08
mRNA O 0 1.088854872932643e-08
splicing O 0 1.7593173140539875e-08
of O 0 5.159638050145077e-09
the O 0 1.0971793251712825e-08
gene O 0 8.406836116137129e-08
. O 0 9.68347876550979e-07

To O 0 1.407708083434045e-07
our O 0 4.225618255304653e-08
knowledge O 0 4.8374655392535715e-08
, O 0 3.6719707829924175e-10
this O 0 1.4443111984174806e-10
is O 0 6.950941905392582e-11
the O 0 4.083577920255266e-10
first O 0 1.4401444481393355e-09
report O 0 2.0081030172036662e-09
regarding O 0 5.775060873958182e-09
effects O 0 2.36711343859497e-08
on O 0 2.6576936207334256e-08
pre O 0 1.1744177186301386e-07
- O 0 1.8482907648831315e-08
mRNA O 0 1.762535006832877e-08
splicing O 0 1.4253801694508184e-08
of O 0 2.6261881558298228e-09
a O 0 8.114104388390331e-10
mutation O 0 1.981133701534077e-09
at O 0 1.693681817016568e-08
the O 0 2.8147386643695427e-09
- O 0 9.019437641200057e-09
2 O 0 1.3289247036141205e-08
position O 0 4.862488367507467e-08
of O 0 1.7555430886773138e-08
a O 0 1.4181288143788606e-08
5 O 0 1.9018987984509295e-07
splice O 0 2.78477978099545e-06
site O 0 6.743154585819866e-07
. O 0 1.5229462633215007e-06

ATM O 0 0.00018790039757732302
germline O 0 6.322974513750523e-05
mutations O 0 4.744615580420941e-07
in O 0 1.3310751967310352e-07
classical O 1 0.999984622001648
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.0007145990966819227
in O 0 5.514010936735758e-08
the O 0 8.815953123075815e-08
Dutch O 0 1.59677929332247e-05
population O 0 4.882261706029567e-09
. O 0 3.715273066973168e-07

Germline O 0 0.00013005390064790845
mutations O 0 2.5896875399666897e-07
in O 0 2.377497665406736e-08
the O 0 2.937369281141855e-08
ATM O 0 6.482522962869552e-07
gene O 0 3.1532354505259264e-09
are O 0 3.1795657773336927e-10
responsible O 0 1.4341960952179988e-09
for O 0 8.518133420842844e-10
the O 0 1.1869347872561775e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.0014809959102422e-06
. O 0 1.844961047936522e-06

In O 0 4.311946213420015e-07
our O 0 8.398373552154226e-08
study O 0 4.533700970199561e-09
, O 0 6.426673637704994e-10
we O 0 6.148068720790434e-10
have O 0 2.4870591697201405e-10
determined O 0 5.007469106033113e-09
the O 0 3.850609608946343e-09
ATM O 0 2.0442027448552835e-07
mutation O 0 8.087424063774051e-09
spectrum O 0 2.538292243059459e-08
in O 0 2.671918686303343e-09
19 O 0 5.800874447459137e-08
classical O 0 4.981545316695701e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 7.592230844011283e-09
, O 0 1.261623860937533e-10
including O 0 2.3688079275885343e-11
some O 0 2.2853803918754245e-11
immigrant O 0 3.0029259634467564e-10
populations O 0 8.637051490678616e-11
, O 0 4.816310891775366e-11
as O 0 8.217344166228102e-11
well O 0 9.066584982786452e-11
as O 0 1.663013615704756e-10
12 O 0 1.0658304239186123e-09
of O 0 8.752779612208883e-10
Dutch O 0 1.7218478376435087e-07
ethnic O 0 1.5017272758655054e-08
origin O 0 2.2041254510440922e-07
. O 0 2.2196686586539727e-06

Both O 0 5.012928454561916e-07
the O 0 1.952357990830933e-07
protein O 0 7.517133582268798e-08
truncation O 0 1.7000535308397957e-06
test O 0 4.871437795372913e-07
( O 0 3.9586527833535e-08
PTT O 0 1.5086166058608796e-06
) O 0 1.7787277206693375e-09
and O 0 1.1294039037323955e-09
the O 0 1.4632838274408755e-09
restriction O 0 5.340436981526864e-09
endonuclease O 0 2.0017240842662432e-07
fingerprinting O 0 1.8477115304449399e-07
( O 0 3.5395077979671896e-09
REF O 0 2.8539912477754115e-07
) O 0 1.0971865777031908e-10
method O 0 1.0825363938593568e-09
were O 0 8.842349630278079e-10
used O 0 7.986447614349856e-10
and O 0 2.7078681519299153e-09
compared O 0 2.4020190281248688e-09
for O 0 4.957554922135898e-10
their O 0 6.821717635219215e-10
detection O 0 2.2189306392306207e-08
efficiency O 0 1.6179484418898937e-08
, O 0 4.553761812076118e-10
identifying O 0 2.182150238283498e-09
76 O 0 1.6912728995066573e-09
% O 0 4.146569546059631e-11
and O 0 1.2113100800181797e-10
60 O 0 4.235644335270905e-10
% O 0 1.0779062364907332e-10
of O 0 8.972659282235895e-10
the O 0 2.7823809922722376e-09
mutations O 0 1.2858827780348747e-08
, O 0 1.3701185963554963e-08
respectively O 0 3.6400444969331147e-07
. O 0 1.5023194919194793e-06

Most O 0 9.333550110568467e-08
patients O 0 1.7453931633326647e-08
were O 0 7.652668720936617e-09
found O 0 2.4269053433556564e-09
to O 0 1.9919133009693724e-09
be O 0 1.3444358515357635e-08
compound O 0 9.657406963015092e-07
heterozygote O 0 1.187183806905523e-05
. O 0 6.331126769509865e-06

Seventeen O 0 1.903807515191147e-06
mutations O 0 5.5493032391495944e-08
were O 0 2.8416359043603734e-08
distinct O 0 1.3275516685951061e-08
, O 0 1.2817659156283412e-09
of O 0 2.6666593377910885e-09
which O 0 6.04725824970842e-10
10 O 0 4.06914146822146e-09
were O 0 3.357267797099439e-09
not O 0 3.5305538492735877e-09
reported O 0 4.998063474204173e-08
previously O 0 1.861715048789847e-07
. O 0 1.6088632719402085e-06

Mutations O 0 3.195825911461725e-06
are O 0 1.1907316022075065e-08
small O 0 1.577201302893627e-08
deletions O 0 3.0651253268842993e-07
or O 0 8.210368918071254e-08
point O 0 5.610016842183541e-07
mutations O 0 3.276432209986524e-07
frequently O 0 7.080925712443786e-08
affecting O 0 1.7131701213202177e-07
splice O 0 1.9579847503337078e-06
sites O 0 6.170901656332717e-07
. O 0 2.9564064334408613e-06

Moreover O 0 3.438823796386714e-06
, O 0 1.4496011147002719e-07
a O 0 8.356079206350842e-08
16 O 0 1.8768942027236335e-06
. O 0 3.4750785289361374e-06

7 O 0 0.00011955866648349911
- O 0 1.8376231309957802e-05
kb O 0 2.2068603357183747e-05
genomic O 0 1.9700625841778674e-07
deletion O 0 9.86965176252852e-08
of O 0 1.7314174982629993e-08
the O 0 6.014249098740265e-09
3 O 0 7.1126002865185e-08
end O 0 3.4728042663800807e-08
of O 0 8.477632817971426e-09
the O 0 4.141673226598641e-09
gene O 0 1.8317948269341855e-09
, O 0 5.732695984583813e-10
most O 0 2.500949447536982e-10
likely O 0 4.638241346555105e-09
a O 0 1.6825597581870966e-09
result O 0 8.447900157193544e-09
of O 0 1.1599403215711845e-08
recombination O 0 4.971951295118515e-09
between O 0 4.3576235952969e-09
two O 0 1.2064548249313134e-09
LINE O 0 1.8039020943660944e-08
elements O 0 1.0573147690706719e-08
, O 0 3.1033013936365705e-09
was O 0 3.523693692386587e-08
identified O 0 6.897398918681574e-08
. O 0 7.696496595599456e-07

The O 0 2.660600273429736e-07
most O 0 2.6665678554138594e-09
frequently O 0 1.0717585707809008e-09
found O 0 1.0844665165876677e-09
mutation O 0 3.80162790136751e-09
, O 0 1.153999229508429e-09
identified O 0 8.435663723105336e-09
in O 0 4.434425715515999e-09
three O 0 1.1650489462056157e-08
unrelated O 0 2.383409878348175e-07
Turkish O 0 9.558993042446673e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
individuals O 0 8.205261359250926e-09
, O 0 1.3691486833167232e-09
was O 0 9.822604063458584e-09
previously O 0 4.053439806028791e-09
described O 0 2.4629709383106047e-09
to O 0 5.646435541351025e-10
be O 0 2.514937813558049e-09
a O 0 7.860744055676605e-09
Turkish O 0 2.705949100345606e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
founder O 0 0.00021171370462980121
mutation O 0 2.8786937491531717e-06
. O 0 3.470643605396617e-06

The O 0 7.754804300930118e-07
presence O 0 6.034888144768047e-08
of O 0 1.510771880930406e-07
a O 0 2.780780050670728e-08
founder O 0 4.856533450947609e-07
mutation O 0 1.787326020519231e-08
among O 0 8.399438922168656e-10
relatively O 0 4.712017442898286e-10
small O 0 1.1366710350735332e-10
ethnic O 0 2.6961885501997074e-10
population O 0 4.4488062539427276e-11
groups O 0 5.900583494033995e-11
in O 0 4.3516742986859924e-10
Western O 0 2.4184226177226265e-08
Europe O 0 1.264165661041261e-07
could O 0 1.2271898164328832e-08
indicate O 0 8.526509276407523e-09
a O 0 2.2459636372929026e-09
high O 0 1.1013874257059797e-08
carrier O 0 9.729109740064246e-10
frequency O 0 1.4242576895640013e-08
in O 0 4.067502445970206e-10
such O 0 6.679090058803183e-10
communities O 0 1.369556823505036e-08
. O 0 2.302891743966029e-07

In O 0 3.1543385148324887e-07
patients O 0 2.801163212495794e-08
of O 0 3.628910505426575e-08
Dutch O 0 1.157534006779315e-05
ethnic O 0 8.420183661428382e-09
origin O 0 1.7017772080407667e-08
, O 0 1.0599149335988045e-09
however O 0 5.3897908358635505e-09
, O 0 9.913224685575983e-10
no O 0 2.1926265247884658e-09
significant O 0 8.881009705419274e-09
founder O 0 6.047471146075623e-08
effect O 0 3.115811608722652e-08
could O 0 7.349609365547849e-09
be O 0 1.2374283819838183e-08
identified O 0 2.8209592528583016e-07
. O 0 9.083497616302338e-07

The O 0 5.023500193601649e-07
observed O 0 1.7367200655371562e-07
genetic O 0 3.564399975175547e-08
heterogeneity O 0 2.559821723480127e-07
including O 0 4.925681196255027e-09
the O 0 1.4983511320565412e-08
relative O 0 4.570992189201206e-07
high O 0 5.695243999070954e-06
percentage O 0 9.998398553534571e-08
of O 0 9.412855916934859e-08
splice O 0 5.656482699123444e-06
- O 0 4.1005310436048603e-07
site O 0 2.1261284288698334e-08
mutations O 0 1.6216311848893383e-08
had O 0 8.194642298064991e-09
no O 0 4.962533939334435e-09
reflection O 0 9.156882185834547e-08
on O 0 1.0568111008524284e-07
the O 0 6.923271911318807e-08
phenotype O 0 5.17991293236264e-06
. O 0 1.922241153806681e-06

All O 0 1.4295326877800107e-07
patients O 0 2.5843256423740968e-08
manifested O 0 8.696540731989444e-08
classical O 0 8.282609655907436e-07
A B-Disease 1 0.9999988079071045
- I-Disease 1 0.9999459981918335
T I-Disease 1 1.0
and O 0 1.1709339986509804e-07
increased O 0 8.976227405810278e-08
cellular O 0 3.401301853500627e-07
radioresistant O 0 7.83501377554785e-07
DNA O 0 1.7770423710317118e-07
synthesis O 0 2.5833159611465817e-07
. O 0 3.843201170639077e-07

Determination O 0 1.645303564146161e-05
of O 0 1.4459079693551757e-06
the O 0 6.781002781508505e-08
genomic O 0 5.1123940636443876e-08
structure O 0 6.76892071282964e-08
of O 0 1.5503845318676213e-08
the O 0 1.1799204280293907e-08
COL4A4 O 0 1.9238605091231875e-06
gene O 0 2.733106851948719e-09
and O 0 1.4399988979008072e-09
of O 0 5.420627058327909e-09
novel O 0 1.3450210190057987e-07
mutations O 0 0.0003259341756347567
causing O 0 0.04132161661982536
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9997759461402893

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 8.5428246165975e-06
a O 0 1.067032030732662e-06
progressive O 1 0.9999978542327881
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.00045423387200571597
by O 0 7.559749519714387e-07
glomerular B-Disease 1 0.9949702620506287
basement I-Disease 1 0.9996050000190735
membrane I-Disease 0 0.000393270660424605
abnormalities I-Disease 1 0.8862763047218323
and O 0 6.464323121235793e-08
associated O 0 2.846296354164224e-07
with O 0 6.129875718130506e-09
mutations O 0 3.16758388407834e-08
in O 0 8.433379328209867e-09
either O 0 4.900419980913284e-08
the O 0 6.930869034249554e-08
COL4A3 O 0 3.2715994166210294e-05
or O 0 5.432405192351553e-09
the O 0 7.186809369841285e-09
COL4A4 O 0 6.888070060995233e-07
gene O 0 1.6756356302494169e-09
, O 0 4.198491831974849e-10
which O 0 3.9825653885827705e-10
encode O 0 5.558346671818981e-09
the O 0 5.566749727847764e-09
alpha3 O 0 3.4479882060622913e-07
and O 0 1.2977788621526543e-08
alpha4 O 0 1.018560396914836e-06
type O 0 5.327569851942826e-07
IV O 1 0.9994121789932251
collagen O 0 1.9113675080006942e-05
chains O 0 5.682314281330036e-07
, O 0 8.304582621576628e-08
respectively O 0 1.181747961709334e-06
. O 0 1.255633947039314e-06

To O 0 1.0468484390457888e-07
date O 0 7.734405471637729e-07
, O 0 4.421504051776992e-09
mutation O 0 1.3024599176958418e-09
screening O 0 1.2538446947374382e-09
in O 0 3.4875036192261177e-10
the O 0 1.1791324583398932e-09
two O 0 4.2804670918883403e-10
genes O 0 8.304401610814693e-10
has O 0 2.0684699786333027e-10
been O 0 4.0332323592018327e-10
hampered O 0 1.189483089802934e-08
by O 0 4.133218767243818e-10
the O 0 2.1837034402949485e-09
lack O 0 2.3088681189165072e-08
of O 0 1.7212693492751896e-08
genomic O 0 3.1348509565987115e-08
structure O 0 1.8206048935098806e-07
information O 0 6.540372510244197e-08
. O 0 5.278423031995771e-07

We O 0 1.088252702174941e-06
report O 0 6.046410305771133e-08
here O 0 6.4663305820999994e-09
the O 0 1.198587673556517e-09
complete O 0 3.324451380848359e-09
characterization O 0 9.327246530688171e-09
of O 0 4.64566074498407e-09
the O 0 3.8263614499101095e-09
48 O 0 2.664540765806578e-08
exons O 0 9.364827491253891e-08
of O 0 2.0886433915734415e-08
the O 0 1.6013695258720873e-08
COL4A4 O 0 5.195426638238132e-06
gene O 0 1.2746355082526861e-08
, O 0 3.0853948285169963e-09
a O 0 3.7155896137619493e-09
comprehensive O 0 3.4662328118884034e-08
gene O 0 4.746142590050795e-09
screen O 0 4.277500664784384e-08
, O 0 4.0723091565553204e-09
and O 0 2.6797173369175198e-09
the O 0 1.5542208631202925e-09
subsequent O 0 1.7613276392935973e-09
detection O 0 8.48899173178097e-09
of O 0 1.920773984309676e-09
10 O 0 2.795797149346413e-09
novel O 0 2.4638118212294557e-09
mutations O 0 1.1823692247503459e-08
in O 0 2.375044383384761e-09
eight O 0 4.63277096685033e-08
patients O 0 9.137289680438698e-08
diagnosed O 0 0.00026173677179031074
with O 0 4.7922690100676846e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9580976963043213

Furthermore O 0 3.564367261787993e-06
, O 0 6.914153516390797e-08
we O 0 3.266114489974825e-08
identified O 0 2.5497923772377362e-08
a O 0 1.584573894319874e-08
glycine O 0 1.3806332788135478e-07
to O 0 1.1797696153337256e-08
alanine O 0 1.2723089071187133e-07
substitution O 0 5.933886626507956e-08
in O 0 1.1510760344890514e-08
the O 0 4.578963341828057e-08
collagenous O 0 2.232340193586424e-06
domain O 0 9.45789757622606e-09
that O 0 2.1423195162295627e-10
is O 0 2.896999307111514e-10
apparently O 0 8.954062380439609e-09
silent O 0 2.6392655172458035e-08
in O 0 1.1757187445837758e-09
the O 0 2.0642969555950685e-09
heterozygous O 0 4.439131284783571e-09
carriers O 0 1.1071896732772757e-09
, O 0 2.2309263325581696e-09
in O 0 8.55909743080474e-09
11 O 0 5.302600811774028e-07
. O 0 2.176449925173074e-06

5 O 0 1.2028455103063607e-06
% O 0 1.8910357724166715e-08
of O 0 1.483954203962412e-08
all O 0 2.1182020581989036e-09
control O 0 1.1230825158747848e-08
individuals O 0 2.3784252345393497e-10
, O 0 1.62166349793047e-10
and O 0 2.808532295617283e-10
in O 0 2.649132857523995e-10
one O 0 4.55299770107942e-10
control O 0 2.36160135891339e-09
individual O 0 6.699568122492394e-10
homozygous O 0 8.201803680663033e-09
for O 0 1.0543256268036316e-09
this O 0 2.599119364177227e-09
glycine O 0 2.83070392015361e-07
substitution O 0 7.84531721365056e-07
. O 0 1.06721824977285e-06

There O 0 1.9018445129859174e-07
has O 0 3.920075819507929e-09
been O 0 1.8307469984435443e-09
no O 0 1.189001674894996e-09
previous O 0 3.979332863224272e-09
finding O 0 9.609972373425535e-09
of O 0 3.6278500203934527e-09
a O 0 2.945727661796127e-09
glycine O 0 2.001099375092963e-08
substitution O 0 6.7427343708459375e-09
that O 0 2.287042777382453e-10
is O 0 9.658437938320219e-11
not O 0 1.3387614627990985e-10
associated O 0 6.267367180790018e-10
with O 0 3.3867204179971466e-11
any O 0 2.353743866478908e-10
obvious O 0 4.04159727906972e-09
phenotype O 0 1.3161004730477543e-08
in O 0 1.998729626251361e-09
homozygous O 0 8.091237901908244e-08
individuals O 0 1.9353450397829874e-08
. O 0 9.275727279600687e-07

Founder O 0 0.0005411807796917856
BRCA1 O 0 9.76337742031319e-06
and O 0 5.863457204213773e-07
BRCA2 O 0 7.322515784835559e-07
mutations O 0 4.988044466358588e-08
in O 0 2.1213244494333594e-08
French O 0 0.4434053301811218
Canadian O 1 0.9999338388442993
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.3794273399980739e-05
. O 0 4.910670395474881e-05

We O 0 2.71350046432417e-07
have O 0 6.170050692588802e-09
identified O 0 1.2804544091693515e-08
four O 0 1.4178468399350663e-09
mutations O 0 2.4948665355850608e-09
in O 0 1.7693851939171168e-09
each O 0 3.6340137565815667e-09
of O 0 7.55644862238114e-07
the O 0 8.557663386454806e-05
breast B-Disease 1 0.9999933242797852
cancer I-Disease 1 0.9587555527687073
- O 1 0.7830451726913452
susceptibility O 0 1.589257772138808e-05
genes O 0 1.790940302726085e-07
, O 0 1.9428716413472102e-08
BRCA1 O 0 1.1102929420303553e-07
and O 0 4.054895441640838e-08
BRCA2 O 0 1.4139632753540354e-07
, O 0 2.9269096035733355e-09
in O 0 7.713306438006384e-09
French O 0 0.0004495452740229666
Canadian O 0 0.014230484142899513
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 1 1.0
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.173211607394478e-07
from O 0 1.3431957768261782e-07
Quebec O 0 1.5518186046392657e-05
. O 0 1.4406514310394414e-05

To O 0 1.255000597666367e-06
identify O 0 6.78913738738629e-06
founder O 0 7.079142960719764e-06
effects O 0 1.5860236089793034e-05
, O 0 4.293529798360396e-08
we O 0 2.46459332942095e-08
examined O 0 4.1606220690937334e-08
independently O 0 5.01618702131168e-09
ascertained O 0 5.724878349155915e-08
French O 0 4.0317141269952117e-07
Canadian O 0 1.1154764933962724e-07
cancer B-Disease 0 1.5807256659172708e-07
families O 0 7.141970903568051e-10
for O 0 2.1348141310273405e-10
the O 0 7.512224176053905e-10
distribution O 0 9.437908232712289e-10
of O 0 2.1120778459504663e-09
these O 0 2.300949208944303e-09
eight O 0 2.4034543244511042e-08
mutations O 0 3.083602564402099e-07
. O 0 8.51019876790815e-07

Mutations O 0 3.5324120517543633e-07
were O 0 3.401064319064062e-08
found O 0 3.010043769791082e-09
in O 0 4.374278272933907e-09
41 O 0 4.961116673030119e-08
of O 0 4.784282126024664e-08
97 O 0 1.061257535184268e-06
families O 0 6.652688000485796e-08
. O 0 1.3913517022956512e-06

Six O 0 7.525352430093335e-07
of O 0 8.264510853450702e-08
eight O 0 2.676505594934042e-08
mutations O 0 1.6645353539956886e-08
were O 0 2.8632568316311335e-08
observed O 0 7.785573075125285e-08
at O 0 1.3725620817695017e-07
least O 0 1.749873135281632e-08
twice O 0 3.072110814628104e-07
. O 0 1.2155638842159533e-06

The O 0 5.578839136433089e-06
BRCA1 O 0 8.15209023130592e-06
C4446T O 0 6.376815690600779e-06
mutation O 0 1.9145886653859634e-07
was O 0 6.011453024257207e-08
the O 0 2.1021751006600198e-09
most O 0 1.63016988796727e-10
common O 0 9.492828745294446e-10
mutation O 0 1.000348359703196e-09
found O 0 6.004938213344246e-10
, O 0 6.754031778299918e-10
followed O 0 3.008373550272836e-09
by O 0 1.4089478472811834e-09
the O 0 6.061097224119294e-08
BRCA2 O 0 4.334930508775869e-06
8765delAG O 0 8.704307219886687e-06
mutation O 0 2.0160612166364444e-06
. O 0 6.641304935328662e-06

Together O 0 5.732472274644351e-08
, O 0 1.7181882583372499e-09
these O 0 2.728990367018014e-10
mutations O 0 7.39996341980742e-10
were O 0 1.1378256115079921e-09
found O 0 3.319691188607976e-10
in O 0 5.827094917698616e-10
28 O 0 2.860625691880614e-08
of O 0 2.633402296225995e-08
41 O 0 4.9381384314983734e-08
families O 0 1.0419112239645756e-09
identified O 0 4.622503713136439e-09
to O 0 1.7844875577210928e-09
have O 0 7.532300116963597e-09
a O 0 7.493341769304607e-08
mutation O 0 3.1139779821387492e-06
. O 0 1.0346061571908649e-05

The O 0 6.16671854913875e-07
odds O 0 3.07116943076835e-06
of O 0 4.8658097995257776e-08
detection O 0 9.747579809982199e-08
of O 0 5.094840105357434e-09
any O 0 1.7773745808469243e-09
of O 0 7.308511573711485e-09
the O 0 6.8254171203818714e-09
four O 0 1.3532215348277532e-08
BRCA1 O 0 5.687731530201745e-08
mutations O 0 5.45912328675513e-08
was O 0 1.9379018567633466e-07
18 O 0 7.659782568225637e-07
. O 0 3.634616177805583e-06

7x O 0 0.002035134704783559
greater O 0 5.432045213638048e-07
if O 0 5.5401866205784245e-08
one O 0 2.670466736631738e-09
or O 0 6.869047552982011e-10
more O 0 6.529519286369023e-11
cases O 0 1.164186524960087e-09
of O 0 2.8781644800801587e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 1.0191011057258947e-07
also O 0 1.3761285444502391e-09
present O 0 1.6250113477056516e-09
in O 0 2.04863903618957e-09
the O 0 1.5971965083849682e-08
family O 0 3.428059613952428e-08
. O 0 5.62891273148125e-07

The O 0 1.4976760667195776e-06
odds O 0 1.921293687701109e-06
of O 0 2.7973030114480935e-08
detection O 0 1.214382763237154e-07
of O 0 5.851533479983573e-09
any O 0 2.360484474550617e-09
of O 0 9.874223216854716e-09
the O 0 4.676117715263217e-09
four O 0 4.6758144023328896e-09
BRCA2 O 0 4.352052229705805e-08
mutations O 0 1.3917717645028915e-08
was O 0 1.541330476584335e-07
5 O 0 7.740316050330875e-07
. O 0 2.0754450815729797e-06

3x O 0 5.2863688324578106e-05
greater O 0 9.570538139769269e-08
if O 0 9.167136383325669e-09
there O 0 4.327623148725479e-09
were O 0 1.2586110820222984e-08
at O 0 9.581201609876189e-09
least O 0 1.0148522022745965e-09
five O 0 1.6174137584812343e-09
cases O 0 1.4733013697920683e-09
of O 0 2.6414209486347318e-08
breast B-Disease 0 4.476315098145278e-06
cancer I-Disease 0 3.3113062158918183e-07
in O 0 5.0388585748351034e-08
the O 0 3.8288973769340373e-07
family O 0 1.1807019717480216e-07
. O 0 1.0337571438867599e-06

Interestingly O 0 7.082288902893197e-06
, O 0 2.317232805637559e-08
the O 0 6.939437469100085e-09
presence O 0 5.96089311244441e-09
of O 0 3.2148594186764967e-07
a O 0 4.6286109522952756e-07
breast B-Disease 0 0.0001467806432629004
cancer I-Disease 0 7.560596259281738e-06
case O 0 1.011382323667931e-06
< O 0 1.5958939911797643e-06
36 O 0 7.196771178996642e-08
years O 0 5.180375683977445e-09
of O 0 3.406795290317177e-09
age O 0 1.1557090395797331e-08
was O 0 5.744388520412258e-09
strongly O 0 7.339183705212804e-10
predictive O 0 1.384688808059309e-08
of O 0 1.9566939180037934e-09
the O 0 5.263056102045027e-10
presence O 0 2.9654792510491745e-10
of O 0 5.283292692226382e-10
any O 0 4.902209749246822e-10
of O 0 1.5852349433131963e-09
the O 0 2.4393145281464967e-09
eight O 0 1.5483957227502287e-08
mutations O 0 7.684631242454998e-08
screened O 0 2.9981907800902263e-07
. O 0 1.1429069672885817e-06

Carriers O 0 8.526112651452422e-07
of O 0 2.9726439265687077e-07
the O 0 1.840825269994184e-08
same O 0 3.2047555720282617e-09
mutation O 0 2.2079991168766355e-09
, O 0 3.1299129954476257e-10
from O 0 1.2681133920722232e-10
different O 0 5.67591362798936e-10
families O 0 1.5362740246605e-10
, O 0 3.9553885167187275e-10
shared O 0 1.5716179468938662e-09
similar O 0 2.6075357428823054e-09
haplotypes O 0 5.4514860181598124e-08
, O 0 7.087310738285169e-10
indicating O 0 2.7164914762067838e-09
that O 0 1.7963844300972198e-10
the O 0 7.827943293570172e-10
mutant O 0 6.516064576800318e-09
alleles O 0 6.25020435407464e-09
were O 0 1.9147385899032088e-09
likely O 0 1.2903339507985834e-09
to O 0 2.654949871061518e-10
be O 0 4.13597128767762e-10
identical O 0 3.444061924540165e-09
by O 0 2.2946938793566574e-10
descent O 0 5.766101374149457e-09
for O 0 4.728646363361122e-10
a O 0 7.208248997692124e-10
mutation O 0 2.989742897696601e-09
in O 0 2.648007813021991e-09
the O 0 1.717062225736754e-08
founder O 0 3.703747495364951e-07
population O 0 7.898768750180807e-09
. O 0 5.15166618697549e-07

The O 0 9.985439675119778e-08
identification O 0 9.748546858645568e-08
of O 0 9.977328829791077e-08
common O 0 9.474148328081355e-07
BRCA1 O 0 3.5030452636419795e-06
and O 0 2.9869511308788788e-06
BRCA2 O 0 6.6598690864339005e-06
mutations O 0 2.916763719440496e-07
will O 0 3.616845845044736e-08
facilitate O 0 4.6873807946212764e-08
carrier O 0 8.319259947597857e-09
detection O 0 2.1074035316814843e-07
in O 0 3.187973263152344e-08
French O 1 0.5688071846961975
Canadian O 1 0.642988920211792
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 1 0.9999998807907104
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.816859695391031e-06
. O 0 1.5415393136208877e-05

Are O 0 3.3410890409868443e-07
Dp71 O 0 2.1485049728653394e-05
and O 0 2.3564915352380922e-07
Dp140 O 0 5.230964234215207e-06
brain O 0 1.2771265573974233e-05
dystrophin O 0 2.1001378627261147e-06
isoforms O 0 7.720454959780909e-07
related O 0 3.4488493838580325e-08
to O 0 7.317046968324803e-09
cognitive B-Disease 0 0.0005462439730763435
impairment I-Disease 1 0.96566241979599
in O 0 3.25916480505839e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9999455213546753

Molecular O 0 7.526511126343394e-06
study O 0 5.950048276304187e-08
and O 0 7.235732901733627e-09
neuropsychological O 0 2.4509898821634124e-07
analysis O 0 1.1077774253465122e-08
were O 0 4.8110457839811716e-09
performed O 0 1.834774110420767e-09
concurrently O 0 5.687717852254082e-09
on O 0 1.1118162390744146e-08
49 O 0 3.2251893600232506e-08
patients O 0 1.999615228953644e-08
with O 0 1.226535573550791e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9942545294761658
DMD B-Disease 1 1.0
) O 0 3.2316347375882515e-09
in O 0 3.4004446480828676e-10
order O 0 1.75789094392087e-09
to O 0 3.0847635557051944e-10
find O 0 1.7839600907620934e-09
a O 0 3.278944615825452e-10
molecular O 0 1.2927932502293515e-08
explanation O 0 3.47295481262222e-09
for O 0 6.619230163984469e-10
the O 0 5.567875493994734e-09
cognitive B-Disease 0 1.9409793821978383e-05
impairment I-Disease 0 1.3985340956423897e-06
observed O 0 6.041497524478245e-09
in O 0 3.543472848477336e-09
most O 0 3.704764139911276e-08
DMD B-Disease 1 1.0
patients O 0 5.238704829935159e-07
. O 0 1.259494410987827e-06

Complete O 0 5.872035444554058e-07
analysis O 0 4.847302292887434e-08
of O 0 3.916213842103389e-08
the O 0 2.749767347154375e-08
dystrophin O 0 4.954568453285901e-07
gene O 0 1.9413491259001603e-08
was O 0 4.1222246949246255e-08
performed O 0 1.96948435338129e-09
to O 0 9.970604342157685e-10
define O 0 2.5908846623678983e-08
the O 0 1.6267613034415263e-08
localization O 0 1.1009400395778357e-06
of O 0 1.6870401964297344e-08
deletions O 0 4.836543254782555e-08
and O 0 5.876004571803151e-09
duplications O 0 7.585113337427174e-08
in O 0 2.3468820220529096e-09
relation O 0 1.4263808800762945e-08
to O 0 2.54489362916388e-09
the O 0 1.3345434091149855e-08
different O 0 3.6666767755377805e-07
DMD B-Disease 1 1.0
promoters O 0 3.430046490393579e-05
. O 0 3.0142016385070747e-06

Qualitative O 0 6.9758407335029915e-06
analysis O 0 2.7252849577052984e-07
of O 0 1.5646580209249805e-07
the O 0 1.3807544974042685e-07
Dp71 O 0 1.5622616047039628e-05
transcript O 0 7.354043418672518e-07
and O 0 2.0648600607131584e-09
testing O 0 3.926076797000633e-09
for O 0 5.385913937061559e-10
the O 0 1.09156794714238e-09
specific O 0 1.4830846550850652e-09
first O 0 4.4904986395977176e-09
exon O 0 1.8276288926699635e-08
of O 0 4.393334140928573e-09
Dp140 O 0 6.653170459003377e-08
were O 0 6.459957013760231e-09
also O 0 1.913606828551906e-09
carried O 0 1.3963984635267934e-08
out O 0 3.34350431785424e-08
. O 0 4.457035061022907e-07

Neuropsychological O 0 0.00042222405318170786
analysis O 0 1.942225253515062e-06
assessed O 0 3.851449491776293e-06
verbal O 0 8.479094503854867e-06
and O 0 7.968445174810768e-07
visuospatial O 0 5.3114519687369466e-05
intelligence O 0 8.108229962999758e-07
, O 0 3.333443743258613e-08
verbal O 0 1.6928232753343764e-06
memory O 0 0.00012967942166142166
, O 0 5.149406234750131e-08
and O 0 8.337102741506897e-08
reading O 0 7.992693099367898e-06
skills O 0 9.820835111895576e-05
. O 0 4.157515377301024e-06

Comparison O 0 2.439689296807046e-06
of O 0 1.0451500429553562e-06
molecular O 0 6.390439921233337e-06
and O 0 1.2156051809597557e-07
psychometric O 0 7.563899544038577e-06
findings O 0 1.0391773486162492e-07
demonstrated O 0 3.240747048494086e-08
that O 0 1.1995184845403628e-09
deletions O 0 2.560109102489605e-08
and O 0 3.1394149502261826e-09
duplications O 0 4.1407272277638185e-08
that O 0 5.48377843134773e-10
were O 0 5.055259766351128e-09
localized O 0 3.49396529486512e-08
in O 0 9.299162329057253e-09
the O 0 3.731329201173139e-08
distal O 0 1.3711337487620767e-06
part O 0 1.4621211796850275e-08
of O 0 1.1675853528458902e-07
the O 0 2.478093463764708e-08
gene O 0 6.744342417874805e-09
seemed O 0 1.3001498544440437e-08
to O 0 1.3318320890576274e-09
be O 0 3.1715601256365744e-09
preferentially O 0 4.578439671831802e-08
associated O 0 1.1937281385598908e-07
with O 0 9.087945329611102e-08
cognitive B-Disease 1 0.999972939491272
impairment I-Disease 1 0.9993032217025757
. O 0 9.109895472647622e-06

Two O 0 1.0253593245579395e-06
altered O 0 2.3145839804783463e-06
Dp71 O 0 1.6179310478037223e-05
transcripts O 0 8.100571449176641e-07
and O 0 8.157215347637248e-09
two O 0 2.488521833043933e-09
deleted O 0 2.187418779442396e-08
Dp140 O 0 4.820214982714788e-08
DNA O 0 3.0442011134113045e-09
sequences O 0 4.680014709101954e-10
were O 0 1.2947271033070251e-09
found O 0 4.204077364011738e-10
in O 0 8.548390884044466e-10
four O 0 4.8150297082827365e-09
patients O 0 1.1496059215687637e-08
with O 0 9.597336259048461e-08
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 1 0.9273951053619385

These O 0 1.2257983428298758e-07
findings O 0 2.3646494540230378e-08
suggest O 0 1.7239197847018772e-09
that O 0 1.2629480794501546e-10
some O 0 7.333107038265396e-11
sequences O 0 3.05176300896548e-10
located O 0 5.838063921181913e-10
in O 0 3.6500025224484034e-10
the O 0 2.196423043443474e-09
distal O 0 5.274920411579842e-08
part O 0 1.4425691752251169e-09
of O 0 4.819954657619974e-09
the O 0 2.453270475655245e-09
gene O 0 1.5653236484780564e-09
and O 0 1.8257917400177348e-09
, O 0 4.4115869290983767e-10
in O 0 4.4271133980977595e-10
particular O 0 2.7580755457279338e-09
, O 0 2.469198623344937e-09
some O 0 3.893436684165863e-09
DMD B-Disease 1 0.9999982118606567
isoforms O 0 9.79480319074355e-07
expressed O 0 7.101061960668176e-09
in O 0 3.00023095256563e-09
the O 0 8.247201144229166e-09
brain O 0 1.8705028992371808e-07
may O 0 1.96039207089882e-09
be O 0 7.282611180770004e-10
related O 0 2.5655872981644734e-09
to O 0 7.401882995416997e-10
the O 0 1.2891097078693292e-08
cognitive B-Disease 0 0.14978444576263428
impairment I-Disease 0 0.00020900319213978946
associated O 0 3.5213963656133274e-07
with O 0 1.3263462506074575e-07
DMD B-Disease 1 1.0
. O 0 4.3441573893687746e-07
. O 0 1.5650073237338802e-06

I1307K O 0 7.5052201282233e-05
APC O 0 8.13878341432428e-06
and O 0 1.765749289006635e-07
hMLH1 O 0 1.3891602748117293e-06
mutations O 0 5.2612350032177346e-08
in O 0 5.813132197829418e-09
a O 0 7.490337239346445e-09
non O 0 4.650308937925729e-07
- O 0 3.0506521397910547e-07
Jewish O 0 4.959073152122073e-08
family O 0 4.269046449678626e-09
with O 0 4.2636996155920315e-09
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9999562501907349

We O 0 4.170840668393794e-07
describe O 0 8.605820056573066e-08
a O 0 1.6076157294264704e-08
French O 0 7.771217838126177e-07
Canadian O 0 1.9899982817150885e-06
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.02018263190984726
HNPCC B-Disease 1 0.9994738698005676
) O 0 1.2851232611410524e-07
kindred O 0 1.0923204172286205e-06
which O 0 1.2338201571537866e-08
carries O 0 1.3689117395188077e-08
a O 0 6.037695676752719e-09
novel O 0 2.6468677916113847e-08
truncating O 0 1.2003107485725195e-06
mutation O 0 9.125898259298992e-08
in O 0 6.02426268869749e-08
hMLH1 O 0 1.7932912669493817e-05
. O 0 7.194243607955286e-06

Interestingly O 0 3.416784238652326e-06
, O 0 3.251346569754787e-08
the O 0 3.745261523135923e-08
I1307K O 0 1.3433819958663662e-06
APC O 0 3.485064041797159e-07
polymorphism O 0 1.748879725482766e-07
, O 0 2.899538387168832e-09
associated O 0 6.7794876379423386e-09
with O 0 5.266500568978927e-10
an O 0 4.769453165742732e-10
increased O 0 3.340776189020289e-08
risk O 0 0.0014227870851755142
of O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 3.466981013389159e-07
is O 0 2.377690266897048e-10
also O 0 7.481677777310125e-11
present O 0 3.9948902519348906e-10
in O 0 2.356807804471117e-10
this O 0 8.688342822971151e-10
family O 0 9.382524090995048e-09
. O 0 2.393957174717798e-07

The O 0 1.3799385669699404e-06
I1307K O 0 6.919614406797336e-06
polymorphism O 0 6.431823749153409e-07
has O 0 2.659451769915222e-09
previously O 0 3.5448721735775734e-09
only O 0 3.959237937500859e-10
been O 0 9.452194582593165e-10
identified O 0 2.8042461686084152e-09
in O 0 9.819451918247069e-10
individuals O 0 6.349886727541332e-10
of O 0 2.0850093207513964e-08
self O 0 7.857491937102168e-07
- O 0 2.749652367128874e-06
reported O 0 1.8752093922103086e-07
Ashkenazi O 0 7.202524443528091e-07
Jewish O 0 2.96616207151601e-07
origins O 0 2.352818455619854e-06
. O 0 4.926040674035903e-06

In O 0 9.235937881157952e-08
addition O 0 2.089456252463151e-08
, O 0 1.7813590602600016e-09
in O 0 6.24436224949676e-10
this O 0 6.10555439539695e-10
family O 0 7.476959607011224e-10
, O 0 2.237654367354125e-10
there O 0 2.2257146126136718e-10
appears O 0 5.519676937737472e-10
to O 0 1.6302197092255e-10
be O 0 4.5842979412569207e-10
no O 0 9.52224188388584e-10
relationship O 0 1.6399477331674461e-09
between O 0 2.2066983795809847e-09
the O 0 2.7370297139839295e-09
I1307K O 0 2.7297529570091683e-08
polymorphism O 0 4.048294144354259e-09
and O 0 2.7556554260677046e-10
the O 0 3.818529104027135e-10
presence O 0 1.0683175455383775e-09
or O 0 2.3150845684938304e-09
absence O 0 5.3945448996728373e-08
of O 0 3.1622779061990514e-08
cancer B-Disease 0 9.691353852758766e-08
. O 0 3.91080234862784e-08
. O 0 9.424260838386544e-07

Identification O 0 1.5639031971659278e-06
of O 0 1.4856681218589074e-07
a O 0 7.4215504852759295e-09
novel O 0 1.1695642676556872e-08
mutation O 0 1.228677071196671e-08
of O 0 3.2193874233144015e-08
the O 0 6.19953297587017e-08
CPO O 0 2.551087618485326e-06
gene O 0 1.1235281149879484e-08
in O 0 7.585196470927258e-09
a O 0 2.005799437654332e-08
Japanese O 0 3.1906552067084704e-06
hereditary B-Disease 1 0.9999992847442627
coproporphyria I-Disease 0 0.38503390550613403
family O 0 1.449761725780263e-06
. O 0 6.55101212032605e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 0 0.000794618739746511
HCP B-Disease 1 0.9999998807907104
) O 0 6.905402472057176e-08
is O 0 2.481270522380896e-09
an O 0 1.1759010654088797e-08
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
characterized O 0 1.1114112794530229e-06
by O 0 1.481629308131005e-08
a O 0 6.24466522936018e-08
deficiency B-Disease 0 0.00010484986705705523
of I-Disease 0 1.417849853169173e-05
coproporphyrinogen I-Disease 0 0.00037355851964093745
oxidase I-Disease 0 7.621432018822816e-07
( O 0 5.043067297094694e-09
CPO O 0 4.57379627505361e-07
) O 0 6.276279496120196e-10
caused O 0 1.877116906356946e-09
by O 0 6.938494778729876e-10
a O 0 2.180598368539677e-09
mutation O 0 6.431962518149703e-09
in O 0 6.076003700172805e-09
the O 0 6.118920481412715e-08
CPO O 0 1.2402551874401979e-05
gene O 0 5.443251325232268e-07
. O 0 2.3030945612845244e-06

Only O 0 3.0856705279802554e-07
11 O 0 3.139081741210248e-07
mutations O 0 2.6327995783503866e-08
of O 0 1.211424560665364e-08
the O 0 6.812268527056631e-09
gene O 0 2.975509172387092e-09
have O 0 2.9601348039420827e-09
been O 0 1.6161534333036798e-08
reported O 0 9.16741953460587e-08
in O 0 1.9647153237656312e-07
HCP B-Disease 1 0.9975904226303101
patients O 0 1.924565140143386e-06
. O 0 1.224673633259954e-05

We O 0 9.267530458600959e-07
report O 0 3.7413421694054705e-08
another O 0 7.061151219289741e-09
mutation O 0 1.0159411978349908e-08
in O 0 3.135196102732607e-09
a O 0 1.7001550389750264e-08
Japanese O 0 9.696952929516556e-07
family O 0 6.094031164138869e-07
. O 0 3.3600611004658276e-06

Polymerase O 0 2.6455827537574805e-05
chain O 0 5.2956164608986e-07
reaction O 0 1.1691063406260582e-07
- O 0 4.2534395561233396e-07
single O 0 2.2179150960255356e-08
strand O 0 5.644308842533974e-08
conformational O 0 3.515637558848539e-08
polymorphism O 0 3.8330103535599847e-08
and O 0 1.6222737597715309e-09
direct O 0 2.3012167726932375e-09
sequence O 0 7.115636968535455e-09
analyses O 0 1.2382948000322358e-08
demonstrated O 0 2.467895754421079e-08
a O 0 1.1839195401819325e-08
C O 0 2.887357766212517e-07
to O 0 4.936911324193716e-09
T O 0 4.385307761367585e-08
substitution O 0 9.600408468202204e-09
in O 0 1.1981647896064374e-09
exon O 0 8.190391476148307e-09
1 O 0 8.112064797671792e-09
of O 0 2.140021271301862e-09
the O 0 6.635615612538004e-09
CPO O 0 2.72345062057866e-07
gene O 0 3.269366555258557e-09
at O 0 1.7910560146106036e-08
nucleotide O 0 1.6118365531170298e-09
position O 0 2.3354560951815984e-08
85 O 0 1.0889296575555818e-08
, O 0 4.432749167726513e-10
which O 0 4.1763603686462147e-10
lies O 0 1.5985316181854614e-08
in O 0 2.1241737258037574e-09
the O 0 7.39746885969339e-09
putative O 0 2.2210251415799576e-07
presequence O 0 3.289415531071427e-07
for O 0 4.543275089474719e-09
targeting O 0 4.4595857673357386e-08
to O 0 6.224545501254397e-08
mitochondria O 0 3.5157231650373433e-06
. O 0 3.659906496977783e-06

This O 0 4.5839005480274864e-08
mutation O 0 2.883413863230544e-08
changes O 0 1.5232188843583572e-08
the O 0 8.084663605245623e-09
codon O 0 3.1345877005151124e-08
for O 0 3.7198724101017433e-09
glutamine O 0 2.8356314629718327e-08
to O 0 2.8191011747225048e-09
a O 0 1.0915810477740706e-08
termination O 0 7.936962447274709e-07
codon O 0 1.4664888112747576e-06
at O 0 1.6988055904221255e-06
amino O 0 2.106029199921977e-07
acid O 0 5.850063189427601e-08
position O 0 6.912563321748166e-07
29 O 0 3.094306748607778e-06
. O 0 2.6769350824906724e-06

MaeI O 0 0.00014126136375125498
restriction O 0 5.453804305943777e-07
analysis O 0 1.1226375562500834e-07
showed O 0 4.859669644474707e-08
two O 0 2.468233395447328e-09
other O 0 7.485706499110734e-10
carriers O 0 1.5173285961012084e-09
in O 0 3.0030018471904896e-09
the O 0 3.116465308039551e-08
family O 0 1.0272820816226158e-07
. O 0 1.1640914863164653e-06

The O 0 6.672895779047394e-06
C O 0 0.2603307068347931
- O 0 0.0057885912247002125
T O 0 1.8337327674089465e-06
mutation O 0 9.054979877021196e-09
is O 0 8.397660899994719e-10
located O 0 2.4269375398233706e-09
within O 0 4.1617709278796156e-09
a O 0 1.8977086568838786e-09
recently O 0 5.959460924742643e-09
proposed O 0 8.083675950842917e-09
putative O 0 3.165361306400882e-08
alternative O 0 2.8847120248087776e-08
translation O 0 9.045403004392938e-08
initiation O 0 1.0228244207155512e-07
codon O 0 3.795678082951781e-07
( O 0 2.208771121559039e-08
TIC O 0 1.9429093356393423e-07
- O 0 7.201920482202695e-08
1 O 0 7.603392759847338e-08
) O 0 1.398900884019838e-09
, O 0 5.19793152964354e-10
supporting O 0 4.695180688685241e-09
that O 0 5.3446762571240924e-09
TIC O 0 3.281811018496228e-07
- O 0 1.1947166456138802e-07
1 O 0 1.1315675862988428e-07
is O 0 1.4394935243799978e-09
the O 0 1.2043677166673206e-08
real O 0 6.042404834261106e-07
TIC O 0 3.4216225230920827e-07
rather O 0 2.103483609516843e-08
than O 0 1.6739434727242042e-08
TIC O 0 2.49185347911407e-07
- O 0 4.974628708964701e-08
2 O 0 5.039473549572904e-08
. O 0 2.3187359587950596e-08
. O 0 4.082278053374466e-07

Human B-Disease 0 1.858925656961219e-06
complement I-Disease 0 2.0705699625978014e-06
factor I-Disease 0 0.00023840597714297473
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 0.13955070078372955
with O 1 0.7906576991081238
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999955892562866

This O 0 6.401928942523227e-08
study O 0 1.2830164486388185e-08
reports O 0 5.057130270103016e-09
on O 0 7.005399815795954e-09
six O 0 5.655545809446494e-09
cases O 0 2.816328059651596e-09
of O 0 3.548865379343624e-08
deficiency B-Disease 0 2.082717401208356e-05
in I-Disease 0 2.794988418486355e-08
the I-Disease 0 8.196802525617386e-08
human I-Disease 0 3.705796203234968e-08
complement I-Disease 0 9.03775987382005e-09
regulatory I-Disease 0 2.0491793151222737e-08
protein I-Disease 0 5.789376089637699e-09
Factor I-Disease 0 4.129881858716544e-08
H I-Disease 1 0.9993342757225037
( O 0 4.877356740706773e-09
FH O 0 2.953566990981926e-07
) O 0 1.0316200671489639e-10
in O 0 4.253452798308466e-11
the O 0 1.909463975824366e-10
context O 0 2.84275114559307e-09
of O 0 3.5283724830748042e-09
an O 0 6.28953644721264e-09
acute B-Disease 1 0.9999973773956299
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 1 0.5437650680541992

Five O 0 1.3826665963279083e-06
of O 0 4.5622254418731245e-08
the O 0 2.953727928911576e-09
cases O 0 1.3913490359840353e-09
were O 0 9.093711339502875e-10
observed O 0 1.7907920701887292e-09
in O 0 6.681332709312926e-10
children O 0 3.063270526126871e-09
presenting O 0 1.369703710452086e-07
with O 0 7.731352411610715e-07
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.999923586845398
HUS B-Disease 1 1.0
) O 0 3.355567969265394e-05
. O 0 7.901452772784978e-05

Two O 0 1.2686632544500753e-07
of O 0 6.268185614999311e-08
the O 0 2.397054288394429e-08
children O 0 2.8252322703536947e-09
exhibited O 0 5.4200608445853504e-08
a O 0 6.938514474086332e-08
homozygous O 0 8.139107376337051e-05
deficiency O 0 0.04354977607727051
characterized O 0 7.929519796334716e-08
by O 0 5.257621005227975e-09
the O 0 1.5795555086128843e-08
absence O 0 2.607781652841368e-07
of O 0 8.986557276102758e-08
the O 0 1.2843777597026929e-08
150 O 0 6.323541690278489e-09
- O 0 1.0520041726636009e-08
kD O 0 4.904711659037275e-08
form O 0 6.492564263993472e-10
of O 0 4.1630889846544505e-09
Factor O 0 7.65270087299541e-08
H O 1 0.9975324869155884
and O 0 2.659928721726601e-09
the O 0 8.798474726567918e-10
presence O 0 3.3973845958712445e-10
, O 0 2.3409438276722483e-10
upon O 0 3.875114895635079e-09
immunoblotting O 0 1.2662808046570717e-07
, O 0 8.26289536792757e-10
of O 0 2.0003236844701178e-09
the O 0 6.420428633191477e-09
42 O 0 4.786591389915884e-08
- O 0 6.117706874420037e-08
kD O 0 1.4831429098194349e-06
Factor O 0 3.4371018386991636e-07
H O 1 0.9939690828323364
- O 0 5.809127969769179e-07
like O 0 4.1726200272762526e-09
protein O 0 7.043799321593269e-09
1 O 0 9.838695547159659e-08
( O 0 3.598334297194583e-09
FHL O 0 8.909013899938145e-07
- O 0 1.869528709619317e-08
1 O 0 9.963975422522253e-09
) O 0 4.4469081195153137e-10
and O 0 1.6706573902069977e-09
other O 0 4.088115179712304e-09
FH O 0 6.327951723505976e-06
- O 0 1.0294554186884852e-07
related O 0 3.0315362664623535e-08
protein O 0 2.256630970975948e-08
( O 0 2.723178349484101e-09
FHR O 0 1.501950009696884e-06
) O 0 9.701317971178014e-09
bands O 0 4.909190352009318e-07
. O 0 1.5534088788626832e-06

Southern O 0 5.061638603365282e-06
blot O 0 3.514730906317709e-06
and O 0 2.1088343515884844e-08
PCR O 0 4.1349579760208144e-08
analysis O 0 4.5375769808231325e-09
of O 0 2.057065184857265e-09
DNA O 0 6.564678578513394e-09
of O 0 4.815691401205413e-09
one O 0 1.367843505128974e-09
patient O 0 9.409012236005765e-09
with O 0 5.089178412021056e-09
homozygous O 0 7.08415291228448e-06
deficiency O 0 0.007831382565200329
ruled O 0 1.975772192963632e-06
out O 0 4.253221774774829e-09
the O 0 1.2193032139506954e-09
presence O 0 1.2820079442477095e-09
of O 0 4.682677801071122e-09
a O 0 1.2294173457050306e-09
large O 0 3.6901921518506242e-09
deletion O 0 8.147858210350023e-08
of O 0 7.622661968298416e-08
the O 0 1.6710524164409435e-07
FH O 0 9.576987940818071e-05
gene O 0 3.901824285890143e-08
as O 0 1.8243063948375493e-08
the O 0 2.822642919397822e-08
underlying O 0 1.179639275505906e-05
defect O 0 3.628271542766015e-06
for O 0 1.51087846234077e-07
the O 0 9.833732292463537e-06
deficiency O 1 0.9999508857727051
. O 0 6.129757821327075e-05

The O 0 7.20888749583537e-07
other O 0 1.4316932528402049e-08
four O 0 1.472512778377677e-08
children O 0 2.985019120771426e-09
presented O 0 6.530973450935562e-08
with O 0 2.5142195880789586e-08
heterozygous O 0 5.53724612473161e-06
deficiency O 0 0.01485415082424879
and O 0 1.0779261572224641e-07
exhibited O 0 2.1821436746449763e-07
a O 0 2.6894626969919955e-08
normal O 0 2.179169769078726e-07
immunoblotting O 0 8.579120276408503e-07
pattern O 0 3.8705813665274036e-08
of O 0 4.791548935401124e-09
proteins O 0 1.054892950769215e-09
of O 0 1.6138615777094856e-08
the O 0 9.157807312476507e-08
FH O 0 5.2274990594014525e-05
family O 0 1.283024317899617e-07
. O 0 1.662779595790198e-06

Factor B-Disease 1 0.9998282194137573
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.7219128284627914e-08
the O 0 1.3271212573329194e-08
only O 0 2.6652472229216073e-08
complement B-Disease 1 0.9999992847442627
deficiency I-Disease 1 1.0
associated O 0 6.465654678322608e-07
with O 0 7.719241068571137e-08
HUS B-Disease 1 0.9999998807907104
. O 0 1.592838452779688e-05

These O 0 2.142988222431086e-07
observations O 0 3.320834593978361e-07
suggest O 0 3.605191878364167e-08
a O 0 8.960896913379202e-09
role O 0 2.01143901534806e-08
for O 0 3.180163332672237e-08
FH O 0 0.00025675297365523875
and O 0 5.508796334652288e-07
/ O 0 3.754746649065055e-05
or O 0 2.944131836102315e-07
FH O 0 1.4409233699552715e-05
receptors O 0 2.4686112709559893e-08
in O 0 1.9759485159198675e-09
the O 0 6.944879782366797e-09
pathogenesis O 0 1.867365654106834e-06
of O 0 2.7406880320768323e-08
idiopathic O 0 0.000298848346574232
HUS B-Disease 1 0.9999942779541016
. O 0 8.549831136406283e-07
. O 0 4.556166004476836e-06

Further O 0 1.3639927942676877e-07
evidence O 0 7.218216069304617e-08
for O 0 7.785536104698565e-10
a O 0 2.5839974604480176e-10
major O 0 8.515534388742196e-10
ancient O 0 4.436509470906458e-08
mutation O 0 2.6646532660379307e-06
underlying O 1 0.9962761402130127
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 2.2024237011919467e-07
linkage O 0 2.141265440513962e-06
disequilibrium O 0 1.6930250694713322e-06
studies O 0 6.45365227924799e-09
in O 0 6.706279975787766e-10
the O 0 2.0048538384997983e-09
Japanese O 0 2.793975717452213e-08
population O 0 2.487772210457706e-09
. O 0 2.700566597013676e-07

The O 1 0.9946953654289246
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9836471676826477
DM B-Disease 1 1.0
) O 0 8.071939561204999e-08
mutation O 0 3.398048775693496e-08
is O 0 1.3136320919926447e-09
an O 0 2.6811333153631267e-09
unstable O 0 1.5965713373589097e-06
( O 0 7.468343454775095e-08
CTG O 0 6.953995125513757e-06
) O 0 7.367026544358168e-09
n O 0 5.5903630169495955e-08
repeat O 0 3.9061653467342694e-08
, O 0 1.7142798292013595e-09
present O 0 2.5589115271174023e-09
at O 0 1.4913657864212837e-08
a O 0 5.24566834414486e-10
copy O 0 3.132470505207152e-09
number O 0 1.2477705535474115e-09
of O 0 3.775901369351686e-09
5 O 0 5.443973805085989e-08
- O 0 4.308106937855882e-08
37 O 0 1.8305733817669534e-08
repeats O 0 1.1092573970472586e-08
on O 0 2.1703918662296928e-08
normal O 0 7.776665533754112e-09
chromosomes O 0 3.536862358544113e-09
but O 0 1.0968774777353474e-09
amplified O 0 6.514201178475787e-09
to O 0 7.505822630093917e-10
50 O 0 7.466559814872653e-09
- O 0 1.663148552211169e-08
3000 O 0 1.8651620692367032e-08
copies O 0 2.8659011164222647e-08
on O 0 4.712557597486011e-07
DM B-Disease 1 0.9998177886009216
chromosomes O 0 2.43542831412924e-06
. O 0 1.094704316528805e-06

Previous O 0 2.4627290713397088e-06
findings O 0 5.127335498400498e-07
in O 0 1.8194830531115258e-08
Caucasian O 0 4.986960107089544e-07
populations O 0 2.6227406024759148e-08
of O 0 2.7565738491830416e-07
a O 0 9.464302820560988e-06
DM B-Disease 1 1.0
founder O 1 0.9925398230552673
chromosome O 0 1.0009539437305648e-06
raise O 0 2.286927625050339e-08
a O 0 4.511635509629741e-09
question O 0 1.5046001777818674e-08
about O 0 4.091951499862745e-10
the O 0 6.653647077747848e-10
molecular O 0 2.221255357426344e-08
events O 0 2.653376851569078e-09
involved O 0 8.919116001315786e-10
in O 0 5.706807804095604e-10
the O 0 3.873799503395503e-09
expansion O 0 4.885748339233942e-08
mutation O 0 4.305638299229031e-07
. O 0 9.102852800424444e-07

To O 0 6.906151952534856e-07
investigate O 0 6.770017648705107e-07
whether O 0 9.42201765496975e-08
a O 0 5.6606641152257e-08
founder O 0 1.0364215086156037e-06
chromosome O 0 1.4369778966738522e-07
for O 0 1.544888128535149e-08
the O 0 1.9069896950441034e-07
DM B-Disease 1 1.0
mutation O 0 7.477690466828335e-09
exists O 0 1.2352016076633276e-09
in O 0 2.1983918851997686e-10
the O 0 3.6601324748808395e-10
Japanese O 0 4.10666833872142e-09
population O 0 5.838673294844554e-11
, O 0 3.163595496680216e-10
we O 0 4.695754007855157e-09
genotyped O 0 1.8462249329331826e-07
families O 0 6.125057128159028e-10
using O 0 2.5354265353882965e-09
polymorphic O 0 3.117440172673014e-08
markers O 0 5.8133352354161616e-08
near O 0 1.6454920626074454e-07
the O 0 6.190906987058042e-08
( O 0 3.807333470717822e-08
CTG O 0 5.836783657287015e-06
) O 0 9.076907225846753e-09
n O 0 1.0142299800008914e-07
repeat O 0 1.2216879952120507e-07
region O 0 3.817746829781754e-08
and O 0 4.3255457882196424e-08
constructed O 0 7.076247356962995e-07
haplotypes O 0 4.547379830910359e-06
. O 0 1.6817285768411239e-06

Six O 0 8.165366125467699e-07
different O 0 2.1201755018296353e-08
haplotypes O 0 2.0427060576366785e-07
were O 0 1.4579133456038562e-08
found O 0 8.311298316243665e-09
and O 0 3.960291650173531e-08
DM B-Disease 1 1.0
alleles O 0 2.2518334219512326e-07
were O 0 6.785467121517286e-08
always O 0 6.187742940255703e-08
haplotype O 0 1.4266197467804886e-06
A O 0 5.99705231252301e-07
. O 0 2.955986246888642e-06

To O 0 1.3020115829931456e-07
find O 0 3.3700942481118545e-08
an O 0 8.565363973644935e-10
origin O 0 6.423674481226271e-09
of O 0 2.272959775950767e-08
the O 0 2.043009139640617e-08
( O 0 2.171389823502068e-08
CTG O 0 2.8222068522154586e-06
) O 0 6.5538316995628065e-09
n O 0 9.415406054813502e-08
repeat O 0 4.5434944695443846e-08
mutation O 0 9.120222799197109e-09
and O 0 1.5152781251970282e-09
to O 0 9.992384697454781e-10
investigate O 0 7.1584631555765554e-09
the O 0 1.1655774123653373e-09
mechanism O 0 2.0260358724044636e-08
of O 0 2.1866084498611826e-09
the O 0 6.017826237325608e-10
expansion O 0 7.76142761171883e-10
mutation O 0 3.478959897940115e-10
in O 0 5.7389617363901024e-11
the O 0 1.266479421335731e-10
Japanese O 0 9.046999815964796e-10
population O 0 8.018324719472059e-12
we O 0 1.8352562525247862e-10
have O 0 1.2127387982729942e-10
studied O 0 2.128863485495458e-08
90 O 0 1.5669733954837284e-08
Japanese O 0 4.177169614649756e-07
DM B-Disease 1 0.9999998807907104
families O 0 8.2351920838164e-09
comprising O 0 5.9992286693955066e-09
190 O 0 7.708644389481378e-09
affected O 0 4.927541485955089e-09
and O 0 4.658704977344996e-09
130 O 0 4.7756664400822046e-08
unaffected O 0 2.015375883956949e-07
members O 0 5.699981997508985e-08
. O 0 8.181438602150592e-07

The O 0 1.5565631201752694e-06
results O 0 8.87980036168301e-07
suggest O 0 3.205906651260193e-08
that O 0 3.9013067776316745e-10
a O 0 6.745149438991405e-10
few O 0 2.3485879907525486e-09
common O 0 3.829880856898171e-09
ancestral O 0 1.0141619100068056e-08
mutations O 0 1.517273751083792e-09
in O 0 4.762199523611343e-10
both O 0 1.5876950865134631e-09
Caucasian O 0 2.890406669564527e-08
and O 0 2.8565840803906895e-09
Japanese O 0 1.584984943292511e-08
populations O 0 2.2646616526511565e-10
have O 0 9.016178081910908e-11
originated O 0 3.2966160357084107e-10
by O 0 6.626729720515812e-11
expansion O 0 1.985930975223482e-09
of O 0 1.146622796710517e-09
an O 0 3.5753525140513887e-10
ancestral O 0 9.668621459013593e-09
n O 0 3.9155864328677126e-08
= O 0 7.439141569420826e-08
5 O 0 2.4597657244385118e-08
repeat O 0 1.3145551314153181e-08
to O 0 3.546434701462431e-09
n O 0 1.0443395126458199e-07
= O 0 2.052410792430237e-07
19 O 0 1.5029341682293307e-07
- O 0 6.443126210342598e-08
37 O 0 1.798559878807282e-08
copies O 0 9.893607000321936e-08
. O 0 8.468908276881848e-07

These O 0 7.41061967346468e-08
data O 0 3.353595801058873e-08
support O 0 7.239874477704689e-09
multistep O 0 6.372052325787081e-07
models O 0 5.093551180834766e-07
of O 0 1.8134515755718894e-07
triplet O 0 3.460196921878378e-06
repeat O 0 3.3322358206078206e-08
expansion O 0 7.177028304994337e-09
that O 0 8.26358426131435e-11
have O 0 1.2929497750224783e-10
been O 0 2.486850447791511e-10
proposed O 0 5.173441675054846e-10
for O 0 2.432896661908046e-10
both O 0 2.1607966971259884e-08
DM B-Disease 1 1.0
and O 0 1.2200534627027082e-07
Friedreichs B-Disease 0 4.403376078698784e-05
ataxia I-Disease 0 0.0001056866385624744
. O 0 2.903630615946895e-07
. O 0 2.5042656943696784e-06

The O 0 2.8965004617020895e-07
molecular O 0 7.408067972392018e-07
basis O 0 1.1210021284568938e-06
of O 0 9.876536205410957e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 4.7273712056039585e-08
the O 0 1.8359791909006162e-08
western O 0 4.759235139317752e-08
Cape O 0 1.2652116083700093e-06
, O 0 5.164748184682821e-09
South O 0 4.939787245916705e-08
Africa O 0 5.180947368899069e-07
. O 0 9.763560910869273e-07

Deficiency B-Disease 1 0.9999568462371826
of I-Disease 0 0.0001508622954133898
the I-Disease 0 1.6804987126306514e-06
sixth I-Disease 0 1.1344087624820531e-06
component I-Disease 0 7.202717000609482e-08
of I-Disease 0 4.29370174970245e-08
human I-Disease 0 1.5060873437278133e-08
complement I-Disease 0 8.149769570309218e-08
( O 0 2.3545949190406645e-08
C6 O 0 0.00015845995221752673
) O 0 1.98177629862073e-09
has O 0 4.772310879808117e-10
been O 0 1.4851994079023711e-09
reported O 0 1.0541728601154432e-09
in O 0 1.5367047911940546e-10
a O 0 2.0694249092123584e-10
number O 0 2.974032409230887e-10
of O 0 1.0785607962304766e-09
families O 0 6.942846297874894e-11
from O 0 1.381824793478259e-10
the O 0 1.3335198500996626e-09
western O 0 2.6449145096307802e-08
Cape O 0 1.0727908374974504e-06
, O 0 1.2122266745961952e-08
South O 0 1.550125006133385e-07
Africa O 0 1.1877802990056807e-06
. O 0 1.7727459180605365e-06

Meningococcal B-Disease 1 1.0
disease I-Disease 1 0.9733747839927673
is O 0 1.653255488065497e-08
endemic O 0 6.983507105928766e-09
in O 0 1.459749099375074e-09
the O 0 1.0748257395221117e-08
Cape O 0 7.77665206896927e-07
and O 0 1.6943531022661773e-09
almost O 0 1.0969297692398072e-09
all O 0 4.90930240903964e-10
pedigrees O 0 1.1086482842870282e-08
of O 0 6.998855273110394e-09
total O 0 5.422614322014851e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.3093881534587126e-07
C6Q0 O 0 1.6519319615326822e-05
) O 0 1.8943886459510395e-09
have O 0 4.4912845664768497e-10
been O 0 8.81765938043344e-10
ascertained O 0 8.711665344662833e-08
because O 0 3.5698553002561084e-09
of O 0 6.397413443437472e-08
recurrent O 0 6.582904461538419e-05
disease O 0 0.000563211680855602
. O 0 6.51078880764544e-06

We O 0 3.049014480893675e-07
have O 0 9.006922319088062e-09
sequenced O 0 2.786535624466069e-08
the O 0 3.9395864348534815e-09
expressed O 0 8.251528349489945e-09
exons O 0 2.147780122641052e-07
of O 0 5.1081734397939726e-08
the O 0 4.4536182741694574e-08
C6 O 0 1.408668867952656e-05
gene O 0 2.5622814980863495e-09
from O 0 3.119316471789091e-10
selected O 0 2.4817485844152998e-09
cases O 0 5.291108107208231e-10
and O 0 6.076417702338688e-10
have O 0 5.883055709254847e-10
found O 0 4.374954176711299e-09
three O 0 8.869871059857815e-09
molecular O 0 0.15338274836540222
defects O 1 0.9900022745132446
leading O 0 5.1247425290057436e-06
to O 0 5.9593954659931114e-08
total O 0 6.60562648135965e-07
deficiency O 1 0.9998894929885864
879delG O 0 0.0003474552358966321
, O 0 5.239821021518765e-09
which O 0 6.908530969518267e-10
is O 0 1.5449219681329396e-10
the O 0 1.2509255853387913e-09
common O 0 7.194750573091824e-09
defect O 0 2.557434619632204e-08
in O 0 4.2467935834622494e-09
the O 0 2.096754059266459e-08
Cape O 0 8.543115086467878e-07
and O 0 9.210074480847652e-09
hitherto O 0 7.414153913032351e-08
unreported O 0 2.6609601633253988e-08
, O 0 5.246879042353214e-10
and O 0 2.891552330908098e-09
1195delC O 0 1.610089839232387e-07
and O 0 6.508823258144503e-09
1936delG O 0 1.0255964610905721e-07
, O 0 4.635267447650193e-10
which O 0 1.2739584387411185e-10
have O 0 3.1484440055074003e-10
been O 0 1.1227005991543137e-09
previously O 0 3.1120441779108887e-09
reported O 0 4.156154531642642e-09
in O 0 6.324603063490031e-09
African O 0 1.4350089259096421e-06
- O 0 3.6201797115609224e-07
Americans O 0 1.1498674012955235e-07
. O 0 1.4868277276036679e-06

We O 0 7.475460961359204e-07
also O 0 1.5006335729594866e-08
show O 0 2.171036683762395e-09
that O 0 2.6136939834664474e-10
the O 0 3.500300493897157e-09
879delG O 0 4.494751522088336e-07
and O 0 2.922883091116546e-08
1195delC O 0 3.946096967410995e-06
defects O 0 2.934600161097478e-06
are O 0 5.4974473862046125e-09
associated O 0 7.798592349672617e-08
with O 0 6.026629506550307e-08
characteristic O 1 0.9999986886978149
C6 O 1 1.0
/ O 1 0.9999990463256836
C7 O 1 0.5192030072212219
region O 0 2.4716294433346775e-07
DNA O 0 2.0054558547144552e-07
marker O 0 1.0452043852637871e-07
haplotypes O 0 2.5193608976792348e-08
, O 0 3.7109698647341816e-10
although O 0 3.444704244071062e-10
small O 0 7.196407358911472e-10
variations O 0 8.265626405545845e-09
were O 0 2.433052159744875e-08
observed O 0 3.705916640228679e-07
. O 0 9.231902140527382e-07

The O 0 1.1327783795422874e-06
1936delG O 0 1.3691927961190231e-05
defect O 0 1.6144515484484145e-06
was O 0 1.0143345008373217e-07
observed O 0 1.1409251321481406e-08
only O 0 7.318439187997683e-10
once O 0 2.429447754082048e-09
in O 0 1.085967316072356e-09
the O 0 6.0015863390106006e-09
Cape O 0 3.4634351209206216e-07
, O 0 5.457597707092532e-10
but O 0 2.915363783717595e-10
its O 0 3.121792546689761e-10
associated O 0 1.1410034694847582e-08
haplotype O 0 5.137927416853927e-08
could O 0 1.1671173361094134e-08
be O 0 4.9467921314771957e-08
deduced O 0 1.688624479356804e-06
. O 0 1.1541261528691393e-06

The O 0 5.061972956355021e-07
data O 0 3.27197575700211e-08
from O 0 2.1601693767081542e-09
the O 0 2.4212414295732287e-09
haplotypes O 0 2.192155079683289e-08
indicate O 0 4.324949287592972e-09
that O 0 4.898751404525115e-10
these O 0 2.730293102715109e-09
three O 0 6.956612619291036e-09
molecular O 0 5.606053309747949e-05
defects O 0 2.1622397980536334e-05
account O 0 5.231971744734665e-09
for O 0 6.376128958152094e-09
the O 0 7.41013863603257e-08
defects O 0 7.254132469824981e-06
in O 0 7.793874878814222e-09
all O 0 4.02584054981503e-09
the O 0 8.930695294395719e-09
38 O 0 2.4097200679307207e-08
unrelated O 0 1.6147453152370872e-08
C6Q0 O 0 4.090957475000323e-07
individuals O 0 1.9958484864801562e-10
we O 0 8.877889534630867e-10
have O 0 3.5217817551114194e-10
studied O 0 1.2339825161689078e-08
from O 0 1.734173027401198e-09
the O 0 3.2060714971748894e-08
Cape O 0 6.156796644063434e-06
. O 0 1.5648909084120532e-06

We O 0 3.8807831970189e-07
have O 0 1.0225119417839323e-08
also O 0 4.823412780297076e-09
observed O 0 2.438934387782865e-08
the O 0 8.101365800428084e-09
879delG O 0 6.244546852940402e-07
defect O 0 1.3357178829664917e-07
in O 0 1.9510078885787152e-08
two O 0 1.3615846228276496e-07
Dutch O 1 0.9999998807907104
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 0.00021042730077169836
, O 0 6.968976506982472e-09
but O 0 5.614167797318714e-09
the O 0 2.151518962989485e-08
879delG O 0 1.4229714224711643e-06
defect O 0 3.2612038580737135e-07
in O 0 1.8813475222145826e-08
the O 0 5.524232449261035e-08
Cape O 0 2.107482941937633e-06
probably O 0 1.5416913967669643e-08
did O 0 2.2891561979321295e-09
not O 0 9.833114322788106e-10
come O 0 1.5974853662115152e-09
from O 0 4.060944358563745e-10
The O 0 7.253877054580471e-09
Netherlands O 0 2.2960233536650776e-07
. O 0 3.4443264240735516e-08
. O 0 4.925740313410643e-07

Complement B-Disease 1 0.9999998807907104
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 3.256776381022064e-06
seven O 0 1.576711810002962e-07
further O 0 1.110625476030691e-07
molecular O 0 4.093028110219166e-05
defects O 0 1.2010472346446477e-05
and O 0 1.602658983301808e-08
their O 0 2.18198081824994e-08
associated O 0 2.5849030294011754e-07
marker O 0 1.8349905985814985e-06
haplotypes O 0 9.386549209011719e-06
. O 0 9.597053576726466e-06

Seven O 0 1.9216931832488626e-06
further O 0 1.1964108637130266e-07
molecular O 0 4.345930904037232e-07
bases O 0 1.389038146726307e-07
of O 0 0.0008156962576322258
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 7.098030891938834e-07
described O 0 1.0726731716204085e-06
. O 0 1.8509880419514957e-06

All O 0 1.1160531698806153e-07
these O 0 1.4454590413492951e-08
new O 0 3.0996822886208975e-08
molecular O 0 3.701717332660337e-06
defects O 0 8.97964980595134e-07
involve O 0 2.0577253678766283e-08
single O 0 2.1449590548172637e-08
- O 0 3.932059655653575e-07
nucleotide O 0 2.2215349559928654e-08
events O 0 6.7902155009846865e-09
, O 0 9.476871509761509e-10
deletions O 0 1.0955691465142081e-08
and O 0 2.1682062811834157e-09
substitutions O 0 2.0114429233331066e-08
, O 0 7.363174514551929e-10
some O 0 3.828820038798142e-10
of O 0 1.7128024554224908e-09
which O 0 2.5520194846251343e-09
alter O 0 7.458918815927973e-08
splice O 0 2.137591650352988e-07
sites O 0 1.9422602193230887e-08
, O 0 2.037404689403388e-09
and O 0 8.268117746013104e-09
others O 0 2.2313999537004747e-08
codons O 0 1.1424405101934099e-06
. O 0 3.2880370781640522e-06

They O 0 6.185371148603735e-08
are O 0 1.8859560579898016e-09
distributed O 0 1.279194083991797e-09
along O 0 3.031523254648505e-09
the O 0 2.5361485356256708e-08
C7 O 0 1.0853862477233633e-05
gene O 0 5.5426361278421155e-09
, O 0 1.170125885074924e-09
but O 0 8.048579580588466e-10
predominantly O 0 1.1675287403534185e-09
towards O 0 1.1952598022446637e-08
the O 0 7.68841079690219e-09
3 O 0 1.807386240670894e-07
end O 0 9.455625900045561e-07
. O 0 1.6959855884124408e-06

All O 0 7.199077600716919e-08
were O 0 1.7467552737571168e-08
found O 0 2.5416435622815925e-09
in O 0 2.001258714301457e-09
compound O 0 9.88289414749488e-08
heterozygous O 0 1.3786623753730964e-07
individuals O 0 4.126787445102309e-08
. O 0 1.428713744644483e-06

The O 0 0.0002261881745653227
C6 O 1 1.0
/ O 1 0.9998509883880615
C7 O 0 0.1402561366558075
marker O 0 3.302137429272989e-06
haplotypes O 0 1.2475010180423851e-06
associated O 0 2.915523396040953e-07
with O 0 4.13674854371493e-08
most O 0 6.166736170598597e-07
C7 B-Disease 1 1.0
defects I-Disease 1 0.9956081509590149
are O 0 1.7670632246336027e-07
tabulated O 0 5.140445409779204e-06
. O 0 2.9552350611083966e-07
. O 0 2.5225738227163674e-06

A O 0 2.2558155251317658e-05
genome O 0 1.0099134897245676e-06
- O 0 1.1917311439901823e-06
wide O 0 1.5255919549872488e-07
search O 0 8.662983930207702e-08
for O 0 1.0204389333523523e-08
chromosomal O 0 3.1054521969053894e-05
loci O 0 6.21979488641955e-05
linked O 0 5.6634456996107474e-05
to O 0 3.84187472945996e-07
mental O 1 0.9998482465744019
health O 0 4.123686267121229e-06
wellness O 0 6.1655168792640325e-06
in O 0 3.8209446273640424e-08
relatives O 0 6.449729283986017e-08
at O 0 2.2478060657249443e-07
high O 0 1.4787406144023407e-06
risk O 0 7.099994263626286e-07
for O 0 1.8373440298091737e-06
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 0.9999984502792358
among O 0 7.017103342832343e-08
the O 0 4.426957644909635e-08
Old O 0 1.2896834959974512e-06
Order O 0 8.269058184851019e-07
Amish O 0 6.032327291904949e-06
. O 0 2.3145728391682496e-06

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.20758092403411865
BPAD B-Disease 1 1.0
; O 1 0.9999837875366211
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 4.6650202989440004e-07
is O 0 2.0015680224361176e-09
characterized O 0 1.7397155938070341e-09
by O 0 6.260987284179009e-10
episodes O 0 3.4543464977332405e-08
of O 0 7.460896966904329e-08
mania B-Disease 0 1.232509816873062e-06
and O 0 3.521517442095501e-07
/ O 0 0.0003266487328801304
or O 0 1.9734841316676466e-06
hypomania B-Disease 0 0.0010799453593790531
interspersed O 0 7.670396939829516e-08
with O 0 2.8620270597912167e-09
periods O 0 3.925701150819805e-07
of O 0 2.9224102604530344e-07
depression B-Disease 0 1.944112045748625e-05
. O 0 2.666628461156506e-06

Compelling O 0 3.0709059046785114e-06
evidence O 0 8.179769679372839e-07
supports O 0 4.3315228737128564e-08
a O 0 4.122623575852913e-09
significant O 0 5.969825078722124e-09
genetic O 0 2.1348855128167088e-08
component O 0 1.9861781552776847e-08
in O 0 3.0622950841774355e-09
the O 0 9.719284044251708e-09
susceptibility O 0 1.0133753391983191e-07
to O 0 3.857668673390435e-08
develop O 0 2.0376821339596063e-05
BPAD B-Disease 1 1.0
. O 0 3.209782516933046e-05

To O 0 4.367261041693382e-08
date O 0 5.634498165818513e-07
, O 0 3.767700373913385e-09
however O 0 9.956661273236023e-09
, O 0 1.7194341506154842e-09
linkage O 0 1.793732806731896e-08
studies O 0 9.65656332674314e-10
have O 0 2.54675697197726e-10
attempted O 0 6.902792115681677e-09
only O 0 5.312069673024666e-10
to O 0 1.1890946005621572e-09
identify O 0 5.078252840462483e-08
chromosomal O 0 2.7759160730056465e-06
loci O 0 1.1362168379491777e-06
that O 0 6.5619620848167415e-09
cause O 0 1.8830694159532868e-07
or O 0 1.4873432263584618e-08
increase O 0 2.241940411096266e-09
the O 0 4.880371662352445e-09
risk O 0 2.6489130888762702e-08
of O 0 1.812675236578798e-07
developing O 0 0.00027681744541041553
BPAD B-Disease 1 1.0
. O 0 2.657566437846981e-05

To O 0 1.3130132003880135e-07
determine O 0 1.4410565540856624e-07
whether O 0 3.875220500049181e-08
there O 0 6.332594004732073e-09
could O 0 4.750046134205377e-09
be O 0 4.068652526001415e-09
protective O 0 4.704604705807469e-08
alleles O 0 4.0780399501727516e-08
that O 0 8.272246776463987e-10
prevent O 0 6.400229679570657e-09
or O 0 4.047043589139321e-09
reduce O 0 1.4644266244090431e-08
the O 0 5.040202033512742e-09
risk O 0 2.145179855972401e-08
of O 0 1.264381523924385e-07
developing O 0 0.0020586377941071987
BPAD B-Disease 1 1.0
, O 0 1.1244880582239603e-09
similar O 0 8.923569522201191e-11
to O 0 5.391039697988376e-11
what O 0 6.923776829648176e-11
is O 0 2.175507170243396e-11
observed O 0 7.021033199272608e-10
in O 0 1.5935708308489893e-10
other O 0 1.9242914817141354e-08
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 1.915655634121549e-09
we O 0 2.330537762773588e-09
used O 0 1.786651004920259e-08
mental O 0 6.282830145210028e-05
health O 0 1.6052128160026768e-07
wellness O 0 6.227923563528748e-07
( O 0 9.860479099899067e-10
absence O 0 1.2519383751907753e-08
of O 0 9.663496669531924e-09
any O 0 2.5310407991696593e-08
psychiatric B-Disease 0 2.6332792913308367e-05
disorder I-Disease 0 7.756165700811835e-07
) O 0 4.622547677968214e-09
as O 0 7.912958288613936e-09
the O 0 2.85918009268471e-08
phenotype O 0 2.668472802724864e-07
in O 0 3.099410506024469e-08
our O 0 1.6455986440178094e-07
genome O 0 3.497839529131852e-08
- O 0 5.272888756735483e-07
wide O 0 4.5545485249931517e-07
linkage O 0 7.610849479533499e-07
scan O 0 1.0843854170161649e-06
of O 0 3.1492099594743195e-08
several O 0 6.3214318224424915e-09
large O 0 8.321751288065116e-09
multigeneration O 0 9.73262331172009e-07
Old O 0 4.415969385718199e-07
Order O 0 3.1314152693084907e-07
Amish O 0 1.1811507647507824e-06
pedigrees O 0 2.501367646345898e-07
exhibiting O 0 6.983496803059097e-08
an O 0 5.172713812839902e-09
extremely O 0 1.8125560075077374e-07
high O 0 1.4658716281701345e-05
incidence O 0 0.0003124528157059103
of O 0 6.5552034357097e-05
BPAD B-Disease 1 1.0
. O 0 7.999808440217748e-05

We O 0 3.034869280327257e-07
have O 0 4.114422580414612e-09
found O 0 4.670992037603128e-09
strong O 0 4.905729156234884e-09
evidence O 0 3.500208478612876e-08
for O 0 2.9905069531821482e-09
a O 0 5.346307396791872e-09
locus O 0 2.1150343343379063e-07
on O 0 4.804491595677973e-07
chromosome O 0 1.5573040172967012e-06
4p O 0 3.759408355108462e-05
at O 0 1.6444328139186837e-06
D4S2949 O 0 1.3675595482709468e-06
( O 0 9.879327578232733e-09
maximum O 0 2.1802216565447452e-07
GENEHUNTER O 0 6.51108121019206e-06
- O 0 1.8954871450205246e-07
PLUS O 0 1.018316098111427e-07
nonparametric O 0 8.247517939707905e-07
linkage O 0 3.4592783748621514e-08
score O 0 2.735256821040366e-08
= O 0 2.8687123787562996e-08
4 O 0 1.3421529665436083e-08
. O 0 1.2115671799151073e-09
05 O 0 1.634082309465157e-07
, O 0 3.900728184902391e-09
P O 0 2.522797331039328e-07
= O 0 2.777981222834569e-08
5 O 0 5.315965001528866e-09
. O 0 4.4747133776112946e-10
22 O 0 3.1844284986703997e-09
x O 0 1.9641133164327584e-08
10 O 0 1.4011581228601244e-08
( O 0 1.861358511767719e-09
- O 0 6.54209175721121e-09
4 O 0 1.6036315386713795e-08
) O 0 5.865061769583235e-10
; O 0 2.937502241451284e-09
SIBPAL O 0 1.5355307141362573e-06
Pempirical O 0 7.197923537205497e-07
value O 0 1.9699811559803493e-08
< O 0 8.84882069840387e-08
3 O 0 2.644334529122716e-08
x O 0 2.7047310169336924e-08
10 O 0 1.784855996334045e-08
( O 0 1.738448385246727e-09
- O 0 5.558092208701737e-09
5 O 0 8.278611574041861e-09
) O 0 5.479491860249652e-10
) O 0 3.6435895967024123e-10
and O 0 9.008722101633282e-10
suggestive O 0 2.367844764705751e-08
evidence O 0 1.8253018652103492e-08
for O 0 1.9215362634383837e-09
a O 0 4.027553401897421e-09
locus O 0 1.9028186670766445e-07
on O 0 5.685924975296075e-07
chromosome O 0 5.096600943943486e-06
4q O 0 3.930515595129691e-05
at O 0 2.4047765236900887e-06
D4S397 O 0 2.606725047371583e-06
( O 0 3.625894251513273e-08
maximum O 0 1.1104937129857717e-06
GENEHUNTER O 0 1.5876519682933576e-05
- O 0 4.580601569159626e-07
PLUS O 0 1.0717861442799403e-07
nonparametric O 0 4.3892325152228295e-07
linkage O 0 2.7330509411171988e-08
score O 0 1.946562377952432e-08
= O 0 1.1595930438090818e-08
3 O 0 5.176483686142319e-09
. O 0 2.8825367093254783e-10
29 O 0 7.4357764390242664e-09
, O 0 9.69463620492661e-10
P O 0 1.5564576472115732e-07
= O 0 1.6247518885847967e-08
2 O 0 5.347653431186927e-09
. O 0 4.2965236923819816e-10
57 O 0 3.973280815472435e-09
x O 0 2.8380990002574435e-08
10 O 0 2.3416248495777836e-08
( O 0 2.150336353423654e-09
- O 0 8.141640250869386e-09
3 O 0 1.8138765156550107e-08
) O 0 6.346302927617842e-10
; O 0 2.6483308879221568e-09
SIBPAL O 0 2.7240218969382113e-06
Pempirical O 0 1.1646154689515242e-06
value O 0 2.0987068083400118e-08
< O 0 1.0691256591144338e-07
1 O 0 1.755054235275111e-08
x O 0 4.83067026380013e-08
10 O 0 1.4349766708221523e-08
( O 0 1.2824310502423941e-09
- O 0 5.1026205483140075e-09
3 O 0 4.517818119609274e-09
) O 0 1.380707770337608e-10
) O 0 3.6943295644853436e-11
that O 0 4.160369965200417e-11
are O 0 3.7167219302247645e-10
linked O 0 5.314061723993291e-08
to O 0 3.728263209268334e-08
mental O 1 0.9371017813682556
health O 0 7.65554159443127e-06
wellness O 0 1.1909576642210595e-05
. O 0 3.756547812372446e-06

These O 0 8.701452713921753e-08
findings O 0 1.1503347252528329e-07
are O 0 9.463956285316044e-10
consistent O 0 9.012799395691218e-09
with O 0 2.1688793816476704e-10
the O 0 7.103280186271377e-10
hypothesis O 0 4.616344639885028e-09
that O 0 2.715975881695254e-11
certain O 0 3.3346042593862535e-10
alleles O 0 6.5458616305136275e-09
could O 0 1.942215055450447e-09
prevent O 0 5.70857405790548e-09
or O 0 2.7403519453628178e-09
modify O 0 1.693610762742992e-08
the O 0 2.208053961894052e-09
clinical O 0 3.150976723986787e-08
manifestations O 0 3.4672686410885944e-07
of O 0 7.319241746017724e-08
BPAD B-Disease 1 1.0
and O 0 6.538710906056622e-09
perhaps O 0 6.318152667716959e-09
other O 0 6.364003102277138e-09
related O 0 1.0131371709576342e-05
affective B-Disease 1 0.9988572597503662
disorders I-Disease 1 0.9996047616004944
. O 0 1.1476207873784006e-05

Segregation O 0 0.0007304361206479371
distortion O 1 0.8249928951263428
in O 0 0.00012024580064462498
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.04098416119813919

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999998807907104
DM B-Disease 1 1.0
) O 0 5.544551981984114e-07
is O 0 2.0119712562660652e-09
an O 0 1.3189697112281351e-09
autosomal B-Disease 1 0.9996947050094604
dominant I-Disease 1 0.9999969005584717
disease I-Disease 0 0.015024413354694843
which O 0 1.1975775926487131e-09
, O 0 3.662478931243385e-10
in O 0 3.3848818192794283e-10
the O 0 1.6585987028250315e-09
typical O 0 8.368452597551368e-09
pedigree O 0 1.480222699967726e-08
, O 0 1.1990975989917274e-09
shows O 0 2.530455400773235e-09
a O 0 3.06453284970587e-09
three O 0 7.336709906269334e-09
generation O 0 2.637238196712133e-07
anticipation O 0 7.85677229941939e-07
cascade O 0 4.660641025111545e-06
. O 0 2.4573189421062125e-06

This O 0 2.019376843520604e-08
results O 0 1.1833240165515235e-07
in O 0 6.498070348470719e-08
infertility B-Disease 1 0.9791392683982849
and O 1 0.9985007047653198
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9680227041244507
CDM B-Disease 1 0.6250705122947693
) O 0 1.5059256064375859e-09
with O 0 1.8756558806121149e-10
the O 0 5.1972892656237946e-09
disappearance O 0 2.3131795501285524e-07
of O 0 1.0155617502505265e-07
DM B-Disease 1 1.0
in O 0 1.490171541718155e-08
that O 0 4.633687655797303e-09
pedigree O 0 6.554196829711145e-07
. O 0 1.7138709154096432e-06

The O 0 1.5607801628902962e-07
concept O 0 7.950358593689089e-08
of O 0 5.8360768662168994e-08
segregation O 0 6.905269742674136e-07
distortion O 0 9.010308303913916e-07
, O 0 6.74535483025096e-10
where O 0 5.149567439133307e-10
there O 0 2.74753136908501e-10
is O 0 1.7672324714723686e-10
preferential O 0 1.0222155566452784e-08
transmission O 0 4.977590251087349e-08
of O 0 3.58880680728646e-09
the O 0 1.7006147601250632e-09
larger O 0 3.98309918381301e-09
allele O 0 7.766558951516345e-08
at O 0 6.175151412435298e-08
the O 0 3.361844491678312e-08
DM B-Disease 1 1.0
locus O 0 2.1736923372372985e-07
, O 0 2.318000680290311e-09
has O 0 6.022188858700872e-10
been O 0 1.2565548601628507e-09
put O 0 8.16855028062946e-09
forward O 0 3.8288821002652185e-08
to O 0 4.47277859194628e-09
explain O 0 7.359025033792932e-08
partially O 0 1.0560897578670847e-07
the O 0 1.1843080294227093e-08
maintenance O 0 5.3281492995438384e-08
of O 0 1.1832020874180671e-07
DM B-Disease 1 1.0
in O 0 3.0944605100557965e-08
the O 0 2.5386700741591994e-08
population O 0 2.917133867796906e-09
. O 0 2.139133243872493e-07

In O 0 5.802694431622513e-07
a O 0 7.517018474345605e-08
survey O 0 3.4017713090861434e-08
of O 0 1.867048950998651e-07
DM B-Disease 1 1.0
in O 0 4.562895483672946e-08
Northern O 0 2.209648073403514e-07
Ireland O 0 1.8426278813876706e-07
, O 0 9.420180191455074e-09
59 O 0 4.746135928712647e-08
pedigrees O 0 1.1160383195374379e-07
were O 0 7.894810494235571e-08
ascertained O 0 8.2634505815804e-06
. O 0 3.0000148854014697e-06

Sibships O 0 5.2147337555652484e-05
where O 0 4.0662342826180975e-08
the O 0 4.141767817600339e-09
status O 0 6.732274293597129e-09
of O 0 4.825151833642849e-09
all O 0 5.325319074600543e-10
the O 0 7.349017505653421e-10
members O 0 2.7272936686806304e-10
had O 0 1.1121337184505364e-09
been O 0 2.3998345533016163e-09
identified O 0 9.021123403840647e-09
were O 0 6.2991412086432774e-09
examined O 0 1.980099462173257e-08
to O 0 8.211316071538022e-10
determine O 0 2.8971959054047147e-08
the O 0 4.6570104217380504e-08
transmission O 0 2.8216954888193868e-05
of O 0 6.222990123205818e-07
the O 0 1.283064989365812e-06
DM B-Disease 1 1.0
expansion O 0 1.2680149552579678e-07
from O 0 1.296006968409813e-09
affected O 0 1.063322652150589e-09
parents O 0 1.7808823860043788e-10
to O 0 2.3320662068115894e-10
their O 0 4.382588070228621e-09
offspring O 0 2.1881704981296934e-07
. O 0 5.609824142993602e-07

Where O 0 5.335318746801931e-07
the O 0 2.400436187599553e-07
transmitting O 0 5.638494258164428e-06
parent O 0 5.1153595137520824e-08
was O 0 1.702765075606294e-07
male O 0 5.996633944960195e-08
, O 0 3.552509042492602e-08
58 O 0 1.0329894166716258e-06
. O 0 3.376540007593576e-06

3 O 0 1.3539414567276253e-06
% O 0 2.0017100865743487e-08
of O 0 1.7364939708386373e-08
the O 0 8.018627539740919e-09
offspring O 0 1.2477974209446074e-08
were O 0 9.830588787451688e-09
affected O 0 3.0444797793904854e-09
, O 0 5.529392499425967e-10
and O 0 7.262539458707806e-10
in O 0 6.205170266504467e-10
the O 0 1.7593164702844888e-09
case O 0 7.2919141835825485e-09
of O 0 6.270288288590109e-09
a O 0 7.199747020791847e-09
female O 0 8.895185743540424e-08
transmitting O 0 1.18585626296408e-06
parent O 0 1.3035024437613174e-07
, O 0 8.829987763192548e-08
68 O 0 2.5394410840817727e-06
. O 0 4.29009014624171e-06

7 O 0 4.622771029971773e-06
% O 0 1.443652166699394e-07
were O 0 2.929864137968252e-07
affected O 0 6.769527090000338e-07
. O 0 3.161890617775498e-06

Studies O 0 5.775300451205112e-06
on O 0 1.0429008625578717e-06
meiotic O 0 2.0213428797433153e-05
drive O 0 1.140924950959743e-06
in O 0 2.845788742433797e-07
DM B-Disease 1 1.0
have O 0 2.803210286117519e-08
shown O 0 9.743821749452763e-09
increased O 0 4.944676668117154e-09
transmission O 0 5.183610340964151e-08
of O 0 1.8658370404267544e-09
the O 0 6.61685650715782e-10
larger O 0 2.4064901182896392e-09
allele O 0 3.848277074780526e-08
at O 0 4.606012637964341e-08
the O 0 2.401277932051471e-08
DM B-Disease 1 0.9999586343765259
locus O 0 1.2896659029593138e-07
in O 0 1.4880638943282065e-08
non O 0 4.379842721391469e-06
- O 0 5.047904051025398e-05
DM O 1 1.0
heterozygotes O 0 3.71875785276643e-06
for O 0 8.987516508796034e-08
CTGn O 0 5.819484795210883e-05
. O 0 2.383990249654744e-06

This O 0 1.2072821675701562e-07
study O 0 2.4650823604588368e-08
provides O 0 2.298295553870844e-09
further O 0 4.703471390143932e-09
evidence O 0 2.287315759019748e-08
that O 0 1.8099807208571406e-09
the O 0 2.5896200739339292e-08
DM B-Disease 1 1.0
expansion O 0 6.663571383569433e-08
tends O 0 1.7289357501226732e-08
to O 0 9.147796409259001e-10
be O 0 6.871160529442477e-09
transmitted O 0 4.243435824946573e-08
preferentially O 0 1.9168230380728346e-07
. O 0 4.4958576950193674e-07

Diagnosis O 1 0.9999990463256836
of O 1 0.5322695374488831
hemochromatosis B-Disease 1 1.0
. O 0 0.01496405154466629

If O 0 4.832301419810392e-05
untreated O 1 0.9999971389770508
, O 0 1.985937160497997e-05
hemochromatosis B-Disease 1 1.0
can O 0 3.9878777897683904e-05
cause O 0 0.20801138877868652
serious O 1 0.7655142545700073
illness O 0 0.0039194305427372456
and O 0 1.3716690894227668e-08
early B-Disease 0 2.5829314154179883e-07
death I-Disease 0 3.099783612015017e-07
, O 0 7.825420311746711e-10
but O 0 1.89123317007045e-09
the O 0 1.6298047356144707e-08
disease O 0 3.030131949799397e-07
is O 0 1.0418476081852646e-09
still O 0 4.452860302706085e-09
substantially O 0 8.616430591246171e-08
under O 0 3.259089567109186e-07
- O 0 4.263152732164599e-05
diagnosed O 0 3.1873300031293184e-05
. O 0 1.9066546883550473e-06

The O 0 2.4116848180710804e-06
cornerstone O 0 1.4445654414885212e-05
of O 0 5.628033150628653e-08
screening O 0 1.4523847013947488e-08
and O 0 2.6567192890070146e-09
case O 0 6.242269368073039e-09
detection O 0 4.3460385512616995e-08
is O 0 9.096782216388988e-10
the O 0 5.154886739688891e-09
measurement O 0 1.3211638361099176e-07
of O 0 4.128582631324207e-08
serum O 0 1.2082497846677143e-07
transferrin O 0 6.353878347908903e-07
saturation O 0 3.237794032884267e-07
and O 0 2.6286150145438114e-08
the O 0 3.126837100353441e-08
serum O 0 3.1405369327330845e-07
ferritin O 0 6.759625193808461e-06
level O 0 2.4071741790976375e-06
. O 0 5.728547876060475e-07

Once O 0 2.920912947956822e-06
the O 0 1.0017620866165089e-07
diagnosis O 0 3.0439754482358694e-05
is O 0 6.356857706890651e-09
suspected O 0 2.3259656245500082e-07
, O 0 2.8419178121907862e-08
physicians O 0 4.294340527621898e-08
must O 0 4.768794070741933e-08
use O 0 1.6060380403359886e-07
serum O 0 1.4952798892409191e-06
ferritin O 0 0.0002097924443660304
levels O 0 0.0001487644185544923
and O 0 4.292053745302837e-06
hepatic O 1 0.9998732805252075
iron O 0 0.016247160732746124
stores O 0 2.630852691254404e-07
on O 0 5.480991376316524e-07
liver O 0 8.972142495622393e-07
biopsy O 0 1.9807555418083211e-07
specimens O 0 9.802746170350929e-09
to O 0 1.4258008107503883e-09
assess O 0 3.427928874089048e-08
patients O 0 1.6358271404115499e-09
for O 0 8.000459184032138e-10
the O 0 2.4254660502265324e-09
presence O 0 6.982082023654357e-09
of O 0 1.9674602924624196e-07
iron B-Disease 0 0.06688368320465088
overload I-Disease 0 0.00032520631793886423
. O 0 8.838453140924685e-06

Liver O 0 0.1315084546804428
biopsy O 0 0.3406570851802826
is O 0 1.004158711737091e-08
also O 0 5.182635987033279e-10
used O 0 3.637374845766317e-10
to O 0 5.121407187225202e-10
establish O 0 1.738475030599318e-09
the O 0 9.49478384804081e-10
presence O 0 1.0750466072906306e-09
or O 0 3.747346433158327e-09
absence O 0 4.907584738589321e-08
of O 0 4.1338854117611845e-08
cirrhosis B-Disease 0 0.4575965106487274
, O 0 1.2478610367239185e-09
which O 0 5.194937813257638e-10
can O 0 1.1444684089312318e-09
affect O 0 4.457247015920984e-08
prognosis O 0 4.687399268732406e-06
and O 0 8.332492740237285e-08
management O 0 7.27480824025406e-07
. O 0 8.617594744464441e-07

A O 0 2.3994618914002785e-06
DNA O 0 4.043489241212228e-07
- O 0 7.232880250285234e-08
based O 0 1.0838131503376758e-09
test O 0 2.0892969132546568e-08
for O 0 3.1123588151160675e-09
the O 0 2.833971457505413e-08
HFE O 0 1.011381118587451e-05
gene O 0 1.1772138819310385e-08
is O 0 2.0785707877113424e-10
commercially O 0 7.789606182306841e-10
available O 0 5.595243157685559e-10
, O 0 6.800486562763552e-11
but O 0 1.0959442381386353e-10
its O 0 4.907988945812569e-11
place O 0 1.8598644846434809e-09
in O 0 2.9359883968460565e-10
the O 0 1.4806680326273636e-09
diagnosis O 0 2.040016624960117e-06
of O 0 3.286192509222019e-07
hemochromatosis B-Disease 1 1.0
is O 0 2.1876148892374658e-08
still O 0 2.947454369461866e-08
being O 0 8.587521449499036e-08
evaluated O 0 9.913381973092328e-07
. O 0 1.170531390926044e-06

Currently O 0 4.6510271545230353e-07
, O 0 1.3269896292911199e-08
the O 0 5.71005553950954e-09
most O 0 3.3773431273864674e-10
useful O 0 4.6460066904785435e-09
role O 0 1.561235696279084e-09
for O 0 2.0415816259777841e-10
this O 0 9.83725531589208e-11
test O 0 2.703192558684009e-09
is O 0 7.812114150018701e-11
in O 0 1.271594080032301e-10
the O 0 4.617654036920271e-10
detection O 0 7.825920533832686e-08
of O 0 1.0839133324225259e-07
hemochromatosis B-Disease 1 1.0
in O 0 5.1510170351320994e-08
the O 0 3.552461436129306e-08
family O 0 1.5691050680999297e-09
members O 0 9.922512811399997e-10
of O 0 2.454866532275446e-09
patients O 0 8.064791612305555e-10
with O 0 3.637125045585776e-10
a O 0 2.484552341641688e-09
proven O 0 6.376118903972383e-07
case O 0 1.9419535135511978e-07
of O 0 1.4076383081373933e-07
the O 0 5.840218477715098e-07
disease O 0 2.1625777662848122e-05
. O 0 1.5449727470695507e-06

It O 0 9.182224403048167e-08
is O 0 9.899340902563836e-09
crucial O 0 2.2393544441001723e-07
to O 0 1.0128343319593114e-07
diagnose O 1 0.9999996423721313
hemochromatosis B-Disease 1 1.0
before O 1 0.9999969005584717
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 0.00010200838732998818
because O 0 1.8692723813273915e-07
phlebotomy O 0 0.28276801109313965
therapy O 0 6.350770854623988e-05
can O 0 8.123464567688643e-08
avert O 0 4.626153167919256e-05
serious O 1 0.9999971389770508
chronic O 1 1.0
disease O 1 0.9999980926513672
and O 0 1.9548892282728048e-08
can O 0 3.271437565288693e-09
even O 0 1.3345325955427256e-09
lead O 0 4.48213866022229e-09
to O 0 1.8928896228231906e-09
normal O 0 5.8116057743973215e-08
life O 0 1.3057713132980098e-08
expectancy O 0 1.0963969288013686e-08
. O 0 5.505800260152682e-09
. O 0 2.2826965562217083e-07

Prevalence O 0 6.346612644847482e-05
of O 0 7.617283017680165e-07
the O 0 2.5514302137708e-07
I1307K O 0 2.5140864181594225e-06
APC B-Disease 0 1.6091411225716001e-07
gene O 0 1.7816783604018838e-09
variant O 0 1.4273606296910657e-08
in O 0 9.153293678565433e-10
Israeli O 0 2.4035461620997012e-08
Jews O 0 3.3729028459106303e-09
of O 0 5.761943144833026e-10
differing O 0 7.166546800441154e-10
ethnic O 0 7.734620166566231e-10
origin O 0 7.883175889844551e-09
and O 0 2.4755566485623604e-08
risk O 0 2.8284689506108407e-06
for O 0 0.13461093604564667
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9838369488716125

BACKGROUND O 0 1.8835749870049767e-05
& O 0 5.8732566685648635e-06
AIMS O 0 6.341619496197382e-07
Israeli O 0 3.323527550946892e-07
Jews O 0 5.839093830672937e-08
of O 0 3.848622043278738e-08
European O 0 1.583036777219604e-07
birth O 0 6.172772515355973e-08
, O 0 2.8859983292051083e-09
i O 0 8.64762661478835e-09
. O 0 1.4154176719571865e-09
e O 0 5.025169613759317e-09
. O 0 1.3850631752632125e-09
, O 0 2.808994592484737e-09
Ashkenazim O 0 8.526429837729665e-07
, O 0 3.937175030443996e-09
have O 0 4.441417456035879e-09
the O 0 8.405761064977924e-08
highest O 1 0.9999973773956299
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 7.993631152203307e-05
of O 0 7.827085113376597e-08
any O 0 1.0042430886869624e-08
Israeli O 0 1.0015584166467306e-06
ethnic O 0 1.2862169285199343e-07
group O 0 2.4559994926676154e-07
. O 0 1.9912854440917727e-06

The O 0 3.6736421407113085e-06
I1307K O 0 1.5508361684624106e-05
APC B-Disease 0 1.1243962489970727e-06
gene O 0 1.4571184259182246e-08
variant O 0 1.0224635360600587e-07
was O 0 7.413136415834742e-08
found O 0 5.601941577282332e-09
in O 0 1.3247540842087346e-08
6 O 0 3.2619177545711864e-06
. O 0 2.72994634542556e-06

1 O 0 7.315535412999452e-07
% O 0 6.311287936711096e-09
of O 0 3.6715872564485608e-09
American O 0 2.878153715357712e-09
Jews O 0 1.4148623606047295e-08
, O 0 1.3578824731297345e-09
28 O 0 1.4299875061851708e-08
% O 0 1.3770263818102535e-09
of O 0 2.34488748418471e-08
their O 0 2.0628378479159437e-05
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 6.743695394106908e-06
, O 0 1.5863026447959783e-09
but O 0 1.1364201801811191e-09
not O 0 8.02030608593185e-10
in O 0 1.3750159899572623e-09
non O 0 8.8076333781828e-08
- O 0 6.486504844360752e-08
Jews O 0 1.9262861883362348e-07
. O 0 1.0058179213956464e-06

We O 0 2.619914084789343e-06
assessed O 0 3.1187894364848034e-06
the O 0 5.027396454693189e-08
I1307K O 0 3.6731654518007417e-07
prevalence O 0 3.161553863151312e-08
in O 0 4.159150246429988e-10
Israeli O 0 2.1176374431775002e-08
Jews O 0 6.189523116262308e-09
of O 0 6.305737043632575e-10
differing O 0 1.5675675202331263e-09
ethnic O 0 1.8664494394471376e-09
origin O 0 1.3454054759165501e-08
and O 0 4.435857903217766e-08
risk O 0 5.50998083781451e-06
for O 0 0.2980164587497711
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.989087700843811

METHODS O 0 4.340564828453353e-06
DNA O 0 1.275243874943044e-07
samples O 0 7.533076384902415e-09
from O 0 3.330010711621867e-09
500 O 0 6.664027107916581e-09
unrelated O 0 1.0575043063454359e-08
Jews O 0 1.7857958667377716e-08
of O 0 1.0972504682627005e-08
European O 0 6.360777149438945e-08
or O 0 1.3442409851904813e-08
non O 0 1.426920164249168e-07
- O 0 8.137976514888123e-09
European O 0 2.5744404386074393e-09
origin O 0 1.0831228136609639e-09
, O 0 1.0988494836272622e-10
with O 0 2.6592006374670518e-11
or O 0 2.822656275380808e-10
without O 0 8.753447411358195e-10
a O 0 4.5023662575971457e-10
personal O 0 5.127303026597474e-09
and O 0 2.522645026203918e-08
/ O 0 3.1230099466483807e-06
or O 0 2.3512875202413852e-08
family O 0 1.3958011413350846e-09
history O 0 4.443307499713001e-09
of O 0 1.2590985143390299e-08
neoplasia B-Disease 0 5.227204383118078e-06
, O 0 1.2778194502516271e-08
were O 0 3.929989489392938e-08
examined O 0 1.3644704210946657e-07
for O 0 4.3268801874774e-09
the O 0 1.880694533440419e-08
I1307K O 0 1.5711084699887579e-07
variant O 0 1.1506715225095832e-07
by O 0 5.893795673728164e-09
the O 0 1.4340436393922573e-08
allele O 0 2.1414091122551326e-07
- O 0 5.855712004176894e-08
specific O 0 1.1731612126197888e-08
oligonucleotide O 0 5.890303214073356e-07
( O 0 1.435910323976941e-08
ASO O 0 3.760490699278307e-06
) O 0 1.1407859545897736e-08
method O 0 2.4417533950327197e-07
. O 0 6.609180900341016e-07

RESULTS O 0 5.530480848392472e-06
In O 0 1.349038143416692e-07
persons O 0 7.92298848750761e-08
at O 0 2.3771447388298839e-07
average O 0 1.4287826033410056e-08
risk O 0 2.3759636746945034e-07
for O 0 7.019420445431024e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.1861101256727125e-07
I1307K O 0 3.1534634103991266e-07
was O 0 2.2437596669533377e-08
found O 0 1.146782446781458e-09
in O 0 5.5245243935075905e-09
5 O 0 4.797577730641933e-07
. O 0 1.44683485814312e-06

0 O 0 7.761403821859858e-07
% O 0 1.53328691965271e-08
of O 0 2.0560422697712966e-08
120 O 0 3.849965324320692e-08
European O 0 1.1826707435602657e-07
and O 0 4.5934140047165783e-08
1 O 0 7.831488346710103e-07
. O 0 6.875173994558281e-07

6 O 0 6.838125500507886e-06
% O 0 4.1541593276406275e-08
of O 0 4.321389468486814e-08
188 O 0 6.448953371318566e-08
non O 0 1.4417645388675737e-07
- O 0 5.3094417751253786e-08
European O 0 2.476916982629973e-08
Jews O 0 3.433608597447346e-08
( O 0 3.951499571996919e-09
P O 0 2.974200867811305e-07
= O 0 4.1729169453219583e-08
0 O 0 1.6431044969067443e-08
. O 0 3.4812515092852436e-09
08 O 0 2.5803564085435937e-07
) O 0 2.0208178241887254e-08
. O 0 7.007339490883169e-07

It O 0 1.7935451523953816e-07
occurred O 0 1.6855851754371542e-06
in O 0 3.241810375698151e-08
15 O 0 5.842012456014345e-07
. O 0 1.9722724573512096e-06

4 O 0 2.6609252472553635e-06
% O 0 3.39772476820599e-08
of O 0 6.22339371147973e-08
52 O 0 1.571916357079317e-07
Ashkenazi O 0 9.957326483345241e-07
Israelis O 0 6.725262551299238e-07
with O 0 4.35024318790056e-08
familial O 0 3.1420668165083043e-06
cancer B-Disease 0 8.150457688316237e-06
( O 0 1.1649827058590745e-07
P O 0 4.9687278078636155e-05
= O 0 5.468481276693637e-07
0 O 0 5.415793324914375e-08
. O 0 3.213288080061716e-09
02 O 0 9.334475237210427e-08
) O 0 1.8924085909421962e-10
and O 0 5.459450669320631e-10
was O 0 4.302750600260197e-09
not O 0 4.2285649981543827e-10
detected O 0 2.610466731667316e-09
in O 0 1.183598330456448e-09
51 O 0 1.2079179612101143e-07
non O 0 1.8884966266341507e-06
- O 0 4.6709993739568745e-07
European O 0 5.131199714014656e-07
Jews O 0 1.6905197242067516e-07
at O 0 1.4516845681100676e-07
increased O 0 2.3581142372108843e-08
cancer B-Disease 0 3.7268628716446983e-07
risk O 0 2.771562037651165e-07
. O 0 2.8092588308936683e-06

Colorectal B-Disease 1 0.9999996423721313
neoplasia I-Disease 1 0.9995601773262024
occurred O 0 0.0005723012727685273
personally O 0 2.930341622686683e-07
or O 0 7.489794562332008e-09
in O 0 2.3420927419692816e-09
the O 0 4.934181507820767e-09
families O 0 4.839629252906263e-10
of O 0 3.389140967868798e-09
13 O 0 4.6892942862086784e-08
of O 0 7.128245727017202e-08
20 O 0 2.288424667540312e-07
Ashkenazi O 0 7.549786005256465e-07
I1307K O 0 1.8397989265395154e-07
carriers O 0 2.7183728601443136e-09
, O 0 1.878313282688282e-09
8 O 0 3.980002460934884e-08
of O 0 1.3690971023549992e-08
whom O 0 5.0723091504778495e-08
also O 0 5.700022231991397e-09
had O 0 8.978363830181024e-09
a O 0 2.2006665378881962e-09
personal O 0 2.8619245640015833e-08
or O 0 2.2909484087563214e-08
family O 0 3.7470822000784665e-09
history O 0 2.0363838615367058e-08
of O 0 2.586165521734074e-07
noncolonic O 0 5.7504996220814064e-05
neoplasia B-Disease 0 0.006635864265263081
. O 0 0.00010525739344302565

CONCLUSIONS O 0 2.843833681254182e-05
The O 0 7.962094628055638e-07
I1307K O 0 3.234675659768982e-06
APC O 0 6.276601993704389e-07
variant O 0 4.228956811402895e-07
may O 0 3.140482363050978e-08
represent O 0 2.072096805250112e-08
a O 0 2.156917844331474e-08
susceptibility O 0 6.36165111700393e-07
gene O 0 2.3226472478654614e-07
for O 0 4.538237305951043e-07
colorectal B-Disease 1 1.0
, I-Disease 0 8.08963136478269e-07
or I-Disease 0 1.5054432367378467e-07
other I-Disease 0 3.4136511395388425e-09
, I-Disease 0 3.1242246567586562e-09
cancers I-Disease 0 1.5124643937269866e-07
in O 0 2.2313477732183173e-09
Ashkenazi O 0 2.6875969183493e-07
Jews O 0 5.6657945890492556e-08
, O 0 2.8934170615002586e-09
and O 0 4.707743972431899e-09
partially O 0 1.0156161067698122e-07
explains O 0 1.1509245112506505e-08
the O 0 9.677035173183413e-09
higher O 0 8.60306897720875e-07
incidence O 1 0.733820378780365
of O 1 0.9999490976333618
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.8360244047908054e-07
European O 0 3.0978055747254984e-06
Israelis O 0 4.823654307983816e-06
. O 0 1.0015135103458306e-06

Systematic O 0 2.1684095372620504e-06
analysis O 0 2.841257185082213e-07
of O 0 6.815707820351236e-07
coproporphyrinogen O 0 0.00012207921827211976
oxidase O 0 4.759469811688177e-05
gene O 0 3.955260126531357e-06
defects O 0 0.00010259546979796141
in O 0 3.1943588396643463e-07
hereditary B-Disease 1 0.9999997615814209
coproporphyria I-Disease 1 0.9969462752342224
and O 0 3.410787257962511e-06
mutation O 0 1.153150265054137e-06
update O 0 1.3817750186717603e-05
. O 0 7.881885721872095e-06

Hereditary B-Disease 1 0.9999998807907104
coproporphyria I-Disease 1 0.9999955892562866
( O 0 5.099897407490062e-06
HC B-Disease 1 0.9999998807907104
) O 0 1.0895242752440026e-07
is O 0 4.379203222271144e-09
an O 0 7.405783986058623e-09
acute O 1 0.9999973773956299
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.002980111399665475
autosomal O 1 1.0
dominant O 1 0.9999521970748901
inheritance O 0 2.6661997253540903e-05
caused O 0 3.222490363441466e-07
by O 0 8.973022325164948e-09
deficient B-Disease 0 1.4428842121105845e-07
activity I-Disease 0 6.886408954187573e-08
of I-Disease 0 9.749179241680395e-08
coproporphyrinogen I-Disease 0 3.995956376456888e-06
III I-Disease 0 0.0024964308831840754
oxidase I-Disease 0 1.7374253502566717e-06
( O 0 2.9129321177379097e-08
CPO O 0 3.573597950889962e-06
) O 0 5.1059821259968885e-08
. O 0 9.96875769487815e-07

Clinical O 0 0.0007878788164816797
manifestations O 0 0.06637657433748245
of O 0 5.868005246156827e-06
the O 0 2.0848640360782156e-06
disease O 0 0.005617896560579538
are O 0 1.168796504025238e-09
characterized O 0 5.684366310987343e-09
by O 0 1.3644353424879796e-09
acute O 0 0.000117740775749553
attacks O 0 5.020391199650476e-06
of O 1 0.9999991655349731
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 2.7359229193280044e-07
precipitated O 0 2.017423810229957e-07
by O 0 2.004632015939478e-09
drugs O 0 2.019014821996734e-08
, O 0 1.4337016907006728e-08
fasting O 0 3.374875404915656e-06
, O 0 5.14981870480824e-08
cyclical O 0 1.2083264664397575e-05
hormonal O 0 4.931535386276664e-06
changes O 0 3.63024724947536e-07
, O 0 1.6273267533506441e-07
or O 0 1.8869679479394108e-05
infectious B-Disease 0 0.3912246823310852
diseases I-Disease 0 0.16284973919391632
. O 0 8.642939064884558e-06

Skin O 1 1.0
photosensitivity O 1 0.9999312162399292
may O 0 1.0622989975672681e-05
also O 0 3.838322015781159e-08
be O 0 2.568399182223402e-08
present O 0 6.080713177425423e-08
. O 0 1.1356102049830952e-06

The O 0 1.2516301239884342e-06
seven O 0 5.585310418609879e-07
exons O 0 1.437730816178373e-06
, O 0 2.0945277512396387e-08
the O 0 5.5182930225328164e-08
exon O 0 2.8715598432427214e-07
/ O 0 2.504611700260284e-07
intron O 0 5.86053907625228e-08
boundaries O 0 1.3560455869310317e-08
and O 0 1.4319410102103802e-09
part O 0 1.2452765485448936e-09
of O 0 1.0181138598852613e-08
3 O 0 1.1940230137952312e-07
noncoding O 0 3.7265568408884064e-08
sequence O 0 5.582997175679338e-09
of O 0 8.792674144331158e-09
the O 0 2.00709688868983e-08
CPO O 0 1.1408357067921315e-06
gene O 0 1.3223810491069798e-08
were O 0 2.9485340391488535e-08
systematically O 0 6.68067556830465e-08
analyzed O 0 2.329796799926953e-08
by O 0 1.3887216931962598e-09
an O 0 2.6538020669875095e-09
exon O 0 1.079419860161579e-07
- O 0 1.5669830588649347e-07
by O 0 6.873064251067262e-08
- O 0 1.6457930541946553e-05
exon O 0 1.0433253919472918e-05
denaturing O 0 5.757692997576669e-05
gradient O 0 5.5418845477106515e-06
gel O 0 1.3328082104635541e-06
electrophoresis O 0 3.78611218820879e-07
( O 0 1.423950735102153e-08
DGGE O 0 1.4900798532835324e-06
) O 0 1.13264841949956e-09
strategy O 0 4.024190314311227e-09
followed O 0 8.217552194267341e-10
by O 0 1.8180727756611503e-10
direct O 0 7.903677712306489e-10
sequencing O 0 5.4425588480455644e-09
in O 0 1.6871102292981277e-09
seven O 0 2.6314944889804792e-08
unrelated O 0 1.374348670424297e-07
heterozygous O 0 5.265300728751754e-07
HC B-Disease 0 0.002160364994779229
patients O 0 2.0653102339451834e-08
from O 0 5.6278479654281455e-09
France O 0 4.047188895128784e-07
, O 0 8.765062453619521e-09
Holland O 0 1.7217887204878934e-07
, O 0 2.178927038798406e-09
and O 0 2.0930450705947123e-09
Czech O 0 1.6082896081570652e-07
Republic O 0 1.7841756516645546e-06
. O 0 4.443696980160894e-06

Seven O 0 7.320232384699921e-07
novel O 0 2.8549461461579995e-08
mutations O 0 1.5405390740852454e-08
and O 0 2.090403850019129e-09
two O 0 1.2315999331491412e-09
new O 0 1.009863215273299e-08
polymorphisms O 0 5.055339258319691e-08
were O 0 1.025614082550419e-07
detected O 0 1.009482048175414e-06
. O 0 1.8623202322487487e-06

Among O 0 9.670451817100911e-08
these O 0 8.582147437152798e-09
mutations O 0 1.3477992943933259e-08
two O 0 2.087077399792747e-09
are O 0 2.601529880408293e-09
missense O 0 2.986940330629295e-07
( O 0 1.2552690442646508e-08
G197W O 0 5.066672201792244e-07
, O 0 5.031931316068494e-09
W427R O 0 1.658454493735917e-07
) O 0 1.2637992874431347e-09
, O 0 4.1002642947596257e-10
two O 0 6.062109703108831e-10
are O 0 7.23622717302419e-10
nonsense O 0 1.0127454430630678e-07
( O 0 2.9688933533833506e-09
Q306X O 0 6.188167844811687e-08
, O 0 1.3570591317346725e-09
Q385X O 0 4.268926545591967e-08
) O 0 6.194657564684292e-10
, O 0 4.267244890776567e-10
two O 0 5.187551499474807e-10
are O 0 4.4480621963494116e-10
small O 0 2.581422409164702e-09
deletions O 0 8.549083929665358e-08
( O 0 9.129864864121373e-09
662de14bp O 0 2.801642153826833e-07
; O 0 1.1478269001941044e-08
1168del3bp O 0 2.011926198974834e-06
removing O 0 5.714982194149343e-07
a O 0 7.73091102246326e-08
glycine O 0 2.508630245756649e-07
at O 0 1.8507185473026766e-07
position O 0 1.0422898810702463e-07
390 O 0 4.1217923296699155e-08
) O 0 4.280050758254106e-10
, O 0 2.4278995480742083e-10
and O 0 4.881998694195033e-10
one O 0 9.148808377545947e-10
is O 0 7.954552572186913e-10
a O 0 4.085013216581501e-09
splicing O 0 1.727308216459278e-07
mutation O 0 9.251770194396158e-08
( O 0 2.2261074761331656e-08
IVS1 O 0 6.45344152871985e-06
- O 0 7.319674182326708e-07
15c O 0 1.8986110035257298e-06
- O 0 3.838446787085559e-07
- O 0 1.0383649851064547e-07
> O 0 9.155484548273307e-08
g O 0 2.348530969698004e-08
) O 0 8.024819697638463e-10
which O 0 4.663983643737879e-10
creates O 0 2.5817079585266356e-09
a O 0 1.0073695211332279e-09
new O 0 5.303730787886707e-09
acceptor O 0 2.985072100614161e-08
splice O 0 2.248104919999605e-06
site O 0 3.9889138747639663e-07
. O 0 8.71821214332158e-07

The O 0 1.169197162198543e-06
pathological O 0 1.9439041807345347e-06
significance O 0 3.5834671052725753e-07
of O 0 1.0183239140815203e-07
the O 0 2.4882860216735025e-08
point O 0 1.1987945924829546e-07
mutations O 0 4.425429622756383e-08
G197W O 0 5.705463195226912e-07
, O 0 1.0972965647226829e-08
W427R O 0 3.781038913075463e-07
, O 0 4.706864231707186e-09
and O 0 4.4498120743696745e-09
the O 0 5.4769131452303554e-09
in O 0 1.2779583613564682e-08
- O 0 1.2710695784790005e-07
frame O 0 6.1365227566057e-07
deletion O 0 8.517215377423781e-08
390delGly O 0 1.1579788861126872e-07
were O 0 5.567907024328633e-09
assessed O 0 2.2275685296335723e-08
by O 0 3.4165481554992994e-10
their O 0 1.2954137762477558e-09
respective O 0 1.6261500590530886e-08
expression O 0 9.78893854863827e-09
in O 0 3.30103477885757e-09
a O 0 2.1231609803606943e-09
prokaryotic O 0 5.230255339938594e-09
system O 0 2.3769568535669805e-09
using O 0 1.5550986054435612e-09
site O 0 1.7306083677226525e-08
- O 0 4.107516815565759e-08
directed O 0 2.940710253085399e-08
mutagenesis O 0 7.551459020760376e-06
. O 0 5.241331109573366e-06

These O 0 4.8127457574764776e-08
mutations O 0 7.243565391945594e-08
resulted O 0 3.477424215247993e-08
in O 0 3.5622780281130417e-09
the O 0 6.83720946526023e-09
absence O 0 1.0980862441556383e-07
or O 0 7.960536230200432e-09
a O 0 1.975428709499738e-09
dramatic O 0 2.6739542136056116e-08
decrease O 0 3.563414452401048e-08
of O 0 3.467936551260209e-07
CPO O 0 1.3504735761671327e-05
activity O 0 2.3191664695332292e-06
. O 0 2.5529300273774425e-06

The O 0 3.828429839813907e-07
two O 0 3.0020125052487856e-08
polymorphisms O 0 5.810674608142108e-08
were O 0 7.45644079813701e-09
localized O 0 4.530565789195862e-08
in O 0 6.432686383561759e-09
noncoding O 0 4.776212847446004e-08
part O 0 4.614082449450052e-09
of O 0 7.787649636270544e-09
the O 0 5.4453930253828275e-09
gene O 0 1.0272146466761e-09
1 O 0 1.843129915357622e-08
) O 0 7.965741954940597e-10
a O 0 4.9516231115376286e-09
C O 0 9.303225851908792e-07
/ O 0 3.009566285072651e-07
G O 0 1.4886380483858375e-07
polymorphism O 0 1.429583917911259e-08
in O 0 1.530031656926667e-09
the O 0 1.132953553195648e-08
promotor O 0 5.173341833142331e-06
region O 0 8.446905752634848e-08
, O 0 2.8469308688272577e-08
142 O 0 2.2718420211731427e-07
bp O 0 2.341136422501222e-07
upstream O 0 3.7700601751566865e-08
from O 0 5.513471457163632e-09
the O 0 2.1650047088428437e-08
transcriptional O 0 2.370235705484447e-07
initiation O 0 1.468208381538716e-07
site O 0 5.954703041766152e-08
( O 0 8.895233882810771e-09
- O 0 6.573075950200291e-08
142C O 0 9.772606972546782e-07
/ O 0 4.468747931696271e-07
G O 0 1.934504325618036e-07
) O 0 2.1345138989659063e-09
, O 0 8.422315067591057e-10
and O 0 1.5048833290620678e-09
2 O 0 3.1787685372819396e-08
) O 0 1.3619729788416635e-09
a O 0 4.41760139580083e-09
6 O 0 2.2546956301994214e-07
bp O 0 1.2184952424831863e-07
deletion O 0 2.4532528897225347e-08
polymorphism O 0 1.5841839839936256e-08
in O 0 1.2618553979493186e-09
the O 0 2.7485809184213394e-09
3 O 0 2.2823563483598264e-08
noncoding O 0 5.508985978508463e-08
part O 0 4.293167599200842e-09
of O 0 3.844747809012006e-08
the O 0 8.76367920454868e-08
CPO O 0 4.401557362143649e-06
gene O 0 1.4273068416059687e-07
, O 0 9.564753611357446e-08
574 O 0 1.2071801620550104e-06
bp O 0 2.3733865361919015e-07
downstream O 0 5.3939999133945093e-08
of O 0 2.5064247566319864e-08
the O 0 8.805042028825483e-09
last O 0 1.0008660566995786e-08
base O 0 4.287005861414173e-09
of O 0 3.4862750464270675e-09
the O 0 9.698358560683573e-09
normal O 0 1.1770975305580578e-07
termination O 0 1.5119697138743504e-07
codon O 0 3.3880638738992275e-07
( O 0 2.342974170232992e-08
+ O 0 5.691122169082519e-07
574 O 0 9.248468018085987e-07
delATTCTT O 0 2.56904172601935e-06
) O 0 1.0740269118514334e-07
. O 0 1.3094809219182935e-06

Five O 0 8.084548426268157e-06
intragenic O 0 3.400940840947442e-05
dimorphisms O 0 6.073960321373306e-06
are O 0 7.575452265484728e-09
now O 0 1.943942118387554e-09
well O 0 7.202833884889515e-10
characterized O 0 2.347656513634888e-09
and O 0 8.55261417243014e-10
the O 0 1.2123507753258878e-09
high O 0 1.4026661609989333e-08
degree O 0 2.9335172513356156e-08
of O 0 3.814338178642629e-09
allelic O 0 1.9836117814975296e-07
heterogeneity O 0 1.5744818426810525e-07
in O 0 1.8413800262351288e-08
HC B-Disease 0 0.02021302655339241
is O 0 3.83527565261943e-09
demonstrated O 0 1.2994036069358117e-08
with O 0 3.2021693630035486e-10
seven O 0 6.493678927910196e-10
new O 0 2.4898119677096986e-10
different O 0 1.9645160498349412e-10
mutations O 0 7.126825796177627e-10
making O 0 2.836018087037928e-10
a O 0 2.0438725711890982e-10
total O 0 5.577842632220609e-10
of O 0 8.23880608180616e-09
nineteen O 0 1.367376967209566e-06
CPO O 0 6.231966108316556e-05
gene B-Disease 0 4.791469564224826e-06
defects I-Disease 0 1.5701059965067543e-05
reported O 0 7.605191143511547e-08
so O 0 1.2434473006806002e-08
far O 0 1.443288244473706e-08
. O 0 4.7291205618194e-08
. O 0 1.3347034837352112e-06

Coincidence O 0 1.6088009942905046e-05
of O 0 4.612606403497921e-07
two O 0 2.1394917837369576e-08
novel O 0 7.193064988086917e-08
arylsulfatase O 0 1.427791630703723e-06
A O 0 7.82296538659466e-08
alleles O 0 2.5487403831903066e-07
and O 0 7.357972009458535e-08
mutation O 0 3.3647191344243765e-07
459 O 0 7.714735943409323e-07
+ O 0 2.1981818463245872e-06
1G O 0 2.5170680601149797e-05
> O 0 8.151648671628209e-07
A O 0 5.10775493012261e-08
within O 0 1.6759498677743068e-08
a O 0 4.887870996839183e-09
family O 0 4.278608578545118e-09
with O 0 1.6251920698096e-08
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 0.9999994039535522
: O 0 5.183172557821081e-09
molecular O 0 1.7677736607879524e-08
basis O 0 1.172778674174424e-08
of O 0 2.5265213920988572e-08
phenotypic O 0 1.0021775779023301e-05
heterogeneity O 0 3.302680124761537e-05
. O 0 1.7570710042491555e-05

In O 0 2.1710674502628535e-07
a O 0 4.833453459696102e-08
family O 0 4.363944761109906e-09
with O 0 1.100647684104672e-09
three O 0 3.2452112108671827e-09
siblings O 0 1.1261541921214757e-08
, O 0 3.368298140404846e-10
one O 0 2.007761040756506e-10
developed O 0 4.028191114002766e-09
classical O 0 3.8066949059611943e-07
late O 0 0.0029306376818567514
infantile O 1 0.999998927116394
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 2.4200610937441525e-07
MLD B-Disease 1 0.9999997615814209
) O 0 1.761059920113439e-08
, O 0 7.42640748896406e-09
fatal O 0 4.2732929728117597e-07
at O 0 1.5313293033614173e-07
age O 0 9.484945451276872e-08
5 O 0 8.135186391200477e-08
years O 0 4.5902237566508575e-09
, O 0 1.1138787670006423e-09
with O 0 1.7908706739788727e-09
deficient O 0 5.292662876854592e-07
arylsulfatase O 0 3.2583484426140785e-06
A O 0 2.5305442363787733e-07
( O 0 1.8189243888855344e-08
ARSA O 0 2.2894471385370707e-06
) O 0 1.0653060655840818e-09
activity O 0 4.435339207020661e-09
and O 0 7.033565396774577e-10
increased O 0 1.0834478203491926e-08
galactosylsulfatide O 0 3.0974038054409903e-06
( O 0 8.639667470333734e-08
GS O 1 0.9998416900634766
) O 0 5.3928477683484743e-08
excretion O 0 5.968256573396502e-07
. O 0 4.838453264710552e-07

The O 0 5.59149270884518e-07
two O 0 4.0911285026368205e-08
other O 0 8.810368434808424e-09
siblings O 0 8.492445147112448e-08
, O 0 2.6409914255509648e-09
apparently O 0 4.3260900639552347e-08
healthy O 0 2.619555949934238e-08
at O 0 1.1982595538029273e-07
12 O 0 3.1998279581557654e-08
( O 0 1.8303594195856476e-09
1 O 0 5.380888268291528e-08
/ O 0 3.8117800471582086e-08
2 O 0 2.027474010901642e-08
) O 0 2.800941423242165e-10
and O 0 2.0377922960168604e-10
15 O 0 1.3772418760993332e-09
years O 0 5.331416974563297e-10
, O 0 2.2715010428164817e-10
respectively O 0 1.6517037737528995e-09
, O 0 1.7691142994991083e-10
and O 0 2.9046734462134793e-10
their O 0 1.0002472183856526e-09
father O 0 1.4214325716466192e-08
, O 0 2.452615444070716e-09
apparently O 0 1.2663914361610296e-08
healthy O 0 5.5825495337558095e-09
as O 0 1.1691421164528037e-09
well O 0 1.905179569661186e-09
, O 0 3.896059030950028e-09
presented O 0 2.72626238029261e-07
ARSA O 0 3.9644706703256816e-05
and O 0 1.2481049793677812e-07
GS O 1 0.9999902248382568
values O 0 1.3605430559948672e-08
within O 0 5.378997247618145e-09
the O 0 2.0623489582760612e-09
range O 0 6.885253611699227e-08
of O 0 2.314046696483274e-07
MLD B-Disease 1 1.0
patients O 0 5.368452775655896e-07
. O 0 1.487465965510637e-06

Mutation O 0 1.2610015573955025e-06
screening O 0 1.4752936294826213e-07
and O 0 1.2662368931160017e-08
sequence O 0 1.1339956529354822e-08
analysis O 0 1.3804983822751637e-08
disclosed O 0 5.439105876803296e-08
the O 0 2.80642398209352e-09
involvement O 0 1.0243468295811908e-08
of O 0 1.680344574594983e-08
three O 0 6.7959557981112084e-09
different O 0 2.451110781009902e-08
ARSA O 0 8.54189602250699e-06
mutations O 0 3.5035750300949076e-08
being O 0 1.5761248306489506e-08
the O 0 2.0440060755078093e-09
molecular O 0 2.2515147080071074e-08
basis O 0 3.1617890527968484e-08
of O 0 4.0086181485321504e-08
intrafamilial O 0 4.572436409944203e-06
phenotypic O 0 2.1417927200673148e-05
heterogeneity O 0 2.8589936846401542e-05
. O 0 1.1380494470358826e-05

The O 0 1.898989467008505e-06
late O 0 0.000651561829727143
infantile O 0 0.03947313874959946
patient O 0 1.7498891224931867e-07
inherited O 0 7.229334642033791e-07
from O 0 3.1168337244480426e-08
his O 0 1.9835172793136735e-07
mother O 0 4.231917927199902e-08
the O 0 3.556563044071481e-08
frequent O 0 1.708861496751979e-08
0 O 0 1.0418084457342047e-06
- O 0 6.076690510781191e-07
type O 0 1.0658471865099273e-06
mutation O 0 5.839572736476839e-07
459 O 0 6.923958153493004e-07
+ O 0 4.181653707746591e-07
1G O 0 1.8731749378275708e-06
> O 0 1.0626506252719992e-07
A O 0 1.3236654439197082e-08
, O 0 5.627866506152657e-10
and O 0 5.278779635631281e-10
from O 0 3.1892349872109094e-10
his O 0 1.4401966286214929e-09
father O 0 5.954904569449582e-09
a O 0 7.478684893591492e-10
novel O 0 2.331983051107045e-09
, O 0 2.454342284963218e-09
single O 0 2.1586545884133557e-08
basepair O 0 1.6728859009162989e-06
microdeletion O 0 2.247273414468509e-06
of O 0 2.1384785497957637e-07
guanine O 0 4.976583909410692e-07
at O 0 4.449594257494027e-07
nucleotide O 0 4.695317556979717e-08
7 O 0 7.501778753749022e-08
in O 0 7.665831525116573e-09
exon O 0 9.080304153030738e-08
1 O 0 1.1885514794585106e-07
( O 0 7.703030213690454e-09
7delG O 0 6.878282761135779e-07
) O 0 2.374538432547979e-08
. O 0 3.7352387494138384e-07

The O 0 8.213099818021874e-07
two O 0 1.384776453505765e-07
clinically O 0 3.286628270871006e-05
unaffected O 0 9.321858556177176e-07
siblings O 0 3.153568570724019e-07
carried O 0 7.432588944311647e-08
the O 0 4.521207941365901e-08
maternal O 0 4.357563909707096e-07
mutation O 0 2.8682808306257357e-07
459 O 0 7.945050697344413e-07
+ O 0 2.485900949977804e-06
1G O 0 2.3635193429072388e-05
> O 0 7.569604463242285e-07
A O 0 4.146623311385156e-08
and O 0 7.074780761229249e-09
, O 0 1.3299105150466062e-09
on O 0 6.197177437883283e-09
their O 0 1.6493364451974912e-09
paternal O 0 1.7949716379916936e-08
allele O 0 4.771969486228045e-08
, O 0 1.8067627394202646e-09
a O 0 1.6745845821120042e-09
novel O 0 1.3572410750839481e-08
cytosine O 0 1.4405303261355584e-07
to O 0 1.2418876593756067e-08
thymidine O 0 2.3442200927092927e-06
transition O 0 2.0263662463548826e-06
at O 0 1.165115463663824e-06
nucleotide O 0 7.68020470331976e-07
2435 O 0 1.1222387001907919e-05
in O 0 3.467145504032487e-08
exon O 0 2.1594746613118332e-07
8 O 0 1.2251065584223397e-07
, O 0 1.4822448823892387e-09
resulting O 0 2.8820377195870606e-09
in O 0 1.2835077445316756e-09
substitution O 0 1.6023106397256015e-08
of O 0 3.5982946400281435e-08
alanine O 0 1.7636304505685985e-07
464 O 0 1.418337660652469e-07
by O 0 4.7885453824392243e-08
valine O 0 1.9652656192192808e-05
( O 0 1.0754331469797762e-07
A464V O 0 7.268114131875336e-06
) O 0 1.8341755492201628e-07
. O 0 2.427236495350371e-06

The O 0 2.23979964175669e-06
fathers O 0 1.4941680319680017e-06
genotype O 0 9.06790887711395e-07
thus O 0 2.129022362851174e-07
was O 0 1.13301825876988e-06
7delG O 0 9.447907359572127e-06
/ O 0 1.0432935596327297e-05
A464V O 0 4.6760069380979985e-05
. O 0 5.370980034058448e-06

Mutation O 0 4.608095878211316e-06
A464V O 0 5.2885079639963806e-06
was O 0 8.868606471423846e-08
not O 0 1.31425359484183e-09
found O 0 1.64896218901589e-09
in O 0 2.306709934174478e-09
18 O 0 3.1491174468101235e-07
unrelated O 0 6.131776899565011e-06
MLD B-Disease 1 1.0
patients O 0 1.1622915963016567e-07
and O 0 7.454083572611125e-08
50 O 0 1.5860862845329393e-07
controls O 0 1.3844030490872683e-06
. O 0 3.783108923016698e-06

A464V O 0 1.299287032452412e-05
, O 0 1.5693332855448716e-08
although O 0 1.4072887744021045e-08
clearly O 0 6.671024266324821e-08
modifying O 0 1.2341836281848373e-06
ARSA O 0 0.0002651395625434816
and O 0 1.0278206445946125e-06
GS O 1 1.0
levels O 0 3.4294140505153337e-07
, O 0 1.1688165990619837e-09
apparently O 0 5.19303844370711e-09
bears O 0 6.905293670200763e-09
little O 0 9.754266283579227e-10
significance O 0 7.610557517523375e-09
for O 0 5.321277862790907e-10
clinical O 0 2.3704114227030004e-08
manifestation O 0 3.0958187835494755e-07
of O 0 9.009113455249462e-07
MLD B-Disease 1 1.0
, O 0 1.708142178813432e-07
mimicking O 0 7.514430535593419e-07
the O 0 1.4700579242798995e-07
frequent O 0 1.0473212341821636e-06
ARSA O 0 0.00048059289110824466
pseudodeficiency O 0 0.00018903685850091279
allele O 0 9.413099178345874e-05
. O 0 2.5011271645780653e-05

Our O 0 2.110638888552785e-06
results O 0 2.0908761655391572e-07
demonstrate O 0 2.108593122329694e-08
that O 0 2.4297294731745467e-10
in O 0 2.0654146448695343e-10
certain O 0 1.6027499327719852e-09
genetic O 0 2.295712562272456e-07
conditions O 0 4.684579380409559e-06
MLD B-Disease 1 1.0
- O 0 0.05471860244870186
like O 0 1.7491282733317348e-07
ARSA O 0 0.0025765991304069757
and O 0 3.8149082115523925e-07
GS O 1 0.9999996423721313
values O 0 4.878752513093332e-09
need O 0 6.500543991982966e-10
not O 0 8.691885405864852e-11
be O 0 3.988479546634949e-10
paralleled O 0 3.546049009983676e-09
by O 0 4.895052696518576e-10
clinical O 0 2.9856612400180893e-06
disease O 0 1.1035975830964162e-06
, O 0 1.171059138549424e-09
a O 0 1.182386633047372e-09
finding O 0 9.236674536339251e-09
with O 0 1.0610455847270828e-09
serious O 0 1.7434192045584496e-07
diagnostic O 0 2.3831287307984894e-06
and O 0 8.285928743134718e-08
prognostic O 0 0.0003285328857600689
implications O 0 2.3619852072442882e-05
. O 0 5.921031061006943e-06

Moreover O 0 7.882689715188462e-06
, O 0 1.8684882263642066e-07
further O 0 7.641307888661686e-07
ARSA O 0 0.0002607404312584549
alleles O 0 1.1379930811017402e-06
functionally O 0 8.953144003953639e-08
similar O 0 2.1546471273836687e-09
to O 0 2.123970999079461e-09
A464V O 0 6.748037861825651e-08
might O 0 3.150914862359855e-09
exist O 0 4.013091192689444e-09
which O 0 6.645440864261332e-10
, O 0 4.0036013393418557e-10
together O 0 2.996574932634388e-10
with O 0 1.8197900131244893e-10
0 O 0 2.8797753515164004e-08
- O 0 7.782436917125324e-09
type O 0 8.416795260757226e-09
mutations O 0 1.0444706433077044e-08
, O 0 7.237289656458756e-10
may O 0 1.8193928141840843e-08
cause O 0 1.9649041860247962e-06
pathological O 0 0.008532911539077759
ARSA O 0 0.04910163953900337
and O 0 1.931749466166366e-06
GS O 1 1.0
levels O 0 7.748714381250466e-08
, O 0 1.9270628148770896e-10
but O 0 7.327793927203174e-11
not O 0 5.462094318509081e-11
clinical O 0 3.6895868582575986e-09
outbreak O 0 5.442389872101216e-10
of O 0 2.757633676964133e-09
the O 0 1.5897079208571085e-08
disease O 0 9.069486139878791e-08
. O 0 2.5475028309074332e-08
. O 0 8.639170232527249e-07

Human O 1 0.999871015548706
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 0 0.00043476803693920374
to O 0 2.1536739041039255e-06
hematological B-Disease 1 0.9999977350234985
malignancy I-Disease 1 0.9999837875366211
and O 0 7.02056240697857e-06
neurofibromatosis B-Disease 0 0.2962507903575897
type I-Disease 0 0.04374273121356964
1 I-Disease 0 0.07790187746286392
. O 0 1.2396803867886774e-05

Heterozygous O 0 2.686121479200665e-05
germ O 0 7.507389091188088e-05
- O 0 1.0167291293328162e-05
line O 0 3.047241534659406e-07
mutations O 0 6.1274462836991e-08
in O 0 6.1402900541907e-09
the O 0 4.6211390269945696e-08
DNA O 0 1.2885438991361298e-06
mismatch O 0 7.509788702009246e-05
repair O 0 5.408161541708978e-06
genes O 0 1.9211492485737836e-07
lead O 0 3.4152199646086956e-07
to O 0 4.578081700401526e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9990695118904114

The O 0 2.7384339773561805e-06
disease O 0 5.649038030242082e-06
susceptibility O 0 2.2438672431235318e-07
of O 0 1.4600553299715102e-07
individuals O 0 3.1362967778392203e-09
who O 0 1.1973270375165157e-08
constitutionally O 0 1.6956349213614885e-07
lack O 0 6.125694085312716e-07
both O 0 8.212577284893996e-08
wild O 0 6.935047025535823e-08
- O 0 3.5265916409343845e-08
type O 0 2.3847142927024834e-08
alleles O 0 5.97236677890578e-08
is O 0 3.663717329516203e-09
unknown O 0 2.7494326104715583e-07
. O 0 7.90510000570066e-07

We O 0 2.4105597162815684e-07
have O 0 5.374341416342077e-09
identified O 0 1.5829758837071495e-08
three O 0 1.3755196981435347e-09
offspring O 0 5.7421538635082925e-09
in O 0 2.791768594079258e-09
a O 0 8.149661567813382e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 3.838718475890346e-05
who O 0 1.7254542683531326e-07
developed O 0 4.372069088276476e-05
hematological B-Disease 1 0.9999988079071045
malignancy I-Disease 1 0.999991774559021
at O 0 1.0259246664645616e-05
a O 0 1.7287238307517327e-09
very O 0 8.505908755118696e-10
early O 0 1.908097146952059e-08
age O 0 9.683127188964136e-09
, O 0 3.8531791646256863e-10
and O 0 5.813062808890379e-10
at O 0 8.363473469330529e-09
least O 0 7.681165148376579e-10
two O 0 1.4775528023314166e-10
of O 0 4.544919718352247e-10
them O 0 4.502924422222776e-10
displayed O 0 8.834970088855698e-09
signs O 0 4.6583693347201915e-08
of O 0 3.725000752297092e-08
neurofibromatosis B-Disease 0 2.0440672869881382e-06
type I-Disease 0 7.612047738803085e-07
1 I-Disease 0 3.263560756749939e-06
( O 0 1.815184802467229e-08
NF1 B-Disease 0 6.0126740208943374e-06
) O 0 4.2921950438312706e-08
. O 0 5.869113124390424e-07

DNA O 0 1.2209792430439848e-06
sequence O 0 1.0399505612213034e-07
analysis O 0 2.077807792488784e-08
and O 0 8.027992492998237e-09
allele O 0 8.066814416451962e-08
- O 0 1.430271279190265e-08
specific O 0 1.50792034414593e-09
amplification O 0 1.2231518908834005e-08
in O 0 1.3652032837541128e-09
two O 0 6.447549161237021e-09
siblings O 0 1.426191005293731e-07
revealed O 0 2.7822582637782034e-07
a O 0 7.800615975384062e-08
homozygous O 0 2.7165738174517173e-06
MLH1 O 0 0.00028756685787811875
mutation O 0 1.2566750910991686e-06
( O 0 1.7695624876523652e-07
C676T O 0 5.476719252328621e-06
- O 0 7.051381544442847e-06
- O 0 2.312779088242678e-06
> O 0 1.2614947308975388e-06
Arg226Stop O 0 6.007182946632383e-06
) O 0 4.2951189271889234e-08
. O 0 5.128298994350189e-07

Thus O 0 4.637289293896174e-06
, O 0 1.5641745676475693e-07
a O 0 6.795698936912231e-08
homozygous O 0 1.083437496163242e-06
germ O 0 0.00034457776928320527
- O 0 0.0006393452640622854
line O 0 2.8024034691043198e-05
MLH1 O 1 0.9840028882026672
mutation O 0 1.2282047237022198e-06
and O 0 1.5181537094122177e-07
consequent O 0 0.03792257979512215
mismatch O 1 1.0
repair O 1 0.9999998807907104
deficiency O 1 1.0
results O 1 0.6651423573493958
in O 0 8.911495115171419e-07
a O 0 4.937634230373078e-07
mutator O 0 0.05468219146132469
phenotype O 0 2.874191977753071e-06
characterized O 0 2.5675468862118578e-08
by O 0 5.915306466874881e-09
leukemia B-Disease 1 0.9999977350234985
and O 1 0.6795977354049683
/ O 1 1.0
or O 1 0.9999995231628418
lymphoma B-Disease 1 1.0
associated O 1 0.7785917520523071
with O 0 1.9733569445179455e-07
neurofibromatosis B-Disease 1 0.600364625453949
type I-Disease 0 3.700202069012448e-05
1 I-Disease 0 1.854831316450145e-05
. O 0 1.4732830777575145e-07
. O 0 8.649071219224425e-07

Missense O 0 0.0001128916337620467
mutations O 0 1.1427413255660213e-06
in O 0 3.3875011240525055e-08
the O 0 1.4738894549282122e-08
most O 0 1.952898287527205e-09
ancient O 0 1.8799269696501142e-08
residues O 0 7.015082559291841e-08
of O 0 1.7189824674801457e-08
the O 0 7.135373181199611e-08
PAX6 O 0 0.00021818482491653413
paired O 0 9.766271205080557e-07
domain O 0 4.6369257233891403e-07
underlie O 0 1.7263347444895771e-06
a O 0 1.2852257036399806e-08
spectrum O 0 2.0502993720583618e-06
of O 0 3.912025476893177e-06
human O 1 0.9999986886978149
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.16699190437793732

Mutations O 0 2.9801337859680643e-06
of O 0 4.506984510044276e-07
the O 0 2.1824391183145053e-07
human O 0 8.207485393540992e-07
PAX6 O 0 0.0009519559098407626
gene O 0 7.658184586034622e-06
underlie O 1 0.9999082088470459
aniridia B-Disease 1 1.0
( O 0 0.49400073289871216
congenital B-Disease 1 1.0
absence I-Disease 0 0.009877573698759079
of I-Disease 0 0.0013180357636883855
the I-Disease 0 4.6642071538371965e-06
iris I-Disease 0 0.000195150583749637
) O 0 1.4981997864538243e-08
, O 0 3.9765253312396e-09
a O 0 1.078773159690627e-08
rare O 0 3.3514970709802583e-06
dominant O 1 1.0
malformation B-Disease 1 1.0
of I-Disease 1 0.9877204298973083
the I-Disease 0 0.0061722672544419765
eye I-Disease 1 0.9937410950660706
. O 0 4.120230005355552e-05

The O 0 1.8571289501778665e-06
spectrum O 0 5.921454430790618e-06
of O 0 1.2524909607236623e-06
PAX6 O 0 0.0009450705838389695
mutations O 0 3.1241420401784126e-06
in O 0 2.1146794892956677e-07
aniridia B-Disease 1 1.0
patients O 0 7.686360703473838e-08
is O 0 1.5871620684393406e-09
highly O 0 8.382686544905482e-09
biased O 0 4.880849147070876e-08
, O 0 5.21846454937247e-10
with O 0 1.720879966304878e-10
92 O 0 1.174300834350106e-08
% O 0 3.5247924023984467e-10
of O 0 2.3800690307496097e-09
all O 0 2.969686274667538e-09
reported O 0 1.4856590624390265e-08
mutations O 0 3.375465951194201e-08
leading O 0 3.735587839059917e-08
to O 0 7.455843054060551e-09
premature O 0 1.8971165616221697e-07
truncation O 0 8.981516543826729e-07
of O 0 2.3071739008173608e-07
the O 0 3.525683567318083e-08
protein O 0 6.966627097426681e-08
( O 0 4.150577659345345e-09
nonsense O 0 5.502359812226132e-08
, O 0 2.0027555169832567e-09
splicing O 0 1.8848169247576152e-08
, O 0 6.980440114823239e-10
insertions O 0 7.278102120977792e-09
and O 0 1.635206414718482e-09
deletions O 0 1.3372646989751047e-08
) O 0 1.5479726389600046e-09
and O 0 4.0131524770004035e-09
just O 0 7.518478284396224e-09
2 O 0 4.544109799553553e-08
% O 0 1.6267324154384255e-09
leading O 0 4.064146796878276e-09
to O 0 6.006289909876728e-10
substitution O 0 2.0588089455486625e-08
of O 0 4.2631246088831176e-08
one O 0 2.0282243440306047e-08
amino O 0 2.881429139733882e-08
acid O 0 1.6512660128142898e-09
by O 0 4.2046308101895136e-10
another O 0 3.5190441671772987e-09
( O 0 1.0987960763486626e-08
missense O 0 2.2347792310029035e-06
) O 0 1.2241932267897937e-07
. O 0 1.5097160712684854e-06

The O 0 8.085219747044903e-07
extraordinary O 0 4.528526744707051e-07
conservation O 0 5.0088758030142344e-08
of O 0 1.8738338880552874e-08
the O 0 7.407482627286299e-08
PAX6 O 0 1.2404490917106159e-05
protein O 0 1.9379831428523175e-07
at O 0 2.3996395270842186e-07
the O 0 6.016362164018574e-08
amino O 0 3.4182403396698646e-07
acid O 0 1.4732465558608965e-07
level O 0 6.66779442326515e-06
amongst O 0 8.29093892207311e-07
vertebrates O 0 1.2061285588060855e-06
predicts O 0 2.594564030289348e-08
that O 0 1.363993029634969e-09
pathological O 0 1.8849788148145308e-06
missense O 0 1.4761367310711648e-06
mutations O 0 1.0096518110458419e-07
should O 0 6.937267205131548e-09
in O 0 1.0349867629599885e-09
fact O 0 9.93171433982809e-10
be O 0 7.104811183822335e-10
common O 0 4.922767193882294e-10
even O 0 1.2071768584753784e-10
though O 0 6.750075498551666e-11
they O 0 1.9607689083489532e-10
are O 0 1.3856860103800273e-10
hardly O 0 5.618709941757061e-09
ever O 0 1.5195798397371618e-08
seen O 0 4.208309434261537e-08
in O 0 4.367311134956253e-08
aniridia B-Disease 1 0.999998927116394
patients O 0 3.919042796951544e-07
. O 0 1.4084992017160403e-06

This O 0 3.238158186036344e-08
indicates O 0 3.286542948899296e-08
that O 0 4.844885048704839e-10
there O 0 1.1342070616038313e-09
is O 0 2.954875788496736e-10
a O 0 1.2558336592860542e-09
heavy O 0 4.835357572119392e-07
ascertainment O 0 0.000111809276859276
bias O 0 1.0878013654291863e-06
in O 0 5.3566782121095e-09
the O 0 2.133374366053431e-09
selection O 0 1.074534683453976e-08
of O 0 3.7242100514589538e-09
patients O 0 1.1019499757125573e-09
for O 0 2.903279172628004e-09
PAX6 O 0 3.1066660994838458e-06
mutation O 0 1.7147188557942172e-08
analysis O 0 6.894120829770145e-09
and O 0 1.0387086746277419e-09
that O 0 4.909152528931315e-10
the O 0 1.552686867967168e-08
missing O 0 9.174510182674567e-07
PAX6 O 0 0.000529490876942873
missense O 0 2.5695177100715227e-05
mutations O 0 1.291930061597668e-06
frequently O 0 8.617778490815908e-08
may O 0 1.7592979872915748e-07
underlie O 0 5.900383712287294e-06
phenotypes O 0 1.6239112028415548e-06
distinct O 0 5.637229349986228e-08
from O 0 3.747462784531308e-08
textbook O 0 1.7424019461032003e-05
aniridia B-Disease 1 0.9999992847442627
. O 0 1.371895723423222e-05

Here O 0 1.008309254757478e-06
we O 0 1.8654040090382296e-08
present O 0 1.2868005327959509e-08
four O 0 7.607103391649161e-09
novel O 0 7.508192112481993e-08
PAX6 O 0 1.9329185306560248e-05
missense O 0 3.0454621082753874e-06
mutations O 0 2.4091508521451033e-07
, O 0 1.3123178987939355e-08
two O 0 8.82116335532146e-09
in O 0 1.0539060291137048e-08
association O 0 3.1515234866219544e-08
with O 0 8.07125832835709e-09
atypical O 0 7.437186468450818e-06
phenotypes O 0 2.871946526283864e-05
ectopia B-Disease 0 2.0138122636126354e-05
pupillae I-Disease 0 5.918778242630651e-06
( O 0 4.4707402224730686e-09
displaced B-Disease 0 1.4543972248759474e-08
pupils I-Disease 0 2.5185255481119384e-07
) O 0 4.171484491166666e-08
and O 0 3.507141809677705e-05
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9999991655349731
( O 0 6.12120857113041e-07
searching B-Disease 0 1.0018038665293716e-06
gaze I-Disease 0 4.920546871289844e-06
) O 0 5.863264540550972e-09
, O 0 1.3549615873742482e-09
and O 0 3.876985399386967e-09
two O 0 7.915358146703966e-09
in O 0 1.111803449305171e-08
association O 0 8.834043718763951e-09
with O 0 9.311244553167342e-10
more O 0 2.439849877688971e-09
recognizable O 0 2.6273628463968635e-06
aniridia B-Disease 1 0.9999990463256836
phenotypes O 0 1.120971137424931e-05
. O 0 1.560344117024215e-06

Strikingly O 0 1.4059967725188471e-05
, O 0 4.406167519732662e-08
all O 0 1.4311881457729214e-08
four O 0 6.460622703485797e-09
mutations O 0 3.5001135323398103e-09
are O 0 7.119516087783495e-10
located O 0 3.485530308822149e-09
within O 0 1.4264081471537793e-08
the O 0 6.7917859780664e-08
PAX6 O 0 2.4057853806880303e-05
paired O 0 3.9407541407854296e-07
domain O 0 1.570591621202766e-07
and O 0 4.174254186750659e-08
affect O 0 1.5225715799260797e-07
amino O 0 2.4923092922790602e-08
acids O 0 7.119244083142462e-10
which O 0 1.7726067835788228e-10
are O 0 4.2082712314872595e-11
highly O 0 3.2849037379101276e-10
conserved O 0 1.009069494628534e-09
in O 0 2.419402733710996e-10
all O 0 6.392345541783584e-10
known O 0 2.0033286141085682e-09
paired O 0 1.201825217123087e-08
domain O 0 2.999580317464279e-08
proteins O 0 3.529518721734348e-08
. O 0 2.714349420784856e-07

Our O 0 2.1277710402500816e-06
results O 0 1.8671076418286248e-07
support O 0 9.276734935781406e-09
the O 0 5.425322857632864e-09
hypothesis O 0 4.336141667948823e-09
that O 0 4.72667009698835e-11
the O 0 1.6513375389326512e-10
under O 0 1.1206254812989869e-09
- O 0 4.310110046645832e-09
representation O 0 1.562413309841304e-08
of O 0 2.2702300483956606e-08
missense O 0 1.835135776673269e-06
mutations O 0 1.341656883369069e-07
is O 0 1.4526221336907952e-09
caused O 0 1.171484242945553e-08
by O 0 7.937400958724083e-09
ascertainment O 0 8.975582750281319e-05
bias O 0 5.219980721449247e-06
and O 0 2.4623522776323625e-08
suggest O 0 8.827105268949254e-09
that O 0 4.927031560519879e-10
a O 0 1.5148649001872627e-09
substantial O 0 2.6591743917947497e-08
burden O 0 8.860657771947444e-07
of O 0 0.0001313634420512244
PAX6 B-Disease 1 1.0
- I-Disease 1 0.9999991655349731
related I-Disease 0 0.0846502035856247
disease I-Disease 0 5.407220305642113e-05
remains O 0 1.566471397040914e-08
to O 0 9.010182600022176e-10
be O 0 4.194876002117098e-09
uncovered O 0 1.9496282277486898e-07
. O 0 4.2122522359022696e-08
. O 0 7.509938768635038e-07

The O 0 6.609143383684568e-07
chromosomal O 0 1.4075607168706483e-06
order O 0 3.661784546693525e-07
of O 0 7.754390480840812e-07
genes O 0 2.8363302817524527e-07
controlling O 0 2.3241127564688213e-06
the O 0 9.614262808099738e-07
major O 0 3.1673532703280216e-06
histocompatibility O 1 0.8063562512397766
complex O 0 5.035980393586215e-06
, O 0 5.620178100684825e-09
properdin O 0 6.466517987746556e-08
factor O 0 1.3484317662459944e-08
B O 0 1.879967044260411e-07
, O 0 2.7933453328188307e-09
and O 0 1.3414389599120113e-08
deficiency B-Disease 0 2.39641804000712e-06
of I-Disease 0 2.3225743461807724e-07
the I-Disease 0 4.566761546698217e-08
second I-Disease 0 4.7265508840155235e-08
component I-Disease 0 1.6563991067641837e-08
of I-Disease 0 4.627392513611994e-08
complement I-Disease 0 3.148937537389429e-07
. O 0 2.2870378870720742e-06

The O 0 2.611584477563156e-07
relationship O 0 4.3512304870318985e-08
of O 0 3.049415298050917e-08
the O 0 2.381468888756899e-08
genes O 0 8.488068914402902e-09
coding O 0 4.630624417245599e-08
for O 0 4.43273462380489e-09
HLA O 0 8.374364313112892e-08
to O 0 6.442174016463298e-10
those O 0 8.11466116523718e-10
coding O 0 1.4821495142314234e-08
for O 0 7.847841265729016e-10
properdin O 0 5.3519620735187345e-08
Factor O 0 1.5573018430359298e-08
B O 0 1.6942642844242073e-07
allotypes O 0 3.6612325970963866e-07
and O 0 2.7352344833531106e-09
for O 0 6.026328769337397e-09
deficiency B-Disease 0 9.987960538637708e-07
of I-Disease 0 4.0313288707238826e-08
the I-Disease 0 9.336377893021108e-09
second I-Disease 0 1.2101059709834772e-08
component I-Disease 0 7.458545780991699e-09
of I-Disease 0 5.395993429857526e-09
complement I-Disease 0 3.906195189529171e-08
( O 0 5.821820803220135e-09
C2 O 0 1.5477777424166561e-06
) O 0 1.3526453290779727e-09
was O 0 4.5671333381847035e-09
studied O 0 1.1079929862489735e-08
in O 0 3.6527605939973284e-10
families O 0 4.062191416576155e-10
of O 0 6.053354706381242e-09
patients O 0 2.5212596455048697e-08
with O 0 3.517687616749754e-07
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 0.0838117003440857

Patients O 0 3.8967303339632053e-07
were O 0 1.4946861526254906e-08
selected O 0 2.978126634189948e-09
because O 0 2.9836344506151136e-10
they O 0 5.872371477977367e-10
were O 0 3.5255338648454426e-09
heterozygous O 0 1.6225035537331678e-08
or O 0 3.200761966581922e-08
homozygous O 0 2.0392367332533468e-06
for O 0 3.8856892388139386e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0004226966411806643

12 O 0 5.624257028102875e-06
families O 0 3.295689054994e-08
with O 0 1.4632678180248604e-08
15 O 0 4.6157217070685874e-07
matings O 0 4.629586692317389e-05
informative O 0 3.646319601102732e-05
for O 0 8.649749361211434e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 3.2584416658210102e-06
found O 0 1.9560499708859425e-07
. O 0 1.6144978189913672e-06

Of O 0 1.219857222167775e-05
57 O 0 5.195962330617476e-06
informative O 0 1.5432351574418135e-06
meioses O 0 2.2652529878541827e-06
, O 0 4.3499421842341235e-09
two O 0 1.2638425861410951e-09
crossovers O 0 1.1470434380100869e-08
were O 0 9.307395743007874e-09
noted O 0 1.005565497536054e-08
between O 0 9.6454535025714e-08
the O 0 2.5636729333200492e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.0876032519036016e-08
and O 0 9.07614516876265e-09
the O 0 2.0252477028748217e-08
HLA O 0 2.722939029808913e-07
- O 0 4.1706890385739825e-08
B O 0 6.475676883610504e-08
gene O 0 5.962641491663589e-10
, O 0 1.608264216246269e-10
with O 0 1.3258751041522743e-10
a O 0 4.928159547112898e-10
recombinant O 0 2.8943887286914105e-09
fraction O 0 2.454440428678595e-09
of O 0 1.4086396049606265e-08
0 O 0 6.570486448254087e-07
. O 0 6.695178740301344e-07

035 O 0 0.021745193749666214
. O 0 0.00015236363105941564

A O 0 3.0562507618014934e-06
lod O 0 1.4455522432399448e-05
score O 0 1.3799251519230893e-07
of O 0 2.69316888790172e-08
13 O 0 5.744534092855247e-08
was O 0 1.3761003003764927e-08
calculated O 0 1.256361326085198e-08
for O 0 4.844119771973965e-09
linkage O 0 2.7373971533961594e-06
between O 0 0.0003972102713305503
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 7.021066039669677e-07
HLA O 0 1.5277146303560585e-06
- O 0 7.606279694982732e-08
B O 0 9.2726878619942e-08
at O 0 4.743382575611577e-09
a O 0 1.7466603163818206e-10
maximum O 0 1.6600607555261604e-09
likelihood O 0 1.4042073059883364e-09
value O 0 7.423953674035033e-10
of O 0 5.388708923526053e-10
the O 0 3.5578148760428974e-10
recombinant O 0 6.642932315337191e-10
fraction O 0 4.033409162218504e-10
of O 0 2.049764580291935e-09
0 O 0 1.495023127517925e-07
. O 0 2.4548731403228885e-07

04 O 0 0.00503751402720809
. O 0 0.00019894909928552806

18 O 0 4.469828127184883e-06
families O 0 2.2447313341444897e-08
with O 0 1.183915099289834e-08
21 O 0 4.3859307652382995e-07
informative O 0 3.279836562342098e-07
matings O 0 4.7690576820969e-07
for O 0 4.151147869890792e-09
both O 0 2.070133575671207e-08
properdin O 0 5.472717816701334e-07
Factor O 0 1.0625471702496725e-07
B O 0 6.750767056473705e-07
allotype O 0 3.718371033301082e-07
and O 0 2.403188759103614e-08
HLA O 0 3.619196036197536e-07
- O 0 2.690109290881537e-08
B O 0 6.222242632247799e-08
were O 0 7.674126223378153e-09
found O 0 1.3653472130670252e-08
. O 0 3.61655622782564e-07

Of O 0 1.2512883586168755e-05
72 O 0 8.672530384501442e-06
informative O 0 1.943005145221832e-06
meioses O 0 4.239032932673581e-06
, O 0 1.2076434074970166e-08
three O 0 6.7254459779064746e-09
recombinants O 0 3.153207615014253e-07
were O 0 1.712577990531372e-08
found O 0 4.1641050607665875e-09
, O 0 1.3282398514391502e-09
giving O 0 1.0507001935167182e-09
a O 0 8.898741743479377e-10
recombinant O 0 3.6732403785322276e-09
fraction O 0 2.815866206873352e-09
of O 0 1.4790684232934836e-08
0 O 0 5.660830879605783e-07
. O 0 1.034849105963076e-06

042 O 0 0.003286815481260419
. O 0 0.00015408323088195175

A O 0 3.1079346172191435e-06
lod O 0 2.008721639867872e-05
score O 0 4.2569254787849786e-07
of O 0 1.1985498815647588e-07
16 O 0 3.4437948670529295e-07
between O 0 1.6902988875244773e-07
HLA O 0 1.3730782484344672e-06
- O 0 7.002142865530914e-08
B O 0 4.6129848385589867e-08
and O 0 9.938990741531484e-10
Factor O 0 5.468395514185431e-09
B O 0 5.2206104328433867e-08
allotypes O 0 1.2390347592372564e-07
was O 0 4.708767598060604e-09
calculated O 0 1.8078208929850348e-09
at O 0 4.247482365826727e-09
a O 0 2.0968560221490407e-10
maximum O 0 6.450969092242076e-09
likelihood O 0 3.4279530325420637e-09
value O 0 9.457405969470756e-10
of O 0 1.7538820396012511e-09
the O 0 6.198392354939131e-10
recombinant O 0 3.5989913826917075e-10
fraction O 0 5.465181085462234e-10
of O 0 2.6354560755947887e-09
0 O 0 8.508285986863484e-08
. O 0 4.145295520174841e-07

04 O 0 0.0052535757422447205
. O 0 0.00020635045075323433

A O 0 3.2546014949730306e-07
crossover O 0 1.9479408308598067e-07
was O 0 3.819130256488279e-08
shown O 0 9.86461801133487e-10
to O 0 4.460721236831944e-10
have O 0 3.6726149899024563e-10
occurred O 0 9.10739395010296e-09
between O 0 5.70040015190898e-10
genes O 0 1.3709824941976478e-10
for O 0 1.1357997875549586e-10
Factor O 0 4.86320939074858e-09
B O 0 5.001782454883141e-08
and O 0 1.19199503600953e-08
HLA O 0 2.0344975837360835e-07
- O 0 2.228159168282673e-08
D O 0 3.019809469151369e-08
, O 0 7.962779879910897e-10
in O 0 8.163842379893538e-10
which O 0 4.90393281538104e-09
HLA O 0 6.014985274305218e-07
- O 0 1.3794645781217696e-07
D O 0 3.482924171294144e-07
segregared O 0 1.2066230965501745e-06
with O 0 1.7973320609598886e-08
HLA O 0 1.3815199508826481e-06
- O 0 4.9085581821373125e-08
A O 0 1.589762455012078e-08
and O 0 2.785897912360724e-08
B O 0 3.0217743187677115e-06
. O 0 8.57362465467304e-07

These O 0 8.569523402002233e-08
studies O 0 2.272491528287901e-08
suggest O 0 3.843499296607433e-09
that O 0 3.876961252036182e-10
the O 0 8.659555850165646e-10
genes O 0 4.628641359083474e-10
for O 0 2.282789235419358e-10
Factor O 0 4.354617999524635e-08
B O 0 4.5221575419418514e-05
and O 0 1.1689714483509306e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.3343327271163616e-09
located O 0 1.112354430787832e-09
outside O 0 1.3082711580736373e-09
those O 0 1.5515455586978533e-10
for O 0 3.612457277757386e-10
HLA O 0 2.4900474571154518e-08
, O 0 9.178149906752253e-11
that O 0 3.667244286020832e-11
the O 0 2.19352480623769e-10
order O 0 2.452718472767401e-09
of O 0 7.4769630487026e-09
genese O 0 7.440374929501559e-07
is O 0 1.1701487778736919e-08
HLA O 0 6.11833741004375e-07
- O 0 9.423311553291569e-08
A O 0 3.884470700654674e-08
, O 0 7.787025246841495e-09
- O 0 5.462914742793146e-08
B O 0 2.2424040935220546e-07
, O 0 5.991064089272413e-09
- O 0 1.3799192899455193e-08
D O 0 1.0339021194738507e-08
, O 0 7.091042752982446e-10
Factor O 0 4.521656293832166e-08
B O 0 1.3986448266223306e-06
allotype O 0 1.2480312761908863e-05
, O 0 7.298685886780731e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 1.9488091140829056e-09
that O 0 1.978111979772379e-10
the O 0 2.918374875093832e-09
genes O 0 3.311403773409438e-08
coding O 0 1.5224452454276616e-06
for O 0 4.5146762772674265e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 5.025517069157104e-08
Factor O 0 1.359298522629615e-07
B O 0 1.3728762837672548e-07
allotypes O 0 1.315053452799475e-07
are O 0 4.259162467157296e-10
approximately O 0 1.2226684109606367e-09
3 O 0 1.2214616873507111e-08
- O 0 6.853804190853907e-09
- O 0 5.78344927504304e-09
5 O 0 1.4303449091812581e-08
centimorgans O 0 1.2345374500455364e-07
from O 0 2.2694279788737504e-09
the O 0 1.573514474273452e-08
HLA O 0 1.748769591358723e-07
- O 0 1.3935141929266592e-08
A O 0 1.0708865794128997e-08
and O 0 1.0498752978094217e-08
HLA O 0 2.513103254386806e-07
- O 0 2.7394545298875528e-08
B O 0 3.127212977460658e-08
loci O 0 5.942581982054662e-09
, O 0 2.799712961465417e-10
and O 0 2.3995494480288926e-10
that O 0 6.563195126263466e-11
the O 0 4.400829423101271e-10
apparent O 0 1.480527611619209e-08
lack O 0 1.0893767665720588e-07
of O 0 1.0580232157053615e-07
recombinants O 0 5.816834232064139e-07
between O 0 6.417184117424313e-09
the O 0 6.4961973578192556e-09
Factor O 0 1.6217245502048172e-07
B O 0 5.65790151085821e-06
gene O 0 1.7644828176344163e-06
and O 0 0.000641600985545665
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.5911002293478305e-08
suggests O 0 1.4784388158162187e-09
that O 0 3.9882111502187456e-11
these O 0 2.055989267724101e-10
two O 0 3.752343713525619e-10
genes O 0 1.7380472616679299e-09
lie O 0 1.4511524426552569e-08
in O 0 2.1475325961972658e-09
close O 0 2.285893963005492e-08
proximity O 0 1.4595938679917708e-08
to O 0 4.90159468569118e-09
one O 0 6.982601608029881e-09
another O 0 3.946184179426382e-08
. O 0 1.4683024573969305e-06

Distribution O 0 2.0278394003980793e-06
of O 0 1.8239604742120719e-06
emerin O 0 5.579290518653579e-05
and O 0 2.0093074226679164e-07
lamins O 0 3.0791157769272104e-05
in O 0 4.867666447694319e-08
the O 0 4.69642813527571e-08
heart O 0 3.238859562770813e-07
and O 0 2.8451230704718e-08
implications O 0 1.7012649777825573e-06
for O 0 1.0065330258157701e-07
Emery B-Disease 1 0.9999765157699585
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0007089694263413548

Emerin O 0 0.0041254060342907906
is O 0 1.752357263740123e-07
a O 0 6.142002462183882e-08
nuclear O 0 8.305009373543726e-07
membrane O 0 5.936959723840118e-07
protein O 0 3.3713735803075906e-08
which O 0 9.885129381714819e-10
is O 0 8.45008840677508e-10
missing O 0 1.7125618256841335e-08
or O 0 5.081670639839331e-09
defective O 0 4.2953072920681734e-07
in O 0 7.992611728013799e-08
Emery B-Disease 1 0.9999908208847046
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 5.460822649183683e-05
EDMD B-Disease 1 1.0
) O 0 4.738167262985371e-07
. O 0 1.1239427522014012e-06

It O 0 7.50422586293098e-08
is O 0 4.3866186238972205e-09
one O 0 4.66879246374674e-09
member O 0 1.1351642292822817e-08
of O 0 4.156695609935923e-08
a O 0 2.1180010634225255e-08
family O 0 1.3726374703537658e-08
of O 0 1.6683692649621662e-07
lamina O 0 0.2503308951854706
- O 0 0.0009153507417067885
associated O 0 4.695057782555523e-07
proteins O 0 5.697435412344021e-09
which O 0 6.155510323679891e-09
includes O 0 1.1822226753110954e-08
LAP1 O 0 8.075994628597982e-06
, O 0 3.551519967004424e-08
LAP2 O 0 8.058199455263093e-06
and O 0 1.094821726610462e-07
lamin O 0 1.0910918717854656e-05
B O 0 2.5875667688524118e-06
receptor O 0 3.4339271337557875e-07
( O 0 3.7882749381878966e-08
LBR O 0 3.270446086389711e-06
) O 0 1.0513485904084519e-07
. O 0 2.062788780676783e-06

A O 0 1.0980734259646852e-05
panel O 0 4.833476850762963e-06
of O 0 2.6697736643654935e-07
16 O 0 2.370002931684212e-07
monoclonal O 0 2.4221156635917396e-08
antibodies O 0 6.995678702992336e-09
( O 0 9.39575794944858e-09
mAbs O 0 4.2739370087474526e-07
) O 0 2.139217469832033e-09
has O 0 4.5444689678042494e-10
been O 0 1.3967332845865599e-09
mapped O 0 2.475380567190655e-09
to O 0 5.68781244325578e-10
six O 0 1.366039392713958e-09
specific O 0 1.0765096591924816e-09
sites O 0 3.4984448671337987e-09
throughout O 0 3.4300722262514682e-09
the O 0 1.4771259770895995e-08
emerin O 0 2.2622556627993617e-07
molecule O 0 5.9162652554789474e-09
using O 0 5.9653064710119e-09
phage O 0 1.779798424195178e-07
- O 0 2.2143519018413826e-08
displayed O 0 8.133072881832959e-09
peptide O 0 1.7933111662316037e-09
libraries O 0 6.201774094272139e-10
and O 0 3.082740174242815e-10
has O 0 4.257097452331493e-11
been O 0 4.875045506169684e-11
used O 0 6.987883882647594e-11
to O 0 4.281462961941429e-10
localize O 0 2.3953523964337364e-07
emerin O 0 1.1763248721763375e-06
in O 0 1.7198090063175187e-08
human O 0 2.1729316301843937e-07
and O 0 2.238735277160231e-07
rabbit O 0 9.103078468797321e-07
heart O 0 2.6196914859610843e-06
. O 0 1.0903224392677657e-05

Several O 0 1.1268405160080874e-06
mAbs O 0 7.302832727873465e-06
against O 0 5.398836151471187e-07
different O 0 1.37133866928707e-07
emerin O 0 6.283930815698113e-06
epitopes O 0 1.1278242482148926e-06
did O 0 2.6888267612434902e-08
not O 0 5.387262635991874e-09
recognize O 0 4.129298858401853e-08
intercalated O 0 1.1104016266472172e-06
discs O 0 6.660038707195781e-07
in O 0 6.021939391587239e-09
the O 0 5.546506809395169e-09
heart O 0 1.2343920552382315e-08
, O 0 3.361828315728843e-10
though O 0 3.2419553153140157e-10
they O 0 4.497713868012454e-10
recognized O 0 2.8272322261102545e-09
cardiomyocyte O 0 9.209446005797872e-08
nuclei O 0 5.560194793474693e-08
strongly O 0 1.3073488069892392e-08
, O 0 2.4826432021285427e-09
both O 0 7.572519500342878e-09
at O 0 1.3091424762023962e-06
the O 0 3.7351817638864304e-08
rim O 0 2.689099289909791e-07
and O 0 3.573561224712307e-09
in O 0 6.827630461003764e-09
intranuclear O 0 9.919111789713497e-07
spots O 0 5.010901986679528e-07
or O 0 5.223588672720325e-08
channels O 0 5.597036079052486e-07
. O 0 6.439674393732275e-07

A O 0 1.617900124983862e-05
polyclonal O 0 5.385082113207318e-05
rabbit O 0 4.088588866579812e-06
antiserum O 0 1.528929169580806e-05
against O 0 2.284709808009211e-06
emerin O 0 2.058165227936115e-05
did O 0 6.815715636321329e-08
recognize O 0 4.042100343326638e-08
both O 0 1.4939850245809794e-08
nuclear O 0 5.042733732807392e-07
membrane O 0 1.5531999508766603e-07
and O 0 8.246918703491701e-09
intercalated O 0 1.0261776139941503e-07
discs O 0 3.899339162671822e-08
but O 0 5.752553988713771e-10
, O 0 2.669345022798808e-10
after O 0 1.2269317783974998e-09
affinity O 0 1.103274915870145e-09
purification O 0 4.3658263670920405e-09
against O 0 3.938865233976685e-09
a O 0 2.477784866172783e-09
pure O 0 1.4197667042026296e-07
- O 0 2.304710875478122e-07
emerin O 0 6.196837603056338e-07
band O 0 3.6604571818088516e-08
on O 0 1.8177104266214883e-08
a O 0 2.728554271413941e-09
western O 0 1.4353846111703206e-08
blot O 0 5.268435074867739e-07
, O 0 4.956063559546919e-09
it O 0 2.4672448528662017e-09
stained O 0 9.122964002017397e-07
only O 0 4.696201649778686e-09
the O 0 1.0330388100499022e-08
nuclear O 0 7.191048325694283e-07
membrane O 0 3.436201268414152e-06
. O 0 1.2877379731435212e-06

These O 0 1.679832593026731e-07
results O 0 1.2859433695666667e-07
would O 0 2.72174505155931e-09
not O 0 9.480668472505727e-10
be O 0 1.4617357324553382e-09
expected O 0 9.162347325286646e-09
if O 0 1.3427162492973821e-08
immunostaining O 0 1.5096211427589878e-06
at O 0 8.2367826337304e-08
intercalated O 0 1.497321875376656e-07
discs O 0 1.0019704177466338e-07
were O 0 3.359522438017848e-09
due O 0 7.453795802803143e-09
to O 0 4.8691750631491e-10
a O 0 5.5162246992424e-10
product O 0 1.8364756382283076e-09
of O 0 8.967924181035869e-09
the O 0 1.33618875963748e-08
emerin O 0 5.997263770041172e-07
gene O 0 4.284847587854301e-09
and O 0 1.732635590556697e-09
, O 0 5.614732012659829e-10
therefore O 0 1.6390533374988081e-09
, O 0 2.702907897500495e-10
cast O 0 1.0397335215017733e-09
some O 0 1.8370492627095558e-10
doubt O 0 5.502619249142526e-09
upon O 0 3.1353519780452643e-09
the O 0 2.443729441026221e-09
hypothesis O 0 4.3237804447926464e-08
that O 0 2.935429899153519e-09
cardiac B-Disease 0 5.039885581936687e-05
defects I-Disease 0 6.75885021337308e-05
in O 0 9.295856102653488e-07
EDMD B-Disease 1 1.0
are O 0 3.9001204044097904e-08
caused O 0 3.1390452903679034e-08
by O 0 3.484008193055388e-09
absence O 0 2.7147638093083515e-07
of O 0 2.9272359824972227e-07
emerin O 0 3.8460648283944465e-06
from O 0 3.243838975208746e-08
intercalated O 0 3.261507117713336e-06
discs O 0 6.483879133156734e-06
. O 0 2.2865644950798014e-06

Although O 0 2.0260763449186925e-06
emerin O 0 2.782362571451813e-05
was O 0 3.735677012173255e-07
abundant O 0 7.611635055582155e-08
in O 0 5.617680987057838e-09
the O 0 1.381172776149242e-08
membranes O 0 5.601880204153531e-08
of O 0 4.582746626624612e-08
cardiomyocyte O 0 3.6882173048979894e-07
nuclei O 0 9.67936415463555e-08
, O 0 1.7013416231392853e-09
it O 0 5.812574865871056e-10
was O 0 1.87375555071867e-08
absent O 0 4.707243661528082e-08
from O 0 1.1519101228429918e-09
many O 0 8.228781545049912e-10
non O 0 1.2465955023799324e-07
- O 0 9.487152397014142e-08
myocyte O 0 2.992489100961393e-07
cells O 0 7.292553227955523e-09
in O 0 2.7356936715960956e-09
the O 0 1.5574801892626056e-08
heart O 0 4.2697732283158985e-07
. O 0 2.2876029106555507e-06

This O 0 2.6829457766552878e-08
distribution O 0 3.773138956830735e-08
of O 0 3.831877748439183e-08
emerin O 0 1.5641418258383055e-06
was O 0 2.044673763634819e-08
similar O 0 4.5157311223675833e-10
to O 0 5.04162211978354e-10
that O 0 9.691401015032852e-10
of O 0 5.004988778978259e-08
lamin O 0 1.5547739167232066e-05
A O 0 4.457221791653865e-08
, O 0 1.3294056966373091e-09
a O 0 1.4117130797686173e-09
candidate O 0 2.5147231852429286e-08
gene O 0 6.969947285995204e-09
for O 0 1.3376619811822366e-09
an O 0 1.250982872846862e-09
autosomal O 0 2.4795977537905856e-07
form O 0 9.412880217496422e-07
of O 0 0.0007227489259094
EDMD B-Disease 1 1.0
. O 0 0.0001751331437844783

In O 0 9.739289907884086e-07
contrast O 0 8.068443548836512e-07
, O 0 2.5447161533520557e-07
lamin O 0 9.006678737932816e-05
B1 O 0 0.0001056094843079336
was O 0 8.726638611733506e-07
absent O 0 5.519687533706019e-07
from O 0 2.7224581700124872e-08
cardiomyocyte O 0 5.846833914802119e-07
nuclei O 0 3.038356055640179e-07
, O 0 1.8168959670106233e-08
showing O 0 6.231993410210634e-08
that O 0 3.263748027393376e-08
lamin O 0 3.4060136385960504e-05
B1 O 0 8.052392331592273e-06
is O 0 1.064083599011667e-09
not O 0 5.937786373699794e-10
essential O 0 7.845704530495823e-09
for O 0 3.12228842780371e-09
localization O 0 9.65939648267522e-07
of O 0 3.9113245975386235e-08
emerin O 0 8.219274718612724e-07
to O 0 8.080007773969555e-09
the O 0 1.0195405053536888e-07
nuclear O 0 9.796609447221272e-06
lamina O 1 0.998537540435791
. O 0 2.3819402485969476e-05

Lamin O 1 0.998909592628479
B1 O 1 0.9934301972389221
is O 0 7.310271143978753e-08
also O 0 9.07451713771934e-09
almost O 0 6.805839891654841e-09
completely O 0 1.3037474388966075e-07
absent O 0 4.0312409055331955e-07
from O 0 2.6079352011265655e-08
skeletal O 0 1.682764559518546e-05
muscle O 0 1.7110814951593056e-06
nuclei O 0 9.44795465329662e-05
. O 0 2.9903265385655686e-05

In O 0 9.913306712405756e-06
EDMD B-Disease 1 1.0
, O 0 4.8570193200703216e-08
the O 0 8.155161879130901e-09
additional O 0 4.96127539051372e-09
absence O 0 1.277006163036276e-07
of O 0 2.7663600121741183e-07
lamin O 0 0.00021209877741057426
B1 O 0 0.0006587793468497694
from O 0 1.5428805966166692e-07
heart O 0 0.0006815704400651157
and O 0 7.745562470518053e-05
skeletal O 1 0.9999821186065674
muscle O 0 6.491607109637698e-06
nuclei O 0 0.006280312314629555
which O 0 1.9483292135191732e-07
already O 0 7.995813433581134e-08
lack O 0 8.676030120113865e-06
emerin O 0 3.460483640083112e-05
may O 0 6.609190972284296e-09
offer O 0 9.02438901384528e-10
an O 0 4.248118176675142e-11
alternative O 0 9.480162210806498e-10
explanation O 0 1.376653457896282e-09
of O 0 8.318098432269494e-10
why O 0 7.66372187932518e-10
these O 0 1.763495044437846e-10
tissues O 0 3.613092935950135e-09
are O 0 2.431403134384169e-10
particularly O 0 8.845065790907825e-10
affected O 0 4.302815881374045e-09
. O 0 2.1086332679942643e-08
. O 0 8.020127779673203e-07

Genetic O 0 6.028082680131774e-06
mapping O 0 1.3286760349728866e-06
of O 0 4.510536371071794e-07
the O 0 4.7637578859394125e-07
copper B-Disease 0 9.438045708520804e-06
toxicosis I-Disease 0 0.00029835954774171114
locus O 0 2.807239525282057e-06
in O 0 3.9585253830409783e-07
Bedlington O 0 0.00010236405796604231
terriers O 0 3.135795395792229e-06
to O 0 1.8234610266176787e-08
dog O 0 3.1964184188382205e-08
chromosome O 0 7.339694718666578e-08
10 O 0 2.9618588470725626e-08
, O 0 1.5225847249666913e-09
in O 0 1.3408345544974054e-09
a O 0 3.8763126042340446e-09
region O 0 3.0603406031559643e-08
syntenic O 0 1.3067362942820182e-06
to O 0 1.277968042501243e-08
human O 0 6.765642268646843e-08
chromosome O 0 1.6890950860215526e-07
region O 0 1.8720645300618344e-07
2p13 O 0 1.287496525037568e-05
- O 0 7.864450708439108e-06
p16 O 0 6.5962808548647445e-06
. O 0 1.6689166386640863e-06

Abnormal O 1 1.0
hepatic B-Disease 1 1.0
copper I-Disease 0 0.0277576744556427
accumulation I-Disease 0 0.00016897339082788676
is O 0 4.554232990727769e-09
recognized O 0 2.637040141806324e-09
as O 0 1.9813681806368777e-09
an O 0 3.923366964642128e-09
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 1.4795276683798875e-06
man O 0 3.914685294148512e-05
, O 0 8.362361114677697e-08
mouse O 0 7.647176403224876e-07
, O 0 1.3696539724605827e-07
rat O 0 7.898701710473688e-07
and O 0 1.8533184231728228e-07
dog O 0 2.0287582174205454e-06
. O 0 5.977944965707138e-06

The O 0 5.553088158194441e-07
major O 0 4.3171675656594743e-07
cause O 0 2.3106418666429818e-05
of O 0 0.03711290284991264
hepatic B-Disease 1 1.0
copper I-Disease 0 0.03837284445762634
accumulation I-Disease 0 0.38859620690345764
in O 0 4.9184168346982915e-06
man O 0 7.647130405530334e-05
is O 0 6.576960309701008e-09
a O 0 1.714790798246213e-08
dysfunctional O 0 2.853876992503501e-07
ATP7B O 0 2.4240573111455888e-05
gene O 0 6.532368246325859e-08
, O 0 1.4328871422719658e-08
causing O 0 6.016477414050314e-07
Wilson B-Disease 0 1.1811061085609253e-05
disease I-Disease 0 6.618001498281956e-05
( O 0 1.3181748670376692e-07
WD B-Disease 0 0.00020154555386397988
) O 0 4.65730806809006e-07
. O 0 2.8809183731937082e-06

Mutations O 0 2.0820702957280446e-06
in O 0 7.027188786423721e-08
the O 0 5.7111908091656005e-08
ATP7B O 0 5.354297627491178e-06
genes O 0 5.628491894782428e-09
have O 0 4.1676628814713013e-10
also O 0 2.7532703894550536e-10
been O 0 9.200519235363913e-10
demonstrated O 0 2.2383481734777888e-08
in O 0 1.9841182918867162e-08
mouse O 0 5.356322958505189e-07
and O 0 5.273371357361611e-07
rat O 0 3.709282964337035e-06
. O 0 1.4524561038342654e-06

The O 0 1.33646244648844e-06
ATP7B O 0 8.650805102661252e-05
gene O 0 4.680447673877097e-08
has O 0 2.1428558927283348e-09
been O 0 1.6907116817677093e-09
excluded O 0 1.0527849703123593e-08
in O 0 6.887598269500472e-10
the O 0 2.065128068551303e-09
much O 0 9.753751584185011e-09
rarer O 0 2.4260691134259105e-05
human O 0 5.472526936500799e-06
copper B-Disease 0 0.001193118980154395
overload I-Disease 1 0.9719244241714478
disease O 1 0.7681949734687805
non B-Disease 0 3.7567810068139806e-05
- I-Disease 0 2.623729642436956e-06
Indian I-Disease 0 6.558411058676938e-08
childhood I-Disease 0 6.112750270403922e-07
cirrhosis I-Disease 0 0.002471067477017641
, O 0 5.67184699207246e-09
indicating O 0 9.712541526596397e-08
genetic O 0 5.111365339871554e-07
heterogeneity O 0 8.103994332486764e-06
. O 0 9.37651111598825e-06

By O 0 1.8957021552523656e-07
investigating O 0 4.2009475009763264e-07
the O 0 4.262433606072591e-08
common O 0 8.5953552115825e-06
autosomal O 1 0.9999995231628418
recessive O 1 0.9999992847442627
copper B-Disease 1 0.9980267882347107
toxicosis I-Disease 1 0.9999711513519287
( O 0 8.304692755700671e-07
CT B-Disease 0 0.0015119804302230477
) O 0 3.7723616230778134e-08
in O 0 5.3297753765946254e-08
Bedlington O 0 0.00013021024642512202
terriers O 0 4.111489943170454e-06
, O 0 2.9795412803679255e-09
we O 0 2.758670181179923e-09
have O 0 3.0369617931569337e-10
identified O 0 1.5274423947886362e-09
a O 0 2.2270564559168093e-10
new O 0 9.461988970116408e-10
locus O 0 2.4703870948883377e-08
involved O 0 1.3484677374719922e-08
in O 0 7.596927531494657e-08
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.00025450967950746417

We O 0 5.762926207353303e-07
examined O 0 2.2883025962983083e-07
whether O 0 8.002752238667199e-09
the O 0 2.026387413422981e-08
WD B-Disease 0 8.274507308669854e-06
gene O 0 2.3788432201854448e-07
ATP7B O 0 2.7925647373194806e-05
was O 0 1.5345133874689054e-07
also O 0 6.579607969570134e-09
causative O 0 4.135328524057513e-08
for O 0 7.924965572669862e-09
CT B-Disease 0 1.169020379165886e-05
by O 0 2.9669646295360508e-08
investigating O 0 1.9244903626258747e-07
the O 0 4.32434958952399e-08
chromosomal O 0 9.142881935986225e-06
co O 0 8.72951204655692e-06
- O 0 1.4132410797174089e-05
localization O 0 4.277108018868603e-05
of O 0 8.877150889929908e-07
ATP7B O 0 4.945432738168165e-05
and O 0 3.247404833928158e-08
C04107 O 0 1.9968943831827346e-07
, O 0 1.6171084471494623e-09
using O 0 2.63438582059905e-09
fluorescence O 0 8.101059734144656e-08
in O 0 6.026638743605872e-09
situ O 0 2.9615830499096774e-07
hybridization O 0 6.136721708571713e-08
( O 0 7.418168745942921e-09
FISH O 0 3.7874158920203627e-07
) O 0 4.752930138351985e-08
. O 0 1.0985979770339327e-06

C04107 O 0 6.0806083638453856e-05
is O 0 2.9142659840886154e-08
an O 0 4.079080184737904e-09
anonymous O 0 5.59240014297302e-08
microsatellite O 0 3.628337253758218e-06
marker O 0 3.825192379736109e-06
closely O 0 3.4299961271244683e-07
linked O 0 9.765851700649364e-07
to O 0 4.980016683475696e-07
CT B-Disease 1 0.9956041574478149
. O 0 6.87256979290396e-05

However O 0 2.578754674686934e-06
, O 0 3.752530517431296e-07
BAC O 0 1.6126827176776715e-05
clones O 0 2.8351186642794346e-07
containing O 0 1.1465167659707731e-07
ATP7B O 0 1.4389761417987756e-05
and O 0 9.255494859417013e-08
C04107 O 0 9.98273208097089e-07
mapped O 0 6.015788756030815e-08
to O 0 4.148757337674169e-09
the O 0 2.3607288568427975e-08
canine O 0 4.80914422951173e-07
chromosome O 0 6.446580300689675e-07
regions O 0 2.130525444954401e-07
CFA22q11 O 0 2.4541912353015505e-05
and O 0 1.882521729612563e-07
CFA10q26 O 0 2.3014803446130827e-05
, O 0 1.213068490102387e-08
respectively O 0 2.4532717191050324e-08
, O 0 7.64695973209939e-10
demonstrating O 0 8.887720781558528e-09
that O 0 8.16065048869774e-10
WD B-Disease 0 9.924713140208041e-07
cannot O 0 3.434951523217933e-08
be O 0 1.5621688831402025e-08
homologous O 0 1.081864411389688e-07
to O 0 1.0522212789965124e-07
CT B-Disease 0 0.0006137683521956205
. O 0 6.6004781729134265e-06

The O 0 7.227236892504152e-06
copper O 0 2.624798071337864e-06
transport O 0 4.291532320621627e-07
genes O 0 7.276953084556226e-08
CTR1 O 0 4.325432200857904e-06
and O 0 1.4263863867824966e-08
CTR2 O 0 1.4412023119803052e-05
were O 0 1.7699127496939582e-08
also O 0 1.6726916518550183e-09
excluded O 0 8.608410873023331e-09
as O 0 1.065064370031621e-09
candidate O 0 6.392922191622574e-09
genes O 0 1.1558297652314309e-09
for O 0 5.529919855362664e-10
CT B-Disease 0 8.15167254586413e-07
since O 0 5.9022555731758075e-09
they O 0 1.6543018066528248e-09
both O 0 3.0070541612303714e-09
mapped O 0 2.3414862937443104e-08
to O 0 6.246748007754377e-09
canine O 0 8.815740670797823e-07
chromosome O 0 1.053737150868983e-06
region O 0 1.422215632373991e-06
CFA11q22 O 0 0.0004073208256158978
. O 0 2.0596571630449034e-05

2 O 0 9.16149074328132e-05
- O 0 2.79115884040948e-05
22 O 0 7.136262865969911e-06
. O 0 5.455096925288672e-06

5 O 0 0.00016208643501158804
. O 0 5.9528589190449566e-05

A O 0 3.002023959197686e-06
transcribed O 0 8.643694968668569e-07
sequence O 0 5.920139756199205e-08
identified O 0 3.6453101870392857e-08
from O 0 1.4009923887670084e-08
the O 0 3.6702164862845166e-08
C04107 O 0 8.712361250218237e-07
- O 0 1.0151396168112115e-07
containing O 0 3.4150072991678826e-08
BAC O 0 1.3864754691894632e-05
was O 0 2.0268087652652866e-08
found O 0 6.554378706447039e-10
to O 0 3.7942513020361446e-10
be O 0 1.2853820230418478e-09
homologous O 0 2.720904390685064e-09
to O 0 6.100072114101351e-10
a O 0 1.5350007931402843e-09
gene O 0 7.45359685083713e-09
expressed O 0 6.937280527807843e-09
from O 0 2.188052938834062e-08
human O 0 9.515096621726116e-08
chromosome O 0 2.2578069547307678e-07
2p13 O 0 1.2663209645324969e-06
- O 0 2.2617916783929104e-07
p16 O 0 4.606882342272911e-08
, O 0 8.085214164843535e-10
a O 0 7.490162379220067e-10
region O 0 2.740310200977092e-09
devoid O 0 1.7481110603512207e-07
of O 0 3.043278073988631e-09
any O 0 2.0408426060214424e-09
positional O 0 4.765657024563552e-07
candidate O 0 5.257999760033272e-07
genes O 0 5.234434752310335e-07
. O 0 2.0928159756294917e-06

Molecular O 0 2.327617266928428e-06
analysis O 0 9.55106287392482e-08
of O 0 7.628742082488316e-08
the O 0 5.214818443732838e-08
APC B-Disease 0 1.3355420946936647e-07
gene O 0 7.162341386646176e-09
in O 0 9.300439529624782e-09
205 O 0 5.7281113186036237e-08
families O 0 1.882175526546348e-09
: O 0 5.978473716083954e-09
extended O 0 1.6373800804103666e-07
genotype O 0 3.3619267014728393e-06
- O 0 1.4611811138820485e-06
phenotype O 0 3.0697296438120247e-07
correlations O 0 1.906835080944802e-07
in O 0 6.399326402117822e-09
FAP B-Disease 0 1.0641210934636547e-07
and O 0 1.6178797190846694e-09
evidence O 0 3.846917451255649e-09
for O 0 3.2928329507520004e-10
the O 0 1.4651493351891531e-09
role O 0 1.5470407177531342e-08
of O 0 1.6011473746857519e-07
APC B-Disease 0 1.5591333522024797e-06
amino O 0 3.2503706393072207e-07
acid O 0 7.892476361348599e-08
changes O 0 8.872106036506011e-07
in O 0 0.0054894015192985535
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.97388756275177
. O 0 5.658004738506861e-05

BACKGROUND O 0 0.0006852832739241421
/ O 0 0.0002572989324107766
AIMS O 0 1.2774760762113146e-05
The O 0 3.6295344330028456e-07
development O 0 8.330278069479391e-05
of O 1 0.9997687935829163
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.7524392603718297e-07
a O 0 4.915319706810806e-09
variable O 0 2.67191495595398e-08
range O 0 1.9535995932074002e-08
of O 0 1.353903122947031e-08
extracolonic O 0 1.5876539691817015e-06
manifestations O 0 1.8847449609893374e-05
in O 0 8.493317977809056e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 3.3929313758562785e-06
FAP B-Disease 0 4.178809831500985e-06
) O 0 6.4445493386244834e-09
is O 0 5.019611393208834e-10
the O 0 1.1817170575412206e-09
result O 0 7.225072984340386e-09
of O 0 1.296109086723618e-08
the O 0 1.0070800193773266e-08
dominant O 0 3.738175564649282e-06
inheritance O 0 2.282348987137084e-06
of O 0 2.672778100532014e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9997064471244812
coli I-Disease 1 0.999985933303833
( O 0 9.185339990835928e-07
APC B-Disease 0 2.649135922183632e-06
) O 0 1.0697764452061165e-07
gene O 0 3.1790449384061503e-07
mutations O 0 3.7576514841930475e-06
. O 0 8.071944648690987e-06

In O 0 1.1928460708077182e-07
this O 0 4.067178593913923e-09
study O 0 2.7095523602582716e-09
, O 0 3.9466918622110825e-10
direct O 0 7.273629476500787e-10
mutation O 0 1.049002107400554e-09
analysis O 0 1.8719612526751916e-09
of O 0 2.80762324500472e-09
the O 0 5.512609480007313e-09
APC B-Disease 0 2.2902186813666958e-08
gene O 0 2.808876686799522e-09
was O 0 1.1624519125064126e-08
performed O 0 2.1220758483764257e-09
to O 0 1.909057134596992e-09
determine O 0 1.0587923782168218e-07
genotype O 0 2.1473060769494623e-06
- O 0 2.060374526990927e-06
phenotype O 0 2.6110066642104357e-07
correlations O 0 1.6448001360913622e-07
for O 0 5.982374595703277e-09
nine O 0 5.8242672906771986e-08
extracolonic O 0 6.010547508594755e-07
manifestations O 0 6.656686082351371e-07
and O 0 4.242899365181074e-09
to O 0 1.8423768066710977e-09
investigate O 0 1.5858375945754233e-08
the O 0 8.782583549304945e-09
incidence O 0 4.946971330355154e-07
of O 0 9.687916247003159e-08
APC B-Disease 0 3.8246636790972843e-07
mutations O 0 1.5118499163691013e-07
in O 0 1.974382968228383e-07
non O 1 0.9999979734420776
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.000503823917824775

METHODS O 0 5.017241619498236e-06
The O 0 4.208980044495547e-07
APC B-Disease 0 3.7563225419035007e-07
gene O 0 1.0561638674744245e-08
was O 0 4.036714784660944e-08
analysed O 0 8.050230348999321e-08
in O 0 4.198206227101764e-09
190 O 0 3.207258103543609e-08
unrelated O 0 7.260703682732128e-08
FAP B-Disease 0 7.849253620406671e-07
and O 0 3.68504551317983e-08
15 O 0 3.038656586795696e-06
non O 1 0.9999903440475464
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.3706618346986943e-06
using O 0 6.375304906214296e-07
denaturing O 0 4.712517693405971e-05
gradient O 0 4.200468993076356e-06
gel O 0 9.105336289394472e-07
electrophoresis O 0 7.120554812445334e-08
, O 0 2.682770450235239e-09
the O 0 5.960995252962675e-09
protein O 0 6.880380265528174e-09
truncation O 0 6.455783818637428e-08
test O 0 2.7194271723374186e-08
, O 0 8.904259551911764e-10
and O 0 1.7942555219363499e-09
direct O 0 1.8447829930323678e-08
sequencing O 0 3.308758778075571e-07
. O 0 7.163853297242895e-07

RESULTS O 0 0.00031066409428603947
Chain O 0 2.641467290231958e-06
terminating O 0 5.615433451566787e-07
signals O 0 1.200778569909744e-07
were O 0 1.1236781283230357e-08
only O 0 4.2135259170628103e-10
identified O 0 3.821074123777635e-09
in O 0 6.831352705738425e-10
patients O 0 1.4729192310269923e-09
belonging O 0 5.891907406407881e-09
to O 0 5.91667159710596e-09
the O 0 4.1553878560307567e-08
FAP B-Disease 0 1.0000026122725103e-06
group O 0 2.306517465910929e-08
( O 0 1.2473952537561672e-08
105 O 0 2.06971577654258e-07
patients O 0 1.5691627552882892e-08
) O 0 4.4370256802039876e-08
. O 0 1.7429367744625779e-06

Amino O 0 3.946718152292306e-06
acid O 0 5.2205308520569815e-08
changes O 0 1.2856621545154212e-08
were O 0 5.246301171268897e-09
identified O 0 2.7462017104795677e-09
in O 0 6.585015865923083e-10
four O 0 1.3513430374700874e-09
patients O 0 3.2335073507638867e-10
, O 0 4.974063938512074e-10
three O 0 1.0956103801973427e-09
of O 0 8.924565086942948e-09
whom O 0 2.9038954352245128e-08
belonged O 0 3.551926397449279e-08
to O 0 7.1034733650776616e-09
the O 0 5.387008528145998e-08
non O 0 7.522804662585258e-05
- O 0 0.0207682978361845
FAP O 0 0.00015118546434678137
group O 0 1.3757403394265566e-06
of O 1 0.9999992847442627
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.0002199214941356331
. O 0 2.034218232438434e-05

Genotype O 0 0.004137784708291292
- O 0 0.0004407519882079214
phenotype O 0 5.858566510141827e-06
correlations O 0 1.2618532991837128e-06
identified O 0 6.866866186783227e-08
significant O 0 5.945688830166773e-09
differences O 0 2.116226767157059e-07
in O 0 1.2622026979158818e-08
the O 0 1.0326408173000345e-08
nature O 0 6.544762953808458e-09
of O 0 3.1484277407400896e-09
certain O 0 6.501527316515876e-09
extracolonic O 0 5.228228587839112e-07
manifestations O 0 4.839893108510296e-07
in O 0 3.5904159645383515e-09
FAP B-Disease 0 1.390000221590526e-07
patients O 0 3.511199997419112e-09
belonging O 0 7.79142350637585e-09
to O 0 9.28780075071245e-09
three O 0 5.048998730217136e-08
mutation O 0 8.659050081405439e-07
subgroups O 0 6.463709723902866e-06
. O 0 7.16351723895059e-06

CONCLUSIONS O 0 6.245286203920841e-05
Extended O 0 8.963924301497173e-06
genotype O 0 2.0943829440511763e-05
- O 0 3.585556441976223e-06
phenotype O 0 5.67747747481917e-07
correlations O 0 3.203489598035958e-07
made O 0 5.947378589610253e-09
in O 0 8.229001369208788e-10
this O 0 2.1816165540755605e-10
study O 0 4.332303682463845e-10
may O 0 5.466057051428663e-10
have O 0 2.3256077619215887e-10
the O 0 4.610244130898167e-10
potential O 0 5.328560370720936e-10
to O 0 1.7538810681561046e-10
determine O 0 5.017335436008352e-09
the O 0 1.574018027028501e-09
most O 0 4.5575593299318484e-10
appropriate O 0 9.061286831979487e-09
surveillance O 0 1.3703067125447888e-08
and O 0 3.59393070858971e-09
prophylactic O 0 2.684702167243813e-06
treatment O 0 7.950767866304886e-08
regimens O 0 6.209734237927478e-08
for O 0 9.035756032282904e-10
those O 0 8.711357746271631e-10
patients O 0 5.047828821602707e-10
with O 0 1.3555735700609972e-10
mutations O 0 1.3225625927759666e-08
associated O 0 1.9262818895526834e-08
with O 0 2.8449642641703576e-09
life O 0 3.9005815466452987e-08
threatening O 0 8.834247751110524e-07
conditions O 0 4.559482476906851e-06
. O 0 3.093447958235629e-06

This O 0 7.380658217925884e-08
study O 0 1.191204024308945e-08
also O 0 9.046948190594151e-10
provided O 0 1.1011768163982083e-09
evidence O 0 3.8342515829015156e-09
for O 0 6.041263600486957e-10
the O 0 2.352555705797954e-09
pathological O 0 2.28719628125873e-07
nature O 0 4.795363750531578e-08
of O 0 8.229621784039409e-08
amino O 0 3.699842565652034e-08
acid O 0 4.280118481858608e-09
changes O 0 5.923378676442326e-09
in O 0 5.026875804503561e-09
APC O 0 1.026451670327333e-07
associated O 0 8.542233587149894e-09
with O 0 7.906059695805823e-10
both O 0 8.190297329235818e-09
FAP B-Disease 0 1.1343470305291703e-06
and O 0 1.5963689747877652e-07
non O 1 0.9999876022338867
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 2.660468396697979e-07
. O 0 1.6461794416500197e-07
. O 0 1.6073158803919796e-06

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 1 0.9972519278526306
cancer B-Disease 1 0.9941166639328003
risk O 0 2.418225676592556e-06
of O 0 9.923938705469482e-06
the O 0 4.925655048282351e-06
APC O 0 6.0085239965701476e-06
I1307K O 0 6.340153959172312e-06
polymorphism O 0 6.6244660956726875e-06
. O 0 2.946880613308167e-06

Germ O 0 0.03056967817246914
- O 0 0.0005411660531535745
line O 0 2.1554596969508566e-06
and O 0 7.386531564179677e-08
somatic O 0 9.819260640142602e-07
truncating O 0 4.732590355160937e-07
mutations O 0 9.369416353877114e-09
of O 0 9.244430110300073e-09
the O 0 1.151302253532549e-08
APC B-Disease 0 6.355587345296954e-08
gene O 0 6.130670637816138e-09
are O 0 1.320399345416945e-09
thought O 0 1.4199747155885234e-08
to O 0 1.9760022951231804e-08
initiate O 0 3.905990070052212e-06
colorectal B-Disease 1 1.0
tumor I-Disease 0 4.50077532150317e-05
formation O 0 2.4960256268968806e-05
in O 0 2.5972411094699055e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 1 0.9999641180038452
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 1.4475233911070973e-05
respectively O 0 2.8252687116037123e-05
. O 0 1.817167503759265e-05

Recently O 0 4.991174591850722e-06
, O 0 7.87875933383475e-08
an O 0 4.219835503249669e-08
isoleucine O 0 1.8095548512064852e-05
- O 0 3.0938437703298405e-05
- O 0 0.0001182130363304168
> O 0 2.7050669814343564e-05
lysine O 0 9.327308362117037e-06
polymorphism O 0 3.1668170663579076e-07
at O 0 1.812058343375611e-07
codon O 0 1.628764465522181e-07
1307 O 0 7.1701265369483735e-06
( O 0 5.703349792440804e-09
I1307K O 0 9.702672798539425e-08
) O 0 8.65549298900703e-10
of O 0 3.779929702574236e-09
the O 0 9.01498253824684e-09
APC B-Disease 0 5.3105765118743875e-08
gene O 0 3.0072204726394602e-09
has O 0 8.965406195216019e-10
been O 0 1.280331618502828e-09
identified O 0 2.8123878781372014e-09
in O 0 9.115452836994109e-10
6 O 0 6.264146179546515e-08
% O 0 2.5286506222244043e-09
- O 0 1.5685643006690952e-08
7 O 0 3.6411964998706026e-08
% O 0 1.0775265124607358e-09
of O 0 4.421571553336889e-09
the O 0 1.2638215807214692e-08
Ashkenazi O 0 1.2420541395385953e-07
Jewish O 0 2.136478371994599e-08
population O 0 2.162337642275247e-09
. O 0 5.142726990925439e-07

To O 0 1.8834914783383283e-07
assess O 0 8.332124821208708e-07
the O 0 1.3551431976566164e-08
risk O 0 8.599253753516223e-09
of O 0 4.667616959608267e-09
this O 0 1.123608983633062e-09
common O 0 3.2291286089503046e-08
APC B-Disease 0 4.941049382978235e-07
allelic O 0 7.994096449692734e-06
variant O 0 0.00018807391461450607
in O 0 8.998905286716763e-06
colorectal O 1 1.0
carcinogenesis O 1 0.9999728202819824
, O 0 6.861773016453299e-08
we O 0 1.4972226125564703e-08
have O 0 1.4896052169532936e-09
analyzed O 0 8.60192717055952e-09
a O 0 5.728029162099801e-10
large O 0 1.3285793576400806e-09
cohort O 0 8.12343330380827e-08
of O 0 3.4554336281189535e-08
unselected O 0 2.2505444576381706e-05
Ashkenazi O 0 2.6110019462066703e-06
Jewish O 0 1.431060354661895e-07
subjects O 0 1.2165160114818718e-06
with O 0 2.7602084173850017e-08
adenomatous B-Disease 0 1.7545979062560946e-05
polyps I-Disease 0 9.374141882290132e-06
and O 0 1.1243732700449982e-07
. O 0 7.186193670349894e-06
or O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.2666190229992935e-07
for O 0 1.1021229262553334e-08
the O 0 7.326211459712795e-08
APC O 0 1.0090499245052342e-06
I1307K O 0 2.063369038296514e-06
polymorphism O 0 1.5186850532700191e-06
. O 0 9.290759521718428e-07

The O 0 5.78882691115723e-06
APC O 0 6.566524007212138e-06
I1307K O 0 3.1004033189674374e-06
allele O 0 4.5348625121732766e-07
was O 0 8.879320745336372e-08
identified O 0 1.8369389565009442e-08
in O 0 3.8061260809740816e-09
48 O 0 4.0521122457448655e-08
( O 0 2.407968269224625e-09
10 O 0 3.0978368759093655e-09
. O 0 6.911035077550309e-10
1 O 0 1.7687382225517467e-08
% O 0 1.3543542953797783e-09
) O 0 1.0392080529442183e-09
of O 0 1.5606440584292613e-08
476 O 0 1.949446044591241e-07
patients O 0 6.12485209217084e-08
. O 0 9.915253258441226e-07

Compared O 0 1.3386994623942883e-07
with O 0 1.7659966822236584e-09
the O 0 2.3046431429918357e-09
frequency O 0 1.0093471836114531e-08
in O 0 2.781923302830336e-10
two O 0 1.7449253153500877e-10
separate O 0 1.3868071968570206e-10
population O 0 9.517620198906673e-12
control O 0 3.7498182337003527e-10
groups O 0 2.5717789009505054e-10
, O 0 6.850429112859047e-10
the O 0 5.581655582176381e-09
APC O 0 6.756718562428432e-08
I1307K O 0 1.796647097762616e-07
allele O 0 8.513415394872936e-08
is O 0 1.1461810389690186e-09
associated O 0 2.827976519625963e-09
with O 0 9.701493081104573e-11
an O 0 7.922781181113336e-11
estimated O 0 5.451002427214746e-10
relative O 0 7.685727609896276e-09
risk O 0 1.8932190926079784e-08
of O 0 1.0237300074322775e-07
1 O 0 5.585179223999148e-06
. O 0 3.6658134376921225e-06

5 O 0 4.0796810935717076e-05
- O 0 1.7779229892767034e-05
1 O 0 1.023565619107103e-05
. O 0 6.836456122982781e-06

7 O 0 0.00018450479547027498
for O 0 1.2572332707350142e-05
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9804476499557495
( O 0 1.7825824727424333e-07
both O 0 1.4377222612438345e-07
P O 0 8.269548561656848e-05
= O 0 7.247876965266187e-07
. O 0 4.086791705049109e-08
01 O 0 1.3586134173237951e-06
) O 0 3.612385057749634e-08
. O 0 7.458996265086171e-07

Furthermore O 0 3.426527882766095e-06
, O 0 3.918724544860197e-08
compared O 0 4.9303835680802877e-08
with O 0 1.083067679985561e-08
noncarriers O 0 3.5304994980833726e-06
, O 0 4.043326384817192e-08
APC O 0 5.843539270244946e-07
I1307K O 0 4.5366795120571624e-07
carriers O 0 6.380094674796055e-09
had O 0 3.278921356653086e-09
increased O 0 2.0758696983591562e-09
numbers O 0 4.304441247882096e-09
of O 0 9.74259890540452e-08
adenomas B-Disease 1 0.9999849796295166
and O 1 0.9674477577209473
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999953508377075
per O 0 8.409578100554427e-08
patient O 0 3.146172034007577e-08
( O 0 9.834602465730313e-09
P O 0 4.647281457437202e-06
= O 0 1.4376139745309047e-07
. O 0 2.520440967046511e-09
03 O 0 1.1205196415176033e-07
) O 0 3.352850774795968e-10
, O 0 1.1593618426397612e-10
as O 0 2.7179933304033455e-10
well O 0 5.463336449906819e-10
as O 0 6.099292737538065e-10
a O 0 1.3544783072916289e-09
younger O 0 1.3765853168479225e-07
age O 0 4.542679619135015e-07
at O 0 4.1910078607543255e-07
diagnosis O 0 7.154279501264682e-06
. O 0 1.0079995718115242e-06

We O 0 8.625636382930679e-07
conclude O 0 9.976013188861543e-07
that O 0 4.4515182651139185e-09
the O 0 2.6172985556627282e-08
APC O 0 4.5923368929834396e-07
I1307K O 0 5.574507895289571e-07
variant O 0 1.5415729421874858e-06
leads O 0 5.809045688920378e-08
to O 0 6.264430307822977e-09
increased O 0 3.765368035146821e-07
adenoma B-Disease 1 1.0
formation O 0 4.113218892598525e-06
and O 0 1.9655260530271335e-08
directly O 0 2.052362280124953e-09
contributes O 0 2.5405422210411643e-10
to O 0 2.849823710349142e-10
3 O 0 6.108004324545391e-09
% O 0 2.572465573891236e-10
- O 0 1.2540790628179366e-09
4 O 0 3.478563437298021e-09
% O 0 1.279510664087269e-10
of O 0 6.160464360860374e-10
all O 0 4.627866978523798e-09
Ashkenazi O 0 3.420445409574313e-06
Jewish O 0 7.982357783475891e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.8386342819430865e-05

The O 0 1.3081966017125524e-06
estimated O 0 5.689749471571304e-08
relative O 0 4.009914675862092e-07
risk O 0 6.884189929223794e-08
for O 0 6.25100282647395e-09
carriers O 0 8.715400845460408e-09
may O 0 4.007349119206083e-08
justify O 0 6.794791573838665e-08
specific O 0 5.173187656026812e-09
clinical O 0 9.759092201022668e-09
screening O 0 1.6977368400006299e-09
for O 0 4.0158457115246904e-10
the O 0 2.644272800722547e-09
360 O 0 2.0363877695217525e-08
, O 0 9.973438741539553e-10
000 O 0 5.059561658526945e-09
Americans O 0 5.1698012537571e-10
expected O 0 2.462148929183172e-09
to O 0 9.12564745991773e-10
harbor O 0 1.1149974277202546e-08
this O 0 5.926200641326318e-10
allele O 0 2.4402513787435964e-08
, O 0 8.994334166345652e-10
and O 0 6.288981557744933e-10
genetic O 0 8.343171709057629e-10
testing O 0 1.4193430875053537e-09
in O 0 2.374354879375318e-10
the O 0 1.6027590366007871e-09
setting O 0 1.2552379580199613e-08
of O 0 9.373062326289983e-09
long O 0 7.2143317986217426e-09
- O 0 3.203687626296414e-08
term O 0 5.5729564962803124e-08
- O 0 2.780016572501154e-08
outcome O 0 5.5824248335056836e-08
studies O 0 3.9669805218522924e-09
may O 0 1.943378569180254e-09
impact O 0 6.009148734165137e-08
significantly O 0 1.3258987792141852e-06
on O 1 0.9998291730880737
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 2.3307138690142892e-06
in O 0 7.922785205671801e-10
this O 0 3.230671563603238e-10
population O 0 6.012341735583959e-10
. O 0 1.6785544687536458e-07

Localization O 0 0.00022243056446313858
of O 0 3.07116943076835e-06
human O 0 4.065680343501299e-07
BRCA1 O 0 2.2170317492964386e-07
and O 0 1.89213622547868e-08
its O 0 7.997000395221221e-09
loss O 0 6.19978095528495e-07
in O 0 4.499116812439752e-08
high O 0 0.004135754890739918
- O 0 4.9872185627464205e-05
grade O 1 0.8734526634216309
, O 0 5.206391051615356e-07
non B-Disease 1 0.99996018409729
- I-Disease 1 0.9999642372131348
inherited I-Disease 1 0.9999998807907104
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.0010693779913708568

Although O 0 2.4892290184652666e-07
the O 0 4.2599140215315856e-08
link O 0 8.4410750389452e-08
between O 0 8.60112692180337e-08
the O 0 1.4511668666727928e-07
BRCA1 O 0 2.8543497592181666e-06
tumour B-Disease 1 1.0
- O 0 2.2913254724699073e-05
suppressor O 0 3.2175139494938776e-06
gene O 0 1.9370961013009946e-07
and O 0 1.6570837715335074e-06
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 9.722872391648707e-07
established O 0 9.226464925404798e-08
, O 0 6.269065266906182e-10
the O 0 7.529868950584273e-10
role O 0 1.9330494982483515e-09
, O 0 1.6572317129703862e-10
if O 0 1.0743757966613643e-10
any O 0 3.92761767553651e-10
, O 0 1.0858740573382875e-09
of O 0 1.0391729254877191e-08
BRCA1 O 0 1.820832409293871e-07
in O 0 9.625127717072246e-08
non B-Disease 1 0.9986743927001953
- I-Disease 1 0.9995583891868591
familial I-Disease 0 0.38082218170166016
cancers I-Disease 1 0.9999120235443115
is O 0 4.170243173007293e-08
unclear O 0 1.5192152886811527e-06
. O 0 5.4822535275889095e-06

BRCA1 O 0 1.7019876395352185e-05
mutations O 0 5.583547704191005e-07
are O 0 9.103295006696044e-09
rare O 0 1.8156038450456435e-08
in O 0 1.660758286448072e-08
sporadic B-Disease 0 5.474577847053297e-05
cancers I-Disease 1 0.9999552965164185
, O 0 1.5605220227143946e-08
but O 0 1.586164266598189e-08
loss O 0 3.1111028420127695e-07
of O 0 1.767993609291807e-07
BRCA1 O 0 4.8809983610453855e-08
resulting O 0 2.1498001601116812e-08
from O 0 3.1346820694722055e-09
reduced O 0 6.02313647846131e-08
expression O 0 2.999591686148051e-08
or O 0 8.611728219420911e-09
incorrect O 0 5.986177598060749e-08
subcellular O 0 6.576812552339106e-07
localization O 0 5.880615390196908e-07
is O 0 7.904250587387196e-10
postulated O 0 1.1978912084487092e-08
to O 0 6.114271866586307e-10
be O 0 1.3135167398203862e-09
important O 0 6.21560936053811e-09
in O 0 5.1869406547666586e-09
non B-Disease 0 0.00016735869576223195
- I-Disease 1 0.7634913921356201
familial I-Disease 1 0.9999949932098389
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 1 0.9999983310699463

Epigenetic O 0 0.0012576153967529535
loss O 0 2.57357405644143e-05
, O 0 2.1615099043970076e-08
however O 0 1.5965936128736757e-08
, O 0 8.552565322617056e-10
has O 0 4.1013258761379845e-11
not O 0 4.4321889908216505e-11
received O 0 4.669243880428553e-10
general O 0 1.2394851811592389e-09
acceptance O 0 4.720206003838712e-09
due O 0 2.028421519639778e-08
to O 0 3.164840611802333e-09
controversy O 0 2.4753724403581145e-08
regarding O 0 7.328922890792455e-08
the O 0 2.4844824864089787e-08
subcellular O 0 1.9323499600432115e-06
localization O 0 1.8345601802138845e-06
of O 0 7.655518174942699e-08
BRCA1 O 0 4.669595909945201e-08
proteins O 0 1.5008788656345473e-09
, O 0 1.823508788412198e-09
reports O 0 3.7336622682460074e-09
of O 0 2.4306066048751518e-09
which O 0 9.365712649866964e-10
have O 0 1.053127918204666e-09
ranged O 0 5.6804029924251154e-08
from O 0 2.0054196081531472e-09
exclusively O 0 2.4373334461813556e-09
nuclear O 0 3.9321641054357315e-08
, O 0 2.1607051703398383e-09
to O 0 1.2964619378053044e-09
conditionally O 0 8.920893179720224e-08
nuclear O 0 6.851298195442723e-08
, O 0 1.1372897068540055e-09
to O 0 1.421014306224322e-09
the O 0 1.9474908796723867e-08
ER O 0 1.1365981663402636e-05
/ O 0 9.054220981852268e-07
golgi O 0 1.0871355016206508e-06
, O 0 2.2056294568528756e-09
to O 0 2.5668109859822152e-09
cytoplasmic O 0 6.40596056200593e-07
invaginations O 0 2.3003374280960998e-06
into O 0 3.685924099272597e-08
the O 0 6.947387021227769e-08
nucleus O 0 2.2171616365085356e-06
. O 0 1.7663551261648536e-06

In O 0 4.899246732747997e-07
an O 0 1.5298514455253098e-08
attempt O 0 1.377747622655079e-07
to O 0 1.1146167544495711e-08
resolve O 0 3.275073083841562e-07
this O 0 2.620714090184606e-09
issue O 0 2.5570297879085047e-08
, O 0 2.0710686499114672e-09
we O 0 4.44828440748779e-09
have O 0 3.5667719888721194e-09
comprehensively O 0 2.4757866867730627e-06
characterized O 0 7.070345731108318e-08
19 O 0 3.398266983367648e-07
anti O 0 2.6209233965346357e-06
- O 0 1.7201593436766416e-05
BRCA1 O 0 9.54417600951274e-07
antibodies O 0 1.6373863331864413e-07
. O 0 1.5484096138607129e-06

These O 0 5.885631253477186e-07
reagents O 0 1.2550497103802627e-06
detect O 0 3.8482701825159893e-07
a O 0 4.9459245587968326e-08
220 O 0 5.858404392711236e-07
- O 0 2.5608183022995945e-06
kD O 0 3.981691861554282e-06
protein O 0 3.265105519290046e-08
localized O 0 1.1102379460226075e-07
in O 0 6.736641466886795e-09
discrete O 0 1.2153049055996235e-07
nuclear O 0 1.509668692278865e-07
foci O 0 7.011349794083799e-07
in O 0 4.385648288973698e-09
all O 0 5.5856919090047086e-09
epithelial O 0 9.458226202241349e-08
cell O 0 9.878446149969022e-08
lines O 0 3.97006871821759e-09
, O 0 2.243000091217695e-10
including O 0 2.0376718368186886e-10
those O 0 1.955319794966215e-10
derived O 0 9.49672607220009e-09
from O 0 4.420730448373433e-08
breast B-Disease 0 1.525238712929422e-05
malignancies I-Disease 0 6.796602974645793e-05
. O 0 1.5951400200719945e-05

Immunohistochemical O 0 0.001612774096429348
staining O 0 0.0014116704696789384
of O 0 0.00012587697710841894
human O 0 1.8984619600814767e-05
breast O 0 3.08073140331544e-05
specimens O 0 1.3050079132881365e-06
also O 0 5.166662617739348e-07
revealed O 0 1.1865442502312362e-05
BRCA1 O 0 2.8400727387634106e-06
nuclear O 0 1.756601886881981e-05
foci O 0 0.1163320317864418
in O 0 3.454074430919718e-06
benign O 1 1.0
breast O 1 1.0
, O 0 7.18645824235864e-05
invasive B-Disease 1 0.9999994039535522
lobular I-Disease 1 1.0
cancers I-Disease 1 1.0
and O 0 0.03450879827141762
low B-Disease 1 1.0
- I-Disease 1 1.0
grade I-Disease 1 1.0
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.00038221501745283604

Conversely O 0 7.059402378217783e-06
, O 0 1.806090494937962e-07
BRCA1 O 0 3.8869242757755273e-07
expression O 0 9.288122981843117e-08
was O 0 1.0397106109394372e-07
reduced O 0 2.9487084773904826e-08
or O 0 2.876995752743028e-09
undetectable O 0 2.6889807713814662e-08
in O 0 3.690535377298687e-10
the O 0 5.510756295734609e-10
majority O 0 5.816168102690256e-10
of O 0 6.846305300456379e-09
high O 0 1.5249097486957908e-06
- O 0 7.512732054237858e-07
grade O 0 3.7503592466237023e-05
, O 0 3.010439115769259e-07
ductal B-Disease 1 0.9999861717224121
carcinomas I-Disease 1 1.0
, O 0 9.929711275447062e-09
suggesting O 0 7.3022685675994126e-09
that O 0 9.173865556100225e-10
absence O 0 1.3015460353926755e-07
of O 0 1.84855579732357e-07
BRCA1 O 0 9.981935988889745e-08
may O 0 6.226216875404589e-09
contribute O 0 2.3516451008731565e-09
to O 0 1.7275867403299117e-09
the O 0 5.880399722713037e-09
pathogenesis O 0 1.1059786402256577e-06
of O 0 3.1733693450775036e-09
a O 0 3.468008380469456e-10
significant O 0 1.892236367595501e-09
percentage O 0 2.887993133526834e-08
of O 0 9.298793202106026e-08
sporadic B-Disease 0 0.000854946207255125
breast I-Disease 1 0.7292340397834778
cancers I-Disease 0 0.0076219928450882435
. O 0 7.533624852840148e-07
. O 0 8.790246283751912e-06

